title,type,agency_names,abstract,citation,document_number,html_url,pdf_url,publication_date,Title Product,Title Note,Assignment,Product Name,Number of Patents,Count,Assignment,Patent No.,Patent Issued,Patent Owner,Patent Extended Period (days),Company,Reg Rev Period,Testing Phase,Approval Phase,IND/IDE Filing Date,NDA/PMA Filing Date,Approval Date,Application No.,Pat Term Ext,row_identifier,Date Designated,Orphan Designation,Orphan Designation Status,Date Designation Withdrawn or Revoked,FDA Orphan Approval Status,Approved Labeled Indication,Marketing Approval Date,Exclusivity End Date,"Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)",Sponsor Company,Proprietary Name,Active Ingredient/Moiety,Applicant,NDA/BLA,Application Number(1),Application Number(2),FDA Receipt Date,FDA Approval Date,Approval Year,Abbreviated Indication(s),Approved Use(s),Review Designation,Orphan Drug Designation,Accelerated Approval,Breakthrough Therapy Designation,Fast Track Designation
Determination of Regulatory Review Period for Purposes of Patent Extension; BetaseronRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Betaseron<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biologic product.",59 FR 305,94-36,https://www.federalregister.gov/documents/1994/01/04/94-36/determination-of-regulatory-review-period-for-purposes-of-patent-extension-betaseronregister,,1/4/1994, BetaseronRegister,,,Betaseron<Register>,1,1,Anthony,4588585,n/a,n/a,1516,the Cetus Oncology Corp.,3720,3319,401,1983-05-19,1983-05-19,1993-07-23,PLA 92-0495,1500,920495,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ImagentRegister GI,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Imagent<Register> GI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-4802,https://www.federalregister.gov/documents/1994/03/03/94-4802/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imagentregister-gi,,3/3/1994, ImagentRegister GI,,,Imagent<Register> GI,1,2,Anthony,3975512,n/a,,,the Board of Trustees of the University of Illinois,7493,6469,1024,1973-02-08,1973-02-08,1993-08-13,NDA 20-091,730,20091,,,,,,,,,,,Imagent GI,perflubron,Alliance,NDA,20091,,1990-10-25,1993-08-13,1993,Indicated for use with magnetic resonance imaging to enhance the delineation of the bowel in order to distinguish it from adjacent organs and areas of suspected pathology,,Priority,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PirsueSUPTM Aqueous Gel,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Pirsue<SUP>TM Aqueous Gel and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",,94-4801,https://www.federalregister.gov/documents/1994/03/03/94-4801/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pirsuesuptm-aqueous-gel,,3/3/1994, PirsueSUPTM Aqueous Gel,,,Pirsue<SUP>TM Aqueous Gel,1,3,Anthony,3975512,n/a,,,The Upjohn Co.,3860,3778,82,1983-02-17,1993-09-10,1993-09-10,NADA 141-036,1095,141036,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SporanoxRegister,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Sporanox<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-5635,https://www.federalregister.gov/documents/1994/03/11/94-5635/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sporanoxregister,,3/11/1994, SporanoxRegister,,,Sporanox<Register>,1,4,Anthony,4267179,1981-05-12,Janssen Pharmaceutica N.V.,2 years,Janssen Pharmaceutica N.V.,2990,2155,835,1984-07-07,1984-07-07,1992-09-11,NDA 20-,1510,20,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PRO OSTEONSUPTM Implant 500 Coralline Hydroxyapatite Bone Void Filler,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for PRO OSTEON<SUP>TM Implant 500 Coralline Hydroxyapatite Bone Void Filler and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",,94-5672,https://www.federalregister.gov/documents/1994/03/11/94-5672/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pro-osteonsuptm-implant,,3/11/1994, PRO OSTEONSUPTM Implant 500 Coralline Hydroxyapatite Bone Void Filler,,,the PRO OSTEON<SUP>TM Implant 500 Coralline Hydroxyapatite Bone Void Filler,1,5,Anthony,3929971,n/a,,,Research Corp. Technologies,3774,2049,1725,1982-07-02,1982-07-02,1992-10-29,PMA P860005,730,860005,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SupprelinRegister; Correction,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of June 2, 1992 (57 FR 23237), that announced its determination of the regulatory review period for purposes of patent extension for Supprelin<Register> (histrelin acetate). The document was published with some mathematical errors. The document incorrectly stated, ``FDA has determined that the applicable regulatory review period for Supprelin<Register> is 2,876 days. Of this time, 1,930 days occurred during the testing phase of the regulatory review period, while 946 days occurred during the approval phase.'' It should have stated, ``FDA has determined that the applicable regulatory review period for Supprelin<Register> is 2,878 days. Of this time, 1,931 days occurred during the testing phase of the regulatory review period, while 947 days occurred during the approval phase.'' This document corrects those errors.",,94-9047,https://www.federalregister.gov/documents/1994/04/14/94-9047/determination-of-regulatory-review-period-for-purposes-of-patent-extension-supprelinregister,,4/14/1994, SupprelinRegister, Correction,,,0,5,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MycobutinSUPTM,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Mycobutin<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-9099,https://www.federalregister.gov/documents/1994/04/15/94-9099/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mycobutinsuptm,,4/15/1994, MycobutinSUPTM,,,Mycobutin<SUP>TM,1,6,Anthony,4219478,n/a,Farmitalia Carlo Erba S.r.l.,1406,Adria Laboratories,2831,2124,707,1986-03-23,1986-03-23,1992-12-23,NDA 50-689,1392,50689,,,,,,,,,,,Mycobutin,rifabutin,Adria,NDA,50689,,1992-01-17,1992-12-23,1992,prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection,,Priority,Yes,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MycobutinSUPTM; Correction,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of April 15, 1994 (59 FR 18133), that announced its determination of the regulatory review period for purposes of patent extension for Mycobutin<SUP>TM (rifabutin). The document was published with some mathematical errors. The document incorrectly stated, ``FDA has determined that the applicable regulatory review period for Mycobutin<SUP>TM is 2,831 days. Of this time, 2,124 days occurred during the testing phase of the regulatory review period, while 707 days occurred during the approval phase.'' It should have stated, ``FDA has determined that the applicable regulatory review period for Mycobutin<SUP>TM is 2,469 days. Of this time, 2,127 days occurred during the testing phase of the regulatory review period, while 342 days occurred during the approval phase.'' This document corrects those errors.",,94-14446,https://www.federalregister.gov/documents/1994/06/14/94-14446/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mycobutinsuptm-correction,,6/14/1994, MycobutinSUPTM, Correction,,,0,6,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; RealitySUPTM Female Condom,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Reality<SUP>TM Female Condom and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",,94-14445,https://www.federalregister.gov/documents/1994/06/14/94-14445/determination-of-regulatory-review-period-for-purposes-of-patent-extension-realitysuptm-female,,6/14/1994, RealitySUPTM Female Condom,,,the Reality<SUP>TM Female Condom,1,7,Anthony,4735621,1988-04-05,dismissed,,Chartex International Plc,2017,1460,557,1987-10-31,1991-10-29,1993-05-07,PMA P910064,762,910064,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AceonSUPTM,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Aceon<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-17737,https://www.federalregister.gov/documents/1994/07/21/94-17737/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aceonsuptm,,7/21/1994, AceonSUPTM,,,Aceon<SUP>TM,1,8,Anthony,4508729,1985-04-02,Adir,1601,Adir,2284,1367,917,1987-10-01,1987-10-01,1993-12-30,NDA 20-184,1588,20184,,,,,,,,,,,Aceon,perindopril erbumine,RW Johnson Pharmaceutical Development,NDA,20184,,1991-06-28,1993-12-30,1993,treatment of patients with essential hypertension,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DemadexSUPTM,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Demadex<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-17738,https://www.federalregister.gov/documents/1994/07/21/94-17738/determination-of-regulatory-review-period-for-purposes-of-patent-extension-demadexsuptm,,7/21/1994, DemadexSUPTM,,,Demadex<SUP>TM,1,9,Anthony,Re. 30633,,,,A. Christians Societe Anonyme,2790,1882,908,1986-01-04,1986-01-10,1993-08-23,NDA 20-136,5,20136,,,,,,,,,,,Demadex,torsemide,Boehringer Mannheim,NDA,20136,20137,1991-02-28,1993-08-23,1993,"treatment of edema associated with congestive heart failure (CHF), renal disease, or hepatic disease; treatment of hypertension",,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CattlystRegister 50 Type A Medicated Article,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Cattlyst<Register> 50 Type A Medicated Article and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",,94-17814,https://www.federalregister.gov/documents/1994/07/22/94-17814/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cattlystregister-50-type,,7/22/1994, CattlystRegister 50 Type A Medicated Article,,,Cattlyst<Register> 50 Type A Medicated Article,1,10,Anthony,4431665,n/a,,,"Syntex (U.S.A), Inc.",4253,3762,491,1982-07-14,1982-07-14,1994-03-04,NADA 141-025,3,141025,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DovonexRegister,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Dovonex<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-21156,https://www.federalregister.gov/documents/1994/08/29/94-21156/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dovonexregister,,8/29/1994, DovonexRegister,,,Dovonex<Register>,1,11,Anthony,4866048,1989-09-12,"Leo Pharmaceutical Products, Ltd.",473,"Leo Pharmaceutical Products, Ltd.",1149,510,639,1990-11-08,1990-11-08,1993-12-29,NDA 20-273,473,20273,,,,,,,,,,,Dovonex,calcipotriene,Bristol-Myers,NDA,20273,,1992-03-31,1993-12-29,1993,treatment of moderate plaque psoriasis,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; EffexorRegister,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Effexor<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-21287,https://www.federalregister.gov/documents/1994/08/30/94-21287/determination-of-regulatory-review-period-for-purposes-of-patent-extension-effexorregister,,8/30/1994, EffexorRegister,,,Effexor<Register>,1,12,Anthony,4535186,1985-08-13,American Home Products Corp.,5 years,American Home Products Corp.,2959,1981,978,1985-11-23,1991-04-26,1993-12-28,NDA 20-151,5,20151,,,,,,,,,,,Effexor,venlafaxine hydrochloride,Wyeth-Ayerst,NDA,20151,,1991-04-26,1993-12-28,1993,treatment of depression,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; KytrilSUPTM,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Kytril<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-21282,https://www.federalregister.gov/documents/1994/08/30/94-21282/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kytrilsuptm,,8/30/1994, KytrilSUPTM,,,Kytril<SUP>TM,1,13,Anthony,4886808,,,,Beecham Group p.l.c.,1996,1371,625,1988-07-14,1988-07-14,1993-12-29,NDA 20-,382,20,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LipidilRegister,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Lipidil<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-21285,https://www.federalregister.gov/documents/1994/08/30/94-21285/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lipidilregister,,8/30/1994, LipidilRegister,,,Lipidil<Register>,1,14,Anthony,4739101,,,,Fournier Innovation et Synergie,4501,1003,3498,1981-09-06,1981-09-06,1993-12-31,NDA 19-304,256,19304,,,,,,,,,,,Lipidil,fenofibrate,Fournier,NDA,19304,,1984-06-04,1993-12-31,1993,adjunctive therapy to diet for treatment of adult patients with very high elevations of serum triglyceride levels (types IV and V hyperlipidemia) who are at risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LivostinRegister,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Livostin<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-21283,https://www.federalregister.gov/documents/1994/08/30/94-21283/determination-of-regulatory-review-period-for-purposes-of-patent-extension-livostinregister,,8/30/1994, LivostinRegister,,,Livostin<Register>,1,15,Anthony,4369184,,,,Janssen Pharmaceutica N.V.,2779,2000,779,1986-04-04,1986-04-04,1993-11-10,NDA 20-219,1779,20219,,,,,,,,,,,Livostin,levocabastine hydrochloride,Iolab,NDA,20219,,1991-09-24,1993-11-10,1993,temporary relief of the signs and symptoms of seasonal allergic conjunctivitis,,Priority,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NeurontinRegister,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Neurontin<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-21288,https://www.federalregister.gov/documents/1994/08/30/94-21288/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neurontinregister,,8/30/1994, NeurontinRegister,,,Neurontin<Register>,1,16,Anthony,4087544,,,,Warner-Lambert Co.,2740,2040,700,1986-07-02,1992-01-31,1993-12-30,NDA 20-235,1726,20235,,,,,,,,,,,Neurontin,gabapentin,Parke-Davis,NDA,20235,,1992-01-31,1993-12-30,1993,indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults with epilepsy,,Priority,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NeutrexinSUPTM,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Neutrexin<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-21280,https://www.federalregister.gov/documents/1994/08/30/94-21280/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neutrexinsuptm,,8/30/1994, NeutrexinSUPTM,,,Neutrexin<SUP>TM,1,17,Anthony,4376858,,,,Warner-Lambert Co.,2251,1934,317,1987-10-21,1987-03-30,1993-12-17,IND 29,1310,29,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; RisperdalRegister,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Risperdal<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-21284,https://www.federalregister.gov/documents/1994/08/30/94-21284/determination-of-regulatory-review-period-for-purposes-of-patent-extension-risperdalregister,,8/30/1994, RisperdalRegister,,,Risperdal<Register>,1,18,Anthony,4804663,,,,Janssen Pharmaceutica N.V.,1940,1316,624,1988-09-08,1988-09-08,1993-12-29,NDA 20-272,683,20272,,,,,,,,,,,Risperdal,risperidone,Janssen,NDA,20272,,1992-04-15,1993-12-29,1993,management of the manifestations of psychotic disorders,,Priority,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZosynRegister,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Zosyn<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-21286,https://www.federalregister.gov/documents/1994/08/30/94-21286/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zosynregister,,8/30/1994, ZosynRegister,,,Zosyn<Register>,1,19,Anthony,4562073,,,,"Taiho Pharmaceutical Co., Ltd.",1819,1038,781,1988-10-31,1988-06-14,1993-10-22,IND 31,1358,31,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AviaxRegister,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Aviax<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",,94-21789,https://www.federalregister.gov/documents/1994/09/06/94-21789/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aviaxregister,,9/6/1994, AviaxRegister,,,Aviax<Register>,1,20,Anthony,4804680,,,,Pfizer Inc.,2438,736,1702,1987-07-09,1994-03-10,1994-03-10,NADA 140-940,755,140940,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PrografSUPTM,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Prograf<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-22036,https://www.federalregister.gov/documents/1994/09/07/94-22036/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prografsuptm,,9/7/1994, PrografSUPTM,,,,0,20,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZemuronSUPTM Injection,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Zemuron<SUP>TM Injection and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-22760,https://www.federalregister.gov/documents/1994/09/15/94-22760/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zemuronsuptm-injection,,9/15/1994, ZemuronSUPTM Injection,,,Zemuron<SUP>TM Injection,1,21,Anthony,4894369,,,,"Akzo Nobel, N.V.",1889,1627,262,1994-01-15,1994-01-15,1994-03-17,NDA 20-214,427,20214,,,,,,,,,,,Zemuron,rocuronium bromide,Organon,NDA,20214,,1993-06-29,1994-03-17,1994,"indicated for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation",,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SemprexSUPTM-D Capsules,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Semprex<SUP>TM-D Capsules and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-23276,https://www.federalregister.gov/documents/1994/09/21/94-23276/determination-of-regulatory-review-period-for-purposes-of-patent-extension-semprexsuptm-d-capsules,,9/21/1994, SemprexSUPTM-D Capsules,,,Semprex<SUP>TM-D Capsules,1,22,Anthony,4650807,,,,Burroughs Wellcome Co.,3489,1210,2279,1984-09-06,1984-09-06,1994-03-25,NDA 19-806,1469,19806,,,,,,,,,,,Semprex-D,"acrivastine, pseudoephedrine hydrochloride",Burroughs Wellcome,NDA,19806,,1987-12-29,1994-03-25,1994,"indicated for relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion",,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Netrexingreek-Tgreek-M,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,,,X94-41005,https://www.federalregister.gov/documents/1994/10/05/X94-41005/determination-of-regulatory-review-period-for-purposes-of-patent-extension-netrexingreek-tgreek-m,,10/5/1994, Netrexingreek-Tgreek-M,,,,0,22,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NeurontinRegister,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,,,X94-51005,https://www.federalregister.gov/documents/1994/10/05/X94-51005/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neurontinregister,,10/5/1994, NeurontinRegister,,,,0,22,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CPIRegister VentakRegister PRxRegister AICD System,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for CPI<Register> Ventak<Register> PRx<Register> AICD System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",,94-28064,https://www.federalregister.gov/documents/1994/11/15/94-28064/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cpiregister,,11/15/1994, CPIRegister VentakRegister PRxRegister AICD System,,,CPI<Register> Ventak<Register> PRx<Register> AICD System,1,23,Anthony,4407288,,,,"Cardiac Pacemakers, Inc.",1306,398,908,1990-11-21,1990-11-21,1994-06-17,PMA P910077,394,910077,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZeritRegister,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Zerit<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-28194,https://www.federalregister.gov/documents/1994/11/16/94-28194/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zeritregister,,11/16/1994, ZeritRegister,,,Zerit<Register>,1,24,Anthony,4978655,,,,Yale University,1984,1805,179,1989-01-19,1988-12-16,1994-06-24,IND 32,188,32,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period For Purposes of Patent Extension; CognexRegister,Uncategorized Document,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Cognex<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",,94-30235,https://www.federalregister.gov/documents/1994/12/08/94-30235/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cognexregister,,12/8/1994, CognexRegister,,,Cognex<Register>,1,25,Anthony,4 816456,,,,William K. Summers,2289,1095,1194,1987-06-06,1990-06-04,1993-09-09,NDA 20-,531,20,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZemuronSUPTM Injection; Correction,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) is correcting the notice that appeared in the Federal Register of September 15, 1994. The document announced FDA's determination of the regulatory review period for purposes of patent extension for Zeuron<SUP>TM Injection (rocuronium bromide). The document was published with some errors. The document incorrectly stated: ``1. The date an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act became effective: January 15, 1994. The applicant claims January 14, 1989, as [[Page 130]] the date the investigational new drug application (IND) became effective. However, FDA records indicate that the IND effective date was January 15, 1994, which was 30 days after FDA receipt of the IND.'' The document should have stated: ``1. The date an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act became effective: January 15, 1989. The applicant claims January 14, 1989, as the date the investigational new drug application (IND) became effective. However, FDA records indicate that the IND effective date was January 15, 1989, which was 30 days after FDA receipt of the IND.'' This document corrects those errors.",60 FR 129,94-32242,https://www.federalregister.gov/documents/1995/01/03/94-32242/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zemuronsuptm-injection,https://www.govinfo.gov/content/pkg/FR-1995-01-03/pdf/94-32242.pdf,1/3/1995, ZemuronSUPTM Injection, Correction,,,0,25,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NetrexinSUPTM,Correction,Health and Human Services Department; Food and Drug Administration,,60 FR 5252,X95-50126,https://www.federalregister.gov/documents/1995/01/26/X95-50126/determination-of-regulatory-review-period-for-purposes-of-patent-extension-netrexinsuptm,https://www.govinfo.gov/content/pkg/FR-1995-01-26/pdf/X95-50126.pdf,1/26/1995, NetrexinSUPTM,,,,0,25,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AlbunexRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Albunex<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",60 FR 11671,95-5183,https://www.federalregister.gov/documents/1995/03/02/95-5183/determination-of-regulatory-review-period-for-purposes-of-patent-extension-albunexregister,https://www.govinfo.gov/content/pkg/FR-1995-03-02/pdf/95-5183.pdf,3/2/1995, AlbunexRegister,,,Albunex<Register>,1,26,Anthony,4844882,,,,"Molecular Biosystems, Inc.",2397,975,1422,1988-01-14,1988-01-14,1994-08-05,PMA P900059,763,900059,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SemprexSUPTM-D Capsules,Correction,Health and Human Services Department; Food and Drug Administration,,60 FR 15822,X95-30327,https://www.federalregister.gov/documents/1995/03/27/X95-30327/determination-of-regulatory-review-period-for-purposes-of-patent-extension-semprexsuptm-d-capsules,https://www.govinfo.gov/content/pkg/FR-1995-03-27/pdf/X95-30327.pdf,3/27/1995, SemprexSUPTM-D Capsules,,,,0,26,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LUVOXSUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for LUVOX<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 20105,95-10073,https://www.federalregister.gov/documents/1995/04/24/95-10073/determination-of-regulatory-review-period-for-purposes-of-patent-extension-luvoxsuptm,https://www.govinfo.gov/content/pkg/FR-1995-04-24/pdf/95-10073.pdf,4/24/1995, LUVOXSUPTM,,,LUVOX<SUP>TM,1,27,Anthony,4085225,,,,Duphar International,6958,5886,1072,1975-11-19,1975-11-19,1994-12-05,NDA 20-243,730,20243,,,,,,,,,,,Luvox,fluvoxamine maleate,Solvay,NDA,20243,,1991-12-30,1994-12-05,1994,treatment of obsessions and compulsions in patients with obsessive-compulsive disorder,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SERZONERegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for SERZONE<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 20106,95-10077,https://www.federalregister.gov/documents/1995/04/24/95-10077/determination-of-regulatory-review-period-for-purposes-of-patent-extension-serzoneregister,https://www.govinfo.gov/content/pkg/FR-1995-04-24/pdf/95-10077.pdf,4/24/1995, SERZONERegister,,,SERZONE<Register>,1,28,Anthony,4338317,,,,Bristol-Myers Squibb,4420,3216,1204,1982-11-17,1982-11-17,1994-12-22,NDA 20-152,730,20152,,,,,,,,,,,Serzone,nefazodone hydrochloride,Bristol-Myers,NDA,20152,,1991-09-06,1994-12-22,1994,treatment of depression,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZosynRegister; Correction,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) is correcting the notice that appeared in the Federal Register of August 30, 1994. The document announced FDA's determination of the regulatory review period for purposes of patent extension for Zosyn<Register> (tazobactam sodium and piperacillin sodium). The document was published with some errors. The document incorrectly stated: FDA has determined that the applicable regulatory review period for Zosyn<Register> is 1,819 days. Of this time, 1,038 days occurred during the testing phase of the regulatory review period, while 781 days occurred during the approval phase. 1. The date an exemption under 505(i) of the Federal Food, Drug, and Cosmetic Act became effective: October 31, 1988. The applicant claims July 10, 1988, as the date the investigational new drug application (IND) for Zosyn<Register> (IND 31,705) became effective. However, IND 31,705 was received on June 14, 1988, and it was placed on clinical hold on July 1, 1988. It was removed from clinical hold on October 31, 1988, making the IND effective date October 31, 1988. It should have stated: FDA has determined that the applicable regulatory review period for Zosyn<Register> is 1,906 days. Of this time, 1,125 days occurred during the testing phase of the regulatory review period, while 781 days occurred during the approval phase. 1. The date an exemption under 505(i) of the Federal Food, Drug, and Cosmetic Act became effective: August 5, 1988. The applicant claims July 10, 1988, as the date the investigational new drug application (IND) for Zosyn<Register> (IND 31,705) became effective. However, IND 31,705 was received on June 14, 1988, and it was placed on clinical hold on July 1, 1988. It was removed from clinical hold on August 5, 1988, making the IND effective date August 5, 1988. This document corrects those errors. FOR FURTHER INFORMATION CONTACT: Brian J. Malkin, Office of Health Affairs (HFY-20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-1382.",60 FR 20107,95-10074,https://www.federalregister.gov/documents/1995/04/24/95-10074/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zosynregister-correction,https://www.govinfo.gov/content/pkg/FR-1995-04-24/pdf/95-10074.pdf,4/24/1995, ZosynRegister, Correction,,,0,28,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Sonic Accelerated Fracture Healing System (SAFHSRegister),Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for SAFHS<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",60 FR 20107,95-10076,https://www.federalregister.gov/documents/1995/04/24/95-10076/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sonic-accelerated,https://www.govinfo.gov/content/pkg/FR-1995-04-24/pdf/95-10076.pdf,4/24/1995, Sonic Accelerated Fracture Healing System (SAFHSRegister),,,,0,28,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FRAGMINRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for FRAGMIN<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 27981,95-13032,https://www.federalregister.gov/documents/1995/05/26/95-13032/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fragminregister,https://www.govinfo.gov/content/pkg/FR-1995-05-26/pdf/95-13032.pdf,5/26/1995, FRAGMINRegister,,,FRAGMIN<Register>,1,29,Anthony,4303651,,,,Pharmacia Aktiebolag,3555,2832,723,1985-03-31,1985-03-31,1994-12-22,IND 25,661,25,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NeuroliteRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Neurolite<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 27982,95-13033,https://www.federalregister.gov/documents/1995/05/26/95-13033/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neuroliteregister,https://www.govinfo.gov/content/pkg/FR-1995-05-26/pdf/95-13033.pdf,5/26/1995, NeuroliteRegister,,,Neurolite<Register>,1,30,Anthony,5279811,,,,Dupont Merck Pharmaceutical Co.,2595,1602,993,1987-10-18,1987-10-18,1994-11-23,NDA 20-256,156,20256,,,,,,,,,,,Neurolite,technetium Tc-99m bicisate,Dupont Merck,NDA,20256,,1992-03-06,1994-11-23,1994,indicated as an adjunct to conventional CT or MRI imaging in the localization of stroke in patients in whom stroke has already been diagnosed,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; RENORMAXRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for RENORMAX<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 36291,95-17345,https://www.federalregister.gov/documents/1995/07/14/95-17345/determination-of-regulatory-review-period-for-purposes-of-patent-extension-renormaxregister,https://www.govinfo.gov/content/pkg/FR-1995-07-14/pdf/95-17345.pdf,7/14/1995, RENORMAXRegister,,,RENORMAX<Register>,1,31,Anthony,4470972,,,,Schering Corp.,3996,2901,1095,1984-01-22,1984-01-22,1994-12-29,NDA 20-240,730,20240,,,,,,,,,,,Renormax,spirapril hydrochloride,Sandoz,NDA,20240,,1991-12-31,1994-12-29,1994,treatment of hypertension,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NAVELBINERegister Injection,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for NAVELBINE<Register> Injection and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 36812,95-17503,https://www.federalregister.gov/documents/1995/07/18/95-17503/determination-of-regulatory-review-period-for-purposes-of-patent-extension-navelbineregister,https://www.govinfo.gov/content/pkg/FR-1995-07-18/pdf/95-17503.pdf,7/18/1995, NAVELBINERegister Injection,,,NAVELBINE<Register> Injection,1,32,Anthony,4307100,,,,Burroughs Wellcome Co.,1621,1137,484,1990-07-18,1990-07-18,1994-12-23,NDA 20-388,1067,20388,,,,,,,,,,,Navelbine,vinorelbine tartrate,Burroughs Wellcome,NDA,20388,,1993-08-27,1994-12-23,1994,"as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC)",,Priority,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LAMICTALRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for LAMICTAL<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 36813,95-17504,https://www.federalregister.gov/documents/1995/07/18/95-17504/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lamictalregister,https://www.govinfo.gov/content/pkg/FR-1995-07-18/pdf/95-17504.pdf,7/18/1995, LAMICTALRegister,,,LAMICTAL<Register>,1,33,Anthony,4602017,,,,Burroughs Wellcome Co.,3703,2693,1010,1984-11-08,1984-04-12,1994-12-27,IND 23,1825,23,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NISOCOR,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for NISOCOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 39000,95-18687,https://www.federalregister.gov/documents/1995/07/31/95-18687/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nisocor,https://www.govinfo.gov/content/pkg/FR-1995-07-31/pdf/95-18687.pdf,7/31/1995, NISOCOR,,,NISOCOR,1,34,Anthony,4154839,,,,Bayer AG,4965,4292,673,1981-07-02,1981-07-02,1995-02-02,IND 33,1377,33,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Allergen Patch Test (Thin-layer Rapid Use Epicutaneous (T.R.U.E.) TestSUPTM),Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Allergen Patch Test (Thin-layer Rapid Use Epicutaneous (T.R.U.E.) Test<SUP>TM) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biologic product.",60 FR 39752,95-19060,https://www.federalregister.gov/documents/1995/08/03/95-19060/determination-of-regulatory-review-period-for-purposes-of-patent-extension-allergen-patch-test,https://www.govinfo.gov/content/pkg/FR-1995-08-03/pdf/95-19060.pdf,8/3/1995, Allergen Patch Test (Thin-layer Rapid Use Epicutaneous (T.R.U.E.) TestSUPTM),,,,0,34,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ExcimedSUPTM UV200LA/SVS APEX Excimer Laser Systems,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Excimed<SUP>TM UV200LA/SVS APEX Excimer Laser Systems and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",60 FR 40183,95-19425,https://www.federalregister.gov/documents/1995/08/07/95-19425/determination-of-regulatory-review-period-for-purposes-of-patent-extension-excimedsuptm-uv200lasvs,https://www.govinfo.gov/content/pkg/FR-1995-08-07/pdf/95-19425.pdf,8/7/1995, ExcimedSUPTM UV200LA/SVS APEX Excimer Laser Systems,,,,0,34,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ULTRAVISTRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for ULTRAVIST<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 54694,95-26501,https://www.federalregister.gov/documents/1995/10/25/95-26501/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ultravistregister,https://www.govinfo.gov/content/pkg/FR-1995-10-25/pdf/95-26501.pdf,10/25/1995, ULTRAVISTRegister,,,ULTRAVIST<Register>,1,35,Anthony,4364921,,,,Schering Aktiengesellschaft,2518,1353,1165,1988-06-19,1988-06-19,1995-05-10,NDA 20-220,1825,20220,,,,,,,,,,,Ultravist,iopromide,Berlex Laboratories,NDA,20220,,1992-03-02,1995-05-10,1995,"intra-arterial Ultravist is indicated for intra-arterial digital subtraction angiography, cerebral arteriography, and peripheral arteriography, and coronary arteriography and left ventriculography, visceral angiography, and aortography; intravenous Ultravist is indicated for peripheral venography and for contrast enhanced computed tomographic (CECT) imaging of the head and body, and excretory urography",,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CELLCEPTRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CELLCEPT<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 62865,95-29768,https://www.federalregister.gov/documents/1995/12/07/95-29768/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cellceptregister,https://www.govinfo.gov/content/pkg/FR-1995-12-07/pdf/95-29768.pdf,12/7/1995, CELLCEPTRegister,,,CELLCEPT<Register>,1,36,Anthony,4753935,,,,"Syntex, Inc.",2479,2304,175,1988-07-21,1988-07-21,1995-05-03,IND 31,824,31,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZINECARDSUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZINECARD<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 62866,95-29769,https://www.federalregister.gov/documents/1995/12/07/95-29769/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zinecardsuptm,https://www.govinfo.gov/content/pkg/FR-1995-12-07/pdf/95-29769.pdf,12/7/1995, ZINECARDSUPTM,,,ZINECARD<SUP>TM,1,37,Anthony,4275063,,,,British Technology Group Ltd.,2748,1546,1202,1987-11-18,1987-09-22,1995-05-26,IND 30,1825,30,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CPIRegister VentakRegister P2 AICD System,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for CPI<Register> Ventak<Register> P2 AICD System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",60 FR 62867,95-29766,https://www.federalregister.gov/documents/1995/12/07/95-29766/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cpiregister,https://www.govinfo.gov/content/pkg/FR-1995-12-07/pdf/95-29766.pdf,12/7/1995, CPIRegister VentakRegister P2 AICD System,,,CPI<Register> Ventak<Register> P2 AICD System,1,38,Anthony,Re. 34879,,,,"Cardiac Pacemakers, Inc.",1178,620,558,1991-12-20,1991-12-20,1995-03-10,PMA P930035,363,930035,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent - Extension; VALTREXRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for VALTREX<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 62868,95-29809,https://www.federalregister.gov/documents/1995/12/07/95-29809/determination-of-regulatory-review-period-for-purposes-of-patent---extension-valtrexregister,https://www.govinfo.gov/content/pkg/FR-1995-12-07/pdf/95-29809.pdf,12/7/1995, VALTREXRegister,,,VALTREX<Register>,1,39,Anthony,4957924,,,,Burroughs Wellcome Co.,1907,1541,366,1990-04-05,1990-03-06,1995-06-23,IND 34,1052,34,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ULTANESUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for ULTANE<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",60 FR 62869,95-29808,https://www.federalregister.gov/documents/1995/12/07/95-29808/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ultanesuptm,https://www.govinfo.gov/content/pkg/FR-1995-12-07/pdf/95-29808.pdf,12/7/1995, ULTANESUPTM,,,ULTANE<SUP>TM,1,40,Anthony,4250334,,,,"Baxter International, Inc.",3418,3086,332,1986-01-29,1994-07-08,1995-06-07,IND 27,1826,27,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PREVACIDRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PREVACID<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 72,95-31557,https://www.federalregister.gov/documents/1996/01/02/95-31557/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prevacidregister,https://www.govinfo.gov/content/pkg/FR-1996-01-02/pdf/95-31557.pdf,1/2/1996, PREVACIDRegister,,,PREVACID<Register>,1,41,Anthony,4628098,,,,Hiroshi Akimoto,2870,2328,542,1987-07-03,1987-07-03,1995-05-10,NDA 20-406,1706,20406,,,,,,,,,,,Prevacid,lansoprazole,TAP Holdings,NDA,20406,,1993-11-15,1995-05-10,1995,short-term treatment (up to four weeks) for healing and symptom relief of active duodenal ulcer; short-term treatment (up to eight weeks) for healing and symptom relief of all grades of erosive esophagitis; long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ADENOSCANRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for ADENOSCAN<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 73,95-31555,https://www.federalregister.gov/documents/1996/01/02/95-31555/determination-of-regulatory-review-period-for-purposes-of-patent-extension-adenoscanregister,https://www.govinfo.gov/content/pkg/FR-1996-01-02/pdf/95-31555.pdf,1/2/1996, ADENOSCANRegister,,,ADENOSCAN<Register>,1,42,Anthony,5070877,,,,"Medco Research, Inc.",2688,768,1920,1988-01-09,1988-01-09,1995-05-18,NDA 20-059,159,20059,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; IMMITICIDERegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IMMITICIDE<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",61 FR 11054,96-6454,https://www.federalregister.gov/documents/1996/03/18/96-6454/determination-of-regulatory-review-period-for-purposes-of-patent-extension-immiticideregister,https://www.govinfo.gov/content/pkg/FR-1996-03-18/pdf/96-6454.pdf,3/18/1996, IMMITICIDERegister,,,IMMITICIDE<Register>,1,43,Anthony,4514390,,,,Rockefeller University,2650,2037,613,1988-04-20,1988-04-20,1995-07-21,NADA 141-042,1095,141042,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; OPTIMMUNERegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPTIMMUNE<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",61 FR 15264,96-8474,https://www.federalregister.gov/documents/1996/04/05/96-8474/determination-of-regulatory-review-period-for-purposes-of-patent-extension-optimmuneregister,https://www.govinfo.gov/content/pkg/FR-1996-04-05/pdf/96-8474.pdf,4/5/1996, OPTIMMUNERegister,,,OPTIMMUNE<Register>,1,44,Anthony,4839342,,,,Schering Corp.,1898,1668,230,1990-05-24,1995-08-02,1995-08-02,NADA 141-052,698,141052,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FLOLANRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for FLOLAN<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 15265,96-8363,https://www.federalregister.gov/documents/1996/04/05/96-8363/determination-of-regulatory-review-period-for-purposes-of-patent-extension-flolanregister,https://www.govinfo.gov/content/pkg/FR-1996-04-05/pdf/96-8363.pdf,4/5/1996, FLOLANRegister,,,FLOLAN<Register>,2,46,Anthony,4338325 and 4883812,,,,Glaxo Wellcome Inc.,5927,5357,570,1979-07-01,1979-07-01,1995-09-20,IND 16,730,16,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CASODEXRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for CASODEX<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 17308,96-9671,https://www.federalregister.gov/documents/1996/04/19/96-9671/determination-of-regulatory-review-period-for-purposes-of-patent-extension-casodexregister,https://www.govinfo.gov/content/pkg/FR-1996-04-19/pdf/96-9671.pdf,4/19/1996, CASODEXRegister,,,CASODEX<Register>,1,47,Anthony,4636505,,,,Zeneca Ltd.,3059,2673,386,1987-05-22,1987-05-22,1995-10-14,NDA 20-498,1721,20498,,,,,,,,,,,Casodex,bicalutamide,Zeneca,NDA,20498,,1994-09-14,1995-10-04,1995,use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced prostate cancer,,Standard,No,Yes,,
Determination of Regulatory Review Period for Purposes of Patent Extension; EPIVIRSUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for EPIVIR<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application of the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product. ADDRESSES: Written comments and petitions should be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.",61 FR 24316,96-12092,https://www.federalregister.gov/documents/1996/05/14/96-12092/determination-of-regulatory-review-period-for-purposes-of-patent-extension-epivirsuptm,https://www.govinfo.gov/content/pkg/FR-1996-05-14/pdf/96-12092.pdf,5/14/1996, EPIVIRSUPTM,,,,0,47,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TRUSOPTRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for TRUSOPT<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 24317,96-12093,https://www.federalregister.gov/documents/1996/05/14/96-12093/determination-of-regulatory-review-period-for-purposes-of-patent-extension-trusoptregister,https://www.govinfo.gov/content/pkg/FR-1996-05-14/pdf/96-12093.pdf,5/14/1996, TRUSOPTRegister,,,TRUSOPT<Register>,1,48,Anthony,4797413,,,,"Merck & Co., Inc.",2101,1736,365,1989-03-11,1989-03-11,1994-12-09,NDA 20-408,1232,20408,,,,,,,,,,,Trusopt,dorzolamide hydrochloride,Merck,NDA,20408,,1993-12-10,1994-12-09,1994,treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma,,Priority,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; COREGRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for COREG<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 26911,96-13307,https://www.federalregister.gov/documents/1996/05/29/96-13307/determination-of-regulatory-review-period-for-purposes-of-patent-extension-coregregister,https://www.govinfo.gov/content/pkg/FR-1996-05-29/pdf/96-13307.pdf,5/29/1996, COREGRegister,,,COREG<Register>,1,49,Anthony,4503067,,,,Boehringer Mannheim GmbH,3625,2727,898,1985-10-13,1985-10-13,1995-09-14,NDA 20-,1825,20,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FOSAMAXRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for FOSAMAX<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 26912,96-13308,https://www.federalregister.gov/documents/1996/05/29/96-13308/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fosamaxregister,https://www.govinfo.gov/content/pkg/FR-1996-05-29/pdf/96-13308.pdf,5/29/1996, FOSAMAXRegister,,,FOSAMAX<Register>,1,50,Anthony,4621077,,,,Instituto Gentili S.p.A.,2558,2375,183,1988-09-29,1988-09-29,1995-09-29,NDA 20-560,1369,20560,,,,,,,,,,,Fosamax,alendronate sodium,Merck,NDA,20560,,1995-03-31,1995-09-29,1995,treatment of osteoporosis in postmenopausal women; treatment of Paget's disease of the bone.,,Priority,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZYRTECSUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZYRTEC<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product. ADDRESSES: Written comments and petitions should be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.",61 FR 26913,96-13310,https://www.federalregister.gov/documents/1996/05/29/96-13310/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zyrtecsuptm,https://www.govinfo.gov/content/pkg/FR-1996-05-29/pdf/96-13310.pdf,5/29/1996, ZYRTECSUPTM,,,ZYRTEC<SUP>TM,1,51,Anthony,4525358,,,,"UCB PHARMA, INC.",4210,1493,2717,1984-05-31,1984-05-31,1995-12-08,NDA 19-835,1826,19835,,,,,,,,,,,Zyrtec,cetirizine,Pfizer,NDA,19835,,1988-07-01,1995-12-08,1995,"relief of symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, and chronic urticaria",,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AMARYLRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for AMARYL<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims human drug product.",61 FR 26913,96-13311,https://www.federalregister.gov/documents/1996/05/29/96-13311/determination-of-regulatory-review-period-for-purposes-of-patent-extension-amarylregister,https://www.govinfo.gov/content/pkg/FR-1996-05-29/pdf/96-13311.pdf,5/29/1996, AMARYLRegister,,,AMARYL<Register>,1,52,Anthony,4379785,,,,Hoechst Atiengesellschaft,2683,2225,458,1988-07-28,1988-07-28,1995-11-30,NDA 20-,1569,20,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PRECOSESUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for PRECOSE<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 27085,96-13535,https://www.federalregister.gov/documents/1996/05/30/96-13535/determination-of-regulatory-review-period-for-purposes-of-patent-extension-precosesuptm,https://www.govinfo.gov/content/pkg/FR-1996-05-30/pdf/96-13535.pdf,5/30/1996, PRECOSESUPTM,,,PRECOSE<SUP>TM,1,53,Anthony,4904769,,,,Bayer AG,5647,3789,1858,1980-03-23,1980-03-23,1995-09-06,NDA 20-,922,20,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CEDAXRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for CEDAX<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 41635,96-20339,https://www.federalregister.gov/documents/1996/08/09/96-20339/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cedaxregister,https://www.govinfo.gov/content/pkg/FR-1996-08-09/pdf/96-20339.pdf,8/9/1996, CEDAXRegister,,,CEDAX<Register>,1,54,Anthony,4812561,,,,Schering-Plough Corp.,2641,1179,1462,1988-09-28,1988-09-28,1995-12-20,NDA 50-686,902,50686,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DYNABACRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for DYNABAC<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 41636,96-20340,https://www.federalregister.gov/documents/1996/08/09/96-20340/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dynabacregister,https://www.govinfo.gov/content/pkg/FR-1996-08-09/pdf/96-20340.pdf,8/9/1996, DYNABACRegister,,,DYNABAC<Register>,1,55,Anthony,4048306,,,,Boehringer Ingelheim GmbH,2469,1687,782,1988-09-16,1988-09-16,1995-06-19,NDA 50-678,1726,50678,,,,,,,,,,,Dynabac,dirithromycin,Lilly,NDA,50678,,1993-04-29,1995-06-19,1995,"treatment of individuals 12 years of age or older with mild-to-moderate infections caused by susceptible strains of designated microorganisms in the following specific conditions: acute bacterial exacerbation of chronic bronchitis, secondary bacterial infection of acute bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, uncomplicated skin and skin structure infections,",,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CORVERT,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for CORVERT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 41637,96-20342,https://www.federalregister.gov/documents/1996/08/09/96-20342/determination-of-regulatory-review-period-for-purposes-of-patent-extension-corvert,https://www.govinfo.gov/content/pkg/FR-1996-08-09/pdf/96-20342.pdf,8/9/1996, CORVERT,,,CORVERT,1,56,Anthony,5155268,,,,the Upjohn Co.,2292,1865,427,1989-09-20,1989-09-20,1995-12-28,NDA 20-491,73,20491,,,,,,,,,,,Corvert,ibutilide fumurate,Upjohn,NDA,20491,,1994-10-28,1995-12-28,1995,indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MAXIPIMERegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for MAXIPIME<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 41638,96-20343,https://www.federalregister.gov/documents/1996/08/09/96-20343/determination-of-regulatory-review-period-for-purposes-of-patent-extension-maxipimeregister,https://www.govinfo.gov/content/pkg/FR-1996-08-09/pdf/96-20343.pdf,8/9/1996, MAXIPIMERegister,,,MAXIPIME<Register>[[Page 41639]],1,57,Anthony,4406899,,,,Bristol-Myers Squibb Co.,3741,2444,1297,1985-10-23,1985-10-23,1996-01-18,NDA 50-,1825,50,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ARIMIDEXRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for ARIMIDEX<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 44069,96-21849,https://www.federalregister.gov/documents/1996/08/27/96-21849/determination-of-regulatory-review-period-for-purposes-of-patent-extension-arimidexregister,https://www.govinfo.gov/content/pkg/FR-1996-08-27/pdf/96-21849.pdf,8/27/1996, ARIMIDEXRegister,,,ARIMIDEX<Register>,1,58,Anthony,4935437,,,,Zeneca Ltd.,1336,1062,274,1992-05-02,1992-05-02,1995-12-27,NDA 20-541,565,20541,,,,,,,,,,,Arimidex,anastrozole,Zeneca,NDA,20541,,1995-03-29,1995-12-27,1995,treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CEDAXRegister Oral Suspension,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for CEDAX<Register> Oral Suspension and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 44068,96-21844,https://www.federalregister.gov/documents/1996/08/27/96-21844/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cedaxregister-oral,https://www.govinfo.gov/content/pkg/FR-1996-08-27/pdf/96-21844.pdf,8/27/1996, CEDAXRegister Oral Suspension,,,CEDAX<Register> Oral Suspension,1,59,Anthony,4634697,,,,Schering-Plough Corp.,2641,1179,1462,1988-09-28,1988-09-28,1995-12-20,NDA 50-686,1826,50686,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposed of Patent Extension; CEDAXRegister Capsules,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for CEDAX<Register> Capsules and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 44070,96-21851,https://www.federalregister.gov/documents/1996/08/27/96-21851/determination-of-regulatory-review-period-for-purposed-of-patent-extension-cedaxregister-capsules,https://www.govinfo.gov/content/pkg/FR-1996-08-27/pdf/96-21851.pdf,8/27/1996, CEDAXRegister Capsules,,,CEDAX<Register> Capsules,1,60,Anthony,4812561,,,,Schering-Plough Corp.,3065,1603,1462,1987-08-01,1987-08-01,1995-12-20,NDA 50-685,902,50685,,,,,,,,,,,Cedax,ceftibuten,Schering Plough,NDA,50685,50686,1991-12-20,1995-12-20,1995,"indicated for the treatment of individuals with mild-to-moderate infections caused by susceptible strains of designated microorganisms in the following conditions: acute bacterial exacerbations of chronic bronchitis, acute bacterial otitis media, pharyngitis and tonsillitis",,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; VEXOLSUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for VEXOL<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 45433,96-22123,https://www.federalregister.gov/documents/1996/08/29/96-22123/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vexolsuptm,https://www.govinfo.gov/content/pkg/FR-1996-08-29/pdf/96-22123.pdf,8/29/1996, VEXOLSUPTM,,,VEXOL<SUP>TM,1,61,Anthony,4686214,,,,"Alcon Laboratories, Inc.",1779,1566,213,1990-02-17,1990-02-17,1994-12-30,NDA 20-474,995,20474,,,,,,,,,,,Vexol,rimexalone,Alcon,NDA,20474,,1994-06-01,1994-12-30,1994,treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis,,Priority,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CEDAXRegister Capsules,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CEDAX<Register> capsules and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 46465,96-22285,https://www.federalregister.gov/documents/1996/09/03/96-22285/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cedaxregister-capsules,https://www.govinfo.gov/content/pkg/FR-1996-09-03/pdf/96-22285.pdf,9/3/1996, CEDAXRegister Capsules,,,CEDAX<Register> capsules,1,62,Anthony,4 634697,,,,Schering-Plough Corp.,3065,1603,1462,1987-08-01,1987-08-01,1995-12-20,NDA 20-685,1826,20685,,,,,,,,,,,Crixivan,indinavir sulfate,Merck,NDA,20685,,1996-01-31,1996-03-13,1996,treatment of HIV infection in adults when antiretroviral therapy is warranted,,Priority,No,Yes,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NeutrexinSUPTM; Correction,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) is correcting the notice that appeared in the Federal Register of August 30, 1994 (59 FR 44737). The document announced FDA's determination of the regulatory review period for purposes of patent extension for Neutrexin<SUP>TM (trimetrexate glucuronate). The document was published with an error in one of the dates stated as part of the regulatory review period and requires additional clarification between the patent extension applicant's records and FDA's records.",61 FR 53748,96-26301,https://www.federalregister.gov/documents/1996/10/15/96-26301/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neutrexinsuptm-correction,https://www.govinfo.gov/content/pkg/FR-1996-10-15/pdf/96-26301.pdf,10/15/1996, NeutrexinSUPTM, Correction,,,0,62,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NuflorRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Nuflor<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",61 FR 60106,96-30196,https://www.federalregister.gov/documents/1996/11/26/96-30196/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nuflorregister,https://www.govinfo.gov/content/pkg/FR-1996-11-26/pdf/96-30196.pdf,11/26/1996, NuflorRegister,,,Nuflor<Register>,1,63,Anthony,4235892,,,,Schering Corp.,4209,4205,4,1984-11-23,1984-11-23,1996-05-31,NADA 141-063,1096,141063,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Buphenyl Powder,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Buphenyl Powder and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 60107,96-30195,https://www.federalregister.gov/documents/1996/11/26/96-30195/determination-of-regulatory-review-period-for-purposes-of-patent-extension-buphenyl-powder,https://www.govinfo.gov/content/pkg/FR-1996-11-26/pdf/96-30195.pdf,11/26/1996, Buphenyl Powder,,,[[Page 60108]]Buphenyl Powder,1,64,Anthony,4457942,,,,"Ucyclyd Pharma, Inc.",4528,4089,439,1983-12-09,1983-12-09,1996-04-30,NDA 20-573,730,20573,,,,,,,,,,,Buphenyl,sodium phenylbutyrate,Ucyclyd,NDA,20573,,1995-02-17,1996-04-30,1996,"indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinic acid synthetase",,Priority,Yes,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DOMITORRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DOMITOR<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",61 FR 60708,96-30388,https://www.federalregister.gov/documents/1996/11/29/96-30388/determination-of-regulatory-review-period-for-purposes-of-patent-extension-domitorregister,https://www.govinfo.gov/content/pkg/FR-1996-11-29/pdf/96-30388.pdf,11/29/1996, DOMITORRegister,,,DOMITOR<Register>,1,65,Anthony,4544664,,,,ORION-YHTYMA OY,4000,2294,1706,1985-04-08,1985-04-08,1996-03-19,NADA 140-999,1095,140999,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DOMITORRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for DOMITOR<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",61 FR 60709,96-30389,https://www.federalregister.gov/documents/1996/11/29/96-30389/determination-of-regulatory-review-period-for-purposes-of-patent-extension-domitorregister,https://www.govinfo.gov/content/pkg/FR-1996-11-29/pdf/96-30389.pdf,11/29/1996, DOMITORRegister,,,DOMITOR<Register>,1,66,Anthony,4670455,,,,ORION-YHTYMA OY,4000,2294,1706,1985-04-08,1985-04-08,1996-03-19,NADA 140-999,1095,140999,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TAXOTERERegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for TAXOTERE<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 60710,96-30386,https://www.federalregister.gov/documents/1996/11/29/96-30386/determination-of-regulatory-review-period-for-purposes-of-patent-extension-taxotereregister,https://www.govinfo.gov/content/pkg/FR-1996-11-29/pdf/96-30386.pdf,11/29/1996, TAXOTERERegister,,,TAXOTERE<Register>,1,67,Anthony,4814470,,,,Rhone-Poulenc Rorer S.A.,2016,1358,658,1990-11-08,1990-11-08,1996-05-14,NDA 20-449,1035,20449,,,,,,,,,,,Taxotere,docetaxel,Rhone-Poulenc,NDA,20449,,1994-07-27,1996-05-14,1996,treatment of patients with locally advanced or metastatic breast cancer who have progressed during anthracycline-based therapy or have relapsed during anthracycline-based adjuvant therapy,,Priority,No,Yes,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MYOVIEWSUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for MYOVIEW<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 60711,96-30387,https://www.federalregister.gov/documents/1996/11/29/96-30387/determination-of-regulatory-review-period-for-purposes-of-patent-extension-myoviewsuptm,https://www.govinfo.gov/content/pkg/FR-1996-11-29/pdf/96-30387.pdf,11/29/1996, MYOVIEWSUPTM,,,MYOVIEW<SUP>TM,1,68,Anthony,5045302,,,,Amersham International PLC,2062,1084,978,1990-06-20,1990-06-20,1996-02-09,NDA 20-372,491,20372,,,,,,,,,,,Myoview,technetium Tc-99m tetrofosmin,Medi Physics,NDA,20372,,1993-06-07,1996-02-09,1996,indicated for scientific imaging of the myocardium following separate administrations under exercise and resting conditions to enhance the delineation of regions of reversible myocardial ischemia in the presence or absence of infarcted myocardium,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; VISTIDESUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for VISTIDE<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",61 FR 66675,96-32033,https://www.federalregister.gov/documents/1996/12/18/96-32033/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vistidesuptm,https://www.govinfo.gov/content/pkg/FR-1996-12-18/pdf/96-32033.pdf,12/18/1996, VISTIDESUPTM,,,VISTIDE<SUP>TM,1,69,Anthony,5142051,,,,the Institute of Organic Chemistry & Biochemistry of the Academy of Science of the Czech Republic,1533,1266,267,1992-04-17,1992-04-17,1996-06-26,NDA 20-638,305,20638,,,,,,,,,,,Vistide,cidofovir,Gilead Sciences,NDA,20638,,1995-10-04,1996-06-26,1996,treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS),,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DIFFERIN Solution,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for DIFFERIN Solution and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 101,96-33381,https://www.federalregister.gov/documents/1997/01/02/96-33381/determination-of-regulatory-review-period-for-purposes-of-patent-extension-differin-solution,https://www.govinfo.gov/content/pkg/FR-1997-01-02/pdf/96-33381.pdf,1/2/1997, DIFFERIN Solution,,,DIFFERIN Solution,1,70,Anthony,5212303,,,,Centre International de Recherches Dermatologiques (CIRD),2814,1651,1163,1988-09-18,1988-09-18,1996-05-31,NDA 20-338,13,20338,,,,,,,,,,,Differin,adapalene,Galderma,NDA,20338,20380,1993-03-26,1996-05-31,1996,indicated for the topical treatment of acne vulgaris,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Olean,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Olean and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that food additive product.",62 FR 763,97-138,https://www.federalregister.gov/documents/1997/01/06/97-138/determination-of-regulatory-review-period-for-purposes-of-patent-extension-olean,https://www.govinfo.gov/content/pkg/FR-1997-01-06/pdf/97-138.pdf,1/6/1997, Olean,,,,0,70,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CAMPTOSARRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for CAMPTOSAR<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 4066,97-2067,https://www.federalregister.gov/documents/1997/01/28/97-2067/determination-of-regulatory-review-period-for-purposes-of-patent-extension-camptosarregister,https://www.govinfo.gov/content/pkg/FR-1997-01-28/pdf/97-2067.pdf,1/28/1997, CAMPTOSARRegister,,,CAMPTOSAR<Register>,1,71,Anthony,4604463,,,,Kabushiki Kaisha Yakult Honsha,2111,1941,170,1990-09-05,1990-09-05,1996-06-14,NDA 20-571,1139,20571,,,,,,,,,,,Camptosar,irinotecan hydrochloride,Pharmacia and Upjohn,NDA,20571,,1995-12-28,1996-06-14,1996,treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy,,Priority,No,Yes,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DIFFERIN Solution,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for DIFFERIN Solution and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 4065,97-2066,https://www.federalregister.gov/documents/1997/01/28/97-2066/determination-of-regulatory-review-period-for-purposes-of-patent-extension-differin-solution,https://www.govinfo.gov/content/pkg/FR-1997-01-28/pdf/97-2066.pdf,1/28/1997, DIFFERIN Solution,,,DIFFERIN Solution,1,72,Anthony,4717720,,,,Centre International de Recherches Dermatologiques (CIRD),2814,1651,1163,1988-09-18,1988-09-18,1996-05-31,NDA 20-338,1512,20338,,,,,,,,,,,Differin,adapalene,Galderma,NDA,20338,20380,1993-03-26,1996-05-31,1996,indicated for the topical treatment of acne vulgaris,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DIFFERIN Solution,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for DIFFERIN Solution and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 4067,97-2068,https://www.federalregister.gov/documents/1997/01/28/97-2068/determination-of-regulatory-review-period-for-purposes-of-patent-extension-differin-solution,https://www.govinfo.gov/content/pkg/FR-1997-01-28/pdf/97-2068.pdf,1/28/1997, DIFFERIN Solution,,,DIFFERIN Solution,1,73,Anthony,5015758,,,,Centre International de Recherches Dermatologiques (CIRD),2814,1651,1163,1988-09-18,1988-09-18,1996-05-31,NDA 20-338,257,20338,,,,,,,,,,,Differin,adapalene,Galderma,NDA,20338,20380,1993-03-26,1996-05-31,1996,indicated for the topical treatment of acne vulgaris,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DIFFERIN Topical Gel,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DIFFERIN Topical Gel and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 4064,97-2064,https://www.federalregister.gov/documents/1997/01/28/97-2064/determination-of-regulatory-review-period-for-purposes-of-patent-extension-differin-topical-gel,https://www.govinfo.gov/content/pkg/FR-1997-01-28/pdf/97-2064.pdf,1/28/1997, DIFFERIN Topical Gel,,,DIFFERIN Topical Gel,1,74,Anthony,5212303,,,,Centre International de Recherches Dermatologiques (CIRD),2447,1401,1046,1989-09-20,1989-09-20,1996-05-31,NDA 20-380,13,20380,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DIFFERIN Topical Gel,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for DIFFERIN Topical Gel and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 4065,97-2065,https://www.federalregister.gov/documents/1997/01/28/97-2065/determination-of-regulatory-review-period-for-purposes-of-patent-extension-differin-topical-gel,https://www.govinfo.gov/content/pkg/FR-1997-01-28/pdf/97-2065.pdf,1/28/1997, DIFFERIN Topical Gel,,,DIFFERIN Topical Gel,1,75,Anthony,5015758,,,,Centre International de Recherches Dermatologiques (``CIRD''),2447,1401,1046,1989-09-20,1989-09-20,1996-05-31,NDA 20-380,257,20380,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DIFFERIN Solution,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DIFFERIN Solution and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 4300,97-2141,https://www.federalregister.gov/documents/1997/01/29/97-2141/determination-of-regulatory-review-period-for-purposes-of-patent-extension-differin-solution,https://www.govinfo.gov/content/pkg/FR-1997-01-29/pdf/97-2141.pdf,1/29/1997, DIFFERIN Solution,,,DIFFERIN Solution,1,76,Anthony,Re. 34440,,,,Centre International de Recherches Dermatologiques (CIRD),2814,1651,1163,1988-09-18,1988-09-18,1996-05-31,NDA 20-338,433,20338,,,,,,,,,,,Differin,adapalene,Galderma,NDA,20338,20380,1993-03-26,1996-05-31,1996,indicated for the topical treatment of acne vulgaris,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DIFFERIN Topical Gel,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for DIFFERIN Topical Gel and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 5432,97-2871,https://www.federalregister.gov/documents/1997/02/05/97-2871/determination-of-regulatory-review-period-for-purposes-of-patent-extension-differin-topical-gel,https://www.govinfo.gov/content/pkg/FR-1997-02-05/pdf/97-2871.pdf,2/5/1997, DIFFERIN Topical Gel,,,DIFFERIN Topical Gel,1,77,Anthony,Re. 34440,,,,Centre International de Recherches Dermatologiques (CIRD),2447,1401,1046,1989-09-20,1989-09-20,1996-05-31,NDA 20-,433,20,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DECTOMAX,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for DECTOMAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",62 FR 6263,97-3315,https://www.federalregister.gov/documents/1997/02/11/97-3315/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dectomax,https://www.govinfo.gov/content/pkg/FR-1997-02-11/pdf/97-3315.pdf,2/11/1997, DECTOMAX,,,DECTOMAX,1,78,Anthony,5089480,,,,"Pfizer, Inc.",21,2836,2695,1988-10-26,1996-07-30,1996-07-30,NADA 141-061,527,141061,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MERREMRegister I.V.,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MERREM<Register> I.V. and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 6261,97-3313,https://www.federalregister.gov/documents/1997/02/11/97-3313/determination-of-regulatory-review-period-for-purposes-of-patent-extension-merremregister-iv,https://www.govinfo.gov/content/pkg/FR-1997-02-11/pdf/97-3313.pdf,2/11/1997, MERREMRegister I.V.,,,,0,78,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DIFFERIN Topical Gel,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for DIFFERIN Topical Gel and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 6262,97-3314,https://www.federalregister.gov/documents/1997/02/11/97-3314/determination-of-regulatory-review-period-for-purposes-of-patent-extension-differin-topical-gel,https://www.govinfo.gov/content/pkg/FR-1997-02-11/pdf/97-3314.pdf,2/11/1997, DIFFERIN Topical Gel,,,DIFFERIN Topical Gel,1,79,Anthony,4717720,,,,Centre International de Recherches Dermatologiques (CIRD),2447,1401,1046,1989-09-20,1989-09-20,1996-05-31,NDA 20-380,1512,20380,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ULTIVASUPTM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ULTIVA<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 6549,97-3417,https://www.federalregister.gov/documents/1997/02/12/97-3417/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ultivasuptm,https://www.govinfo.gov/content/pkg/FR-1997-02-12/pdf/97-3417.pdf,2/12/1997, ULTIVASUPTM,,,ULTIVA<SUP>TM,1,80,Anthony,5019583,,,,"Glaxo Wellcome, Inc.",2222,1920,302,1990-06-14,1990-06-14,1996-07-12,NDA 20-,1088,20,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; REDUXSUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for REDUX<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 9198,97-4961,https://www.federalregister.gov/documents/1997/02/28/97-4961/determination-of-regulatory-review-period-for-purposes-of-patent-extension-reduxsuptm,https://www.govinfo.gov/content/pkg/FR-1997-02-28/pdf/97-4961.pdf,2/28/1997, REDUXSUPTM,,,REDUX<SUP>TM,1,81,Anthony,4309445,,,,"Interneuron Pharmaceuticals, Inc.",1613,541,1072,1991-12-01,1991-12-01,1996-04-29,IND 38,1322,38,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Olean; Correction,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of January 6, 1997 (62 FR 763). The document announced FDA's determination of the regulatory review period for purposes of patent extension for Olean (olestra). The document was published with an error. This document corrects that error.",62 FR 9197,97-4960,https://www.federalregister.gov/documents/1997/02/28/97-4960/determination-of-regulatory-review-period-for-purposes-of-patent-extension-olean-correction,https://www.govinfo.gov/content/pkg/FR-1997-02-28/pdf/97-4960.pdf,2/28/1997, Olean, Correction,,,0,81,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; EXCENELRegister Sterile Suspension,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for EXCENEL<Register> Sterile Suspension and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",62 FR 9195,97-4954,https://www.federalregister.gov/documents/1997/02/28/97-4954/determination-of-regulatory-review-period-for-purposes-of-patent-extension-excenelregister-sterile,https://www.govinfo.gov/content/pkg/FR-1997-02-28/pdf/97-4954.pdf,2/28/1997, EXCENELRegister Sterile Suspension,,,EXCENEL<Register> Sterile Suspension,1,82,Anthony,4902683,,,,Pharmacia & Upjohn Co.,900,881,19,1993-11-10,1993-11-10,1996-04-26,NADA 140-890,1151,140890,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; IVY BLOCKSUPTM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IVY BLOCK<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 12652,97-6590,https://www.federalregister.gov/documents/1997/03/17/97-6590/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ivy-blocksuptm,https://www.govinfo.gov/content/pkg/FR-1997-03-17/pdf/97-6590.pdf,3/17/1997, IVY BLOCKSUPTM,,,IVY BLOCK<SUP>TM,1,83,Anthony,4861584,,,,"United Catalysts, Inc.",2644,1946,698,1989-06-02,1989-06-02,1996-08-26,IND 33,1825,33,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; BAYTRILRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BAYTRIL<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",62 FR 12831,97-6719,https://www.federalregister.gov/documents/1997/03/18/97-6719/determination-of-regulatory-review-period-for-purposes-of-patent-extension-baytrilregister,https://www.govinfo.gov/content/pkg/FR-1997-03-18/pdf/97-6719.pdf,3/18/1997, BAYTRILRegister,,,BAYTRIL<Register>,1,84,Anthony,4670444,,,,Bayer Aktiengesellschaft,4334,648,3686,1984-11-24,1996-10-04,1996-10-04,NADA 140-828,1827,140828,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CEREBYXRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CEREBYX<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 13387,97-6976,https://www.federalregister.gov/documents/1997/03/20/97-6976/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cerebyxregister,https://www.govinfo.gov/content/pkg/FR-1997-03-20/pdf/97-6976.pdf,3/20/1997, CEREBYXRegister,,,CEREBYX<Register>,1,85,Anthony,4260769,,,,Warner-Lambert Co.,3748,3218,530,1986-05-04,1986-05-04,1996-08-05,NDA 20-450,1826,20450,,,,,,,,,,,Cerebyx,fosphenytoin sodium,Parke-Davis,NDA,20450,,1995-02-23,1996-08-05,1996,"for short-term parenteral administration when other means of phenytoin administration are unavailable, inappropriate or deemed less advantageous, indicated for the following:
[A] control of generalized convulsive status epilepticus
[B] prevention and treatment of seizures occurring during neuorsurgery
[C] as a substitute, short-term, for oral phenytoin",,Standard,Yes (indication [A] only),No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; HYCAMTINSUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for HYCAMTIN<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 13388,97-6977,https://www.federalregister.gov/documents/1997/03/20/97-6977/determination-of-regulatory-review-period-for-purposes-of-patent-extension-hycamtinsuptm,https://www.govinfo.gov/content/pkg/FR-1997-03-20/pdf/97-6977.pdf,3/20/1997, HYCAMTINSUPTM,,,HYCAMTIN<SUP>TM,1,86,Anthony,5004758,,,,SmithKline Beecham Corp.,2644,2485,159,1989-03-04,1989-02-02,1996-05-28,IND 32,572,32,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DAUNOXOMERegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for DAUNOXOME<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 13651,97-7135,https://www.federalregister.gov/documents/1997/03/21/97-7135/determination-of-regulatory-review-period-for-purposes-of-patent-extension-daunoxomeregister,https://www.govinfo.gov/content/pkg/FR-1997-03-21/pdf/97-7135.pdf,3/21/1997, DAUNOXOMERegister,,,DAUNOXOME<Register>,3,89,Anthony,5435989; 5441745; and 5019369,,,,"NeXstar Pharmaceuticals, Inc.",2771,1629,1142,1988-09-08,1988-09-08,1996-04-08,IND 31,258,31,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ACCOLATERegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for ACCOLATE<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 16164,97-8622,https://www.federalregister.gov/documents/1997/04/04/97-8622/determination-of-regulatory-review-period-for-purposes-of-patent-extension-accolateregister,https://www.govinfo.gov/content/pkg/FR-1997-04-04/pdf/97-8622.pdf,4/4/1997, ACCOLATERegister,,,ACCOLATE<Register>,1,90,Anthony,4859692,,,,"Zeneca, Inc.",3110,2651,459,1988-03-24,1988-03-24,1996-09-26,NDA 20-547,1496,20547,,,,,,,,,,,Accolate,zafirlukast,Zeneca,NDA,20547,,1995-06-26,1996-09-26,1996,prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TRITECRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for TRITEC<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 16166,97-8624,https://www.federalregister.gov/documents/1997/04/04/97-8624/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tritecregister,https://www.govinfo.gov/content/pkg/FR-1997-04-04/pdf/97-8624.pdf,4/4/1997, TRITECRegister,,,TRITEC<Register>,1,91,Anthony,5008256,,,,"Glaxo Wellcome, Inc.",1074,485,589,1993-09-01,1993-09-01,1996-08-08,NDA 20-,831,20,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PHOTOFRINRegister,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for PHOTOFRIN<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 16163,97-8621,https://www.federalregister.gov/documents/1997/04/04/97-8621/determination-of-regulatory-review-period-for-purposes-of-patent-extension-photofrinregister,https://www.govinfo.gov/content/pkg/FR-1997-04-04/pdf/97-8621.pdf,4/4/1997, PHOTOFRINRegister,,,PHOTOFRIN<Register>,1,92,Anthony,5145863,,,,"Health Research, Inc.",4065,3441,624,1984-11-11,1984-11-11,1995-12-27,NDA 20-,915,20,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; XALATANSUPTM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XALATAN<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 16162,97-8619,https://www.federalregister.gov/documents/1997/04/04/97-8619/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xalatansuptm,https://www.govinfo.gov/content/pkg/FR-1997-04-04/pdf/97-8619.pdf,4/4/1997, XALATANSUPTM,,,XALATAN<SUP>TM,1,93,Anthony,4599353,,,,the Trustees of Columbia University in the City of New York,1875,1519,356,1991-04-20,1991-04-20,1996-06-05,NDA 20-597,1116,20597,,,,,,,,,,,Xalatan,latanoprost,Pharmacia and Upjohn,NDA,20597,,1995-06-16,1996-06-05,1996,indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma and/or ocular hypertension who were intolerant of other IOP-lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another IOP-lowering medication,,Priority,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; REMERONSUPTM,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for REMERON<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 16165,97-8623,https://www.federalregister.gov/documents/1997/04/04/97-8623/determination-of-regulatory-review-period-for-purposes-of-patent-extension-remeronsuptm,https://www.govinfo.gov/content/pkg/FR-1997-04-04/pdf/97-8623.pdf,4/4/1997, REMERONSUPTM,,,REMERON<SUP>TM,1,94,Anthony,4062848,,,,Akzona Inc.,5003,4501,502,1982-10-05,1982-10-05,1996-06-14,NDA 20-415,730,20415,,,,,,,,,,,Remeron,mirtazapine,Organon,NDA,20415,,1995-01-30,1996-06-14,1996,treatment of depression,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AstelinRegister Nasal Spray,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for Astelin<Register> Nasal Spray and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 16167,97-8626,https://www.federalregister.gov/documents/1997/04/04/97-8626/determination-of-regulatory-review-period-for-purposes-of-patent-extension-astelinregister-nasal,https://www.govinfo.gov/content/pkg/FR-1997-04-04/pdf/97-8626.pdf,4/4/1997, AstelinRegister Nasal Spray,,,Astelin<Register> Nasal Spray,1,95,Anthony,5164194,,,,Astra Medica AG,2797,749,2048,1989-03-08,1989-03-08,1996-11-01,NDA 20-114,349,20114,,,,,,,,,,,Astelin,azelastine hydrochloride,Wallace Lab,NDA,20114,,1991-03-26,1996-11-01,1996,"treatment of the symptoms of seasonal allergic rhinitis such as rhinorrhea, sneezing, and nasal pruritus in adults and children 12 years and older",,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MERETEK UBTSUPTM Breath Test,Notice,Health and Human Services Department,"The Food and Drug Administration (FDA) has determined the regulatory review period for MERETEK UBT<SUP>TM Breath Test and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 16166,97-8625,https://www.federalregister.gov/documents/1997/04/04/97-8625/determination-of-regulatory-review-period-for-purposes-of-patent-extension-meretek-ubtsuptm-breath,https://www.govinfo.gov/content/pkg/FR-1997-04-04/pdf/97-8625.pdf,4/4/1997, MERETEK UBTSUPTM Breath Test,,,MERETEK UBT<SUP>TM Breath Test,1,96,Anthony,4830010,,,,"Meretekdiagnostics, Inc.",2023,1527,496,1991-03-07,1985-08-07,1996-09-17,IND 26,780,26,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; OXILANSUPTM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OXILAN<SUP>TM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 18775,97-9917,https://www.federalregister.gov/documents/1997/04/17/97-9917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-oxilansuptm,https://www.govinfo.gov/content/pkg/FR-1997-04-17/pdf/97-9917.pdf,4/17/1997, OXILANSUPTM,,,OXILAN<SUP>TM,1,97,Anthony,4954348,,,,Cook Imaging Corp.,2757,1644,1113,1988-06-05,1988-06-05,1995-12-21,NDA 20-,737,20,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MENTAX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MENTAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 19324,97-10133,https://www.federalregister.gov/documents/1997/04/21/97-10133/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mentax,https://www.govinfo.gov/content/pkg/FR-1997-04-21/pdf/97-10133.pdf,4/21/1997, MENTAX,,,MENTAX,1,98,Anthony,5021458,,,,"Penederm, Inc.",1201,638,563,1993-07-07,1993-07-07,1996-10-18,NDA 20-524,866,20524,,,,,,,,,,,Mentax,butenafine hydrochloride,Penederm,NDA,20524,,1995-04-05,1996-10-18,1996,treatment of interdigital tinea pedis,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PATANOLSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PATANOL<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 29143,97-14108,https://www.federalregister.gov/documents/1997/05/29/97-14108/determination-of-regulatory-review-period-for-purposes-of-patent-extension-patanolsuptmsup,https://www.govinfo.gov/content/pkg/FR-1997-05-29/pdf/97-14108.pdf,5/29/1997, PATANOLSUPTM/SUP,,,,0,98,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ALLEGRASUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ALLEGRA<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 37267,97-18125,https://www.federalregister.gov/documents/1997/07/11/97-18125/determination-of-regulatory-review-period-for-purposes-of-patent-extension-allegrasuptmsup,https://www.govinfo.gov/content/pkg/FR-1997-07-11/pdf/97-18125.pdf,7/11/1997, ALLEGRASUPTM/SUP,,,,0,98,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ANTISEDANRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ANTISEDAN<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",62 FR 38563,97-18911,https://www.federalregister.gov/documents/1997/07/18/97-18911/determination-of-regulatory-review-period-for-purposes-of-patent-extension-antisedanregister,https://www.govinfo.gov/content/pkg/FR-1997-07-18/pdf/97-18911.pdf,7/18/1997, ANTISEDANRegister,,,ANTISEDAN<Register>,1,99,Anthony,4689339,,,,ANTISEDAN<Register>,2663,1429,1234,1989-04-24,1989-04-24,1996-08-06,NADA 141-033,1718,141033,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; GLYSETSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GLYSET<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 38561,97-18909,https://www.federalregister.gov/documents/1997/07/18/97-18909/determination-of-regulatory-review-period-for-purposes-of-patent-extension-glysetsuptmsup,https://www.govinfo.gov/content/pkg/FR-1997-07-18/pdf/97-18909.pdf,7/18/1997, GLYSETSUPTM/SUP,,,,0,99,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZYFLOSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZYFLO<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 38562,97-18910,https://www.federalregister.gov/documents/1997/07/18/97-18910/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zyflosuptmsup,https://www.govinfo.gov/content/pkg/FR-1997-07-18/pdf/97-18910.pdf,7/18/1997, ZYFLOSUPTM/SUP,,,,0,99,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LipitorSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Lipitor<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 38564,97-18915,https://www.federalregister.gov/documents/1997/07/18/97-18915/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lipitorsuptmsup,https://www.govinfo.gov/content/pkg/FR-1997-07-18/pdf/97-18915.pdf,7/18/1997, LipitorSUPTM/SUP,,,,0,99,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ARICEPTSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ARICEPT<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 38564,97-18916,https://www.federalregister.gov/documents/1997/07/18/97-18916/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ariceptsuptmsup,https://www.govinfo.gov/content/pkg/FR-1997-07-18/pdf/97-18916.pdf,7/18/1997, ARICEPTSUPTM/SUP,,,,0,99,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NAROPINSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NAROPIN<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 38565,97-18917,https://www.federalregister.gov/documents/1997/07/18/97-18917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-naropinsuptmsup,https://www.govinfo.gov/content/pkg/FR-1997-07-18/pdf/97-18917.pdf,7/18/1997, NAROPINSUPTM/SUP,,,,0,99,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MONUROLSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MONUROL<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 38566,97-18919,https://www.federalregister.gov/documents/1997/07/18/97-18919/determination-of-regulatory-review-period-for-purposes-of-patent-extension-monurolsuptmsup,https://www.govinfo.gov/content/pkg/FR-1997-07-18/pdf/97-18919.pdf,7/18/1997, MONUROLSUPTM/SUP,,,,0,99,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ProstaScintSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ProstaScint<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biologic product.",62 FR 39002,97-19011,https://www.federalregister.gov/documents/1997/07/21/97-19011/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prostascintsuptmsup,https://www.govinfo.gov/content/pkg/FR-1997-07-21/pdf/97-19011.pdf,7/21/1997, ProstaScintSUPTM/SUP,,,,0,99,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; BAKSUPTM/SUP Interbody Fusion System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BAK<SUP>TM</SUP> Interbody Fusion System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",62 FR 40829,97-19984,https://www.federalregister.gov/documents/1997/07/30/97-19984/determination-of-regulatory-review-period-for-purposes-of-patent-extension-baksuptmsup-interbody,https://www.govinfo.gov/content/pkg/FR-1997-07-30/pdf/97-19984.pdf,7/30/1997, BAKSUPTM/SUP Interbody Fusion System,,,,0,99,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; INTEGRARegister Artificial Skin,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INTEGRA<Register> Artificial Skin and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",62 FR 44477,97-22266,https://www.federalregister.gov/documents/1997/08/21/97-22266/determination-of-regulatory-review-period-for-purposes-of-patent-extension-integraregister,https://www.govinfo.gov/content/pkg/FR-1997-08-21/pdf/97-22266.pdf,8/21/1997, INTEGRARegister Artificial Skin,,,INTEGRA<Register> Artificial Skin,1,100,Anthony,4947840,,,,the Massachusetts Institute of Technology,4477,3173,1304,1983-11-30,1983-11-30,1996-03-01,PMA P900033,923,900033,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PRELAYSUPTM/SUP and REZULINSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PRELAY<SUP>TM</SUP> and REZULIN<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",62 FR 46501,97-23244,https://www.federalregister.gov/documents/1997/09/03/97-23244/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prelaysuptmsup-and,https://www.govinfo.gov/content/pkg/FR-1997-09-03/pdf/97-23244.pdf,9/3/1997, PRELAYSUPTM/SUP and REZULINSUPTM/SUP,,,,0,100,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LEVAQUINSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LEVAQUIN<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 18204,98-9703,https://www.federalregister.gov/documents/1998/04/14/98-9703/determination-of-regulatory-review-period-for-purposes-of-patent-extension-levaquinsuptmsup,https://www.govinfo.gov/content/pkg/FR-1998-04-14/pdf/98-9703.pdf,4/14/1998, LEVAQUINSUPTM/SUP,,,,0,100,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZAGAMRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZAGAM<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 18431,98-9864,https://www.federalregister.gov/documents/1998/04/15/98-9864/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zagamregister,https://www.govinfo.gov/content/pkg/FR-1998-04-15/pdf/98-9864.pdf,4/15/1998, ZAGAMRegister,,,ZAGAM<Register>,1,101,Anthony,4795751,,,,"Dainippon Pharmaceutical Co., Ltd.",2030,1671,359,1991-06-01,1991-06-01,1996-12-19,NDA 20-677,1194,20677,,,,,,,,,,,Zagam,sparfloxacin,Rhone-Poulenc Rorer,NDA,20677,,1995-12-27,1996-12-19,1996,indicated for the treatment of adults with the following infections caused by susceptible strains of designated organisms: community-acquired pneumonia; acute bacterial exacerbations of chronic bronchitis,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LIPOSORBERRegister LA-15 System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LIPOSORBER<Register> LA-15 System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",63 FR 24557,98-11682,https://www.federalregister.gov/documents/1998/05/04/98-11682/determination-of-regulatory-review-period-for-purposes-of-patent-extension-liposorberregister-la-15,https://www.govinfo.gov/content/pkg/FR-1998-05-04/pdf/98-11682.pdf,5/4/1998, LIPOSORBERRegister LA-15 System,,,LIPOSORBER<Register> LA-15 System,1,102,Anthony,4637994,,,,Kanegafuchi Kagaku Kogyo Kabushiki Kaisha,3598,1995,1603,1986-04-18,1996-04-18,1996-02-21,PMA 880019,1825,880019,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; IVOMECRegister EPRINEXSUPTM/SUP Pour-On for Beef and Dairy Cattle,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IVOMEC<Register> EPRINEX<SUP>TM</SUP> Pour-On for Beef and Dairy Cattle and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",63 FR 36922,98-18141,https://www.federalregister.gov/documents/1998/07/08/98-18141/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ivomecregister,https://www.govinfo.gov/content/pkg/FR-1998-07-08/pdf/98-18141.pdf,7/8/1998, IVOMECRegister EPRINEXSUPTM/SUP Pour-On for Beef and Dairy Cattle,,,Beef and Dairy Cattle,1,103,Anthony,4427663,,,,"Merck & Co., Inc.",2492,2475,17,1990-06-22,1990-06-22,1997-04-16,NADA 141-079,1255,141079,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; STROMECTOLRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for STROMECTOL<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 37398,98-18400,https://www.federalregister.gov/documents/1998/07/10/98-18400/determination-of-regulatory-review-period-for-purposes-of-patent-extension-stromectolregister,https://www.govinfo.gov/content/pkg/FR-1998-07-10/pdf/98-18400.pdf,7/10/1998, STROMECTOLRegister,,,STROMECTOL<Register>,1,104,Anthony,4199569,,,,"Merck & Co., Inc.",2291,2055,236,1990-08-17,1990-08-17,1996-11-22,NDA 50-742,1026,50742,,,,,,,,,,,Stromectol,ivermectin,Merck,NDA,50742,,1996-04-01,1996-11-22,1996,indicated for the treatment of intestinal strongyloidiasis due to the nematode parasite Strongyloides stercoralis; also indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus,,Priority,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; VERLUMASUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VERLUMA<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",63 FR 37397,98-18408,https://www.federalregister.gov/documents/1998/07/10/98-18408/determination-of-regulatory-review-period-for-purposes-of-patent-extension-verlumasuptmsup,https://www.govinfo.gov/content/pkg/FR-1998-07-10/pdf/98-18408.pdf,7/10/1998, VERLUMASUPTM/SUP,,,,0,104,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FlowmaxSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Flowmax<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 37399,98-18407,https://www.federalregister.gov/documents/1998/07/10/98-18407/determination-of-regulatory-review-period-for-purposes-of-patent-extension-flowmaxsuptmsup,https://www.govinfo.gov/content/pkg/FR-1998-07-10/pdf/98-18407.pdf,7/10/1998, FlowmaxSUPTM/SUP,,,,0,104,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PANDEL Cream,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PANDEL Cream and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 38410,98-18878,https://www.federalregister.gov/documents/1998/07/16/98-18878/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pandel-cream,https://www.govinfo.gov/content/pkg/FR-1998-07-16/pdf/98-18878.pdf,7/16/1998, PANDEL Cream,,,PANDEL Cream,1,105,Anthony,4290962,,,,Taisho Pharmaceutical Co. Ltd.,4165,3078,1087,1985-10-06,1985-10-06,1997-02-28,NDA 20-453,1096,20453,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; QUADRAMETRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for QUADRAMET<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 38656,98-19027,https://www.federalregister.gov/documents/1998/07/17/98-19027/determination-of-regulatory-review-period-for-purposes-of-patent-extension-quadrametregister,https://www.govinfo.gov/content/pkg/FR-1998-07-17/pdf/98-19027.pdf,7/17/1998, QUADRAMETRegister,,,QUADRAMET<Register>,1,106,Anthony,4898724,,,,The Dow Chemical Co.,2844,2189,655,1989-06-16,1989-05-16,1997-03-28,IND 33,1412,33,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FlowmaxSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Flowmax<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 39097,98-19379,https://www.federalregister.gov/documents/1998/07/21/98-19379/determination-of-regulatory-review-period-for-purposes-of-patent-extension-flowmaxsuptmsup,https://www.govinfo.gov/content/pkg/FR-1998-07-21/pdf/98-19379.pdf,7/21/1998, FlowmaxSUPTM/SUP,,,,0,106,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; GEMZARRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GEMZAR<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 41263,98-20593,https://www.federalregister.gov/documents/1998/08/03/98-20593/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gemzarregister,https://www.govinfo.gov/content/pkg/FR-1998-08-03/pdf/98-20593.pdf,8/3/1998, GEMZARRegister,,,GEMZAR<Register>,1,107,Anthony,4808614,,,,Eli Lilly & Co.,3293,2824,469,1987-05-12,1987-05-12,1996-05-15,NDA 20-509,1537,20509,,,,,,,,,,,Gemzar,gemcitabine hydrochloride,Lilly,NDA,20509,,1995-02-02,1996-05-15,1996,first-line treatment for patients with locally advanced (nonresectable stage II or III) or metastatic (stage IV) adenocarcinoma of the pancreas; also indicated for patients previously treated with 5-fluorouracil,,Priority,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PosicorRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Posicor<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 41582,98-20743,https://www.federalregister.gov/documents/1998/08/04/98-20743/determination-of-regulatory-review-period-for-purposes-of-patent-extension-posicorregister,https://www.govinfo.gov/content/pkg/FR-1998-08-04/pdf/98-20743.pdf,8/4/1998, PosicorRegister,,,Posicor<Register>,1,108,Anthony,4808605,,,,"Hoffman-La Roche, Inc.",1793,1326,467,1992-07-25,1992-07-25,1997-06-20,NDA 20-689,1130,20689,,,,,,,,,,,Posicor,mibefradil dihydrochloride,Roche,NDA,20689,,1996-03-11,1997-06-20,1997,treatment of hypertension and chronic stable angina pectoris,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AniprylRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Anipryl<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",63 FR 41578,98-20708,https://www.federalregister.gov/documents/1998/08/04/98-20708/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aniprylregister,https://www.govinfo.gov/content/pkg/FR-1998-08-04/pdf/98-20708.pdf,8/4/1998, AniprylRegister,,,Anipryl<Register>,1,109,Anthony,5192808,,,,"Deprenyl Animal Health, Inc.",2329,2275,54,1991-01-15,1997-05-30,1997-05-30,NADA 141-080,448,141080,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DostinexRegister Tablets,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Dostinex<Register> Tablets and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 41581,98-20739,https://www.federalregister.gov/documents/1998/08/04/98-20739/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dostinexregister-tablets,https://www.govinfo.gov/content/pkg/FR-1998-08-04/pdf/98-20739.pdf,8/4/1998, DostinexRegister Tablets,,,Dostinex<Register> Tablets,1,110,Anthony,4526892,,,,Upjohn & Pharmacia,2188,1825,363,1990-12-29,1990-12-29,1996-12-23,NDA 20-664,1273,20664,,,,,,,,,,,Dostinex,cabergoline,Pharmacia and Upjohn,NDA,20664,,1995-12-27,1996-12-23,1996,"treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas",,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; BeneFIXSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BeneFIX<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",63 FR 41579,98-20742,https://www.federalregister.gov/documents/1998/08/04/98-20742/determination-of-regulatory-review-period-for-purposes-of-patent-extension-benefixsuptmsup,https://www.govinfo.gov/content/pkg/FR-1998-08-04/pdf/98-20742.pdf,8/4/1998, BeneFIXSUPTM/SUP,,,,0,110,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AQUEOUS ARYL FLUOROPHOSPHITE SUSPENSION,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AQUEOUS ARYL FLUOROPHOSPHITE SUSPENSION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that food additive.",63 FR 41580,98-20707,https://www.federalregister.gov/documents/1998/08/04/98-20707/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aqueous-aryl,https://www.govinfo.gov/content/pkg/FR-1998-08-04/pdf/98-20707.pdf,8/4/1998, AQUEOUS ARYL FLUOROPHOSPHITE SUSPENSION,,,,0,110,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ETOPOPHOSRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ETOPOPHOS<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 41859,98-20826,https://www.federalregister.gov/documents/1998/08/05/98-20826/determination-of-regulatory-review-period-for-purposes-of-patent-extension-etopophosregister,https://www.govinfo.gov/content/pkg/FR-1998-08-05/pdf/98-20826.pdf,8/5/1998, ETOPOPHOSRegister,,,ETOPOPHOS<Register>,1,111,Anthony,4904768,,,,Bristol-Myers Squibb Co.,1719,1029,690,1991-09-04,1991-09-04,1996-05-17,NDA 20-457,1017,20457,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MirapexRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Mirapex<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 42407,98-21090,https://www.federalregister.gov/documents/1998/08/07/98-21090/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mirapexregister,https://www.govinfo.gov/content/pkg/FR-1998-08-07/pdf/98-21090.pdf,8/7/1998, MirapexRegister,,,Mirapex<Register>,1,112,Anthony,4886812,,,,Boehringer Ingelheim International GmbH,2576,2024,552,1990-06-14,1990-06-14,1997-07-01,NDA 20-667,1440,20667,,,,,,,,,,,Mirapex,pramipexole dihydrochloride,Pharmacia and Upjohn,NDA,20667,,1995-12-28,1997-07-01,1997,treatment of the signs and symptoms of idiopathic Parkinson's disease,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Aqueous Aryl Fluorophosphite Suspension,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Aqueous Aryl Fluorophosphite Suspension and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that food additive.",63 FR 42405,98-21130,https://www.federalregister.gov/documents/1998/08/07/98-21130/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aqueous-aryl,https://www.govinfo.gov/content/pkg/FR-1998-08-07/pdf/98-21130.pdf,8/7/1998, Aqueous Aryl Fluorophosphite Suspension,,,,0,112,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Cook GRIISUPTM/SUP Coronary Stent,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Cook GRII<SUP>TM</SUP> Coronary Stent and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",63 FR 42408,98-21089,https://www.federalregister.gov/documents/1998/08/07/98-21089/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cook-griisuptmsup,https://www.govinfo.gov/content/pkg/FR-1998-08-07/pdf/98-21089.pdf,8/7/1998, Cook GRIISUPTM/SUP Coronary Stent,,,,0,112,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FarestonRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Fareston<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product. ADDRESSES: Written comments and petitions should be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.",63 FR 42857,98-21407,https://www.federalregister.gov/documents/1998/08/11/98-21407/determination-of-regulatory-review-period-for-purposes-of-patent-extension-farestonregister,https://www.govinfo.gov/content/pkg/FR-1998-08-11/pdf/98-21407.pdf,8/11/1998, FarestonRegister,,,Fareston<Register>,1,113,Anthony,4696949,,,,ORION-YHTYMA OY,3706,2828,878,1987-04-08,1987-04-08,1997-05-29,NDA 20-497,1827,20497,,,,,,,,,,,Fareston,toremifene citrate,Orion,NDA,20497,,1995-01-03,1997-05-29,1997,treatment of metastatic breast cancer in postmenopausal women with estrogen receptor positive or receptor unknown tumors,,Standard,Yes,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Silvacote K,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Silvacote K and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that food additive.",63 FR 51939,98-25908,https://www.federalregister.gov/documents/1998/09/29/98-25908/determination-of-regulatory-review-period-for-purposes-of-patent-extension-silvacote-k,https://www.govinfo.gov/content/pkg/FR-1998-09-29/pdf/98-25908.pdf,9/29/1998, Silvacote K,,,,0,113,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SkelidRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Skelid<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 54481,98-27078,https://www.federalregister.gov/documents/1998/10/09/98-27078/determination-of-regulatory-review-period-for-purposes-of-patent-extension-skelidregister,https://www.govinfo.gov/content/pkg/FR-1998-10-09/pdf/98-27078.pdf,10/9/1998, SkelidRegister,,,Skelid<Register>,1,114,Anthony,4876248,,,,"Sanofi Pharmaceuticals, Inc.",2013,1639,374,1991-09-04,1991-09-04,1997-03-07,NDA 20-707,1192,20707,,,,,,,,,,,Skelid,tiludronate disodium,Sanofi Winthrop,NDA,20707,,1996-02-28,1997-03-07,1997,treatment of Paget's disease of bone,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Rimadyl,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Rimadyl and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",63 FR 54716,98-27285,https://www.federalregister.gov/documents/1998/10/13/98-27285/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rimadyl,https://www.govinfo.gov/content/pkg/FR-1998-10-13/pdf/98-27285.pdf,10/13/1998, Rimadyl,,,Rimadyl,1,115,Anthony,4264500,,,,Pfizer Inc.,6572,5910,662,1978-10-30,1996-10-25,1996-10-25,NADA 141-053,1095,141053,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NormifloRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Normiflo<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 54717,98-27286,https://www.federalregister.gov/documents/1998/10/13/98-27286/determination-of-regulatory-review-period-for-purposes-of-patent-extension-normifloregister,https://www.govinfo.gov/content/pkg/FR-1998-10-13/pdf/98-27286.pdf,10/13/1998, NormifloRegister,,,Normiflo<Register>,1,116,Anthony,4757057,,,,Pharmacia & Upjohn Aktiebolag,3503,1883,1620,1987-10-22,1987-10-22,1997-05-23,NDA 20-227,1820,20227,,,,,,,,,,,Normiflo,ardeparin sodium,Wyeth-Ayerst,NDA,20227,,1992-12-16,1997-05-23,1997,prevention of deep venous thrombosis which may lead to pulmonary embolism following knee replacement surgery,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CorlopamRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Corlopam<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 54718,98-27357,https://www.federalregister.gov/documents/1998/10/13/98-27357/determination-of-regulatory-review-period-for-purposes-of-patent-extension-corlopamregister,https://www.govinfo.gov/content/pkg/FR-1998-10-13/pdf/98-27357.pdf,10/13/1998, CorlopamRegister,,,Corlopam<Register>,1,117,Anthony,4197297,,,,Neurex Corp.,5081,1873,3208,1983-10-28,1983-10-28,1997-09-23,NDA 19-922,730,19922,,,,,,,,,,,Corlopam,fenoldopam mesylate,Neurex,NDA,19922,,1988-12-12,1997-09-23,1997,"indicated for the in-hospital, short-term (up to 48 hours) use in the management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function",,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; WiktorRegister Prime Coronary Stent System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Wiktor<Register> Prime Coronary Stent System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",63 FR 54720,98-27392,https://www.federalregister.gov/documents/1998/10/13/98-27392/determination-of-regulatory-review-period-for-purposes-of-patent-extension-wiktorregister-prime,https://www.govinfo.gov/content/pkg/FR-1998-10-13/pdf/98-27392.pdf,10/13/1998, WiktorRegister Prime Coronary Stent System,,,Wiktor<Register> Prime Coronary Stent System,1,118,Anthony,4886062,,,,"Medtronic, Inc.",2489,2066,423,1990-09-05,1990-09-05,1997-06-27,PMA P960010,1347,960010,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Ray Threaded Fusion CageSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Ray Threaded Fusion Cage<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",63 FR 54719,98-27284,https://www.federalregister.gov/documents/1998/10/13/98-27284/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ray-threaded-fusion,https://www.govinfo.gov/content/pkg/FR-1998-10-13/pdf/98-27284.pdf,10/13/1998, Ray Threaded Fusion CageSUPTM/SUP,,,,0,118,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Determination of Regulatory Review Period for Purposes of Patent Extension; AldaraSUPTM/SUP (4,689,338)",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Aldara<SUP>TM</SUP> (4,689,338) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 55398,98-27584,https://www.federalregister.gov/documents/1998/10/15/98-27584/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aldarasuptmsup-4689338,https://www.govinfo.gov/content/pkg/FR-1998-10-15/pdf/98-27584.pdf,10/15/1998," AldaraSUPTM/SUP (4,689,338)",,,,0,118,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Determination of Regulatory Review Period for Purposes of Patent Extension; AldaraSUPTM/SUP (5,238,944)",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Aldara<SUP>TM</SUP> (5,238,944) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 56035,98-27995,https://www.federalregister.gov/documents/1998/10/20/98-27995/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aldarasuptmsup-5238944,https://www.govinfo.gov/content/pkg/FR-1998-10-20/pdf/98-27995.pdf,10/20/1998," AldaraSUPTM/SUP (5,238,944)",,,,0,118,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Neuro Cybernetic Prosthesis (NCPRegister) System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Neuro Cybernetic Prosthesis (NCP<Register>) System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",63 FR 63066,98-30005,https://www.federalregister.gov/documents/1998/11/10/98-30005/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neuro-cybernetic,https://www.govinfo.gov/content/pkg/FR-1998-11-10/pdf/98-30005.pdf,11/10/1998, Neuro Cybernetic Prosthesis (NCPRegister) System,,,,0,118,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AvaproRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Avapro<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 64268,98-30990,https://www.federalregister.gov/documents/1998/11/19/98-30990/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avaproregister,https://www.govinfo.gov/content/pkg/FR-1998-11-19/pdf/98-30990.pdf,11/19/1998, AvaproRegister,,,Avapro<Register>,1,119,Anthony,5270317,,,,Sanofi,1616,1246,370,1993-04-30,1993-04-30,1997-09-30,NDA 20-757,194,20757,,,,,,,,,,,Avapro,irbesartan,Sanofi,NDA,20757,,1996-09-26,1997-09-30,1997,treatment of hypertension,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SeroquelRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Seroquel<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 64721,98-31101,https://www.federalregister.gov/documents/1998/11/23/98-31101/determination-of-regulatory-review-period-for-purposes-of-patent-extension-seroquelregister,https://www.govinfo.gov/content/pkg/FR-1998-11-23/pdf/98-31101.pdf,11/23/1998, SeroquelRegister,,,Seroquel<Register>,1,120,Anthony,4879288,,,,Zeneca Inc.,3264,2839,425,1988-10-21,1988-10-21,1997-09-26,NDA 20-639,1651,20639,,,,,,,,,,,Seroquel,quetiapine fumarate,Zeneca,NDA,20639,,1996-07-29,1997-09-26,1997,treatment of the manifestations of psychotic disorders,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Tisseel VH Kit,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Tisseel VH Kit and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",63 FR 65211,98-31413,https://www.federalregister.gov/documents/1998/11/25/98-31413/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tisseel-vh-kit,https://www.govinfo.gov/content/pkg/FR-1998-11-25/pdf/98-31413.pdf,11/25/1998, Tisseel VH Kit,,,Tisseel VH Kit,1,121,Anthony,4362567,,,,Immuno Aktiengesellschaft fur chemsih-medizinshe Produkte,5065,1203,3862,1984-06-20,1984-06-20,1998-05-01,PLA 87-,1827,87,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Tasmar,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Tasmar and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 65599,98-31576,https://www.federalregister.gov/documents/1998/11/27/98-31576/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tasmar,https://www.govinfo.gov/content/pkg/FR-1998-11-27/pdf/98-31576.pdf,11/27/1998, Tasmar,,,Tasmar<Register>,1,122,Anthony,5236952,,,,"Hoffman-La Roche, Inc.",2618,2014,604,1990-12-01,1990-12-01,1998-01-29,NDA 20-697,530,20697,,,,,,,,,,,Tasmar,tolcapone,Roche,NDA,20697,,1996-06-05,1998-01-29,1998,indicated as an adjunct to levodopa and carbidopa for the treatment of the signs and symptoms of idiopathic Parkinsons disease,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VitreonRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Vitreon<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",63 FR 69633,98-33457,https://www.federalregister.gov/documents/1998/12/17/98-33457/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vitreonregister,https://www.govinfo.gov/content/pkg/FR-1998-12-17/pdf/98-33457.pdf,12/17/1998, VitreonRegister,,,Vitreon<Register>,1,123,Anthony,4490351,,,,"Vitrophage, Inc.",2729,603,2126,1990-04-13,1990-04-13,1997-09-30,PMA P910068,1826,910068,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Silicone AMORegister ARRAYRegister Multifocal IOL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Silicone AMO<Register> ARRAY<Register> multifocal IOL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",63 FR 69632,98-33453,https://www.federalregister.gov/documents/1998/12/17/98-33453/determination-of-regulatory-review-period-for-purposes-of-patent-extension-silicone-amoregister,https://www.govinfo.gov/content/pkg/FR-1998-12-17/pdf/98-33453.pdf,12/17/1998, Silicone AMORegister ARRAYRegister Multifocal IOL,,,Silicone AMO<Register> ARRAY<Register> multifocal IOL,1,124,Anthony,4898461,,,,"Vision Pharmaceuticals, L.P.",2846,2478,368,1989-11-22,1989-11-22,1997-09-05,PMA P960028,1533,960028,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Sucralose,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Sucralose and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that food additive.",63 FR 70411,98-33638,https://www.federalregister.gov/documents/1998/12/21/98-33638/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sucralose,https://www.govinfo.gov/content/pkg/FR-1998-12-21/pdf/98-33638.pdf,12/21/1998, Sucralose,,,,0,124,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Requip,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Requip and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 70411,98-33639,https://www.federalregister.gov/documents/1998/12/21/98-33639/determination-of-regulatory-review-period-for-purposes-of-patent-extension-requip,https://www.govinfo.gov/content/pkg/FR-1998-12-21/pdf/98-33639.pdf,12/21/1998, Requip,,,Requip,1,125,Anthony,4452808,,,,SmithKline Beecham Corp.,3356,2729,627,1988-07-14,1988-07-14,1997-09-19,NDA 20-658,1826,20658,,,,,,,,,,,Requip,ropinirole hydrochloride,SmithKline Beecham,NDA,20658,,1996-01-02,1997-09-19,1997,treatment of the signs and symptoms of idiopathic Parkinson's disease,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MeridiaRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Meridia<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",63 FR 71493,98-34171,https://www.federalregister.gov/documents/1998/12/28/98-34171/determination-of-regulatory-review-period-for-purposes-of-patent-extension-meridiaregister,https://www.govinfo.gov/content/pkg/FR-1998-12-28/pdf/98-34171.pdf,12/28/1998, MeridiaRegister,,,Meridia<Register>,1,126,Anthony,4746680,,,,Knoll Aktiengesellschaft,4323,3486,837,1986-01-23,1986-01-23,1997-11-22,NDA 20-632,1825,20632,,,,,,,,,,,Meridia,sibutramine hydrochloride,Knoll  Pharmacuticals,NDA,20632,,1995-08-09,1997-11-22,1997,"indicated for the management of obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a reduced calorie diet",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; AnzemetRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Anzemet<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 3953,99-1710,https://www.federalregister.gov/documents/1999/01/26/99-1710/determination-of-regulatory-review-period-for-purposes-of-patent-extension-anzemetregister,https://www.govinfo.gov/content/pkg/FR-1999-01-26/pdf/99-1710.pdf,1/26/1999, AnzemetRegister,,,Anzemet<Register>,1,127,Anthony,4906755,,,,"Hoechst Marion Roussel, Inc.",2443,1729,714,1991-01-05,1991-01-05,1997-09-11,NDA 20-623,1578,20623,,,,,,,,,,,Anzemet,dolasetron mesylate,Hoechst Marion Roussel,NDA,20623,20624,1995-09-29,1997-09-11,1997,prevention of chemotherapy-induced nausea and vomiting; prevention of postoperative nausea and vomiting,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ViagraSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Viagra<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 4115,99-1796,https://www.federalregister.gov/documents/1999/01/27/99-1796/determination-of-regulatory-review-period-for-purposes-of-patent-extension-viagrasuptmsup,https://www.govinfo.gov/content/pkg/FR-1999-01-27/pdf/99-1796.pdf,1/27/1999, ViagraSUPTM/SUP,,,,0,127,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; XelodaSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Xeloda<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 4115,99-1851,https://www.federalregister.gov/documents/1999/01/27/99-1851/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xelodasuptmsup,https://www.govinfo.gov/content/pkg/FR-1999-01-27/pdf/99-1851.pdf,1/27/1999, XelodaSUPTM/SUP,,,,0,127,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; EmadineSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Emadine<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 4116,99-1792,https://www.federalregister.gov/documents/1999/01/27/99-1792/determination-of-regulatory-review-period-for-purposes-of-patent-extension-emadinesuptmsup,https://www.govinfo.gov/content/pkg/FR-1999-01-27/pdf/99-1792.pdf,1/27/1999, EmadineSUPTM/SUP,,,,0,127,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Determination of Regulatory Review Period for Purposes of Patent Extension; Prandin (5,312,924)",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Prandin and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 4426,99-1937,https://www.federalregister.gov/documents/1999/01/28/99-1937/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prandin-5312924,https://www.govinfo.gov/content/pkg/FR-1999-01-28/pdf/99-1937.pdf,1/28/1999," Prandin (5,312,924)",,,Prandin,1,128,Anthony,5312924,,,,Dr. Karl Thomae GmbH,2091,1916,175,1992-04-03,1992-04-03,1997-12-22,NDA 20-741,747,20741,,,,,,,,,,,Prandin,repaglinide,Novo Nordisk,NDA,20741,,1997-07-01,1997-12-22,1997,"indicated as an adjunct to diet and exercise to lower blood glucose in patients with non-insulin dependent (type 2) diabetes whose hyperglycemia cannot be controlled satisfactorily by diet and exercise alone; in combination with metformin to lower blood glucose in patients whose hyperglycemia cannot be controlled satisfactorily by exercise, diet, and either repaglinide or metformin alone",,Priority,No,No,,No
"Determination of Regulatory Review Period for Purposes of Patent Extension; PrandinSUPTM/SUP (5,216,167)",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Prandin<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 4425,99-1936,https://www.federalregister.gov/documents/1999/01/28/99-1936/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prandinsuptmsup-5216167,https://www.govinfo.gov/content/pkg/FR-1999-01-28/pdf/99-1936.pdf,1/28/1999," PrandinSUPTM/SUP (5,216,167)",,,,0,128,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Zemplar,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Zemplar and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 10003,99-4877,https://www.federalregister.gov/documents/1999/03/01/99-4877/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zemplar,https://www.govinfo.gov/content/pkg/FR-1999-03-01/pdf/99-4877.pdf,3/1/1999, Zemplar,,,Zemplar,1,129,Anthony,5246925,,,,Wisconsin Alumni Research Foundation,1079,623,456,1995-05-06,1995-05-06,1998-04-17,NDA 20-819,574,20819,10/27/2015,Treatment of pediatric hyperparathyroidism,Designated/Approved,,,Indicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 and CKD Stage 5 in patients on hemodialysis or peritoneal dialysis,10/18/2016,10/18/2023,Indicated in pediatric patients ages 10 -16 years for treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 and pediatric patients ages 10-16 years for treatment of secondary hyperparathyroidism associated with CKD Stage 5.,"Abbvie, inc.",Zemplar,paricalcitol,Abbott Laboratories,NDA,20819,,1997-01-17,1998-04-17,1998,prevention and treatment of secondary hyperparathyroidism encountered with chronic renal failure,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Atacand,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Atacand and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 10156,99-5032,https://www.federalregister.gov/documents/1999/03/02/99-5032/determination-of-regulatory-review-period-for-purposes-of-patent-extension-atacand,https://www.govinfo.gov/content/pkg/FR-1999-03-02/pdf/99-5032.pdf,3/2/1999, Atacand,,,Atacand,1,130,Anthony,5196444,,,,Takeda Chemical Industries Ltd.,1087,686,401,1995-06-15,1995-06-15,1998-06-04,NDA 20,413,20,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SingulairRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Singulair<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 10304,99-5132,https://www.federalregister.gov/documents/1999/03/03/99-5132/determination-of-regulatory-review-period-for-purposes-of-patent-extension-singulairregister,https://www.govinfo.gov/content/pkg/FR-1999-03-03/pdf/99-5132.pdf,3/3/1999, SingulairRegister,,,Singulair<Register>,1,131,Anthony,5565473,,,,Merck & Co.,2090,1725,365,1992-06-03,1992-06-03,1998-02-20,NDA 20-,428,20,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LumenHanceRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LumenHance<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 10303,99-5130,https://www.federalregister.gov/documents/1999/03/03/99-5130/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lumenhanceregister,https://www.govinfo.gov/content/pkg/FR-1999-03-03/pdf/99-5130.pdf,3/3/1999, LumenHanceRegister,,,LumenHance<Register>,1,132,Anthony,5368840,,,,Bracco Diagnostics Inc.,1796,1067,729,1993-01-18,1993-01-20,1997-12-19,NDA 20-686,20,20686,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; RegranexRegister and Becaplermin Concentrate,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Regranex<Register> and Becaplermin Concentrate and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims those human biological products.",64 FR 10474,99-5388,https://www.federalregister.gov/documents/1999/03/04/99-5388/determination-of-regulatory-review-period-for-purposes-of-patent-extension-regranexregister-and,https://www.govinfo.gov/content/pkg/FR-1999-03-04/pdf/99-5388.pdf,3/4/1999, RegranexRegister and Becaplermin Concentrate,,,Regranex<Register> and Becaplermin Concentrate,1,133,Anthony,4845075,,,,"ZymoGenetics, Inc.",2790,2424,366,1990-04-29,1990-04-29,1997-12-16,PLA 96-1408,1593,961408,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AmergeSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Amerge<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 23086,99-10698,https://www.federalregister.gov/documents/1999/04/29/99-10698/determination-of-regulatory-review-period-for-purposes-of-patent-extension-amergesuptmsup,https://www.govinfo.gov/content/pkg/FR-1999-04-29/pdf/99-10698.pdf,4/29/1999, AmergeSUPTM/SUP,,,,0,133,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Gonal-FRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Gonal-F<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 23338,99-10846,https://www.federalregister.gov/documents/1999/04/30/99-10846/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gonal-fregister,https://www.govinfo.gov/content/pkg/FR-1999-04-30/pdf/99-10846.pdf,4/30/1999, Gonal-FRegister,,,Gonal-F<Register>,1,134,Anthony,5156957,,,,Genzyme Corp.,2044,569,1475,1992-02-26,1992-02-26,1997-09-29,NDA 20-378,1605,20378,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ApligrafSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Apligraf<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",64 FR 23339,99-10795,https://www.federalregister.gov/documents/1999/04/30/99-10795/determination-of-regulatory-review-period-for-purposes-of-patent-extension-apligrafsuptmsup,https://www.govinfo.gov/content/pkg/FR-1999-04-30/pdf/99-10795.pdf,4/30/1999, ApligrafSUPTM/SUP,,,,0,134,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FemaraRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Femara<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 25046,99-11584,https://www.federalregister.gov/documents/1999/05/10/99-11584/determination-of-regulatory-review-period-for-purposes-of-patent-extension-femararegister,https://www.govinfo.gov/content/pkg/FR-1999-05-10/pdf/99-11584.pdf,5/10/1999, FemaraRegister,,,Femara<Register>,1,135,Anthony,4978672,,,,Novartis Corp.,2160,1794,366,1991-08-28,1991-08-28,1997-07-25,NDA 20-726,1232,20726,,,,,,,,,,,Femara,letrozole,Novartis Pharmaceuticals,NDA,20726,,1996-07-25,1997-07-25,1997,indicated for the treatment of advanced breast cancer in postmenopausal women,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DenavirSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Denavir<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 25047,99-11585,https://www.federalregister.gov/documents/1999/05/10/99-11585/determination-of-regulatory-review-period-for-purposes-of-patent-extension-denavirsuptmsup,https://www.govinfo.gov/content/pkg/FR-1999-05-10/pdf/99-11585.pdf,5/10/1999, DenavirSUPTM/SUP,,,,0,135,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; GenESARegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GenESA<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 25350,99-11822,https://www.federalregister.gov/documents/1999/05/11/99-11822/determination-of-regulatory-review-period-for-purposes-of-patent-extension-genesaregister,https://www.govinfo.gov/content/pkg/FR-1999-05-11/pdf/99-11822.pdf,5/11/1999, GenESARegister,,,GenESA<Register>,1,136,Anthony,5234404,,,,"Gensia Sicor, Inc.",2641,1295,1346,1990-06-22,1990-06-22,1997-09-12,NDA 20-420,399,20420,,,,,,,,,,,Genesa,arbutamine hydrochloride,Gensia,NDA,20420,,1994-01-06,1997-09-12,1997,indicated for us as an aid in diagnosing the presence or absence of coronary artery disease in patients who cannot exercise adequately when used in conjunction with radionuclide myocardial perfusion imaging or echocardiography,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AggrastatRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Aggrastat<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 25350,99-11821,https://www.federalregister.gov/documents/1999/05/11/99-11821/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aggrastatregister,https://www.govinfo.gov/content/pkg/FR-1999-05-11/pdf/99-11821.pdf,5/11/1999, AggrastatRegister,,,Aggrastat<Register>,1,137,Anthony,5292756,,,,Merck & Co.,2247,2051,196,1992-03-21,1992-03-21,1998-05-14,NDA 20-912,433,20912,,,,,,,,,,,Aggrastat,tirofiban hydrochloride,Merck,NDA,20912,20913,1997-10-31,1998-05-14,1998,"in combination with heparin, for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy",,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LotemaxSUPTM/SUP and AlrexSUPTM/SUP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Lotemax<SUP>TM</SUP> and Alrex<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 26986,99-12392,https://www.federalregister.gov/documents/1999/05/18/99-12392/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lotemaxsuptmsup-and,https://www.govinfo.gov/content/pkg/FR-1999-05-18/pdf/99-12392.pdf,5/18/1999, LotemaxSUPTM/SUP and AlrexSUPTM/SUP,,,,0,137,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Trovan,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Trovan and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 27272,99-12526,https://www.federalregister.gov/documents/1999/05/19/99-12526/determination-of-regulatory-review-period-for-purposes-of-patent-extension-trovan,https://www.govinfo.gov/content/pkg/FR-1999-05-19/pdf/99-12526.pdf,5/19/1999, Trovan,,,Trovan,1,138,Anthony,5164402,,,,"Pfizer, Inc.",1967,1613,354,1992-08-01,1992-08-01,1997-12-18,NDA 20-759,761,20759,,,,,,,,,,,Trovan,trovafloxacin mesylate,Pfizer,NDA,20759,,1996-12-30,1997-12-18,1997,indicated for the treatment of infections caused by susceptible strains of designated microorganisms in the following conditions:,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; NeumegaRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Neumega<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",64 FR 27271,99-12527,https://www.federalregister.gov/documents/1999/05/19/99-12527/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neumegaregister,https://www.govinfo.gov/content/pkg/FR-1999-05-19/pdf/99-12527.pdf,5/19/1999, NeumegaRegister,,,Neumega<Register>,1,139,Anthony,5215895,,,,"Genetics Institute, Inc.",1854,1513,341,1992-10-30,1992-10-30,1997-11-25,PLA 96-1433,542,961433,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MonostrutSUPTM/SUP Cardiac Valve Prosthesis,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Monostrut<SUP>TM</SUP> Cardiac Valve Prosthesis and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",64 FR 27273,99-12528,https://www.federalregister.gov/documents/1999/05/19/99-12528/determination-of-regulatory-review-period-for-purposes-of-patent-extension-monostrutsuptmsup-cardiac,https://www.govinfo.gov/content/pkg/FR-1999-05-19/pdf/99-12528.pdf,5/19/1999, MonostrutSUPTM/SUP Cardiac Valve Prosthesis,,,,0,139,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TazoracRegister,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Tazorac<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 27578,99-12652,https://www.federalregister.gov/documents/1999/05/20/99-12652/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tazoracregister,https://www.govinfo.gov/content/pkg/FR-1999-05-20/pdf/99-12652.pdf,5/20/1999, TazoracRegister,,,Tazorac<Register>,1,140,Anthony,5089509,,,,"Allergan, Inc.",2684,1958,726,1990-02-08,1990-02-08,1997-06-13,NDA 20-600,845,20600,,,,,,,,,,,Tazorac,tazarotene,Allergan,NDA,20600,,1995-06-19,1997-06-13,1997,indicated for the topical treatment of patients with stable plaque psoriasis of up to 20% body surface area involvement and topical treatment of patients with facial acne vulgaris of mild to moderate severity,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; OmnicefRegister Tablets,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Omnicef<Register> Tablets and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 27578,99-12651,https://www.federalregister.gov/documents/1999/05/20/99-12651/determination-of-regulatory-review-period-for-purposes-of-patent-extension-omnicefregister-tablets,https://www.govinfo.gov/content/pkg/FR-1999-05-20/pdf/99-12651.pdf,5/20/1999, OmnicefRegister Tablets,,,Omnicef<Register> Tablets,1,141,Anthony,4559334,,,,Warner-Lambert Co.,2745,2288,457,1990-06-01,1990-06-01,1997-12-04,NDA 50-739,1601,50739,,,,,,,,,,,Omnicef,cefdinir,Parke-Davis,NDA,50739,50749,1996-09-04,1997-12-04,1997,"indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of designated microorganisms in the following conditions:  community-acquired pneumonia, acute exacerbations of chronic bronchitis, acute bacterial otitis media, acute maxillary sinusitis, pharyngitis/tonsillitis and uncomplicated skin and skin structure infections",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; OmnicefRegister Oral Suspension,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Omnicef<Register> Oral Suspension and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",64 FR 27579,99-12654,https://www.federalregister.gov/documents/1999/05/20/99-12654/determination-of-regulatory-review-period-for-purposes-of-patent-extension-omnicefregister-oral,https://www.govinfo.gov/content/pkg/FR-1999-05-20/pdf/99-12654.pdf,5/20/1999, OmnicefRegister Oral Suspension,,,Omnicef<Register> Oral Suspension,1,142,Anthony,4935507,,,,Warner-Lambert Co.,2745,2406,339,1990-06-01,1990-06-01,1997-12-04,NDA 50-749,1213,50749,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Therma ChoiceSUPTM/SUP Uterine Ballon Therapy System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Therma Choice<SUP>TM</SUP> Uterine Ballon Therapy System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",64 FR 29046,99-13671,https://www.federalregister.gov/documents/1999/05/28/99-13671/determination-of-regulatory-review-period-for-purposes-of-patent-extension-therma-choicesuptmsup,https://www.govinfo.gov/content/pkg/FR-1999-05-28/pdf/99-13671.pdf,5/28/1999, Therma ChoiceSUPTM/SUP Uterine Ballon Therapy System,,,,0,142,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZiagenTM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Ziagen<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",65 FR 4431,00-1871,https://www.federalregister.gov/documents/2000/01/27/00-1871/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ziagentm,https://www.govinfo.gov/content/pkg/FR-2000-01-27/pdf/00-1871.pdf,1/27/2000, ZiagenTM,,Benson,Ziagen (abacavir),1,143,Anthony,5034394,,,,Glaxo Wellcome,1632,1455,177,1994-07-01,1998-06-24,1998-12-17,NDA 20-977,906,20977,,,,,,,,,,,Ziagen,abacavir sulfate,Glaxo Wellcome,NDA,20977,20978,1998-06-24,1998-12-17,1998,"in combination with other antiretroviral agents, for the treatment of HIV-1 infection",,Priority,No,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; VitraveneTM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Vitravene<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",65 FR 4434,00-1874,https://www.federalregister.gov/documents/2000/01/27/00-1874/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vitravenetm,https://www.govinfo.gov/content/pkg/FR-2000-01-27/pdf/00-1874.pdf,1/27/2000, VitraveneTM,,Benson,Vitravene (fomivirsen sodium),1,144,Anthony,4689320,,,,Isis Pharmaceuticals,1738,1598,140,1993-11-24,1998-04-09,1998-08-26,NDA 30-961,954,30961,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AzoptTM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Azopt<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",65 FR 4435,00-1875,https://www.federalregister.gov/documents/2000/01/27/00-1875/determination-of-regulatory-review-period-for-purposes-of-patent-extension-azopttm,https://www.govinfo.gov/content/pkg/FR-2000-01-27/pdf/00-1875.pdf,1/27/2000, AzoptTM,,Benson,Azopt^TM (brinzolamide),1,145,Anthony,5378703,,,,Alcon Laboratories,2049,1620,429,1992-08-23,1997-01-28,1998-04-01,NDA 20-816,579,20816,,,,,,,,,,,Azopt,brinzolamide,Alcon,NDA,20816,,1997-01-28,1998-04-01,1998,treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Maxalt,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Maxalt<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",65 FR 4428,00-1865,https://www.federalregister.gov/documents/2000/01/27/00-1865/determination-of-regulatory-review-period-for-purposes-of-patent-extension-maxalt,https://www.govinfo.gov/content/pkg/FR-2000-01-27/pdf/00-1865.pdf,1/27/2000, Maxalt,,Anthony,Maxalt  (rizatriptan benzoate),1,146,Anthony,5298520,,,,Merck & Co.,2099,1734,365,1992-10-01,1997-06-30,1998-06-29,NDA 20-864,153,20864,,,,,,,,,,,Maxalt; Maxalt-MLT,rizatriptan benzoate,Merck,NDA,20864,20865,1997-06-30,1998-06-29,1998,acute treatment of migraine headache,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Plavix,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Plavix<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",65 FR 4430,00-1868,https://www.federalregister.gov/documents/2000/01/27/00-1868/determination-of-regulatory-review-period-for-purposes-of-patent-extension-plavix,https://www.govinfo.gov/content/pkg/FR-2000-01-27/pdf/00-1868.pdf,1/27/2000, Plavix,,Anthony,Plavix  (clopidogrel bisulfate),1,147,Anthony,4847265,,,,Sanofi Pharmaceuticals,2755,2551,204,1990-05-05,1997-04-28,1997-11-17,NDA 20-839,1374,20839,,,,,,,,,,,Plavix,clopidogrel bisulfate,Sanofi,NDA,20839,,1997-04-28,1997-11-17,1997,"indicated for the reduction of atherosclerotic events (myocardial infarction, stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease",,Priority,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Refludan,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Refludan<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",65 FR 4431,00-1870,https://www.federalregister.gov/documents/2000/01/27/00-1870/determination-of-regulatory-review-period-for-purposes-of-patent-extension-refludan,https://www.govinfo.gov/content/pkg/FR-2000-01-27/pdf/00-1870.pdf,1/27/2000, Refludan,,Anthony,Refludan  (lepirudin),1,148,Anthony,5180668,,,,Hoechst AG,1149,718,431,1995-01-14,1996-12-31,1998-03-06,NDA 20-807,777,20807,,,,,,,,,,,Refludan,lepirudin,Hoechst Marion Roussel,NDA,20807,,1996-12-31,1998-03-06,1998,anticoagulation in patients with heparin-induced thrombocytopenia (HIT) and thromboembolic disease in order to prevent further thromboembolic complications,,Priority,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Arava,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Arava<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",65 FR 4429,00-1867,https://www.federalregister.gov/documents/2000/01/27/00-1867/determination-of-regulatory-review-period-for-purposes-of-patent-extension-arava,https://www.govinfo.gov/content/pkg/FR-2000-01-27/pdf/00-1867.pdf,1/27/2000, Arava,,Anthony,Arava (leflunomide),1,149,Anthony,4284786,,,,Hoechst Aktiengesellschaft,2032,1908,124,1993-02-18,1998-05-10,1998-09-10,NDA 20-905,1110,20905,,,,,,,,,,,Arava,leflunomide,Quintiles,NDA,20905,,1998-03-10,1998-09-10,1998,treatment of active rheumatoid arthritis (RA) to reduce signs and symptoms and to retard structural damage as evidenced by X-ray erosions and joint space narrowing,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; GlucaGen,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GlucaGen<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",65 FR 4432,00-1872,https://www.federalregister.gov/documents/2000/01/27/00-1872/determination-of-regulatory-review-period-for-purposes-of-patent-extension-glucagen,https://www.govinfo.gov/content/pkg/FR-2000-01-27/pdf/00-1872.pdf,1/27/2000, GlucaGen,,Anthony,GlucaGen  (glucagon (rDNA origin)),1,150,Anthony,4826763,,,,Novo Nordisk A/S,2569,2296,273,1991-06-12,1997-09-23,1998-06-22,NDA 20-918,1423,20918,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Sentinel Model 2000/2010,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Sentinel Model 2000/2010<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",65 FR 4433,00-1873,https://www.federalregister.gov/documents/2000/01/27/00-1873/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sentinel-model-20002010,https://www.govinfo.gov/content/pkg/FR-2000-01-27/pdf/00-1873.pdf,1/27/2000, Sentinel Model 2000/2010,,Anthony,,0,150,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Teslascan,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Teslascan and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",65 FR 4615,00-2030,https://www.federalregister.gov/documents/2000/01/31/00-2030/determination-of-regulatory-review-period-for-purposes-of-patent-extension-teslascan,https://www.govinfo.gov/content/pkg/FR-2000-01-31/pdf/00-2030.pdf,1/31/2000, Teslascan,,Anthony,Teslascan,1,151,Anthony,4933456,,,,"Nycomed Salutar, Inc.",3129,2325,804,1989-05-05,1989-05-05,1997-11-26,NDA 20-652,1628,20652,,,,,,,,,,,Teslascan,mangafodipir trisodium,Nycomed,NDA,20652,,1995-09-15,1997-11-26,1997,"indicated as an adjunct to MRI to enhance the T1-weighted images used in the detection, localization, characterization, and evaluation of lesions of the liver",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; CertivaTM,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Certiva<SUP>TM</SUP> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",65 FR 4614,00-2031,https://www.federalregister.gov/documents/2000/01/31/00-2031/determination-of-regulatory-review-period-for-purposes-of-patent-extension-certivatm,https://www.govinfo.gov/content/pkg/FR-2000-01-31/pdf/00-2031.pdf,1/31/2000, CertivaTM,,Anthony,,0,151,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Lumbar I/F Cage,Uncategorized Document,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Lumbar I/F Cage<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",65 FR 4616,00-2032,https://www.federalregister.gov/documents/2000/01/31/00-2032/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lumbar-if-cage,https://www.govinfo.gov/content/pkg/FR-2000-01-31/pdf/00-2032.pdf,1/31/2000, Lumbar I/F Cage,,Anthony,,0,151,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Rotashield,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Rotashield<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",65 FR 4983,00-2243,https://www.federalregister.gov/documents/2000/02/02/00-2243/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rotashield,https://www.govinfo.gov/content/pkg/FR-2000-02-02/pdf/00-2243.pdf,2/2/2000, Rotashield,,Anthony,Rotashield<Register>,1,152,Anthony,4704275,,,,American Home Products Corp.,3804,3226,578,1988-04-03,1988-04-03,1998-08-31,PLA 97-0111,1826,970111,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Bapten,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Bapten<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",65 FR 4982,00-2149,https://www.federalregister.gov/documents/2000/02/02/00-2149/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bapten,https://www.govinfo.gov/content/pkg/FR-2000-02-02/pdf/00-2149.pdf,2/2/2000, Bapten,,Anthony,Bapten<Register>,1,153,Anthony,4485088,,,,"Alaco, Inc.",5845,5734,111,1982-06-11,1998-06-10,1998-06-10,NADA 141-107,1825,141107,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Wallstent Coronary Endoprosthesis,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Wallstent Coronary Endoprosthesis and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",65 FR 7023,00-3172,https://www.federalregister.gov/documents/2000/02/11/00-3172/determination-of-regulatory-review-period-for-purposes-of-patent-extension-wallstent-coronary,https://www.govinfo.gov/content/pkg/FR-2000-02-11/pdf/00-3172.pdf,2/11/2000, Wallstent Coronary Endoprosthesis,,Anthony,Wallstent Coronary Endoprosthesis,1,154,Anthony,4954126,,,,Boston Scientific Corp.,1533,1351,182,1994-07-21,1994-07-21,1998-09-29,PMA P980009,857,980009,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Neuro Cybernetic Prosthesis (NCP) System; Amendment,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is amending a previous determination regarding the regulatory review period for the Neuro Cybernetic Prosthesis (NCP<Register>) System that appeared in the Federal Register of November 10, 1998 (63 FR 63066). FDA is amending the notice because the agency agrees with the information provided in a request from the applicant for revision of the regulatory review period (Request) (Docket No. 98E-022 8/PRC 1, dated and received on January 8, 1999).",65 FR 31010,00-12117,https://www.federalregister.gov/documents/2000/05/15/00-12117/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neuro-cybernetic,https://www.govinfo.gov/content/pkg/FR-2000-05-15/pdf/00-12117.pdf,5/15/2000, Neuro Cybernetic Prosthesis (NCP) System, Amendment,Anthony,,0,154,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Determination of Regulatory Review Period for Purposes of Patent Extension; Synvisc Hylan G-F 20 (4,713,448)",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Synvisc Hylan G-F 20 (4,713,448)<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",66 FR 1992,01-681,https://www.federalregister.gov/documents/2001/01/10/01-681/determination-of-regulatory-review-period-for-purposes-of-patent-extension-synvisc-hylan-g-f-20,https://www.govinfo.gov/content/pkg/FR-2001-01-10/pdf/01-681.pdf,1/10/2001," Synvisc Hylan G-F 20 (4,713,448)",,Anthony,,0,154,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Determination of Regulatory Review Period for Purposes of Patent Extension; Synvisc Hylan G-F 20 (5,143,724)",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Synvisc Hylan G-F 20 (5,143,724)<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",66 FR 1993,01-683,https://www.federalregister.gov/documents/2001/01/10/01-683/determination-of-regulatory-review-period-for-purposes-of-patent-extension-synvisc-hylan-g-f-20,https://www.govinfo.gov/content/pkg/FR-2001-01-10/pdf/01-683.pdf,1/10/2001," Synvisc Hylan G-F 20 (5,143,724)",,Anthony,,0,154,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Determination of Regulatory Review Period for Purposes of Patent Extension; Synvisc Hylan G-F 20 (5,099,013)",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Synvisc Hylan G-F 20 (5,099,013)<Register> and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",66 FR 2910,01-974,https://www.federalregister.gov/documents/2001/01/12/01-974/determination-of-regulatory-review-period-for-purposes-of-patent-extension-synvisc-hylan-g-f-20,https://www.govinfo.gov/content/pkg/FR-2001-01-12/pdf/01-974.pdf,1/12/2001," Synvisc Hylan G-F 20 (5,099,013)",,Anthony,,0,154,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AciphexTM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Aciphex\<SUP>TM</SUP>\ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",66 FR 13770,13-Jan,https://www.federalregister.gov/documents/2001/03/07/01-5513/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aciphextm,https://www.govinfo.gov/content/pkg/FR-2001-03-07/pdf/01-5513.pdf,3/7/2001, AciphexTM,,Anthony,,0,154,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Provigil,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Provigil and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",66 FR 14153,12-Jan,https://www.federalregister.gov/documents/2001/03/09/01-5812/determination-of-regulatory-review-period-for-purposes-of-patent-extension-provigil,https://www.govinfo.gov/content/pkg/FR-2001-03-09/pdf/01-5812.pdf,3/9/2001, Provigil,,Anthony,Provigil,1,155,Anthony,4177290,,,,Cephalon,1975,1250,725,1999-05-10,1993-07-30,1998-12-24,NDA 20-717,985,20717,3/15/1993,Treatment of excessive daytime sleepiness in narcolepsy.,Designated/Approved,,,Improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy.,12/24/1998,12/24/2005,,"Cephalon, Inc.",Provigil,modafinil,Cephalon,NDA,20717,,1996-12-30,1998-12-24,1998,indicated  to  improve  wakefulness  in  patients  with  excessive  daytime sleepiness associated with narcolepsy,,Standard,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Baycol,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Baycol and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",66 FR 24144,01-11961,https://www.federalregister.gov/documents/2001/05/11/01-11961/determination-of-regulatory-review-period-for-purposes-of-patent-extension-baycol,https://www.govinfo.gov/content/pkg/FR-2001-05-11/pdf/01-11961.pdf,5/11/2001, Baycol,,Anthony,Baycol,1,156,Anthony,5006530,,,,Bayer Corp.,2262,1896,366,1991-04-19,1991-04-19,1997-06-26,NDA 20-740,890,20740,,,,,,,,,,,Baycol,cerivastatin sodium,Bayer,NDA,20740,,1996-06-26,1997-06-26,1997,indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Frederickson Types IIa and IIb) when the response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures alone has been inadequate,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Infergen,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Infergen and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",66 FR 24389,01-12025,https://www.federalregister.gov/documents/2001/05/14/01-12025/determination-of-regulatory-review-period-for-purposes-of-patent-extension-infergen,https://www.govinfo.gov/content/pkg/FR-2001-05-14/pdf/01-12025.pdf,5/14/2001, Infergen,,Anthony,Infergen,1,157,Anthony,4695623,,,,"Amgen, Inc.",4394,3849,545,1985-09-27,1985-09-27,1997-10-06,PLA 96-0486,1826,960486,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Xenical,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Xenical and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",66 FR 26866,01-12093,https://www.federalregister.gov/documents/2001/05/15/01-12093/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xenical,https://www.govinfo.gov/content/pkg/FR-2001-05-15/pdf/01-12093.pdf,5/15/2001, Xenical,,Anthony,Xenical,1,158,Anthony,4598089,,,,HLR Technology Corporation,3969,3091,878,1988-06-12,1988-06-12,1999-04-23,NDA 20-766,1824,20766,,,,,,,,,,,Xenical,orlistat,Roche,NDA,20766,,1996-11-27,1999-04-23,1999,indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet;  also indicated to reduce the risk for weight re-gain after prior loss,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Uvasorb HA88,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Uvasorb HA88 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that food additive.",66 FR 27149,01-12228,https://www.federalregister.gov/documents/2001/05/16/01-12228/determination-of-regulatory-review-period-for-purposes-of-patent-extension-uvasorb-ha88,https://www.govinfo.gov/content/pkg/FR-2001-05-16/pdf/01-12228.pdf,5/16/2001, Uvasorb HA88,,Anthony,,0,158,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Detrol,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Detrol and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",66 FR 35989,01-17105,https://www.federalregister.gov/documents/2001/07/10/01-17105/determination-of-regulatory-review-period-for-purposes-of-patent-extension-detrol,https://www.govinfo.gov/content/pkg/FR-2001-07-10/pdf/01-17105.pdf,7/10/2001, Detrol,,Anthony,Detrol,1,159,Anthony,5382600,,,,Pharmacia & Upjohn Atiebolag,1267,901,366,1994-10-07,1994-10-07,1998-03-25,NDA 20-771,64,20771,,,,,,,,,,,Detrol,tolterodine tartrate,Pharmacia and Upjohn,NDA,20771,,1997-03-25,1998-03-25,1998,"treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Gabitril,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Gabitril and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",66 FR 35988,01-17103,https://www.federalregister.gov/documents/2001/07/10/01-17103/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gabitril,https://www.govinfo.gov/content/pkg/FR-2001-07-10/pdf/01-17103.pdf,7/10/2001, Gabitril,,Anthony,Gabitril,1,160,Anthony,5010090,,,,Novo Nordisk A/S,2346,1651,695,1991-05-01,1991-05-01,1997-09-30,NDA 20-646,1255,20646,,,,,,,,,,,Gabitril,tiagabine hydrochloride,Abbott Laboratories,NDA,20646,,1995-11-06,1997-09-30,1997,indicated as adjunctive therapy in adults and children 12 years and older in the treatment of partial seizures,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Synercid,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Synercid and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",66 FR 48690,01-23703,https://www.federalregister.gov/documents/2001/09/21/01-23703/determination-of-regulatory-review-period-for-purposes-of-patent-extension-synercid,https://www.govinfo.gov/content/pkg/FR-2001-09-21/pdf/01-23703.pdf,9/21/2001, Synercid,,Anthony,Synercid,1,161,Anthony,4798827,,,,Rhone Poulenc Rorer S.A.,2793,2046,747,1992-01-30,1992-01-30,1999-09-21,NDA 50-748,1770,50748,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Kaletra,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Kaletra and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",66 FR 48687,01-23700,https://www.federalregister.gov/documents/2001/09/21/01-23700/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kaletra,https://www.govinfo.gov/content/pkg/FR-2001-09-21/pdf/01-23700.pdf,9/21/2001, Kaletra,,Anthony,Kaletra,1,162,Anthony,5886036,,,,"Abbott Laboratories, Inc.",1397,1290,107,1996-11-20,1996-11-20,2000-09-15,NDA 21-226,324,21226,,,,,,,,,,,Kaletra,"lopinavir, ritonavir",Abbott Laboratories,NDA,21226,21251,2000-06-01,2000-09-15,2000,in combination with other antiretroviral agents for the treatment of HIV-1 infections in adults and pediatric patients age six months and older,,Priority,No,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; Synercid,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Synercid and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",66 FR 48688,01-23701,https://www.federalregister.gov/documents/2001/09/21/01-23701/determination-of-regulatory-review-period-for-purposes-of-patent-extension-synercid,https://www.govinfo.gov/content/pkg/FR-2001-09-21/pdf/01-23701.pdf,9/21/2001, Synercid,,Anthony,Synercid,1,163,Anthony,4668669,,,,Rhone Poulenc Rorer S.A.,1919,1172,747,1994-06-22,1994-06-22,1999-09-21,NDA 50-747,1333,50747,,,,,,,,,,,Synercid,"dalfopristin, quinupristin",Rhone-Poulenc Rorer,NDA,50747,50748,1997-09-05,1999-09-21,1999,"[A] treatment of vancomycin resistant Enterococcus faecium
[B] treatment of complicated skin and skin structure infections",,Priority (indication [A] only),No,Yes (indication [A] only),,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Rescula,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Rescula and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",66 FR 48689,01-23702,https://www.federalregister.gov/documents/2001/09/21/01-23702/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rescula,https://www.govinfo.gov/content/pkg/FR-2001-09-21/pdf/01-23702.pdf,9/21/2001, Rescula,,Anthony,Rescula,1,164,Anthony,5221763,,,,"R-Tech Veno, Ltd./ Novartis",1347,1186,161,1996-11-27,1996-11-27,2000-08-03,NDA 21-214,774,21214,,,,,,,,,,,Rescula,unoprostone isopropyl,Ciba Vision,NDA,21214,,2000-02-15,2000-08-03,2000,indicated for the lowering of intraocular pressure in patients with open-angel glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Trileptal,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Trileptal and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",66 FR 48882,01-23750,https://www.federalregister.gov/documents/2001/09/24/01-23750/determination-of-regulatory-review-period-for-purposes-of-patent-extension-trileptal,https://www.govinfo.gov/content/pkg/FR-2001-09-24/pdf/01-23750.pdf,9/24/2001, Trileptal,,Anthony,Trileptal,1,165,Anthony,4559174,,,,Novartis,2523,2046,477,1993-02-18,1993-02-18,2000-01-14,NDA 21-014,1690,21014,,,,,,,,,,,Trileptal,oxcarbazepine,Novartis Pharmaceuticals,NDA,21014,,1998-09-25,2000-01-14,2000,indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults with epilepsy and as adjunctive therapy in the treatment of partial seizures in children ages 4-16 with epilepsy,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TNKase,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TNKase and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human biological product.",66 FR 49392,01-24126,https://www.federalregister.gov/documents/2001/09/27/01-24126/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tnkase,https://www.govinfo.gov/content/pkg/FR-2001-09-27/pdf/01-24126.pdf,9/27/2001, TNKase,,Anthony,TNKase,1,166,Anthony,5385732,,,,"Genetech, Inc.",1990,1741,249,1994-12-23,1994-12-23,2000-06-02,BLA 99-0903,853,990903,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Synercid; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of September 21, 2001 (66 FR 486920). The document determined the regulatory review period for Synercid and published the notice of that determination as required by law. The document published with an inadvertent error. This document corrects that error.",66 FR 52774,01-25998,https://www.federalregister.gov/documents/2001/10/17/01-25998/determination-of-regulatory-review-period-for-purposes-of-patent-extension-synercid-correction,https://www.govinfo.gov/content/pkg/FR-2001-10-17/pdf/01-25998.pdf,10/17/2001, Synercid, Correction,Anthony,,0,166,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Heart Laser System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for the Heart Laser System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",67 FR 2663,02-1320,https://www.federalregister.gov/documents/2002/01/18/02-1320/determination-of-regulatory-review-period-for-purposes-of-patent-extension-heart-laser-system,https://www.govinfo.gov/content/pkg/FR-2002-01-18/pdf/02-1320.pdf,1/18/2002, Heart Laser System,,Anthony,the Heart Laser System,1,167,Anthony,5125926,,,,"PLC Medical Systems, Inc.",3135,2586,549,1990-01-21,1990-01-21,1998-08-20,PMA P950015,695,950015,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; T-Scan 2000,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for T-Scan 2000 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",67 FR 3501,02-1723,https://www.federalregister.gov/documents/2002/01/24/02-1723/determination-of-regulatory-review-period-for-purposes-of-patent-extension-t-scan-2000,https://www.govinfo.gov/content/pkg/FR-2002-01-24/pdf/02-1723.pdf,1/24/2002, T-Scan 2000,,Anthony,T-Scan 2000,1,168,Anthony,4291708,,,,Transcan Research,1595,964,631,2000-09-13,1994-12-05,1999-04-16,PMA P970033,1826,970033,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SONATA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SONATA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 3723,25-Feb,https://www.federalregister.gov/documents/2002/01/25/02-1925/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sonata,https://www.govinfo.gov/content/pkg/FR-2002-01-25/pdf/02-1925.pdf,1/25/2002, SONATA,,Anthony,SONATA,1,169,Anthony,4626538,,,,American Cyanamid Co.,3027,2435,592,1991-05-02,1991-05-02,1999-08-13,NDA 20-859,1835,20859,,,,,,,,,,,Sonata,zaleplon,Wyeth-Ayerst,NDA,20859,,1998-01-06,1999-08-13,1999,short-term treatment of insomnia,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; MIFEPREX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MIFEPREX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 3724,26-Feb,https://www.federalregister.gov/documents/2002/01/25/02-1926/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mifeprex,https://www.govinfo.gov/content/pkg/FR-2002-01-25/pdf/02-1926.pdf,1/25/2002, MIFEPREX,,Anthony,MIFEPREX,1,170,Anthony,4386085,,,,the Population Council,49,2249,593,1994-08-03,1994-08-04,2000-09-28,NDA 20-687,1825,20687,,,,,,,,,,,Mifeprex,mifepristone,Population Council,NDA,20687,,1996-03-18,2000-09-28,2000,indicated for medical termination of intrauterine pregnancy through 49 days pregnancy,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KEPPRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KEPPRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 3725,27-Feb,https://www.federalregister.gov/documents/2002/01/25/02-1927/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keppra,https://www.govinfo.gov/content/pkg/FR-2002-01-25/pdf/02-1927.pdf,1/25/2002, KEPPRA,,Anthony,KEPPRA,1,171,Anthony,4943639,,,,UCB Societe Anonyme,2010,1707,303,1994-06-01,1994-06-01,1999-11-30,NDA 21-035,1155,21035,,,,,,,,,,,Keppra,levetiracetam,UCP Pharma,NDA,21035,,1999-02-01,1999-11-30,1999,indicated as an adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; REFACTO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REFACTO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",67 FR 5289,Feb-71,https://www.federalregister.gov/documents/2002/02/05/02-2671/determination-of-regulatory-review-period-for-purposes-of-patent-extension-refacto,https://www.govinfo.gov/content/pkg/FR-2002-02-05/pdf/02-2671.pdf,2/5/2002, REFACTO,,Anthony,REFACTO,1,172,Anthony,4868112,,,,"the Genetics Institute, Inc.",1751,987,764,1995-05-23,1995-05-23,2000-03-06,PLA 98-0137,1475,980137,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Celexa,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Celexa and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 8546,Feb-82,https://www.federalregister.gov/documents/2002/02/25/02-4382/determination-of-regulatory-review-period-for-purposes-of-patent-extension-celexa,https://www.govinfo.gov/content/pkg/FR-2002-02-25/pdf/02-4382.pdf,2/25/2002, Celexa,,Anthony,Celexa,1,173,Anthony,4650884,,,,H. Lundbeck A/S,5498,5061,437,1983-07-30,1983-07-30,1998-07-17,NDA 20-822,1826,20822,,,,,,,,,,,Celexa,citalopram hydrobromide,Forest Laboratories,NDA,20822,,1997-05-12,1998-07-17,1998,treatment of depression,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Menicon Z Rigid Gas Permeable Contact Lens,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Menicon Z Rigid Gas Permeable Contact Lens and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",67 FR 8547,Feb-83,https://www.federalregister.gov/documents/2002/02/25/02-4383/determination-of-regulatory-review-period-for-purposes-of-patent-extension-menicon-z-rigid-gas,https://www.govinfo.gov/content/pkg/FR-2002-02-25/pdf/02-4383.pdf,2/25/2002, Menicon Z Rigid Gas Permeable Contact Lens,,Anthony,Menicon Z Rigid Gas Permeable Contact Lens,1,174,Anthony,4594401,,,,Menicon Co.,7,1917,1435,2001-09-06,2001-09-06,2000-07-11,PMA P990018,1205,990018,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; RELENZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RELENZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 8988,Feb-96,https://www.federalregister.gov/documents/2002/02/27/02-4596/determination-of-regulatory-review-period-for-purposes-of-patent-extension-relenza,https://www.govinfo.gov/content/pkg/FR-2002-02-27/pdf/02-4596.pdf,2/27/2002, RELENZA,,Anthony,RELENZA,1,175,Anthony,5360817,,,,"Glaxo Wellcome, Inc.",1800,1527,273,1994-08-23,1994-08-23,1999-07-26,NDA 21-036,1001,21036,,,,,,,,,,,Relenza,zanamivir,Glaxo Wellcome,NDA,21036,,1998-10-27,1999-07-26,1999,treatment of uncomplicated acute illness due to influenza virus in adults and adolescents twelve years and older who have been symptomatic for no more than two days,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; NEXIUM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NEXIUM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 9299,Feb-81,https://www.federalregister.gov/documents/2002/02/28/02-4681/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nexium,https://www.govinfo.gov/content/pkg/FR-2002-02-28/pdf/02-4681.pdf,2/28/2002, NEXIUM,,Anthony,NEXIUM,1,176,Anthony,4738974,,,,Astrazenica,1284,838,446,1997-08-18,1997-08-18,2001-02-20,NDA 21-153,865,21153,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; REMINYL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REMINYL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 9301,Feb-83,https://www.federalregister.gov/documents/2002/02/28/02-4683/determination-of-regulatory-review-period-for-purposes-of-patent-extension-reminyl,https://www.govinfo.gov/content/pkg/FR-2002-02-28/pdf/02-4683.pdf,2/28/2002, REMINYL,,Anthony,REMINYL,1,177,Anthony,4663318,,,,Janssen Research Foundation,1608,1089,519,1996-10-06,1996-10-06,2001-02-28,NDA 21-169,1063,21169,,,,,,,,,,,Reminyl,galantamine hydrobromide,Janssen Research Foundation,NDA,21169,,1999-09-29,2001-02-28,2001,treatment of mild to moderate dementia of the Alzheimer's type,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; EVISTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EVISTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 9300,Feb-82,https://www.federalregister.gov/documents/2002/02/28/02-4682/determination-of-regulatory-review-period-for-purposes-of-patent-extension-evista,https://www.govinfo.gov/content/pkg/FR-2002-02-28/pdf/02-4682.pdf,2/28/2002, EVISTA,,Anthony,EVISTA,1,178,Anthony,4418068,,,,Eli Lilly,5412,5228,184,1983-02-16,1983-02-16,1997-12-09,NDA 20-815,1103,20815,7/14/2005,Reduction of the risk of breast cancer in postmenopausal women,Designated/Approved,,,Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer,9/13/2007,9/13/2014,,Eli Lilly and Company,Evista,raloxifene hydrochloride,Lilly,NDA,20815,,1997-06-09,1997-12-09,1997,prevention of osteoporosis in postmenopausal women,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ABREVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ABREVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 9303,Feb-85,https://www.federalregister.gov/documents/2002/02/28/02-4685/determination-of-regulatory-review-period-for-purposes-of-patent-extension-abreva,https://www.govinfo.gov/content/pkg/FR-2002-02-28/pdf/02-4685.pdf,2/28/2002, ABREVA,,Anthony,ABREVA,1,179,Anthony,4874794,,,,Avanir Pharmaceuticals,3270,2323,947,1991-08-14,1991-08-14,2000-07-25,NDA 20-941,1825,20941,,,,,,,,,,,Abreva,docosanol,Avanir Pharmaceuticals,NDA,20941,,1997-12-22,2000-07-25,2000,treatment of cold sores and fever blisters,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; AVELOX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVELOX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 9304,Feb-48,https://www.federalregister.gov/documents/2002/02/28/02-4748/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avelox,https://www.govinfo.gov/content/pkg/FR-2002-02-28/pdf/02-4748.pdf,2/28/2002, AVELOX,,Anthony,AVELOX,1,180,Anthony,4490517,,,,Bayer Corp.,1435,1069,366,1996-01-07,1996-01-07,1999-12-10,NDA 21-085,889,21085,,,,,,,,,,,Avelox,moxifloxacin hydrochloride,Bayer,NDA,21085,,1998-12-10,1999-12-10,1999,"indicated for the treatment of adults with infections caused by susceptible strains of  designated microorganisms in the
following conditions: acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; PAYLEAN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PAYLEAN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",67 FR 9298,Feb-47,https://www.federalregister.gov/documents/2002/02/28/02-4747/determination-of-regulatory-review-period-for-purposes-of-patent-extension-paylean,https://www.govinfo.gov/content/pkg/FR-2002-02-28/pdf/02-4747.pdf,2/28/2002, PAYLEAN,,Anthony,PAYLEAN,1,181,Anthony,4690951,,,,Eli Lilly & Co.,5707,1211,4496,1984-05-09,1984-05-09,1999-12-22,NADA 140-863,1095,140863,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TRAVATAN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TRAVATAN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 9302,Feb-84,https://www.federalregister.gov/documents/2002/02/28/02-4684/determination-of-regulatory-review-period-for-purposes-of-patent-extension-travatan,https://www.govinfo.gov/content/pkg/FR-2002-02-28/pdf/02-4684.pdf,2/28/2002, TRAVATAN,,Anthony,TRAVATAN,1,182,Anthony,5889052,,,,"Alcon Laboratories, Inc.",1694,1441,253,1996-07-28,1996-07-28,2001-03-16,NDA 21-257,484,21257,,,,,,,,,,,Travatan,travoprost,Alcon Research,NDA,21257,,2000-07-07,2001-03-16,2001,indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; HECTOROL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HECTOROL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 9455,Feb-89,https://www.federalregister.gov/documents/2002/03/01/02-4889/determination-of-regulatory-review-period-for-purposes-of-patent-extension-hectorol,https://www.govinfo.gov/content/pkg/FR-2002-03-01/pdf/02-4889.pdf,3/1/2002, HECTOROL,,Anthony,HECTOROL,1,183,Anthony,4555364,,,,The Wisconsin Alumni Research Foundation,4072,3614,458,1988-04-17,1988-04-17,1999-06-09,NDA 20-862,1824,20862,,,,,,,,,,,Hectorol,doxercalciferol,Bone Care,NDA,20862,,1998-03-09,1999-06-09,1999,indicated for the reduction of elevated iPTH levels in the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Diphenylmethane Diisocyanate,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for diphenylmethane diisocyanate and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that food additive.",67 FR 9756,Feb-65,https://www.federalregister.gov/documents/2002/03/04/02-4965/determination-of-regulatory-review-period-for-purposes-of-patent-extension-diphenylmethane,https://www.govinfo.gov/content/pkg/FR-2002-03-04/pdf/02-4965.pdf,3/4/2002, Diphenylmethane Diisocyanate,,Anthony,,0,183,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MIFEPREX; Extension of Comment Period,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is extending to April 26, 2002, the comment period for the regulatory review period determination for MIFEPREX, published in the Federal Register of January 25, 2002 (67 FR 3724). The agency is taking this action in response to a request for an extension.",67 FR 18921,Feb-64,https://www.federalregister.gov/documents/2002/04/17/02-9364/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mifeprex-extension-of,https://www.govinfo.gov/content/pkg/FR-2002-04-17/pdf/02-9364.pdf,4/17/2002, MIFEPREX, Extension of Comment Period,Anthony,,0,183,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ACTOS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ACTOS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 34721,02-12092,https://www.federalregister.gov/documents/2002/05/15/02-12092/determination-of-regulatory-review-period-for-purposes-of-patent-extension-actos,https://www.govinfo.gov/content/pkg/FR-2002-05-15/pdf/02-12092.pdf,5/15/2002, ACTOS,,Anthony,ACTOS,1,184,Anthony,4687777,,,,"Takeda Chemical Industries, Ltd.",3556,3374,182,1989-10-21,1989-10-21,1999-07-15,NDA 21-073,1826,21073,,,,,,,,,,,Actos,pioglitazone hydrochloride,Takeda America,NDA,21073,,1999-01-15,1999-07-15,1999,"indicated for the improvement of glycemic control in patients with type 2 diabetes as monotherapy, or in combination with a sulfonylurea, metformin or insulin when diet and the single agent does not result in adequate glycemic control",,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; COMTAN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for COMTAN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 36008,02-12784,https://www.federalregister.gov/documents/2002/05/22/02-12784/determination-of-regulatory-review-period-for-purposes-of-patent-extension-comtan,https://www.govinfo.gov/content/pkg/FR-2002-05-22/pdf/02-12784.pdf,5/22/2002, COMTAN,,Anthony,COMTAN,1,185,Anthony,5446194,,,,Orion Corp.,2937,2281,656,1991-10-06,1991-10-06,1999-10-19,NDA 20-796,416,20796,,,,,,,,,,,Comtan,entacapone,Orion,NDA,20796,,1998-01-02,1999-10-19,1999,"indicated as an adjunct to levodopa/carbidopa to treat patients with idiopathic Parkinsons Disease who experience the signs and symptoms of end-of-dose ""wearing-off"" (so called ""fluctuating"" patients)",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ENBREL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ENBREL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",67 FR 36897,02-13227,https://www.federalregister.gov/documents/2002/05/28/02-13227/determination-of-regulatory-review-period-for-purposes-of-patent-extension-enbrel,https://www.govinfo.gov/content/pkg/FR-2002-05-28/pdf/02-13227.pdf,5/28/2002, ENBREL,,Anthony,ENBREL,1,186,Anthony,5712155,,,,Immunex Corp.,2322,2143,179,1992-06-26,1992-06-26,1998-11-02,BLA 98-0286,240,980286,10/27/1998,Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.,Designated/Approved,,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older,5/27/1999,5/27/2006,,Immunex Corporation,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; BETAXON,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BETAXON and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 43128,02-16052,https://www.federalregister.gov/documents/2002/06/26/02-16052/determination-of-regulatory-review-period-for-purposes-of-patent-extension-betaxon,https://www.govinfo.gov/content/pkg/FR-2002-06-26/pdf/02-16052.pdf,6/26/2002, BETAXON,,Anthony,BETAXON,1,187,Anthony,4911920,,,,Alcon Laboratories,947,765,182,1997-07-23,1997-07-23,2000-02-23,NDA 21-114,579,21114,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Protonix,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Protonix and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 46681,02-17781,https://www.federalregister.gov/documents/2002/07/16/02-17781/determination-of-regulatory-review-period-for-purposes-of-patent-extension-protonix,https://www.govinfo.gov/content/pkg/FR-2002-07-16/pdf/02-17781.pdf,7/16/2002, Protonix,,Anthony,Protonix,1,188,Anthony,4758579,,,,BYK Gulden Lomerg Chemische Fabrik GmbH,10,3401,2818,1990-10-13,1990-10-13,2000-02-02,NDA 20-987,5,20987,,,,,,,,,,,Protonix,pantoprazole sodium,Wyeth-Ayerst Laboratories,NDA,20987,,1998-06-30,2000-02-02,2000,short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Axert,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Axert and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 46682,02-17782,https://www.federalregister.gov/documents/2002/07/16/02-17782/determination-of-regulatory-review-period-for-purposes-of-patent-extension-axert,https://www.govinfo.gov/content/pkg/FR-2002-07-16/pdf/02-17782.pdf,7/16/2002, Axert,,Anthony,Axert,1,189,Anthony,5565447,,,,Almirall Prodesfarma S.A.,1348,843,505,1997-08-30,1997-08-30,2001-05-07,NDA 20-001,569,20001,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PEG-Intron,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PEG-Intron and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",67 FR 46680,02-17783,https://www.federalregister.gov/documents/2002/07/16/02-17783/determination-of-regulatory-review-period-for-purposes-of-patent-extension-peg-intron,https://www.govinfo.gov/content/pkg/FR-2002-07-16/pdf/02-17783.pdf,7/16/2002, PEG-Intron,,Anthony,PEG-Intron,1,190,Anthony,5951974,,,,Schering Corp.,1271,877,394,1997-07-30,1997-07-30,2001-01-19,BLA 99-1488,435,991488,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CeeOn Model 911A,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CeeOn Model 911A and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",67 FR 46989,02-17904,https://www.federalregister.gov/documents/2002/07/17/02-17904/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ceeon-model-911a,https://www.govinfo.gov/content/pkg/FR-2002-07-17/pdf/02-17904.pdf,7/17/2002, CeeOn Model 911A,,Anthony,CeeOn Model 911A,1,191,Anthony,5444106,,,,Pharmacia AB,1594,1101,493,1996-11-25,1996-11-25,2001-04-05,PMA P990080,956,990080,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Definity,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Definity and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 48919,02-18975,https://www.federalregister.gov/documents/2002/07/26/02-18975/determination-of-regulatory-review-period-for-purposes-of-patent-extension-definity,https://www.govinfo.gov/content/pkg/FR-2002-07-26/pdf/02-18975.pdf,7/26/2002, Definity,,Anthony,Definity,1,192,Anthony,5527521,,,,"Dupont Contrast Imaging, Inc.",2160,1193,967,1995-09-03,1995-09-03,2001-07-31,NDA 21-064,1418,21064,,,,,,,,,,,Definity,perflutren lipid microsphere,Dupont Pharmaceuticals,NDA,21064,,1998-12-09,2001-07-31,2001,indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; MIFEPREX; Amendment,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is amending a previous determination of the regulatory review period for MIFEPREX that appeared in the Federal Register of January 25, 2002 (67 FR 3724). The agency is taking this action in response to received comments. FDA is publishing notice of that amendment as required by law.",67 FR 65358,02-27096,https://www.federalregister.gov/documents/2002/10/24/02-27096/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mifeprex-amendment,https://www.govinfo.gov/content/pkg/FR-2002-10-24/pdf/02-27096.pdf,10/24/2002, MIFEPREX, Amendment,Anthony,,0,192,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LOTRONEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LOTRONEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 69014,02-28883,https://www.federalregister.gov/documents/2002/11/14/02-28883/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lotronex,https://www.govinfo.gov/content/pkg/FR-2002-11-14/pdf/02-28883.pdf,11/14/2002, LOTRONEX,,Anthony,LOTRONEX,1,193,Anthony,5360800,,,,"Glaxo Wellcome, Inc.",3564,3339,225,1990-05-10,1990-05-10,2000-02-09,NDA 21-107,1076,21107,,,,,,,,,,,Lotronex,alosetron hydrochloride,Glaxo Wellcome,NDA,21107,,1999-06-30,2000-02-09,2000,treatment of irritable bowel syndrome (IBS) in female patients whose predominant bowel symptom is diarrhea,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SOLAGE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SOLAGE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 69016,02-28885,https://www.federalregister.gov/documents/2002/11/14/02-28885/determination-of-regulatory-review-period-for-purposes-of-patent-extension-solage,https://www.govinfo.gov/content/pkg/FR-2002-11-14/pdf/02-28885.pdf,11/14/2002, SOLAGE,,Anthony,SOLAGE,1,194,Anthony,5194247,,,,Bristol-Myers Squibb Co.,2689,1978,711,1992-08-01,1992-08-01,1999-12-10,NDA 20-922,1365,20922,,,,,,,,,,,Solage,"mequinol, tretinoin",Bristol-Myers Squibb,NDA,20922,,1997-12-30,1999-12-10,1999,treatment of solar lentigines,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; COLAZAL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for COLAZAL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 69014,02-28882,https://www.federalregister.gov/documents/2002/11/14/02-28882/determination-of-regulatory-review-period-for-purposes-of-patent-extension-colazal,https://www.govinfo.gov/content/pkg/FR-2002-11-14/pdf/02-28882.pdf,11/14/2002, COLAZAL,,Anthony,COLAZAL,1,195,Anthony,4412992,,,,Biorex Laboratories Unlimited,2950,1828,1122,1992-06-22,1992-06-22,2000-07-18,NDA 20-610,1825,20610,8/12/2005,Treatment of pediatric patients with ulcerative colitis,Designated/Approved,,,Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established.,12/20/2006,12/20/2013,,"Salix Pharmaceuticals, Inc.",Colazal,balsalazide disodium,Salix Pharmaceuticals,NDA,20610,,1997-06-23,2000-07-18,2000,treatment of mildly to moderate active ulcerative colitis,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ACOVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ACOVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",67 FR 69015,02-28884,https://www.federalregister.gov/documents/2002/11/14/02-28884/determination-of-regulatory-review-period-for-purposes-of-patent-extension-acova,https://www.govinfo.gov/content/pkg/FR-2002-11-14/pdf/02-28884.pdf,11/14/2002, ACOVA,,Anthony,ACOVA,1,196,Anthony,5214052,,,,Texas Biotechnology Corp.,4022,2971,1051,1989-06-28,1989-06-28,2000-06-30,NDA 20-883,839,20883,,,,,,,,,,,Acova,argatroban,Texas Biotechnology Corporation,NDA,20883,,1997-08-15,2000-06-30,2000,indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; GLEEVEC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GLEEVEC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 69533,02-29187,https://www.federalregister.gov/documents/2002/11/18/02-29187/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gleevec,https://www.govinfo.gov/content/pkg/FR-2002-11-18/pdf/02-29187.pdf,11/18/2002, GLEEVEC,,Anthony,GLEEVEC,1,197,Anthony,5521184,,,,Novartis Corp.,1098,1025,73,1998-05-10,1998-05-10,2001-05-10,NDA 21-335,599,21335,1/31/2001,Treatment of chronic myelogenous leukemia,Designated/Approved,,,"Treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy",5/10/2001,5/10/2008,,Novartis Pharmaceuticals Corporation,Gleevec,imatinib mesylate,Novartis Pharmaceuticals,NDA,21335,,2001-02-27,2001-05-10,2001,"indicated for the treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy",,Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; GLEEVEC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GLEEVEC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 69533,02-29187,https://www.federalregister.gov/documents/2002/11/18/02-29187/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gleevec,https://www.govinfo.gov/content/pkg/FR-2002-11-18/pdf/02-29187.pdf,11/18/2002, GLEEVEC,,Anthony,GLEEVEC,1,198,Anthony,5521184,,,,Novartis Corp.,1098,1025,73,1998-05-10,1998-05-10,2001-05-10,NDA 21-335,599,21335,10/11/2005,Treatment of Philadelphia-positive acute lymphoblastic leukemia,Designated/Approved,,,Pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy,1/25/2013,1/25/2020,Treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy,Novartis Pharmaceuticals Corporation,Gleevec,imatinib mesylate,Novartis Pharmaceuticals,NDA,21335,,2001-02-27,2001-05-10,2001,"indicated for the treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy",,Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; GLEEVEC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GLEEVEC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 69533,02-29187,https://www.federalregister.gov/documents/2002/11/18/02-29187/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gleevec,https://www.govinfo.gov/content/pkg/FR-2002-11-18/pdf/02-29187.pdf,11/18/2002, GLEEVEC,,Anthony,GLEEVEC,1,199,Anthony,5521184,,,,Novartis Corp.,1098,1025,73,1998-05-10,1998-05-10,2001-05-10,NDA 21-335,599,21335,10/11/2005,Treatment of Philadelphia-positive acute lymphoblastic leukemia,Designated/Approved,,,Treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL),10/19/2006,10/19/2013,,Novartis Pharmaceuticals Corporation,Gleevec,imatinib mesylate,Novartis Pharmaceuticals,NDA,21335,,2001-02-27,2001-05-10,2001,"indicated for the treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy",,Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; GLEEVEC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GLEEVEC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 69533,02-29187,https://www.federalregister.gov/documents/2002/11/18/02-29187/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gleevec,https://www.govinfo.gov/content/pkg/FR-2002-11-18/pdf/02-29187.pdf,11/18/2002, GLEEVEC,,Anthony,GLEEVEC,1,200,Anthony,5521184,,,,Novartis Corp.,1098,1025,73,1998-05-10,1998-05-10,2001-05-10,NDA 21-335,599,21335,11/1/2001,Treatment of gastrointestinal stromal tumors,Designated/Approved,,,Treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST),2/1/2002,2/1/2009,,Novartis Pharmaceuticals Corp.,Gleevec,imatinib mesylate,Novartis Pharmaceuticals,NDA,21335,,2001-02-27,2001-05-10,2001,"indicated for the treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy",,Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; GLEEVEC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GLEEVEC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 69533,02-29187,https://www.federalregister.gov/documents/2002/11/18/02-29187/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gleevec,https://www.govinfo.gov/content/pkg/FR-2002-11-18/pdf/02-29187.pdf,11/18/2002, GLEEVEC,,Anthony,GLEEVEC,1,201,Anthony,5521184,,,,Novartis Corp.,1098,1025,73,1998-05-10,1998-05-10,2001-05-10,NDA 21-335,599,21335,8/25/2005,Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia,Designated/Approved,,,Treatment of adult patients with hypereosinophic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFR} fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR} fusion kinase negative or unknown,10/19/2006,10/19/2013,,Novartis Pharmaceuticals Corporation,Gleevec,imatinib mesylate,Novartis Pharmaceuticals,NDA,21335,,2001-02-27,2001-05-10,2001,"indicated for the treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy",,Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; GLEEVEC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GLEEVEC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 69533,02-29187,https://www.federalregister.gov/documents/2002/11/18/02-29187/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gleevec,https://www.govinfo.gov/content/pkg/FR-2002-11-18/pdf/02-29187.pdf,11/18/2002, GLEEVEC,,Anthony,GLEEVEC,1,202,Anthony,5521184,,,,Novartis Corp.,1098,1025,73,1998-05-10,1998-05-10,2001-05-10,NDA 21-335,599,21335,10/5/2005,Treatment of myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements,Designated/Approved,,,Treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements,10/19/2006,10/19/2013,,Novartis Pharmaceuticals Corporation,Gleevec,imatinib mesylate,Novartis Pharmaceuticals,NDA,21335,,2001-02-27,2001-05-10,2001,"indicated for the treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy",,Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; GLEEVEC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GLEEVEC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 69533,02-29187,https://www.federalregister.gov/documents/2002/11/18/02-29187/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gleevec,https://www.govinfo.gov/content/pkg/FR-2002-11-18/pdf/02-29187.pdf,11/18/2002, GLEEVEC,,Anthony,GLEEVEC,1,203,Anthony,5521184,,,,Novartis Corp.,1098,1025,73,1998-05-10,1998-05-10,2001-05-10,NDA 21-335,599,21335,9/9/2005,Treatment of systemic mastocytosis without the D816V c-kit mutation,Designated/Approved,,,Treatment of adult patients with aggressive mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown,10/19/2006,10/19/2013,,Novartis Pharmaceuticals Corporation,Gleevec,imatinib mesylate,Novartis Pharmaceuticals,NDA,21335,,2001-02-27,2001-05-10,2001,"indicated for the treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy",,Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; GLEEVEC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GLEEVEC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 69533,02-29187,https://www.federalregister.gov/documents/2002/11/18/02-29187/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gleevec,https://www.govinfo.gov/content/pkg/FR-2002-11-18/pdf/02-29187.pdf,11/18/2002, GLEEVEC,,Anthony,GLEEVEC,1,204,Anthony,5521184,,,,Novartis Corp.,1098,1025,73,1998-05-10,1998-05-10,2001-05-10,NDA 21-335,599,21335,11/1/2001,Treatment of gastrointestinal stromal tumors,Designated/Approved,,,Adjuvant treatment of adult patients following complete resection Kit (CD 117) positive gastrointestinal stromal tumors (GIST).,12/19/2008,12/19/2015,,Novartis Pharmaceuticals Corp.,Gleevec,imatinib mesylate,Novartis Pharmaceuticals,NDA,21335,,2001-02-27,2001-05-10,2001,"indicated for the treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy",,Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; GLEEVEC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GLEEVEC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 69533,02-29187,https://www.federalregister.gov/documents/2002/11/18/02-29187/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gleevec,https://www.govinfo.gov/content/pkg/FR-2002-11-18/pdf/02-29187.pdf,11/18/2002, GLEEVEC,,Anthony,GLEEVEC,1,205,Anthony,5521184,,,,Novartis Corp.,1098,1025,73,1998-05-10,1998-05-10,2001-05-10,NDA 21-335,599,21335,12/19/2005,Treatment of dermatofibrosarcoma protuberans,Designated/Approved,,,"Treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP)",10/19/2006,10/19/2013,,Novartis Pharmaceuticals Corporation,Gleevec,imatinib mesylate,Novartis Pharmaceuticals,NDA,21335,,2001-02-27,2001-05-10,2001,"indicated for the treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy",,Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; EVOXAC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EVOXAC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",67 FR 69533,02-29188,https://www.federalregister.gov/documents/2002/11/18/02-29188/determination-of-regulatory-review-period-for-purposes-of-patent-extension-evoxac,https://www.govinfo.gov/content/pkg/FR-2002-11-18/pdf/02-29188.pdf,11/18/2002, EVOXAC,,Anthony,EVOXAC,1,206,Anthony,4855290,,,,"the State of Israel, Israel Institute for Biological Research",1733,1230,503,1995-04-16,1995-04-16,2000-01-11,NDA 20-989,1133,20989,,,,,,,,,,,Evoxac,cevimeline hydrochloride,Snowbrand Pharmaceuticals,NDA,20989,,1998-08-27,2000-01-11,2000,treatment of symptoms of dry mouth in patients with Sjgren's Syndrome,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; NOVOSEVEN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NOVOSEVEN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",68 FR 3534,03-1567,https://www.federalregister.gov/documents/2003/01/24/03-1567/determination-of-regulatory-review-period-for-purposes-of-patent-extension-novoseven,https://www.govinfo.gov/content/pkg/FR-2003-01-24/pdf/03-1567.pdf,1/24/2003, NOVOSEVEN,,Anthony,NOVOSEVEN,1,207,Anthony,4784950,,,,"ZymoGenetics, Inc.",3954,2904,1050,1988-05-29,1988-05-29,1999-03-25,PLA 96-0597,1826,960597,7/21/2004,Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX,Designated/Approved,,,Prevention of bleeding in surgical interventions or invasive procedures in patients with acquired hemophilia,10/13/2006,10/13/2013,,"Novo Nordisk, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NOVOSEVEN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NOVOSEVEN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",68 FR 3534,03-1567,https://www.federalregister.gov/documents/2003/01/24/03-1567/determination-of-regulatory-review-period-for-purposes-of-patent-extension-novoseven,https://www.govinfo.gov/content/pkg/FR-2003-01-24/pdf/03-1567.pdf,1/24/2003, NOVOSEVEN,,Anthony,NOVOSEVEN,1,208,Anthony,4784950,,,,"ZymoGenetics, Inc.",3954,2904,1050,1988-05-29,1988-05-29,1999-03-25,PLA 96-0597,1826,960597,6/6/1988,Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.,Designated/Approved,,,Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.,3/25/1999,3/25/2006,,"Novo Nordisk, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NOVOSEVEN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NOVOSEVEN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",68 FR 3534,03-1567,https://www.federalregister.gov/documents/2003/01/24/03-1567/determination-of-regulatory-review-period-for-purposes-of-patent-extension-novoseven,https://www.govinfo.gov/content/pkg/FR-2003-01-24/pdf/03-1567.pdf,1/24/2003, NOVOSEVEN,,Anthony,NOVOSEVEN,1,209,Anthony,4784950,,,,"ZymoGenetics, Inc.",3954,2904,1050,1988-05-29,1988-05-29,1999-03-25,PLA 96-0597,1826,960597,9/10/2004,Treatment of bleeding episodes in patients with congenital factor VII deficiency,Designated/Approved,,,Treatment of bleeding episodes in patients with Factor VII Deficiency,7/11/2005,7/11/2012,,"Novo Nordisk, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NOVOSEVEN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NOVOSEVEN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",68 FR 3534,03-1567,https://www.federalregister.gov/documents/2003/01/24/03-1567/determination-of-regulatory-review-period-for-purposes-of-patent-extension-novoseven,https://www.govinfo.gov/content/pkg/FR-2003-01-24/pdf/03-1567.pdf,1/24/2003, NOVOSEVEN,,Anthony,NOVOSEVEN,1,210,Anthony,4784950,,,,"ZymoGenetics, Inc.",3954,2904,1050,1988-05-29,1988-05-29,1999-03-25,PLA 96-0597,1826,960597,6/18/2004,"Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors",Designated/Approved,,,Prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX,8/12/2005,8/12/2012,,"Novo Nordisk, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NOVOSEVEN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NOVOSEVEN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",68 FR 3534,03-1567,https://www.federalregister.gov/documents/2003/01/24/03-1567/determination-of-regulatory-review-period-for-purposes-of-patent-extension-novoseven,https://www.govinfo.gov/content/pkg/FR-2003-01-24/pdf/03-1567.pdf,1/24/2003, NOVOSEVEN,,Anthony,NOVOSEVEN,1,211,Anthony,4784950,,,,"ZymoGenetics, Inc.",3954,2904,1050,1988-05-29,1988-05-29,1999-03-25,PLA 96-0597,1826,960597,7/16/2004,Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX,Designated/Approved,,,Treatment of bleeding episodes in surgical interventions or invasive procedures in patients with acquired hemophilia,10/13/2006,10/13/2013,,"Novo Nordisk, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NOVOSEVEN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NOVOSEVEN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",68 FR 3534,03-1567,https://www.federalregister.gov/documents/2003/01/24/03-1567/determination-of-regulatory-review-period-for-purposes-of-patent-extension-novoseven,https://www.govinfo.gov/content/pkg/FR-2003-01-24/pdf/03-1567.pdf,1/24/2003, NOVOSEVEN,,Anthony,NOVOSEVEN,1,212,Anthony,4784950,,,,"ZymoGenetics, Inc.",3954,2904,1050,1988-05-29,1988-05-29,1999-03-25,PLA 96-0597,1826,960597,9/10/2004,Prevention of bleeding episodes in patients with congenital Factor VII deficiency,Designated/Approved,,,Prevention of bleeding in surgical interventions or invasive procedures in patients with congenital F VII deficiency,7/11/2005,7/11/2012,,"Novo Nordisk, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TEMODAR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TEMODAR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",68 FR 6176,Mar-70,https://www.federalregister.gov/documents/2003/02/06/03-2970/determination-of-regulatory-review-period-for-purposes-of-patent-extension-temodar,https://www.govinfo.gov/content/pkg/FR-2003-02-06/pdf/03-2970.pdf,2/6/2003, TEMODAR,,Anthony,TEMODAR,1,213,Anthony,5260291,,,,Schering Corp.,2032,1668,364,1994-01-19,1994-01-19,1999-08-11,NDA 21-029,1136,21029,10/5/1998,Treatment of recurrent malignant glioma.,Designated/Approved,,,"Treatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse who have experienced disease progression on a drug regimen containing a nitrosourea and procarbazine",8/11/1999,8/11/2006,,Schering-Plough Research Institute,Temodar,temozolomide,Schering,NDA,21029,,1998-08-13,1999-08-11,1999,"treatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse who have experienced disease progression on a drug regimen containing a nitrosourea and procarbazine",,Priority,Yes,Yes,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TEMODAR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TEMODAR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",68 FR 6176,Mar-70,https://www.federalregister.gov/documents/2003/02/06/03-2970/determination-of-regulatory-review-period-for-purposes-of-patent-extension-temodar,https://www.govinfo.gov/content/pkg/FR-2003-02-06/pdf/03-2970.pdf,2/6/2003, TEMODAR,,Anthony,TEMODAR,1,214,Anthony,5260291,,,,Schering Corp.,2032,1668,364,1994-01-19,1994-01-19,1999-08-11,NDA 21-029,1136,21029,10/5/1998,Treatment of recurrent malignant glioma.,Designated/Approved,,,Treatment of adult patients with newly diagnosed glioblastoma multiforme concomitatly with radiotherapy and then as maintenance treatment,3/15/2005,3/15/2012,,Schering-Plough Research Institute,Temodar,temozolomide,Schering,NDA,21029,,1998-08-13,1999-08-11,1999,"treatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse who have experienced disease progression on a drug regimen containing a nitrosourea and procarbazine",,Priority,Yes,Yes,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Rapamune,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Rapamune and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 7382,Mar-56,https://www.federalregister.gov/documents/2003/02/13/03-3556/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rapamune,https://www.govinfo.gov/content/pkg/FR-2003-02-13/pdf/03-3556.pdf,2/13/2003, Rapamune,,Anthony,Rapamune,1,215,Anthony,5100899,,,,Sir Roy Caine,2709,2434,275,1992-04-17,1992-04-17,1999-09-15,NDA 21-083,1492,21083,10/31/2012,Treatment of lymphangioleiomyomatosis,Designated/Approved,,,Treatment of lymphangioleiomyomatosis (LAM),5/28/2015,5/28/2022,Treatment of lymphangioleiomyomatosis (LAM),"Pfizer, Inc.",Rapamune,sirolimus,Wyeth Ayerst Research,NDA,21083,,1998-12-15,1999-09-15,1999,prophylaxis of organ rejection in patients receiving renal transplants,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Avandia,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Avandia and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 7381,Mar-55,https://www.federalregister.gov/documents/2003/02/13/03-3555/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avandia,https://www.govinfo.gov/content/pkg/FR-2003-02-13/pdf/03-3555.pdf,2/13/2003, Avandia,,Anthony,Avandia,1,216,Anthony,5002953,,,,Smithkline Beecham Corp.,2042,1859,183,1993-10-23,1993-10-23,1999-05-25,NDA 21-071,1021,21071,,,,,,,,,,,Avandia,rosiglitazone maleate,SKB Pharms,NDA,21071,,1998-11-25,1999-05-25,1999,indicated as an adjunct to diet and exercise to improve glycemic control in patients with Type 2 diabetes mellitus as monotherapy or in combination with metformin,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VALCYTE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VALCYTE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 8027,Mar-72,https://www.federalregister.gov/documents/2003/02/19/03-3872/determination-of-regulatory-review-period-for-purposes-of-patent-extension-valcyte,https://www.govinfo.gov/content/pkg/FR-2003-02-19/pdf/03-3872.pdf,2/19/2003, VALCYTE,,Anthony,VALCYTE,1,217,Anthony,6083953,,,,Syntex,2101,1919,182,1995-06-30,1995-06-30,2001-03-29,NDA 21-304,226,21304,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CANCIDAS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CANCIDAS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 8028,Mar-73,https://www.federalregister.gov/documents/2003/02/19/03-3873/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cancidas,https://www.govinfo.gov/content/pkg/FR-2003-02-19/pdf/03-3873.pdf,2/19/2003, CANCIDAS,,Anthony,CANCIDAS,1,218,Anthony,5514650,,,,"Merck & Co., Inc.",1974,1791,183,1995-09-03,1995-09-03,2001-01-26,NDA 21-227,682,21227,,,,,,,,,,,Cancidas,caspofungin acetate,Merck Research Laboratories,NDA,21227,,2000-07-28,2001-01-26,2001,treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; Starlix,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Starlix and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 9091,Mar-67,https://www.federalregister.gov/documents/2003/02/27/03-4567/determination-of-regulatory-review-period-for-purposes-of-patent-extension-starlix,https://www.govinfo.gov/content/pkg/FR-2003-02-27/pdf/03-4567.pdf,2/27/2003, Starlix,,Anthony,Starlix,1,219,Anthony,34878,,,,Novartis,2147,1775,372,1995-03-09,1995-03-09,2000-12-22,NDA 21-204,1259,21204,,,,,,,,,,,Starlix,nateglinide,Novartis Pharmaceuticals,NDA,21204,,1999-12-17,2000-12-22,2000,"indicated  as  monotherapy  to  lower  blood  glucose  in  patients  with  Type  2  diabetes (non-insulin   dependent   diabetes   mellitus,   NIDDM)   whose   hyperglycemia   cannot   be adequately controlled by diet and physical exercise and who have not been chronically treated with other anti-diabetic agents; also indicated   for   use   in   combination   with   metformin in  patients   whose hyperglycemia  is  inadequately  controlled  with  metformin,  Starlix    may  be  added  to,  but  not substituted for, metformin",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ZOMETA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZOMETA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 9690,Mar-91,https://www.federalregister.gov/documents/2003/02/28/03-4691/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zometa,https://www.govinfo.gov/content/pkg/FR-2003-02-28/pdf/03-4691.pdf,2/28/2003, ZOMETA,,Anthony,ZOMETA,1,220,Anthony,4939130,,,,Novartis Corp.,2810,2201,609,1993-12-12,1993-12-12,2001-08-20,NDA 21-223,1752,21223,,,,,,,,,,,Zometa,zoledronic acid,Novartis Pharmaceuticals,NDA,21223,,1999-12-21,2001-08-20,2001,treatment of hypercalcemia of malignancy,,Priority,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VITREON; Amendment,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is amending its determination regarding the regulatory review period for purposes of patent extension for VITREON that appeared in the Federal Register of December 17, 1998 (63 FR 69633). FDA is amending the document because the agency agrees with the information provided in a request from the applicant for revision of the regulatory review period.",68 FR 12707,26-Mar,https://www.federalregister.gov/documents/2003/03/17/03-6226/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vitreon-amendment,https://www.govinfo.gov/content/pkg/FR-2003-03-17/pdf/03-6226.pdf,3/17/2003, VITREON, Amendment,Anthony,,0,220,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PRECEDEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PRECEDEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 13314,Mar-90,https://www.federalregister.gov/documents/2003/03/19/03-6490/determination-of-regulatory-review-period-for-purposes-of-patent-extension-precedex,https://www.govinfo.gov/content/pkg/FR-2003-03-19/pdf/03-6490.pdf,3/19/2003, PRECEDEX,,Anthony,PRECEDEX,1,221,Anthony,4910214,,,,Orion Corp.,3894,3529,365,1989-04-21,1989-04-21,1999-12-17,NDA 21-038,3919,21038,,,,,,,,,,,Precedex,dexmedetomidine hydrochloride,Abbott Laboratories,NDA,21038,,1998-12-18,1999-12-17,1999,indicated for the sedation of initially intubated and mechanically ventilated adult patients in an intensive care unit setting,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TOPAMAX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TOPAMAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 13315,7-Mar,https://www.federalregister.gov/documents/2003/03/19/03-6507/determination-of-regulatory-review-period-for-purposes-of-patent-extension-topamax,https://www.govinfo.gov/content/pkg/FR-2003-03-19/pdf/03-6507.pdf,3/19/2003, TOPAMAX,,Anthony,TOPAMAX,1,222,Anthony,4513006,,,,"McNeilab, Inc.",3844,2984,860,1986-06-18,1986-06-18,1996-12-24,NDA 20-505,1826,20505,11/25/1992,Treatment of Lennox-Gastaut syndrome.,Designated/Approved,,,As adjunctive therapy in patients two years and older with siezures associated with Lennox-Gastaut syndrome.,8/28/2001,8/28/2008,,"Johnson & Johnson Pharmaceutical R & D, LLC",Topamax,topiramate,RW Johnson,NDA,20505,,1994-12-30,1996-12-24,1996,adjunctive therapy for the treatment of adults with partial onset seizures,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; GENESIS NEUROSTIMULATION SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GENESIS NEUROSTIMULATION SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",68 FR 14244,Mar-92,https://www.federalregister.gov/documents/2003/03/24/03-6892/determination-of-regulatory-review-period-for-purposes-of-patent-extension-genesis-neurostimulation,https://www.govinfo.gov/content/pkg/FR-2003-03-24/pdf/03-6892.pdf,3/24/2003, GENESIS NEUROSTIMULATION SYSTEM,,Anthony,GENESIS NEUROSTIMULATION SYSTEM,1,223,Anthony,4793353,,,,Advanced Neuromodulation Systems,469,292,177,2000-08-11,2000-08-11,2001-11-21,PMA P010032,840,10032,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TEQUIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TEQUIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 14665,Mar-80,https://www.federalregister.gov/documents/2003/03/26/03-7280/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tequin,https://www.govinfo.gov/content/pkg/FR-2003-03-26/pdf/03-7280.pdf,3/26/2003, TEQUIN,,Anthony,TEQUIN,1,224,Anthony,4980470,,,,Kyorin Pharmaceutical Co. through Bristol Myers Squibb,1087,732,355,2001-05-02,1996-12-27,1999-12-17,NDA 21-061,720,21061,,,,,,,,,,,Tequin,gatifloxacin,Bristol-Myers Squibb,NDA,21061,21062,1998-12-28,1999-12-17,1999,"indicated for the treatment of infections caused by susceptible strains of designated microorganisms in the
following conditions: acute bacterial exacerbation of chronic bronchitis, acute sinusitis, community-acquired pneumonia, uncomplicated and complicated urinary tract infections, pyelonephritis, and uncomplicated gonorrhea",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LEVULAN KERASTICK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LEVULAN KERASTICK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 15730,11-Mar,https://www.federalregister.gov/documents/2003/04/01/03-7711/determination-of-regulatory-review-period-for-purposes-of-patent-extension-levulan-kerastick,https://www.govinfo.gov/content/pkg/FR-2003-04-01/pdf/03-7711.pdf,4/1/2003, LEVULAN KERASTICK,,Anthony,LEVULAN KERASTICK,1,225,Anthony,5079262,,,,"DUSA Pharmaceuticals, Inc.",2528,2007,521,1993-01-02,1993-01-02,1999-12-03,NDA 20-965,1524,20965,,,,,,,,,,,Levulan Kerastick,aminolevulinic acid hydrochloride,Dusa,NDA,20965,,1998-07-01,1999-12-03,1999,Levulan Kerastick plus blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator is indicated for the treatment of non-hyperkeratotic actinic keratoses of the face and scalp,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; GYNECARE INTERGEL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GYNECARE INTERGEL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",68 FR 16061,19-Mar,https://www.federalregister.gov/documents/2003/04/02/03-7819/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gynecare-intergel,https://www.govinfo.gov/content/pkg/FR-2003-04-02/pdf/03-7819.pdf,4/2/2003, GYNECARE INTERGEL,,Anthony,GYNECARE INTERGEL,1,226,Anthony,5532221,,,,"Lifecore Medical, Inc.",2438,1453,985,1995-03-17,1995-03-17,2001-11-16,PMA P990015,867,990015,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; OP-1 IMPLANT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OP-1 IMPLANT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",68 FR 16062,20-Mar,https://www.federalregister.gov/documents/2003/04/02/03-7820/determination-of-regulatory-review-period-for-purposes-of-patent-extension-op-1-implant,https://www.govinfo.gov/content/pkg/FR-2003-04-02/pdf/03-7820.pdf,4/2/2003, OP-1 IMPLANT,,Anthony,,0,226,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FASLODEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FASLODEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 18992,Mar-36,https://www.federalregister.gov/documents/2003/04/17/03-9536/determination-of-regulatory-review-period-for-purposes-of-patent-extension-faslodex,https://www.govinfo.gov/content/pkg/FR-2003-04-17/pdf/03-9536.pdf,4/17/2003, FASLODEX,,Anthony,FASLODEX,1,227,Anthony,4659516,,,,"AstraZeneca UK, Ltd.",1935,1541,394,1997-01-08,1997-01-08,2002-04-25,NDA 21-344,1165,21344,,,,,,,,,,,Faslodex,fulvestrant,AstraZeneca Pharmaceuticals,NDA,21344,,2001-03-28,2002-04-25,2002,treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ZETIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZETIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 18992,Mar-34,https://www.federalregister.gov/documents/2003/04/17/03-9534/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zetia,https://www.govinfo.gov/content/pkg/FR-2003-04-17/pdf/03-9534.pdf,4/17/2003, ZETIA,,Anthony,ZETIA,1,228,Anthony,37721,,,,Schering Corp.,1983,1680,303,1997-05-23,1997-05-23,2002-10-25,NDA 21-445,497,21445,,,,,,,,,,,Zetia,ezetimibe,Schering,NDA,21445,,2001-12-27,2002-10-25,2002,"indicated as adjunctive therapy to diet for reduction of elevated total-C, LDL-C and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia either alone or with an HMG-Co A reductase inhibitor; treatment of homozygous familial hypercholesterolemia in combination with either atorvastatin or simvastatin, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or, if such treatments are unavailable, in combination with either atorvastatin or simvastatin alone; treatment of homozygous familial sitosterolemia as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; HYPERION LTK SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HYPERION LTK SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",68 FR 18990,Mar-35,https://www.federalregister.gov/documents/2003/04/17/03-9535/determination-of-regulatory-review-period-for-purposes-of-patent-extension-hyperion-ltk-system,https://www.govinfo.gov/content/pkg/FR-2003-04-17/pdf/03-9535.pdf,4/17/2003, HYPERION LTK SYSTEM,,Anthony,HYPERION LTK SYSTEM,1,229,Anthony,4976709,,,,"Sunrise Technologies International, Inc.",3047,2806,241,1992-02-28,1992-02-28,2000-06-30,PMA P990078,1644,990078,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; VFEND,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VFEND and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 19212,Mar-77,https://www.federalregister.gov/documents/2003/04/18/03-9577/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vfend,https://www.govinfo.gov/content/pkg/FR-2003-04-18/pdf/03-9577.pdf,4/18/2003, VFEND,,Anthony,VFEND,1,230,Anthony,5567817,,,,"Pfizer, Inc.",2452,1898,554,1995-09-08,1995-09-08,2002-05-24,NDA 21-266,945,21266,,,,,,,,,,,Vfend,voriconazole,Pfizer,NDA,21266,21267,2000-11-17,2002-05-24,2002,"treatment of invasive aspergillosis and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp., including Fusarium solani, in patients intolerant of, or refractory to, other therapy",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TIKOSYN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TIKOSYN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 19212,Mar-78,https://www.federalregister.gov/documents/2003/04/18/03-9578/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tikosyn,https://www.govinfo.gov/content/pkg/FR-2003-04-18/pdf/03-9578.pdf,4/18/2003, TIKOSYN,,Anthony,TIKOSYN,1,231,Anthony,4959366,,,,Pfizer,3350,2778,572,1990-08-01,1990-08-01,1999-10-01,NDA 20-931,1827,20931,,,,,,,,,,,Tikosyn,dofetilide,Pfizer,NDA,20931,,1998-03-09,1999-10-01,1999,indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter) in patients with atrial fibrillation /atrial flutter of greater than one week duration who have been converted to normal sinus rhythm,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; IMAGENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IMAGENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",68 FR 19546,9-Mar,https://www.federalregister.gov/documents/2003/04/21/03-9809/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imagent,https://www.govinfo.gov/content/pkg/FR-2003-04-21/pdf/03-9809.pdf,4/21/2003, IMAGENT,,Anthony,IMAGENT,1,232,Anthony,5639443,,,,Alliance Pharmaceutical Corp.,2264,1303,961,1996-03-21,1996-03-21,2002-05-31,NDA 21-191,423,21191,,,,,,,,,,,Imagent,"dimyristoylphosphatidylcholine, perflexane",Alliance Pharmaceuticals,NDA,21191,,1999-10-14,2002-05-31,2002,indicated for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ZEVALIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZEVALIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",68 FR 19547,Mar-94,https://www.federalregister.gov/documents/2003/04/21/03-9694/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zevalin,https://www.govinfo.gov/content/pkg/FR-2003-04-21/pdf/03-9694.pdf,4/21/2003, ZEVALIN,,Anthony,ZEVALIN,1,233,Anthony,5776456,,,,IDEC Pharmaceuticals Corp.,3363,2887,476,1992-12-07,1992-12-07,2002-02-19,BLA 1250190,227,1250190,9/6/1994,Treatment of B-cell non-Hodgkin's lymphoma.,Designated/Approved,,,"Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma",2/19/2002,2/19/2009,,Acrotech Biopharma LLC,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; EXELON,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EXELON and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",68 FR 19548,Mar-63,https://www.federalregister.gov/documents/2003/04/21/03-9663/determination-of-regulatory-review-period-for-purposes-of-patent-extension-exelon,https://www.govinfo.gov/content/pkg/FR-2003-04-21/pdf/03-9663.pdf,4/21/2003, EXELON,,Anthony,EXELON,1,234,Anthony,4948807,,,,Novartis,3424,2313,1111,1990-12-08,1990-12-08,2000-04-21,NDA 20-823,1825,20823,,,,,,,,,,,Exelon,rivastigmine tartrate,Novartis Pharmaceuticals,NDA,20823,21025,1997-04-07,2000-04-21,2000,treatment of mild to moderate dementia of the Alzheimers type,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; AROMASIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AROMASIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 22390,03-10298,https://www.federalregister.gov/documents/2003/04/28/03-10298/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aromasin,https://www.govinfo.gov/content/pkg/FR-2003-04-28/pdf/03-10298.pdf,4/28/2003, AROMASIN,,Anthony,AROMASIN,1,235,Anthony,4808616,,,,Pharmacia,3153,2848,305,1991-03-06,1991-03-06,1999-10-21,NDA 20-753,1745,20753,9/19/1991,Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.,Designated/Approved,,,Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.,10/21/1999,10/21/2006,,Pharmacia & Upjohn,Aromasin,exemestane,Pharmacia and Upjohn,NDA,20753,,1998-12-21,1999-10-21,1999,treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy,,Standard,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; PREVNAR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PREVNAR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",68 FR 22389,03-10302,https://www.federalregister.gov/documents/2003/04/28/03-10302/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prevnar,https://www.govinfo.gov/content/pkg/FR-2003-04-28/pdf/03-10302.pdf,4/28/2003, PREVNAR,,Anthony,PREVNAR,1,236,Anthony,5360897,,,,the University of Rochester through American Home Products,1910,1648,262,1994-11-27,1994-11-27,2000-02-17,PLA 99-0279,1086,990279,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TRACLEER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TRACLEER and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 24485,03-11215,https://www.federalregister.gov/documents/2003/05/07/03-11215/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tracleer,https://www.govinfo.gov/content/pkg/FR-2003-05-07/pdf/03-11215.pdf,5/7/2003, TRACLEER,,Anthony,TRACLEER,1,237,Anthony,5292740,,,,"Hoffman-La Roche, Inc.",2176,1807,369,1995-12-08,1995-12-08,2001-11-20,NDA 21-290,1259,21290,10/6/2000,Treatment of pulmonary arterial hypertension,Designated/Approved,,,Treatment of pulmonary arterial hypertension.,11/20/2001,11/20/2008,,Actelion Pharmaceuticals Ltd,Tracleer,bosentan,Actelion Pharmaceuticals,NDA,21290,,2000-11-17,2001-11-20,2001,indicated for the treatment of pulmonary arterial hypertension,,Standard,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TRACLEER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TRACLEER and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 24485,03-11215,https://www.federalregister.gov/documents/2003/05/07/03-11215/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tracleer,https://www.govinfo.gov/content/pkg/FR-2003-05-07/pdf/03-11215.pdf,5/7/2003, TRACLEER,,Anthony,TRACLEER,1,238,Anthony,5292740,,,,"Hoffman-La Roche, Inc.",2176,1807,369,1995-12-08,1995-12-08,2001-11-20,NDA 21-290,1259,21290,10/6/2000,Treatment of pulmonary arterial hypertension,Designated/Approved,,,"Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability",9/5/2017,9/5/2024,"Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability",Actelion Pharmaceuticals Ltd,Tracleer,bosentan,Actelion Pharmaceuticals,NDA,21290,,2000-11-17,2001-11-20,2001,indicated for the treatment of pulmonary arterial hypertension,,Standard,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BENICAR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BENICAR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 44954,03-19446,https://www.federalregister.gov/documents/2003/07/31/03-19446/determination-of-regulatory-review-period-for-purposes-of-patent-extension-benicar,https://www.govinfo.gov/content/pkg/FR-2003-07-31/pdf/03-19446.pdf,7/31/2003, BENICAR,,Anthony,BENICAR,1,239,Anthony,5616599,,,,"Sankyo Company, Ltd.",2522,1882,640,1995-06-01,1995-06-01,2002-04-25,NDA 21-286,756,21286,,,,,,,,,,,Benicar,olmesartan medoxomil,Sankyo,NDA,21286,,2000-07-25,2002-04-25,2002,treatment of hypertension,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SPECTRACEF,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SPECTRACEF and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 45245,03-19621,https://www.federalregister.gov/documents/2003/08/01/03-19621/determination-of-regulatory-review-period-for-purposes-of-patent-extension-spectracef,https://www.govinfo.gov/content/pkg/FR-2003-08-01/pdf/03-19621.pdf,8/1/2003, SPECTRACEF,,Anthony,SPECTRACEF,1,240,Anthony,4839350,,,,"Meiji Seika Kaisha, Ltd.",1461,851,610,1997-08-31,1997-08-31,2001-08-29,NDA 21-222,1032,21222,,,,,,,,,,,Spectracef,cefditoren pivoxil,TAP Pharmaceutical Products,NDA,21222,,1999-12-29,2001-08-29,2001,"treatment of acute bacterial exacerbation of chronic bronchitis, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; XIGRIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XIGRIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of three applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of three patents which claim that human biological product.",68 FR 66112,03-29333,https://www.federalregister.gov/documents/2003/11/25/03-29333/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xigris,https://www.govinfo.gov/content/pkg/FR-2003-11-25/pdf/03-29333.pdf,11/25/2003, XIGRIS,,Anthony,XIGRIS,3,243,Anthony,4775624; 5681932; and 5270040,,,,Eli Lilly & Co.,2493,2193,300,1995-01-26,1995-01-26,2001-11-21,BLA 125029,1397,125029,,,,,,,,,,,Xigris,drotrecogin alfa,Eli Lilly,BLA,125029,,2001-01-26,2001-11-21,2001,indicated for the reduction of mortality in adult patients with severe sepsis (sepsis associated with acute organ dysfunction) who have a high risk of death,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ABILIFY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ABILIFY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 66449,03-29464,https://www.federalregister.gov/documents/2003/11/26/03-29464/determination-of-regulatory-review-period-for-purposes-of-patent-extension-abilify,https://www.govinfo.gov/content/pkg/FR-2003-11-26/pdf/03-29464.pdf,11/26/2003, ABILIFY,,Anthony,ABILIFY,1,244,Anthony,5006528,,,,"Otsuka Pharmaceutical Co., Ltd.",3416,3035,381,1993-07-11,1993-07-11,2002-11-15,NDA 21-436,5,21436,1/25/2006,Treatment of Tourette's syndrome,Designated/Approved,,,Treatment of pediatric patients with Tourette's,12/12/2014,12/12/2021,Treatment of pediatric patients with Tourette's,Otsuka Pharmaceutical Development,Abilify,aripiprazole,Otsuka Pharmaceutical,NDA,21436,,2001-10-31,2002-11-15,2002,treatment of schizophrenia,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; DERAMAXX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DERAMAXX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",68 FR 67194,03-29742,https://www.federalregister.gov/documents/2003/12/01/03-29742/determination-of-regulatory-review-period-for-purposes-of-patent-extension-deramaxx,https://www.govinfo.gov/content/pkg/FR-2003-12-01/pdf/03-29742.pdf,12/1/2003, DERAMAXX,,Anthony,DERAMAXX,1,245,Anthony,5521207,,,,G. D. Searle L.L.C.,1675,1578,97,1998-01-21,2002-05-17,2002-08-21,NADA 141-203,882,141203,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LEXAPRO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LEXAPRO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 67455,03-29927,https://www.federalregister.gov/documents/2003/12/02/03-29927/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lexapro,https://www.govinfo.gov/content/pkg/FR-2003-12-02/pdf/03-29927.pdf,12/2/2003, LEXAPRO,,Anthony,LEXAPRO,1,246,Anthony,34712,,,,H. Lundbeck A/S,1146,636,510,1999-06-27,1999-06-27,2002-08-14,NDA 21-323,827,21323,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; INVANZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INVANZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 67457,03-29929,https://www.federalregister.gov/documents/2003/12/02/03-29929/determination-of-regulatory-review-period-for-purposes-of-patent-extension-invanz,https://www.govinfo.gov/content/pkg/FR-2003-12-02/pdf/03-29929.pdf,12/2/2003, INVANZ,,Anthony,INVANZ,1,247,Anthony,5478820,,,,Syngenta Ltd.,2273,1916,357,1995-09-03,1995-09-03,2001-11-21,NDA 21-337,1023,21337,,,,,,,,,,,Invanz,ertapenem sodium,Merck,NDA,21337,,2000-11-30,2001-11-21,2001,"treatment of complicated intra-abdominal infections; complicated skin and skin structure infections; community acquired pneumonia; complicated urinary tract infections including pyelonephritis; acute pelvic infections including postpartum endomyometritis, septic abortion and post surgical gynecologic infections",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ELOXATIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ELOXATIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 67456,03-29928,https://www.federalregister.gov/documents/2003/12/02/03-29928/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eloxatin,https://www.govinfo.gov/content/pkg/FR-2003-12-02/pdf/03-29928.pdf,12/2/2003, ELOXATIN,,Anthony,ELOXATIN,1,248,Anthony,5420319,,,,Sanofi-Synthelabo,3417,3370,47,1993-04-03,1993-08-16,2002-08-09,NDA 21-063,1138,21063,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; STRATTERA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for STRATTERA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",68 FR 67678,03-30028,https://www.federalregister.gov/documents/2003/12/03/03-30028/determination-of-regulatory-review-period-for-purposes-of-patent-extension-strattera,https://www.govinfo.gov/content/pkg/FR-2003-12-03/pdf/03-30028.pdf,12/3/2003, STRATTERA,,Anthony,STRATTERA,1,249,Anthony,5658590,,,,Eli Lilly & Co.,7718,7307,411,1981-10-11,1981-10-11,2002-11-26,NDA 21-411,685,21411,,,,,,,,,,,Strattera,atomoxetine hydrochloride,Eli Lilly,NDA,21411,,2001-10-12,2002-11-26,2002,treatment of Attention-Deficit Hyperactivity Disorder (ADHD) for children and adolescents ages 6-18 and adults,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LUMIGAN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LUMIGAN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",69 FR 4170,E4-130,https://www.federalregister.gov/documents/2004/01/28/E4-130/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lumigan,https://www.govinfo.gov/content/pkg/FR-2004-01-28/pdf/E4-130.pdf,1/28/2004, LUMIGAN,,Anthony,LUMIGAN,1,250,Anthony,5688819,,,,Allergan,1967,1787,180,1995-10-29,1995-10-29,2001-03-16,NDA 21-275,907,21275,,,,,,,,,,,Lumigan,bimatoprost,Allergan,NDA,21275,,2000-09-18,2001-03-16,2001,indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; REMODULIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REMODULIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 4306,04-1841,https://www.federalregister.gov/documents/2004/01/29/04-1841/determination-of-regulatory-review-period-for-purposes-of-patent-extension-remodulin,https://www.govinfo.gov/content/pkg/FR-2004-01-29/pdf/04-1841.pdf,1/29/2004, REMODULIN,,Anthony,REMODULIN,1,251,Anthony,5153222,,,,United Therapeutics,4026,3443,583,1991-05-15,1991-05-15,2002-05-21,NDA 21-272,337,21272,,,,,,,,,,,Remodulin,treprostinil sodium,United Therapeutics,NDA,21272,,2000-10-16,2002-05-21,2002,treatment of pulmonary arterial hypertension,,Priority,Yes,Yes,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; FROVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FROVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of two applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of two patents that claims that human drug product.",69 FR 4305,04-1840,https://www.federalregister.gov/documents/2004/01/29/04-1840/determination-of-regulatory-review-period-for-purposes-of-patent-extension-frova,https://www.govinfo.gov/content/pkg/FR-2004-01-29/pdf/04-1840.pdf,1/29/2004, FROVA,,Anthony,FROVA,2,253,Anthony,5464864 and 5616603,,,,"Vernalis, Ltd.",2201,1186,1015,1995-11-01,1995-11-01,2001-11-08,NDA 21-006,1096,21006,,,,,,,,,,,Frova,frovatriptan,Elan Pharmaceuticals,NDA,21006,,1999-01-29,2001-11-08,2001,acute treatment of migraine,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; EXTRANAEAL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EXTRANAEAL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 5858,Apr-46,https://www.federalregister.gov/documents/2004/02/06/04-2546/determination-of-regulatory-review-period-for-purposes-of-patent-extension-extranaeal,https://www.govinfo.gov/content/pkg/FR-2004-02-06/pdf/04-2546.pdf,2/6/2004, EXTRANAEAL,,Anthony,EXTRANAEAL,1,254,Anthony,4761237,,,,"Baxter International, Inc.",2207,1478,729,1996-12-06,1996-12-06,2002-12-20,NDA 21-321,1467,21321,,,,,,,,,,,Extraneal,icodextrin,Baxter Healthcare,NDA,21321,,2000-12-22,2002-12-20,2002,indicated for a single daily exchange for the long (8-16-hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of chronic renal failure,,Standard,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ORTHO-EVRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ORTHO-EVRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 5859,Apr-47,https://www.federalregister.gov/documents/2004/02/06/04-2547/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ortho-evra,https://www.govinfo.gov/content/pkg/FR-2004-02-06/pdf/04-2547.pdf,2/6/2004, ORTHO-EVRA,,Anthony,ORTHO-EVRA,1,255,Anthony,5876746,,,,Johnson,2001,1666,335,1996-05-31,1996-05-31,2001-11-20,NDA 21-180,664,21180,,,,,,,,,,,Ortho Evra,"norelgestromin, ethinyl estradiol",RW Johnson Pharmaceutical Research,NDA,21180,,2000-12-21,2001-11-20,2001,indicated for the prevention of pregnancy,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ZELNORM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZELNORM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 12161,Apr-58,https://www.federalregister.gov/documents/2004/03/15/04-5758/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zelnorm,https://www.govinfo.gov/content/pkg/FR-2004-03-15/pdf/04-5758.pdf,3/15/2004, ZELNORM,,Anthony,ZELNORM,1,256,Anthony,5510353,,,,Novartis Pharmaceuticals,2826,1931,895,1994-10-30,1994-10-30,2002-07-24,NDA 21-200,1888,21200,,,,,,,,,,,Zelnorm,tegaserod maleate,Novartis Pharmaceuticals,NDA,21200,,2000-02-11,2002-07-24,2002,short-term treatment of women with irritable bowel syndrome whose primary bowel symptom is constipation,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; IPRIVASK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IPRIVASK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 12158,3-Apr,https://www.federalregister.gov/documents/2004/03/15/04-5703/determination-of-regulatory-review-period-for-purposes-of-patent-extension-iprivask,https://www.govinfo.gov/content/pkg/FR-2004-03-15/pdf/04-5703.pdf,3/15/2004, IPRIVASK,,Anthony,IPRIVASK,1,257,Anthony,4745177,,,,Novartis Corp.,4707,3696,1011,1990-05-17,1990-05-17,2003-04-04,NDA 21-271,5,21271,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FABRAZYME,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FABRAZYME and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",69 FR 12159,Apr-60,https://www.federalregister.gov/documents/2004/03/15/04-5760/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fabrazyme,https://www.govinfo.gov/content/pkg/FR-2004-03-15/pdf/04-5760.pdf,3/15/2004, FABRAZYME,,Anthony,FABRAZYME,1,258,Anthony,5356804,,,,Genzyme,1843,807,1036,1998-04-09,1998-04-09,2003-04-24,PLA 103979,1438,103979,1/19/1988,Treatment of Fabry's disease.,Designated/Approved,,,For use in patients with Fabry disease to reduce globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types,4/24/2003,4/24/2010,,Genzyme Corporation,Fabrazyme,agalsidase beta,Genzyme,BLA,103979,,2000-06-23,2003-04-24,2003,indicated for use in patients with Fabry disease to reduce globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types,,Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; FABRAZYME,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FABRAZYME and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",69 FR 12159,Apr-60,https://www.federalregister.gov/documents/2004/03/15/04-5760/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fabrazyme,https://www.govinfo.gov/content/pkg/FR-2004-03-15/pdf/04-5760.pdf,3/15/2004, FABRAZYME,,Anthony,FABRAZYME,1,259,Anthony,5356804,,,,Genzyme,1843,807,1036,1998-04-09,1998-04-09,2003-04-24,PLA 103979,1438,103979,1/19/1988,Treatment of Fabry's disease.,Designated/Approved,,,treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease,3/11/2021,3/11/2028,treatment of pediatric patients 2 years of age up to patients 8 years of age with confirmed Fabry disease,Genzyme Corporation,Fabrazyme,agalsidase beta,Genzyme,BLA,103979,,2000-06-23,2003-04-24,2003,indicated for use in patients with Fabry disease to reduce globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types,,Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; FACTIVE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FACTIVE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of three applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of three patents that claim that human drug product.",69 FR 12160,Apr-59,https://www.federalregister.gov/documents/2004/03/15/04-5759/determination-of-regulatory-review-period-for-purposes-of-patent-extension-factive,https://www.govinfo.gov/content/pkg/FR-2004-03-15/pdf/04-5759.pdf,3/15/2004, FACTIVE,,Anthony,FACTIVE,3,262,Anthony,5962468; 5776944; and 5633262,,,,LG Life Sciences,2038,832,1206,1997-09-06,1997-09-06,2003-04-04,NDA 21-158,659,21158,,,,,,,,,,,Factive,gemifloxacin mesylate,LG Life Sciences,NDA,21158,,1999-12-16,2003-04-04,2003,treatment of community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VELCADE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VELCADE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 13055,Apr-59,https://www.federalregister.gov/documents/2004/03/19/04-6159/determination-of-regulatory-review-period-for-purposes-of-patent-extension-velcade,https://www.govinfo.gov/content/pkg/FR-2004-03-19/pdf/04-6159.pdf,3/19/2004, VELCADE,,Anthony,VELCADE,1,263,Anthony,5780454,,,,Millenium Pharmaceuticals,1723,1610,113,1998-08-26,1998-08-26,2003-05-13,NDA 21-602,920,21602,5/30/2012,Treatment of mantle cell lymphoma.,Designated/Approved,,,Treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.,12/8/2006,12/8/2013,,"Millennium Pharmaceuticals, Inc.",Velcade,bortezomib,Millennium Pharmaceuticals,NDA,21602,,2003-01-21,2003-05-13,2003,treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy,,Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; VELCADE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VELCADE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 13055,Apr-59,https://www.federalregister.gov/documents/2004/03/19/04-6159/determination-of-regulatory-review-period-for-purposes-of-patent-extension-velcade,https://www.govinfo.gov/content/pkg/FR-2004-03-19/pdf/04-6159.pdf,3/19/2004, VELCADE,,Anthony,VELCADE,1,264,Anthony,5780454,,,,Millenium Pharmaceuticals,1723,1610,113,1998-08-26,1998-08-26,2003-05-13,NDA 21-602,920,21602,5/30/2012,Treatment of mantle cell lymphoma.,Designated/Approved,,,Treatment of patients with mantle cell lymphoma.,10/8/2014,10/8/2021,Treatment of patients with mantle cell lymphoma who have not received at least 1 prior therapy,"Millennium Pharmaceuticals, Inc.",Velcade,bortezomib,Millennium Pharmaceuticals,NDA,21602,,2003-01-21,2003-05-13,2003,treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy,,Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; VELCADE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VELCADE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 13055,Apr-59,https://www.federalregister.gov/documents/2004/03/19/04-6159/determination-of-regulatory-review-period-for-purposes-of-patent-extension-velcade,https://www.govinfo.gov/content/pkg/FR-2004-03-19/pdf/04-6159.pdf,3/19/2004, VELCADE,,Anthony,VELCADE,1,265,Anthony,5780454,,,,Millenium Pharmaceuticals,1723,1610,113,1998-08-26,1998-08-26,2003-05-13,NDA 21-602,920,21602,1/15/2003,Treatment of multiple myeloma,Designated/Approved,,,Treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy,5/13/2003,5/13/2010,,"Millennium Pharmaceuticals, Inc.",Velcade,bortezomib,Millennium Pharmaceuticals,NDA,21602,,2003-01-21,2003-05-13,2003,treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy,,Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; VELCADE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VELCADE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 13055,Apr-59,https://www.federalregister.gov/documents/2004/03/19/04-6159/determination-of-regulatory-review-period-for-purposes-of-patent-extension-velcade,https://www.govinfo.gov/content/pkg/FR-2004-03-19/pdf/04-6159.pdf,3/19/2004, VELCADE,,Anthony,VELCADE,1,266,Anthony,5780454,,,,Millenium Pharmaceuticals,1723,1610,113,1998-08-26,1998-08-26,2003-05-13,NDA 21-602,920,21602,1/15/2003,Treatment of multiple myeloma,Designated/Approved,,,Treatment of multiple myeloma patients who have received at least one prior therapy,3/25/2005,3/25/2012,,"Millennium Pharmaceuticals, Inc.",Velcade,bortezomib,Millennium Pharmaceuticals,NDA,21602,,2003-01-21,2003-05-13,2003,treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy,,Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; VELCADE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VELCADE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 13055,Apr-59,https://www.federalregister.gov/documents/2004/03/19/04-6159/determination-of-regulatory-review-period-for-purposes-of-patent-extension-velcade,https://www.govinfo.gov/content/pkg/FR-2004-03-19/pdf/04-6159.pdf,3/19/2004, VELCADE,,Anthony,VELCADE,1,267,Anthony,5780454,,,,Millenium Pharmaceuticals,1723,1610,113,1998-08-26,1998-08-26,2003-05-13,NDA 21-602,920,21602,1/15/2003,Treatment of multiple myeloma,Designated/Approved,,,First-line therapy of multiple myeloma.,6/20/2008,6/20/2015,,"Millennium Pharmaceuticals, Inc.",Velcade,bortezomib,Millennium Pharmaceuticals,NDA,21602,,2003-01-21,2003-05-13,2003,treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy,,Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; Neotame,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for neotame and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that food additive.",69 FR 40946,04-15275,https://www.federalregister.gov/documents/2004/07/07/04-15275/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neotame,https://www.govinfo.gov/content/pkg/FR-2004-07-07/pdf/04-15275.pdf,7/7/2004, Neotame,,Anthony,,0,267,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DAPTACEL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DAPTACEL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",69 FR 40945,04-15274,https://www.federalregister.gov/documents/2004/07/07/04-15274/determination-of-regulatory-review-period-for-purposes-of-patent-extension-daptacel,https://www.govinfo.gov/content/pkg/FR-2004-07-07/pdf/04-15274.pdf,7/7/2004, DAPTACEL,,Anthony,DAPTACEL,1,268,Anthony,5667787,,,,Aventis Pasteur,3591,1415,2176,1992-07-16,1992-07-16,2002-05-14,BLA 103666,242,103666,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NEUTERSOL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NEUTERSOL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of two applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of two patents which claim that animal drug product.",69 FR 40944,04-15301,https://www.federalregister.gov/documents/2004/07/07/04-15301/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neutersol,https://www.govinfo.gov/content/pkg/FR-2004-07-07/pdf/04-15301.pdf,7/7/2004, NEUTERSOL,,Anthony,NEUTERSOL,2,270,Anthony,5070808 and 4937234,,,,"Technology Transfer, Inc.",4222,4188,34,1991-08-27,2003-03-17,2003-03-17,NADA 141-217,5,141217,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ELITEK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ELITEK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",69 FR 41509,04-15569,https://www.federalregister.gov/documents/2004/07/09/04-15569/determination-of-regulatory-review-period-for-purposes-of-patent-extension-elitek,https://www.govinfo.gov/content/pkg/FR-2004-07-09/pdf/04-15569.pdf,7/9/2004, ELITEK,,Anthony,ELITEK,1,271,Anthony,5382518,,,,Sanofi-Synthelabo,2360,1420,940,1996-01-27,1996-01-27,2002-07-12,BLA 103946,1638,103946,10/11/2000,Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.,Designated/Approved,,,"Initial management of plasma uric acid levels in pediatric patients with leukemia,lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.",7/12/2002,7/12/2009,,Sanofi-Synthelabo Research,Elitek,rasburicase,Sanofi-Synthelabo,BLA,103946,,1999-12-16,2002-07-12,2002,"indicated for the initial management of plasma uric acid levels in pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid",,Standard,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; XOPENEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XOPENEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 41812,04-15712,https://www.federalregister.gov/documents/2004/07/12/04-15712/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xopenex,https://www.govinfo.gov/content/pkg/FR-2004-07-12/pdf/04-15712.pdf,7/12/2004, XOPENEX,,Anthony,XOPENEX,1,272,Anthony,5362755,,,,"Sepracor, Inc.",1458,824,634,1995-03-30,1995-03-30,1999-03-25,NDA 20-837,502,20837,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CAMPATH,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CAMPATH and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",69 FR 42059,04-15802,https://www.federalregister.gov/documents/2004/07/13/04-15802/determination-of-regulatory-review-period-for-purposes-of-patent-extension-campath,https://www.govinfo.gov/content/pkg/FR-2004-07-13/pdf/04-15802.pdf,7/13/2004, CAMPATH,,Anthony,CAMPATH,1,273,Anthony,5545403,,,,Millenium,3423,2921,502,1991-12-25,1991-12-25,2001-05-07,BLA 103948,632,103948,10/20/1997,Treatment of chronic lymphocytic leukemia.,Designated/Approved,,,The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.,5/7/2001,5/7/2008,,Genzyme Corporation,Campath,alemtuzumab,Millennium and ILEX Partners,BLA,103948,,1999-12-23,2001-05-07,2001,treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy,,Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; LEA'S SHIELD,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LEA'S SHIELD and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",69 FR 45335,04-17209,https://www.federalregister.gov/documents/2004/07/29/04-17209/determination-of-regulatory-review-period-for-purposes-of-patent-extension-leas-shield,https://www.govinfo.gov/content/pkg/FR-2004-07-29/pdf/04-17209.pdf,7/29/2004, LEA'S SHIELD,,Anthony,,0,273,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; REYATAZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REYATAZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 57937,04-21625,https://www.federalregister.gov/documents/2004/09/28/04-21625/determination-of-regulatory-review-period-for-purposes-of-patent-extension-reyataz,https://www.govinfo.gov/content/pkg/FR-2004-09-28/pdf/04-21625.pdf,9/28/2004, REYATAZ,,Anthony,REYATAZ,1,274,Anthony,5849911,,,,Novartis Corp.,1723,1540,183,1998-10-03,1998-10-03,2003-06-20,NDA 21-567,72,21567,,,,,,,,,,,Reyataz,atazanavir sulfate,Bristol-Myers Squibb,NDA,21567,,2002-12-20,2003-06-20,2003,in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VISUDYNE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VISUDYNE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 57939,04-21678,https://www.federalregister.gov/documents/2004/09/28/04-21678/determination-of-regulatory-review-period-for-purposes-of-patent-extension-visudyne,https://www.govinfo.gov/content/pkg/FR-2004-09-28/pdf/04-21678.pdf,9/28/2004, VISUDYNE,,Anthony,VISUDYNE,1,275,Anthony,5095030,,,,University of British Columbia,3194,2953,241,1991-07-17,1991-07-17,2000-04-12,NDA 21-119,5,21119,,,,,,,,,,,Visudyne,verteporfin,QLT Phototherapeutics,NDA,21119,,1999-08-16,2000-04-12,2000,treatment of age-related macular degeneration in patients with predominantly classic subfoveal choroidal neovascularization,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KINERET,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KINERET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",69 FR 57938,04-21675,https://www.federalregister.gov/documents/2004/09/28/04-21675/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kineret,https://www.govinfo.gov/content/pkg/FR-2004-09-28/pdf/04-21675.pdf,9/28/2004, KINERET,,Anthony,Kineret,1,276,Anthony,5075222,,,,"Amgen, Inc.",4101,3413,688,1990-08-25,1990-08-25,2001-11-14,BLA 103950,1825,103950,6/29/2020,Treatment of Deficiency of IL-1 Receptor Antagonist,Designated/Approved,,,treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA),12/18/2020,12/18/2027,treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA),Swedish Orphan Biovitrum AB (PUBL),Kineret,anakinra,Amgen,BLA,103950,,1999-12-28,2001-11-14,2001,"indicated for the reduction in signs and symptoms of moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed one or more disease modifying antirheumatic drugs (DMARDs)",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KINERET,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KINERET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",69 FR 57938,04-21675,https://www.federalregister.gov/documents/2004/09/28/04-21675/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kineret,https://www.govinfo.gov/content/pkg/FR-2004-09-28/pdf/04-21675.pdf,9/28/2004, KINERET,,Anthony,Kineret,1,277,Anthony,5075222,,,,"Amgen, Inc.",4101,3413,688,1990-08-25,1990-08-25,2001-11-14,BLA 103950,1825,103950,8/19/2010,Treatment of cryopyrin-associated periodic syndromes,Designated/Approved,,,Treatment of neonatal-onset multisystem inflammatory disease (NOMID),12/21/2012,12/21/2019,,Swedish Orphan Biovitrum AB (publ),Kineret,anakinra,Amgen,BLA,103950,,1999-12-28,2001-11-14,2001,"indicated for the reduction in signs and symptoms of moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed one or more disease modifying antirheumatic drugs (DMARDs)",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; DERMAGRAFT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DERMAGRAFT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",69 FR 58176,04-21749,https://www.federalregister.gov/documents/2004/09/29/04-21749/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dermagraft,https://www.govinfo.gov/content/pkg/FR-2004-09-29/pdf/04-21749.pdf,9/29/2004, DERMAGRAFT,,Anthony,Dermagraft,1,278,Anthony,4963489,,,,"Advanced Tissue Sciences, Inc.",4050,3650,400,1990-08-29,1990-08-29,2001-09-28,PMA P00036,5,36,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AMEVIVE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AMEVIVE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",69 FR 58445,04-21874,https://www.federalregister.gov/documents/2004/09/30/04-21874/determination-of-regulatory-review-period-for-purposes-of-patent-extension-amevive,https://www.govinfo.gov/content/pkg/FR-2004-09-30/pdf/04-21874.pdf,9/30/2004, AMEVIVE,,Anthony,AMEVIVE,1,279,Anthony,5547853,,,,"Biogen, Inc.",2104,1618,486,1997-04-29,1997-04-29,2003-01-30,BLA 12536,1259,12536,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; GANIRELIX ACETATE INJECTION (Formerly ANTAGON),Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GANIRELIX ACETATE INJECTION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",69 FR 63547,04-24378,https://www.federalregister.gov/documents/2004/11/02/04-24378/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ganirelix-acetate,https://www.govinfo.gov/content/pkg/FR-2004-11-02/pdf/04-24378.pdf,11/2/2004, GANIRELIX ACETATE INJECTION (Formerly ANTAGON),,Anthony,GANIRELIX ACETATE INJECTION,1,280,Anthony,4801577,,,,Syntex,3558,3376,182,1989-11-02,1989-11-02,1999-07-29,NDA 21-057,5,21057,,,,,,,,,,,Antagon,ganirelix acetate,Organon,NDA,21057,,1999-01-29,1999-07-29,1999,indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; GEODON,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GEODON and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",70 FR 22341,May-87,https://www.federalregister.gov/documents/2005/04/29/05-8587/determination-of-regulatory-review-period-for-purposes-of-patent-extension-geodon,https://www.govinfo.gov/content/pkg/FR-2005-04-29/pdf/05-8587.pdf,4/29/2005, GEODON,,Anthony,GEODON,1,281,Anthony,4831031,,,,"Pfizer, Inc.",3933,2511,1422,1990-05-03,1997-03-17,2001-02-05,NDA 20-825,1825,20825,,,,,,,,,,,Geodon,ziprasidone hydrochloride,Pfizer Central Research,NDA,20825,,1997-03-17,2001-02-05,2001,treatment of schizophrenia,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ERTACZO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ERTACZO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",70 FR 25091,May-62,https://www.federalregister.gov/documents/2005/05/12/05-9462/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ertaczo,https://www.govinfo.gov/content/pkg/FR-2005-05-12/pdf/05-9462.pdf,5/12/2005, ERTACZO,,Anthony,ERTACZO,1,282,Anthony,5135943,,,,"Ferrer Internacional, S.A.",2718,1914,804,1996-07-03,1996-07-03,2003-12-10,NDA 21-385,1776,21385,,,,,,,,,,,Ertaczo,sertaconazole nitrate,Mylan Pharmaceuticals,NDA,21385,,2001-09-28,2003-12-10,2003,"treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; CLARINEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CLARINEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",70 FR 43159,05-14695,https://www.federalregister.gov/documents/2005/07/26/05-14695/determination-of-regulatory-review-period-for-purposes-of-patent-extension-clarinex,https://www.govinfo.gov/content/pkg/FR-2005-07-26/pdf/05-14695.pdf,7/26/2005, CLARINEX,,Anthony,CLARINEX,1,283,Anthony,4659716,,,,Schering Corp.,1354,561,793,1998-04-09,1998-04-09,2001-12-21,NDA 21-165,1074,21165,,,,,,,,,,,Clarinex,desloratadine,Schering,NDA,21165,,1999-10-21,2001-12-21,2001,indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 12 years of age and older,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ATS Open Pivot Bileaf Heart Valve,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ATS Open Pivot Bileaf Heart Valve and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",70 FR 43437,05-14748,https://www.federalregister.gov/documents/2005/07/27/05-14748/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ats-open-pivot-bileaf,https://www.govinfo.gov/content/pkg/FR-2005-07-27/pdf/05-14748.pdf,7/27/2005, ATS Open Pivot Bileaf Heart Valve,,Anthony,ATS Open Pivot Bileaf Heart Valve,1,284,Anthony,5354330,,,,"ATS Medical, Inc.",1418,980,438,1996-11-27,1996-11-27,2000-10-13,PMA P990046,505,990046,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZUBRIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZUBRIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",70 FR 43701,05-14921,https://www.federalregister.gov/documents/2005/07/28/05-14921/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zubrin,https://www.govinfo.gov/content/pkg/FR-2005-07-28/pdf/05-14921.pdf,7/28/2005, ZUBRIN,,Anthony,ZUBRIN,1,285,Anthony,4826868,,,,Johnson & Johnson,2347,1887,460,1996-10-28,2003-03-31,2003-03-31,NADA 141-193,1405,141193,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZOMETA; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of February 28, 2003 (68 FR 9690). The document announced that FDA had determined the regulatory review period for ZOMETA. A Request for Revision of Regulatory Review Period was filed for the product on May 4, 2005. FDA reviewed its records and found that the effective date of the investigational new drug application (IND) was incorrect due to a clerical error. Therefore, FDA is revising the determination of the regulatory review period to reflect the correct effective date for the IND.",70 FR 67178,05-22012,https://www.federalregister.gov/documents/2005/11/04/05-22012/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zometa-correction,https://www.govinfo.gov/content/pkg/FR-2005-11-04/pdf/05-22012.pdf,11/4/2005, ZOMETA, Correction,Anthony,,0,285,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SPIRIVA HANDIHALER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SPIRIVA HANDIHALER and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 4592,E6-1050,https://www.federalregister.gov/documents/2006/01/27/E6-1050/determination-of-regulatory-review-period-for-purposes-of-patent-extension-spiriva-handihaler,https://www.govinfo.gov/content/pkg/FR-2006-01-27/pdf/E6-1050.pdf,1/27/2006, SPIRIVA HANDIHALER,,Anthony,SPIRIVA HANDIHALER,1,286,Anthony,5610163,,,,Boehringer Ingelheim Corporation,3318,2557,761,2004-08-31,1995-01-01,2004-01-30,NDA 21-395,1421,21395,,,,,,,,,,,Spiriva Handihaler,tiotropium bromide,Boehringer Ingelheim Pharmaceuticals,NDA,21395,,2001-12-13,2004-01-30,2004,"long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ENABLEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ENABLEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 4919,E6-1072,https://www.federalregister.gov/documents/2006/01/30/E6-1072/determination-of-regulatory-review-period-for-purposes-of-patent-extension-enablex,https://www.govinfo.gov/content/pkg/FR-2006-01-30/pdf/E6-1072.pdf,1/30/2006, ENABLEX,,Anthony,ENABLEX,1,287,Anthony,5096890,,,,Novartis International Phamaceutical Ltd.,3824,3073,751,2005-07-08,1994-07-06,2004-12-22,NDA 21-513,2298,21513,,,,,,,,,,,Enablex,darifenacin hydrobromide,Novartis Pharmaceuticals,NDA,21513,,2002-12-03,2004-12-22,2004,treatment of overactive bladder,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; XOLAIR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XOLAIR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 4920,E6-1078,https://www.federalregister.gov/documents/2006/01/30/E6-1078/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xolair,https://www.govinfo.gov/content/pkg/FR-2006-01-30/pdf/E6-1078.pdf,1/30/2006, XOLAIR,,Anthony,XOLAIR,1,288,Anthony,6267958,,,,Genentech,3440,2329,1111,2005-04-08,1994-01-20,2003-06-20,BLA 103976,463,103976,,,,,,,,,,,Xolair,omalizumab,Genentech,BLA,103976,,2000-06-05,2003-06-20,2003,indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; HUMIRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HUMIRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 5342,E6-1313,https://www.federalregister.gov/documents/2006/02/01/E6-1313/determination-of-regulatory-review-period-for-purposes-of-patent-extension-humira,https://www.govinfo.gov/content/pkg/FR-2006-02-01/pdf/E6-1313.pdf,2/1/2006, HUMIRA,,Anthony,HUMIRA,1,289,Anthony,6090382,,,,Abbott Biotechnology Ltd.,1722,1443,279,2005-04-08,1998-04-16,2002-12-31,BLA 125057,326,125057,5/13/2015,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),Designated/Approved,,,Treatment of moderate to severe hidradenitis suppurativa,9/9/2015,9/9/2022,Treatment of moderate to severe hidradenitis suppurativa,"AbbVie, Inc.",Humira,adalimumab,Abbott Laboratories,BLA,125057,,2002-03-29,2002-12-31,2002,indicated for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs),,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; HUMIRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HUMIRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 5342,E6-1313,https://www.federalregister.gov/documents/2006/02/01/E6-1313/determination-of-regulatory-review-period-for-purposes-of-patent-extension-humira,https://www.govinfo.gov/content/pkg/FR-2006-02-01/pdf/E6-1313.pdf,2/1/2006, HUMIRA,,Anthony,HUMIRA,1,290,Anthony,6090382,,,,Abbott Biotechnology Ltd.,1722,1443,279,2005-04-08,1998-04-16,2002-12-31,BLA 125057,326,125057,3/21/2005,Treatment of juvenile rheumatoid arthritis,Designated/Approved,,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.,2/21/2008,2/21/2015,,AbbVie Inc.,Humira,adalimumab,Abbott Laboratories,BLA,125057,,2002-03-29,2002-12-31,2002,indicated for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs),,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; HUMIRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HUMIRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 5342,E6-1313,https://www.federalregister.gov/documents/2006/02/01/E6-1313/determination-of-regulatory-review-period-for-purposes-of-patent-extension-humira,https://www.govinfo.gov/content/pkg/FR-2006-02-01/pdf/E6-1313.pdf,2/1/2006, HUMIRA,,Anthony,HUMIRA,1,291,Anthony,6090382,,,,Abbott Biotechnology Ltd.,1722,1443,279,2005-04-08,1998-04-16,2002-12-31,BLA 125057,326,125057,3/21/2005,Treatment of juvenile rheumatoid arthritis,Designated/Approved,,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.,9/30/2014,9/30/2021,Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.,AbbVie Inc.,Humira,adalimumab,Abbott Laboratories,BLA,125057,,2002-03-29,2002-12-31,2002,indicated for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs),,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; HUMIRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HUMIRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 5342,E6-1313,https://www.federalregister.gov/documents/2006/02/01/E6-1313/determination-of-regulatory-review-period-for-purposes-of-patent-extension-humira,https://www.govinfo.gov/content/pkg/FR-2006-02-01/pdf/E6-1313.pdf,2/1/2006, HUMIRA,,Anthony,HUMIRA,1,292,Anthony,6090382,,,,Abbott Biotechnology Ltd.,1722,1443,279,2005-04-08,1998-04-16,2002-12-31,BLA 125057,326,125057,5/13/2014,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",Designated/Approved,,,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",6/30/2016,6/30/2023,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients","AbbVie, Inc.",Humira,adalimumab,Abbott Laboratories,BLA,125057,,2002-03-29,2002-12-31,2002,indicated for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs),,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; HUMIRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HUMIRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 5342,E6-1313,https://www.federalregister.gov/documents/2006/02/01/E6-1313/determination-of-regulatory-review-period-for-purposes-of-patent-extension-humira,https://www.govinfo.gov/content/pkg/FR-2006-02-01/pdf/E6-1313.pdf,2/1/2006, HUMIRA,,Anthony,HUMIRA,1,293,Anthony,6090382,,,,Abbott Biotechnology Ltd.,1722,1443,279,2005-04-08,1998-04-16,2002-12-31,BLA 125057,326,125057,5/13/2015,Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease),Designated/Approved,,,Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.,10/16/2018,10/16/2025,Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.,"AbbVie, Inc.",Humira,adalimumab,Abbott Laboratories,BLA,125057,,2002-03-29,2002-12-31,2002,indicated for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs),,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; HUMIRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HUMIRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 5342,E6-1313,https://www.federalregister.gov/documents/2006/02/01/E6-1313/determination-of-regulatory-review-period-for-purposes-of-patent-extension-humira,https://www.govinfo.gov/content/pkg/FR-2006-02-01/pdf/E6-1313.pdf,2/1/2006, HUMIRA,,Anthony,HUMIRA,1,294,Anthony,6090382,,,,Abbott Biotechnology Ltd.,1722,1443,279,2005-04-08,1998-04-16,2002-12-31,BLA 125057,326,125057,5/11/2011,Treatment of pediatric patients with ulcerative colitis,Designated/Approved,,,treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. Limitations of Use: The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers.,2/24/2021,2/24/2028,treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. Limitations of Use: The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers.,"AbbVie, Inc.",Humira,adalimumab,Abbott Laboratories,BLA,125057,,2002-03-29,2002-12-31,2002,indicated for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs),,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; HUMIRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HUMIRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 5342,E6-1313,https://www.federalregister.gov/documents/2006/02/01/E6-1313/determination-of-regulatory-review-period-for-purposes-of-patent-extension-humira,https://www.govinfo.gov/content/pkg/FR-2006-02-01/pdf/E6-1313.pdf,2/1/2006, HUMIRA,,Anthony,HUMIRA,1,295,Anthony,6090382,,,,Abbott Biotechnology Ltd.,1722,1443,279,2005-04-08,1998-04-16,2002-12-31,BLA 125057,326,125057,5/13/2014,"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",Designated/Approved,,,"Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older",9/28/2018,9/28/2025,"Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older","AbbVie, Inc.",Humira,adalimumab,Abbott Laboratories,BLA,125057,,2002-03-29,2002-12-31,2002,indicated for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs),,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; HUMIRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HUMIRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 5342,E6-1313,https://www.federalregister.gov/documents/2006/02/01/E6-1313/determination-of-regulatory-review-period-for-purposes-of-patent-extension-humira,https://www.govinfo.gov/content/pkg/FR-2006-02-01/pdf/E6-1313.pdf,2/1/2006, HUMIRA,,Anthony,HUMIRA,1,296,Anthony,6090382,,,,Abbott Biotechnology Ltd.,1722,1443,279,2005-04-08,1998-04-16,2002-12-31,BLA 125057,326,125057,10/19/2006,Treatment of pediatric Crohn's disease,Designated/Approved,,,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",9/23/2014,9/23/2021,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.","AbbVie, Inc.",Humira,adalimumab,Abbott Laboratories,BLA,125057,,2002-03-29,2002-12-31,2002,indicated for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs),,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ALOXI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ALOXI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 5668,06-903,https://www.federalregister.gov/documents/2006/02/02/06-903/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aloxi,https://www.govinfo.gov/content/pkg/FR-2006-02-02/pdf/06-903.pdf,2/2/2006, ALOXI,,Anthony,ALOXI,1,297,Anthony,5202333,,,,"Roche Palo Alto, LLC",3867,3565,302,2004-10-19,1992-12-24,2003-07-25,NDA 21-372,1827,21372,,,,,,,,,,,Aloxi,palonosetron hydrochloride,Helsinn Healthcare,NDA,21372,,2002-09-27,2003-07-25,2003,prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy; prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; OMACOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OMACOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of three applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of three patents that claim that human drug product.",71 FR 5669,E6-1365,https://www.federalregister.gov/documents/2006/02/02/E6-1365/determination-of-regulatory-review-period-for-purposes-of-patent-extension-omacor,https://www.govinfo.gov/content/pkg/FR-2006-02-02/pdf/E6-1365.pdf,2/2/2006, OMACOR,,Anthony,,0,297,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CYPHER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CYPHER and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",71 FR 5860,E6-1436,https://www.federalregister.gov/documents/2006/02/03/E6-1436/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cypher,https://www.govinfo.gov/content/pkg/FR-2006-02-03/pdf/E6-1436.pdf,2/3/2006, CYPHER,,Anthony,CYPHER,1,298,Anthony,5563146,,,,Wyeth,814,513,301,2004-06-24,2001-02-01,2003-04-24,PMA P020023,557,20023,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SURPASS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SURPASS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",71 FR 5859,E6-1434,https://www.federalregister.gov/documents/2006/02/03/E6-1434/determination-of-regulatory-review-period-for-purposes-of-patent-extension-surpass,https://www.govinfo.gov/content/pkg/FR-2006-02-03/pdf/E6-1434.pdf,2/3/2006, SURPASS,,Anthony,SURPASS,1,299,Anthony,4937078,,,,"Mezei Associates, Ltd.",2262,1028,1234,2005-04-08,2004-05-13,2004-05-13,NADA 141-186,1590,141186,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ALIMTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ALIMTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 6504,E6-1642,https://www.federalregister.gov/documents/2006/02/08/E6-1642/determination-of-regulatory-review-period-for-purposes-of-patent-extension-alimta,https://www.govinfo.gov/content/pkg/FR-2006-02-08/pdf/E6-1642.pdf,2/8/2006, ALIMTA,,Anthony,ALIMTA,1,300,Anthony,5344932,,,,Eli Lilly,4166,4038,128,2004-08-31,1992-09-10,2004-02-04,NDA 21-462,1784,21462,8/28/2001,Treatment of malignant pleural mesothelioma,Designated/Approved,,,Treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery,2/4/2004,2/4/2011,,Eli Lilly and Company,Alimta,pemetrexed disodium,Eli Lilly,NDA,21462,,2003-09-30,2004-02-04,2004,treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery,,Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ERBITUX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ERBITUX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 8595,E6-2354,https://www.federalregister.gov/documents/2006/02/17/E6-2354/determination-of-regulatory-review-period-for-purposes-of-patent-extension-erbitux,https://www.govinfo.gov/content/pkg/FR-2006-02-17/pdf/E6-2354.pdf,2/17/2006, ERBITUX,,Anthony,ERBITUX,1,301,Anthony,6217866,,,,Aventis Pharmaceuticals,3375,3192,183,2005-07-08,1994-11-18,2004-02-12,BLA 125084,391,125084,7/3/2000,Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,Designated/Approved,,,"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed",3/1/2006,3/1/2013,,ImClone Systems Incorporated,Erbitux,cetuximab,ImClone Systems,BLA,125084,,2003-08-14,2004-02-12,2004,"in combination with irinotecan for treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy; as a single agent for treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy",,Priority,No,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; RELPAX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RELPAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 13408,E6-3711,https://www.federalregister.gov/documents/2006/03/15/E6-3711/determination-of-regulatory-review-period-for-purposes-of-patent-extension-relpax,https://www.govinfo.gov/content/pkg/FR-2006-03-15/pdf/E6-3711.pdf,3/15/2006, RELPAX,,Anthony,RELPAX,1,302,Anthony,5545644,,,,"Pfizer, Inc.",2829,1307,1522,2004-04-06,1995-03-31,2002-12-26,NDA 21-016,1230,21016,,,,,,,,,,,Relpax,eletriptan hydrobromide,Pfizer,NDA,21016,,1998-10-27,2002-12-26,2002,acute treatment of migraine,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; OVIDREL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OVIDREL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 13406,E6-3640,https://www.federalregister.gov/documents/2006/03/15/E6-3640/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ovidrel,https://www.govinfo.gov/content/pkg/FR-2006-03-15/pdf/E6-3640.pdf,3/15/2006, OVIDREL,,Anthony,OVIDREL,1,303,Anthony,4840896,,,,Genzyme Corp.,1787,1485,302,2005-07-08,1995-11-01,2000-09-20,NDA 21-149,1054,21149,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CRESTOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CRESTOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 13407,E6-3641,https://www.federalregister.gov/documents/2006/03/15/E6-3641/determination-of-regulatory-review-period-for-purposes-of-patent-extension-crestor,https://www.govinfo.gov/content/pkg/FR-2006-03-15/pdf/E6-3641.pdf,3/15/2006, CRESTOR,,Anthony,CRESTOR,1,304,Anthony,RE37314,,,,Shionogi Seiyaku Kabushiki Kaisha,1831,1053,778,2004-04-06,2001-06-26,2003-08-12,NDA 21-366,1304,21366,2/14/2014,For the treatment of pediatric homozygous familial hypercholesterolemia,Designated/Approved,,,"An adjunct to diet to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., LDL apheresis).",5/27/2016,5/27/2023,"An adjunct to diet to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., LDL apheresis).","iPR Pharmaceuticals, Inc.",Crestor,rosuvastatin calcium,AstraZeneca Pharmaceuticals,NDA,21366,,2001-06-26,2003-08-12,2003,"indicated as an adjunct to diet to reduce elevated total-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Type IIa and IIb);  as an adjunct to diet for the treatment of patients with elevated serum TG levels (Frederickson Type IV); indicated to reduce LDL-C, total-C, and ApoB in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable)",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; PRIALT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PRIALT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of two applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of two patents which claims that human drug product.",71 FR 13409,E6-3712,https://www.federalregister.gov/documents/2006/03/15/E6-3712/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prialt,https://www.govinfo.gov/content/pkg/FR-2006-03-15/pdf/E6-3712.pdf,3/15/2006, PRIALT,,Anthony,PRIALT,2,306,Anthony,5795864 and 5364842,,,,"Elan Pharmaceuticals, Inc.",3801,1973,1828,2005-07-08,1994-08-04,2004-12-28,NDA 21-060,1228,21060,,,,,,,,,,,Prialt,ziconotide,Elan Pharmaceuticals,NDA,21060,,1999-12-28,2004-12-28,2004,"management of severe chronic pain in patients for whom intrathecal (IT) therapy is warranted and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or IT morphine",,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TYSABRI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TYSABRI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 13604,E6-3781,https://www.federalregister.gov/documents/2006/03/16/E6-3781/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tysabri,https://www.govinfo.gov/content/pkg/FR-2006-03-16/pdf/E6-3781.pdf,3/16/2006, TYSABRI,,Anthony,TYSABRI,1,307,Anthony,5840299,,,,"Athena Neurosciences, Inc.",2924,2740,184,2005-07-08,1996-11-23,2004-11-23,BLA 125104,1189,125104,,,,,,,,,,,Tysabri,natalizumab,Biogen Idec,BLA,125104,,2004-05-24,2004-11-23,2004,treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations,,Priority,No,Yes,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; MYCAMINE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MYCAMINE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 13979,E6-3956,https://www.federalregister.gov/documents/2006/03/20/E6-3956/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mycamine,https://www.govinfo.gov/content/pkg/FR-2006-03-20/pdf/E6-3956.pdf,3/20/2006, MYCAMINE,,Anthony,MYCAMINE,1,308,Anthony,5376634,,,,"Astellas Pharma, Inc.",2546,1493,1053,2005-07-08,1998-03-29,2005-03-16,NDA 21-506,1814,21506,,,,,,,,,,,Mycamine,micafungin sodium,Fujisawa Healthcare,NDA,21506,21754,2002-04-29,2005-03-16,2005,"[A] prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation
[B] treatment of esophageal candidiasis",,Priority (indication [A] only),No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ALAMAST,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ALAMAST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 14707,E6-4163,https://www.federalregister.gov/documents/2006/03/23/E6-4163/determination-of-regulatory-review-period-for-purposes-of-patent-extension-alamast,https://www.govinfo.gov/content/pkg/FR-2006-03-23/pdf/E6-4163.pdf,3/23/2006, ALAMAST,,Anthony,ALAMAST,1,309,Anthony,5034230,,,,"Santen Pharmaceutical Co., Ltd.",1298,1115,183,2000-04-26,1996-03-07,1999-09-24,NDA 21-079,755,21079,,,,,,,,,,,Alamast,pemirolast potassium,Santen,NDA,21079,,1999-03-26,1999-09-24,1999,prevention of itching of the eye due to allergic conjunctivitis,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; MYCAMINE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MYCAMINE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 14709,E6-4165,https://www.federalregister.gov/documents/2006/03/23/E6-4165/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mycamine,https://www.govinfo.gov/content/pkg/FR-2006-03-23/pdf/E6-4165.pdf,3/23/2006, MYCAMINE,,Anthony,MYCAMINE,1,310,Anthony,5376634,,,,"Astellas Pharma, Inc.",2546,2221,325,2005-07-08,1998-03-29,2005-03-16,NDA 21-754,476,21754,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; VESICARE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VESICARE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 14708,E6-4164,https://www.federalregister.gov/documents/2006/03/23/E6-4164/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vesicare,https://www.govinfo.gov/content/pkg/FR-2006-03-23/pdf/E6-4164.pdf,3/23/2006, VESICARE,,Anthony,VESICARE,1,311,Anthony,6017927,,,,"Yamanouchi Pharmaceutical Co., Ltd.",2027,1325,702,2005-07-08,2002-12-19,2004-11-19,NDA 21-518,329,21518,,,,,,,,,,,Vesicare,solifenacin succinate,Yamanouchi Pharma America,NDA,21518,,2002-12-19,2004-11-19,2004,"treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; FASLODEX; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of April 17, 2003 (68 FR 18992). The document announced that FDA had determined the regulatory review period for FASLODEX. A request for revision of regulatory review period was filed for the product on June 16, 2003. FDA reviewed its records and found that the effective date of the investigational new drug application (IND) was incorrect due to a clerical error. Therefore, FDA is revising the determination of the regulatory review period to reflect the correct effective date for the IND.",71 FR 21029,E6-6083,https://www.federalregister.gov/documents/2006/04/24/E6-6083/determination-of-regulatory-review-period-for-purposes-of-patent-extension-faslodex-correction,https://www.govinfo.gov/content/pkg/FR-2006-04-24/pdf/E6-6083.pdf,4/24/2006, FASLODEX, Correction,Anthony,,0,311,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CETROTIDE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CETROTIDE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 33465,E6-9031,https://www.federalregister.gov/documents/2006/06/09/E6-9031/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cetrotide,https://www.govinfo.gov/content/pkg/FR-2006-06-09/pdf/E6-9031.pdf,6/9/2006, CETROTIDE,,Anthony,CETROTIDE,1,312,Anthony,5198533,,,,Administrators of the Tulane Educational Fund,2103,1815,288,2004-04-06,1994-11-10,2000-08-11,NDA 21-197,1491,21197,,,,,,,,,,,Cetrotide,cetrorelix acetate,Asta Medica,NDA,21197,,1999-10-29,2000-08-11,2000,prevention of premature LH surges in women undergoing controlled ovarian stimulation,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; INCRELEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INCRELEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 34135,E6-9138,https://www.federalregister.gov/documents/2006/06/13/E6-9138/determination-of-regulatory-review-period-for-purposes-of-patent-extension-increlex,https://www.govinfo.gov/content/pkg/FR-2006-06-13/pdf/E6-9138.pdf,6/13/2006, INCRELEX,,Anthony,INCRELEX,1,313,Anthony,5681814,,,,"Genentech, Inc.",4828,4644,184,2006-02-24,1992-06-13,2005-08-30,NDA 21-839,1058,21839,12/12/1995,Treatment of growth hormone insensitivity syndrome.,Designated/Approved,,,Long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.,8/30/2005,8/30/2012,,"Ipsen Biopharmaceuticals, Inc.",Increlex,mecasermin (rDNAorigin),Tercica,BLA,21839,,2005-02-28,2005-08-30,2005,long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone,,Priority,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; RESTYLANE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RESTYLANE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",71 FR 34138,E6-9213,https://www.federalregister.gov/documents/2006/06/13/E6-9213/determination-of-regulatory-review-period-for-purposes-of-patent-extension-restylane,https://www.govinfo.gov/content/pkg/FR-2006-06-13/pdf/E6-9213.pdf,6/13/2006, RESTYLANE,,Anthony,RESTYLANE,1,314,Anthony,5827937,,,,Q-Med AB,1491,949,542,1999-11-14,1999-11-14,2003-12-12,PMA P020023,879,20023,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LUVERIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LUVERIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 34136,E6-9139,https://www.federalregister.gov/documents/2006/06/13/E6-9139/determination-of-regulatory-review-period-for-purposes-of-patent-extension-luveris,https://www.govinfo.gov/content/pkg/FR-2006-06-13/pdf/E6-9139.pdf,6/13/2006, LUVERIS,,Anthony,LUVERIS,1,315,Anthony,5639639,,,,Genzyme Corp.,3927,2670,1257,2006-02-24,1994-01-09,2004-10-08,NDA 21-322,1780,21322,10/7/1994,For use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.,Designated/Approved,,,"Luveris (lutropin alfa for injection), concomitantly administered with Gonal-f (follitropin alfa for injection), is indicated for stimulation of follicular development in infertile hypogonadotropic hypogonadal women with profound LH deficiency (LH (less than) 1.2 IU/L).",10/8/2004,10/8/2011,,"EMD Serono, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; UROXATRAL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for UROXATRAL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 34137,E6-9201,https://www.federalregister.gov/documents/2006/06/13/E6-9201/determination-of-regulatory-review-period-for-purposes-of-patent-extension-uroxatral,https://www.govinfo.gov/content/pkg/FR-2006-06-13/pdf/E6-9201.pdf,6/13/2006, UROXATRAL,,Anthony,UROXATRAL,1,316,Anthony,4661491,,,,Sanofi-Synthelabo,2477,1560,917,2004-10-19,1996-09-01,2003-06-12,NDA 21-287,1481,21287,,,,,,,,,,,Uroxatral,alfuzosin hydrochloride,Sanofi-Synthelabo,NDA,21287,,2000-12-08,2003-06-12,2003,treatment of the signs and symptoms of benign prostatic hyperplasia (BPH),,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TYGACIL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TYGACIL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 34139,E6-9214,https://www.federalregister.gov/documents/2006/06/13/E6-9214/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tygacil,https://www.govinfo.gov/content/pkg/FR-2006-06-13/pdf/E6-9214.pdf,6/13/2006, TYGACIL,,Anthony,TYGACIL,1,317,Anthony,5529990,,,,Wyeth Holdings Corp.,2487,2304,183,2006-02-24,1998-08-26,2005-06-15,NDA 21-821,1335,21821,,,,,,,,,,,Tygacil,tigecycline,Wyeth Pharmaceuticals,NDA,21821,,2004-12-15,2005-06-15,2005,treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Complicated Intra-abdominal Infections (cIAI),,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; DUTASTERIDE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DUTASTERIDE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 34374,E6-9224,https://www.federalregister.gov/documents/2006/06/14/E6-9224/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dutasteride,https://www.govinfo.gov/content/pkg/FR-2006-06-14/pdf/E6-9224.pdf,6/14/2006, DUTASTERIDE,,Anthony,DUTASTERIDE,1,318,Anthony,5565467,,,,GlaxoSmithKline,2373,2038,335,2002-10-31,1995-05-25,2001-11-20,NDA 21-319,769,21319,,,,,,,,,,,Avodart,dutasteride,GlaxoSmithKline,NDA,21319,,2000-12-21,2001-11-20,2001,treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate gland,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; CUBICIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CUBICIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 34375,E6-9225,https://www.federalregister.gov/documents/2006/06/14/E6-9225/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cubicin,https://www.govinfo.gov/content/pkg/FR-2006-06-14/pdf/E6-9225.pdf,6/14/2006, CUBICIN,,Anthony,CUBICIN,1,319,Anthony,4885243,,,,"Cubist Pharmaceuticals, Inc.",6444,6177,267,2006-02-24,1986-01-22,2003-09-12,NDA 21-572,1347,21572,,,,,,,,,,,Cubicin,daptomycin,Cubist Pharmaceuticals,NDA,21572,,2002-12-20,2003-09-12,2003,treatment of complicated skin and skin structure infections caused by susceptible strains of Gram-positive microorganisms,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; INSPRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INSPRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 34944,E6-9412,https://www.federalregister.gov/documents/2006/06/16/E6-9412/determination-of-regulatory-review-period-for-purposes-of-patent-extension-inspra,https://www.govinfo.gov/content/pkg/FR-2006-06-16/pdf/E6-9412.pdf,6/16/2006, INSPRA,,Anthony,INSPRA,1,320,Anthony,4559332,,,,Novartis Corp.,2135,1832,303,2003-06-16,1996-11-24,2002-09-27,NDA 21-437,1218,21437,,,,,,,,,,,Inspra,eplerenone,GD Searle,NDA,21437,,2001-11-29,2002-09-27,2002,"treatment of hypertension, alone or in combination with other agents",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SYMLIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SYMLIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 34945,E6-9414,https://www.federalregister.gov/documents/2006/06/16/E6-9414/determination-of-regulatory-review-period-for-purposes-of-patent-extension-symlin,https://www.govinfo.gov/content/pkg/FR-2006-06-16/pdf/E6-9414.pdf,6/16/2006, SYMLIN,,Anthony,SYMLIN,1,321,Anthony,5686411,,,,Amylin Pharmaceuticals,4620,3060,1560,2006-02-24,1992-07-24,2005-03-16,NDA 21-332,1586,21332,,,,,,,,,,,Symlin,pramlintide acetate,Amylin Pharmaceuticals,NDA,21332,,2000-12-08,2005-03-16,2005,"indicated for type 1 diabetes, as an adjunct treatment in patients who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy; indicated for type 2 diabetes, as an adjunct treatment in patients who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy, with or without a concurrent sulfonylurea agent and/or metformin",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ROZEREM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ROZEREM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 35274,E6-9509,https://www.federalregister.gov/documents/2006/06/19/E6-9509/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rozerem,https://www.govinfo.gov/content/pkg/FR-2006-06-19/pdf/E6-9509.pdf,6/19/2006, ROZEREM,,Anthony,ROZEREM,1,322,Anthony,6034239,,,,"Takeda Pharmaceutical Co., Ltd.",2224,1920,304,2006-02-24,1999-06-22,2005-07-22,NDA 21-782,808,21782,,,,,,,,,,,Rozerem,ramelteon,Takeda Global Research & Development Center,NDA,21782,,2004-09-22,2005-07-22,2005,treatment of insomnia characterized by difficulty with sleep onset,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BONIVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BONIVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 35918,E6-9817,https://www.federalregister.gov/documents/2006/06/22/E6-9817/determination-of-regulatory-review-period-for-purposes-of-patent-extension-boniva,https://www.govinfo.gov/content/pkg/FR-2006-06-22/pdf/E6-9817.pdf,6/22/2006, BONIVA,,Anthony,BONIVA,1,323,Anthony,4927814,,,,Hoffmann-La Roche Inc.,2559,2254,305,2004-10-19,1996-05-15,2003-05-16,NDA 21-455,337,21455,,,,,,,,,,,Boniva,ibandronate sodium,Hoffmann-La Roche,NDA,21455,,2002-07-16,2003-05-16,2003,treatment and prevention of postmenopausal osteoporosis,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; CIALIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CIALIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 35919,E6-9899,https://www.federalregister.gov/documents/2006/06/22/E6-9899/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cialis,https://www.govinfo.gov/content/pkg/FR-2006-06-22/pdf/E6-9899.pdf,6/22/2006, CIALIS,,Anthony,CIALIS,1,324,Anthony,5859006,,,,ICOS Corporation,1943,1067,876,2004-10-19,1998-07-29,2003-11-21,NDA 21-368,679,21368,,,,,,,,,,,Cialis,tadalafil,Lilly Icos,NDA,21368,,2001-06-29,2003-11-21,2003,treatment of erectile dysfunction,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TAXUS EXPRESS Paclitaxel-Eluting Coronary Stent System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TAXUS EXPRESS Paclitaxel-Eluting Coronary Stent System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",71 FR 38170,E6-10408,https://www.federalregister.gov/documents/2006/07/05/E6-10408/determination-of-regulatory-review-period-for-purposes-of-patent-extension-taxus-express,https://www.govinfo.gov/content/pkg/FR-2006-07-05/pdf/E6-10408.pdf,7/5/2006, TAXUS EXPRESS Paclitaxel-Eluting Coronary Stent System,,Anthony,TAXUS EXPRESS Paclitaxel-Eluting Coronary Stent System,1,325,Anthony,5716981,,,,"Angiotech Phamaceuticals, Inc.",716,456,260,2006-02-24,2006-02-24,2004-03-04,PMA P030025,807,30025,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MULTIHANCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MULTIHANCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 39120,E6-10796,https://www.federalregister.gov/documents/2006/07/11/E6-10796/determination-of-regulatory-review-period-for-purposes-of-patent-extension-multihance,https://www.govinfo.gov/content/pkg/FR-2006-07-11/pdf/E6-10796.pdf,7/11/2006, MULTIHANCE,,Anthony,MULTIHANCE,1,326,Anthony,4916246,,,,Bracco International B.V.,3789,2482,1307,2005-07-08,1994-07-12,2004-11-23,NDA 21-357,5,21357,,,,,,,,,,,Multihance,gadobenate dimeglumine,Bracco Diagnostics,NDA,21357,21358,2001-04-27,2004-11-23,2004,"indicated for intravenous use in magnetic resonance imaging (MRI) of the central nervous system in adults to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine, and associated tissues",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; CYMBALTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CYMBALTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 44034,E6-12574,https://www.federalregister.gov/documents/2006/08/03/E6-12574/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cymbalta,https://www.govinfo.gov/content/pkg/FR-2006-08-03/pdf/E6-12574.pdf,8/3/2006, CYMBALTA,,Anthony,CYMBALTA,1,327,Anthony,5023269,,,,Eli Lilly,4781,3786,995,2006-02-24,1991-07-04,2004-08-03,NDA 21-427,1826,21427,,,,,,,,,,,Cymbalta,duloxetine hydrochloride,Eli Lilly,NDA,21427,,2001-11-13,2004-08-03,2004,treatment of major depressive disorder (MDD),,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; IPLEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IPLEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 44031,E6-12571,https://www.federalregister.gov/documents/2006/08/03/E6-12571/determination-of-regulatory-review-period-for-purposes-of-patent-extension-iplex,https://www.govinfo.gov/content/pkg/FR-2006-08-03/pdf/E6-12571.pdf,8/3/2006, IPLEX,,Anthony,IPLEX,1,328,Anthony,5681818,,,,Insmed Inc.,3527,3183,344,2006-05-19,1996-04-18,2005-12-12,NDA 21-884,1657,21884,5/17/2002,Treatment of growth hormone insensitivity syndrome (GHIS),Designated/Approved,,,Treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone,12/12/2005,12/12/2012,,"Insmed, Inc.",Iplex,mecasermin rinfabate (rDNAorigin),Insmed,BLA,21884,,2005-01-03,2005-12-12,2005,treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone,,Priority,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; CLINACOX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CLINACOX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",71 FR 44032,E6-12572,https://www.federalregister.gov/documents/2006/08/03/E6-12572/determination-of-regulatory-review-period-for-purposes-of-patent-extension-clinacox,https://www.govinfo.gov/content/pkg/FR-2006-08-03/pdf/E6-12572.pdf,8/3/2006, CLINACOX,,Anthony,CLINACOX,1,329,Anthony,4631278,,,,Janssen Pharmaceutica N.V.,5111,1749,3362,2000-10-04,1985-04-25,1999-04-21,NADA 140-951,1096,140951,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; EMEND,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EMEND and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 44033,E6-12573,https://www.federalregister.gov/documents/2006/08/03/E6-12573/determination-of-regulatory-review-period-for-purposes-of-patent-extension-emend,https://www.govinfo.gov/content/pkg/FR-2006-08-03/pdf/E6-12573.pdf,8/3/2006, EMEND,,Anthony,EMEND,1,330,Anthony,5719147,,,,Merck & Co.,2513,2332,181,2003-11-18,1996-05-10,2003-03-26,NDA 21-549,1022,21549,,,,,,,,,,,Emend,aprepitant,Merck,NDA,21549,,2002-09-27,2003-03-26,2003,"in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin",,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; FUZEON,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FUZEON and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 54996,E6-15554,https://www.federalregister.gov/documents/2006/09/20/E6-15554/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fuzeon,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/E6-15554.pdf,9/20/2006, FUZEON,,Anthony,FUZEON,1,331,Anthony,6133418,,,,Duke University,2312,2133,179,2004-04-06,1996-11-14,2003-03-13,NDA 21-481,569,21481,,,,,,,,,,,Fuzeon,enfuvirtide,Hoffmann-La Roche,NDA,21481,,2002-09-16,2003-03-13,2003,"in combination with other antiretroviral agents, for the treatment of HIV-1 infection in treatment experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy",,Priority,No,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 54997,E6-15555,https://www.federalregister.gov/documents/2006/09/20/E6-15555/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/E6-15555.pdf,9/20/2006, AVASTIN,,Anthony,AVASTIN,1,332,Anthony,6054297,,,,"Genentech, Inc.",2551,2401,150,2005-07-08,1997-03-05,2004-02-26,BLA 125085,307,125085,11/23/2010,Treatment of fallopian tube carcinoma,Designated/Approved,,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.",11/14/2014,11/14/2021,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 54997,E6-15555,https://www.federalregister.gov/documents/2006/09/20/E6-15555/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/E6-15555.pdf,9/20/2006, AVASTIN,,Anthony,AVASTIN,1,333,Anthony,6054297,,,,"Genentech, Inc.",2551,2401,150,2005-07-08,1997-03-05,2004-02-26,BLA 125085,307,125085,2/9/2006,Therapeutic treatment of patients with ovarian cancer,Designated/Approved,,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.",12/6/2016,12/6/2023,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.","Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 54997,E6-15555,https://www.federalregister.gov/documents/2006/09/20/E6-15555/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/E6-15555.pdf,9/20/2006, AVASTIN,,Anthony,AVASTIN,1,334,Anthony,6054297,,,,"Genentech, Inc.",2551,2401,150,2005-07-08,1997-03-05,2004-02-26,BLA 125085,307,125085,2/9/2006,Therapeutic treatment of patients with ovarian cancer,Designated/Approved,,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitiverecurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.",6/13/2018,6/13/2025,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.","Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 54997,E6-15555,https://www.federalregister.gov/documents/2006/09/20/E6-15555/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/E6-15555.pdf,9/20/2006, AVASTIN,,Anthony,AVASTIN,1,335,Anthony,6054297,,,,"Genentech, Inc.",2551,2401,150,2005-07-08,1997-03-05,2004-02-26,BLA 125085,307,125085,2/9/2006,Therapeutic treatment of patients with ovarian cancer,Designated/Approved,,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",11/14/2014,11/14/2021,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 54997,E6-15555,https://www.federalregister.gov/documents/2006/09/20/E6-15555/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/E6-15555.pdf,9/20/2006, AVASTIN,,Anthony,AVASTIN,1,336,Anthony,6054297,,,,"Genentech, Inc.",2551,2401,150,2005-07-08,1997-03-05,2004-02-26,BLA 125085,307,125085,5/26/2006,Treatment of malignant glioma,Designated/Approved,,,Treatment of glioblastoma with progressive disease following prior therapy,5/5/2009,5/5/2016,,"Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 54997,E6-15555,https://www.federalregister.gov/documents/2006/09/20/E6-15555/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/E6-15555.pdf,9/20/2006, AVASTIN,,Anthony,AVASTIN,1,337,Anthony,6054297,,,,"Genentech, Inc.",2551,2401,150,2005-07-08,1997-03-05,2004-02-26,BLA 125085,307,125085,11/6/2003,Treatment of renal cell carcinoma,Designated/Approved,,,Treatment of renal cell carcinoma in combination with interferon alfa,7/31/2009,7/31/2016,,"Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 54997,E6-15555,https://www.federalregister.gov/documents/2006/09/20/E6-15555/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/E6-15555.pdf,9/20/2006, AVASTIN,,Anthony,AVASTIN,1,338,Anthony,6054297,,,,"Genentech, Inc.",2551,2401,150,2005-07-08,1997-03-05,2004-02-26,BLA 125085,307,125085,11/2/2010,Treatment of primary peritoneal carcinoma.,Designated/Approved,,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.",12/6/2016,12/6/2023,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.","Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 54997,E6-15555,https://www.federalregister.gov/documents/2006/09/20/E6-15555/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/E6-15555.pdf,9/20/2006, AVASTIN,,Anthony,AVASTIN,1,339,Anthony,6054297,,,,"Genentech, Inc.",2551,2401,150,2005-07-08,1997-03-05,2004-02-26,BLA 125085,307,125085,11/23/2010,Treatment of fallopian tube carcinoma,Designated/Approved,,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.",12/6/2016,12/6/2023,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.","Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 54997,E6-15555,https://www.federalregister.gov/documents/2006/09/20/E6-15555/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/E6-15555.pdf,9/20/2006, AVASTIN,,Anthony,AVASTIN,1,340,Anthony,6054297,,,,"Genentech, Inc.",2551,2401,150,2005-07-08,1997-03-05,2004-02-26,BLA 125085,307,125085,11/23/2010,Treatment of fallopian tube carcinoma,Designated/Approved,,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitiverecurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.",6/13/2018,6/13/2025,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.","Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 54997,E6-15555,https://www.federalregister.gov/documents/2006/09/20/E6-15555/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/E6-15555.pdf,9/20/2006, AVASTIN,,Anthony,AVASTIN,1,341,Anthony,6054297,,,,"Genentech, Inc.",2551,2401,150,2005-07-08,1997-03-05,2004-02-26,BLA 125085,307,125085,11/2/2010,Treatment of primary peritoneal carcinoma.,Designated/Approved,,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitiverecurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.",6/13/2018,6/13/2025,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.","Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",71 FR 54997,E6-15555,https://www.federalregister.gov/documents/2006/09/20/E6-15555/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/E6-15555.pdf,9/20/2006, AVASTIN,,Anthony,AVASTIN,1,342,Anthony,6054297,,,,"Genentech, Inc.",2551,2401,150,2005-07-08,1997-03-05,2004-02-26,BLA 125085,307,125085,11/2/2010,Treatment of primary peritoneal carcinoma.,Designated/Approved,,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",11/14/2014,11/14/2021,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens","Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; MACUGEN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MACUGEN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 54998,E6-15556,https://www.federalregister.gov/documents/2006/09/20/E6-15556/determination-of-regulatory-review-period-for-purposes-of-patent-extension-macugen,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/E6-15556.pdf,9/20/2006, MACUGEN,,Anthony,MACUGEN,1,343,Anthony,6051698,,,,"Gilead Sciences, Inc.",2312,2128,184,2005-06-28,1998-08-21,2004-12-17,NDA 21-756,990,21756,,,,,,,,,,,Macugen,pegaptanib sodium,Eyetech Pharmaceuticals,NDA,21756,,2004-06-17,2004-12-17,2004,treatment of neovascular (wet) age-related macular degeneration,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; APTIVUS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for APTIVUS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 54995,E6-15553,https://www.federalregister.gov/documents/2006/09/20/E6-15553/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aptivus,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/E6-15553.pdf,9/20/2006, APTIVUS,,Anthony,APTIVUS,1,344,Anthony,5852195,,,,"Pharmacia & Upjohn Co., LLC",3114,2931,183,2006-02-24,1996-12-14,2005-06-22,NDA 21-814,1278,21814,,,,,,,,,,,Aptivus,tipranavir,Boehringer Ingelheim Pharmaceuticals,NDA,21814,,2004-12-22,2005-06-22,2005,"co-administered with ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors",,Priority,No,Yes,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; CYDECTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CYDECTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",71 FR 54993,Jun-00,https://www.federalregister.gov/documents/2006/09/20/06-7800/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cydectin,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/06-7800.pdf,9/20/2006, CYDECTIN,,Anthony,CYDECTIN,1,345,Anthony,4916154,,,,American Cyanamid Company,2857,2841,16,2004-04-06,1998-01-28,1998-01-28,NADA 141-099,1754,141099,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MYCAMINE-New Drug Application 21-754,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MYCAMINE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 54994,Jun-85,https://www.federalregister.gov/documents/2006/09/20/06-7985/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mycamine-new-drug,https://www.govinfo.gov/content/pkg/FR-2006-09-20/pdf/06-7985.pdf,9/20/2006, MYCAMINE-New Drug Application 21-754,,Anthony,MYCAMINE,2,347,Anthony,6107458 and 6265536,,,,"Astellas Pharma, Inc.",2546,2221,325,2006-02-24,1998-03-29,2005-03-16,NDA 21-754,476,21754,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CLOLAR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CLOLAR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 55799,15-Jun,https://www.federalregister.gov/documents/2006/09/25/06-8115/determination-of-regulatory-review-period-for-purposes-of-patent-extension-clolar,https://www.govinfo.gov/content/pkg/FR-2006-09-25/pdf/06-8115.pdf,9/25/2006, CLOLAR,,Anthony,CLOLAR,1,348,Anthony,5661136,,,,Southern Research Institute,2200,1926,274,2006-02-24,1998-12-22,2004-12-28,NDA 21-673,1303,21673,2/7/2002,Treatment of acute lymphoblastic leukemia,Designated/Approved,,,Treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,12/28/2004,12/28/2011,,Genzyme Corporation,Clolar,clofarbine,Genzyme,NDA,21673,,2004-03-30,2004-12-28,2004,treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,,Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; KETEK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KETEK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 56156,E6-15690,https://www.federalregister.gov/documents/2006/09/26/E6-15690/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ketek,https://www.govinfo.gov/content/pkg/FR-2006-09-26/pdf/E6-15690.pdf,9/26/2006, KETEK,,Anthony,KETEK,1,349,Anthony,5635485,,,,Aventis S. A.,2206,713,1493,2006-03-29,1998-03-20,2004-04-01,NDA 21-144,1076,21144,,,,,,,,,,,Ketek,telithromycin,Aventis Pharmaceuticals,NDA,21144,,2000-03-01,2004-04-01,2004,"treatment of infections caused by susceptible strains of  designated microorganisms in the conditions listed below, for patients 18 years old and above:  acute bacterial exacerbation of chronic bronchitis,  acute bacterial sinusitis, community-acquired pneumonia (of mild to moderate severity)",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; MYCAMINE-New Drug Application 21-506,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MYCAMINE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",71 FR 56157,E6-15767,https://www.federalregister.gov/documents/2006/09/26/E6-15767/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mycamine-new-drug,https://www.govinfo.gov/content/pkg/FR-2006-09-26/pdf/E6-15767.pdf,9/26/2006, MYCAMINE-New Drug Application 21-506,,Anthony,MYCAMINE,2,351,Anthony,6107458 and 6265536,,,,"Astellas Pharma, Inc.",2546,1493,1053,2006-02-24,1998-03-29,2005-03-16,NDA 21-506,1192,21506,,,,,,,,,,,Mycamine,micafungin sodium,Fujisawa Healthcare,NDA,21506,21754,2002-04-29,2005-03-16,2005,"[A] prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation
[B] treatment of esophageal candidiasis",,Priority (indication [A] only),No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LYRICA (New Drug Application 21-446),Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LYRICA (new drug application (NDA) 21-446) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 56540,E6-15908,https://www.federalregister.gov/documents/2006/09/27/E6-15908/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lyrica-new-drug,https://www.govinfo.gov/content/pkg/FR-2006-09-27/pdf/E6-15908.pdf,9/27/2006, LYRICA (New Drug Application 21-446),,Anthony,,0,351,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PLENAXIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PLENAXIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 57545,E6-15969,https://www.federalregister.gov/documents/2006/09/29/E6-15969/determination-of-regulatory-review-period-for-purposes-of-patent-extension-plenaxis,https://www.govinfo.gov/content/pkg/FR-2006-09-29/pdf/E6-15969.pdf,9/29/2006, PLENAXIS,,Anthony,PLENAXIS,1,352,Anthony,5843901,,,,"Praecis Pharmaceuticals, Inc.",2566,1487,1079,2004-10-19,1996-11-17,2003-11-25,NDA 21-320,725,21320,,,,,,,,,,,Plenaxis,abarelix,Praecis Pharmaceuticals,NDA,21320,,2000-12-12,2003-11-25,2003,"palliative treatment of men with advanced symptomatic prostate cancer, in whom LHRH agonist therapy is not appropriate and who refuse surgical castration, and have one or more of the following:  risk of neurological compromise due to metastases, ureteral or bladder outlet obstruction due to local encroachment or metastatic disease, or severe bone pain from skeletal metastases persisting on narcotic analgesia",,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TARCEVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TARCEVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 57546,E6-15987,https://www.federalregister.gov/documents/2006/09/29/E6-15987/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tarceva,https://www.govinfo.gov/content/pkg/FR-2006-09-29/pdf/E6-15987.pdf,9/29/2006, TARCEVA,,Anthony,TARCEVA,1,353,Anthony,5747498,,,,"Pfizer, Inc.",2653,2541,112,2005-07-08,1997-08-16,2004-11-18,NDA 21-743,1261,21743,,,,,,,,,,,Tarceva,erlotinib hydrochloride,OSI Pharmaceuticals,NDA,21743,,2004-07-30,2004-11-18,2004,treatment of locally advanced or metastatic Non Small-Cell Lung Cancer (NSCLC) after failure of at least one prior chemotherapy regimen,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; LYRICA (New Drug Application 21-723),Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LYRICA (new drug application (NDA) 21-723) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 57545,E6-15962,https://www.federalregister.gov/documents/2006/09/29/E6-15962/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lyrica-new-drug,https://www.govinfo.gov/content/pkg/FR-2006-09-29/pdf/E6-15962.pdf,9/29/2006, LYRICA (New Drug Application 21-723),,Anthony,,0,353,Anthony,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; BYETTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BYETTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 57977,E6-16086,https://www.federalregister.gov/documents/2006/10/02/E6-16086/determination-of-regulatory-review-period-for-purposes-of-patent-extension-byetta,https://www.govinfo.gov/content/pkg/FR-2006-10-02/pdf/E6-16086.pdf,10/2/2006, BYETTA,,John,BYETTA (exenatide injection),1,354,Anthony,5424286,,,,"Amylin Pharmaceuticals, Inc",2271,1968,303,1999-02-10,2004-06-30,2005-04-28,NDA 21-773,1286,21773,,,,,,,,,,,Byetta,exenatide,Amylin Pharmaceuticals,NDA,21773,,2004-06-30,2005-04-28,2005,"indicated to improve glycemic control in patients with type 2 diabetes mellitus who have not achieved adequate glycemic control on metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; NATRECOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NATRECOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",71 FR 57979,E6-16091,https://www.federalregister.gov/documents/2006/10/02/E6-16091/determination-of-regulatory-review-period-for-purposes-of-patent-extension-natrecor,https://www.govinfo.gov/content/pkg/FR-2006-10-02/pdf/E6-16091.pdf,10/2/2006, NATRECOR,,John,NATRECOR,1,355,Anthony,5114923,,,,"Scios, Inc.",2790,1588,1202,2006-05-19,1993-12-22,2001-08-10,NDA 20-920,5,20920,,,,,,,,,,,Natrecor,nesiritide,Scios,NDA,20920,,1998-04-27,2001-08-10,2001,treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; DRAXXIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DRAXXIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",71 FR 57978,E6-16087,https://www.federalregister.gov/documents/2006/10/02/E6-16087/determination-of-regulatory-review-period-for-purposes-of-patent-extension-draxxin,https://www.govinfo.gov/content/pkg/FR-2006-10-02/pdf/E6-16087.pdf,10/2/2006, DRAXXIN,,John,DRAXXIN,1,1,John,6420536,,,,"Pfizer, Inc.",2451,2414,37,2006-02-24,1998-09-09,2005-05-24,NADA 141-244,360,141244,,,,,,,,,,,,,,,,,,,,,,,,,,
Redetermination of Regulatory Review Period for Purposes of Patent Extension; BONIVA; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of June 22, 2006 (71 FR 35918). The document announced that FDA had determined the regulatory review period for BONIVA. The notice provided that on or before August 21, 2006, anyone with knowledge that any of the dates as published are incorrect may submit a request for a redetermination of the regulatory review period. A request for revision of the regulatory review period was filed for the product on July 25, 2006. FDA reviewed its records and found that the effective date of the investigational new drug application (IND) was incorrect because of a clerical error. Therefore, FDA is republishing a determination of the regulatory review period to reflect the corrected effective date for the IND. FDA has made a determination of the regulatory review period because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",71 FR 59797,E6-16816,https://www.federalregister.gov/documents/2006/10/11/E6-16816/redetermination-of-regulatory-review-period-for-purposes-of-patent-extension-boniva-correction,https://www.govinfo.gov/content/pkg/FR-2006-10-11/pdf/E6-16816.pdf,10/11/2006, BONIVA, Correction,John,BONIVA,1,2,John,4927814,,,,"Hoffmann-La Roche, Inc.",3122,2817,305,2004-10-19,"MD 20857, 301",2003-05-16,NDA 21-455,1713,21455,,,,,,,,,,,Boniva,ibandronate sodium,Hoffmann-La Roche,NDA,21455,,2002-07-16,2003-05-16,2003,treatment and prevention of postmenopausal osteoporosis,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TYGACIL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TYGACIL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 7664,E7-2805,https://www.federalregister.gov/documents/2007/02/16/E7-2805/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tygacil,https://www.govinfo.gov/content/pkg/FR-2007-02-16/pdf/E7-2805.pdf,2/16/2007, TYGACIL,,John,TYGACIL,1,3,John,5494903,,,,Wyeth Holdings Corp.,2487,2304,183,2006-06-14,1998-08-26,2005-06-15,NDA 21-821,1335,21821,,,,,,,,,,,Tygacil,tigecycline,Wyeth Pharmaceuticals,NDA,21821,,2004-12-15,2005-06-15,2005,treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Complicated Intra-abdominal Infections (cIAI),,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LEVEMIR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LEVEMIR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",72 FR 7999,E7-3001,https://www.federalregister.gov/documents/2007/02/22/E7-3001/determination-of-regulatory-review-period-for-purposes-of-patent-extension-levemir,https://www.govinfo.gov/content/pkg/FR-2007-02-22/pdf/E7-3001.pdf,2/22/2007, LEVEMIR,,John,LEVEMIR,1,4,John,5750497,,,,Novo Nordisk A/S,2896,1971,925,2006-07-24,1997-07-14,2005-06-16,NDA 21-536,1496,21536,,,,,,,,,,,Levemir,insulin detemir,Novo Nordisk,BLA,21536,,2002-12-05,2005-06-16,2005,treatment of adult patients with Type 1 or Type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; EXJADE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EXJADE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",72 FR 8180,E7-3041,https://www.federalregister.gov/documents/2007/02/23/E7-3041/determination-of-regulatory-review-period-for-purposes-of-patent-extension-exjade,https://www.govinfo.gov/content/pkg/FR-2007-02-23/pdf/E7-3041.pdf,2/23/2007, EXJADE,,John,EXJADE,1,5,John,6465504,,,,Novartis AG,2288,2103,185,2006-07-24,1999-07-31,2005-11-02,NDA 21-882,648,21882,,,,,,,,,,,Exjade,deferasirox,Novartis Pharmaceuticals,NDA,21882,,2005-05-02,2005-11-02,2005,treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older,,Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; BARACLUDE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BARACLUDE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",72 FR 8181,E7-3042,https://www.federalregister.gov/documents/2007/02/23/E7-3042/determination-of-regulatory-review-period-for-purposes-of-patent-extension-baraclude,https://www.govinfo.gov/content/pkg/FR-2007-02-23/pdf/E7-3042.pdf,2/23/2007, BARACLUDE,,John,BARACLUDE,1,6,John,5206244,,,,Bristol-Myers Squibb Co.,2993,2811,182,2006-09-05,1997-01-19,2005-03-29,NDA 21-797,1587,21797,,,,,,,,,,,Baraclude,entecavir,Bristol-Myers Squibb,NDA,21797,21798,2004-09-29,2005-03-29,2005,treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; AMITIZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AMITIZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 8183,E7-3128,https://www.federalregister.gov/documents/2007/02/23/E7-3128/determination-of-regulatory-review-period-for-purposes-of-patent-extension-amitiza,https://www.govinfo.gov/content/pkg/FR-2007-02-23/pdf/E7-3128.pdf,2/23/2007, AMITIZA,,John,AMITIZA,1,7,John,5284858,,,,Sucampo AG,2197,1890,307,2006-09-05,2000-01-28,2006-01-31,NDA 21-908,1251,21908,,,,,,,,,,,Amitiza,lubiprostone,Sucampo Pharmaceuticals,NDA,21908,,2005-03-31,2006-01-31,2006,treatment of chronic idiopathic constipation in the adult population,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; S8 OVER-THE-WIRE SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for S8 OVER-THE-WIRE SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",72 FR 8182,E7-3127,https://www.federalregister.gov/documents/2007/02/23/E7-3127/determination-of-regulatory-review-period-for-purposes-of-patent-extension-s8-over-the-wire-system,https://www.govinfo.gov/content/pkg/FR-2007-02-23/pdf/E7-3127.pdf,2/23/2007, S8 OVER-THE-WIRE SYSTEM,,John,S8 OVER-THE-WIRE SYSTEM,8,15,John,5292331; 5800509; 5836965; 5879382; 5891190; 6159229; 6309402; and 6344053,,,,Medtronic Vascular,652,477,175,2006-02-24,2001-12-20,2003-10-01,PMA P030009,413,30009,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; REVLIMID,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REVLIMID and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 14118,E7-5439,https://www.federalregister.gov/documents/2007/03/26/E7-5439/determination-of-regulatory-review-period-for-purposes-of-patent-extension-revlimid,https://www.govinfo.gov/content/pkg/FR-2007-03-26/pdf/E7-5439.pdf,3/26/2007, REVLIMID,,John,REVLIMID,1,16,John,5635517,,,,Celgene Corp.,2069,1804,265,2006-06-14,2000-04-30,2005-12-27,NDA 21-880,1166,21880,4/27/2009,Treatment of mantle cell lymphoma,Designated/Approved,,,"Treatment of mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.",6/5/2013,6/5/2020,"Treatment of mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.",Celgene Corporation,Revlimid,lenalidomide,Celgene,NDA,21880,,2005-04-07,2005-12-27,2005,treatment of patients with transfusion dependent anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities,,Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; REVLIMID,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REVLIMID and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 14118,E7-5439,https://www.federalregister.gov/documents/2007/03/26/E7-5439/determination-of-regulatory-review-period-for-purposes-of-patent-extension-revlimid,https://www.govinfo.gov/content/pkg/FR-2007-03-26/pdf/E7-5439.pdf,3/26/2007, REVLIMID,,John,REVLIMID,1,17,John,5635517,,,,Celgene Corp.,2069,1804,265,2006-06-14,2000-04-30,2005-12-27,NDA 21-880,1166,21880,9/20/2001,Treatment of multiple myeloma,Designated/Approved,,,For use in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy,6/29/2006,6/29/2013,,Celgene Corporation,Revlimid,lenalidomide,Celgene,NDA,21880,,2005-04-07,2005-12-27,2005,treatment of patients with transfusion dependent anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities,,Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; REVLIMID,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REVLIMID and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 14118,E7-5439,https://www.federalregister.gov/documents/2007/03/26/E7-5439/determination-of-regulatory-review-period-for-purposes-of-patent-extension-revlimid,https://www.govinfo.gov/content/pkg/FR-2007-03-26/pdf/E7-5439.pdf,3/26/2007, REVLIMID,,John,REVLIMID,1,18,John,5635517,,,,Celgene Corp.,2069,1804,265,2006-06-14,2000-04-30,2005-12-27,NDA 21-880,1166,21880,9/20/2001,Treatment of multiple myeloma,Designated/Approved,,,"Treatment of multiple myeloma (MM), as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)",2/22/2017,2/22/2024,"Treatment of multiple myeloma (MM), as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)",Celgene Corporation,Revlimid,lenalidomide,Celgene,NDA,21880,,2005-04-07,2005-12-27,2005,treatment of patients with transfusion dependent anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities,,Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; REVLIMID,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REVLIMID and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 14118,E7-5439,https://www.federalregister.gov/documents/2007/03/26/E7-5439/determination-of-regulatory-review-period-for-purposes-of-patent-extension-revlimid,https://www.govinfo.gov/content/pkg/FR-2007-03-26/pdf/E7-5439.pdf,3/26/2007, REVLIMID,,John,REVLIMID,1,19,John,5635517,,,,Celgene Corp.,2069,1804,265,2006-06-14,2000-04-30,2005-12-27,NDA 21-880,1166,21880,9/20/2001,Treatment of multiple myeloma,Designated/Approved,,,REVLIMID in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).,2/17/2015,2/17/2022,For use in combination with dexamethasone for the treatment of patients with multiple myeloma who have not received at least one prior therapy (first-line therapy).,Celgene Corporation,Revlimid,lenalidomide,Celgene,NDA,21880,,2005-04-07,2005-12-27,2005,treatment of patients with transfusion dependent anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities,,Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; REVLIMID,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REVLIMID and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 14118,E7-5439,https://www.federalregister.gov/documents/2007/03/26/E7-5439/determination-of-regulatory-review-period-for-purposes-of-patent-extension-revlimid,https://www.govinfo.gov/content/pkg/FR-2007-03-26/pdf/E7-5439.pdf,3/26/2007, REVLIMID,,John,REVLIMID,1,20,John,5635517,,,,Celgene Corp.,2069,1804,265,2006-06-14,2000-04-30,2005-12-27,NDA 21-880,1166,21880,1/29/2004,Treatment of myelodysplastic syndromes,Designated/Approved,,,Treatment of patients with transfusion dependant anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5 q cytogenetic abnormality with or without additional cytogenetic abnormalities,12/27/2005,12/27/2012,,Celgene Corporation,Revlimid,lenalidomide,Celgene,NDA,21880,,2005-04-07,2005-12-27,2005,treatment of patients with transfusion dependent anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities,,Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; REVLIMID,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REVLIMID and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 14118,E7-5439,https://www.federalregister.gov/documents/2007/03/26/E7-5439/determination-of-regulatory-review-period-for-purposes-of-patent-extension-revlimid,https://www.govinfo.gov/content/pkg/FR-2007-03-26/pdf/E7-5439.pdf,3/26/2007, REVLIMID,,John,REVLIMID,1,21,John,5635517,,,,Celgene Corp.,2069,1804,265,2006-06-14,2000-04-30,2005-12-27,NDA 21-880,1166,21880,1/4/2017,Treatment of splenic marginal zone lymphoma,Designated/Approved,,,"REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).",5/28/2019,5/28/2026,In combination with a rituximab product for the treatment of adult patients with previously treated splenic marginal zone lymphoma,Celgene Corporation,Revlimid,lenalidomide,Celgene,NDA,21880,,2005-04-07,2005-12-27,2005,treatment of patients with transfusion dependent anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities,,Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; REVLIMID,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REVLIMID and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 14118,E7-5439,https://www.federalregister.gov/documents/2007/03/26/E7-5439/determination-of-regulatory-review-period-for-purposes-of-patent-extension-revlimid,https://www.govinfo.gov/content/pkg/FR-2007-03-26/pdf/E7-5439.pdf,3/26/2007, REVLIMID,,John,REVLIMID,1,22,John,5635517,,,,Celgene Corp.,2069,1804,265,2006-06-14,2000-04-30,2005-12-27,NDA 21-880,1166,21880,9/17/2013,Treatment of follicular lymphoma,Designated/Approved,,,"REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL).",5/28/2019,5/28/2026,In combination with a rituximab product for the treatment of adult patients with previously treated follicular lymphoma (FL).,Celgene Corporation,Revlimid,lenalidomide,Celgene,NDA,21880,,2005-04-07,2005-12-27,2005,treatment of patients with transfusion dependent anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities,,Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; REVLIMID,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REVLIMID and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 14118,E7-5439,https://www.federalregister.gov/documents/2007/03/26/E7-5439/determination-of-regulatory-review-period-for-purposes-of-patent-extension-revlimid,https://www.govinfo.gov/content/pkg/FR-2007-03-26/pdf/E7-5439.pdf,3/26/2007, REVLIMID,,John,REVLIMID,1,23,John,5635517,,,,Celgene Corp.,2069,1804,265,2006-06-14,2000-04-30,2005-12-27,NDA 21-880,1166,21880,1/4/2017,Treatment of nodal marginal zone lymphoma,Designated/Approved,,,"REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).",5/28/2019,5/28/2026,In combination with a rituximab product for the treatment of adult patients with previously treated nodal marginal zone lymphoma,Celgene Corporation,Revlimid,lenalidomide,Celgene,NDA,21880,,2005-04-07,2005-12-27,2005,treatment of patients with transfusion dependent anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities,,Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; REVLIMID,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REVLIMID and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 14118,E7-5439,https://www.federalregister.gov/documents/2007/03/26/E7-5439/determination-of-regulatory-review-period-for-purposes-of-patent-extension-revlimid,https://www.govinfo.gov/content/pkg/FR-2007-03-26/pdf/E7-5439.pdf,3/26/2007, REVLIMID,,John,REVLIMID,1,24,John,5635517,,,,Celgene Corp.,2069,1804,265,2006-06-14,2000-04-30,2005-12-27,NDA 21-880,1166,21880,4/29/2015,Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue,Designated/Approved,,,"REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).",5/28/2019,5/28/2026,In combination with a rituximab product for the treatment of adult patients with previously treated extranodal marginal zone lymphoma,Celgene Corporation,Revlimid,lenalidomide,Celgene,NDA,21880,,2005-04-07,2005-12-27,2005,treatment of patients with transfusion dependent anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities,,Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; PREVICOX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PREVICOX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",72 FR 14119,E7-5443,https://www.federalregister.gov/documents/2007/03/26/E7-5443/determination-of-regulatory-review-period-for-purposes-of-patent-extension-previcox,https://www.govinfo.gov/content/pkg/FR-2007-03-26/pdf/E7-5443.pdf,3/26/2007, PREVICOX,,John,PREVICOX,1,25,John,5981576,,,,Merck Frosst Canada & Co.,2216,2118,98,2006-06-14,1998-06-29,2004-07-21,NADA 141-230,650,141230,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NOVOLOG,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NOVOLOG and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 14121,E7-5445,https://www.federalregister.gov/documents/2007/03/26/E7-5445/determination-of-regulatory-review-period-for-purposes-of-patent-extension-novolog,https://www.govinfo.gov/content/pkg/FR-2007-03-26/pdf/E7-5445.pdf,3/26/2007, NOVOLOG,,John,NOVOLOG,1,26,John,5618913,,,,Novo Nordisk A/S,1776,1145,631,2006-12-12,1995-07-30,2000-06-07,NDA 20-986,59,20986,,,,,,,,,,,Novolog,insulin aspart recombinant,Novo Nordisk,BLA,20986,,1998-09-16,2000-06-07,2000,"treatment of adult patients with diabetes mellitus, for the control of hyperglycemia",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; EMTRIVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EMTRIVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 14122,E7-5446,https://www.federalregister.gov/documents/2007/03/26/E7-5446/determination-of-regulatory-review-period-for-purposes-of-patent-extension-emtriva,https://www.govinfo.gov/content/pkg/FR-2007-03-26/pdf/E7-5446.pdf,3/26/2007, EMTRIVA,,John,EMTRIVA,1,27,John,5914331,,,,Emory University,2114,1811,303,2005-07-08,1997-09-19,2003-07-02,NDA 21-500,642,21500,,,,,,,,,,,Emtriva,emtricitabine,Gilead Sciences,NDA,21500,,2002-09-03,2003-07-02,2003,indicated for the treatment of HIV infection in adults,,Standard,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ONYX LES,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ONYX LES and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",72 FR 14120,E7-5444,https://www.federalregister.gov/documents/2007/03/26/E7-5444/determination-of-regulatory-review-period-for-purposes-of-patent-extension-onyx-les,https://www.govinfo.gov/content/pkg/FR-2007-03-26/pdf/E7-5444.pdf,3/26/2007, ONYX LES,,John,ONYX LES,1,28,John,5667767,,,,"Micro Therapeutics, Inc.",1682,825,857,2006-06-14,2000-12-14,2005-07-21,PMA P030004,1271,30004,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; A180,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for A180 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",72 FR 14280,E7-5504,https://www.federalregister.gov/documents/2007/03/27/E7-5504/determination-of-regulatory-review-period-for-purposes-of-patent-extension-a180,https://www.govinfo.gov/content/pkg/FR-2007-03-27/pdf/E7-5504.pdf,3/27/2007, A180,,John,A180,1,29,John,4861779,,,,"Pfizer, Inc.",5365,5314,51,2003-07-16,2002-08-01,2002-09-20,NADA 141-,1826,141,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; INFUSE BONE GRAFT/LT-CAGE LUMBAR TAPERED FUSION DEVICE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INFUSE BONE GRAFT/LT-CAGE LUMBAR TAPERED FUSION DEVICE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of two applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that medical device.",72 FR 14582,E7-5635,https://www.federalregister.gov/documents/2007/03/28/E7-5635/determination-of-regulatory-review-period-for-purposes-of-patent-extension-infuse-bone-graftlt-cage,https://www.govinfo.gov/content/pkg/FR-2007-03-28/pdf/E7-5635.pdf,3/28/2007, INFUSE BONE GRAFT/LT-CAGE LUMBAR TAPERED FUSION DEVICE,,John,,0,29,John,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; VAPRISOL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VAPRISOL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent that claims that human drug product.",72 FR 14819,E7-5737,https://www.federalregister.gov/documents/2007/03/29/E7-5737/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vaprisol,https://www.govinfo.gov/content/pkg/FR-2007-03-29/pdf/E7-5737.pdf,3/29/2007, VAPRISOL,,John,VAPRISOL,1,30,John,5723606,,,,"Astellas Pharma, Inc.",2796,2096,700,2006-09-05,2004-01-30,2005-12-29,NDA 21-697,1745,21697,,,,,,,,,,,Vaprisol,conivaptan hydrochloride,Astellas Pharma,NDA,21697,,2004-01-30,2005-12-29,2005,treatment of euvolemic hyponatremia in hospitalized patients,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; RETEVASE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RETEVASE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",72 FR 14818,E7-5736,https://www.federalregister.gov/documents/2007/03/29/E7-5736/determination-of-regulatory-review-period-for-purposes-of-patent-extension-retevase,https://www.govinfo.gov/content/pkg/FR-2007-03-29/pdf/E7-5736.pdf,3/29/2007, RETEVASE,,John,RETEVASE,1,31,John,5223256,,,,Boehringer Mannheim GmbH,1919,1430,489,1997-02-06,1991-08-01,1996-10-30,PLA 95-1167,123,951167,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; KEPIVANCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KEPIVANCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",72 FR 15699,E7-6053,https://www.federalregister.gov/documents/2007/04/02/E7-6053/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kepivance,https://www.govinfo.gov/content/pkg/FR-2007-04-02/pdf/E7-6053.pdf,4/2/2007, KEPIVANCE,,John,KEPIVANCE,1,32,John,5677278,,,,Chiron Corp.,3303,3119,184,2006-06-14,1995-12-02,2004-12-15,BLA 125103,1417,125103,,,,,,,,,,,Kepivance,palifermin,Amgen,BLA,125103,,2004-06-15,2004-12-15,2004,indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; RANEXA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RANEXA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 15700,E7-6061,https://www.federalregister.gov/documents/2007/04/02/E7-6061/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ranexa,https://www.govinfo.gov/content/pkg/FR-2007-04-02/pdf/E7-6061.pdf,4/2/2007, RANEXA,,John,RANEXA,1,33,John,4567264,,,,"Roche Palo Alto, L.L.C.",6770,5645,1125,2006-09-05,1987-07-18,2006-01-27,NDA 21-526,5,21526,,,,,,,,,,,Ranexa,ranolazine,CV Therapeutics,NDA,21526,,2002-12-30,2006-01-27,2006,treatment of chronic angina,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; NOXAFIL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NOXAFIL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 28496,E7-9730,https://www.federalregister.gov/documents/2007/05/21/E7-9730/determination-of-regulatory-review-period-for-purposes-of-patent-extension-noxafil,https://www.govinfo.gov/content/pkg/FR-2007-05-21/pdf/E7-9730.pdf,5/21/2007, NOXAFIL,,John,NOXAFIL,1,34,John,5661151,,,,Schering Corp.,3650,3382,268,2007-03-12,1996-09-19,2006-09-15,NDA 22-003,1789,22003,10/4/2016,Treatment of invasive aspergillosis,Designated/Approved,,,Treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older,6/17/2021,6/17/2028,Treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older,Merck Sharp & Dohme LLC,Noxafil,posaconazole,Schering,NDA,22003,,2005-12-22,2006-09-15,2006,"prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with Graft versus Host Disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy",,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; IRESSA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IRESSA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 28497,E7-9733,https://www.federalregister.gov/documents/2007/05/21/E7-9733/determination-of-regulatory-review-period-for-purposes-of-patent-extension-iressa,https://www.govinfo.gov/content/pkg/FR-2007-05-21/pdf/E7-9733.pdf,5/21/2007, IRESSA,,John,IRESSA,1,35,John,5770599,,,,AstraZeneca UK Limited,1967,1693,274,2004-10-19,1997-12-17,2003-05-05,NDA 21-399,374,21399,8/26/2014,Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer,Designated/Approved,,,For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test,7/13/2015,7/13/2022,For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test,AstraZeneca Pharmaceuticals LP,Iressa,gefitinib,AstraZeneca Pharmaceuticals,NDA,21399,,2002-08-05,2003-05-05,2003,indicated as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies,,Priority,No,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; GALILEO INTRAVASCULAR RADIOTHERAPY SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GALILEO INTRAVASCULAR RADIOTHERAPY SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",72 FR 28498,E7-9720,https://www.federalregister.gov/documents/2007/05/21/E7-9720/determination-of-regulatory-review-period-for-purposes-of-patent-extension-galileo-intravascular,https://www.govinfo.gov/content/pkg/FR-2007-05-21/pdf/E7-9720.pdf,5/21/2007, GALILEO INTRAVASCULAR RADIOTHERAPY SYSTEM,,John,GALILEO INTRAVASCULAR RADIOTHERAPY SYSTEM,1,36,John,5199939,,,,Guidant Corp.,1523,1203,320,2002-10-31,1997-09-03,2001-11-02,PMA P000052,1062,52,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FOSRENOL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FOSRENOL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 28700,E7-9787,https://www.federalregister.gov/documents/2007/05/22/E7-9787/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fosrenol,https://www.govinfo.gov/content/pkg/FR-2007-05-22/pdf/E7-9787.pdf,5/22/2007, FOSRENOL,,John,FOSRENOL,1,37,John,5968976,,,,"Shire International Licensing, B.V.",2449,1538,911,2005-07-08,1998-02-13,2004-10-26,NDA 21-468,951,21468,,,,,,,,,,,Fosrenol,lanthanum carbonate hydrate,Shire Pharmaceutical Development,NDA,21468,,2002-04-30,2004-10-26,2004,indicated to reduce serum phosphate in patients with end stage renal disease,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ORENCIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ORENCIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",72 FR 28978,E7-9945,https://www.federalregister.gov/documents/2007/05/23/E7-9945/determination-of-regulatory-review-period-for-purposes-of-patent-extension-orencia,https://www.govinfo.gov/content/pkg/FR-2007-05-23/pdf/E7-9945.pdf,5/23/2007, ORENCIA,,John,ORENCIA,1,38,John,5851795,,,,Bristol-Myers Squibb Company,3803,3536,267,2006-09-05,1995-07-28,2005-12-23,BLA 125118,1414,125118,12/26/2017,Prevention of graft versus host disease,Designated/Approved,,,"prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor",12/15/2021,12/15/2028,prophylaxis of acute graft versus host disease (aGVHD) in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor,Bristol-Myers Squibb Co.,Orencia,abatacept,Bristol-Myers Squibb,BLA,125118,,2005-04-01,2005-12-23,2005,"indicated for reducing signs and symptoms, inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease Modifying Anti-Rheumatoid Drugs (DMARDs), such as methotrexate or TNF antagonists. Abatacept may be used as monotherapy or concomitantly with DMARDs other than TNF antagonists",,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ELAPRASE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ELAPRASE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",72 FR 28980,E7-9951,https://www.federalregister.gov/documents/2007/05/23/E7-9951/determination-of-regulatory-review-period-for-purposes-of-patent-extension-elaprase,https://www.govinfo.gov/content/pkg/FR-2007-05-23/pdf/E7-9951.pdf,5/23/2007, ELAPRASE,,John,ELAPRASE,1,39,John,5932211,,,,Women's,2008,1764,244,2007-02-06,2001-01-25,2006-07-24,BLA 125151,1103,125151,11/28/2001,Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome),Designated/Approved,,,"Indicated for patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Idursulfase has been shown to improve walking capacity in these patients",7/24/2006,7/24/2013,,"Takeda Pharmaceuticals U.S.A., Inc.",Elaprase,idursulfase,Shire Human Genetic Therapies,BLA,125151,,2005-11-23,2006-07-24,2006,"treatment of patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II)",,Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; BEXTRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BEXTRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 28984,E7-9957,https://www.federalregister.gov/documents/2007/05/23/E7-9957/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bextra,https://www.govinfo.gov/content/pkg/FR-2007-05-23/pdf/E7-9957.pdf,5/23/2007, BEXTRA,,John,BEXTRA,1,40,John,5633272,,,,"G.D. Searle, LLC",1767,1462,305,2004-08-31,1997-01-16,2001-11-16,NDA 21-341,276,21341,,,,,,,,,,,Bextra,valdecoxib,GD Searle,NDA,21341,,2001-01-16,2001-11-16,2001,indicated for the relief of signs and symptoms of osteoarthritis and adult rheumatoid arthritis and for the treatment of primary dysmenorrhea,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; GARDASIL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GARDASIL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",72 FR 28979,E7-9950,https://www.federalregister.gov/documents/2007/05/23/E7-9950/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gardasil,https://www.govinfo.gov/content/pkg/FR-2007-05-23/pdf/E7-9950.pdf,5/23/2007, GARDASIL,,John,GARDASIL,1,41,John,5820870,,,,"Merck & Co., Inc.",2215,2031,184,"Types 6, 11",2000-05-17,2006-06-08,BLA 125126,1200,125126,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SOMAVERT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SOMAVERT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 29172,E7-10052,https://www.federalregister.gov/documents/2007/05/24/E7-10052/determination-of-regulatory-review-period-for-purposes-of-patent-extension-somavert,https://www.govinfo.gov/content/pkg/FR-2007-05-24/pdf/E7-10052.pdf,5/24/2007, SOMAVERT,,John,SOMAVERT,1,42,John,5849535,,,,"Genentech, Inc.",2169,1349,820,2004-04-06,1997-04-18,2003-03-25,NDA 21-106,466,21106,6/24/1997,Treatment of acromegaly.,Designated/Approved,,,"Treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate",3/25/2003,3/25/2010,,Sensus Corporation,Somavert,pegvisomant,Pharmacia and Upjohn,BLA,21106,,2000-12-26,2003-03-25,2003,"treatment of acromegaly in patients who have an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate",,Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; MYOZYME,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MYOZYME and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",72 FR 29333,E7-10087,https://www.federalregister.gov/documents/2007/05/25/E7-10087/determination-of-regulatory-review-period-for-purposes-of-patent-extension-myozyme,https://www.govinfo.gov/content/pkg/FR-2007-05-25/pdf/E7-10087.pdf,5/25/2007, MYOZYME,,John,MYOZYME,1,43,John,6118045,,,,"Genzyme Corp., Erasmus MC, Erasmus Universiteit",1225,950,275,2007-02-06,2002-12-22,2006-04-28,BLA 125141,1251,125141,,,,,,,,,,,Myozyme,alglucosidase alfa,Genzyme,BLA,125141,,2005-07-28,2006-04-28,2006,treatment of Pompe disease (GAA deficiency),,Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; PREZISTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PREZISTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 29335,E7-10147,https://www.federalregister.gov/documents/2007/05/25/E7-10147/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prezista,https://www.govinfo.gov/content/pkg/FR-2007-05-25/pdf/E7-10147.pdf,5/25/2007, PREZISTA,,John,PREZISTA,1,44,John,6248775,,,,G.D. Searle & Co.,1253,1070,183,2007-02-06,2003-01-19,2006-06-23,NDA 21-976,717,21976,,,,,,,,,,,Prezista,darunavir,Tibotec,NDA,21976,,2005-12-23,2006-06-23,2006,"coadministered with ritonavir, indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment-experienced adult patients, such as those with HIV-1 strains resistant to more than one protease inhibitor",,Priority,No,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; KDR 401 and 403 PACEMAKERS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KDR 401 and 403 PACEMAKERS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims those medical devices.",72 FR 29336,E7-10127,https://www.federalregister.gov/documents/2007/05/25/E7-10127/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kdr-401-and-403,https://www.govinfo.gov/content/pkg/FR-2007-05-25/pdf/E7-10127.pdf,5/25/2007, KDR 401 and 403 PACEMAKERS,,John,KDR 401 and 403 PACEMAKERS,1,45,John,4958632,,,,"Medtronic, Inc.",716,358,358,2007-02-22,2007-02-22,1998-01-30,PMA 970012,358,970012,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Periods for Purposes of Patent Extension; SPRYCEL-New Drug Applications 21-986 and 22-072,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SPRYCEL--new drug applications (NDAs) 21- 986 and 22-072 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 29334,E7-10089,https://www.federalregister.gov/documents/2007/05/25/E7-10089/determination-of-regulatory-review-periods-for-purposes-of-patent-extension-sprycel-new-drug,https://www.govinfo.gov/content/pkg/FR-2007-05-25/pdf/E7-10089.pdf,5/25/2007, SPRYCEL-New Drug Applications 21-986 and 22-072,,John,,0,45,John,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZILMAX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZILMAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",72 FR 30594,E7-10602,https://www.federalregister.gov/documents/2007/06/01/E7-10602/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zilmax,https://www.govinfo.gov/content/pkg/FR-2007-06-01/pdf/E7-10602.pdf,6/1/2007, ZILMAX,,John,ZILMAX,1,46,John,4900735,,,,Intervet International B.V.,40,4720,4674,2007-03-05,1993-09-09,2006-08-10,NADA 141-258,5,141258,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LANTUS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LANTUS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 30595,E7-10632,https://www.federalregister.gov/documents/2007/06/01/E7-10632/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lantus,https://www.govinfo.gov/content/pkg/FR-2007-06-01/pdf/E7-10632.pdf,6/1/2007, LANTUS,,John,LANTUS,1,47,John,5101013,,,,Hoechst Aktiengesellschaft,1591,1227,364,2007-01-26,1995-12-14,2000-04-20,NDA 21-081,976,21081,,,,,,,,,,,Lantus,insulin glargine,Aventis Pharmaceuticals,BLA,21081,,1999-04-23,2000-04-20,2000,treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; PHAKIC INTRAOCULAR LENSES,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PHAKIC INTRAOCULAR LENSES and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",72 FR 30597,E7-10631,https://www.federalregister.gov/documents/2007/06/01/E7-10631/determination-of-regulatory-review-period-for-purposes-of-patent-extension-phakic-intraocular-lenses,https://www.govinfo.gov/content/pkg/FR-2007-06-01/pdf/E7-10631.pdf,6/1/2007, PHAKIC INTRAOCULAR LENSES,,John,PHAKIC INTRAOCULAR LENSES,1,48,John,5192319,,,,"Ophtec USA, Inc., subsidiary of Ophtec B.V.",2545,2107,438,2006-09-05,1997-09-24,2004-09-10,PMA P030028,1484,30028,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; GEM 21S GROWTH-FACTOR ENHANCED MATRIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GEM 21S GROWTH-FACTOR ENHANCED MATRIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",72 FR 30598,E7-10633,https://www.federalregister.gov/documents/2007/06/01/E7-10633/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gem-21s-growth-factor,https://www.govinfo.gov/content/pkg/FR-2007-06-01/pdf/E7-10633.pdf,6/1/2007, GEM 21S GROWTH-FACTOR ENHANCED MATRIX,,John,GEM 21S GROWTH-FACTOR ENHANCED MATRIX,1,49,John,5124316,,,,"Biomimetic Therapeutics, Inc. (previously Biomimetic Pharmaceuticals, Inc.)",1361,744,617,2007-01-08,2002-02-28,2005-11-18,PMA P040013,987,40013,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; X-STOP INTERSPINOUS PROCESS DECOMPRESSION SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for X-STOP INTERSPINOUS PROCESS DECOMPRESSION SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",72 FR 30596,E7-10618,https://www.federalregister.gov/documents/2007/06/01/E7-10618/determination-of-regulatory-review-period-for-purposes-of-patent-extension-x-stop-interspinous,https://www.govinfo.gov/content/pkg/FR-2007-06-01/pdf/E7-10618.pdf,6/1/2007, X-STOP INTERSPINOUS PROCESS DECOMPRESSION SYSTEM,,John,X-STOP INTERSPINOUS PROCESS DECOMPRESSION SYSTEM,1,50,John,6235030,,,,"St. Francis Medical Technologies, Inc.",2224,1538,686,2006-12-12,2006-12-12,2005-11-21,PMA P040001,1053,40001,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NAMENDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NAMENDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of two applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",72 FR 31075,E7-10730,https://www.federalregister.gov/documents/2007/06/05/E7-10730/determination-of-regulatory-review-period-for-purposes-of-patent-extension-namenda,https://www.govinfo.gov/content/pkg/FR-2007-06-05/pdf/E7-10730.pdf,6/5/2007, NAMENDA,,John,NAMENDA,2,52,John,5061703 and 5614560,,,,"Forest Laboratories, Inc., acting as agent for Merz Pharma GmbH & Co. KGaA",5001,4699,302,2007-01-26,1990-02-07,2003-10-16,NDA 21-487,1250,21487,,,,,,,,,,,Namenda,memantine hydrochloride,Forest Laboratories,NDA,21487,,2002-12-19,2003-10-16,2003,treatment of moderate to severe dementia of the Alzheimer's type,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; RAPLON,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RAPLON and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 31331,E7-10853,https://www.federalregister.gov/documents/2007/06/06/E7-10853/determination-of-regulatory-review-period-for-purposes-of-patent-extension-raplon,https://www.govinfo.gov/content/pkg/FR-2007-06-06/pdf/E7-10853.pdf,6/6/2007, RAPLON,,John,RAPLON,1,53,John,5418226,,,,Akzo Nobel N.V.,1724,1304,420,2000-04-26,1994-11-30,1999-08-18,NDA 20-984,126,20984,,,,,,,,,,,Raplon,rapacuronium bromide,Organon,NDA,20984,,1998-06-25,1999-08-18,1999,"indicated for outpatients and inpatients as an adjunct to general anesthesia to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgical procedures",,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; CHANTIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CHANTIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",72 FR 31588,E7-10915,https://www.federalregister.gov/documents/2007/06/07/E7-10915/determination-of-regulatory-review-period-for-purposes-of-patent-extension-chantix,https://www.govinfo.gov/content/pkg/FR-2007-06-07/pdf/E7-10915.pdf,6/7/2007, CHANTIX,,John,CHANTIX,1,54,John,6410550,,,,"Pfizer, Inc.",2401,2219,182,2007-01-26,1999-10-15,2006-05-10,NDA 21-928,545,21928,,,,,,,,,,,Chantix,varenicline,Pfizer,NDA,21928,,2005-11-10,2006-05-10,2006,indicated as an aid to smoking cessation treatment,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ACRYSOF,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ACRYSOF and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",73 FR 17985,E8-6851,https://www.federalregister.gov/documents/2008/04/02/E8-6851/determination-of-regulatory-review-period-for-purposes-of-patent-extension-acrysof,https://www.govinfo.gov/content/pkg/FR-2008-04-02/pdf/E8-6851.pdf,4/2/2008, ACRYSOF,,John,ACRYSOF,1,55,John,5470932,,,,"Alcon Manufacturing, Ltd.",1084,538,546,2000-07-07,2000-07-07,2003-06-24,PMA P930014,832,930014,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ARTEFILL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ARTEFILL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",73 FR 24072,E8-9592,https://www.federalregister.gov/documents/2008/05/01/E8-9592/determination-of-regulatory-review-period-for-purposes-of-patent-extension-artefill,https://www.govinfo.gov/content/pkg/FR-2008-05-01/pdf/E8-9592.pdf,5/1/2008, ARTEFILL,,John,ARTEFILL,1,56,John,5344452,,,,"Artes Medical USA, Inc.",3530,1859,1671,1997-02-28,1997-02-28,2006-10-27,PMA P020012,1827,20012,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AZILECT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AZILECT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",73 FR 24073,E8-9591,https://www.federalregister.gov/documents/2008/05/01/E8-9591/determination-of-regulatory-review-period-for-purposes-of-patent-extension-azilect,https://www.govinfo.gov/content/pkg/FR-2008-05-01/pdf/E8-9591.pdf,5/1/2008, AZILECT,,John,AZILECT,1,57,John,5453446,,,,"Teva Pharmaceutical Industries, Ltd.",4269,3284,985,1994-09-09,1994-09-09,2006-05-16,NDA 21-641,1827,21641,,,,,,,,,,,Azilect,rasagiline mesylate,Teva Pharmaceuticals,NDA,21641,,2003-09-05,2006-05-16,2006,indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease as initial monotherapy and as adjunct therapy to levodopa,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TEKTURNA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TEKTURNA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",73 FR 24295,E8-9699,https://www.federalregister.gov/documents/2008/05/02/E8-9699/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tekturna,https://www.govinfo.gov/content/pkg/FR-2008-05-02/pdf/E8-9699.pdf,5/2/2008, TEKTURNA,,John,TEKTURNA,1,58,John,5559111,,,,Novartis Corporation,2023,1637,386,2001-08-22,2001-08-22,2007-03-05,NDA 21-985,2022,21985,,,,,,,,,,,Tekturna,aliskiren,Novartis Pharmaceuticals,NDA,21985,,2006-02-13,2007-03-05,2007,treatment of hypertension,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; OMNARIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OMNARIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",73 FR 26999,E8-10466,https://www.federalregister.gov/documents/2008/05/12/E8-10466/determination-of-regulatory-review-period-for-purposes-of-patent-extension-omnaris,https://www.govinfo.gov/content/pkg/FR-2008-05-12/pdf/E8-10466.pdf,5/12/2008, OMNARIS,,John,OMNARIS,1,59,John,5482934,,,,Altana Pharma AG,3196,2893,303,1998-01-21,1998-01-21,2006-10-20,NDA 22-004,1748,22004,,,,,,,,,,,Omnaris,ciclesonide,Altana Pharma,NDA,22004,,2005-12-22,2006-10-20,2006,treatment of seasonal and allergic rhinitis in patients 12 years of age and older,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VECTIBIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VECTIBIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",73 FR 27000,E8-10512,https://www.federalregister.gov/documents/2008/05/12/E8-10512/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vectibix,https://www.govinfo.gov/content/pkg/FR-2008-05-12/pdf/E8-10512.pdf,5/12/2008, VECTIBIX,,John,VECTIBIX,1,60,John,6235883,,,,Amgen Fremont Inc.,2662,2479,183,1999-06-16,1999-06-16,2006-09-27,BLA 125147,1122,125147,,,,,,,,,,,Vectibix,panitumumab,Amgen,BLA,125147,,2006-03-29,2006-09-27,2006,"treatment of EGFR-expressing metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy regimens",,Priority,No,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; INVEGA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INVEGA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",73 FR 27837,E8-10685,https://www.federalregister.gov/documents/2008/05/14/E8-10685/determination-of-regulatory-review-period-for-purposes-of-patent-extension-invega,https://www.govinfo.gov/content/pkg/FR-2008-05-14/pdf/E8-10685.pdf,5/14/2008, INVEGA,,John,INVEGA,1,61,John,5158952,,,,"Janssen, L.P.",1406,1021,385,2003-02-14,2003-02-14,2006-12-19,NDA 21-999,896,21999,,,,,,,,,,,Invega,paliperidone,Johnson & Johnson,NDA,21999,,2005-11-30,2006-12-19,2006,treatment of schizophrenia,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ZOLINZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZOLINZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",73 FR 27838,E8-10689,https://www.federalregister.gov/documents/2008/05/14/E8-10689/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zolinza,https://www.govinfo.gov/content/pkg/FR-2008-05-14/pdf/E8-10689.pdf,5/14/2008, ZOLINZA,,John,ZOLINZA,1,62,John,RE38506 E,,,,Sloan-Kettering Institute for Cancer Research,2449,2266,183,2000-01-24,2000-01-24,2006-10-06,NDA 21-991,1433,21991,3/16/2004,Treatment of T-cell non-Hodgkin's lymphoma,Designated/Approved,,,"Treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistant or recurrent disease on or following two systemic therapies.",10/6/2006,10/6/2013,,"Merck & Co., Inc.",Zolinza,vorinostat,Merck,NDA,21991,,2006-04-07,2006-10-06,2006,"treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies",,Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",73 FR 27836,E8-10726,https://www.federalregister.gov/documents/2008/05/14/E8-10726/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2008-05-14/pdf/E8-10726.pdf,5/14/2008, AVASTIN,,John,AVASTIN,1,63,John,6639055,,,,"Genentech, Inc.",2551,2401,150,1997-03-05,1997-03-05,2004-02-26,BLA 125085,121,125085,11/23/2010,Treatment of fallopian tube carcinoma,Designated/Approved,,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.",11/14/2014,11/14/2021,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",73 FR 27836,E8-10726,https://www.federalregister.gov/documents/2008/05/14/E8-10726/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2008-05-14/pdf/E8-10726.pdf,5/14/2008, AVASTIN,,John,AVASTIN,1,64,John,6639055,,,,"Genentech, Inc.",2551,2401,150,1997-03-05,1997-03-05,2004-02-26,BLA 125085,121,125085,2/9/2006,Therapeutic treatment of patients with ovarian cancer,Designated/Approved,,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.",12/6/2016,12/6/2023,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.","Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",73 FR 27836,E8-10726,https://www.federalregister.gov/documents/2008/05/14/E8-10726/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2008-05-14/pdf/E8-10726.pdf,5/14/2008, AVASTIN,,John,AVASTIN,1,65,John,6639055,,,,"Genentech, Inc.",2551,2401,150,1997-03-05,1997-03-05,2004-02-26,BLA 125085,121,125085,2/9/2006,Therapeutic treatment of patients with ovarian cancer,Designated/Approved,,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitiverecurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.",6/13/2018,6/13/2025,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.","Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",73 FR 27836,E8-10726,https://www.federalregister.gov/documents/2008/05/14/E8-10726/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2008-05-14/pdf/E8-10726.pdf,5/14/2008, AVASTIN,,John,AVASTIN,1,66,John,6639055,,,,"Genentech, Inc.",2551,2401,150,1997-03-05,1997-03-05,2004-02-26,BLA 125085,121,125085,2/9/2006,Therapeutic treatment of patients with ovarian cancer,Designated/Approved,,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",11/14/2014,11/14/2021,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",73 FR 27836,E8-10726,https://www.federalregister.gov/documents/2008/05/14/E8-10726/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2008-05-14/pdf/E8-10726.pdf,5/14/2008, AVASTIN,,John,AVASTIN,1,67,John,6639055,,,,"Genentech, Inc.",2551,2401,150,1997-03-05,1997-03-05,2004-02-26,BLA 125085,121,125085,5/26/2006,Treatment of malignant glioma,Designated/Approved,,,Treatment of glioblastoma with progressive disease following prior therapy,5/5/2009,5/5/2016,,"Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",73 FR 27836,E8-10726,https://www.federalregister.gov/documents/2008/05/14/E8-10726/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2008-05-14/pdf/E8-10726.pdf,5/14/2008, AVASTIN,,John,AVASTIN,1,68,John,6639055,,,,"Genentech, Inc.",2551,2401,150,1997-03-05,1997-03-05,2004-02-26,BLA 125085,121,125085,11/6/2003,Treatment of renal cell carcinoma,Designated/Approved,,,Treatment of renal cell carcinoma in combination with interferon alfa,7/31/2009,7/31/2016,,"Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",73 FR 27836,E8-10726,https://www.federalregister.gov/documents/2008/05/14/E8-10726/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2008-05-14/pdf/E8-10726.pdf,5/14/2008, AVASTIN,,John,AVASTIN,1,69,John,6639055,,,,"Genentech, Inc.",2551,2401,150,1997-03-05,1997-03-05,2004-02-26,BLA 125085,121,125085,11/2/2010,Treatment of primary peritoneal carcinoma.,Designated/Approved,,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.",12/6/2016,12/6/2023,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.","Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",73 FR 27836,E8-10726,https://www.federalregister.gov/documents/2008/05/14/E8-10726/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2008-05-14/pdf/E8-10726.pdf,5/14/2008, AVASTIN,,John,AVASTIN,1,70,John,6639055,,,,"Genentech, Inc.",2551,2401,150,1997-03-05,1997-03-05,2004-02-26,BLA 125085,121,125085,11/23/2010,Treatment of fallopian tube carcinoma,Designated/Approved,,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.",12/6/2016,12/6/2023,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.","Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",73 FR 27836,E8-10726,https://www.federalregister.gov/documents/2008/05/14/E8-10726/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2008-05-14/pdf/E8-10726.pdf,5/14/2008, AVASTIN,,John,AVASTIN,1,71,John,6639055,,,,"Genentech, Inc.",2551,2401,150,1997-03-05,1997-03-05,2004-02-26,BLA 125085,121,125085,11/23/2010,Treatment of fallopian tube carcinoma,Designated/Approved,,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitiverecurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.",6/13/2018,6/13/2025,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.","Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",73 FR 27836,E8-10726,https://www.federalregister.gov/documents/2008/05/14/E8-10726/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2008-05-14/pdf/E8-10726.pdf,5/14/2008, AVASTIN,,John,AVASTIN,1,72,John,6639055,,,,"Genentech, Inc.",2551,2401,150,1997-03-05,1997-03-05,2004-02-26,BLA 125085,121,125085,11/2/2010,Treatment of primary peritoneal carcinoma.,Designated/Approved,,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitiverecurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.",6/13/2018,6/13/2025,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.","Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVASTIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AVASTIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",73 FR 27836,E8-10726,https://www.federalregister.gov/documents/2008/05/14/E8-10726/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avastin,https://www.govinfo.gov/content/pkg/FR-2008-05-14/pdf/E8-10726.pdf,5/14/2008, AVASTIN,,John,AVASTIN,1,73,John,6639055,,,,"Genentech, Inc.",2551,2401,150,1997-03-05,1997-03-05,2004-02-26,BLA 125085,121,125085,11/2/2010,Treatment of primary peritoneal carcinoma.,Designated/Approved,,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",11/14/2014,11/14/2021,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens","Genentech, Inc.",Avastin,bevacizumab,Genentech,BLA,125085,,2003-09-30,2004-02-26,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; TYZEKA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TYZEKA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submissions of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",73 FR 28119,E8-10857,https://www.federalregister.gov/documents/2008/05/15/E8-10857/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tyzeka,https://www.govinfo.gov/content/pkg/FR-2008-05-15/pdf/E8-10857.pdf,5/15/2008, TYZEKA,,John,TYZEKA,2,75,John,6395716 and 6569837,,,,"Idenix Pharmaceuticals, Inc., Centre National de La Recherche Scientifique",2309,2009,300,2000-07-01,2000-08-15,2006-10-25,NDA 22-011,442,22011,,,,,,,,,,,Tyzeka,telbivudine,Idenix Pharmaceuticals,NDA,22011,,2005-12-30,2006-10-25,2006,treatment of chronic hepatitis B (CHB) in patients with evidence of viral replication and active liver inflammation,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LUCENTIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LUCENTIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human biological product.",73 FR 30949,E8-12007,https://www.federalregister.gov/documents/2008/05/29/E8-12007/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lucentis,https://www.govinfo.gov/content/pkg/FR-2008-05-29/pdf/E8-12007.pdf,5/29/2008, LUCENTIS,,John,LUCENTIS,3,78,John,6407213; 6884879; and 7060269,,,,"Genentech, Inc.",2430,2247,183,1999-11-06,1999-11-06,2006-06-30,BLA 125156,378,125156,,,,,,,,,,,Lucentis,ranibizumab,Genentech,BLA,125156,,2005-12-30,2006-06-30,2006,treatment of patients with neovascular (wet) age-related macular degeneration,,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VEREGEN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VEREGEN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",73 FR 31697,E8-12296,https://www.federalregister.gov/documents/2008/06/03/E8-12296/determination-of-regulatory-review-period-for-purposes-of-patent-extension-veregen,https://www.govinfo.gov/content/pkg/FR-2008-06-03/pdf/E8-12296.pdf,6/3/2008, VEREGEN,,John,VEREGEN,2,80,John,5795911 and 5968973,,,,"Mitsui Norin Co., Ltd.",3002,2605,397,1998-08-14,1998-08-14,2006-10-31,NDA 21-902,1300,21902,,,,,,,,,,,Veregen,kunecatechins,Medigene,NDA,21902,,2005-09-30,2006-10-31,2006,treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TYZEKA; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of May 15, 2008 (73 FR 28119), announcing FDA's determination of the regulatory review period for TYZEKA. The document published with an incorrect docket number. This document corrects that error.",73 FR 31697,E8-12300,https://www.federalregister.gov/documents/2008/06/03/E8-12300/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tyzeka-correction,https://www.govinfo.gov/content/pkg/FR-2008-06-03/pdf/E8-12300.pdf,6/3/2008, TYZEKA, Correction,John,,0,80,John,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ROTATEQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ROTATEQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",73 FR 33095,E8-13109,https://www.federalregister.gov/documents/2008/06/11/E8-13109/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rotateq,https://www.govinfo.gov/content/pkg/FR-2008-06-11/pdf/E8-13109.pdf,6/11/2008, ROTATEQ,,John,ROTATEQ,1,81,John,5626851,,,,the Wistar Institute of Anatomy,4577,4272,305,1993-07-26,1993-07-26,2006-02-03,BLA 125122,1751,125122,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ERAXIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ERAXIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",73 FR 35402,E8-14156,https://www.federalregister.gov/documents/2008/06/23/E8-14156/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eraxis,https://www.govinfo.gov/content/pkg/FR-2008-06-23/pdf/E8-14156.pdf,6/23/2008, ERAXIS,,John,ERAXIS,1,82,John,5965525,,,,Eli Lilly,3476,2446,1030,1996-08-14,1996-08-14,2006-02-17,NDA 21-948,1224,21948,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TYKERB,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TYKERB and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",73 FR 66647,E8-26679,https://www.federalregister.gov/documents/2008/11/10/E8-26679/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tykerb,https://www.govinfo.gov/content/pkg/FR-2008-11-10/pdf/E8-26679.pdf,11/10/2008, TYKERB,,John,TYKERB,1,83,John,6713485,,,,SmithKline Beecham Corp. (doing business as GlaxoSmithKline),2260,2078,182,2001-01-05,2001-01-05,2007-03-13,NDA 22-059,628,22059,,,,,,,,,,,Tykerb,lapatinib,GlaxoSmithKline,NDA,22059,,2006-09-13,2007-03-13,2007,"in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors over-express HER2 (ErbB2) and who have received prior therapy including and anthracycline, a taxane and trastuzumab",,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; IXEMPRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IXEMPRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",73 FR 66646,E8-26678,https://www.federalregister.gov/documents/2008/11/10/E8-26678/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ixempra,https://www.govinfo.gov/content/pkg/FR-2008-11-10/pdf/E8-26678.pdf,11/10/2008, IXEMPRA,,John,IXEMPRA,1,84,John,6605599,,,,Bristol Myers Squibb Co.,3002,2818,184,1999-07-30,1999-07-30,2007-10-16,NDA 22-065,854,22065,,,,,,,,,,,Ixempra,ixabepilone,Bristol-Myers Squibb,NDA,22065,,2007-04-16,2007-10-16,2007,,"IXEMPRA is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting. 
IXEMPRA is indicated as monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.",Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SOMATULINE DEPOT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SOMATULINE DEPOT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",73 FR 67874,E8-27179,https://www.federalregister.gov/documents/2008/11/17/E8-27179/determination-of-regulatory-review-period-for-purposes-of-patent-extension-somatuline-depot,https://www.govinfo.gov/content/pkg/FR-2008-11-17/pdf/E8-27179.pdf,11/17/2008, SOMATULINE DEPOT,,John,SOMATULINE DEPOT,1,85,John,5595760,,,,Society De Conseils De Recherches Et D'Applications Scientifiques,3629,3324,305,1997-09-24,1997-09-24,2007-08-30,NDA 22-074,5,22074,9/11/2000,Treatment for acromegly,Designated/Approved,,,Long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy,8/30/2007,8/30/2014,,"IPSEN, Inc.",Somatuline Depot,lanreotide,Beaufour Ipsen Pharma,NDA,22074,,2006-10-30,2007-08-30,2007,long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy,,Standard,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SOMATULINE DEPOT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SOMATULINE DEPOT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",73 FR 67874,E8-27179,https://www.federalregister.gov/documents/2008/11/17/E8-27179/determination-of-regulatory-review-period-for-purposes-of-patent-extension-somatuline-depot,https://www.govinfo.gov/content/pkg/FR-2008-11-17/pdf/E8-27179.pdf,11/17/2008, SOMATULINE DEPOT,,John,SOMATULINE DEPOT,1,86,John,5595760,,,,Society De Conseils De Recherches Et D'Applications Scientifiques,3629,3324,305,1997-09-24,1997-09-24,2007-08-30,NDA 22-074,5,22074,8/25/2011,Treatment of neuroendocrine tumors,Designated/Approved,,,"Treatment of patients with unresectable,well- or moderately-differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival",12/16/2014,12/16/2021,"Treatment of patients with unresectable,well- or moderately-differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival","Ipsen Biopharmaceuticals, Inc.",Somatuline Depot,lanreotide,Beaufour Ipsen Pharma,NDA,22074,,2006-10-30,2007-08-30,2007,long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy,,Standard,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LETAIRIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LETAIRIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",74 FR 6635,E9-2683,https://www.federalregister.gov/documents/2009/02/10/E9-2683/determination-of-regulatory-review-period-for-purposes-of-patent-extension-letairis,https://www.govinfo.gov/content/pkg/FR-2009-02-10/pdf/E9-2683.pdf,2/10/2009, LETAIRIS,,John,LETAIRIS,4,90,John,5703017; 5840722; 5932730; and 7109205,,,,"Abbott Gmbh & Co., KG",1871,1691,180,2002-05-03,2002-05-03,2007-06-15,NDA 22-081,995,22081,7/16/2004,Treatment of pulmonary arterial hypertension,Designated/Approved,,,Treatment of pulmonary arterial hypertension (WHO group I) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening,6/15/2007,6/15/2014,,Gilead Colorado,Letairis,ambrisentan,Gilead Sciences,NDA,22081,,2006-12-18,2007-06-15,2007,treatment of pulmonary arterial hypertension (WHO Group I) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening,,Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; LUNESTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LUNESTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 6636,E9-2681,https://www.federalregister.gov/documents/2009/02/10/E9-2681/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lunesta,https://www.govinfo.gov/content/pkg/FR-2009-02-10/pdf/E9-2681.pdf,2/10/2009, LUNESTA,,John,LUNESTA,1,91,John,6444673,,,,"Sepracor, Inc.",1941,1256,685,1999-08-25,1999-08-25,2004-12-15,NDA 21-476,760,21476,,,,,,,,,,,Lunesta,eszopiclone,Sepracor,NDA,21476,,2003-01-31,2004-12-15,2004,treatment of insomnia,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; MIRCERA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MIRCERA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",74 FR 6637,E9-2812,https://www.federalregister.gov/documents/2009/02/10/E9-2812/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mircera,https://www.govinfo.gov/content/pkg/FR-2009-02-10/pdf/E9-2812.pdf,2/10/2009, MIRCERA,,John,MIRCERA,1,92,John,6583272,,,,Hoffmann-La Roche Inc.,2140,1565,575,2002-01-06,2002-01-06,2007-11-14,BLA B125164,5,125164,,,,,,,,,,,Mircera,methoxy polyethylene glycol-epoetin beta,Hoffmann-La Roche,BLA,125164,,2006-04-19,2007-11-14,2007,,"Mircera is indicated for the treatment of anemia associated with chronic renal failure (CRF) in adults, including patients on dialysis and not on dialysis.
Mircera is not indicated for the treatment of anemia due to cancer chemotherapy.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SELZENTRY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SELZENTRY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 6638,E9-2813,https://www.federalregister.gov/documents/2009/02/10/E9-2813/determination-of-regulatory-review-period-for-purposes-of-patent-extension-selzentry,https://www.govinfo.gov/content/pkg/FR-2009-02-10/pdf/E9-2813.pdf,2/10/2009, SELZENTRY,,John,SELZENTRY,1,93,John,6667314,,,,Pfizer Inc.,1524,1294,230,2003-06-06,2003-06-06,2007-08-06,NDA 22-128,73,22128,,,,,,,,,,,Selzentry,maraviroc,Pfizer,NDA,22128,,2006-12-20,2007-08-06,2007,treatment of patients infected with CCR5-tropic HIV-1,,Priority,No,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; VETMEDIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VETMEDIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",74 FR 6639,E9-2684,https://www.federalregister.gov/documents/2009/02/10/E9-2684/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vetmedin,https://www.govinfo.gov/content/pkg/FR-2009-02-10/pdf/E9-2684.pdf,2/10/2009, VETMEDIN,,John,VETMEDIN,1,94,John,5364646,,,,Dr. Karl Thomae GmbH,2751,2715,36,1999-10-20,2007-03-26,2007-04-30,NADA 141-273,1492,141273,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MACROPLASTIQUE IMPLANTS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MACROPLASTIQUE IMPLANTS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that medical device.",74 FR 6901,E9-2903,https://www.federalregister.gov/documents/2009/02/11/E9-2903/determination-of-regulatory-review-period-for-purposes-of-patent-extension-macroplastique-implants,https://www.govinfo.gov/content/pkg/FR-2009-02-11/pdf/E9-2903.pdf,2/11/2009, MACROPLASTIQUE IMPLANTS,,John,MACROPLASTIQUE IMPLANTS,3,97,John,5258028;. 5336263; and 5571182,,,,"Uroplasty, Inc.",2651,1973,678,1999-07-30,1999-07-30,2006-10-30,PMA P040050,1640,40050,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ENDEAVOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ENDEAVOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",74 FR 9249,E9-4374,https://www.federalregister.gov/documents/2009/03/03/E9-4374/determination-of-regulatory-review-period-for-purposes-of-patent-extension-endeavor,https://www.govinfo.gov/content/pkg/FR-2009-03-03/pdf/E9-4374.pdf,3/3/2009, ENDEAVOR,,John,ENDEAVOR,1,98,John,5624411,,,,"Medtronic, Inc.",1507,1068,439,2003-12-19,2003-12-19,2008-02-01,PMA P060033,954,60033,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SOLIRIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SOLIRIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",74 FR 9406,E9-4526,https://www.federalregister.gov/documents/2009/03/04/E9-4526/determination-of-regulatory-review-period-for-purposes-of-patent-extension-soliris,https://www.govinfo.gov/content/pkg/FR-2009-03-04/pdf/E9-4526.pdf,3/4/2009, SOLIRIS,,John,SOLIRIS,1,99,John,6355245,,,,"Alexion Pharmaceuticals, Inc.",1360,1177,183,2003-06-27,2003-06-27,2007-03-16,BLA 125166,735,125166,6/24/2013,Treatment of neuromyelitis optica,Designated/Approved,,,Soliris is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.,6/27/2019,6/27/2026,For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,"Alexion Pharmaceuticals, Inc.",Soliris,eculizumab,Alexion Pharmaceuticals,BLA,125166,,2006-09-15,2007-03-16,2007,treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis,,Priority,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SOLIRIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SOLIRIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",74 FR 9406,E9-4526,https://www.federalregister.gov/documents/2009/03/04/E9-4526/determination-of-regulatory-review-period-for-purposes-of-patent-extension-soliris,https://www.govinfo.gov/content/pkg/FR-2009-03-04/pdf/E9-4526.pdf,3/4/2009, SOLIRIS,,John,SOLIRIS,1,100,John,6355245,,,,"Alexion Pharmaceuticals, Inc.",1360,1177,183,2003-06-27,2003-06-27,2007-03-16,BLA 125166,735,125166,4/29/2009,Treatment of atypical hemolytic uremic syndrome,Designated/Approved,,,For the treatment of atypical Hemolytic Uremic Syndrome (aHUS),9/23/2011,9/23/2018,,"Alexion Pharmaceuticals, Inc.",Soliris,eculizumab,Alexion Pharmaceuticals,BLA,125166,,2006-09-15,2007-03-16,2007,treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis,,Priority,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SOLIRIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SOLIRIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",74 FR 9406,E9-4526,https://www.federalregister.gov/documents/2009/03/04/E9-4526/determination-of-regulatory-review-period-for-purposes-of-patent-extension-soliris,https://www.govinfo.gov/content/pkg/FR-2009-03-04/pdf/E9-4526.pdf,3/4/2009, SOLIRIS,,John,SOLIRIS,1,101,John,6355245,,,,"Alexion Pharmaceuticals, Inc.",1360,1177,183,2003-06-27,2003-06-27,2007-03-16,BLA 125166,735,125166,6/12/2014,Treatment of Myasthenia Gravis,Designated/Approved,,,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive,10/23/2017,10/23/2024,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive,"Alexion Pharmaceuticals, Inc.",Soliris,eculizumab,Alexion Pharmaceuticals,BLA,125166,,2006-09-15,2007-03-16,2007,treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis,,Priority,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SOLIRIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SOLIRIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",74 FR 9406,E9-4526,https://www.federalregister.gov/documents/2009/03/04/E9-4526/determination-of-regulatory-review-period-for-purposes-of-patent-extension-soliris,https://www.govinfo.gov/content/pkg/FR-2009-03-04/pdf/E9-4526.pdf,3/4/2009, SOLIRIS,,John,SOLIRIS,1,102,John,6355245,,,,"Alexion Pharmaceuticals, Inc.",1360,1177,183,2003-06-27,2003-06-27,2007-03-16,BLA 125166,735,125166,8/20/2003,Treatment of paroxysmal nocturnal hemoglobinuria,Designated/Approved,,,Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis,3/16/2007,3/16/2014,,"Alexion Pharmaceuticals, Inc.",Soliris,eculizumab,Alexion Pharmaceuticals,BLA,125166,,2006-09-15,2007-03-16,2007,treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis,,Priority,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ARRANON,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ARRANON and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 9823,E9-4770,https://www.federalregister.gov/documents/2009/03/06/E9-4770/determination-of-regulatory-review-period-for-purposes-of-patent-extension-arranon,https://www.govinfo.gov/content/pkg/FR-2009-03-06/pdf/E9-4770.pdf,3/6/2009, ARRANON,,John,,0,102,John,,,,,,,,,,,,,,,8/10/2004,Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma,Designated/Approved,,,Treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens,10/28/2005,10/28/2012,,Novartis Pharmaceuticals Corp.,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ALTABAX OINTMENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ALTABAX OINTMENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 10055,E9-4914,https://www.federalregister.gov/documents/2009/03/09/E9-4914/determination-of-regulatory-review-period-for-purposes-of-patent-extension-altabax-ointment,https://www.govinfo.gov/content/pkg/FR-2009-03-09/pdf/E9-4914.pdf,3/9/2009, ALTABAX OINTMENT,,John,ALTABAX OINTMENT,1,103,John,RE39128E,,,,SmithKline Beecham P.L.C.,1602,1297,305,2002-11-24,2002-11-24,2007-04-12,NDA 22-055,833,22055,,,,,,,,,,,Altabax,retapamulin,GlaxoSmithKline,NDA,22055,,2006-06-12,2007-04-12,2007,treatment of impetigo,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; CERENIA TABLETS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CERENIA TABLETS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",74 FR 10597,E9-5109,https://www.federalregister.gov/documents/2009/03/11/E9-5109/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cerenia-tablets,https://www.govinfo.gov/content/pkg/FR-2009-03-11/pdf/E9-5109.pdf,3/11/2009, CERENIA TABLETS,,John,CERENIA TABLETS,1,104,John,6255320,,,,Pfizer Inc.,1887,1841,46,2001-12-01,2007-01-29,2007-01-29,NADA 141-262,267,141262,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CERENIA INJECTABLE SOLUTION,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CERENIA INJECTABLE SOLUTION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",74 FR 10596,E9-5112,https://www.federalregister.gov/documents/2009/03/11/E9-5112/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cerenia-injectable,https://www.govinfo.gov/content/pkg/FR-2009-03-11/pdf/E9-5112.pdf,3/11/2009, CERENIA INJECTABLE SOLUTION,,John,CERENIA INJECTABLE SOLUTION,1,105,John,6222038,,,,Pfizer Inc.,1887,1841,46,2001-12-01,2007-01-29,2007-01-29,NADA 141-263,1078,141263,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PROFENDER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PROFENDER and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",74 FR 10744,E9-5374,https://www.federalregister.gov/documents/2009/03/12/E9-5374/determination-of-regulatory-review-period-for-purposes-of-patent-extension-profender,https://www.govinfo.gov/content/pkg/FR-2009-03-12/pdf/E9-5374.pdf,3/12/2009, PROFENDER,,John,PROFENDER,1,106,John,5514773,,,,Astellas Pharma Inc.,1585,1542,43,2003-02-27,2007-06-29,2007-06-29,NADA 141-275,1314,141275,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NEUPRO TRANSDERMAL SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NEUPRO TRANSDERMAL SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 21696,E9-10818,https://www.federalregister.gov/documents/2009/05/08/E9-10818/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neupro-transdermal-system,https://www.govinfo.gov/content/pkg/FR-2009-05-08/pdf/E9-10818.pdf,5/8/2009, NEUPRO TRANSDERMAL SYSTEM,,John,NEUPRO TRANSDERMAL SYSTEM,1,107,John,6884434,,,,Schwarz Pharma Limited,4367,3535,832,1995-05-27,1995-05-27,2007-05-09,NDA 21-829,744,21829,,,,,,,,,,,Neupro,rotigotine,Schwarz BioSciences,NDA,21829,,2005-01-28,2007-05-09,2007,treatment of the signs and symptoms of early-stage idiopathic Parkinsons disease,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SENSIPAR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SENSIPAR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 22750,E9-11219,https://www.federalregister.gov/documents/2009/05/14/E9-11219/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sensipar,https://www.govinfo.gov/content/pkg/FR-2009-05-14/pdf/E9-11219.pdf,5/14/2009, SENSIPAR,,John,SENSIPAR,3,110,John,6011068; 6211244; and 6313146,,,,"NPS Pharmaceuticals, Inc.",2089,1906,183,1998-06-21,1998-06-21,2004-03-08,NDA 21-688,449,21688,4/30/2010,"Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery",Designated/Approved,,,Treatment of severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy,2/25/2011,2/25/2018,,"Amgen, Inc.",Sensipar,cinacalcet hydrochloride,Amgen,NDA,21688,,2003-09-08,2004-03-08,2004,"[A] treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis
[B] treatment of hypercalcemia in patients with parathyroid carcinoma",,Priority,Yes (indication [B] only),No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SENSIPAR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SENSIPAR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 22750,E9-11219,https://www.federalregister.gov/documents/2009/05/14/E9-11219/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sensipar,https://www.govinfo.gov/content/pkg/FR-2009-05-14/pdf/E9-11219.pdf,5/14/2009, SENSIPAR,,John,SENSIPAR,3,113,John,6011068; 6211244; and 6313146,,,,"NPS Pharmaceuticals, Inc.",2089,1906,183,1998-06-21,1998-06-21,2004-03-08,NDA 21-688,449,21688,4/30/2010,"Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery",Designated/Approved,,,"Treatment of hypercalcemia in adult patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy.",11/21/2014,11/21/2021,"Treatment of less severe hypercalcemia (serum calcium >11.2 mg/dl and <= 12.5 mg/dl) in adult patients with primary hyperparathyroidism (HPT) for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy.","Amgen, Inc.",Sensipar,cinacalcet hydrochloride,Amgen,NDA,21688,,2003-09-08,2004-03-08,2004,"[A] treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis
[B] treatment of hypercalcemia in patients with parathyroid carcinoma",,Priority,Yes (indication [B] only),No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SENSIPAR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SENSIPAR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 22750,E9-11219,https://www.federalregister.gov/documents/2009/05/14/E9-11219/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sensipar,https://www.govinfo.gov/content/pkg/FR-2009-05-14/pdf/E9-11219.pdf,5/14/2009, SENSIPAR,,John,SENSIPAR,3,116,John,6011068; 6211244; and 6313146,,,,"NPS Pharmaceuticals, Inc.",2089,1906,183,1998-06-21,1998-06-21,2004-03-08,NDA 21-688,449,21688,5/12/2003,Treatment of hypercalcemia in patients with parathyroid carcinoma,Designated/Approved,,,Treatment of hypercalcemia in patients with parathyroid carcinoma,3/8/2004,3/8/2011,,"Amgen, Inc.",Sensipar,cinacalcet hydrochloride,Amgen,NDA,21688,,2003-09-08,2004-03-08,2004,"[A] treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis
[B] treatment of hypercalcemia in patients with parathyroid carcinoma",,Priority,Yes (indication [B] only),No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; INTELENCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INTELENCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 24014,E9-12050,https://www.federalregister.gov/documents/2009/05/22/E9-12050/determination-of-regulatory-review-period-for-purposes-of-patent-extension-intelence,https://www.govinfo.gov/content/pkg/FR-2009-05-22/pdf/E9-12050.pdf,5/22/2009, INTELENCE,,John,INTELENCE,1,117,John,7037917,,,,"Janssen Pharmaceutica, N.V.",2235,2050,185,2001-12-07,2001-12-07,2008-01-18,NDA 22-187,404,22187,,,,,,,,,,,Intelence,etravirine,Tibotec,NDA,22187,,2007-07-18,2008-01-18,2008,,"INTELENCE, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) and other antiretroviral agents.
This indication is based on Week 24 analyses from 2 randomized, double-blind, placebo-controlled trials of INTELENCE. Both studies were conducted in clinically advanced, 3-class antiretroviral (NNRTI, N[t]RTI, PI) treatment-experienced adults. 
The following points should be considered when initiating therapy with INTELENCE: 
- Treatment history and, when available, resistance testing, should guide the use of INTELENCE. 
- The use of other active antiretroviral agents with INTELENCE is associated with an increased likelihood of treatment response. 
- In patients who have experienced virologic failure on an NNRTI-containing regimen, do not use INTELENCE in combination with only N[t]RTIs. 
- The risks and benefits of INTELENCE have not been established in pediatric patients or in treatment-nave adult patients.",Priority,No,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; DUREZOL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DUREZOL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 37716,E9-18034,https://www.federalregister.gov/documents/2009/07/29/E9-18034/determination-of-regulatory-review-period-for-purposes-of-patent-extension-durezol,https://www.govinfo.gov/content/pkg/FR-2009-07-29/pdf/E9-18034.pdf,7/29/2009, DUREZOL,,John,DUREZOL,1,118,John,6114319,,,,Senju Pharmaceutical Co. Ltd.,560,369,181,2006-12-13,2006-12-13,2008-06-23,NDA 22-212,369,22212,9/30/2008,Treatment of endogenous and traumatic anterior uveitis and panuveitis.,Designated/Approved,,,Treatment of endogenous anterior uveitis,6/13/2012,6/13/2019,,Alcon Pharmaceuticals. Ltd.,Durezol,difluprednate,Sirion Therapeutics,NDA,22212,,2007-12-26,2008-06-23,2008,,"Durezol (difluprednate ophthalmic emulsion) 0.05%, a topical corticosteroid, is indicated for the treatment of inflammation and pain associated with ocular surgery.",Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; RAPAFLO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RAPAFLO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 37715,E9-18032,https://www.federalregister.gov/documents/2009/07/29/E9-18032/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rapaflo,https://www.govinfo.gov/content/pkg/FR-2009-07-29/pdf/E9-18032.pdf,7/29/2009, RAPAFLO,,John,RAPAFLO,1,119,John,5387603,,,,"Kissei Pharmaceutical Co., Ltd.",3681,3380,301,1998-09-12,1998-09-12,2008-10-08,NDA 22-206,1826,22206,,,,,,,,,,,Rapaflo,silodosin,Watson Laboratories,NDA,22206,,2007-12-13,2008-10-08,2008,,"RAPAFLO, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). RAPAFLO is not indicated for the treatment of hypertension.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; EOVIST,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EOVIST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 38660,E9-18527,https://www.federalregister.gov/documents/2009/08/04/E9-18527/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eovist,https://www.govinfo.gov/content/pkg/FR-2009-08-04/pdf/E9-18527.pdf,8/4/2009, EOVIST,,John,EOVIST,1,120,John,6039931,,,,Bayer Schering Pharma Aktiengesellschaft,3818,3450,368,1998-01-21,1998-01-21,2008-07-03,NDA 22-090,1699,22090,,,,,,,,,,,Eovist,gadoxetate disodium,Bayer Healthcare Pharmaceuticals,NDA,22090,,2007-07-02,2008-07-03,2008,,EOVIST Injection is a gadolinium-based contrast agent indicated for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; RECOTHROM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RECOTHROM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of three applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human biological product.",74 FR 38658,E9-18528,https://www.federalregister.gov/documents/2009/08/04/E9-18528/determination-of-regulatory-review-period-for-purposes-of-patent-extension-recothrom,https://www.govinfo.gov/content/pkg/FR-2009-08-04/pdf/E9-18528.pdf,8/4/2009, RECOTHROM,,John,RECOTHROM,3,123,John,5476777; 5502034; and 5527692,,,,"ZymoGenetics, Inc.",1511,1115,396,2003-11-30,2003-11-30,2008-01-17,BLA 125248,952,125248,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; XIENCE V EECSS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XIENCE V EECSS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",74 FR 38659,E9-18530,https://www.federalregister.gov/documents/2009/08/04/E9-18530/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xience-v-eecss,https://www.govinfo.gov/content/pkg/FR-2009-08-04/pdf/E9-18530.pdf,8/4/2009, XIENCE V EECSS,,John,XIENCE V EECSS,1,124,John,5451233,,,,"Abbott Cardiovascular Systems, Inc.",1157,759,398,2005-05-04,2005-05-04,2008-07-02,PMA 70015,937,70015,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NPLATE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NPLATE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",74 FR 40205,E9-19233,https://www.federalregister.gov/documents/2009/08/11/E9-19233/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nplate,https://www.govinfo.gov/content/pkg/FR-2009-08-11/pdf/E9-19233.pdf,8/11/2009, NPLATE,,John,NPLATE,1,125,John,6835809,,,,Amgen Inc.,2319,2014,305,2002-04-19,2002-04-19,2008-08-22,BLA 125268,818,125268,3/27/2003,Treatment of immune thrombocytopenic purpura,Designated/Approved,,,"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy",8/22/2008,8/22/2015,,"Amgen, Inc.",Nplate,romiplostim,Amgen,BLA,125268,,2007-10-23,2008-08-22,2008,,"Nplate is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts.",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; NPLATE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NPLATE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",74 FR 40205,E9-19233,https://www.federalregister.gov/documents/2009/08/11/E9-19233/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nplate,https://www.govinfo.gov/content/pkg/FR-2009-08-11/pdf/E9-19233.pdf,8/11/2009, NPLATE,,John,NPLATE,1,126,John,6835809,,,,Amgen Inc.,2319,2014,305,2002-04-19,2002-04-19,2008-08-22,BLA 125268,818,125268,3/27/2003,Treatment of immune thrombocytopenic purpura,Designated/Approved,,,"Nplate is indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy",10/17/2019,10/17/2026,"For the treatment of thrombocytopenia in adult patients with non-chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.",Nplate,romiplostim,Amgen,BLA,125268,,2007-10-23,2008-08-22,2008,,"Nplate is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts.",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; NPLATE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NPLATE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",74 FR 40205,E9-19233,https://www.federalregister.gov/documents/2009/08/11/E9-19233/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nplate,https://www.govinfo.gov/content/pkg/FR-2009-08-11/pdf/E9-19233.pdf,8/11/2009, NPLATE,,John,NPLATE,1,127,John,6835809,,,,Amgen Inc.,2319,2014,305,2002-04-19,2002-04-19,2008-08-22,BLA 125268,818,125268,3/27/2003,Treatment of immune thrombocytopenic purpura,Designated/Approved,,,"Nplate is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.",12/14/2018,12/14/2025,"Nplate is indicated for the treatment of pediatric patients 1 year of age and older with immune thrombocytopenia (ITP) for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.",Nplate,romiplostim,Amgen,BLA,125268,,2007-10-23,2008-08-22,2008,,"Nplate is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts.",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; NPLATE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NPLATE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",74 FR 40205,E9-19233,https://www.federalregister.gov/documents/2009/08/11/E9-19233/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nplate,https://www.govinfo.gov/content/pkg/FR-2009-08-11/pdf/E9-19233.pdf,8/11/2009, NPLATE,,John,NPLATE,1,128,John,6835809,,,,Amgen Inc.,2319,2014,305,2002-04-19,2002-04-19,2008-08-22,BLA 125268,818,125268,5/24/2018,Treatment of patients acutely exposed to myelosuppressive doses of radiation following radiological/nuclear incident,Designated/Approved,,,to increase survival in adults and pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]),1/28/2021,1/28/2028,to increase survival in adults and pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]),Amgen Inc.,Nplate,romiplostim,Amgen,BLA,125268,,2007-10-23,2008-08-22,2008,,"Nplate is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts.",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; LEXISCAN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LEXISCAN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",74 FR 42678,E9-20307,https://www.federalregister.gov/documents/2009/08/24/E9-20307/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lexiscan,https://www.govinfo.gov/content/pkg/FR-2009-08-24/pdf/E9-20307.pdf,8/24/2009, LEXISCAN,,John,LEXISCAN,2,130,John,6403567 and 6642210,,,,"CV Therapeutics, Inc.",2446,2113,333,2001-08-01,2001-08-01,2008-04-10,NDA 22-161,977,22161,,,,,,,,,,,Lexiscan,regadenoson,CV Therapeutics,NDA,22161,,2007-05-14,2008-04-10,2008,,Lexiscan (regadenoson) injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TAPENTADOL HYDROCHLORIDE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TAPENTADOL HYDROCHLORIDE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 45225,E9-21100,https://www.federalregister.gov/documents/2009/09/01/E9-21100/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tapentadol-hydrochloride,https://www.govinfo.gov/content/pkg/FR-2009-09-01/pdf/E9-21100.pdf,9/1/2009, TAPENTADOL HYDROCHLORIDE,,John,TAPENTADOL HYDROCHLORIDE,1,131,John,RE 39593,,,,Grunenthal GmbH,2880,2577,303,2001-01-03,2001-01-03,2008-11-20,NDA 22-304,1492,22304,,,,,,,,,,,Nucynta,tapentadol,Johnson & Johnson,NDA,22304,,2008-01-23,2008-11-20,2008,,tapentadol is indicated for the relief of moderate to severe acute pain in patients 18 years of age or older.,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BANZEL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BANZEL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 45864,E9-21428,https://www.federalregister.gov/documents/2009/09/04/E9-21428/determination-of-regulatory-review-period-for-purposes-of-patent-extension-banzel,https://www.govinfo.gov/content/pkg/FR-2009-09-04/pdf/E9-21428.pdf,9/4/2009, BANZEL,,John,BANZEL,1,132,John,6740669,,,,Novartis AG,6595,5501,1094,1990-10-27,1990-10-27,2008-11-14,NDA 21-911,819,21911,10/8/2004,Treatment of Lennox-Gastaut Syndrome.,Designated/Approved,,,Adjunctive therapy of seizures associated with Lennox-Gastaut syndrome.,11/14/2008,11/14/2015,,"Eisai, Inc.",Banzel,rufinamide,Eisai Medical Research,NDA,21911,,2005-11-17,2008-11-14,2008,,BANZEL (rufinamide) is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults.,Standard,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; DORIBAX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DORIBAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 45863,E9-21365,https://www.federalregister.gov/documents/2009/09/04/E9-21365/determination-of-regulatory-review-period-for-purposes-of-patent-extension-doribax,https://www.govinfo.gov/content/pkg/FR-2009-09-04/pdf/E9-21365.pdf,9/4/2009, DORIBAX,,John,DORIBAX,1,133,John,5317016,,,,Shionogi Seiyaku Kabushiki Kaisha,1746,1442,304,2003-01-02,2003-01-02,2007-10-12,NDA 22-106,1025,22106,,,,,,,,,,,Doribax,doripenem,Johnson & Johnson,NDA,22106,,2006-12-13,2007-10-12,2007,,"Doribax is indicated to reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX and other antibacterial drugs, DORIBAX should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting and modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. 
DORIBAX (doripenem for injection) is indicated as a single agent for the treatment of complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus and Peptostreptococcus micros. 
DORIBAX (doripenem for injection) is indicated as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TALENT ABDOMINAL STENT GRAFT SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TALENT ABDOMINAL STENT GRAFT SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",74 FR 45865,E9-21424,https://www.federalregister.gov/documents/2009/09/04/E9-21424/determination-of-regulatory-review-period-for-purposes-of-patent-extension-talent-abdominal-stent,https://www.govinfo.gov/content/pkg/FR-2009-09-04/pdf/E9-21424.pdf,9/4/2009, TALENT ABDOMINAL STENT GRAFT SYSTEM,,John,TALENT ABDOMINAL STENT GRAFT SYSTEM,1,134,John,6306141,,,,"Medtronic, Inc.",4024,3843,181,1997-04-11,1997-04-11,2008-04-15,PMA P070027,1183,70027,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CLEVIPREX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CLEVIPREX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 50801,E9-23650,https://www.federalregister.gov/documents/2009/10/01/E9-23650/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cleviprex,https://www.govinfo.gov/content/pkg/FR-2009-10-01/pdf/E9-23650.pdf,10/1/2009, CLEVIPREX,,John,CLEVIPREX,2,136,John,5739152 and 5856346,,,,AstraZeneca AB,4475,4078,397,1996-05-03,1996-05-03,2008-08-01,NDA 22-156,1314,22156,,,,,,,,,,,Cleviprex,clevidipine,The Medicines Company,NDA,22156,,2007-07-02,2008-08-01,2008,,Cleviprex is indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable.,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; EMEND FOR INJECTION,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EMEND FOR INJECTION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",74 FR 51159,E9-23900,https://www.federalregister.gov/documents/2009/10/05/E9-23900/determination-of-regulatory-review-period-for-purposes-of-patent-extension-emend-for-injection,https://www.govinfo.gov/content/pkg/FR-2009-10-05/pdf/E9-23900.pdf,10/5/2009, EMEND FOR INJECTION,,John,EMEND FOR INJECTION,1,137,John,5691336,,,,"Merck & Co., Inc.",4473,3810,663,1995-10-29,1995-10-29,2008-01-25,NDA 22-023,1826,22023,,,,,,,,,,,Emend,fosaprepitant dimeglumine,Merck,NDA,22023,,2006-04-03,2008-01-25,2008,,"EMEND for Injection, in combination with other antiemetic agents, is indicated for the: 
- prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin 
- prevention of nausea and vomiting associated with initial and repeated courses of moderately emetogenic cancer chemotherapy.",Standard,No,No,,No
"Determination of Regulatory Review Period for Purposes of Patent Extension; ENTEREG; U.S. Patent Nos. 5,250,542 and 5,434,171",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ENTEREG and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",74 FR 52241,E9-24457,https://www.federalregister.gov/documents/2009/10/09/E9-24457/determination-of-regulatory-review-period-for-purposes-of-patent-extension-entereg-us-patent-nos,https://www.govinfo.gov/content/pkg/FR-2009-10-09/pdf/E9-24457.pdf,10/9/2009, ENTEREG," U.S. Patent Nos. 5,250,542 and 5,434,171",John,ENTEREG,2,139,John,5250542 and 5434171,,,,Eli Lilly,5305,3879,1426,1993-11-12,1993-11-12,2008-05-20,NDA 21-775,1827,21775,,,,,,,,,,,Entereg,alvimopan,Adolor,NDA,21775,,2004-06-25,2008-05-20,2008,,ENTEREG is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis.,Standard,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; FIRMAGON,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FIRMAGON and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 9227,2010-4159,https://www.federalregister.gov/documents/2010/03/01/2010-4159/determination-of-regulatory-review-period-for-purposes-of-patent-extension-firmagon,https://www.govinfo.gov/content/pkg/FR-2010-03-01/pdf/2010-4159.pdf,3/1/2010, FIRMAGON,,John,FIRMAGON,1,140,John,5925730,,,,Ferring BV,2695,2394,301,2001-08-10,2001-08-10,2008-12-24,NDA 22-201,1498,22201,,,,,,,,,,,Firmagon,degarelix,Ferring Pharmaceuticals,NDA,22201,,2008-02-28,2008-12-24,2008,,degarelix is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer.,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LUSEDRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LUSEDRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 17142,2010-7516,https://www.federalregister.gov/documents/2010/04/05/2010-7516/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lusedra,https://www.govinfo.gov/content/pkg/FR-2010-04-05/pdf/2010-7516.pdf,4/5/2010, LUSEDRA,,John,LUSEDRA,2,142,John,6204257 and 6872838,,,,University of Kansas,2405,1962,443,2002-05-15,2002-05-15,2008-12-12,NDA 22-244,1424,22244,,,,,,,,,,,Lusedra,fospropofol disodium,Eisai Medical Research,NDA,22244,,2007-09-27,2008-12-12,2008,,LUSEDRA (fospropofol disodium) injection is an intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; FANAPT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FANAPT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 17415,2010-7678,https://www.federalregister.gov/documents/2010/04/06/2010-7678/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fanapt,https://www.govinfo.gov/content/pkg/FR-2010-04-06/pdf/2010-7678.pdf,4/6/2010, FANAPT,,John,FANAPT,1,143,John,RE39198,,,,Aventis Holdings Inc.,6552,5964,588,1991-05-31,1991-05-31,2009-05-06,NDA 22-192,5,22192,,,,,,,,,,,Fanapt,iloperidone,Vanda Pharmaceuticals,NDA,22192,,2007-09-27,2009-05-06,2009,,"FANAPT tablets are indicated for the acute treatment of adults with schizophrenia. 
When deciding among the alternative treatments available for this condition, the prescriber should consider the finding that FANAPT is associated with prolongation of the QTc interval. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia which can result in sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether FANAPT will cause torsade de pointes or increase the rate of sudden death is not yet known. 
Patients must be titrated to an effective dose of FANAPT. Thus, control of symptoms may be delayed during the first 1 to 2 weeks of treatment compared to some other antipsychotic drugs that do not require a similar titration. Prescribers should be mindful of this delay when selecting an antipsychotic drug for the acute treatment of schizophrenia. 
The effectiveness of FANAPT in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use FANAPT for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TOVIAZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TOVIAZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 17414,2010-7679,https://www.federalregister.gov/documents/2010/04/06/2010-7679/determination-of-regulatory-review-period-for-purposes-of-patent-extension-toviaz,https://www.govinfo.gov/content/pkg/FR-2010-04-06/pdf/2010-7679.pdf,4/6/2010, TOVIAZ,,John,TOVIAZ,1,144,John,6858650,,,,Schwarz Pharma AG,2395,1445,950,2002-04-13,2002-04-13,2008-10-31,NDA 22-030,1155,22030,,,,,,,,,,,Toviaz,fesoterodine fumarate,Pfizer,NDA,22030,,2006-03-27,2008-10-31,2008,,"Toviaz is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; MOZOBIL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MOZOBIL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 18213,2010-8172,https://www.federalregister.gov/documents/2010/04/09/2010-8172/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mozobil,https://www.govinfo.gov/content/pkg/FR-2010-04-09/pdf/2010-8172.pdf,4/9/2010, MOZOBIL,,John,MOZOBIL,1,145,John,5583131,,,,Genzyme Corp.,3849,3666,183,1998-06-04,1998-06-04,2008-12-15,NDA 22-311,1826,22311,,,,,,,,,,,Mozobil,plerixafor,Genzyme,NDA,22311,,2008-06-16,2008-12-15,2008,,Mozobil (plerixafor injection) is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkins lymphoma (NHL) and multiple myeloma (MM).,Priority,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; AFINITOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AFINITOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 19406,2010-8443,https://www.federalregister.gov/documents/2010/04/14/2010-8443/determination-of-regulatory-review-period-for-purposes-of-patent-extension-afinitor,https://www.govinfo.gov/content/pkg/FR-2010-04-14/pdf/2010-8443.pdf,4/14/2010, AFINITOR,,John,AFINITOR,1,146,John,5665772,,,,Novartis AG,4486,4212,274,1996-12-19,1996-12-19,2009-03-30,NDA 22-334,1826,22334,6/8/2009,"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)",Designated/Approved,,,Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical resection,10/29/2010,10/29/2017,,Novartis Pharmaceuticals Corp.,Afinitor,everolimus,Novartis Pharmaceuticals,NDA,22334,,2008-06-30,2009-03-30,2009,,AFINITOR is indicated for the treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; AFINITOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AFINITOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 19406,2010-8443,https://www.federalregister.gov/documents/2010/04/14/2010-8443/determination-of-regulatory-review-period-for-purposes-of-patent-extension-afinitor,https://www.govinfo.gov/content/pkg/FR-2010-04-14/pdf/2010-8443.pdf,4/14/2010, AFINITOR,,John,AFINITOR,1,147,John,5665772,,,,Novartis AG,4486,4212,274,1996-12-19,1996-12-19,2009-03-30,NDA 22-334,1826,22334,6/8/2009,"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)",Designated/Approved,,,Treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery.,4/26/2012,4/26/2019,,Novartis Pharmaceuticals Corp.,Afinitor,everolimus,Novartis Pharmaceuticals,NDA,22334,,2008-06-30,2009-03-30,2009,,AFINITOR is indicated for the treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; AFINITOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AFINITOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 19406,2010-8443,https://www.federalregister.gov/documents/2010/04/14/2010-8443/determination-of-regulatory-review-period-for-purposes-of-patent-extension-afinitor,https://www.govinfo.gov/content/pkg/FR-2010-04-14/pdf/2010-8443.pdf,4/14/2010, AFINITOR,,John,AFINITOR,1,148,John,5665772,,,,Novartis AG,4486,4212,274,1996-12-19,1996-12-19,2009-03-30,NDA 22-334,1826,22334,6/8/2009,"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)",Designated/Approved,,,For the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures.,4/10/2018,4/10/2025,For the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures.,Novartis Pharmaceuticals Corp.,Afinitor,everolimus,Novartis Pharmaceuticals,NDA,22334,,2008-06-30,2009-03-30,2009,,AFINITOR is indicated for the treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; AFINITOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AFINITOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 19406,2010-8443,https://www.federalregister.gov/documents/2010/04/14/2010-8443/determination-of-regulatory-review-period-for-purposes-of-patent-extension-afinitor,https://www.govinfo.gov/content/pkg/FR-2010-04-14/pdf/2010-8443.pdf,4/14/2010, AFINITOR,,John,AFINITOR,1,149,John,5665772,,,,Novartis AG,4486,4212,274,1996-12-19,1996-12-19,2009-03-30,NDA 22-334,1826,22334,2/14/2008,Treatment of neuroendocrine tumors,Designated/Approved,,,"Treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease.",5/5/2011,5/5/2018,,Novartis Pharmaceuticals Corp.,Afinitor,everolimus,Novartis Pharmaceuticals,NDA,22334,,2008-06-30,2009-03-30,2009,,AFINITOR is indicated for the treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; AFINITOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AFINITOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 19406,2010-8443,https://www.federalregister.gov/documents/2010/04/14/2010-8443/determination-of-regulatory-review-period-for-purposes-of-patent-extension-afinitor,https://www.govinfo.gov/content/pkg/FR-2010-04-14/pdf/2010-8443.pdf,4/14/2010, AFINITOR,,John,AFINITOR,1,150,John,5665772,,,,Novartis AG,4486,4212,274,1996-12-19,1996-12-19,2009-03-30,NDA 22-334,1826,22334,2/14/2008,Treatment of neuroendocrine tumors,Designated/Approved,,,"Treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease; and treatment of adult patients with progressive, well-differentiated, non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin, with unresectable, locally advanced or metastatic disease.",2/26/2016,2/26/2023,"Treatment of adult patients with progressive, well-differentiated, non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) (excluding pancreatic) or lung origin, with unresectable, locally advanced or metastatic disease.",Novartis Pharmaceuticals Corp.,Afinitor,everolimus,Novartis Pharmaceuticals,NDA,22334,,2008-06-30,2009-03-30,2009,,AFINITOR is indicated for the treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SAVELLA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SAVELLA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",75 FR 19407,2010-8518,https://www.federalregister.gov/documents/2010/04/14/2010-8518/determination-of-regulatory-review-period-for-purposes-of-patent-extension-savella,https://www.govinfo.gov/content/pkg/FR-2010-04-14/pdf/2010-8518.pdf,4/14/2010, SAVELLA,,John,SAVELLA,2,152,John,6602911 and 6992110,,,,"Cypress Bioscience, Inc.",2571,2177,394,2002-01-02,2002-01-02,2009-01-14,NDA 22-256,435,22256,,,,,,,,,,,Savella,milnacipran hydrochloride,Cypress Bioscience,NDA,22256,,2007-12-18,2009-01-14,2009,,"Savella is indicated for the management of fibromyalgia. 
Savella is not approved for use in pediatric patients.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VIMPAT-NDA 22-254,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VIMPAT based on new drug application (NDA) 22-254 for VIMPAT injection and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim the human drug product, VIMPAT. The regulatory review period determination for VIMPAT Tablets is publishing in this issue of the Federal Register.",75 FR 21299,2010-9509,https://www.federalregister.gov/documents/2010/04/23/2010-9509/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vimpat-nda-22-254,https://www.govinfo.gov/content/pkg/FR-2010-04-23/pdf/2010-9509.pdf,4/23/2010, VIMPAT-NDA 22-254,,John,VIMPAT,2,154,John,5654301 and RE38551,,,,"Research Corporation Technologies, Inc.",3452,3055,397,1999-05-19,2009-09-29,2008-10-28,NDA 22-254,1104,22254,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; VIMPAT -NDA 22-253,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VIMPAT based on new drug application (NDA) 22-253 for VIMPAT TABLETS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extensions of patents which claim the human drug product, VIMPAT. The regulatory review period determination for VIMPAT Injection is publishing in this issue of the Federal Register.",75 FR 21298,2010-9512,https://www.federalregister.gov/documents/2010/04/23/2010-9512/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vimpat--nda-22-253,https://www.govinfo.gov/content/pkg/FR-2010-04-23/pdf/2010-9512.pdf,4/23/2010, VIMPAT -NDA 22-253,,John,VIMPAT,2,156,John,5654301 and RE38551,,,,"Research Corporation Technologies, Inc.",3452,3055,397,1999-05-19,2009-09-29,2008-10-28,NDA 22-253,1827,22253,,,,,,,,,,,Vimpat,lacosamide,Schwarz Biosciences,NDA,22253,22254,2007-09-28,2008-10-28,2008,,"VIMPAT (lacosamide) tablets are indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older. 
VIMPAT (lacosamide) injection for intravenous use is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older when oral administration is temporarily not feasible.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ABLAVAR,Notice,Health and Human Services Department; Food and Drug Administration,The Food and Drug Administration (FDA) has determined the,75 FR 32479,2010-13655,https://www.federalregister.gov/documents/2010/06/08/2010-13655/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ablavar,https://www.govinfo.gov/content/pkg/FR-2010-06-08/pdf/2010-13655.pdf,6/8/2010, ABLAVAR,,John,ABLAVAR,2,158,John,6676929 and 7060250,,,,"Epix Pharmaceuticals, Inc.",4508,2673,1835,1996-08-21,1996-08-21,2008-12-22,NDA 21-711,1806,21711,,,,,,,,,,,Vasovist,gadofosveset trisodium,Epix Pharmaceuticals,NDA,21711,,2003-12-15,2008-12-22,2008,,VASOVIST is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; PROMACTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PROMACTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 32951,2010-13905,https://www.federalregister.gov/documents/2010/06/10/2010-13905/determination-of-regulatory-review-period-for-purposes-of-patent-extension-promacta,https://www.govinfo.gov/content/pkg/FR-2010-06-10/pdf/2010-13905.pdf,6/10/2010, PROMACTA,,John,PROMACTA,1,159,John,7160870,,,,SmithKline Beecham Corp. (DBA GlaxoSmithKline),1485,1147,338,2004-10-29,2004-10-29,2008-11-20,NDA 22-291,347,22291,11/8/2013,Treatment of aplastic anemia,Designated/Approved,,,PROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia.,11/16/2018,11/16/2025,PROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia.,Novartis Pharmaceuticals Corp.,Promacta,eltrombopag,GlaxoSmithKline,NDA,22291,,2007-12-19,2008-11-20,2008,,"PROMACTA is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. PROMACTA should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. PROMACTA should not be used in an attempt to normalize platelet counts.",Priority,Yes,Yes,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; PROMACTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PROMACTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 32951,2010-13905,https://www.federalregister.gov/documents/2010/06/10/2010-13905/determination-of-regulatory-review-period-for-purposes-of-patent-extension-promacta,https://www.govinfo.gov/content/pkg/FR-2010-06-10/pdf/2010-13905.pdf,6/10/2010, PROMACTA,,John,PROMACTA,1,160,John,7160870,,,,SmithKline Beecham Corp. (DBA GlaxoSmithKline),1485,1147,338,2004-10-29,2004-10-29,2008-11-20,NDA 22-291,347,22291,11/8/2013,Treatment of aplastic anemia,Designated/Approved,,,Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.,8/26/2014,8/26/2021,Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.,Novartis Pharmaceuticals Corp.,Promacta,eltrombopag,GlaxoSmithKline,NDA,22291,,2007-12-19,2008-11-20,2008,,"PROMACTA is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. PROMACTA should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. PROMACTA should not be used in an attempt to normalize platelet counts.",Priority,Yes,Yes,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; PROMACTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PROMACTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 32951,2010-13905,https://www.federalregister.gov/documents/2010/06/10/2010-13905/determination-of-regulatory-review-period-for-purposes-of-patent-extension-promacta,https://www.govinfo.gov/content/pkg/FR-2010-06-10/pdf/2010-13905.pdf,6/10/2010, PROMACTA,,John,PROMACTA,1,161,John,7160870,,,,SmithKline Beecham Corp. (DBA GlaxoSmithKline),1485,1147,338,2004-10-29,2004-10-29,2008-11-20,NDA 22-291,347,22291,5/5/2008,Treatment of idiopathic thrombocytopenia purpura,Designated/Approved,,,"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy",11/20/2008,11/20/2015,,Novartis Pharmaceuticals Corp.,Promacta,eltrombopag,GlaxoSmithKline,NDA,22291,,2007-12-19,2008-11-20,2008,,"PROMACTA is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. PROMACTA should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. PROMACTA should not be used in an attempt to normalize platelet counts.",Priority,Yes,Yes,,No
"Determination of Regulatory Review Period for Purposes of Patent Extension; BYSTOLIC; U.S. Patent Nos. 5,759,580 and 6,545,040",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BYSTOLIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 34749,2010-14814,https://www.federalregister.gov/documents/2010/06/18/2010-14814/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bystolic-us-patent-nos,https://www.govinfo.gov/content/pkg/FR-2010-06-18/pdf/2010-14814.pdf,6/18/2010, BYSTOLIC," U.S. Patent Nos. 5,759,580 and 6,545,040",John,BYSTOLIC,2,163,John,5759580 and 6545040,,,,"Forest Laboratories, Inc.",6790,5463,1327,1989-05-17,1989-05-17,2007-12-17,NDA 21-742,1828,21742,,,,,,,,,,,Bystolic,nebivolol,Mylan Bertek Pharmaceuticals,NDA,21742,,2004-04-30,2007-12-17,2007,,BYSTOLIC is indicated for the treatment of hypertension. BYSTOLIC may be used alone or in combination with other antihypertensive agents.,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; PRISTIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PRISTIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",75 FR 53314,2010-21586,https://www.federalregister.gov/documents/2010/08/31/2010-21586/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pristiq,https://www.govinfo.gov/content/pkg/FR-2010-08-31/pdf/2010-21586.pdf,8/31/2010, PRISTIQ,,John,PRISTIQ,2,165,John,6673838 and 7291347,,,,Wyeth,2124,1324,800,2002-05-09,2002-05-09,2008-02-29,NDA 21-966,17,21966,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ONGLYZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ONGLYZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 53315,2010-21583,https://www.federalregister.gov/documents/2010/08/31/2010-21583/determination-of-regulatory-review-period-for-purposes-of-patent-extension-onglyza,https://www.govinfo.gov/content/pkg/FR-2010-08-31/pdf/2010-21583.pdf,8/31/2010, ONGLYZA,,John,ONGLYZA,1,166,John,6395767,,,,Bristol-Myers Squibb Co.,2794,2397,397,2001-12-08,2001-12-08,2009-07-31,NDA 22-350,896,22350,,,,,,,,,,,Onglyza,saxagliptin,Bristol-Myers Squibb,NDA,22350,,2008-06-30,2009-07-31,2009,,"Monotherapy and Combination Therapy:
ONGLYZA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 
Important Limitations of Use: 
ONGLYZA should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. 
ONGLYZA has not been studied in combination with insulin.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ONGLYZA,Notice,Health and Human Services Department; Food and Drug Administration,,75 FR 53969,C1-2010-21583,https://www.federalregister.gov/documents/2010/09/02/C1-2010-21583/determination-of-regulatory-review-period-for-purposes-of-patent-extension-onglyza,https://www.govinfo.gov/content/pkg/FR-2010-09-02/pdf/C1-2010-21583.pdf,9/2/2010, ONGLYZA,,John,,0,166,John,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PRISTIQ,Notice,Health and Human Services Department; Food and Drug Administration,,75 FR 53969,C1-2010-21586,https://www.federalregister.gov/documents/2010/09/02/C1-2010-21586/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pristiq,https://www.govinfo.gov/content/pkg/FR-2010-09-02/pdf/C1-2010-21586.pdf,9/2/2010, PRISTIQ,,John,,0,166,John,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NEURX DIAPHRAGM PACING SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NEURX DIAPHRAGM PACING SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",75 FR 54152,2010-22081,https://www.federalregister.gov/documents/2010/09/03/2010-22081/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neurx-diaphragm-pacing,https://www.govinfo.gov/content/pkg/FR-2010-09-03/pdf/2010-22081.pdf,9/3/2010, NEURX DIAPHRAGM PACING SYSTEM,,John,,0,166,John,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; EFFIENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EFFIENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 54344,2010-22234,https://www.federalregister.gov/documents/2010/09/07/2010-22234/determination-of-regulatory-review-period-for-purposes-of-patent-extension-effient,https://www.govinfo.gov/content/pkg/FR-2010-09-07/pdf/2010-22234.pdf,9/7/2010, EFFIENT,,John,EFFIENT,1,167,John,5288726,,,,Daiichi Sankyo Co. Ltd.,2795,2232,563,2001-11-16,2001-11-16,2009-07-10,NDA 22-307,1679,22307,,,,,,,,,,,Effient,prasugrel,Eli Lilly,NDA,22307,,2007-12-26,2009-07-10,2009,,"Effient is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI) as follows:  
- Patients with unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI).  
- Patients with ST-elevation myocardial infarction (STEMI) when managed with either primary or delayed PCI. 
Effient has been shown to reduce the rate of a combined endpoint of cardiovascular death, nonfatal myocardial infarction (MI), or nonfatal stroke compared to clopidogrel. The difference between treatments was driven predominantly by MI, with no difference on strokes and little difference on CV death. 
It is generally recommended that antiplatelet therapy be administered promptly in the management of ACS because many cardiovascular events occur within hours of initial presentation. In the clinical trial that established the efficacy of Effient, Effient and the control drug were not administered to UA/NSTEMI patients until coronary anatomy was established. For the small fraction of patients that required urgent CABG after treatment with Effient, the risk of significant bleeding was substantial. Because the large majority of patients are managed without CABG, however, treatment can be considered before determining coronary anatomy if need for CABG is considered unlikely. The advantages of earlier treatment with Effient must then be balanced against the increased rate of bleeding in patients who do need to undergo urgent CABG.",Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BRYAN CERVICAL DISC SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BRYAN CERVICAL DISC SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",75 FR 54345,2010-22177,https://www.federalregister.gov/documents/2010/09/07/2010-22177/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bryan-cervical-disc,https://www.govinfo.gov/content/pkg/FR-2010-09-07/pdf/2010-22177.pdf,9/7/2010, BRYAN CERVICAL DISC SYSTEM,,John,BRYAN CERVICAL DISC SYSTEM,1,168,John,6156067,,,,"Medtronic Sofamor Danek, Inc.",2702,1653,1049,2001-12-20,2001-12-20,2009-05-12,PMA P060023,1826,60023,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; IXIARO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IXIARO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",75 FR 54888,2010-22394,https://www.federalregister.gov/documents/2010/09/09/2010-22394/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ixiaro,https://www.govinfo.gov/content/pkg/FR-2010-09-09/pdf/2010-22394.pdf,9/9/2010, IXIARO,,John,IXIARO,1,169,John,6309650,,,,Chiel Jedang Corp.,3461,2994,467,1999-10-10,1999-10-10,2009-03-30,BLA B125280,1588,125280,9/25/2012,Prevention of Japanese encephalitis virus in pediatric patients.,Designated/Approved,,,IXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus (JEV). IXIARO is approved for use in individuals 2 months of age and older.,5/17/2013,5/17/2020,"To extend the age range to include infants, children, and adolescents 2 months to less than 17 years of age for active immunization for the prevention of disease caused by Japanese encephalitis virus.",Intercell AG,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; REPEL-CV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REPEL-CV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",75 FR 54887,2010-22496,https://www.federalregister.gov/documents/2010/09/09/2010-22496/determination-of-regulatory-review-period-for-purposes-of-patent-extension-repel-cv,https://www.govinfo.gov/content/pkg/FR-2010-09-09/pdf/2010-22496.pdf,9/9/2010, REPEL-CV,,John,REPEL-CV,1,170,John,5711958,,,,"SyntheMed, Inc.",4023,3256,767,1998-03-03,1998-03-03,2009-03-06,PMA P070005,1742,70005,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SAPHRIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SAPHRIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 55331,2010-22519,https://www.federalregister.gov/documents/2010/09/10/2010-22519/determination-of-regulatory-review-period-for-purposes-of-patent-extension-saphris,https://www.govinfo.gov/content/pkg/FR-2010-09-10/pdf/2010-22519.pdf,9/10/2010, SAPHRIS,,John,SAPHRIS,1,171,John,5763476,,,,NV Organon,4547,3833,714,1997-03-04,1997-03-04,2009-08-13,NDA 22-117,1827,22117,,,,,,,,,,,Saphris,asenapine,Organon,NDA,22117,,2007-08-31,2009-08-13,2009,,"SAPHRIS is indicated for the acute treatment of schizophrenia in adults. The physician who elects to use SAPHRIS for extended periods in schizophrenia should periodically re-evaluate the long-term risks and benefits of the drug for the individual patient. 
SAPHRIS is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults. If SAPHRIS is used for extended periods in bipolar disorder, the physician should periodically re-evaluate the long-term risks and benefits of the drug for the individual patient.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ULORIC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ULORIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 55332,2010-22521,https://www.federalregister.gov/documents/2010/09/10/2010-22521/determination-of-regulatory-review-period-for-purposes-of-patent-extension-uloric,https://www.govinfo.gov/content/pkg/FR-2010-09-10/pdf/2010-22521.pdf,9/10/2010, ULORIC,,John,ULORIC,1,172,John,5614520,,,,Teijin Pharma Ltd.,3395,1873,1522,1999-10-31,1999-10-31,2009-02-13,NDA 21-856,5,21856,,,,,,,,,,,Uloric,febuxostat,Takeda Pharmaceuticals,NDA,21856,,2004-12-15,2009-02-13,2009,,"ULORIC is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in patients with gout. 
ULORIC is not recommended for the treatment of asymptomatic hyperuricemia.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; STELARA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for STELARA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",75 FR 75678,2010-30512,https://www.federalregister.gov/documents/2010/12/06/2010-30512/determination-of-regulatory-review-period-for-purposes-of-patent-extension-stelara,https://www.govinfo.gov/content/pkg/FR-2010-12-06/pdf/2010-30512.pdf,12/6/2010, STELARA,,John,STELARA,2,174,John,6902734 and 7166285,,,,Centocor Ortho Biotech Inc.,3165,2498,667,2001-01-27,2001-01-27,2009-09-25,BLA 125261,510,125261,,,,,,,,,,,Stelara,ustekinumab,Centocor Ortho Biotech,BLA,125261,,2007-11-29,2009-09-25,2009,,STELARA is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BESIVANCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BESIVANCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 75679,2010-30510,https://www.federalregister.gov/documents/2010/12/06/2010-30510/determination-of-regulatory-review-period-for-purposes-of-patent-extension-besivance,https://www.govinfo.gov/content/pkg/FR-2010-12-06/pdf/2010-30510.pdf,12/6/2010, BESIVANCE,,John,BESIVANCE,1,175,John,5447926,,,,Bausch & Lomb Inc.,2271,1910,361,2003-03-12,2003-03-12,2009-05-28,NDA 22-308,1316,22308,,,,,,,,,,,Besivance,besifloxacin,Bausch & Lomb,NDA,22308,,2008-06-02,2009-05-28,2009,,"Besivance (besifloxacin ophthalmic suspension) 0.6%, is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: 
CDC coryneform group G 
Corynebacterium pseudodiphtheriticum*
Corynebacterium striatum*
Haemophilus influenzae
Moraxella lacunata*
Staphylococcus aureus
Staphylococcus epidermidis
Staphylococcus hominis*
Staphylococcus lugdunensis*
Streptococcus mitis group
Streptococcus oralis
Streptococcus pneumoniae
Streptococcus salivarius*
*Efficacy for this organism was studied in fewer than 10 infections.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ILARIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ILARIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",75 FR 76739,2010-30992,https://www.federalregister.gov/documents/2010/12/09/2010-30992/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ilaris,https://www.govinfo.gov/content/pkg/FR-2010-12-09/pdf/2010-30992.pdf,12/9/2010, ILARIS,,John,ILARIS,1,176,John,7446175,,,,Novartis AG,1072,889,183,2006-07-13,2006-07-13,2009-06-17,BLA 125319,177,125319,12/18/2007,Treatment of cryopyrin-associated periodic syndromes,Designated/Approved,,,"Treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older.",6/17/2009,6/17/2016,,Novartis Pharmaceuticals Corporation,Ilaris,canakinumab,Novartis Pharmaceuticals,BLA,125319,,2008-12-17,2009-06-17,2009,,"ILARIS (canakinumab) is an interleukin-1beta blocker indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older including: 
- Familial Cold Autoinflammatory Syndrom (FCAS) 
- Muckle-Wells Syndrome (MWS)",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ILARIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ILARIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",75 FR 76739,2010-30992,https://www.federalregister.gov/documents/2010/12/09/2010-30992/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ilaris,https://www.govinfo.gov/content/pkg/FR-2010-12-09/pdf/2010-30992.pdf,12/9/2010, ILARIS,,John,ILARIS,1,177,John,7446175,,,,Novartis AG,1072,889,183,2006-07-13,2006-07-13,2009-06-17,BLA 125319,177,125319,12/5/2013,Treatment of hyperimmunoglobulinemia D and periodic fever syndrome,Designated/Approved,,,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients,9/23/2016,9/23/2023,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients,Novartis Pharmaceuticals Corporation,Ilaris,canakinumab,Novartis Pharmaceuticals,BLA,125319,,2008-12-17,2009-06-17,2009,,"ILARIS (canakinumab) is an interleukin-1beta blocker indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older including: 
- Familial Cold Autoinflammatory Syndrom (FCAS) 
- Muckle-Wells Syndrome (MWS)",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ILARIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ILARIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",75 FR 76739,2010-30992,https://www.federalregister.gov/documents/2010/12/09/2010-30992/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ilaris,https://www.govinfo.gov/content/pkg/FR-2010-12-09/pdf/2010-30992.pdf,12/9/2010, ILARIS,,John,ILARIS,1,178,John,7446175,,,,Novartis AG,1072,889,183,2006-07-13,2006-07-13,2009-06-17,BLA 125319,177,125319,9/4/2012,Treatment of TNF-receptor associated periodic syndrome (TRAPS),Designated/Approved,,,Indicated for the treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients,9/23/2016,9/23/2023,Indicated for treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients,Novartis Pharmaceuticals Corporation,Ilaris,canakinumab,Novartis Pharmaceuticals,BLA,125319,,2008-12-17,2009-06-17,2009,,"ILARIS (canakinumab) is an interleukin-1beta blocker indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older including: 
- Familial Cold Autoinflammatory Syndrom (FCAS) 
- Muckle-Wells Syndrome (MWS)",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ILARIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ILARIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",75 FR 76739,2010-30992,https://www.federalregister.gov/documents/2010/12/09/2010-30992/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ilaris,https://www.govinfo.gov/content/pkg/FR-2010-12-09/pdf/2010-30992.pdf,12/9/2010, ILARIS,,John,ILARIS,1,179,John,7446175,,,,Novartis AG,1072,889,183,2006-07-13,2006-07-13,2009-06-17,BLA 125319,177,125319,12/5/2013,Treatment of familial mediterranean fever,Designated/Approved,,,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients,9/23/2016,9/23/2023,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients,Novartis Pharmaceuticals Corporation,Ilaris,canakinumab,Novartis Pharmaceuticals,BLA,125319,,2008-12-17,2009-06-17,2009,,"ILARIS (canakinumab) is an interleukin-1beta blocker indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older including: 
- Familial Cold Autoinflammatory Syndrom (FCAS) 
- Muckle-Wells Syndrome (MWS)",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ILARIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ILARIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",75 FR 76739,2010-30992,https://www.federalregister.gov/documents/2010/12/09/2010-30992/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ilaris,https://www.govinfo.gov/content/pkg/FR-2010-12-09/pdf/2010-30992.pdf,12/9/2010, ILARIS,,John,ILARIS,1,180,John,7446175,,,,Novartis AG,1072,889,183,2006-07-13,2006-07-13,2009-06-17,BLA 125319,177,125319,9/30/2008,Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.,Designated/Approved,,,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.,5/9/2013,5/9/2020,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 through 16 years.,Novartis Pharmaceuticals Corporation,Ilaris,canakinumab,Novartis Pharmaceuticals,BLA,125319,,2008-12-17,2009-06-17,2009,,"ILARIS (canakinumab) is an interleukin-1beta blocker indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older including: 
- Familial Cold Autoinflammatory Syndrom (FCAS) 
- Muckle-Wells Syndrome (MWS)",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; BEPREVE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BEPREVE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 76740,2010-30991,https://www.federalregister.gov/documents/2010/12/09/2010-30991/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bepreve,https://www.govinfo.gov/content/pkg/FR-2010-12-09/pdf/2010-30991.pdf,12/9/2010, BEPREVE,,John,BEPREVE,1,181,John,6780877,,,,"Ube Industries, Ltd.",964,663,301,2007-01-20,2007-01-20,2009-09-08,NDA 22-288,631,22288,,,,,,,,,,,Bepreve,bepotastine besilate,Ista Pharmaceuticals,NDA,22288,,2008-11-12,2009-09-08,2009,,Bepreve (bepotastine besilate ophthalmic solution) 1.5% is a histamine H1 receptor antagonist indicated for the treatment of itching associated with signs and symptoms of allergic conjunctivitis.,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SABRIL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SABRIL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 76741,2010-30995,https://www.federalregister.gov/documents/2010/12/09/2010-30995/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sabril,https://www.govinfo.gov/content/pkg/FR-2010-12-09/pdf/2010-30995.pdf,12/9/2010, SABRIL,,John,SABRIL,1,182,John,5380936,,,,"Lundbeck, Inc.",10205,4614,5591,1981-09-14,1981-09-14,2009-08-21,NDA 20-427,5,20427,6/12/2000,Treatment of infantile spasms.,Designated/Approved,,,For infantile spasms (IS) - 1 month to 2 years of age.,8/21/2009,8/21/2016,,H. Lundbeck A/S,Sabril,vigabatrin,Lundbeck,NDA,20427,22006,1994-05-02,2009-08-21,2009,,"[A] SABRIL is indicated as adjunctive therapy for adult patients with refractory complex partial seizures (CPS) who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss. SABRIL is not indicated as a first line agent for complex partial seizures.
[B] SABRIL is indicated as monotherapy for pediatric patients with infantile spasms (IS) for whom the potential benefits outweigh the potential risk of vision loss.",Priority (indication [B] only),Yes (indication [B] only),No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; COARTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for COARTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 76990,2010-31074,https://www.federalregister.gov/documents/2010/12/10/2010-31074/determination-of-regulatory-review-period-for-purposes-of-patent-extension-coartem,https://www.govinfo.gov/content/pkg/FR-2010-12-10/pdf/2010-31074.pdf,12/10/2010, COARTEM,,John,COARTEM,1,183,John,5677331,,,,Novartis AG,285,285,284,2008-06-27,2008-06-27,2009-04-07,NDA 22-268,284,22268,8/31/2007,For the treatment of infections due to Plasmodium falciparum or mixed infections including P. falciparum.,Designated/Approved,,,"Treatment of malaria in patients of 5 kg bodyweight or above with acute, uncomplicated malaria due to Plasmodium falciparum or mixed infections including P. falciparum",4/7/2009,4/7/2016,,Novartis Pharmaceuticals,Coartem,"artemether, lumefantrine",Novartis Pharmaceuticals,NDA,22268,,2008-06-27,2009-04-07,2009,,"Coartem (artemether/lumefantrine) Tablets are indicated for treatment of acute, uncomplicated malaria infections due to Plasmodium falciparum in patients of 5 kg bodyweight and above. Coartem Tablets have been shown to be effective in geographical regions where resistance to chloroquine has been reported. 
Limitations of Use: 
- Coartem Tablets are not approved for patients with severe or complicated P. falciparum malaria. 
- Coartem Tablets are not approved for the prevention of malaria.",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; MULTAQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MULTAQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",75 FR 76991,2010-31064,https://www.federalregister.gov/documents/2010/12/10/2010-31064/determination-of-regulatory-review-period-for-purposes-of-patent-extension-multaq,https://www.govinfo.gov/content/pkg/FR-2010-12-10/pdf/2010-31064.pdf,12/10/2010, MULTAQ,,John,MULTAQ,2,185,John,5223510 and 7323493,,,,Sanofi-Aventis,5076,3593,1483,1995-08-10,1995-08-10,2009-07-01,NDA 21-913,519,21913,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; VIBATIV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VIBATIV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",75 FR 77877,2010-31250,https://www.federalregister.gov/documents/2010/12/14/2010-31250/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vibativ,https://www.govinfo.gov/content/pkg/FR-2010-12-14/pdf/2010-31250.pdf,12/14/2010, VIBATIV,,John,VIBATIV,3,188,John,6635618; 6872701; and 7208471,,,,"Theravance, Inc.",2635,1637,998,2002-06-27,2002-06-27,2009-09-11,NDA 22-110,863,22110,,,,,,,,,,,Vibativ,telavancin,Theravance,NDA,22110,,2006-12-19,2009-09-11,2009,,"To reduce the development of drug-resistant bacteria and maintain the effectiveness of VIBATIV and other antibacterial drugs, VIBATIV should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. 
VIBATIV is indicated for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), or Enterococcus faecalis (vancomycin-susceptible isolates only). 
Combination therapy may be clinically indicated if the documented or presumed pathogens include Gram-negative organisms. 
Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to telavancin. VIBATIV may be initiated as empiric therapy before results of these tests are known.",Standard,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; SAMSCA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SAMSCA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",75 FR 77879,2010-31298,https://www.federalregister.gov/documents/2010/12/14/2010-31298/determination-of-regulatory-review-period-for-purposes-of-patent-extension-samsca,https://www.govinfo.gov/content/pkg/FR-2010-12-14/pdf/2010-31298.pdf,12/14/2010, SAMSCA,,John,SAMSCA,2,190,John,5258510 and 5753677,,,,"Otsuka Pharmaceutical Co., Ltd.",4722,4147,575,1996-06-16,1996-06-16,2009-05-19,NDA 22-275,1826,22275,,,,,,,,,,,Samsca,tolvaptan,Otsuka Pharmaceutical,NDA,22275,,2007-10-23,2009-05-19,2009,,"SAMSCA is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium < 125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure, cirrhosis, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). Important Limitations: Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with SAMSCA. It has not been established that raising serum sodium with SAMSCA provides a symptomatic benefit to patients.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; FREESTYLE NAVIGATOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FREESTYLE NAVIGATOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",75 FR 77878,2010-31240,https://www.federalregister.gov/documents/2010/12/14/2010-31240/determination-of-regulatory-review-period-for-purposes-of-patent-extension-freestyle-navigator,https://www.govinfo.gov/content/pkg/FR-2010-12-14/pdf/2010-31240.pdf,12/14/2010, FREESTYLE NAVIGATOR,,John,FREESTYLE NAVIGATOR,1,191,John,5262035,,,,Abbott Diabetes Care Inc.,2320,750,1570,2001-11-06,2001-11-06,2008-03-12,PMA P030048,1826,30048,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ANGIOMAX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ANGIOMAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 78714,2010-31583,https://www.federalregister.gov/documents/2010/12/16/2010-31583/determination-of-regulatory-review-period-for-purposes-of-patent-extension-angiomax,https://www.govinfo.gov/content/pkg/FR-2010-12-16/pdf/2010-31583.pdf,12/16/2010, ANGIOMAX,,John,ANGIOMAX,1,192,John,5196404,,,,The Medicines Company,3665,2576,1089,1990-12-05,1990-12-05,2000-12-15,NDA 20-873,1773,20873,,,,,,,,,,,Angiomax,bivalirudin,The Medicines Company,NDA,20873,,1997-12-23,2000-12-15,2000,indicated for use as an anticoagulant in conjunction with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA),,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; FOLOTYN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FOLOTYN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 79381,2010-31846,https://www.federalregister.gov/documents/2010/12/20/2010-31846/determination-of-regulatory-review-period-for-purposes-of-patent-extension-folotyn,https://www.govinfo.gov/content/pkg/FR-2010-12-20/pdf/2010-31846.pdf,12/20/2010, FOLOTYN,,John,FOLOTYN,1,193,John,6028071,,,,"Southern Research Institute, Sloan-Kettering Institute for Cancer Research",4591,4406,185,1997-03-02,1997-03-02,2009-09-24,NDA 22-468,1826,22468,7/20/2006,Treatment of T-cell lymphoma,Designated/Approved,,,Treatment of patients with relapsed or refractory peripheral T-cell lymphoma,9/24/2009,9/24/2016,,Acrotech Biopharma LLC,Folotyn,pralatrexate,Allos Therapeutics,NDA,22468,,2009-03-24,2009-09-24,2009,,FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated.,Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; LIVALO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LIVALO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",75 FR 79382,2010-31847,https://www.federalregister.gov/documents/2010/12/20/2010-31847/determination-of-regulatory-review-period-for-purposes-of-patent-extension-livalo,https://www.govinfo.gov/content/pkg/FR-2010-12-20/pdf/2010-31847.pdf,12/20/2010, LIVALO,,John,LIVALO,1,194,John,5856336,,,,"Nissan Chemical Industries, Ltd.",3341,3036,305,2000-06-12,2000-06-12,2009-08-03,NDA 22-363,1826,22363,,,,,,,,,,,Livalo,pitavastatin,Kowa Research Institute,NDA,22363,,2008-10-03,2009-08-03,2009,,"Drug therapy should be one component of multiple-risk-factor intervention in individuals who require modifications of their lipid profile. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol only when the response to diet and other nonpharmacological measures has been inadequate. 
LIVALO is indicated as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. 
Limitations of Use: 
Doses of LIVALO greater than 4 mg once daily were associated with an increased risk for severe myopathy in premarketing clinical studies. Do not exceed 4 mg once daily dosing of LIVALO. 
The effect of LIVALO on cardiovascular morbidity and mortality has not been determined. 
LIVALO has not been studied in patients with severe renal impairment (glomerular filtration rate < 30 mL/min/1.73 m2) not on hemodialysis. LIVALO should not be used in this patient population. 
LIVALO has not been studied with the protease inhibitor combination lopinavir/ritonavir. LIVALO should not be used with this combination of protease inhibitors. 
LIVALO has not been studied in Fredrickson Type I, III, and V dyslipidemias.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; AMPYRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AMPYRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",76 FR 12974,2011-5312,https://www.federalregister.gov/documents/2011/03/09/2011-5312/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ampyra,https://www.govinfo.gov/content/pkg/FR-2011-03-09/pdf/2011-5312.pdf,3/9/2011, AMPYRA,,John,AMPYRA,2,196,John,5370879 and 5540938,,,,Elan Pharma International Ltd.,9845,9569,276,1983-02-10,1983-02-10,2010-01-22,NDA 22-250,1826,22250,6/2/1987,Relief of symptoms of multiple sclerosis,Designated/Approved,,,Treatment to improve walking in patients with multiple sclerosis,1/22/2010,1/22/2017,,Acorda Therapeutics,Ampyra,dalfampridine,Acorda Therapeutics,NDA,22250,,2009-04-22,2010-01-22,2010,,AMPYRA (dalfampridine) is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.,Priority,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; CERVARIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CERVARIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",76 FR 12975,2011-5310,https://www.federalregister.gov/documents/2011/03/09/2011-5310/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cervarix,https://www.govinfo.gov/content/pkg/FR-2011-03-09/pdf/2011-5310.pdf,3/9/2011, CERVARIX,,John,CERVARIX,1,197,John,7351533,,,,"MedImmune, LLC.",4027,3094,933,2010-10-26,1998-10-09,2009-10-16,BLA 125259,562,125259,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ISTODAX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ISTODAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 14671,2011-6162,https://www.federalregister.gov/documents/2011/03/17/2011-6162/determination-of-regulatory-review-period-for-purposes-of-patent-extension-istodax,https://www.govinfo.gov/content/pkg/FR-2011-03-17/pdf/2011-6162.pdf,3/17/2011, ISTODAX,,John,ISTODAX,1,198,John,4977138,,,,"Gloucester Pharmaceuticals, Inc.",2717,2419,298,2002-05-31,2002-05-31,2009-11-05,NDA 22-393,1523,22393,9/30/2004,Treatment of non-Hodgkin T-cell lymphomas,Designated/Approved,,,Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy,11/5/2009,11/5/2016,,Celgene Corporation,Istodax,romidepsin,Gloucester Pharmaceuticals,NDA,22393,,2009-01-12,2009-11-05,2009,,ISTODAX is indicated for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.,Standard,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ISTODAX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ISTODAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 14671,2011-6162,https://www.federalregister.gov/documents/2011/03/17/2011-6162/determination-of-regulatory-review-period-for-purposes-of-patent-extension-istodax,https://www.govinfo.gov/content/pkg/FR-2011-03-17/pdf/2011-6162.pdf,3/17/2011, ISTODAX,,John,ISTODAX,1,199,John,4977138,,,,"Gloucester Pharmaceuticals, Inc.",2717,2419,298,2002-05-31,2002-05-31,2009-11-05,NDA 22-393,1523,22393,9/30/2004,Treatment of non-Hodgkin T-cell lymphomas,Designated/Approved,,,Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy,6/16/2011,6/16/2018,,Celgene Corporation,Istodax,romidepsin,Gloucester Pharmaceuticals,NDA,22393,,2009-01-12,2009-11-05,2009,,ISTODAX is indicated for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.,Standard,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; VPRIV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VPRIV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 15322,2011-6514,https://www.federalregister.gov/documents/2011/03/21/2011-6514/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vpriv,https://www.govinfo.gov/content/pkg/FR-2011-03-21/pdf/2011-6514.pdf,3/21/2011, VPRIV,,John,VPRIV,1,200,John,7138262,,,,"Shire Human Genetic Therapies, Inc.",2221,2041,180,2004-01-30,2004-01-30,2010-02-26,NDA 22-575,687,22575,6/8/2009,Treatment of Gaucher disease,Designated/Approved,,,Treatment of Type I Gaucher Disease,2/26/2010,,,"Takeda Development Center Americas, Inc.",Vpriv,velaglucerase alfa,Shire Human Genetic Therapies,BLA,22575,,2009-08-31,2010-02-26,2010,,VPRIV (velaglucerase alfa for injection) is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease.,Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ATRYN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ATRYN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",76 FR 15323,2011-6509,https://www.federalregister.gov/documents/2011/03/21/2011-6509/determination-of-regulatory-review-period-for-purposes-of-patent-extension-atryn,https://www.govinfo.gov/content/pkg/FR-2011-03-21/pdf/2011-6509.pdf,3/21/2011, ATRYN,,John,ATRYN,1,201,John,6441145,,,,"GTC Biotherapeutics, Inc.",4468,4285,183,1996-11-15,1996-11-15,2009-02-06,BLA 125284,1243,125284,12/7/2007,"Treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures",Designated/Approved,,,"Prevention of peri-operative and peri-partum thromboembolic events, in hereditary antithrombin deficient patients.",2/6/2009,2/6/2016,,"GTC Biotherapeutics, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ATRYN; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of March 21, 2011 (76 FR 15323). The document announced the determination of the regulatory review period for ATRYN. The document was published with an incorrect docket number. This document corrects that error.",76 FR 21381,2011-9153,https://www.federalregister.gov/documents/2011/04/15/2011-9153/determination-of-regulatory-review-period-for-purposes-of-patent-extension-atryn-correction,https://www.govinfo.gov/content/pkg/FR-2011-04-15/pdf/2011-9153.pdf,4/15/2011, ATRYN, Correction,John,,0,201,John,,,,,,,,,,,,,,,12/7/2007,"Treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures",Designated/Approved,,,"Prevention of peri-operative and peri-partum thromboembolic events, in hereditary antithrombin deficient patients.",2/6/2009,2/6/2016,,"GTC Biotherapeutics, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CONVENIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CONVENIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",76 FR 24034,2011-10379,https://www.federalregister.gov/documents/2011/04/29/2011-10379/determination-of-regulatory-review-period-for-purposes-of-patent-extension-convenia,https://www.govinfo.gov/content/pkg/FR-2011-04-29/pdf/2011-10379.pdf,4/29/2011, CONVENIA,,John,CONVENIA,1,202,John,6020329,,,,"Pfizer, Inc.",2841,2801,40,2000-07-17,2008-04-25,2008-04-25,NADA 141-285,1462,141285,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; VOTRIENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VOTRIENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 25357,2011-10870,https://www.federalregister.gov/documents/2011/05/04/2011-10870/determination-of-regulatory-review-period-for-purposes-of-patent-extension-votrient,https://www.govinfo.gov/content/pkg/FR-2011-05-04/pdf/2011-10870.pdf,5/4/2011, VOTRIENT,,John,VOTRIENT,1,203,John,7105530,,,,"GlaxoSmithKline, LLC.",2568,2263,305,2002-10-10,2002-10-10,2009-10-19,NDA 22-465,719,22465,10/20/2009,Treatment of soft tissue sarcomas,Designated/Approved,,,Advanced soft tissue sarcoma (STS) who have received prior chemotherapy,4/26/2012,4/26/2019,,Novartis Pharmaceuticals Corp,Votrient,pazopanib,GlaxoSmithKline,NDA,22465,,2008-12-19,2009-10-19,2009,,VOTRIENT is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; PRISTIQ; Correction and Reopening of the Comment Period,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting notices concerning FDA's determination of the regulatory review period for PRISTIQ that appeared in the Federal Registers of August 31, 2010 (75 FR 53314) and September 2, 2010 (75 FR 53969). The documents omitted docket number FDA-2009-E-0086. This document corrects those omissions. Because the comment period for the notices closed on February 28, 2011, FDA is reopening the comment period to allow interested parties to submit comments or petitions to docket number FDA-2009-E-0086.",76 FR 28235,2011-11903,https://www.federalregister.gov/documents/2011/05/16/2011-11903/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pristiq-correction-and,https://www.govinfo.gov/content/pkg/FR-2011-05-16/pdf/2011-11903.pdf,5/16/2011, PRISTIQ, Correction and Reopening of the Comment Period,John,,0,203,John,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ACTEMRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ACTEMRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human biological product.",76 FR 31349,2011-13388,https://www.federalregister.gov/documents/2011/05/31/2011-13388/determination-of-regulatory-review-period-for-purposes-of-patent-extension-actemra,https://www.govinfo.gov/content/pkg/FR-2011-05-31/pdf/2011-13388.pdf,5/31/2011, ACTEMRA,,John,,0,203,John,,,,,,,,,,,,,,,7/31/2012,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,Designated/Approved,,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older,5/11/2018,,,"Genentech, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ACTEMRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ACTEMRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human biological product.",76 FR 31349,2011-13388,https://www.federalregister.gov/documents/2011/05/31/2011-13388/determination-of-regulatory-review-period-for-purposes-of-patent-extension-actemra,https://www.govinfo.gov/content/pkg/FR-2011-05-31/pdf/2011-13388.pdf,5/31/2011, ACTEMRA,,John,,0,203,John,,,,,,,,,,,,,,,8/1/2017,Treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome,Designated/Approved,,,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older,8/30/2017,8/30/2024,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older,"Genentech Inc., a member of the Roche Group",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ACTEMRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ACTEMRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human biological product.",76 FR 31349,2011-13388,https://www.federalregister.gov/documents/2011/05/31/2011-13388/determination-of-regulatory-review-period-for-purposes-of-patent-extension-actemra,https://www.govinfo.gov/content/pkg/FR-2011-05-31/pdf/2011-13388.pdf,5/31/2011, ACTEMRA,,John,,0,203,John,,,,,,,,,,,,,,,4/17/2013,Treatment of systemic sclerosis,Designated/Approved,,,slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease,3/4/2021,3/4/2028,slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease,"Genentech, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ACTEMRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ACTEMRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human biological product.",76 FR 31349,2011-13388,https://www.federalregister.gov/documents/2011/05/31/2011-13388/determination-of-regulatory-review-period-for-purposes-of-patent-extension-actemra,https://www.govinfo.gov/content/pkg/FR-2011-05-31/pdf/2011-13388.pdf,5/31/2011, ACTEMRA,,John,,0,203,John,,,,,,,,,,,,,,,7/31/2012,Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,Designated/Approved,,,ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older,4/29/2013,4/29/2020,Treatment of active polyarticular juvenile idiopathic arthritis in patients 2 through 16 years of age.,"Genentech, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MYFORTIC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MYFORTIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 35899,2011-15197,https://www.federalregister.gov/documents/2011/06/20/2011-15197/determination-of-regulatory-review-period-for-purposes-of-patent-extension-myfortic,https://www.govinfo.gov/content/pkg/FR-2011-06-20/pdf/2011-15197.pdf,6/20/2011, MYFORTIC,,John,MYFORTIC,1,204,John,6306900,,,,Novartis AG,1947,1643,304,1998-10-31,1998-10-31,2004-02-27,NDA 50-791,323,50791,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; METVIXIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for METVIXIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 36548,2011-15625,https://www.federalregister.gov/documents/2011/06/22/2011-15625/determination-of-regulatory-review-period-for-purposes-of-patent-extension-metvixia,https://www.govinfo.gov/content/pkg/FR-2011-06-22/pdf/2011-15625.pdf,6/22/2011, METVIXIA,,John,METVIXIA,1,205,John,6034267,,,,PhotoCure ASA,1695,659,1036,1999-12-08,1999-12-08,2004-07-27,NDA 21-415,871,21415,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; BROVANA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BROVANA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 36928,2011-15691,https://www.federalregister.gov/documents/2011/06/23/2011-15691/determination-of-regulatory-review-period-for-purposes-of-patent-extension-brovana,https://www.govinfo.gov/content/pkg/FR-2011-06-23/pdf/2011-15691.pdf,6/23/2011, BROVANA,,John,BROVANA,1,206,John,6589508,,,,"Sepracor Inc. (now Sunovion Pharmaceuticals, Inc.)",3118,2819,299,1998-03-26,1998-03-26,2006-10-06,NDA 21-912,745,21912,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DEXILANT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DEXILANT (previously KAPIDEX) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 36929,2011-15692,https://www.federalregister.gov/documents/2011/06/23/2011-15692/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dexilant,https://www.govinfo.gov/content/pkg/FR-2011-06-23/pdf/2011-15692.pdf,6/23/2011, DEXILANT,,John,DEXILANT,3,209,John,6462058; 6664276; and 6939971,,,,"Takeda Pharmaceutical Co., Ltd.",1675,1278,397,2004-07-02,2004-07-02,2009-01-30,NDA 22-287,959,22287,,,,,,,,,,,,,,,,,,,,,,,,,,
"Determination of Regulatory Review Period for Purposes of Patent Extension; Fusilev, Levoleucovorin",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Fusilev (Levoleucovorin) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 36927,2011-15689,https://www.federalregister.gov/documents/2011/06/23/2011-15689/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fusilev-levoleucovorin,https://www.govinfo.gov/content/pkg/FR-2011-06-23/pdf/2011-15689.pdf,6/23/2011," Fusilev, Levoleucovorin",,John,Fusilev,1,210,John,6500829,,,,the University of Strathclyde,6993,703,6290,1989-01-15,1989-01-15,2008-03-07,NDA 20-140,797,20140,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; XYZAL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XYZAL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 37127,2011-15910,https://www.federalregister.gov/documents/2011/06/24/2011-15910/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xyzal,https://www.govinfo.gov/content/pkg/FR-2011-06-24/pdf/2011-15910.pdf,6/24/2011, XYZAL,,John,XYZAL,1,211,John,5698558,,,,UCB Inc.,305,0,305,2006-07-25,2006-07-25,2007-05-25,NDA 22-064,245,22064,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; INVEGA SUSTENNA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INVEGA SUSTENNA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",76 FR 37128,2011-15905,https://www.federalregister.gov/documents/2011/06/24/2011-15905/determination-of-regulatory-review-period-for-purposes-of-patent-extension-invega-sustenna,https://www.govinfo.gov/content/pkg/FR-2011-06-24/pdf/2011-15905.pdf,6/24/2011, INVEGA SUSTENNA,,John,INVEGA SUSTENNA,1,212,John,5254556,,,,"Janssen, L.P.",2253,1608,645,2003-06-02,2003-06-02,2009-07-31,NDA 22-264,1449,22264,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FLECTOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FLECTOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 20644,2012-8235,https://www.federalregister.gov/documents/2012/04/05/2012-8235/determination-of-regulatory-review-period-for-purposes-of-patent-extension-flector,https://www.govinfo.gov/content/pkg/FR-2012-04-05/pdf/2012-8235.pdf,4/5/2012, FLECTOR,,John,FLECTOR,1,213,John,5607690,,,,Altergon S.A.,4031,1796,2235,1996-01-20,1996-01-20,2007-01-31,NDA 21-344,1825,21344,,,,,,,,,,,Faslodex,fulvestrant,AstraZeneca Pharmaceuticals,NDA,21344,,2001-03-28,2002-04-25,2002,treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy,,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VIIBRYD,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VIIBRYD and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",77 FR 20830,2012-8341,https://www.federalregister.gov/documents/2012/04/06/2012-8341/determination-of-regulatory-review-period-for-purposes-of-patent-extension-viibryd,https://www.govinfo.gov/content/pkg/FR-2012-04-06/pdf/2012-8341.pdf,4/6/2012, VIIBRYD,,John,,0,213,John,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TEFLARO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TEFLARO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",77 FR 20827,2012-8339,https://www.federalregister.gov/documents/2012/04/06/2012-8339/determination-of-regulatory-review-period-for-purposes-of-patent-extension-teflaro,https://www.govinfo.gov/content/pkg/FR-2012-04-06/pdf/2012-8339.pdf,4/6/2012, TEFLARO,,John,TEFLARO,2,215,John,6417175 and 6906055,,,,Takeda Pharmaceutical Company Limited,2118,1814,304,2005-01-12,2005-01-12,2010-10-29,NDA 200-327,1211,200327,,,,,,,,,,,Teflaro,ceftaroline fosamil,Cerexa,NDA,200327,,2009-12-30,2010-10-29,2010,,"Teflaro (ceftaroline fosamil) is indicated for the treatment of patients with the following infections caused by susceptible isolates of the designated microorganisms. 
[A] Teflaro is indicated for the treatment of actute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive and Gram-negative microorganisms: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca.  
[B] Teflaro is indicated for the treatment of community-acquired bacterial pneumonia (CABP) caused by susceptible isolates of the following Gram-positive and Gram-negative microorganisms: Streptococcus pneumonia (including cases with concurrent bacteremia), Staphylococcus aureus (methicillin-susceptible isolates only), Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella oxytoca, and Escherichia coli. 
Usage: To reduce the development of drug-resistant bacteria and maintain the effectiveness of Teflaro and other antibacterial drugs, Teflaro should be used to treat only ABSSSI or CABP that are proven or strongly suspected to be caused by susceptible bacteria.  Appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to ceftaroline.  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Standard,No,No,,Yes (indication [A] only)
Determination of Regulatory Review Period for Purposes of Patent Extension; NATROBA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NATROBA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human drug product.",77 FR 20829,2012-8337,https://www.federalregister.gov/documents/2012/04/06/2012-8337/determination-of-regulatory-review-period-for-purposes-of-patent-extension-natroba,https://www.govinfo.gov/content/pkg/FR-2012-04-06/pdf/2012-8337.pdf,4/6/2012, NATROBA,,John,NATROBA,2,217,John,6063771 and 6342482,,,,Eli Lilly,2261,1534,727,2004-11-11,2004-11-11,2011-01-18,NDA 22-408,1493,22408,,,,,,,,,,,Natroba,spinosad,Parapro,NDA,22408,,2009-01-22,2011-01-18,2011,,"NATROBA (spinosad) Topical Suspension is indicated for the topical treatment of head lice infestation in patients four (4) years of age and older.  
Adjunctive Measures:
NATROBA Topical Suspension should be used in the context of an overall lice management program:  
- Wash (in hot water) or dry-clean all recently worn clothing, hats, used bedding and towels.  
- Wash personal care items such as combs, brushes and hair clips in hot water.  
- A fine-tooth comb or special nit comb may be used to remove dead lice and nits.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; DATSCAN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DATSCAN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 20829,2012-8340,https://www.federalregister.gov/documents/2012/04/06/2012-8340/determination-of-regulatory-review-period-for-purposes-of-patent-extension-datscan,https://www.govinfo.gov/content/pkg/FR-2012-04-06/pdf/2012-8340.pdf,4/6/2012, DATSCAN,,John,DATSCAN,1,218,John,5310912,,,,GE Healthcare Limited,677,0,677,1997-06-19,2009-03-09,2011-01-14,NDA 22-454,5,22454,,,,,,,,,,,DaTscan,ioflupane I 123,GE Healthcare,NDA,22454,,2009-03-09,2011-01-14,2011,,"DaTscan is a radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult patients with suspected Parkinsonian syndromes (PS).  In these patients, DaTscan may be used to help differentiate essential tremor from tremor due to PS (idiopathic Parkinsons disease, multiple system atrophy and progressive supranuclear palsy). DaTscan is an adjunct to other diagnostic evaluations.",Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LATUDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LATUDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 20828,2012-8354,https://www.federalregister.gov/documents/2012/04/06/2012-8354/determination-of-regulatory-review-period-for-purposes-of-patent-extension-latuda,https://www.govinfo.gov/content/pkg/FR-2012-04-06/pdf/2012-8354.pdf,4/6/2012, LATUDA,,John,LATUDA,1,219,John,5532372,,,,"Dainippon Sumitomo Pharma Co., Ltd.",3602,3299,303,2000-12-19,2000-12-19,2010-10-28,NDA 200-603,1826,200603,,,,,,,,,,,Latuda,lurasidone hydrochloride,Sunovion Pharmaceuticals,NDA,200603,,2009-12-30,2010-10-28,2010,,"LATUDA is indicated for the treatment of patients with schizophrenia. 
The efficacy of LATUDA in schizophrenia was established in four 6-week controlled studies of adult patients with schizophrenia. 
The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug in the individual patient.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KEPIVANCE; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of April 2, 2007 (72 FR 15699). The document concerned FDA's determination of the regulatory review period for KEPIVANCE. The document cited an incorrect statute under which the KEPIVANCE biologics license application was submitted. This document corrects the citation.",77 FR 23268,2012-9325,https://www.federalregister.gov/documents/2012/04/18/2012-9325/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kepivance-correction,https://www.govinfo.gov/content/pkg/FR-2012-04-18/pdf/2012-9325.pdf,4/18/2012, KEPIVANCE, Correction,John,,0,219,John,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; KALBITOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KALBITOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",77 FR 26017,2012-10518,https://www.federalregister.gov/documents/2012/05/02/2012-10518/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kalbitor,https://www.govinfo.gov/content/pkg/FR-2012-05-02/pdf/2012-10518.pdf,5/2/2012, KALBITOR,,John,KALBITOR,2,221,John,5795685 and 7276480,,,,Dyax Corp.,2855,2420,435,2002-02-08,2002-02-08,2009-12-01,BLA 125277,178,125277,2/4/2003,Treatment of angioedema,Designated/Approved,,,Treatment of acute attacks of hereditary angioedema in patients 16 years of age and older,12/1/2009,12/1/2016,,"Takeda Pharmaceuticals U.S.A., Inc.",Kalbitor,ecallantide,Dyax,BLA,125277,,2008-09-23,2009-12-01,2009,,KALBITOR (ecallantide) is indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.,Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; KALBITOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KALBITOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",77 FR 26017,2012-10518,https://www.federalregister.gov/documents/2012/05/02/2012-10518/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kalbitor,https://www.govinfo.gov/content/pkg/FR-2012-05-02/pdf/2012-10518.pdf,5/2/2012, KALBITOR,,John,KALBITOR,2,223,John,5795685 and 7276480,,,,Dyax Corp.,2855,2420,435,2002-02-08,2002-02-08,2009-12-01,BLA 125277,178,125277,2/4/2003,Treatment of angioedema,Designated/Approved,,,Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older,3/28/2014,3/28/2021,Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 through 15 years of age.,"Takeda Pharmaceuticals U.S.A., Inc.",Kalbitor,ecallantide,Dyax,BLA,125277,,2008-09-23,2009-12-01,2009,,KALBITOR (ecallantide) is indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.,Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; Victoza,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Victoza and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 26018,2012-10517,https://www.federalregister.gov/documents/2012/05/02/2012-10517/determination-of-regulatory-review-period-for-purposes-of-patent-extension-victoza,https://www.govinfo.gov/content/pkg/FR-2012-05-02/pdf/2012-10517.pdf,5/2/2012, Victoza,,John,Victoza,1,224,John,6268343,,,,Novo Nordisk A/S,3370,2757,613,2000-11-05,2000-11-05,2010-01-25,NDA 22-341,1826,22341,,,,,,,,,,,Victoza,liraglutide,Novo Nordisk,NDA,22341,,2008-05-23,2010-01-25,2010,,Victoza is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Alair Bronchial Thermoplasty System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Alair Bronchial Thermoplasty System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",77 FR 26016,2012-10516,https://www.federalregister.gov/documents/2012/05/02/2012-10516/determination-of-regulatory-review-period-for-purposes-of-patent-extension-alair-bronchial,https://www.govinfo.gov/content/pkg/FR-2012-05-02/pdf/2012-10516.pdf,5/2/2012, Alair Bronchial Thermoplasty System,,John,Alair Bronchial Thermoplasty System,1,225,John,6411852,,,,"Asthmatx, Inc.",1743,1259,484,2005-07-21,2005-07-21,2010-04-27,PMA P080032,1114,80032,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; HALAVEN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HALAVEN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 26288,2012-10716,https://www.federalregister.gov/documents/2012/05/03/2012-10716/determination-of-regulatory-review-period-for-purposes-of-patent-extension-halaven,https://www.govinfo.gov/content/pkg/FR-2012-05-03/pdf/2012-10716.pdf,5/3/2012, HALAVEN,,John,HALAVEN,1,226,John,6214865,,,,"Eisai R&D Management Co., Ltd.",2758,2527,231,2003-04-30,2003-04-30,2010-11-15,NDA 201-532,1495,201532,5/14/2012,Treatment of soft tissue sarcoma,Designated/Approved,,,Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen,1/28/2016,1/28/2023,Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen,Eisai Inc.,Halaven,eribulin mesylate,Eisai,NDA,201532,,2010-03-30,2010-11-15,2010,,HALAVEN is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease.  Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; KRYSTEXXA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KRYSTEXXA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",77 FR 26290,2012-10697,https://www.federalregister.gov/documents/2012/05/03/2012-10697/determination-of-regulatory-review-period-for-purposes-of-patent-extension-krystexxa,https://www.govinfo.gov/content/pkg/FR-2012-05-03/pdf/2012-10697.pdf,5/3/2012, KRYSTEXXA,,John,KRYSTEXXA,1,227,John,[[Page 26291]]6783965,,,,"Mountain View Pharmaceuticals, Inc.",3193,2509,684,2001-12-19,2001-12-19,2010-09-14,BLA 125293,1445,125293,2/21/2001,To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective,Designated/Approved,,,Treatment of chronic gout in adult patients refractory to conventional treatment,9/14/2010,9/14/2017,,Horizon Therapeutics Ireland DAC,Krystexxa,pegloticase,Savient Pharmaceuticals,BLA,125293,,2008-10-31,2010-09-14,2010,,"KRYSTEXXA (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment  of chronic gout in adult patients refractory to conventional therapy. 
Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated. 
Important limitations of use: 
KRSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.",Priority,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KRYSTEXXA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KRYSTEXXA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",77 FR 26290,2012-10697,https://www.federalregister.gov/documents/2012/05/03/2012-10697/determination-of-regulatory-review-period-for-purposes-of-patent-extension-krystexxa,https://www.govinfo.gov/content/pkg/FR-2012-05-03/pdf/2012-10697.pdf,5/3/2012, KRYSTEXXA,,John,KRYSTEXXA,1,228,John,[[Page 26291]]6783965,,,,"Mountain View Pharmaceuticals, Inc.",3193,2509,684,2001-12-19,2001-12-19,2010-09-14,BLA 125293,1445,125293,2/21/2001,To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.,Designated/Approved,,,Treatment of chronic gout in adult patients refractory to conventional therapy,7/7/2022,,,Horizon Therapeutics Ireland DAC,Krystexxa,pegloticase,Savient Pharmaceuticals,BLA,125293,,2008-10-31,2010-09-14,2010,,"KRYSTEXXA (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment  of chronic gout in adult patients refractory to conventional therapy. 
Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated. 
Important limitations of use: 
KRSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.",Priority,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LASTACAFT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LASTACAFT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 26291,2012-10694,https://www.federalregister.gov/documents/2012/05/03/2012-10694/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lastacaft,https://www.govinfo.gov/content/pkg/FR-2012-05-03/pdf/2012-10694.pdf,5/3/2012, LASTACAFT,,John,LASTACAFT,1,229,John,5468743,,,,Janssen Pharmaceutica N.V.,2189,1886,303,2004-08-01,2004-08-01,2010-07-28,NDA 22-134,1246,22134,,,,,,,,,,,Lastacaft,alcaftadine,Vistakon Pharmaceuticals,NDA,22134,,2009-09-29,2010-07-28,2010,,LASTACAFT is a H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; PRADAXA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PRADAXA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 26289,2012-10712,https://www.federalregister.gov/documents/2012/05/03/2012-10712/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pradaxa,https://www.govinfo.gov/content/pkg/FR-2012-05-03/pdf/2012-10712.pdf,5/3/2012, PRADAXA,,John,PRADAXA,1,230,John,6087380,,,,Boehringer Ingelheim Pharma GmbH & Co. KG,2633,2449,184,2003-08-06,2003-08-06,2010-10-19,NDA 22-512,1469,22512,,,,,,,,,,,Pradaxa,dabigatran etexilate mesylate,Boehringer Ingelheim Pharmaceuticals,NDA,22512,,2010-04-19,2010-10-19,2010,,PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; GILENYA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GILENYA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 26554,2012-10819,https://www.federalregister.gov/documents/2012/05/04/2012-10819/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gilenya,https://www.govinfo.gov/content/pkg/FR-2012-05-04/pdf/2012-10819.pdf,5/4/2012, GILENYA,,John,GILENYA,1,231,John,5604229,,,,Novartis Pharmaceuticals Corp.,4296,4021,275,1998-12-19,1998-12-19,2010-09-21,NDA 22-527,5,22527,,,,,,,,,,,Gilenya,fingolimod,Novartis Pharmaceuticals,NDA,22527,,2009-12-21,2010-09-21,2010,,GILENYA is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; EGRIFTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EGRIFTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 26555,2012-10808,https://www.federalregister.gov/documents/2012/05/04/2012-10808/determination-of-regulatory-review-period-for-purposes-of-patent-extension-egrifta,https://www.govinfo.gov/content/pkg/FR-2012-05-04/pdf/2012-10808.pdf,5/4/2012, EGRIFTA,,John,EGRIFTA,1,232,John,5861379,,,,"Theratechnologies, Inc.",3284,2753,531,2001-11-15,2001-11-15,2010-11-10,NDA 22-505,1827,22505,,,,,,,,,,,Egrifta,tesamorelin,Kendle International,BLA,22505,,2009-05-29,2010-11-10,2010,,"EGRIFTA (tesamorelin for injection) is indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.  
Limitations of Use: 
- Since the long-term cardiovascular safety and potential long-term cardiovascular benefit of EGRIFTA treatment have not been studied and are not known, careful consideration should be given whether to continue EGRIFTA treatment in patients who do not show a clear efficacy response as judged by the degree of reduction in visceral adipose tissue measured by waist circumference or CT scan. 
- EGRIFTA is not indicated for weight loss management (weight neutral effect).  
- There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA. ",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; FERAHEME,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FERAHEME and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 26557,2012-10849,https://www.federalregister.gov/documents/2012/05/04/2012-10849/determination-of-regulatory-review-period-for-purposes-of-patent-extension-feraheme,https://www.govinfo.gov/content/pkg/FR-2012-05-04/pdf/2012-10849.pdf,5/4/2012, FERAHEME,,John,FERAHEME,1,233,John,6599498,,,,"AMAG Pharmaceuticals, Inc.",3680,3120,560,1999-06-05,1999-06-05,2009-06-30,NDA 22-180,1209,22180,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; JEVTANA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for JEVTANA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 26558,2012-10828,https://www.federalregister.gov/documents/2012/05/04/2012-10828/determination-of-regulatory-review-period-for-purposes-of-patent-extension-jevtana,https://www.govinfo.gov/content/pkg/FR-2012-05-04/pdf/2012-10828.pdf,5/4/2012, JEVTANA,,John,JEVTANA,2,235,John,5847170 and 6331635,,,,Aventis Pharma S.A.,4250,4171,79,1998-10-30,1998-10-30,2010-06-17,NDA 201023,1591,201023,,,,,,,,,,,Jevtana,cabazitaxel,Sanofi-Aventis,NDA,201023,,2010-03-31,2010-06-17,2010,,JEVTANA is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.,Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; EQUIDONE GEL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EQUIDONE GEL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",77 FR 26556,2012-10853,https://www.federalregister.gov/documents/2012/05/04/2012-10853/determination-of-regulatory-review-period-for-purposes-of-patent-extension-equidone-gel,https://www.govinfo.gov/content/pkg/FR-2012-05-04/pdf/2012-10853.pdf,5/4/2012, EQUIDONE GEL,,John,EQUIDONE GEL,1,236,John,5372818,,,,"Dechra, Ltd.",6378,6336,42,1993-03-26,2010-09-09,2010-09-09,NADA 141-314,5,141314,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PROLIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PROLIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",77 FR 26768,2012-10959,https://www.federalregister.gov/documents/2012/05/07/2012-10959/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prolia,https://www.govinfo.gov/content/pkg/FR-2012-05-07/pdf/2012-10959.pdf,5/7/2012, PROLIA,,John,,0,236,John,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; KALBITOR; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of May 2, 2012 (77 FR 26017). The document concerned FDA's determination of the regulatory review period for KALBITOR. The document published with an incorrect patent number for KALBITOR. This document corrects that error.",77 FR 34051,2012-13902,https://www.federalregister.gov/documents/2012/06/08/2012-13902/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kalbitor-correction,https://www.govinfo.gov/content/pkg/FR-2012-06-08/pdf/2012-13902.pdf,6/8/2012, KALBITOR, Correction,John,,0,236,John,,,,,,,,,,,,,,,2/4/2003,Treatment of angioedema,Designated/Approved,,,Treatment of acute attacks of hereditary angioedema in patients 16 years of age and older,12/1/2009,12/1/2016,,"Takeda Pharmaceuticals U.S.A., Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; KALBITOR; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of May 2, 2012 (77 FR 26017). The document concerned FDA's determination of the regulatory review period for KALBITOR. The document published with an incorrect patent number for KALBITOR. This document corrects that error.",77 FR 34051,2012-13902,https://www.federalregister.gov/documents/2012/06/08/2012-13902/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kalbitor-correction,https://www.govinfo.gov/content/pkg/FR-2012-06-08/pdf/2012-13902.pdf,6/8/2012, KALBITOR, Correction,John,,0,236,John,,,,,,,,,,,,,,,2/4/2003,Treatment of angioedema,Designated/Approved,,,Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older,3/28/2014,3/28/2021,Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 through 15 years of age.,"Takeda Pharmaceuticals U.S.A., Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CYSVIEW (Previously HEXVIX),Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CYSVIEW (previously HEXVIX) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 34388,2012-14003,https://www.federalregister.gov/documents/2012/06/11/2012-14003/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cysview-previously-hexvix,https://www.govinfo.gov/content/pkg/FR-2012-06-11/pdf/2012-14003.pdf,6/11/2012, CYSVIEW (Previously HEXVIX),,John,CYSVIEW,2,238,John,7247655 and 7348361,,,,Photocure ASA,3103,2770,333,2001-11-30,2001-11-30,2010-05-28,NDA 22-555,686,22555,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Progel Pleural Air Leak Sealant,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Progel Pleural Air Leak Sealant and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",77 FR 34389,2012-14000,https://www.federalregister.gov/documents/2012/06/11/2012-14000/determination-of-regulatory-review-period-for-purposes-of-patent-extension-progel-pleural-air-leak,https://www.govinfo.gov/content/pkg/FR-2012-06-11/pdf/2012-14000.pdf,6/11/2012, Progel Pleural Air Leak Sealant,,John,Progel Pleural Air Leak Sealant,1,239,John,RE38158,,,,"Neomend, Inc.",3854,787,3067,1999-06-29,1999-06-29,2010-01-14,PMA P010047,5,10047,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TORISEL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TORISEL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",77 FR 52035,2012-21239,https://www.federalregister.gov/documents/2012/08/28/2012-21239/determination-of-regulatory-review-period-for-purposes-of-patent-extension-torisel,https://www.govinfo.gov/content/pkg/FR-2012-08-28/pdf/2012-21239.pdf,8/28/2012, TORISEL,,John,TORISEL,1,240,John,5362718,,,,Wyeth,3290,3052,238,1998-05-29,1998-05-29,2007-05-30,NDA 22-088,1764,22088,12/16/2004,Treatment of renal cell carcinoma,Designated/Approved,,,Treatment of advanced renal cell carcinoma,5/30/2007,5/30/2014,,"Wyeth Pharmaceuticals, Inc.",Torisel,temsirolimus,Wyeth,NDA,22088,,2006-10-05,2007-05-30,2007,treatment of advanced renal cell carcinoma,,Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; XALKORI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XALKORI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",78 FR 6826,2013-02085,https://www.federalregister.gov/documents/2013/01/31/2013-02085/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xalkori,https://www.govinfo.gov/content/pkg/FR-2013-01-31/pdf/2013-02085.pdf,1/31/2013, XALKORI,,John,XALKORI,1,241,John,7230098,,,,Pfizer Inc.,2054,1904,150,2006-01-12,2006-01-12,2011-08-26,NDA 202-570,178,202570,9/13/2010,"Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer",Designated/Approved,,,Treatment of patients with locally advanced or metastatic non-small cell lungcancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDAapprovedtest,8/26/2011,8/26/2018,,"Pfizer, Inc.",Xalkori,crizotinib,Pfizer,NDA,202570,,2011-03-30,2011-08-26,2011,,"XALKORI is indicated for the treatment of patients with locally advanced metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.  
This indication is based on response rate.  There are no data available demonstrating improvement in patient reported outcomes or survival with XALKORI.",Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; XALKORI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XALKORI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",78 FR 6826,2013-02085,https://www.federalregister.gov/documents/2013/01/31/2013-02085/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xalkori,https://www.govinfo.gov/content/pkg/FR-2013-01-31/pdf/2013-02085.pdf,1/31/2013, XALKORI,,John,XALKORI,1,242,John,7230098,,,,Pfizer Inc.,2054,1904,150,2006-01-12,2006-01-12,2011-08-26,NDA 202-570,178,202570,12/20/2021,Treatment of inflammatory myofibroblastic tumor,Designated/Approved,,,"treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive",9/7/2023,,,Pfizer Inc.,Xalkori,crizotinib,Pfizer,NDA,202570,,2011-03-30,2011-08-26,2011,,"XALKORI is indicated for the treatment of patients with locally advanced metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.  
This indication is based on response rate.  There are no data available demonstrating improvement in patient reported outcomes or survival with XALKORI.",Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; XALKORI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XALKORI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",78 FR 6826,2013-02085,https://www.federalregister.gov/documents/2013/01/31/2013-02085/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xalkori,https://www.govinfo.gov/content/pkg/FR-2013-01-31/pdf/2013-02085.pdf,1/31/2013, XALKORI,,John,XALKORI,1,243,John,7230098,,,,Pfizer Inc.,2054,1904,150,2006-01-12,2006-01-12,2011-08-26,NDA 202-570,178,202570,9/28/2012,Treatment of anaplastic large cell lymphoma,Designated/Approved,,,"treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive",9/7/2023,,,"Pfizer, Inc.",Xalkori,crizotinib,Pfizer,NDA,202570,,2011-03-30,2011-08-26,2011,,"XALKORI is indicated for the treatment of patients with locally advanced metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.  
This indication is based on response rate.  There are no data available demonstrating improvement in patient reported outcomes or survival with XALKORI.",Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; XALKORI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XALKORI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",78 FR 6826,2013-02085,https://www.federalregister.gov/documents/2013/01/31/2013-02085/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xalkori,https://www.govinfo.gov/content/pkg/FR-2013-01-31/pdf/2013-02085.pdf,1/31/2013, XALKORI,,John,XALKORI,1,244,John,7230098,,,,Pfizer Inc.,2054,1904,150,2006-01-12,2006-01-12,2011-08-26,NDA 202-570,178,202570,9/13/2010,"Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer",Designated/Approved,,,treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test,9/7/2023,,,"Pfizer, Inc.",Xalkori,crizotinib,Pfizer,NDA,202570,,2011-03-30,2011-08-26,2011,,"XALKORI is indicated for the treatment of patients with locally advanced metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.  
This indication is based on response rate.  There are no data available demonstrating improvement in patient reported outcomes or survival with XALKORI.",Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; XALKORI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XALKORI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",78 FR 6826,2013-02085,https://www.federalregister.gov/documents/2013/01/31/2013-02085/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xalkori,https://www.govinfo.gov/content/pkg/FR-2013-01-31/pdf/2013-02085.pdf,1/31/2013, XALKORI,,John,XALKORI,1,245,John,7230098,,,,Pfizer Inc.,2054,1904,150,2006-01-12,2006-01-12,2011-08-26,NDA 202-570,178,202570,12/20/2021,Treatment of inflammatory myofibroblastic tumor,Designated/Approved,,,"Treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive",7/14/2022,7/14/2029,"Treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive",Pfizer Inc.,Xalkori,crizotinib,Pfizer,NDA,202570,,2011-03-30,2011-08-26,2011,,"XALKORI is indicated for the treatment of patients with locally advanced metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.  
This indication is based on response rate.  There are no data available demonstrating improvement in patient reported outcomes or survival with XALKORI.",Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; XALKORI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XALKORI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",78 FR 6826,2013-02085,https://www.federalregister.gov/documents/2013/01/31/2013-02085/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xalkori,https://www.govinfo.gov/content/pkg/FR-2013-01-31/pdf/2013-02085.pdf,1/31/2013, XALKORI,,John,XALKORI,1,246,John,7230098,,,,Pfizer Inc.,2054,1904,150,2006-01-12,2006-01-12,2011-08-26,NDA 202-570,178,202570,9/28/2012,Treatment of anaplastic large cell lymphoma,Designated/Approved,,,"treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive",1/14/2021,1/14/2028,"treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.","Pfizer, Inc.",Xalkori,crizotinib,Pfizer,NDA,202570,,2011-03-30,2011-08-26,2011,,"XALKORI is indicated for the treatment of patients with locally advanced metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.  
This indication is based on response rate.  There are no data available demonstrating improvement in patient reported outcomes or survival with XALKORI.",Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; XALKORI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XALKORI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",78 FR 6826,2013-02085,https://www.federalregister.gov/documents/2013/01/31/2013-02085/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xalkori,https://www.govinfo.gov/content/pkg/FR-2013-01-31/pdf/2013-02085.pdf,1/31/2013, XALKORI,,John,XALKORI,1,247,John,7230098,,,,Pfizer Inc.,2054,1904,150,2006-01-12,2006-01-12,2011-08-26,NDA 202-570,178,202570,9/13/2010,"Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer",Designated/Approved,,,Treatment of patients with metastatic NSCLC whose tumors are ROS1-positive,3/11/2016,3/11/2023,Treatment of patients with metastatic NSCLC whose tumors are ROS1-positive,"Pfizer, Inc.",Xalkori,crizotinib,Pfizer,NDA,202570,,2011-03-30,2011-08-26,2011,,"XALKORI is indicated for the treatment of patients with locally advanced metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.  
This indication is based on response rate.  There are no data available demonstrating improvement in patient reported outcomes or survival with XALKORI.",Priority,Yes,Yes,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; BEYAZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BEYAZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",78 FR 6826,2013-02086,https://www.federalregister.gov/documents/2013/01/31/2013-02086/determination-of-regulatory-review-period-for-purposes-of-patent-extension-beyaz,https://www.govinfo.gov/content/pkg/FR-2013-01-31/pdf/2013-02086.pdf,1/31/2013, BEYAZ,,John,BEYAZ,1,248,John,6441168,,,,Eprova AG,1271,874,397,2007-04-04,2007-04-04,2010-09-24,NDA 22-532,834,22532,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SAPIEN TRANSCATHETER HEART VALVE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SAPIEN TRANSCATHETER HEART VALVE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",78 FR 12330,2013-04016,https://www.federalregister.gov/documents/2013/02/22/2013-04016/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sapien-transcatheter,https://www.govinfo.gov/content/pkg/FR-2013-02-22/pdf/2013-04016.pdf,2/22/2013, SAPIEN TRANSCATHETER HEART VALVE,,John,SAPIEN TRANSCATHETER HEART VALVE,1,249,John,5411552,,,,Edwards Lifesciences AG,2473,2106,367,2005-01-26,2005-01-26,2011-11-02,PMA P100041,1757,100041,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZYTIGA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZYTIGA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",78 FR 13684,2013-04645,https://www.federalregister.gov/documents/2013/02/28/2013-04645/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zytiga,https://www.govinfo.gov/content/pkg/FR-2013-02-28/pdf/2013-04645.pdf,2/28/2013, ZYTIGA,,John,ZYTIGA,1,250,John,5604213,,,,BTG International LTD,1927,1797,130,2006-01-19,2006-01-19,2011-04-28,NDA 202-379,1024,202379,,,,,,,,,,,Zytiga,abiraterone acetate,Ortho Biotech Oncology Research and Development,NDA,202379,,2010-12-20,2011-04-28,2011,,ZYTIGA in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) who have received prior chemotherapy containing docetaxel.,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LAVIV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LAVIV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",78 FR 13685,2013-04646,https://www.federalregister.gov/documents/2013/02/28/2013-04646/determination-of-regulatory-review-period-for-purposes-of-patent-extension-laviv,https://www.govinfo.gov/content/pkg/FR-2013-02-28/pdf/2013-04646.pdf,2/28/2013, LAVIV,,John,LAVIV,1,251,John,5591444,,,,"Fibrocell Technologies, Inc.",3338,2500,838,2002-05-03,2002-05-03,2011-06-21,BLA 125348,5,125348,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; GADAVIST,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GADAVIST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 3832,2014-01307,https://www.federalregister.gov/documents/2014/01/23/2014-01307/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gadavist,https://www.govinfo.gov/content/pkg/FR-2014-01-23/pdf/2014-01307.pdf,1/23/2014, GADAVIST,,John,GADAVIST,1,252,John,5980864,,,,Bayer Schering Pharma Aktiengesellschaft,4269,3964,305,1999-07-08,1999-07-08,2011-03-14,NDA 201-277,1470,201277,,,,,,,,,,,Gadavist,gadobutrol,Bayer HealthCare Pharmaceuticals,NDA,201277,,2010-05-14,2011-03-14,2011,,Gadavast is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system.,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; DALIRESP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for DALIRESP and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 3831,2014-01306,https://www.federalregister.gov/documents/2014/01/23/2014-01306/determination-of-regulatory-review-period-for-purposes-of-patent-extension-daliresp,https://www.govinfo.gov/content/pkg/FR-2014-01-23/pdf/2014-01306.pdf,1/23/2014, DALIRESP,,John,DALIRESP,1,253,John,5712298,,,,Nycomed GmbH,4237,3645,592,1999-07-26,1999-07-26,2011-02-28,NDA 22-522,1826,22522,,,,,,,,,,,Daliresp,roflumilast,Forest Research Institute,NDA,22522,,2009-07-17,2011-02-28,2011,,"DALIRESP is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.  
Limitations of Use: 
DALIRESP is not a bronchodilator and is not indicated for the relief of acute bronchospasm.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; NULOJIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NULOJIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 18036,2014-07060,https://www.federalregister.gov/documents/2014/03/31/2014-07060/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nulojix,https://www.govinfo.gov/content/pkg/FR-2014-03-31/pdf/2014-07060.pdf,3/31/2014, NULOJIX,,John,NULOJIX,1,254,John,7094874,,,,Bristol-Myers Squibb Company,4479,3764,715,1999-03-13,1999-03-13,2011-06-15,BLA 125288,789,125288,2/20/2008,Prophylaxis of organ rejection in renal allograft recipients,Designated/Approved,,,Prophylaxis of organ rejection in adult patients receiving kidney transplants,6/15/2011,6/15/2018,,Bristol-Myers Squibb Company,Nulojix,belatacept,Bristol-Myers Squibb,BLA,125288,,2009-07-01,2011-06-15,2011,,"NULOJIX (belatacept) is indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant.  NULOJIX is to be used in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids.  
Limitations of use:  
Use NULOJIX only in patients who are EBV seropositive.  
Use of NULOJIX for the prophylaxis of organ rejection in transplanted organs other than kidney has not been established.",Standard,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; PREVNAR-13,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PREVNAR-13 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 18035,2014-07058,https://www.federalregister.gov/documents/2014/03/31/2014-07058/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prevnar-13,https://www.govinfo.gov/content/pkg/FR-2014-03-31/pdf/2014-07058.pdf,3/31/2014, PREVNAR-13,,John,PREVNAR-13,1,255,John,5614382,,,,Wyeth Holdings Corp.,2102,1771,331,2004-05-26,2004-05-26,2010-02-24,BLA 125324,1312,125324,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; POTIGA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for POTIGA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 18564,2014-07334,https://www.federalregister.gov/documents/2014/04/02/2014-07334/determination-of-regulatory-review-period-for-purposes-of-patent-extension-potiga,https://www.govinfo.gov/content/pkg/FR-2014-04-02/pdf/2014-07334.pdf,4/2/2014, POTIGA,,John,POTIGA,1,256,John,6538151,,,,Valeant Pharmaceuticals North America,5021,4432,589,1997-09-12,1997-09-12,2011-06-10,NDA 22-345,1794,22345,,,,,,,,,,,Potiga,ezogabine,Valeant Pharmaceuticals,NDA,22345,,2009-10-30,2011-06-10,2011,,POTIGA is indicated as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; FIRAZYR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FIRAZYR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 18565,2014-07331,https://www.federalregister.gov/documents/2014/04/02/2014-07331/determination-of-regulatory-review-period-for-purposes-of-patent-extension-firazyr,https://www.govinfo.gov/content/pkg/FR-2014-04-02/pdf/2014-07331.pdf,4/2/2014, FIRAZYR,,John,FIRAZYR,1,257,John,5648333,,,,Sanofi-Aventis Deutschland GmbH,2663,1263,1400,2004-05-12,2004-05-12,2011-08-25,NDA 22-150,5,22150,11/25/2003,Treatment of angioedema,Designated/Approved,,,Treatment of acute attacks of hereditary angioedema in adults 18 years of age and older,8/25/2011,8/25/2018,,"Takeda Development Center Americas, Inc.",Firazyr,icatibant,Shire Orphan Therapies,NDA,22150,,2007-10-26,2011-08-25,2011,,FIRAZYR (icatibant) is indicated for the treatment of acute attacts of hereditary angioedema (HAE) in adults 18 years of age and older.,Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; EYLEA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EYLEA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 18566,2014-07333,https://www.federalregister.gov/documents/2014/04/02/2014-07333/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eylea,https://www.govinfo.gov/content/pkg/FR-2014-04-02/pdf/2014-07333.pdf,4/2/2014, EYLEA,,John,EYLEA,3,260,John,7070959; 7374757; and 7374758,,,,"Regeneron Pharmaceuticals, Inc.",2349,2075,274,2005-06-15,2005-06-15,2011-11-18,BLA 125387,1118,125387,7/23/2019,Treatment of Retinopathy of Prematurity,Designated/Approved,,,treatment of retinopathy of prematurity (ROP),2/8/2023,2/8/2030,treatment of retinopathy of prematurity (ROP),"Regeneron Pharmaceuticals, Inc.",Eylea,aflibercept,Regeneron Pharmaceuticals,BLA,125387,,2011-02-18,2011-11-18,2011,,EYLEA is indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD).,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ONSIOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ONSIOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",79 FR 18563,2014-07336,https://www.federalregister.gov/documents/2014/04/02/2014-07336/determination-of-regulatory-review-period-for-purposes-of-patent-extension-onsior,https://www.govinfo.gov/content/pkg/FR-2014-04-02/pdf/2014-07336.pdf,4/2/2014, ONSIOR,,John,ONSIOR,2,262,John,6291523 and 7115662,,,,"Novartis Animal Health US, Inc.",3,1704,1650,2006-07-10,2011-03-08,2011-03-08,NADA 141-320,1308,141320,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NOVOTFF-100A SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NOVOTFF-100A SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",79 FR 18567,2014-07329,https://www.federalregister.gov/documents/2014/04/02/2014-07329/determination-of-regulatory-review-period-for-purposes-of-patent-extension-novotff-100a-system,https://www.govinfo.gov/content/pkg/FR-2014-04-02/pdf/2014-07329.pdf,4/2/2014, NOVOTFF-100A SYSTEM,,John,NOVOTFF-100A SYSTEM,1,263,John,7136699,,,,Novocure Limited,1704,1468,236,2006-08-10,2006-08-10,2011-04-08,PMA P100034,807,100034,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MELAFIND SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MELAFIND SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",79 FR 19101,2014-07657,https://www.federalregister.gov/documents/2014/04/07/2014-07657/determination-of-regulatory-review-period-for-purposes-of-patent-extension-melafind-system,https://www.govinfo.gov/content/pkg/FR-2014-04-07/pdf/2014-07657.pdf,4/7/2014, MELAFIND SYSTEM,,John,MELAFIND SYSTEM,1,264,John,6208749,,,,MELA Sciences Inc.,3837,2961,876,2001-05-02,2009-06-09,2011-11-01,PMA P090012,2355,90012,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; BRILINTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BRILINTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 24444,2014-09772,https://www.federalregister.gov/documents/2014/04/30/2014-09772/determination-of-regulatory-review-period-for-purposes-of-patent-extension-brilinta,https://www.govinfo.gov/content/pkg/FR-2014-04-30/pdf/2014-09772.pdf,4/30/2014, BRILINTA,,John,BRILINTA,4,268,John,6525060; 6251910; 7250419; and 7265124,,,,AstraZeneca UK Limited,2976,2364,612,2003-05-29,2003-05-29,2011-07-20,NDA 22-433,1794,22433,,,,,,,,,,,Brilinta,ticagrelor,AstraZeneca Pharmaceuticals,NDA,22433,,2009-11-16,2011-07-20,2011,,"BRILINTA is a P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction). BRILINTA has been shown to reduce the rate of a combined endpoint of cardiovascular death, myocardial infarction or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with PCI, it also reduces the rate of stent thrombosis.  
BRILINTA has been studied in ACS in combination with aspirin.  Maintenance doses of aspirin above 100 mg decreased the effectiveness of BRILINTA.  Avoid maintenance doses of aspirin above 100 mg daily. ",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; YERVOY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for YERVOY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 24735,2014-09910,https://www.federalregister.gov/documents/2014/05/01/2014-09910/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yervoy,https://www.govinfo.gov/content/pkg/FR-2014-05-01/pdf/2014-09910.pdf,5/1/2014, YERVOY,,Jonathan,YERVOY (ipilimumab),2,270,John,"6,984,720; 7,605,238",,,,"Medarex, Inc.",3879,3605,274,2000-08-12,2010-06-25,2011-03-25,BLA 125377/0,966 or 398 days,1253770,10/9/2014,Treatment of Stage IIb to Stage IV melanoma,Designated/Approved,,,"as a single agent or in combination with nivolumab, for the treatment of unresectable or metastatic melanoma in adult and pediatric patients 12 years and older",2/15/2023,,,Bristol-Myers Squibb Company,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; YERVOY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for YERVOY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 24735,2014-09910,https://www.federalregister.gov/documents/2014/05/01/2014-09910/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yervoy,https://www.govinfo.gov/content/pkg/FR-2014-05-01/pdf/2014-09910.pdf,5/1/2014, YERVOY,,Jonathan,YERVOY (ipilimumab),2,272,John,"6,984,720; 7,605,238",,,,"Medarex, Inc.",3879,3605,274,2000-08-12,2010-06-25,2011-03-25,BLA 125377/0,966 or 398 days,1253770,6/3/2004,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",Designated/Approved,,,treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older),7/21/2017,7/21/2024,treatment of unresectable or metastatic melanoma in pediatric patients (12 years and older).,Bristol-Myers Squibb Company,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; YERVOY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for YERVOY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 24735,2014-09910,https://www.federalregister.gov/documents/2014/05/01/2014-09910/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yervoy,https://www.govinfo.gov/content/pkg/FR-2014-05-01/pdf/2014-09910.pdf,5/1/2014, YERVOY,,Jonathan,YERVOY (ipilimumab),2,274,John,"6,984,720; 7,605,238",,,,"Medarex, Inc.",3879,3605,274,2000-08-12,2010-06-25,2011-03-25,BLA 125377/0,966 or 398 days,1253770,6/3/2004,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",Designated/Approved,,,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.",10/28/2015,10/28/2022,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.",Bristol-Myers Squibb Company,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; YERVOY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for YERVOY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 24735,2014-09910,https://www.federalregister.gov/documents/2014/05/01/2014-09910/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yervoy,https://www.govinfo.gov/content/pkg/FR-2014-05-01/pdf/2014-09910.pdf,5/1/2014, YERVOY,,Jonathan,YERVOY (ipilimumab),2,276,John,"6,984,720; 7,605,238",,,,"Medarex, Inc.",3879,3605,274,2000-08-12,2010-06-25,2011-03-25,BLA 125377/0,966 or 398 days,1253770,6/3/2004,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",Designated/Approved,,,"In combination with nivolumab, for the treatment of unresectable or metastatic melanoma in adult patients",5/25/2021,,,Bristol-Myers Squibb Company,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; YERVOY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for YERVOY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 24735,2014-09910,https://www.federalregister.gov/documents/2014/05/01/2014-09910/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yervoy,https://www.govinfo.gov/content/pkg/FR-2014-05-01/pdf/2014-09910.pdf,5/1/2014, YERVOY,,Jonathan,YERVOY (ipilimumab),2,278,John,"6,984,720; 7,605,238",,,,"Medarex, Inc.",3879,3605,274,2000-08-12,2010-06-25,2011-03-25,BLA 125377/0,966 or 398 days,1253770,6/3/2004,"Treatment of high risk Stage II, Stage III, and Stage IV melanoma",Designated/Approved,,,Treatment of unresectable or metastatic melanoma,3/25/2011,3/25/2018,,Bristol-Myers Squibb Company,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; EDURANT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EDURANT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 24736,2014-09911,https://www.federalregister.gov/documents/2014/05/01/2014-09911/determination-of-regulatory-review-period-for-purposes-of-patent-extension-edurant,https://www.govinfo.gov/content/pkg/FR-2014-05-01/pdf/2014-09911.pdf,5/1/2014, EDURANT,,Jonathan,EDURANT (rilpivirine hydrochloride),1,279,John,7125879,,,,Janssen Pharmaceutica N.V.,2396,2094,302,2004-10-29,2010-07-23,2011-05-20,NDA 202022,768,202022,,,,,,,,,,,Edurant,rilpivirine,Tibotec,NDA,202022,,2010-07-23,2011-05-20,2011,,"EDURANT, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-nave adult patients.  
This indication is based on Week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, Phase 3 trials in treatment-nave subjects and Week 96 safety and efficacy analyses from a Phase 2b trial in treatment-nave subjects.  
The following points should be considered when initiating therapy with EDURANT:  
- More EDURANT treated subjects with HIV-1 RNA greater than 100,000 copies/mL at the start of therapy experienced virologic failure compared to subjects with HIV-1 RNA less than 100,000 copies/mL at the start of therapy.  
- The observed virologic failure rate in EDURANT treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the NNRTI class compared to efavirenze.  
- More subjects treated with EDURANT developed lamivudine/emtricitabine associated resistance compared to efavirenz.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SURFAXIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SURFAXIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 27314,2014-10904,https://www.federalregister.gov/documents/2014/05/13/2014-10904/determination-of-regulatory-review-period-for-purposes-of-patent-extension-surfaxin,https://www.govinfo.gov/content/pkg/FR-2014-05-13/pdf/2014-10904.pdf,5/13/2014, SURFAXIN,,Jonathan,"SURFAXIN (lucinactant, which is a combination of four active ingredientssinapultide, colfosceril palmitate, POPG (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol), and palmitic acid)",1,280,John,5407914,,,,"Discovery Laboratories, Inc.",7124,4239,2885,1992-09-05,2004-04-13,2012-03-06,NDA 21-746,5 years,21746,,,,,,,,,,,Surfaxin,lucinactant,Discovery Laboratories,NDA,21746,,2004-04-13,2012-03-06,2012,,SURFAXIN (lucinactant) Intratracheal Suspension is indicated for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.  SURFAXIN reduces the incidence of RDS at 24 hours and mortality due to RDS.  ,Standard,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; TRADJENTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TRADJENTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 27316,2014-10945,https://www.federalregister.gov/documents/2014/05/13/2014-10945/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tradjenta,https://www.govinfo.gov/content/pkg/FR-2014-05-13/pdf/2014-10945.pdf,5/13/2014, TRADJENTA,,Jonathan,TRADJENTA (linagliptin),1,281,John,7407955,,,,Boehringer Ingelheim Pharma GmbH & Co. KGA,2051,1746,305,2005-09-21,2010-07-02,2011-05-02,NDA 201-280,629,201280,,,,,,,,,,,Tradjenta,linagliptin,Boehringer Ingelheim Pharmaceuticals,NDA,201280,,2010-07-02,2011-05-02,2011,,"Monotherapy and Combination Therapy:
TRADJENTA tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 
Important Limitations of Use:
TRADJENTA should not be used in patients with type 1 diabetes for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.
TRADJENTA has not been studied in combination with insulin.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; IMPROVEST,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IMPROVEST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",79 FR 27315,2014-10951,https://www.federalregister.gov/documents/2014/05/13/2014-10951/determination-of-regulatory-review-period-for-purposes-of-patent-extension-improvest,https://www.govinfo.gov/content/pkg/FR-2014-05-13/pdf/2014-10951.pdf,5/13/2014, IMPROVEST,,Jonathan,IMPROVEST (gonadotropin releasing factor analog-diptheria toxoid conjugate),1,282,John,7534441,,,,Pfizer Inc.,2555,2498,57,2004-03-25,2011-01-25,2011-03-22,NADA 141-322,366,141322,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; KYPROLIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KYPROLIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 27877,2014-11175,https://www.federalregister.gov/documents/2014/05/15/2014-11175/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kyprolis,https://www.govinfo.gov/content/pkg/FR-2014-05-15/pdf/2014-11175.pdf,5/15/2014, KYPROLIS,,Jonathan,KYPROLIS (carfilzomib),7,289,John,"7,232,818; 7,417,042; 7,491,704; 8,207,125; 8,207,126; 8,207,127; and 8,207,297",,,,"Onyx Therapeutics, Inc.",2565,2267,298,2005-07-14,2011-09-27,2012-07-20,NDA 202714,24 days; 43 days; or 462 days,202714,1/18/2008,Treatment of multiple myeloma,Designated/Approved,,,Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.,7/20/2012,7/20/2019,,"Onyx Therapeutics, Inc.",Kyprolis,carfilzomib,Onyx Pharmaceuticals,NDA,202714,,2011-09-27,2012-07-20,2012,,"KYPROLIS is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.  Approval is based on response rate.  Clinical benefit, such as improvement in survival or symptoms, has not been verified. ",Standard,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; KYPROLIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KYPROLIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 27877,2014-11175,https://www.federalregister.gov/documents/2014/05/15/2014-11175/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kyprolis,https://www.govinfo.gov/content/pkg/FR-2014-05-15/pdf/2014-11175.pdf,5/15/2014, KYPROLIS,,Jonathan,KYPROLIS (carfilzomib),7,296,John,"7,232,818; 7,417,042; 7,491,704; 8,207,125; 8,207,126; 8,207,127; and 8,207,297",,,,"Onyx Therapeutics, Inc.",2565,2267,298,2005-07-14,2011-09-27,2012-07-20,NDA 202714,24 days; 43 days; or 462 days,202714,1/18/2008,Treatment of multiple myeloma,Designated/Approved,,,treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with daratumumab and hyaluronidase-fihj and dexamethasone,11/30/2021,,,"Onyx Therapeutics, Inc.",Kyprolis,carfilzomib,Onyx Pharmaceuticals,NDA,202714,,2011-09-27,2012-07-20,2012,,"KYPROLIS is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.  Approval is based on response rate.  Clinical benefit, such as improvement in survival or symptoms, has not been verified. ",Standard,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; KYPROLIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KYPROLIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 27877,2014-11175,https://www.federalregister.gov/documents/2014/05/15/2014-11175/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kyprolis,https://www.govinfo.gov/content/pkg/FR-2014-05-15/pdf/2014-11175.pdf,5/15/2014, KYPROLIS,,Jonathan,KYPROLIS (carfilzomib),7,303,John,"7,232,818; 7,417,042; 7,491,704; 8,207,125; 8,207,126; 8,207,127; and 8,207,297",,,,"Onyx Therapeutics, Inc.",2565,2267,298,2005-07-14,2011-09-27,2012-07-20,NDA 202714,24 days; 43 days; or 462 days,202714,1/18/2008,Treatment of multiple myeloma,Designated/Approved,,,Treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with isatuximab and dexamethasone,6/30/2022,,,"Onyx Therapeutics, Inc.",Kyprolis,carfilzomib,Onyx Pharmaceuticals,NDA,202714,,2011-09-27,2012-07-20,2012,,"KYPROLIS is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.  Approval is based on response rate.  Clinical benefit, such as improvement in survival or symptoms, has not been verified. ",Standard,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; KYPROLIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KYPROLIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 27877,2014-11175,https://www.federalregister.gov/documents/2014/05/15/2014-11175/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kyprolis,https://www.govinfo.gov/content/pkg/FR-2014-05-15/pdf/2014-11175.pdf,5/15/2014, KYPROLIS,,Jonathan,KYPROLIS (carfilzomib),7,310,John,"7,232,818; 7,417,042; 7,491,704; 8,207,125; 8,207,126; 8,207,127; and 8,207,297",,,,"Onyx Therapeutics, Inc.",2565,2267,298,2005-07-14,2011-09-27,2012-07-20,NDA 202714,24 days; 43 days; or 462 days,202714,1/18/2008,Treatment of multiple myeloma,Designated/Approved,,,Treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with daratumumab and dexamethasone.,8/20/2020,,,"Onyx Therapeutics, Inc.",Kyprolis,carfilzomib,Onyx Pharmaceuticals,NDA,202714,,2011-09-27,2012-07-20,2012,,"KYPROLIS is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.  Approval is based on response rate.  Clinical benefit, such as improvement in survival or symptoms, has not been verified. ",Standard,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; BENLYSTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BENLYSTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 27878,2014-11176,https://www.federalregister.gov/documents/2014/05/15/2014-11176/determination-of-regulatory-review-period-for-purposes-of-patent-extension-benlysta,https://www.govinfo.gov/content/pkg/FR-2014-05-15/pdf/2014-11176.pdf,5/15/2014, BENLYSTA,,Jonathan,BENLYSTA (belimumab),3,313,John,"6,403,770; 7,138,501; and 7,879,328",,,,Human Genome Sciences Inc.,3426,3152,274,2001-10-23,2010-06-09,2011-03-09,BLA 125370/0,"1,733 days or 610 days or 37 days",1253700,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PALLADIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PALLADIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",79 FR 27879,2014-11172,https://www.federalregister.gov/documents/2014/05/15/2014-11172/determination-of-regulatory-review-period-for-purposes-of-patent-extension-palladia,https://www.govinfo.gov/content/pkg/FR-2014-05-15/pdf/2014-11172.pdf,5/15/2014, PALLADIA,,Jonathan,PALLADIA (toceranib phosphate),1,314,John,6573293,,,,"Sugen, Inc. and Pharmacia & Upjohn Company LLC",2711,2681,30,2001-12-21,2009-04-23,2009-05-22,NADA 141-295,827,141295,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ELELYSO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ELELYSO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 28733,2014-11516,https://www.federalregister.gov/documents/2014/05/19/2014-11516/determination-of-regulatory-review-period-for-purposes-of-patent-extension-elelyso,https://www.govinfo.gov/content/pkg/FR-2014-05-19/pdf/2014-11516.pdf,5/19/2014, ELELYSO,,Jonathan,ELELYSO (taliglucerase alfa),1,315,John,7951557,,,,Protalix Ltd.,2483,1746,737,2005-07-16,2010-04-26,2012-05-01,NDA 22-458,336,22458,,,,,,,,,,,Elelyso,taliglucerase alfa,Protalix,BLA,22458,,2010-04-26,2012-05-01,2012,,ELELYSO (taliglucerase alfa) for injection is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for adults with a confirmed diagnosis of Type 1 Gaucher disease.  ,Standard,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ZIOPTAN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZIOPTAN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 28735,2014-11517,https://www.federalregister.gov/documents/2014/05/19/2014-11517/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zioptan,https://www.govinfo.gov/content/pkg/FR-2014-05-19/pdf/2014-11517.pdf,5/19/2014, ZIOPTAN,,Jonathan,ZIOPTAN (tafluprost),1,316,John,5886035,,,,Asahi Glass Company Ltd.,3881,3481,400,2001-06-28,2011-01-07,2012-02-10,NDA 202514,5 years,202514,,,,,,,,,,,Zioptan,tafluprost,Merck,NDA,202514,,2011-01-07,2012-02-10,2012,,ZIOPTAN (tafluprost ophthalmic solution) 0.0015% is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; PERJETA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PERJETA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 28734,2014-11515,https://www.federalregister.gov/documents/2014/05/19/2014-11515/determination-of-regulatory-review-period-for-purposes-of-patent-extension-perjeta,https://www.govinfo.gov/content/pkg/FR-2014-05-19/pdf/2014-11515.pdf,5/19/2014, PERJETA,,Jonathan,PERJETA (pertuzumab),3,319,John,"6,949,245; 7,560,111; 7,862,817",,,,"Genentech, Inc.",3925,3741,184,2001-09-11,2011-12-08,2012-06-08,BLA 125409,"1,317 or 624 or 354 days",125409,,,,,,,,,,,Perjeta,pertuzumab,Genentech,BLA,125409,,2011-12-08,2012-06-08,2012,,PERJETA is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.,Priority,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; PICATO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PICATO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 28928,2014-11521,https://www.federalregister.gov/documents/2014/05/20/2014-11521/determination-of-regulatory-review-period-for-purposes-of-patent-extension-picato,https://www.govinfo.gov/content/pkg/FR-2014-05-20/pdf/2014-11521.pdf,5/20/2014, PICATO,,Jonathan,PICATO (ingenol mebutate),1,320,John,7410656,,,,Leo Laboratories Ltd.,2737,2432,305,2004-07-28,2011-03-25,2012-01-23,NDA 202833,783,202833,,,,,,,,,,,Picato,ingenol mebutate,Leo Pharma,NDA,202833,,2011-03-25,2012-01-23,2012,,Picato gel is indicated for the topical treatment of actinic keratosis.,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; OMONTYS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OMONTYS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 28930,2014-11523,https://www.federalregister.gov/documents/2014/05/20/2014-11523/determination-of-regulatory-review-period-for-purposes-of-patent-extension-omontys,https://www.govinfo.gov/content/pkg/FR-2014-05-20/pdf/2014-11523.pdf,5/20/2014, OMONTYS,,Jonathan,OMONTYS (Peginesatide acetate),1,321,John,7414105,,,,"Affymax, Inc.",2528,2222,306,2005-04-27,2011-05-27,2012-03-27,NDA 202799,684,202799,,,,,,,,,,,Omontys,peginesatide,Affymax,NDA,202799,,2011-05-27,2012-03-27,2012,,"OMONTYS is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.  
Limitations of Use:
OMONTYS is not indicated and is not recommended for use: 
- In patients with CKD not on dialysis because of safety concerns in this population.  
- In patients receiving treatment for cancer and whose anemia is not due to CKD, because ESAs have shown harm in some settings and the benefit-risk factors for OMONTYS in this setting have not been evaluated.  
- As a substitute for RBC transfusions in patients who require immediate correction of anemia.  
- OMONTYS has not been shown to improve symptoms, physical functioning or health-related quality of life.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; INCIVEK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INCIVEK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 28929,2014-11525,https://www.federalregister.gov/documents/2014/05/20/2014-11525/determination-of-regulatory-review-period-for-purposes-of-patent-extension-incivek,https://www.govinfo.gov/content/pkg/FR-2014-05-20/pdf/2014-11525.pdf,5/20/2014, INCIVEK,,Jonathan,INCIVEK (telaprevir),1,322,John,7820671,,,,Vertex Pharmaceuticals Incorporated,2003,1821,182,2005-11-29,2010-11-23,2011-05-23,NDA 201-917,87,201917,,,,,,,,,,,Incivek,telaprevir,Vertex Pharmaceuticals,NDA,201917,,2010-11-23,2011-05-23,2011,,"INCIVEK (telaprevir), in combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including cirrhosis, who are treatment-nave or who have previously been treated with interferon-based treatment, including prior null responders, partial responders, and relapsers.  
The following points should be considered when initiating treatment with INCIVEK: 
- INCIVEK must not be administered as monotherapy and must only be prescribed with both peginterferon alfa and ribavirin.  
- A high proportion of previous null responders (particularly those with cirrhosis) did not achieve a Sustained Virologic Response (SVR) and had telaprevir resistance-associated substitutions emerge on treatment with INCIVEK combination treatment. 
- INCIVEK efficacy has not been established for patients who have previously failed therapy with a treatment regimen that includes INCIVEK or other HCV NS3/4A protease inhibitors. ",Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; LINZESS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LINZESS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 29782,2014-11926,https://www.federalregister.gov/documents/2014/05/23/2014-11926/determination-of-regulatory-review-period-for-purposes-of-patent-extension-linzess,https://www.govinfo.gov/content/pkg/FR-2014-05-23/pdf/2014-11926.pdf,5/23/2014, LINZESS,,Jonathan,LINZESS (linaclotide),1,323,John,7304036,,,,"Ironwood Pharmaceuticals, Inc.",2863,2475,388,2004-10-30,2011-08-09,2012-08-30,NDA 202811,945,202811,,,,,,,,,,,Linzess,linaclotide,Forest Laboratories,NDA,202811,,2011-08-09,2012-08-30,2012,,"LINZESS (linaclotide) is indicated in adults for the treatment of irritable bowel syndrome with constipation (IBS-C).  
LINZESS is indicated in adults for the treatment of chronic idiopathic constipation (CIC).",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; INLYTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INLYTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 29783,2014-11925,https://www.federalregister.gov/documents/2014/05/23/2014-11925/determination-of-regulatory-review-period-for-purposes-of-patent-extension-inlyta,https://www.govinfo.gov/content/pkg/FR-2014-05-23/pdf/2014-11925.pdf,5/23/2014, INLYTA,,Jonathan,INLYTA (axitinib),1,324,John,6534524,,,,"Agouron Pharmaceuticals, Inc.",3699,3410,289,2001-12-13,2011-04-14,2012-01-27,NDA 202324,1763,202324,,,,,,,,,,,Inlyta,axitinib,Pfizer,NDA,202324,,2011-04-14,2012-01-27,2012,,INLYTA is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.,Standard,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; MYRBETRIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MYRBETRIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 30622,2014-12292,https://www.federalregister.gov/documents/2014/05/28/2014-12292/determination-of-regulatory-review-period-for-purposes-of-patent-extension-myrbetriq,https://www.govinfo.gov/content/pkg/FR-2014-05-28/pdf/2014-12292.pdf,5/28/2014, MYRBETRIQ,,Jonathan,MYRBETRIQ (mirabegron),3,327,John,"6,346,532; 7,342,117; 7,750,029",,,,Astellas Pharma Inc.,2213,1908,305,2006-06-09,2011-08-29,2012-06-28,NDA 202611,"515, 938, or 1,259 days",202611,,,,,,,,,,,Myrbetriq,mirabegron,Astellas Pharma,NDA,202611,,2011-08-29,2012-06-28,2012,,"Myrbetriq is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; MENHIBRIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MENHIBRIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 30621,2014-12294,https://www.federalregister.gov/documents/2014/05/28/2014-12294/determination-of-regulatory-review-period-for-purposes-of-patent-extension-menhibrix,https://www.govinfo.gov/content/pkg/FR-2014-05-28/pdf/2014-12294.pdf,5/28/2014, MENHIBRIX,,Jonathan,MENHIBRIX (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine),2,329,John,"5,693,326 and 5,955,079",,,,Henry M. Jackson Foundation for the Advancement of Military Medicine,2924,1886,1038,2004-06-14,2009-08-12,2012-06-14,BLA 125363,1825,125363,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ADCETRIS-Biologics License Application 125399,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ADCETRIS based on biologics license application (BLA) 125399 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human biological product, ADCETRIS.",79 FR 30624,2014-12279,https://www.federalregister.gov/documents/2014/05/28/2014-12279/determination-of-regulatory-review-period-for-purposes-of-patent-extension-adcetris-biologics,https://www.govinfo.gov/content/pkg/FR-2014-05-28/pdf/2014-12279.pdf,5/28/2014, ADCETRIS-Biologics License Application 125399,,Jonathan,ADCETRIS (brentuximab vedotin),2,331,John,"7,829,531 and 7,090,843",,,,"Seattle Genetics, Inc.",1851,1678,173,2006-07-27,2011-02-28,2011-08-19,BLA 125399,229,125399,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ADCETRIS-Biologics License Application 125388,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ADCETRIS based on biologics license application (BLA) 125388 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that human biological product, ADCETRIS.",79 FR 30625,2014-12277,https://www.federalregister.gov/documents/2014/05/28/2014-12277/determination-of-regulatory-review-period-for-purposes-of-patent-extension-adcetris-biologics,https://www.govinfo.gov/content/pkg/FR-2014-05-28/pdf/2014-12277.pdf,5/28/2014, ADCETRIS-Biologics License Application 125388,,Jonathan,ADCETRIS (brentuximab vedotin),2,333,John,"7,090,843 and 7,829,531",,,,"Seattle Genetics, Inc.",1851,1678,173,2006-07-27,2011-02-28,2011-08-19,BLA 125388,1002,125388,,,,,,,,,,,Adcetris,brentuximab vedotin,Seattle Genetics,BLA,125388,,2011-02-28,2011-08-19,2011,,"These indications are based on response rate.  There are no data available demonstrating improvement in patient reported outcomes or survival with ADCETRIS. 
[A] ADCETRIS (brentuximab vedotin) is indicated for treatment of patients with Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.  
[B] ADCETRIS is indicated for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.",Priority,Yes,Yes,,Yes (indication [A] only)
Determination of Regulatory Review Period for Purposes of Patent Extension; RESOLUTE INTEGRITY ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RESOLUTE INTEGRITY ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",79 FR 30623,2014-12295,https://www.federalregister.gov/documents/2014/05/28/2014-12295/determination-of-regulatory-review-period-for-purposes-of-patent-extension-resolute-integrity,https://www.govinfo.gov/content/pkg/FR-2014-05-28/pdf/2014-12295.pdf,5/28/2014, RESOLUTE INTEGRITY ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM,,Jonathan,RESOLUTE INTEGRITY ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM,1,334,John,7419696,,,,"Medtronic, Inc.",1586,1263,323,2007-10-17,2011-04-01,2012-02-17,PMA P110013,794,110013,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; XARELTO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XARELTO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 30855,2014-12349,https://www.federalregister.gov/documents/2014/05/29/2014-12349/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xarelto,https://www.govinfo.gov/content/pkg/FR-2014-05-29/pdf/2014-12349.pdf,5/29/2014, XARELTO,,Jonathan,XARELTO (rivaroxaban),1,335,John,7157456,,,,Bayer Pharma Aktiengesellschaft,3291,2222,1069,2002-06-29,2008-07-28,2011-07-01,NDA 22-406,1354,22406,,,,,,,,,,,Xarelto,rivaroxaban,Johnson & Johnson,NDA,22406,,2008-07-28,2011-07-01,2011,,"XARELTO (rivaroxaban) Tablets are indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ZACTRAN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZACTRAN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that animal drug product.",79 FR 30854,2014-12350,https://www.federalregister.gov/documents/2014/05/29/2014-12350/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zactran,https://www.govinfo.gov/content/pkg/FR-2014-05-29/pdf/2014-12350.pdf,5/29/2014, ZACTRAN,,Jonathan,ZACTRAN (gamithromycin),1,336,John,5985844,,,,Merck Sharp & Dohme Corp.,2990,2930,60,2003-04-11,2011-04-18,2011-06-16,NADA 141-328,1826,141328,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; KALYDECO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KALYDECO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 31118,2014-12561,https://www.federalregister.gov/documents/2014/05/30/2014-12561/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kalydeco,https://www.govinfo.gov/content/pkg/FR-2014-05-30/pdf/2014-12561.pdf,5/30/2014, KALYDECO,,Jonathan,KALYDECO (ivacaftor),1,337,John,7495103,,,,Vertex Pharmaceuticals Inc.,2121,2015,106,2006-04-13,2011-10-18,2012-01-31,NDA 203188,0,203188,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,,Treatment of cystic fibrosis (CF) in patients age 12 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.,8/15/2018,8/15/2025,For the treatment of cystic fibrosis (CF) in patients age 12 months to less than 2 years who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,"Vertex Pharmaceuticals, Inc.",Kalydeco,ivacaftor,Vertex Pharmaceuticals,NDA,203188,,2011-10-18,2012-01-31,2012,,"KALYDECO is classified as a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene. If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the G551D mutation.
Limitations of Use:
KALYDECO is not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene and has not been studied in other populations of patients with CF.",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; KALYDECO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KALYDECO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 31118,2014-12561,https://www.federalregister.gov/documents/2014/05/30/2014-12561/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kalydeco,https://www.govinfo.gov/content/pkg/FR-2014-05-30/pdf/2014-12561.pdf,5/30/2014, KALYDECO,,Jonathan,KALYDECO (ivacaftor),1,338,John,7495103,,,,Vertex Pharmaceuticals Inc.,2121,2015,106,2006-04-13,2011-10-18,2012-01-31,NDA 203188,0,203188,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,,"Treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.",2/21/2014,2/21/2021,"Treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.","Vertex Pharmaceuticals, Inc.",Kalydeco,ivacaftor,Vertex Pharmaceuticals,NDA,203188,,2011-10-18,2012-01-31,2012,,"KALYDECO is classified as a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene. If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the G551D mutation.
Limitations of Use:
KALYDECO is not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene and has not been studied in other populations of patients with CF.",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; KALYDECO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KALYDECO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 31118,2014-12561,https://www.federalregister.gov/documents/2014/05/30/2014-12561/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kalydeco,https://www.govinfo.gov/content/pkg/FR-2014-05-30/pdf/2014-12561.pdf,5/30/2014, KALYDECO,,Jonathan,KALYDECO (ivacaftor),1,339,John,7495103,,,,Vertex Pharmaceuticals Inc.,2121,2015,106,2006-04-13,2011-10-18,2012-01-31,NDA 203188,0,203188,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,,Treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene.,1/31/2012,1/31/2019,,"Vertex Pharmaceuticals, Inc.",Kalydeco,ivacaftor,Vertex Pharmaceuticals,NDA,203188,,2011-10-18,2012-01-31,2012,,"KALYDECO is classified as a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene. If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the G551D mutation.
Limitations of Use:
KALYDECO is not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene and has not been studied in other populations of patients with CF.",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; KALYDECO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KALYDECO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 31118,2014-12561,https://www.federalregister.gov/documents/2014/05/30/2014-12561/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kalydeco,https://www.govinfo.gov/content/pkg/FR-2014-05-30/pdf/2014-12561.pdf,5/30/2014, KALYDECO,,Jonathan,KALYDECO (ivacaftor),1,340,John,7495103,,,,Vertex Pharmaceuticals Inc.,2121,2015,106,2006-04-13,2011-10-18,2012-01-31,NDA 203188,0,203188,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,,treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,12/21/2020,12/21/2027,"treatment of cystic fibrosis (CF) in patients age 4 months and older who have one of the additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that have been identified as responsive to ivacaftor potentiation based on in vitro data and identified in the approval on December 21, 2020.","Vertex Pharmaceuticals, Inc.",Kalydeco,ivacaftor,Vertex Pharmaceuticals,NDA,203188,,2011-10-18,2012-01-31,2012,,"KALYDECO is classified as a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene. If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the G551D mutation.
Limitations of Use:
KALYDECO is not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene and has not been studied in other populations of patients with CF.",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; KALYDECO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KALYDECO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 31118,2014-12561,https://www.federalregister.gov/documents/2014/05/30/2014-12561/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kalydeco,https://www.govinfo.gov/content/pkg/FR-2014-05-30/pdf/2014-12561.pdf,5/30/2014, KALYDECO,,Jonathan,KALYDECO (ivacaftor),1,341,John,7495103,,,,Vertex Pharmaceuticals Inc.,2121,2015,106,2006-04-13,2011-10-18,2012-01-31,NDA 203188,0,203188,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,,KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,9/24/2020,9/24/2027,treatment of cystic fibrosis (CF) in patients age 4 months to less than 6 months who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,"Vertex Pharmaceuticals, Inc.",Kalydeco,ivacaftor,Vertex Pharmaceuticals,NDA,203188,,2011-10-18,2012-01-31,2012,,"KALYDECO is classified as a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene. If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the G551D mutation.
Limitations of Use:
KALYDECO is not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene and has not been studied in other populations of patients with CF.",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; KALYDECO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KALYDECO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 31118,2014-12561,https://www.federalregister.gov/documents/2014/05/30/2014-12561/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kalydeco,https://www.govinfo.gov/content/pkg/FR-2014-05-30/pdf/2014-12561.pdf,5/30/2014, KALYDECO,,Jonathan,KALYDECO (ivacaftor),1,342,John,7495103,,,,Vertex Pharmaceuticals Inc.,2121,2015,106,2006-04-13,2011-10-18,2012-01-31,NDA 203188,0,203188,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,,KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,4/29/2019,4/29/2026,For the treatment of cystic fibrosis (CF) in patients age 6 months to less than 12 months who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,"Vertex Pharmaceuticals, Inc.",Kalydeco,ivacaftor,Vertex Pharmaceuticals,NDA,203188,,2011-10-18,2012-01-31,2012,,"KALYDECO is classified as a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene. If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the G551D mutation.
Limitations of Use:
KALYDECO is not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene and has not been studied in other populations of patients with CF.",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; KALYDECO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KALYDECO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 31118,2014-12561,https://www.federalregister.gov/documents/2014/05/30/2014-12561/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kalydeco,https://www.govinfo.gov/content/pkg/FR-2014-05-30/pdf/2014-12561.pdf,5/30/2014, KALYDECO,,Jonathan,KALYDECO (ivacaftor),1,343,John,7495103,,,,Vertex Pharmaceuticals Inc.,2121,2015,106,2006-04-13,2011-10-18,2012-01-31,NDA 203188,0,203188,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,,"Treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R; and treatment of CF in patients age 6 years and older who have an R117H mutation in the CFTR gene.",12/29/2014,12/29/2021,Treatment of cystic fibrosis (CF) in patients age 6 years and older who have an R117H mutation in the CFTR gene.,"Vertex Pharmaceuticals, Inc.",Kalydeco,ivacaftor,Vertex Pharmaceuticals,NDA,203188,,2011-10-18,2012-01-31,2012,,"KALYDECO is classified as a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene. If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the G551D mutation.
Limitations of Use:
KALYDECO is not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene and has not been studied in other populations of patients with CF.",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; KALYDECO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KALYDECO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 31118,2014-12561,https://www.federalregister.gov/documents/2014/05/30/2014-12561/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kalydeco,https://www.govinfo.gov/content/pkg/FR-2014-05-30/pdf/2014-12561.pdf,5/30/2014, KALYDECO,,Jonathan,KALYDECO (ivacaftor),1,344,John,7495103,,,,Vertex Pharmaceuticals Inc.,2121,2015,106,2006-04-13,2011-10-18,2012-01-31,NDA 203188,0,203188,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,,Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.,7/31/2017,7/31/2024,"Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: 711+3A G, E831X, 2789+5G A, 3272-26A G, and 3849+10kbC T.","Vertex Pharmaceuticals, Inc.",Kalydeco,ivacaftor,Vertex Pharmaceuticals,NDA,203188,,2011-10-18,2012-01-31,2012,,"KALYDECO is classified as a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene. If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the G551D mutation.
Limitations of Use:
KALYDECO is not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene and has not been studied in other populations of patients with CF.",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; KALYDECO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KALYDECO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 31118,2014-12561,https://www.federalregister.gov/documents/2014/05/30/2014-12561/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kalydeco,https://www.govinfo.gov/content/pkg/FR-2014-05-30/pdf/2014-12561.pdf,5/30/2014, KALYDECO,,Jonathan,KALYDECO (ivacaftor),1,345,John,7495103,,,,Vertex Pharmaceuticals Inc.,2121,2015,106,2006-04-13,2011-10-18,2012-01-31,NDA 203188,0,203188,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,,Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.,5/17/2017,5/17/2024,"Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, and D1270N.","Vertex Pharmaceuticals, Inc.",Kalydeco,ivacaftor,Vertex Pharmaceuticals,NDA,203188,,2011-10-18,2012-01-31,2012,,"KALYDECO is classified as a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene. If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the G551D mutation.
Limitations of Use:
KALYDECO is not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene and has not been studied in other populations of patients with CF.",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; KALYDECO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KALYDECO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 31118,2014-12561,https://www.federalregister.gov/documents/2014/05/30/2014-12561/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kalydeco,https://www.govinfo.gov/content/pkg/FR-2014-05-30/pdf/2014-12561.pdf,5/30/2014, KALYDECO,,Jonathan,KALYDECO (ivacaftor),1,346,John,7495103,,,,Vertex Pharmaceuticals Inc.,2121,2015,106,2006-04-13,2011-10-18,2012-01-31,NDA 203188,0,203188,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,,"Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R ; and treatment of CF in patients age 2 years and older who have an R117H mutation in the CFTR gene.",3/17/2015,3/17/2022,"Treatment of cystic fibrosis (CF) in patients ages 2 to less than 6 years who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, and R117H.","Vertex Pharmaceuticals, Inc.",Kalydeco,ivacaftor,Vertex Pharmaceuticals,NDA,203188,,2011-10-18,2012-01-31,2012,,"KALYDECO is classified as a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene. If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the G551D mutation.
Limitations of Use:
KALYDECO is not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene and has not been studied in other populations of patients with CF.",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; KALYDECO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KALYDECO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 31118,2014-12561,https://www.federalregister.gov/documents/2014/05/30/2014-12561/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kalydeco,https://www.govinfo.gov/content/pkg/FR-2014-05-30/pdf/2014-12561.pdf,5/30/2014, KALYDECO,,Jonathan,KALYDECO (ivacaftor),1,347,John,7495103,,,,Vertex Pharmaceuticals Inc.,2121,2015,106,2006-04-13,2011-10-18,2012-01-31,NDA 203188,0,203188,12/20/2006,Treatment of patients with cystic fibrosis,Designated/Approved,,,treatment of cystic fibrosis (CF) in patients age 1 month and older who have at least one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,5/3/2023,5/3/2030,treatment of cystic fibrosis (CF) in patients 1 month to less than 4 months of age who have at least one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,"Vertex Pharmaceuticals, Inc.",Kalydeco,ivacaftor,Vertex Pharmaceuticals,NDA,203188,,2011-10-18,2012-01-31,2012,,"KALYDECO is classified as a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene. If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the G551D mutation.
Limitations of Use:
KALYDECO is not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene and has not been studied in other populations of patients with CF.",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; PROGENSA PCA3 ASSAY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PROGENSA PCA3 ASSAY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that medical device.",79 FR 31119,2014-12562,https://www.federalregister.gov/documents/2014/05/30/2014-12562/determination-of-regulatory-review-period-for-purposes-of-patent-extension-progensa-pca3-assay,https://www.govinfo.gov/content/pkg/FR-2014-05-30/pdf/2014-12562.pdf,5/30/2014, PROGENSA PCA3 ASSAY,,Jonathan,PROGENSA PCA3 ASSAY,1,348,John,7008765,,,,"The Johns Hopkins University & The Stichting Katholieke Universiteit, The University Medical Centre Nijmegen",936,383,553,2009-07-24,2010-08-10,2012-02-13,PMA P100033,745,100033,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; XIAFLEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XIAFLEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 31951,2014-12808,https://www.federalregister.gov/documents/2014/06/03/2014-12808/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xiaflex,https://www.govinfo.gov/content/pkg/FR-2014-06-03/pdf/2014-12808.pdf,6/3/2014, XIAFLEX,,Jonathan,XIAFLEX,1,349,John,RE39941,,,,"Auxilium Pharmaceuticals, Inc.",5278,4937,341,1995-08-24,1995-08-24,2010-02-02,BLA 125338,1806,125338,3/12/1996,Treatment of Peyronie's disease.,Designated/Approved,,,Treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.,12/6/2013,12/6/2020,Treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.,"Auxilium Pharmaceuticals, Inc.",Xiaflex,clostridialcollagenasehistolyticum,Auxilium Pharmaceuticals,BLA,125338,,2009-02-27,2010-02-02,2010,,XIAFLEX is indicated for the treatment of adult patients with Dupuytren's contracture with a palpable cord.,Priority,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; XIAFLEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XIAFLEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human biological product.",79 FR 31951,2014-12808,https://www.federalregister.gov/documents/2014/06/03/2014-12808/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xiaflex,https://www.govinfo.gov/content/pkg/FR-2014-06-03/pdf/2014-12808.pdf,6/3/2014, XIAFLEX,,Jonathan,XIAFLEX,1,350,John,RE39941,,,,"Auxilium Pharmaceuticals, Inc.",5278,4937,341,1995-08-24,1995-08-24,2010-02-02,BLA 125338,1806,125338,5/23/1996,Treatment of advanced (involutional or residual stage) Dupuytren's disease,Designated/Approved,,,Treatment of adult patients with Dupuytren's contracture with a palpable cord,2/2/2010,2/2/2017,,"Auxilium Pharmaceuticals, Inc.",Xiaflex,clostridialcollagenasehistolyticum,Auxilium Pharmaceuticals,BLA,125338,,2009-02-27,2010-02-02,2010,,XIAFLEX is indicated for the treatment of adult patients with Dupuytren's contracture with a palpable cord.,Priority,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; STENDRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for STENDRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 33198,2014-13444,https://www.federalregister.gov/documents/2014/06/10/2014-13444/determination-of-regulatory-review-period-for-purposes-of-patent-extension-stendra,https://www.govinfo.gov/content/pkg/FR-2014-06-10/pdf/2014-13444.pdf,6/10/2014, STENDRA,,Jonathan,STENDRA,1,351,John,6656935,,,,Mitsubishi Tanabe Pharma Corp.,3770,3466,304,2002-01-02,2002-01-02,2012-04-27,NDA 202276,1686,202276,,,,,,,,,,,Stendra,avanafil,Vivus,NDA,202276,,2011-06-29,2012-04-27,2012,,STENDRA is a phosphodieasterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction. ,Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Xience Prime Ll Everolimus Eluting Coronary Stent System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Xience Prime Ll Everolimus Eluting Coronary Stent System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",79 FR 33199,2014-13445,https://www.federalregister.gov/documents/2014/06/10/2014-13445/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xience-prime-ll,https://www.govinfo.gov/content/pkg/FR-2014-06-10/pdf/2014-13445.pdf,6/10/2014, Xience Prime Ll Everolimus Eluting Coronary Stent System,,Jonathan,Xience Prime Ll Everolimus Eluting Coronary Stent System,1,352,John,5514154,,,,Abbott Cardiovascular Systems Inc.,890,694,196,2009-05-27,2009-05-27,2011-11-01,PMA P110019,630,110019,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Vandetanib,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Vandetanib and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 33563,2014-13566,https://www.federalregister.gov/documents/2014/06/11/2014-13566/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vandetanib,https://www.govinfo.gov/content/pkg/FR-2014-06-11/pdf/2014-13566.pdf,6/11/2014, Vandetanib,,Jonathan,Vandetanib,1,353,John,7173038,,,,AstraZeneca AB,4009,3735,274,2000-04-16,2000-04-16,2011-04-06,NDA 22-405,898,22405,,,,,,,,,,,Caprelsa,vandetanib,AstraZeneca Pharmaceuticals,NDA,22405,,2010-07-07,2011-04-06,2011,,"Vandetanib is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.  
Use of vandetanib in patients with indolent, asymptomatic or slowly progressing disease should be carefully considered because of the treatment related risks of vandetanib.",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; Vandetanib,Notice,Health and Human Services Department; Food and Drug Administration,The Food and Drug Administration (FDA) has determined the regulatory review period for VANDETANIB and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO) for the extension of a patent which claims that human drug product.,79 FR 33562,2014-13567,https://www.federalregister.gov/documents/2014/06/11/2014-13567/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vandetanib,https://www.govinfo.gov/content/pkg/FR-2014-06-11/pdf/2014-13567.pdf,6/11/2014, Vandetanib,,Jonathan,Vandetanib,1,354,John,RE42353,,,,AstraZeneca UK Limited,4009,3735,274,2000-04-16,2000-04-16,2011-04-06,NDA 22-405,1738,22405,,,,,,,,,,,Caprelsa,vandetanib,AstraZeneca Pharmaceuticals,NDA,22405,,2010-07-07,2011-04-06,2011,,"Vandetanib is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.  
Use of vandetanib in patients with indolent, asymptomatic or slowly progressing disease should be carefully considered because of the treatment related risks of vandetanib.",Priority,Yes,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; Zuprevo,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZUPREVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that animal drug product.",79 FR 33763,2014-13637,https://www.federalregister.gov/documents/2014/06/12/2014-13637/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zuprevo,https://www.govinfo.gov/content/pkg/FR-2014-06-12/pdf/2014-13637.pdf,6/12/2014, Zuprevo,,Jonathan,ZUPREVO,1,355,John,6514946,,,,Koueki Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai,2903,2842,61,2004-06-04,2012-05-14,2012-05-14,NADA 141-334,1524,141334,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Arcapta Neohaler,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Arcapta Neohaler and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 33761,2014-13638,https://www.federalregister.gov/documents/2014/06/12/2014-13638/determination-of-regulatory-review-period-for-purposes-of-patent-extension-arcapta-neohaler,https://www.govinfo.gov/content/pkg/FR-2014-06-12/pdf/2014-13638.pdf,6/12/2014, Arcapta Neohaler,,Jonathan,Arcapta Neohaler,1,1,Jonathan,6878721,,,,Novartis AG,3097,2171,926,2003-01-09,2003-01-09,2011-07-01,NDA 22-383,1597,22383,,,,,,,,,,,Arcapta Neohaler,indacaterol,Novartis Pharmaceuticals,NDA,22383,,2008-12-18,2011-07-01,2011,,"ARCAPTA NEOHALER is a long-acting beta2-agonist indicated for long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. 
Important Limitations of Use:  
ARCAPTA NEOHALER is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease.  
ARCAPTA NEOHALER is not indicated to treat asthma.  The safety and effectiveness of ARCAPTA NEOHALER in asthma have not been established.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Arctic Front Cryocatheter System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Arctic Front Cryocatheter System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of Patents and Trademarks, Department of Commerce, for the extension of patents which claim that medical device.",79 FR 33762,2014-13640,https://www.federalregister.gov/documents/2014/06/12/2014-13640/determination-of-regulatory-review-period-for-purposes-of-patent-extension-arctic-front-cryocatheter,https://www.govinfo.gov/content/pkg/FR-2014-06-12/pdf/2014-13640.pdf,6/12/2014, Arctic Front Cryocatheter System,,Jonathan,Arctic Front Cryocatheter System,3,4,Jonathan,6575966; 7648497; and 7727228,,,,Medtronic CryoCath LP,2670,2389,281,2003-08-28,2003-08-28,2010-12-17,PMA P100010,1476,100010,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; VICTRELIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VICTRELIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 36535,2014-15021,https://www.federalregister.gov/documents/2014/06/27/2014-15021/determination-of-regulatory-review-period-for-purposes-of-patent-extension-victrelis,https://www.govinfo.gov/content/pkg/FR-2014-06-27/pdf/2014-15021.pdf,6/27/2014, VICTRELIS,,Jonathan,VICTRELIS,1,5,Jonathan,RE43298,,,,Schering Corporation,2160,1980,180,2005-06-15,2005-06-15,2011-05-13,NDA 202-258,1032,202258,,,,,,,,,,,Victrelis,boceprevir,Schering,NDA,202258,,2010-11-15,2011-05-13,2011,,"VICTRELIS (boceprevir) is indicated for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients (18 years and older) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy.  
The following points should be considered when initiating VICTRELIS for treatment of chronic hepatitis C infection:  
- VICTRELIS must not be used as monotherapy and should only be used in combination with peginterferon alfa and ribavirin.  
- VICTRELIS efficacy has not been studied in patients who have previously failed therapy with a treatment regimen that includes VICTRELIS or other HCV NS3/4A protease inhibitors.  
- VICTRELIS in combination with peginterferon alfa and ribavirin has not been studied in patients documented to be historical null responders (less than a 2-log10 HCV-RNA decline by treatment week 12) during prior therapy with peginterferon alfa and ribavirin. The clinical studies included subjects who were poorly interferon responsive. Subjects with less than 0.5-log10 HCV-RNA decline in viral load at Treatment Week 4 with peginterferon alfa plus ribavirin alone are predicted to have a null response (less than 2-log10 viral load decline at Treatment Week 12) to peginterferon alfa and ribavirin therapy.  
- Poorly interferon responsive patients who were treated with VICTRELIS in combination with peginterferon alfa and ribavirin have a lower likelihood of achieving a sustained virologic response (SVR), and a higher rate of detection of resistance-associated substitutions upon treatment failure, compared to patients with a greater response to peginterferon alfa and ribavirin.",Priority,No,No,,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; HORIZANT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HORIZANT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",79 FR 40108,2014-16237,https://www.federalregister.gov/documents/2014/07/11/2014-16237/determination-of-regulatory-review-period-for-purposes-of-patent-extension-horizant,https://www.govinfo.gov/content/pkg/FR-2014-07-11/pdf/2014-16237.pdf,7/11/2014, HORIZANT,,Jonathan,HORIZANT,1,6,Jonathan,6818787,,,,"XenoPort, Inc.",2277,1459,818,2005-01-12,2005-01-12,2011-04-06,NDA 22-399,882,22399,6/7/2011,Treatment of postherpetic neuralgia,Designated/Approved,,,Management of postherpetic neuralgia in adults.,6/6/2012,6/6/2019,,"Arbor Pharmaceuticals, LLC",Horizant,gabapentin enacarbil,GlaxoSmithKline,NDA,22399,,2009-01-09,2011-04-06,2011,,"HORIZANT (gabapentin enacarbil) Extended-Release Tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults.  
HORIZANT is not recommended for patients who are required to sleep during the daytime and remain awake at night.",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; CARBON DIOXIDE LASER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CARBON DIOXIDE LASER and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the United States Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that food additive.",79 FR 63132,2014-25032,https://www.federalregister.gov/documents/2014/10/22/2014-25032/determination-of-regulatory-review-period-for-purposes-of-patent-extension-carbon-dioxide-laser,https://www.govinfo.gov/content/pkg/FR-2014-10-22/pdf/2014-25032.pdf,10/22/2014, CARBON DIOXIDE LASER,,Jonathan,,0,6,Jonathan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; JUXTAPID,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for JUXTAPID and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 18414,2015-07809,https://www.federalregister.gov/documents/2015/04/06/2015-07809/determination-of-regulatory-review-period-for-purposes-of-patent-extension-juxtapid,https://www.govinfo.gov/content/pkg/FR-2015-04-06/pdf/2015-07809.pdf,4/6/2015, JUXTAPID,,Jonathan,JUXTAPID,1,7,Jonathan,5712279,,,,"Aegerion Pharmaceuticals, Inc.",6002,5705,297,1996-07-18,1996-07-18,2012-12-21,NDA 203-858,5,203858,10/23/2007,Treatment of homozygous familial hypercholesterolemia,Designated/Approved,,,"Adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).",12/21/2012,12/21/2019,,Chiesi Farmaceutici S.p.A.,Juxtapid,lomitapide,Aegerion Pharmaceuticals,NDA,203858,,2012-02-29,2012-12-21,2012,,"JUXTAPID is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH). 
Limitations of Use: 
- The safety and effectiveness of JUXTAPID have not been established in patients with hypercholesterolemia who do not have HoFH. 
- The effect of JUXTAPID on cardiovascular morbidity and mortality has not been determined. ",Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ELVITEGRAVIR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ELVITEGRAVIR (as a component of STRIBILD) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 19671,2015-08362,https://www.federalregister.gov/documents/2015/04/13/2015-08362/determination-of-regulatory-review-period-for-purposes-of-patent-extension-elvitegravir,https://www.govinfo.gov/content/pkg/FR-2015-04-13/pdf/2015-08362.pdf,4/13/2015, ELVITEGRAVIR,,Jonathan,,0,7,Jonathan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
"Determination of Regulatory Review Period for Purposes of Patent Extension; AUBAGIO-Patent No. 5,679,709",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AUBAGIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 20227,2015-08615,https://www.federalregister.gov/documents/2015/04/15/2015-08615/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aubagio-patent-no-5679709,https://www.govinfo.gov/content/pkg/FR-2015-04-15/pdf/2015-08615.pdf,4/15/2015," AUBAGIO-Patent No. 5,679,709",,Jonathan,AUBAGIO,1,8,Jonathan,5679709,,,,sanofi-aventis Deutschland GMBH,2940,2542,398,2004-08-27,2004-08-27,2012-09-12,NDA 202992,5,202992,,,,,,,,,,,Aubagio,teriflunomide,Sanofi-Aventis,NDA,202992,,2011-08-12,2012-09-12,2012,,AUBAGIO is indicated for the treatment of patients with relapsing forms of multiple sclerosis.,Standard,No,No,No,No
"Determination of Regulatory Review Period for Purposes of Patent Extension; AUBAGIO-Patent No. 6,794,410",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for AUBAGIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 20228,2015-08616,https://www.federalregister.gov/documents/2015/04/15/2015-08616/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aubagio-patent-no-6794410,https://www.govinfo.gov/content/pkg/FR-2015-04-15/pdf/2015-08616.pdf,4/15/2015," AUBAGIO-Patent No. 6,794,410",,Jonathan,AUBAGIO,1,9,Jonathan,6794410,,,,Aventis Pharmaceuticals Inc.,2940,2542,398,2004-08-27,2004-08-27,2012-09-12,NDA 202992,1625,202992,,,,,,,,,,,Aubagio,teriflunomide,Sanofi-Aventis,NDA,202992,,2011-08-12,2012-09-12,2012,,AUBAGIO is indicated for the treatment of patients with relapsing forms of multiple sclerosis.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; RAVICTI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RAVICTI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 21247,2015-08845,https://www.federalregister.gov/documents/2015/04/17/2015-08845/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ravicti,https://www.govinfo.gov/content/pkg/FR-2015-04-17/pdf/2015-08845.pdf,4/17/2015, RAVICTI,,Jonathan,RAVICTI,1,10,Jonathan,5968979,,,,"Hyperion Therapeutics, Inc.",2126,1719,407,2007-04-10,2007-04-10,2013-02-01,NDA 203284,1450,203284,4/27/2009,Maintenance treatment of patients with deficiencies in enzymes of the urea cycle,Designated/Approved,,,"Use as a nitrogen-binding agent for chronic management of adult and pediatric patients > or =2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (eg, essential amino acids, arginine, citrulline, protein-free calorie supplements).",2/1/2013,2/1/2020,"Use as a nitrogen-binding adjunctive therapy for chronic management of adult and pediatric patients at least 2 years of age with urea cycle disorders (UCDs) that cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (eg, essential amino acids, arginine, citrulline, protein-free calorie supplements).","Horizon Pharma USA, INc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; RAVICTI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RAVICTI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 21247,2015-08845,https://www.federalregister.gov/documents/2015/04/17/2015-08845/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ravicti,https://www.govinfo.gov/content/pkg/FR-2015-04-17/pdf/2015-08845.pdf,4/17/2015, RAVICTI,,Jonathan,RAVICTI,1,11,Jonathan,5968979,,,,"Hyperion Therapeutics, Inc.",2126,1719,407,2007-04-10,2007-04-10,2013-02-01,NDA 203284,1450,203284,4/27/2009,Maintenance treatment of patients with deficiencies in enzymes of the urea cycle,Designated/Approved,,,For use as a nitrogen-binding agent for chronic management of patients 2 months of age and older with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.,4/28/2017,4/28/2024,For use as a nitrogen-binding agent for chronic management of pediatric patients > or =2 months and,"Horizon Pharma USA, INc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; COMETRIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for COMETRIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 22528,2015-09302,https://www.federalregister.gov/documents/2015/04/22/2015-09302/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cometriq,https://www.govinfo.gov/content/pkg/FR-2015-04-22/pdf/2015-09302.pdf,4/22/2015, COMETRIQ,,Jonathan,COMETRIQ,1,12,Jonathan,7579473,,,,"Exelixis, Incorporated",2698,2513,185,2005-07-13,2005-07-13,2012-11-29,NDA 203756,688,203756,11/29/2010,"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.",Designated/Approved,,,"Treatment of progressive, metastatic medullary thyroid cancer (MTC).",11/29/2012,11/29/2019,,"Exelixis, Inc.",Cometriq,cabozantinib,Exelixis,NDA,203756,,2012-05-29,2012-11-29,2012,,"COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).",Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; FLUBLOK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FLUBLOK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",80 FR 23034,2015-09521,https://www.federalregister.gov/documents/2015/04/24/2015-09521/determination-of-regulatory-review-period-for-purposes-of-patent-extension-flublok,https://www.govinfo.gov/content/pkg/FR-2015-04-24/pdf/2015-09521.pdf,4/24/2015, FLUBLOK,,Jonathan,FLUBLOK,1,13,Jonathan,5762939,,,,Protein Sciences Corporation,3010,1275,1735,2004-10-22,2004-10-22,2013-01-16,BLA 125285,5,125285,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; KYNAMRO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KYNAMRO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 23035,2015-09522,https://www.federalregister.gov/documents/2015/04/24/2015-09522/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kynamro,https://www.govinfo.gov/content/pkg/FR-2015-04-24/pdf/2015-09522.pdf,4/24/2015, KYNAMRO,,Jonathan,KYNAMRO,1,14,Jonathan,7511131,,,,Genzyme Corporation,2601,2294,307,2005-12-18,2005-12-18,2013-01-29,NDA 203568,853,203568,5/23/2006,Treatment of homozygous familial hypercholesterolemia,Designated/Approved,,,"Adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).",1/29/2013,1/29/2020,"Adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).","Kastle Therapeutics, LLC",Kynamro,mipomersen sodium,Genzyme,NDA,203568,,2012-03-29,2013-01-29,2013,,"KYNAMRO is indicated as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH). 
Limitations of Use : 
- The safety and effectiveness of KYNAMRO have not been established in patients with hypercholesterolemia who do not have HoFH.  
- The effect of KYNAMRO on cardiovascular morbidity has not been determined.  
- The safety and effectiveness of KYNAMRO as an adjunct to LDL apheresis have not been established; therefore, the use of KYNAMRO as an adjunct to LDL apheresis is not recommended.",Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Xience Xpedition Everolimus Eluting Coronary Stent System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for Xience Xpedition Everolimus Eluting Coronary Stent System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",80 FR 23801,2015-09902,https://www.federalregister.gov/documents/2015/04/29/2015-09902/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xience-xpedition,https://www.govinfo.gov/content/pkg/FR-2015-04-29/pdf/2015-09902.pdf,4/29/2015, Xience Xpedition Everolimus Eluting Coronary Stent System,,Jonathan,Xience Xpedition Everolimus Eluting Coronary Stent System,1,15,Jonathan,7828766,,,,Abbott Cardiovascular Systems Inc.,178,178,178,2012-06-27,2012-06-27,2012-12-21,PMA P110019,178,110019,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NESINA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NESINA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 25300,2015-10337,https://www.federalregister.gov/documents/2015/05/04/2015-10337/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nesina,https://www.govinfo.gov/content/pkg/FR-2015-05-04/pdf/2015-10337.pdf,5/4/2015, NESINA,,Jonathan,NESINA,1,16,Jonathan,8173663,,,,Takeda Pharmaceuticals U.S.A.,3021,1164,1857,2004-10-20,2004-10-20,2013-01-25,NDA 22-271,264,22271,,,,,,,,,,,Nesina,alogliptin,Takeda Pharmaceuticals,NDA,22271,,2007-12-27,2013-01-25,2013,,"NESINA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.   
Limitation of Use:
NESINA should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BOSULIF,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BOSULIF and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 25301,2015-10333,https://www.federalregister.gov/documents/2015/05/04/2015-10333/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bosulif,https://www.govinfo.gov/content/pkg/FR-2015-05-04/pdf/2015-10333.pdf,5/4/2015, BOSULIF,,Jonathan,BOSULIF,1,17,Jonathan,RE42376,,,,Wyeth Holdings Corporation,3032,2739,293,2004-05-19,2004-05-19,2012-09-04,NDA 203-341,1664,203341,2/24/2009,Treatment of chronic myelogenous leukemia,Designated/Approved,,,"treatment of pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy",9/26/2023,9/26/2030,"treatment of pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy",PF PRISM C.V.,Bosulif,bosutinib,Wyeth Pharmaceuticals,NDA,203341,,2011-11-17,2012-09-04,2012,,"BOSULIF is indicated for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.",Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BOSULIF,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BOSULIF and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 25301,2015-10333,https://www.federalregister.gov/documents/2015/05/04/2015-10333/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bosulif,https://www.govinfo.gov/content/pkg/FR-2015-05-04/pdf/2015-10333.pdf,5/4/2015, BOSULIF,,Jonathan,BOSULIF,1,18,Jonathan,RE42376,,,,Wyeth Holdings Corporation,3032,2739,293,2004-05-19,2004-05-19,2012-09-04,NDA 203-341,1664,203341,2/24/2009,Treatment of chronic myelogenous leukemia,Designated/Approved,,,"Treatment of adult patients with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy",9/4/2012,9/4/2019,,PF PRISM C.V.,Bosulif,bosutinib,Wyeth Pharmaceuticals,NDA,203341,,2011-11-17,2012-09-04,2012,,"BOSULIF is indicated for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.",Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BOSULIF,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BOSULIF and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 25301,2015-10333,https://www.federalregister.gov/documents/2015/05/04/2015-10333/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bosulif,https://www.govinfo.gov/content/pkg/FR-2015-05-04/pdf/2015-10333.pdf,5/4/2015, BOSULIF,,Jonathan,BOSULIF,1,19,Jonathan,RE42376,,,,Wyeth Holdings Corporation,3032,2739,293,2004-05-19,2004-05-19,2012-09-04,NDA 203-341,1664,203341,2/24/2009,Treatment of chronic myelogenous leukemia,Designated/Approved,,,BOSULIF is indicated for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML).,12/19/2017,12/19/2024,Treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).,PF PRISM C.V.,Bosulif,bosutinib,Wyeth Pharmaceuticals,NDA,203341,,2011-11-17,2012-09-04,2012,,"BOSULIF is indicated for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.",Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KAZANO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KAZANO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 25302,2015-10335,https://www.federalregister.gov/documents/2015/05/04/2015-10335/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kazano,https://www.govinfo.gov/content/pkg/FR-2015-05-04/pdf/2015-10335.pdf,5/4/2015, KAZANO,,Jonathan,KAZANO,1,20,Jonathan,8288539,,,,Takeda Pharmaceutical Company Limited,1365,934,431,2009-05-03,2009-05-03,2013-01-25,NDA 203-414,102,203414,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TUDORZA PRESSAIR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TUDORZA PRESSAIR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 25303,2015-10336,https://www.federalregister.gov/documents/2015/05/04/2015-10336/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tudorza-pressair,https://www.govinfo.gov/content/pkg/FR-2015-05-04/pdf/2015-10336.pdf,5/4/2015, TUDORZA PRESSAIR,,Jonathan,TUDORZA PRESSAIR,2,22,Jonathan,6750226 and 7078412,,,,"Almiral, S.A.",3136,2739,397,2003-12-24,2003-12-24,2012-07-23,NDA 202-450,1298,202450,,,,,,,,,,,Tudorza Pressair,aclidinium bromide,Forest Laboratories,NDA,202450,,2011-06-23,2012-07-23,2012,,"TUDORZA Pressair (aclidinium bromide inhalation powder) is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; CAMERON HEALTH S-ICD SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CAMERON HEALTH S-ICD SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",80 FR 25299,2015-10334,https://www.federalregister.gov/documents/2015/05/04/2015-10334/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cameron-health-s-icd,https://www.govinfo.gov/content/pkg/FR-2015-05-04/pdf/2015-10334.pdf,5/4/2015, CAMERON HEALTH S-ICD SYSTEM,,Jonathan,CAMERON HEALTH S-ICD SYSTEM,2,24,Jonathan,6856835 and 7149575,,,,Cameron Health Inc.,1024,743,281,2009-12-11,2009-12-11,2012-09-28,PMA P110042,651,110042,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for the RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",80 FR 25298,2015-10338,https://www.federalregister.gov/documents/2015/05/04/2015-10338/determination-of-regulatory-review-period-for-purposes-of-patent-extension-relay-thoracic,https://www.govinfo.gov/content/pkg/FR-2015-05-04/pdf/2015-10338.pdf,5/4/2015, RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM,,Jonathan,the RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM,1,25,Jonathan,8062345 B2,,,,Bolton Medical Inc.,2852,2529,323,2004-12-02,2004-12-02,2012-09-21,PMA P110038,225,110038,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SYNRIBO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SYNRIBO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 26271,2015-11004,https://www.federalregister.gov/documents/2015/05/07/2015-11004/determination-of-regulatory-review-period-for-purposes-of-patent-extension-synribo,https://www.govinfo.gov/content/pkg/FR-2015-05-07/pdf/2015-11004.pdf,5/7/2015, SYNRIBO,,Jonathan,,0,25,Jonathan,,,,,,,,,,,,,,,3/10/2006,Treatment of chronic myelogenous leukemia,Designated/Approved,,,Treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI),10/26/2012,10/26/2019,,IVAX International GmbH,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; GATTEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GATTEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 26272,2015-11000,https://www.federalregister.gov/documents/2015/05/07/2015-11000/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gattex,https://www.govinfo.gov/content/pkg/FR-2015-05-07/pdf/2015-11000.pdf,5/7/2015, GATTEX,,Jonathan,GATTEX,2,27,Jonathan,5789379 and 7056886,,,,"NPS Pharmaceuticals, Inc.",4959,4571,388,1999-05-27,1999-05-27,2012-12-21,NDA 203441,1388,203441,,,,,,,,,,,Gattex,teduglutide(rDNAorigin),NPS Pharmaceuticals,NDA,203441,,2011-11-30,2012-12-21,2012,,GATTEX (teduglutide [rDNA origin]) for injection is indicated for the treatment of adult patiens with Short Bowel Syndrome (SBS) who are dependent on parenteral support.,Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SIGNIFOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SIGNIFOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 26276,2015-10994,https://www.federalregister.gov/documents/2015/05/07/2015-10994/determination-of-regulatory-review-period-for-purposes-of-patent-extension-signifor,https://www.govinfo.gov/content/pkg/FR-2015-05-07/pdf/2015-10994.pdf,5/7/2015, SIGNIFOR,,Jonathan,SIGNIFOR,1,28,Jonathan,7473761,,,,Novartis AG,3440,3138,302,2003-07-17,2003-07-17,2012-12-14,NDA 200677,503,200677,7/24/2009,Treatment of Cushing's disease,Designated/Approved,,,SIGNIFOR LAR is indicated for the treatment of patients with Cushings disease for whom pituitary surgery is not an option or has not been curative.,6/29/2018,6/29/2025,Indicated for treatment of patients with Cushings disease for whom pituitary surgery is not an option or has not been curative.,Novartis Pharmaceuticals Corporation,Signifor,pasireotide,Novartis Pharmaceuticals,NDA,200677,,2012-02-17,2012-12-14,2012,,SIGNIFOR is indicated for the treatment of adult patients with Cushings disease for whom pituitary surgery is not an option or has not been curative.,Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SIGNIFOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SIGNIFOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 26276,2015-10994,https://www.federalregister.gov/documents/2015/05/07/2015-10994/determination-of-regulatory-review-period-for-purposes-of-patent-extension-signifor,https://www.govinfo.gov/content/pkg/FR-2015-05-07/pdf/2015-10994.pdf,5/7/2015, SIGNIFOR,,Jonathan,SIGNIFOR,1,29,Jonathan,7473761,,,,Novartis AG,3440,3138,302,2003-07-17,2003-07-17,2012-12-14,NDA 200677,503,200677,7/24/2009,Treatment of Cushing's disease,Designated/Approved,,,Treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative,12/14/2012,12/14/2019,,Novartis Pharmaceuticals Corporation,Signifor,pasireotide,Novartis Pharmaceuticals,NDA,200677,,2012-02-17,2012-12-14,2012,,SIGNIFOR is indicated for the treatment of adult patients with Cushings disease for whom pituitary surgery is not an option or has not been curative.,Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; OSENI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OSENI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 26277,2015-11002,https://www.federalregister.gov/documents/2015/05/07/2015-11002/determination-of-regulatory-review-period-for-purposes-of-patent-extension-oseni,https://www.govinfo.gov/content/pkg/FR-2015-05-07/pdf/2015-11002.pdf,5/7/2015, OSENI,,Jonathan,OSENI,1,30,Jonathan,6329404,,,,Takeda Pharmaceutical Company Limited,2482,895,1587,2006-04-12,2006-04-12,2013-01-25,NDA 22-426,1826,22426,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; OVUGEL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OVUGEL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of U.S. Patents and Trademarks Office (USPTO), Department of Commerce, for the extension of a patent which claims that animal drug product.",80 FR 26274,2015-11003,https://www.federalregister.gov/documents/2015/05/07/2015-11003/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ovugel,https://www.govinfo.gov/content/pkg/FR-2015-05-07/pdf/2015-11003.pdf,5/7/2015, OVUGEL,,Jonathan,OVUGEL,2,32,Jonathan,5985320 and RE 42072,,,,Penn State Research Foundation,3692,3644,48,2002-08-12,2012-09-18,2012-09-18,NADA 141-,1826,141,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; COFLEX INTERLAMINAR TECHNOLOGY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for COFLEX INTERLAMINAR TECHNOLOGY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patents and Trademarks Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",80 FR 26273,2015-10998,https://www.federalregister.gov/documents/2015/05/07/2015-10998/determination-of-regulatory-review-period-for-purposes-of-patent-extension-coflex-interlaminar,https://www.govinfo.gov/content/pkg/FR-2015-05-07/pdf/2015-10998.pdf,5/7/2015, COFLEX INTERLAMINAR TECHNOLOGY,,Jonathan,COFLEX INTERLAMINAR TECHNOLOGY,1,33,Jonathan,5645599,,,,"Paradigm Spine, LLC",2382,1787,595,2006-04-12,2006-04-12,2012-10-17,PMA P110008,1503,110008,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; HVAD ROTARY BLOOD PUMP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HVAD ROTARY BLOOD PUMP and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",80 FR 26275,2015-11001,https://www.federalregister.gov/documents/2015/05/07/2015-11001/determination-of-regulatory-review-period-for-purposes-of-patent-extension-hvad-rotary-blood-pump,https://www.govinfo.gov/content/pkg/FR-2015-05-07/pdf/2015-11001.pdf,5/7/2015, HVAD ROTARY BLOOD PUMP,,Jonathan,HVAD ROTARY BLOOD PUMP,1,34,Jonathan,6234772,,,,"HeartWare, Inc.",1667,973,694,2008-04-30,2008-04-30,2012-11-20,PMA P100047,818,100047,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ISTENT TRABECULAR MICRO-BYPASS STENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for the ISTENT TRABECULAR MICRO-BYPASS STENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",80 FR 26268,2015-10999,https://www.federalregister.gov/documents/2015/05/07/2015-10999/determination-of-regulatory-review-period-for-purposes-of-patent-extension-istent-trabecular,https://www.govinfo.gov/content/pkg/FR-2015-05-07/pdf/2015-10999.pdf,5/7/2015, ISTENT TRABECULAR MICRO-BYPASS STENT,,Jonathan,the ISTENT TRABECULAR MICRO-BYPASS STENT,1,35,Jonathan,6626858,,,,Glaukos Corporation,2820,1535,1285,2004-10-07,2004-10-07,2012-06-25,PMA P080030,5,80030,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; STIVARGA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for STIVARGA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 29723,2015-12577,https://www.federalregister.gov/documents/2015/05/22/2015-12577/determination-of-regulatory-review-period-for-purposes-of-patent-extension-stivarga,https://www.govinfo.gov/content/pkg/FR-2015-05-22/pdf/2015-12577.pdf,5/22/2015, STIVARGA,,Jonathan,STIVARGA,1,36,Jonathan,7351834,,,,Bayer HealthCare LLC,2234,2080,154,2006-08-18,2006-08-18,2012-09-27,NDA 203085,898,203085,6/4/2015,Treatment of hepatocellular carcinoma,Designated/Approved,,,Treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with sorafenib.,4/27/2017,4/27/2024,Treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with sorafenib.,"Bayer HealthCare Pharmaceuticals, Inc.",Stivarga,regorafenib,Bayer HealthCare Pharmaceuticals,NDA,203085,,2012-04-27,2012-09-27,2012,,"Stivarga is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and anti-VEGF therapy, and, if KRAS wild type, and anti-EGFR therapy.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; STIVARGA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for STIVARGA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 29723,2015-12577,https://www.federalregister.gov/documents/2015/05/22/2015-12577/determination-of-regulatory-review-period-for-purposes-of-patent-extension-stivarga,https://www.govinfo.gov/content/pkg/FR-2015-05-22/pdf/2015-12577.pdf,5/22/2015, STIVARGA,,Jonathan,STIVARGA,1,37,Jonathan,7351834,,,,Bayer HealthCare LLC,2234,2080,154,2006-08-18,2006-08-18,2012-09-27,NDA 203085,898,203085,1/12/2011,Treatment gastrointestinal stromal tumors,Designated/Approved,,,"Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.",2/25/2013,2/25/2020,"Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.","Bayer HealthCare Pharmaceuticals, Inc.",Stivarga,regorafenib,Bayer HealthCare Pharmaceuticals,NDA,203085,,2012-04-27,2012-09-27,2012,,"Stivarga is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and anti-VEGF therapy, and, if KRAS wild type, and anti-EGFR therapy.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; FLUCELVAX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FLUCELVAX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",80 FR 29724,2015-12397,https://www.federalregister.gov/documents/2015/05/22/2015-12397/determination-of-regulatory-review-period-for-purposes-of-patent-extension-flucelvax,https://www.govinfo.gov/content/pkg/FR-2015-05-22/pdf/2015-12397.pdf,5/22/2015, FLUCELVAX,,Jonathan,FLUCELVAX,1,38,Jonathan,6656720,,,,Novartis AG,2589,2224,365,2005-10-21,2005-10-21,2012-11-20,BLA 125408,1773,125408,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; XELJANZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XELJANZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 33527,2015-14433,https://www.federalregister.gov/documents/2015/06/12/2015-14433/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xeljanz,https://www.govinfo.gov/content/pkg/FR-2015-06-12/pdf/2015-14433.pdf,6/12/2015, XELJANZ,,Jonathan,XELJANZ,1,39,Jonathan,RE41783,,,,Pfizer Inc.,3947,3564,383,2002-01-18,2002-01-18,2012-11-06,NDA 203214,5,203214,,,,,,,,,,,Xeljanz,tofacitinib,Pfizer,NDA,203214,,2011-10-21,2012-11-06,2012,,"XELJANZ (tofacitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.  It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs)._x000D_
XELJANZ should not be used in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SIRTURO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SIRTURO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 76694,2015-31098,https://www.federalregister.gov/documents/2015/12/10/2015-31098/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sirturo,https://www.govinfo.gov/content/pkg/FR-2015-12-10/pdf/2015-31098.pdf,12/10/2015, SIRTURO,,Jonathan,SIRTURO,1,40,Jonathan,7498343,,,,"Janssen Pharmaceutica, N.V.",2213,2030,183,2006-12-09,2006-12-09,2012-12-28,NDA 204384,741,204384,1/10/2005,Treatment of active tuberculosis,Designated/Approved,,,SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided.,5/27/2020,5/27/2027,As part of combination therapy in the treatment of pediatric patients 5 years and older to less than 12 years of age and weighing at least 15 kg with pulmonary multi-drug resistant tuberculosis (MDR-TB),"Janssen Research & Development, LLC",Sirturo,bedaquiline,Janssen Research & Development,NDA,204384,,2012-06-29,2012-12-28,2012,,"SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adults (>= 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB).  Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided.  SIRTURO should be administered by directly observed therapy (DOT). 
This indication is based on analysis of time to sputum culture conversion from two controlled Phase 2 trials in patients with pulmonary MDR-TB. 
Limitations of Use: 
The safety and efficacy of SIRTURO for the treatment of latent infection due to Mycobacterium tuberculosis has not been established.  The safety and efficacy of SIRTURO for the treatment of drug-sensitive TB has not been established.  In addition, there are no data on the treatment with SIRTURO of extra-pulmonary TB (e.g., central nervous system).  Therefore, use of SIRTURO in these settings is not recommended.",Priority,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; SIRTURO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SIRTURO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 76694,2015-31098,https://www.federalregister.gov/documents/2015/12/10/2015-31098/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sirturo,https://www.govinfo.gov/content/pkg/FR-2015-12-10/pdf/2015-31098.pdf,12/10/2015, SIRTURO,,Jonathan,SIRTURO,1,41,Jonathan,7498343,,,,"Janssen Pharmaceutica, N.V.",2213,2030,183,2006-12-09,2006-12-09,2012-12-28,NDA 204384,741,204384,1/10/2005,Treatment of active tuberculosis,Designated/Approved,,,SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (12 to less than 18 years of age and weighing at least 30 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided.,8/9/2019,8/9/2026,As part of combination therapy in the treatment of pediatric patients (12 to less than 18 years of age and weighing at least 30 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB),"Janssen Research & Development, LLC",Sirturo,bedaquiline,Janssen Research & Development,NDA,204384,,2012-06-29,2012-12-28,2012,,"SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adults (>= 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB).  Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided.  SIRTURO should be administered by directly observed therapy (DOT). 
This indication is based on analysis of time to sputum culture conversion from two controlled Phase 2 trials in patients with pulmonary MDR-TB. 
Limitations of Use: 
The safety and efficacy of SIRTURO for the treatment of latent infection due to Mycobacterium tuberculosis has not been established.  The safety and efficacy of SIRTURO for the treatment of drug-sensitive TB has not been established.  In addition, there are no data on the treatment with SIRTURO of extra-pulmonary TB (e.g., central nervous system).  Therefore, use of SIRTURO in these settings is not recommended.",Priority,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; SIRTURO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SIRTURO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 76694,2015-31098,https://www.federalregister.gov/documents/2015/12/10/2015-31098/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sirturo,https://www.govinfo.gov/content/pkg/FR-2015-12-10/pdf/2015-31098.pdf,12/10/2015, SIRTURO,,Jonathan,SIRTURO,1,42,Jonathan,7498343,,,,"Janssen Pharmaceutica, N.V.",2213,2030,183,2006-12-09,2006-12-09,2012-12-28,NDA 204384,741,204384,1/10/2005,Treatment of active tuberculosis,Designated/Approved,,,Part of combination therapy in adults (greater than or equal to 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB).,12/28/2012,12/28/2019,,"Janssen Research & Development, LLC",Sirturo,bedaquiline,Janssen Research & Development,NDA,204384,,2012-06-29,2012-12-28,2012,,"SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adults (>= 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB).  Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided.  SIRTURO should be administered by directly observed therapy (DOT). 
This indication is based on analysis of time to sputum culture conversion from two controlled Phase 2 trials in patients with pulmonary MDR-TB. 
Limitations of Use: 
The safety and efficacy of SIRTURO for the treatment of latent infection due to Mycobacterium tuberculosis has not been established.  The safety and efficacy of SIRTURO for the treatment of drug-sensitive TB has not been established.  In addition, there are no data on the treatment with SIRTURO of extra-pulmonary TB (e.g., central nervous system).  Therefore, use of SIRTURO in these settings is not recommended.",Priority,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ELIQUIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ELIQUIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 76696,2015-31096,https://www.federalregister.gov/documents/2015/12/10/2015-31096/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eliquis,https://www.govinfo.gov/content/pkg/FR-2015-12-10/pdf/2015-31096.pdf,12/10/2015, ELIQUIS,,Jonathan,ELIQUIS,1,43,Jonathan,6967208,,,,Bristol-Myers Squibb Company,3685,3227,458,2002-11-28,2002-11-28,2012-12-28,NDA 202155,1424,202155,,,,,,,,,,,Eliquis,apixaban,Bristol-Myers Squibb,NDA,202155,,2011-09-28,2012-12-28,2012,,ELIQUIS (apixaban) is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.,Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; VERAFLOX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VERAFLOX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that animal drug product.",80 FR 76701,2015-31099,https://www.federalregister.gov/documents/2015/12/10/2015-31099/determination-of-regulatory-review-period-for-purposes-of-patent-extension-veraflox,https://www.govinfo.gov/content/pkg/FR-2015-12-10/pdf/2015-31099.pdf,12/10/2015, VERAFLOX,,Jonathan,VERAFLOX,1,44,Jonathan,6323213,,,,Bayer Animal Health GmbH,3285,3235,50,2003-11-12,2012-09-19,2012-11-07,NADA 141-344,1901,141344,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FULYZAQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FULYZAQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 76693,2015-31097,https://www.federalregister.gov/documents/2015/12/10/2015-31097/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fulyzaq,https://www.govinfo.gov/content/pkg/FR-2015-12-10/pdf/2015-31097.pdf,12/10/2015, FULYZAQ,,Jonathan,,0,44,Jonathan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ARGUS II VISUAL STIMULATION SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ARGUS II VISUAL STIMULATION SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",80 FR 76697,2015-31095,https://www.federalregister.gov/documents/2015/12/10/2015-31095/determination-of-regulatory-review-period-for-purposes-of-patent-extension-argus-ii-visual,https://www.govinfo.gov/content/pkg/FR-2015-12-10/pdf/2015-31095.pdf,12/10/2015, ARGUS II VISUAL STIMULATION SYSTEM,,Jonathan,,0,44,Jonathan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; VIZAMYL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for VIZAMYL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 77640,2015-31401,https://www.federalregister.gov/documents/2015/12/15/2015-31401/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vizamyl,https://www.govinfo.gov/content/pkg/FR-2015-12-15/pdf/2015-31401.pdf,12/15/2015, VIZAMYL,,Jonathan,VIZAMYL,1,45,Jonathan,7270800,,,,GE Healthcare Limited,1541,1176,365,2009-08-08,2009-08-08,2013-10-25,NDA 203137,951,203137,,,,,,,,,,,Vizamyl,flutemetamol F 18,GE Healthcare,NDA,203137,,2012-10-26,2013-10-25,2013,,"Vizamyl is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimers Disease (AD) and other causes of cognitive decline. 
A negative Vizamyl scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patients cognitive impairment is due to AD.  A positive Vizamyl scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as in older people with normal cognition.  Vizamyl is an adjunct to other diagnostic evaluations.  
Limitations of Use: 
- A positive Vizamyl scan does not establish diagnosis of AD or other cognitive disorder.  
- Safety and effectiveness of Vizamyl have not been established for: 
-- Predicting development of dementia or other neurologic condition. 
--Monitoring responses to therapies.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; RAXIBACUMAB,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RAXIBACUMAB and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",80 FR 77643,2015-31400,https://www.federalregister.gov/documents/2015/12/15/2015-31400/determination-of-regulatory-review-period-for-purposes-of-patent-extension-raxibacumab,https://www.govinfo.gov/content/pkg/FR-2015-12-15/pdf/2015-31400.pdf,12/15/2015, RAXIBACUMAB,,Jonathan,RAXIBACUMAB,1,46,Jonathan,7906119,,,,Human Genome Sciences,3465,2154,1311,2003-06-22,2003-06-22,2012-12-14,BLA 125349,412,125349,,,,,,,,,,,[drug marketed without a proprietary name],raxibacumab,Human Genome Sciences,BLA,125349,,2009-05-14,2012-12-14,2012,,"Raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs.  Raxibacumab is also indicated for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.  
Limitations of Use:
The effectiveness of raxibacumab is based solely on efficacy studies in animal models of inhalational anthrax.  It is not ethical or feasible to conduct controlled clinical trials with intentional exposure of humans to anthrax.  
Safety and pharmacokinetics (PK) of raxibacumab have been studied in healthy volunteers.  There have been no studies of safety or PK of raxibacumab in the pediatric population.  A population PK approach was used to derive dosing regimens that are predicted to provide pediatric patients with exposure comparable to the observed exposure in adults. 
Raxibacumab binds to the protective antigen (PA) of B. anthracis; it does not have direct antibacterial activity.  Raxibacumab does not cross the blood-brain barrier and does not prevent or treat meningitis.  Raxibacumab should be used in combination with appropriate antibacterial drugs.",Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; Trivascular Ovation Abdominal Stent Graft System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TRIVASCULAR OVATION ABDOMINAL STENT GRAFT SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",80 FR 77638,2015-31397,https://www.federalregister.gov/documents/2015/12/15/2015-31397/determination-of-regulatory-review-period-for-purposes-of-patent-extension-trivascular-ovation,https://www.govinfo.gov/content/pkg/FR-2015-12-15/pdf/2015-31397.pdf,12/15/2015, Trivascular Ovation Abdominal Stent Graft System,,Jonathan,TRIVASCULAR OVATION ABDOMINAL STENT GRAFT SYSTEM,1,47,Jonathan,6395019,,,,"TriVascular, Inc.",3607,3429,178,2002-11-22,2002-11-22,2012-10-05,PMA P120006,1802,120006,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; XTANDI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XTANDI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",80 FR 79047,2015-31824,https://www.federalregister.gov/documents/2015/12/18/2015-31824/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xtandi,https://www.govinfo.gov/content/pkg/FR-2015-12-18/pdf/2015-31824.pdf,12/18/2015, XTANDI,,Jonathan,XTANDI,1,48,Jonathan,8183274,,,,The Regents of the University of California,1892,1790,102,2007-06-29,2007-06-29,2012-08-31,NDA 203-415,101,203415,,,,,,,,,,,Xtandi,enzalutamide,Medivation,NDA,203415,,2012-05-22,2012-08-31,2012,,XTANDI is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.,Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; JETREA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for JETREA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",80 FR 79903,2015-32247,https://www.federalregister.gov/documents/2015/12/23/2015-32247/determination-of-regulatory-review-period-for-purposes-of-patent-extension-jetrea,https://www.govinfo.gov/content/pkg/FR-2015-12-23/pdf/2015-32247.pdf,12/23/2015, JETREA,,Jonathan,JETREA,3,51,Jonathan,7445775; 7547435; and 7914783,,,,ThromboGenics NV,2171,1987,184,2006-11-09,2006-11-09,2012-10-17,BLA 125422,435,125422,,,,,,,,,,,Jetrea,ocriplasmin,ThromboGenics,BLA,125422,,2012-04-17,2012-10-17,2012,,JETREA is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion. ,Priority,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KADCYLA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for KADCYLA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",80 FR 80774,2015-32475,https://www.federalregister.gov/documents/2015/12/28/2015-32475/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kadcyla,https://www.govinfo.gov/content/pkg/FR-2015-12-28/pdf/2015-32475.pdf,12/28/2015, KADCYLA,,Jonathan,KADCYLA,2,53,Jonathan,7097840 and 8337856,,,,"Genentech, Inc.",2594,2414,180,2006-01-18,2006-01-18,2013-02-22,BLA 125427,60,125427,,,,,,,,,,,Kadcyla,ado-trastuzumab emtansine,Genentech,BLA,125427,,2012-08-27,2013-02-22,2013,,"KADCYLA, as a single agent, is indicated for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination.  Patients should have either: 
- received prior therapy for metastatic disease, or, 
- developed disease recurrence during or within six months of completing adjuvant therapy.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; BREO ELLIPTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BREO ELLIPTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 8724,2016-03551,https://www.federalregister.gov/documents/2016/02/22/2016-03551/determination-of-regulatory-review-period-for-purposes-of-patent-extension-breo-ellipta,https://www.govinfo.gov/content/pkg/FR-2016-02-22/pdf/2016-03551.pdf,2/22/2016, BREO ELLIPTA,,Jonathan,BREO ELLIPTA,1,54,Jonathan,7439393,,,,Glaxo Group Limited,1980,1677,303,2007-12-10,2007-12-10,2013-05-10,NDA 204275,981,204275,,,,,,,,,,,Breo Ellipta,fluticasone furoate and vilanterol,GlaxoSmithKline,NDA,204275,,2012-07-12,2013-05-10,2013,,"BREO ELLIPTA is a combination inhaled corticosteroid/long-acting beta2-adrenergic agonist (ICS/LABA) indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.  BREO ELLIPTA is also indicated to reduce exacerbations of COPD in patients with history of exacerbations.  
BREO ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SUPERA PERIPHERAL STENT SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SUPERA PERIPHERAL STENT SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",81 FR 8721,2016-03542,https://www.federalregister.gov/documents/2016/02/22/2016-03542/determination-of-regulatory-review-period-for-purposes-of-patent-extension-supera-peripheral-stent,https://www.govinfo.gov/content/pkg/FR-2016-02-22/pdf/2016-03542.pdf,2/22/2016, SUPERA PERIPHERAL STENT SYSTEM,,Jonathan,SUPERA PERIPHERAL STENT SYSTEM,1,55,Jonathan,8419788,,,,IDEV Technologies Inc.,1894,1396,498,2009-01-21,2009-01-21,2014-03-28,PMA P120020,158,120020,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; INVOKANA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INVOKANA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 10629,2016-04369,https://www.federalregister.gov/documents/2016/03/01/2016-04369/determination-of-regulatory-review-period-for-purposes-of-patent-extension-invokana,https://www.govinfo.gov/content/pkg/FR-2016-03-01/pdf/2016-04369.pdf,3/1/2016, INVOKANA,,Jonathan,INVOKANA,1,56,Jonathan,8222219,,,,"Mitsubishi Tanabe Pharma Corporation of Osaka, Japan",2137,1834,303,2007-05-25,2012-05-31,2013-03-29,NDA 204042,256,204042,,,,,,,,,,,Invokana,canagliflozin,Janssen Research & Development,NDA,204042,,2012-05-31,2013-03-29,2013,,"INVOKANA (canagliflozin) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.  
Limitation of Use: 
INVOKANA is not recommended in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. ",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ANORO ELLIPTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ANORO ELLIPTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 10630,2016-04370,https://www.federalregister.gov/documents/2016/03/01/2016-04370/determination-of-regulatory-review-period-for-purposes-of-patent-extension-anoro-ellipta,https://www.govinfo.gov/content/pkg/FR-2016-03-01/pdf/2016-04370.pdf,3/1/2016, ANORO ELLIPTA,,Jonathan,ANORO ELLIPTA,1,57,Jonathan,7488827,,,,Glaxo Group Limited,1589,1223,366,2009-08-14,2009-08-14,2013-12-18,NDA 203975,966,203975,,,,,,,,,,,Anoro Ellipta,"umeclidinium, vilanterol",GlaxoSmithKline,NDA,203975,,2012-12-18,2013-12-18,2013,,"ANORO ELLIPTA is a combination anticholinergic/long-acting beta2-adrenergic agonist (anticholinergic/LABA) indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. 
Important Limitations of Use: ANORO ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; OPSUMIT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPSUMIT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 12741,2016-05389,https://www.federalregister.gov/documents/2016/03/10/2016-05389/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opsumit,https://www.govinfo.gov/content/pkg/FR-2016-03-10/pdf/2016-05389.pdf,3/10/2016, OPSUMIT,,Jonathan,OPSUMIT,1,58,Jonathan,7094781,,,,Actelion Pharmaceuticals Ltd.,1935,1570,365,2008-07-03,2008-07-03,2013-10-18,NDA 204410,1151,204410,9/3/2009,Treatment of pulmonary arterial hypertension,Designated/Approved,,,"Treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). Opsumit also reduced hospitalization for PAH.",10/18/2013,10/18/2020,"Treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). Opsumit also reduced hospitalization for PAH.",Actelion Pharmaceuticals Ltd,Opsumit,macitentan,Actelion Pharmaceuticals,NDA,204410,,2012-10-19,2013-10-18,2013,,"OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression.  Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening or PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment).  OPSUMIT also reduced hospitalization for PAH. _x000D_
Effectiveness was established in a long-term study in PAH patients with predominantly WHO Functional Class II-III symptoms treated for an average of 2 years.  Patients were treated with OPSUMIT monotherapy or in combination with phosphodieasterase-5 inhibitors or inhaled prostanoids.  Patients had idiopathic and heritable PAH (57%), PAH caused by connective tissue disorders (31%), and PAH caused by congenital heart disease with repaired shunts (8%).",Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BRINTELLIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BRINTELLIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 19188,2016-07477,https://www.federalregister.gov/documents/2016/04/04/2016-07477/determination-of-regulatory-review-period-for-purposes-of-patent-extension-brintellix,https://www.govinfo.gov/content/pkg/FR-2016-04-04/pdf/2016-07477.pdf,4/4/2016, BRINTELLIX,,Jonathan,BRINTELLIX,1,59,Jonathan,7144884,,,,H. Lundbeck A/S,2343,1979,364,2007-05-04,2012-10-02,2013-09-30,NDA 204447,1353,204447,,,,,,,,,,,Brintellix,vortioxetine,Takeda Pharmaceuticals,NDA,204447,,2012-10-02,2013-09-30,2013,,BRINTELLIX is indicated for the treatment of major depressive disorder (MDD). The efficacy of BRINTELLIX was established in six 6 to 8 week studies (including one study in the elderly) and one maintenance study in adults.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; GAZYVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GAZYVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 21579,2016-08338,https://www.federalregister.gov/documents/2016/04/12/2016-08338/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gazyva,https://www.govinfo.gov/content/pkg/FR-2016-04-12/pdf/2016-08338.pdf,4/12/2016, GAZYVA,,Jonathan,,0,59,Jonathan,,,,,,,,,,,,,,,4/15/2015,Treatment of follicular lymphoma,Designated/Approved,,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen; and in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma",11/16/2017,11/16/2024,"In combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.","Genentech Inc., a member of the Roche Group",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; GAZYVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GAZYVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 21579,2016-08338,https://www.federalregister.gov/documents/2016/04/12/2016-08338/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gazyva,https://www.govinfo.gov/content/pkg/FR-2016-04-12/pdf/2016-08338.pdf,4/12/2016, GAZYVA,,Jonathan,,0,59,Jonathan,,,,,,,,,,,,,,,4/15/2015,Treatment of follicular lymphoma,Designated/Approved,,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen",2/26/2016,2/26/2023,"in combination with bendamustine followed by Gazyva monotherapy, indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.","Genentech Inc., a member of the Roche Group",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; GAZYVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GAZYVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 21579,2016-08338,https://www.federalregister.gov/documents/2016/04/12/2016-08338/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gazyva,https://www.govinfo.gov/content/pkg/FR-2016-04-12/pdf/2016-08338.pdf,4/12/2016, GAZYVA,,Jonathan,,0,59,Jonathan,,,,,,,,,,,,,,,2/17/2012,Treatment of chronic lymphocytic leukemia,Designated/Approved,,,"GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).",11/1/2013,11/1/2020,Treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.,"Genentech Inc., a member of the Roche Group",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ADEMPAS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ADEMPAS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 21555,2016-08337,https://www.federalregister.gov/documents/2016/04/12/2016-08337/determination-of-regulatory-review-period-for-purposes-of-patent-extension-adempas,https://www.govinfo.gov/content/pkg/FR-2016-04-12/pdf/2016-08337.pdf,4/12/2016, ADEMPAS,,Jonathan,ADEMPAS,1,60,Jonathan,7173037,,,,Bayer Intellectual Property GmbH,2394,2151,243,2007-03-22,2013-02-08,2013-10-08,NDA 204819,1317,204819,9/19/2013,Treatment of pulmonary arterial hypertension.,Designated/Approved,,,"Treatment of adults with pulmonary arterial hypertension (PAH) WHO Group 1, to improve exercise capacity, WHO functional class and to delay clinical worsening.",10/8/2013,10/8/2020,"Treatment of adults with pulmonary arterial hypertension (PAH) WHO Group 1, to improve exercise capacity, WHO functional class and to delay clinical worsening.","Bayer HealthCare Pharmaceuticals, Inc.",Adempas,riociguat,Bayer HealthCare Pharmaceuticals,NDA,204819,,2013-02-08,2013-10-08,2013,,"Adempas is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class. 
Adempas is indicated for the treatment of adults with pulmonary arterial hypertension (PAH), (WHO Group 1), to improve exercise capacity, WHO functional class and to delay clinical worsening. 
Efficacy was shown in patients on Adempas monotherapy or in combination with endothelin receptor antagonists or prostanoids.  Studies establishing effectiveness including predominantly patients with WHO functional class II-III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue disease (25%). ",Priority,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ADEMPAS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ADEMPAS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 21555,2016-08337,https://www.federalregister.gov/documents/2016/04/12/2016-08337/determination-of-regulatory-review-period-for-purposes-of-patent-extension-adempas,https://www.govinfo.gov/content/pkg/FR-2016-04-12/pdf/2016-08337.pdf,4/12/2016, ADEMPAS,,Jonathan,ADEMPAS,1,61,Jonathan,7173037,,,,Bayer Intellectual Property GmbH,2394,2151,243,2007-03-22,2013-02-08,2013-10-08,NDA 204819,1317,204819,9/19/2013,Treatment of chronic thromboembolic pulmonary hypertension,Designated/Approved,,,"Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) WHO Group 4, after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class",10/8/2013,10/8/2020,"Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) WHO Group 4, after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class","Bayer HealthCare Pharmaceuticals, Inc.",Adempas,riociguat,Bayer HealthCare Pharmaceuticals,NDA,204819,,2013-02-08,2013-10-08,2013,,"Adempas is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class. 
Adempas is indicated for the treatment of adults with pulmonary arterial hypertension (PAH), (WHO Group 1), to improve exercise capacity, WHO functional class and to delay clinical worsening. 
Efficacy was shown in patients on Adempas monotherapy or in combination with endothelin receptor antagonists or prostanoids.  Studies establishing effectiveness including predominantly patients with WHO functional class II-III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue disease (25%). ",Priority,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; APOQUEL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for APOQUEL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that animal drug product.",81 FR 21573,2016-08333,https://www.federalregister.gov/documents/2016/04/12/2016-08333/determination-of-regulatory-review-period-for-purposes-of-patent-extension-apoquel,https://www.govinfo.gov/content/pkg/FR-2016-04-12/pdf/2016-08333.pdf,4/12/2016, APOQUEL,,Jonathan,APOQUEL,1,62,Jonathan,6890929,,,,Pfizer Inc.,2226,2172,54,2007-04-12,2007-04-12,2013-05-14,NADA 141-345,1139,141345,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; APTIOM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for APTIOM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 21574,2016-08334,https://www.federalregister.gov/documents/2016/04/12/2016-08334/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aptiom,https://www.govinfo.gov/content/pkg/FR-2016-04-12/pdf/2016-08334.pdf,4/12/2016, APTIOM,,Jonathan,APTIOM,1,63,Jonathan,5753646,,,,"BIAL-PORTELA & CA, S.A.",2517,832,1685,2006-12-20,2009-03-30,2013-11-08,NDA 22-416,1826,22416,,,,,,,,,,,Aptiom,eslicarbazepine acetate,Sunovion Pharmaceuticals,NDA,22416,,2009-03-30,2013-11-08,2013,,APTIOM (eslicarbazepine acetate) is indicated as adjunctive treatment of partial-onset seizures.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; CYRAMZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CYRAMZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 22276,2016-08692,https://www.federalregister.gov/documents/2016/04/15/2016-08692/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cyramza,https://www.govinfo.gov/content/pkg/FR-2016-04-15/pdf/2016-08692.pdf,4/15/2016, CYRAMZA,,Jonathan,CYRAMZA,1,64,Jonathan,7498414,,,,Eli Lilly,3521,3279,242,2004-09-01,2004-09-01,2014-04-21,BLA 125477,1059,125477,2/16/2012,Treatment of gastric cancer,Designated/Approved,,,"Treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after prior fluoropyrimidine- or platinium-containing chemotherapy.",11/5/2014,,,Eli Lilly and Company,Cyramza,ramucirumab,Eli Lilly,BLA,125477,,2013-08-23,2014-04-21,2014,,"Cyramza as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum- containing chemotherapy.",Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; CYRAMZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CYRAMZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 22276,2016-08692,https://www.federalregister.gov/documents/2016/04/15/2016-08692/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cyramza,https://www.govinfo.gov/content/pkg/FR-2016-04-15/pdf/2016-08692.pdf,4/15/2016, CYRAMZA,,Jonathan,CYRAMZA,1,65,Jonathan,7498414,,,,Eli Lilly,3521,3279,242,2004-09-01,2004-09-01,2014-04-21,BLA 125477,1059,125477,2/16/2012,Treatment of gastric cancer,Designated/Approved,,,"CYRAMZA as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.",4/21/2014,4/21/2021,"Treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine-or platinum-containing therapy.",Eli Lilly and Company,Cyramza,ramucirumab,Eli Lilly,BLA,125477,,2013-08-23,2014-04-21,2014,,"Cyramza as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum- containing chemotherapy.",Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; CYRAMZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CYRAMZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 22276,2016-08692,https://www.federalregister.gov/documents/2016/04/15/2016-08692/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cyramza,https://www.govinfo.gov/content/pkg/FR-2016-04-15/pdf/2016-08692.pdf,4/15/2016, CYRAMZA,,Jonathan,CYRAMZA,1,66,Jonathan,7498414,,,,Eli Lilly,3521,3279,242,2004-09-01,2004-09-01,2014-04-21,BLA 125477,1059,125477,11/4/2011,Treatment of hepatocellular carcinoma,Designated/Approved,,,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.",5/10/2019,5/10/2026,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.",Eli Lilly and Company,Cyramza,ramucirumab,Eli Lilly,BLA,125477,,2013-08-23,2014-04-21,2014,,"Cyramza as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum- containing chemotherapy.",Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; LUZU,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LUZU and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 23722,2016-09374,https://www.federalregister.gov/documents/2016/04/22/2016-09374/determination-of-regulatory-review-period-for-purposes-of-patent-extension-luzu,https://www.govinfo.gov/content/pkg/FR-2016-04-22/pdf/2016-09374.pdf,4/22/2016, LUZU,,Jonathan,LUZU,1,67,Jonathan,5900488,,,,"Nihon Nohyaku Co., Ltd.",2242,1903,339,2007-09-27,2012-12-11,2013-11-14,NDA 204153,1289,204153,,,,,,,,,,,Luzu,luliconazole,Medicis Pharmaceutical,NDA,204153,,2012-12-11,2013-11-14,2013,,"LUZU (luliconazole) Cream, 1% is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and older.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; OLYSIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OLYSIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 34352,2016-12708,https://www.federalregister.gov/documents/2016/05/31/2016-12708/determination-of-regulatory-review-period-for-purposes-of-patent-extension-olysio,https://www.govinfo.gov/content/pkg/FR-2016-05-31/pdf/2016-12708.pdf,5/31/2016, OLYSIO,,Jonathan,OLYSIO,2,69,Jonathan,7671032 and 8349869,,,,Medivir AB,2006,1766,240,2008-05-28,2013-03-28,2013-11-22,NDA 205123,280,205123,,,,,,,,,,,Olysio,simeprevir,Janssen Research & Development,NDA,205123,,2013-03-28,2013-11-22,2013,,"OLYSIO is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen.  
- OLYSIO efficacy has been established in combination with peginterferon alfa and ribavirin, in HCV genotype 1 infected subjects with compensated liver disease (including cirrhosis). 
The following points should be considered when initiating OLYSIO for treatment of chronic hepatitis C infection: 
- OLYSIO must not be used as monotherapy. -OLYSIO efficacy in combination with peginterferon alfa and ribavirin is influenced by baseline host and viral factors. 
- OLYSIO efficacy in combination with peginterferon alfa and ribavirin is substantially reduced in patients infected with hepatitis C virus (HCV) genotype 1a without the Q80K polymorphism.  Screening patients with HCV genotype 1a infection for the presence of virus with the NS3 Q80K polymorphism at baseline is strongly recommended.  Alternative therapy should be considered for patients infected with HCV genotype 1a containing the Q80K polymorphism. 
- OLYSIO efficacy has not been studied in patients who have previously failed therapy with a treatment regimen that includes OLYSIO or other HCV protease inhibitors.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OSPHENA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OSPHENA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 35026,2016-12823,https://www.federalregister.gov/documents/2016/06/01/2016-12823/determination-of-regulatory-review-period-for-purposes-of-patent-extension-osphena,https://www.govinfo.gov/content/pkg/FR-2016-06-01/pdf/2016-12823.pdf,6/1/2016, OSPHENA,,Jonathan,OSPHENA,1,70,Jonathan,6245819,,,,Hormos Medical Ltd.,3585,3278,307,2003-05-07,2012-04-26,2013-02-26,NDA 203505,1826,203505,,,,,,,,,,,Osphena,ospemifene,Shionogi,NDA,203505,,2012-04-26,2013-02-26,2013,,"OSPHENA is indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; OTEZLA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OTEZLA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 35029,2016-12829,https://www.federalregister.gov/documents/2016/06/01/2016-12829/determination-of-regulatory-review-period-for-purposes-of-patent-extension-otezla,https://www.govinfo.gov/content/pkg/FR-2016-06-01/pdf/2016-12829.pdf,6/1/2016, OTEZLA,,Jonathan,OTEZLA,1,71,Jonathan,7427638,,,,Celgene Corporation,3494,3128,366,2004-08-28,2013-03-21,2014-03-21,NDA 205437,1186,205437,,,,,,,,,,,Otezla,apremilast,Celgene,NDA,205437,,2013-03-21,2014-03-21,2014,,OTEZLA is indicated for the treatment of adult patients with active psoriatic arthritis.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; MEKINIST,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MEKINIST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 35028,2016-12859,https://www.federalregister.gov/documents/2016/06/01/2016-12859/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mekinist,https://www.govinfo.gov/content/pkg/FR-2016-06-01/pdf/2016-12859.pdf,6/1/2016, MEKINIST,,Jonathan,MEKINIST,1,72,Jonathan,7378423,,,,"Japan Tobacco, Inc.",1842,1542,300,2008-05-15,2012-08-03,2013-05-29,NDA 204-114,623,204114,10/29/2015,Treatment of patients with BRAF mutation positive non-small cell lung cancer.,Designated/Approved,,,"Mekinist in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.",6/22/2017,6/22/2024,"Mekinist in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test; AND Tafinlar in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.",Novartis Pharmaceuticals Corporation,Mekinist,trametinib,GlaxoSmithKline,NDA,204114,,2012-08-03,2013-05-29,2013,,"MEKINIST is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.  _x000D_
MEKINIST is not indicated for treatment of patients who have received prior BRAF-inhibitor therapy.",Standard,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; MEKINIST,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MEKINIST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 35028,2016-12859,https://www.federalregister.gov/documents/2016/06/01/2016-12859/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mekinist,https://www.govinfo.gov/content/pkg/FR-2016-06-01/pdf/2016-12859.pdf,6/1/2016, MEKINIST,,Jonathan,MEKINIST,1,73,Jonathan,7378423,,,,"Japan Tobacco, Inc.",1842,1542,300,2008-05-15,2012-08-03,2013-05-29,NDA 204-114,623,204114,6/24/2022,Treatment of malignant glioma with BRAF V600 mutation,Designated/Approved,,,"in combination with dabrafenib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy",3/16/2023,3/16/2030,treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy,Novartis Pharmaceuticals Corporation,Mekinist,trametinib,GlaxoSmithKline,NDA,204114,,2012-08-03,2013-05-29,2013,,"MEKINIST is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.  _x000D_
MEKINIST is not indicated for treatment of patients who have received prior BRAF-inhibitor therapy.",Standard,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; MEKINIST,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MEKINIST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 35028,2016-12859,https://www.federalregister.gov/documents/2016/06/01/2016-12859/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mekinist,https://www.govinfo.gov/content/pkg/FR-2016-06-01/pdf/2016-12859.pdf,6/1/2016, MEKINIST,,Jonathan,MEKINIST,1,74,Jonathan,7378423,,,,"Japan Tobacco, Inc.",1842,1542,300,2008-05-15,2012-08-03,2013-05-29,NDA 204-114,623,204114,12/20/2010,Treatment of Stage IIb through Stage IV melanoma,Designated/Approved,,,Treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.,5/29/2013,5/29/2020,Treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.,Novartis Pharmaceuticals Corp.,Mekinist,trametinib,GlaxoSmithKline,NDA,204114,,2012-08-03,2013-05-29,2013,,"MEKINIST is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.  _x000D_
MEKINIST is not indicated for treatment of patients who have received prior BRAF-inhibitor therapy.",Standard,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ALPROLIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ALPROLIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human biological product.",81 FR 36928,2016-13526,https://www.federalregister.gov/documents/2016/06/08/2016-13526/determination-of-regulatory-review-period-for-purposes-of-patent-extension-alprolix,https://www.govinfo.gov/content/pkg/FR-2016-06-08/pdf/2016-13526.pdf,6/8/2016, ALPROLIX,,Jonathan,ALPROLIX,3,77,Jonathan,7348004; 7862820; and 8329182,,,,Biogen Idec Hemophilia Inc.,2223,1767,456,2008-02-27,2008-02-27,2014-03-28,BLA 125444,1326,125444,10/30/2008,Control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease),Designated/Approved,,,"Adults and children with Hemophilia B for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.",3/28/2014,3/28/2021,"Adults and children with Hemophilia B for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.","Bioverativ Therapeutics, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ELOCTATE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ELOCTATE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human biological product.",81 FR 36929,2016-13521,https://www.federalregister.gov/documents/2016/06/08/2016-13521/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eloctate,https://www.govinfo.gov/content/pkg/FR-2016-06-08/pdf/2016-13521.pdf,6/8/2016, ELOCTATE,,Jonathan,ELOCTATE,4,81,Jonathan,7348004; 7404956; 7862820; and 8329182,,,,Biogen Idec Hemophilia Inc.,1695,1239,456,2009-10-17,2009-10-17,2014-06-06,BLA 125487,1049,125487,11/23/2010,Treatment of hemophilia A,Designated/Approved,,,"Indicated in adults and children with Hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.",6/6/2014,6/6/2021,"Treatment of adults and children with Hemophilia A (congenital Factor VIII deficiency) for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.","Bioverativ Therapeutics, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TANZEUM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TANZEUM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 37611,2016-13797,https://www.federalregister.gov/documents/2016/06/10/2016-13797/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tanzeum,https://www.govinfo.gov/content/pkg/FR-2016-06-10/pdf/2016-13797.pdf,6/10/2016, TANZEUM,,Jonathan,TANZEUM,1,82,Jonathan,7141547,,,,"Human Genome Sciences, Inc.",3014,2557,457,2006-01-15,2006-01-15,2014-04-15,BLA 125431,1577,125431,,,,,,,,,,,Tanzeum,albiglutide,GlaxoSmithKline,BLA,125431,,2013-01-14,2014-04-15,2014,,"Tanzeum is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.  
Limitations of Use: 
- Tanzeum is not recommended as first-line therapy for patients inadequately controlled on diet and exercise.  
- Tanzeum has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis. 
- Tanzeum is not indicated in the treatment of patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis. 
- Tanzeum has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis. The use of Tanzeum is not recommended in patients with pre-existing severe gastrointestinal disease. 
- Tanzeum has not been studied in combination with prandial insulin.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; POMALYST,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for POMALYST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 37606,2016-13796,https://www.federalregister.gov/documents/2016/06/10/2016-13796/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pomalyst,https://www.govinfo.gov/content/pkg/FR-2016-06-10/pdf/2016-13796.pdf,6/10/2016, POMALYST,,Jonathan,POMALYST,2,84,Jonathan,6316471 and 8198262,,,,Celgene Corporation,60,3716,3411,2002-12-09,2002-12-09,2013-02-08,NDA 204026,241,204026,1/15/2003,Treatment of multiple myeloma,Designated/Approved,,,Treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.,2/8/2013,2/8/2020,Treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.,Celgene Corporation,Pomalyst,pomalidomide,Celgene,NDA,204026,,2012-04-10,2013-02-08,2013,,"POMALYST is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.  Approval is based on response rate.  Clinical benefit, such as improvement in survival or symptoms, has not been verified.",Standard,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ORBACTIV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ORBACTIV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 39649,2016-14353,https://www.federalregister.gov/documents/2016/06/17/2016-14353/determination-of-regulatory-review-period-for-purposes-of-patent-extension-orbactiv,https://www.govinfo.gov/content/pkg/FR-2016-06-17/pdf/2016-14353.pdf,6/17/2016, ORBACTIV,,Jonathan,ORBACTIV,1,85,Jonathan,5840684,,,,Eli Lilly,6539,6295,244,1996-09-12,1996-09-12,2014-08-06,NDA 206334,5,206334,,,,,,,,,,,Orbactiv,oritavancin diphosphate,The Medicines Company,NDA,206334,,2013-12-06,2014-08-06,2014,,"ORBACTIV (Oritavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin-susceptible isolates only). 
Usage: 
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ORBACTIV and other antibacterial drugs, ORBACTIV should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ZILVER PTX DRUG ELUTING PERIPHERAL STENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZILVER PTX DRUG ELUTING PERIPHERAL STENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications by Boston Scientific Scimed, Inc., to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that medical device.",81 FR 39648,2016-14357,https://www.federalregister.gov/documents/2016/06/17/2016-14357/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zilver-ptx-drug-eluting,https://www.govinfo.gov/content/pkg/FR-2016-06-17/pdf/2016-14357.pdf,6/17/2016, ZILVER PTX DRUG ELUTING PERIPHERAL STENT,,Jonathan,ZILVER PTX DRUG ELUTING PERIPHERAL STENT,2,87,Jonathan,6515009 and 7820193,,,,"Boston Scientific Scimed, Inc.",3075,2180,895,2004-06-16,2004-06-16,2012-11-14,PMA P100022,751,100022,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZILVER PTX DRUG ELUTING PERIPHERAL STENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ZILVER PTX DRUG ELUTING PERIPHERAL STENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application by Cook Medical Technologies, LLC, to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",81 FR 39652,2016-14356,https://www.federalregister.gov/documents/2016/06/17/2016-14356/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zilver-ptx-drug-eluting,https://www.govinfo.gov/content/pkg/FR-2016-06-17/pdf/2016-14356.pdf,6/17/2016, ZILVER PTX DRUG ELUTING PERIPHERAL STENT,,Jonathan,ZILVER PTX DRUG ELUTING PERIPHERAL STENT,1,88,Jonathan,6299604,,,,"Cook Medical Technologies, LLC",3075,2180,895,2004-06-16,2004-06-16,2012-11-14,PMA P100022,1826,100022,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; XOFIGO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for XOFIGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 40316,2016-14551,https://www.federalregister.gov/documents/2016/06/21/2016-14551/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xofigo,https://www.govinfo.gov/content/pkg/FR-2016-06-21/pdf/2016-14551.pdf,6/21/2016, XOFIGO,,Jonathan,XOFIGO,1,89,Jonathan,6635234,,,,Algeta ASA,1945,1792,153,2008-01-19,2008-01-19,2013-05-15,NDA 203971,1032,203971,,,,,,,,,,,Xofigo,radium Ra 223 dichloride,Bayer HealthCare Pharmaceuticals,NDA,203971,,2012-12-14,2013-05-15,2013,,"Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; QUTENZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for QUTENZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 47399,2016-17187,https://www.federalregister.gov/documents/2016/07/21/2016-17187/determination-of-regulatory-review-period-for-purposes-of-patent-extension-qutenza,https://www.govinfo.gov/content/pkg/FR-2016-07-21/pdf/2016-17187.pdf,7/21/2016, QUTENZA,,Jonathan,QUTENZA,1,90,Jonathan,6239180,,,,"NeurogesX, Inc.",2944,2547,397,2001-10-27,2001-10-27,2009-11-16,NDA 22-395,1687,22395,5/22/2009,Management of neuropathic pain in patients with postherpetic neuralgia,Designated/Approved,,,Management of neuropathic pain associated with postherpetic neuralgia,11/16/2009,11/16/2016,,"Averitas Pharma, Inc.",Qutenza,capsaicin,Neurogesx,NDA,22395,,2008-10-16,2009-11-16,2009,,Qutenza is indicated for the management of neuropathic pain associated with postherpetic neuralgia.,Standard,Yes,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ENTYVIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ENTYVIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patents and Trademarks Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 63773,2016-22344,https://www.federalregister.gov/documents/2016/09/16/2016-22344/determination-of-regulatory-review-period-for-purposes-of-patent-extension-entyvio,https://www.govinfo.gov/content/pkg/FR-2016-09-16/pdf/2016-22344.pdf,9/16/2016, ENTYVIO,,Jonathan,ENTYVIO,1,91,Jonathan,7147851,,,,"Millenium Pharmaceuticals, Inc.",5066,4731,335,2000-07-08,2000-07-08,2014-05-20,BLA 125476,1526,125476,,,,,,,,,,,Entyvio,vedolizumab,Takeda Pharmaceuticals,BLA,125476,,2013-06-20,2014-05-20,2014,,"Entyvio (vedolizumab) is indicated for: -inducing and maintaining clinical response, 
- inducing and maintaining clinical remission, 
- improving the endoscopic appearance of the mucosa, and 
- achieving corticosteroid-free remission 
in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. 
Entyvio (vedolizumab) is indicated for: 
- achieving clinical response, 
- achieving clinical remission, and 
- achieving corticosteroid-free remission 
in adult patients with moderately to severely active Crohns disease who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; LUMASON,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for LUMASON and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 63770,2016-22345,https://www.federalregister.gov/documents/2016/09/16/2016-22345/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lumason,https://www.govinfo.gov/content/pkg/FR-2016-09-16/pdf/2016-22345.pdf,9/16/2016, LUMASON,,Jonathan,LUMASON,1,92,Jonathan,5686060,,,,Bracco Suisse SA,7199,6174,1025,1995-01-26,1995-01-26,2014-10-10,NDA 203684,5,203684,,,,,,,,,,,Lumason,sulfur hexafluoride lipid-type A microspheres,Bracco Diagnostics,NDA,203684,,2011-12-21,2014-10-10,2014,,Lumason is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; RESQCPR SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RESQCPR SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",81 FR 63771,2016-22343,https://www.federalregister.gov/documents/2016/09/16/2016-22343/determination-of-regulatory-review-period-for-purposes-of-patent-extension-resqcpr-system,https://www.govinfo.gov/content/pkg/FR-2016-09-16/pdf/2016-22343.pdf,9/16/2016, RESQCPR SYSTEM,,Jonathan,RESQCPR SYSTEM,1,93,Jonathan,5454779,,,,University of California,3608,2247,1361,2005-04-21,2005-04-21,2015-03-06,PMA P110024,5,110024,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MYALEPT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for MYALEPT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 65656,2016-22935,https://www.federalregister.gov/documents/2016/09/23/2016-22935/determination-of-regulatory-review-period-for-purposes-of-patent-extension-myalept,https://www.govinfo.gov/content/pkg/FR-2016-09-23/pdf/2016-22935.pdf,9/23/2016, MYALEPT,,Jonathan,,0,93,Jonathan,,,,,,,,,,,,,,,8/22/2001,Treatment of metabolic disorders secondary to lipodystrophy,Designated/Approved,,,Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.,2/24/2014,2/24/2021,Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.,Chiesi Farmaceutici S.p.A.,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FYCOMPA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for FYCOMPA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 65655,2016-22933,https://www.federalregister.gov/documents/2016/09/23/2016-22933/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fycompa,https://www.govinfo.gov/content/pkg/FR-2016-09-23/pdf/2016-22933.pdf,9/23/2016, FYCOMPA,,Jonathan,FYCOMPA,1,94,Jonathan,6949571,,,,"Eisai R&D Management Co., Ltd.",3274,2968,306,2003-11-07,2011-12-22,2012-10-22,NDA 202834,1549,202834,,,,,,,,,,,Fycompa,perampanel,Eisai,NDA,202834,,2011-12-22,2012-10-22,2012,,FYCOMPA (perampanel) is indicated as adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BELVIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BELVIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 65658,2016-22937,https://www.federalregister.gov/documents/2016/09/23/2016-22937/determination-of-regulatory-review-period-for-purposes-of-patent-extension-belviq,https://www.govinfo.gov/content/pkg/FR-2016-09-23/pdf/2016-22937.pdf,9/23/2016, BELVIQ,,Jonathan,BELVIQ,3,97,Jonathan,6953787; 7514422; and 7977329,,,,"Arena Pharmaceuticals, Inc.",2928,2009,919,2004-06-23,2009-12-22,2012-06-27,NDA 22-529,352,22529,,,,,,,,,,,Belviq,lorcaserin hydrochloride,Arena Pharmacueticals,NDA,22529,,2009-12-22,2012-06-27,2012,,"BELVIQ is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 
- 30 kg/m2 or greater (obese), or 
- 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes)  
Limitations of Use: 
- The safety and efficacy of coadministration of BELVIQ with other products intended for weight loss including prescription drugs (e.g., phentermine), over-the-counter drugs, and herbal preparations have not been established  
- The effect of BELVIQ on cardiovascular morbidity and mortality has not been established",Standard,No,No,,No
Determination of Regulatory Review Period for Purposes of Patent Extension; IONSYS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IONSYS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 66662,2016-23330,https://www.federalregister.gov/documents/2016/09/28/2016-23330/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ionsys,https://www.govinfo.gov/content/pkg/FR-2016-09-28/pdf/2016-23330.pdf,9/28/2016, IONSYS,,Jonathan,IONSYS,1,98,Jonathan,5697896,,,,Alza Corp.,4835,3862,973,1993-02-26,1993-02-26,2006-05-22,NDA 21-338,5,21338,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; REPATHA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REPATHA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 72059,2016-25221,https://www.federalregister.gov/documents/2016/10/19/2016-25221/determination-of-regulatory-review-period-for-purposes-of-patent-extension-repatha,https://www.govinfo.gov/content/pkg/FR-2016-10-19/pdf/2016-25221.pdf,10/19/2016, REPATHA,,Jonathan,REPATHA,3,101,Jonathan,8030457; 8829165; and 8981064,,,,Amgen Inc.,2267,1901,366,2009-06-14,2009-06-14,2015-08-27,BLA 125522,164,125522,9/12/2013,Treatment of homozygous familial hypercholesterolemia,Designated/Approved,,,"As an adjunct to other low-density lipoprotein cholesterol (LDL-C)-lowering therapies in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C",9/24/2021,9/24/2028,to reduce LDL-C in pediatric patients aged 10 to less than 13 years with homozygous familial hypercholesterolemia (HoFH),Amgen Inc.,Repatha,evolocumab,Amgen,BLA,125522,,2014-08-27,2015-08-27,2015,,"[A] REPATHA is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (CVD), who require additional lowering of low density lipoprotein cholesterol (LDL-C). 
[B] REPATHA is indicated as an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH) who require additional lowering of LDL-C.
Limitations of Use: 
The effect of REPATHA on cardiovascular morbidity and mortality has not been determined.",Standard,Yes (indication [B] only),No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; REPATHA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for REPATHA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 72059,2016-25221,https://www.federalregister.gov/documents/2016/10/19/2016-25221/determination-of-regulatory-review-period-for-purposes-of-patent-extension-repatha,https://www.govinfo.gov/content/pkg/FR-2016-10-19/pdf/2016-25221.pdf,10/19/2016, REPATHA,,Jonathan,REPATHA,3,104,Jonathan,8030457; 8829165; and 8981064,,,,Amgen Inc.,2267,1901,366,2009-06-14,2009-06-14,2015-08-27,BLA 125522,164,125522,9/12/2013,Treatment of homozygous familial hypercholesterolemia,Designated/Approved,,,"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C.",8/27/2015,8/27/2022,"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C.",Amgen Inc.,Repatha,evolocumab,Amgen,BLA,125522,,2014-08-27,2015-08-27,2015,,"[A] REPATHA is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (CVD), who require additional lowering of low density lipoprotein cholesterol (LDL-C). 
[B] REPATHA is indicated as an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH) who require additional lowering of LDL-C.
Limitations of Use: 
The effect of REPATHA on cardiovascular morbidity and mortality has not been determined.",Standard,Yes (indication [B] only),No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; PLEGRIDY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PLEGRIDY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 72062,2016-25222,https://www.federalregister.gov/documents/2016/10/19/2016-25222/determination-of-regulatory-review-period-for-purposes-of-patent-extension-plegridy,https://www.govinfo.gov/content/pkg/FR-2016-10-19/pdf/2016-25222.pdf,10/19/2016, PLEGRIDY,,Jonathan,PLEGRIDY,3,107,Jonathan,7446173; 8017733; and 8524660,,,,Biogen Idec MA Inc.,2643,2186,457,2007-05-23,2007-05-23,2014-08-15,BLA 125499,346,125499,,,,,,,,,,,Plegridy,peginterferon beta-1a,Biogen Idec,BLA,125499,,2013-05-16,2014-08-15,2014,,PLEGRIDY (peginterferon beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; PRILOSEC OTC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for PRILOSEC OTC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 72060,2016-25220,https://www.federalregister.gov/documents/2016/10/19/2016-25220/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prilosec-otc,https://www.govinfo.gov/content/pkg/FR-2016-10-19/pdf/2016-25220.pdf,10/19/2016, PRILOSEC OTC,,Jonathan,PRILOSEC OTC,1,108,Jonathan,5817338,,,,AstraZeneca AB,2045,804,1241,1997-11-15,1997-11-15,2003-06-20,NDA 21-229,623,21229,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ANAVIP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ANAVIP and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 83845,2016-28049,https://www.federalregister.gov/documents/2016/11/22/2016-28049/determination-of-regulatory-review-period-for-purposes-of-patent-extension-anavip,https://www.govinfo.gov/content/pkg/FR-2016-11-22/pdf/2016-28049.pdf,11/22/2016, ANAVIP,,Jonathan,ANAVIP,1,109,Jonathan,6709655,,,,"Instituto Bioclon, SA de CV",4223,3443,780,2003-10-15,2003-10-15,2015-05-06,BLA 125488,5,125488,1/29/2004,Treatment of envenomation by Crotaline snakes,Designated/Approved,,,Management of adult and pediatric patients with North American rattlesnake envenomation,5/6/2015,5/6/2022,Management of adult and pediatric patients with North American rattlesnake envenomation,"Rare Disease Therapeutics, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ANAVIP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ANAVIP and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 83845,2016-28049,https://www.federalregister.gov/documents/2016/11/22/2016-28049/determination-of-regulatory-review-period-for-purposes-of-patent-extension-anavip,https://www.govinfo.gov/content/pkg/FR-2016-11-22/pdf/2016-28049.pdf,11/22/2016, ANAVIP,,Jonathan,ANAVIP,1,110,Jonathan,6709655,,,,"Instituto Bioclon, SA de CV",4223,3443,780,2003-10-15,2003-10-15,2015-05-06,BLA 125488,5,125488,1/29/2004,Treatment of envenomation by Crotaline snakes,Designated/Approved,,,For the management of adult and pediatric patients with North American Pit Viper envenomation,4/1/2021,,,"Rare Disease Therapeutics, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; RUCONEST,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for RUCONEST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 83850,2016-28046,https://www.federalregister.gov/documents/2016/11/22/2016-28046/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ruconest,https://www.govinfo.gov/content/pkg/FR-2016-11-22/pdf/2016-28046.pdf,11/22/2016, RUCONEST,,Jonathan,RUCONEST,2,112,Jonathan,7067713 and RE43691,,,,Pharming Intellectual Property B.V.,3502,3045,457,2004-12-15,2004-12-15,2014-07-16,BLA 125495,557,125495,2/23/1999,Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.,Designated/Approved,,,Treatment of acute attacks of hereditary angioedema (HAE) in adult and adolescent patients.,7/16/2014,7/16/2021,Treatment of acute attacks of hereditary angioedema (HAE) in adult and adolescent patients.,Pharming Group N.V.,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CERDELGA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CERDELGA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 83852,2016-28045,https://www.federalregister.gov/documents/2016/11/22/2016-28045/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cerdelga,https://www.govinfo.gov/content/pkg/FR-2016-11-22/pdf/2016-28045.pdf,11/22/2016, CERDELGA,,Jonathan,CERDELGA,1,113,Jonathan,7196205,,,,Genzyme Corporation,3854,3520,334,2004-02-01,2004-02-01,2014-08-19,NDA 205494,1518,205494,9/17/2008,Treatment of Type I Gaucher disease,Designated/Approved,,,"Long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.",8/19/2014,8/19/2021,"Long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.",Genzyme Corporation,Cerdelga,eliglustat,Genzyme,NDA,205494,,2013-09-20,2014-08-19,2014,,"CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test. 
Limitations of Use: 
- Patients who are CYP2D6 ultra-rapid metabolizers (URMs) may not achieve adequate concentrations of CERDELGA to achieve a therapeutic effect.  
- A specific dosage cannot be recommended for those patients whose CYP2D6 genotype cannot be determined (indeterminate metabolizers).",Priority,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; CORE VALVE SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for CORE VALVE SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",81 FR 83849,2016-28047,https://www.federalregister.gov/documents/2016/11/22/2016-28047/determination-of-regulatory-review-period-for-purposes-of-patent-extension-core-valve-system,https://www.govinfo.gov/content/pkg/FR-2016-11-22/pdf/2016-28047.pdf,11/22/2016, CORE VALVE SYSTEM,,Jonathan,,0,113,Jonathan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; IXINITY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IXINITY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 85965,2016-28653,https://www.federalregister.gov/documents/2016/11/29/2016-28653/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ixinity,https://www.govinfo.gov/content/pkg/FR-2016-11-29/pdf/2016-28653.pdf,11/29/2016, IXINITY,,Jonathan,IXINITY,2,115,Jonathan,7645602 and 8603823,,,,the University of North Carolina at Chapel Hill,2437,1318,1119,2008-08-28,2008-08-28,2015-04-29,BLA 125426,505,125426,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NUWIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NUWIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 85974,2016-28654,https://www.federalregister.gov/documents/2016/11/29/2016-28654/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nuwiq,https://www.govinfo.gov/content/pkg/FR-2016-11-29/pdf/2016-28654.pdf,11/29/2016, NUWIQ,,Jonathan,NUWIQ,1,116,Jonathan,7572619,,,,Octapharma AG,2622,2165,457,2008-07-02,2008-07-02,2015-09-04,BLA 125555,1336,125555,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TRUMENBA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TRUMENBA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87041,2016-28916,https://www.federalregister.gov/documents/2016/12/02/2016-28916/determination-of-regulatory-review-period-for-purposes-of-patent-extension-trumenba,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28916.pdf,12/2/2016, TRUMENBA,,Jonathan,TRUMENBA,2,118,Jonathan,8101194 and 8563007,,,,Wyeth Holdings LLC,2079,1943,136,2009-02-20,2009-02-20,2014-10-29,BLA 125549,573,125549,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; OPDIVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPDIVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87044,2016-28917,https://www.federalregister.gov/documents/2016/12/02/2016-28917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opdivo,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28917.pdf,12/2/2016, OPDIVO,,Jonathan,OPDIVO,1,119,Jonathan,8008449,,,,"E.R. Squibb & Sons, LLC",3071,2925,146,2006-07-28,2006-07-28,2014-12-22,BLA 125554,552,125554,1/23/2013,Treatment of Stage IIb to IV melanoma,Designated/Approved,,,adjuvant treatment of adult and pediatric patients 12 years and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,2/15/2023,2/15/2030,adjuvant treatment of pediatric patients 12 years and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,Bristol-Myers Squibb Co.,Opdivo,nivolumab,Bristol-Myers Squibb,BLA,125554,,2014-07-30,2014-12-22,2014,,"OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. _x000D_
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OPDIVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPDIVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87044,2016-28917,https://www.federalregister.gov/documents/2016/12/02/2016-28917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opdivo,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28917.pdf,12/2/2016, OPDIVO,,Jonathan,OPDIVO,1,120,Jonathan,8008449,,,,"E.R. Squibb & Sons, LLC",3071,2925,146,2006-07-28,2006-07-28,2014-12-22,BLA 125554,552,125554,8/22/2016,Treatment of esophageal cancer,Designated/Approved,,,"In combination with ipilimumab, for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC)",5/27/2022,5/27/2029,First-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC),Bristol-Myers Squibb Company,Opdivo,nivolumab,Bristol-Myers Squibb,BLA,125554,,2014-07-30,2014-12-22,2014,,"OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. _x000D_
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OPDIVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPDIVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87044,2016-28917,https://www.federalregister.gov/documents/2016/12/02/2016-28917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opdivo,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28917.pdf,12/2/2016, OPDIVO,,Jonathan,OPDIVO,1,121,Jonathan,8008449,,,,"E.R. Squibb & Sons, LLC",3071,2925,146,2006-07-28,2006-07-28,2014-12-22,BLA 125554,552,125554,8/22/2016,Treatment of esophageal cancer,Designated/Approved,,,"In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC)",5/27/2022,5/27/2029,First-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC),Bristol-Myers Squibb Company,Opdivo,nivolumab,Bristol-Myers Squibb,BLA,125554,,2014-07-30,2014-12-22,2014,,"OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. _x000D_
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OPDIVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPDIVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87044,2016-28917,https://www.federalregister.gov/documents/2016/12/02/2016-28917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opdivo,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28917.pdf,12/2/2016, OPDIVO,,Jonathan,OPDIVO,1,122,Jonathan,8008449,,,,"E.R. Squibb & Sons, LLC",3071,2925,146,2006-07-28,2006-07-28,2014-12-22,BLA 125554,552,125554,1/23/2013,Treatment of Stage IIb to IV melanoma,Designated/Approved,,,"As a single agent or in combination with ipilimumab, for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma",2/15/2023,2/15/2030,Treatment of pediatric patients 12 years and older with unresectable or metastatic melanoma,Bristol-Myers Squibb Co.,Opdivo,nivolumab,Bristol-Myers Squibb,BLA,125554,,2014-07-30,2014-12-22,2014,,"OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. _x000D_
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OPDIVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPDIVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87044,2016-28917,https://www.federalregister.gov/documents/2016/12/02/2016-28917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opdivo,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28917.pdf,12/2/2016, OPDIVO,,Jonathan,OPDIVO,1,123,Jonathan,8008449,,,,"E.R. Squibb & Sons, LLC",3071,2925,146,2006-07-28,2006-07-28,2014-12-22,BLA 125554,552,125554,12/20/2016,Treatment of gastric cancer and gastro-esophageal junction cancer,Designated/Approved,,,adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT),5/20/2021,5/20/2028,adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT),Bristol-Myers Squibb Company,Opdivo,nivolumab,Bristol-Myers Squibb,BLA,125554,,2014-07-30,2014-12-22,2014,,"OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. _x000D_
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OPDIVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPDIVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87044,2016-28917,https://www.federalregister.gov/documents/2016/12/02/2016-28917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opdivo,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28917.pdf,12/2/2016, OPDIVO,,Jonathan,OPDIVO,1,124,Jonathan,8008449,,,,"E.R. Squibb & Sons, LLC",3071,2925,146,2006-07-28,2006-07-28,2014-12-22,BLA 125554,552,125554,8/7/2014,Treatment of Hodgkin lymphoma,Designated/Approved,,,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin,5/17/2016,5/17/2023,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin,Bristol-Myers Squibb Company,Opdivo,nivolumab,Bristol-Myers Squibb,BLA,125554,,2014-07-30,2014-12-22,2014,,"OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. _x000D_
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OPDIVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPDIVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87044,2016-28917,https://www.federalregister.gov/documents/2016/12/02/2016-28917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opdivo,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28917.pdf,12/2/2016, OPDIVO,,Jonathan,OPDIVO,1,125,Jonathan,8008449,,,,"E.R. Squibb & Sons, LLC",3071,2925,146,2006-07-28,2006-07-28,2014-12-22,BLA 125554,552,125554,10/9/2014,Treatment of Stage IIb to Stage IV melanoma,Designated/Approved,,,"as a single agent or in combination with ipilimumab, for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma",2/15/2023,,,Bristol-Myers Squibb Company,Opdivo,nivolumab,Bristol-Myers Squibb,BLA,125554,,2014-07-30,2014-12-22,2014,,"OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. _x000D_
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OPDIVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPDIVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87044,2016-28917,https://www.federalregister.gov/documents/2016/12/02/2016-28917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opdivo,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28917.pdf,12/2/2016, OPDIVO,,Jonathan,OPDIVO,1,126,Jonathan,8008449,,,,"E.R. Squibb & Sons, LLC",3071,2925,146,2006-07-28,2006-07-28,2014-12-22,BLA 125554,552,125554,8/7/2014,Treatment of Hodgkin lymphoma,Designated/Approved,,,Treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin; or 3 or more lines of systemic therapy that includes autologous HSCT.,4/25/2017,4/25/2024,"Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after 3 or more lines of systemic therapy that includes autologous HSCT, not including any overlap with the orphan exclusivity awarded for the 2016 marketing approval of nivolumab for the treatment of adult patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin.",Bristol-Myers Squibb Company,Opdivo,nivolumab,Bristol-Myers Squibb,BLA,125554,,2014-07-30,2014-12-22,2014,,"OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. _x000D_
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OPDIVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPDIVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87044,2016-28917,https://www.federalregister.gov/documents/2016/12/02/2016-28917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opdivo,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28917.pdf,12/2/2016, OPDIVO,,Jonathan,OPDIVO,1,127,Jonathan,8008449,,,,"E.R. Squibb & Sons, LLC",3071,2925,146,2006-07-28,2006-07-28,2014-12-22,BLA 125554,552,125554,12/20/2016,Treatment of gastric cancer and gastro-esophageal junction cancer,Designated/Approved,,,"in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma",4/16/2021,4/16/2028,"treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma",Bristol-Myers Squibb Company,Opdivo,nivolumab,Bristol-Myers Squibb,BLA,125554,,2014-07-30,2014-12-22,2014,,"OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. _x000D_
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OPDIVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPDIVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87044,2016-28917,https://www.federalregister.gov/documents/2016/12/02/2016-28917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opdivo,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28917.pdf,12/2/2016, OPDIVO,,Jonathan,OPDIVO,1,128,Jonathan,8008449,,,,"E.R. Squibb & Sons, LLC",3071,2925,146,2006-07-28,2006-07-28,2014-12-22,BLA 125554,552,125554,8/22/2016,Treatment of esophageal cancer,Designated/Approved,,,"in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma",4/16/2021,4/16/2028,"treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma",Bristol-Myers Squibb Company,Opdivo,nivolumab,Bristol-Myers Squibb,BLA,125554,,2014-07-30,2014-12-22,2014,,"OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. _x000D_
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OPDIVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPDIVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87044,2016-28917,https://www.federalregister.gov/documents/2016/12/02/2016-28917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opdivo,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28917.pdf,12/2/2016, OPDIVO,,Jonathan,OPDIVO,1,129,Jonathan,8008449,,,,"E.R. Squibb & Sons, LLC",3071,2925,146,2006-07-28,2006-07-28,2014-12-22,BLA 125554,552,125554,8/22/2016,Treatment of esophageal cancer,Designated/Approved,,,adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT),5/20/2021,5/20/2028,adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT),Bristol-Myers Squibb Company,Opdivo,nivolumab,Bristol-Myers Squibb,BLA,125554,,2014-07-30,2014-12-22,2014,,"OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. _x000D_
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OPDIVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPDIVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87044,2016-28917,https://www.federalregister.gov/documents/2016/12/02/2016-28917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opdivo,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28917.pdf,12/2/2016, OPDIVO,,Jonathan,OPDIVO,1,130,Jonathan,8008449,,,,"E.R. Squibb & Sons, LLC",3071,2925,146,2006-07-28,2006-07-28,2014-12-22,BLA 125554,552,125554,1/23/2013,Treatment of Stage IIb to IV melanoma,Designated/Approved,,,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,12/20/2017,12/20/2024,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,Bristol-Myers Squibb Co.,Opdivo,nivolumab,Bristol-Myers Squibb,BLA,125554,,2014-07-30,2014-12-22,2014,,"OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. _x000D_
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OPDIVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPDIVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87044,2016-28917,https://www.federalregister.gov/documents/2016/12/02/2016-28917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opdivo,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28917.pdf,12/2/2016, OPDIVO,,Jonathan,OPDIVO,1,131,Jonathan,8008449,,,,"E.R. Squibb & Sons, LLC",3071,2925,146,2006-07-28,2006-07-28,2014-12-22,BLA 125554,552,125554,8/22/2016,Treatment of esophageal cancer,Designated/Approved,,,"Opdivo (nivolumab) indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.",6/10/2020,6/10/2027,"For the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.",Bristol-Myers Squibb Company,Opdivo,nivolumab,Bristol-Myers Squibb,BLA,125554,,2014-07-30,2014-12-22,2014,,"OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. _x000D_
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OPDIVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPDIVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87044,2016-28917,https://www.federalregister.gov/documents/2016/12/02/2016-28917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opdivo,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28917.pdf,12/2/2016, OPDIVO,,Jonathan,OPDIVO,1,132,Jonathan,8008449,,,,"E.R. Squibb & Sons, LLC",3071,2925,146,2006-07-28,2006-07-28,2014-12-22,BLA 125554,552,125554,1/23/2013,Treatment of Stage IIb to IV melanoma,Designated/Approved,,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor",12/22/2014,12/22/2021,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor",Bristol-Myers Squibb Co.,Opdivo,nivolumab,Bristol-Myers Squibb,BLA,125554,,2014-07-30,2014-12-22,2014,,"OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. _x000D_
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OPDIVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPDIVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87044,2016-28917,https://www.federalregister.gov/documents/2016/12/02/2016-28917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opdivo,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28917.pdf,12/2/2016, OPDIVO,,Jonathan,OPDIVO,1,133,Jonathan,8008449,,,,"E.R. Squibb & Sons, LLC",3071,2925,146,2006-07-28,2006-07-28,2014-12-22,BLA 125554,552,125554,1/23/2013,Treatment of Stage IIb to IV melanoma,Designated/Approved,,,"adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma",10/13/2023,10/13/2030,adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB or Stage IIC melanoma,Bristol-Myers Squibb Co.,Opdivo,nivolumab,Bristol-Myers Squibb,BLA,125554,,2014-07-30,2014-12-22,2014,,"OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. _x000D_
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OPDIVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for OPDIVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87044,2016-28917,https://www.federalregister.gov/documents/2016/12/02/2016-28917/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opdivo,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28917.pdf,12/2/2016, OPDIVO,,Jonathan,OPDIVO,1,134,Jonathan,8008449,,,,"E.R. Squibb & Sons, LLC",3071,2925,146,2006-07-28,2006-07-28,2014-12-22,BLA 125554,552,125554,9/15/2015,Treatment of small cell lung cancer.,Designated/Approved,,,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy. (Indication withdrawn),8/16/2018,12/29/2020,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy. (Indication withdrawn),Bristol-Myers Squibb Company,Opdivo,nivolumab,Bristol-Myers Squibb,BLA,125554,,2014-07-30,2014-12-22,2014,,"OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. _x000D_
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; TRESIBA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TRESIBA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",81 FR 87045,2016-28939,https://www.federalregister.gov/documents/2016/12/02/2016-28939/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tresiba,https://www.govinfo.gov/content/pkg/FR-2016-12-02/pdf/2016-28939.pdf,12/2/2016, TRESIBA,,Jonathan,TRESIBA,1,135,Jonathan,7615532,,,,Novo Nordisk A/S,2914,1456,1458,2007-10-05,2007-10-05,2015-09-25,NDA 203-314,1803,203314,,,,,,,,,,,Tresiba,insulin degludec,Novo Nordisk,BLA,203314,,2011-09-29,2015-09-25,2015,,"TRESIBA is indicated to improve glycemic control in adults with diabetes mellitus. 
Limitations of Use:
TRESIBA is not recommended for the treatment of diabetic ketoacidosis.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BEXSERO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BEXSERO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 87568,2016-29025,https://www.federalregister.gov/documents/2016/12/05/2016-29025/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bexsero,https://www.govinfo.gov/content/pkg/FR-2016-12-05/pdf/2016-29025.pdf,12/5/2016, BEXSERO,,Jonathan,BEXSERO,2,137,Jonathan,8273360 and 8663656,,,,GlaxoSmithKline Biologicals SA,3963,3779,184,2004-03-20,2004-03-20,2015-01-23,BLA 125546,255,125546,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; GARDASIL 9,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for GARDASIL 9 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 88245,2016-29303,https://www.federalregister.gov/documents/2016/12/07/2016-29303/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gardasil-9,https://www.govinfo.gov/content/pkg/FR-2016-12-07/pdf/2016-29303.pdf,12/7/2016, GARDASIL 9,,Jonathan,GARDASIL 9,2,139,Jonathan,7476389 and 7482015,,,,Merck Sharp & Dohme Corp. for CSL Limited,2662,2296,366,"types 6, 11",2007-08-29,2014-12-10,BLA 125508,1254,125508,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NUCALA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NUCALA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 89946,2016-29838,https://www.federalregister.gov/documents/2016/12/13/2016-29838/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nucala,https://www.govinfo.gov/content/pkg/FR-2016-12-13/pdf/2016-29838.pdf,12/13/2016, NUCALA,,Jonathan,NUCALA,1,140,Jonathan,5693323,,,,GlaxoSmithKline LLC,6862,6496,366,1997-01-22,1997-01-22,2015-11-04,BLA 125526,5,125526,7/14/2011,Treatment of Churg-Strauss Syndrome,Designated/Approved,,,NUCALA prefilled autoinjector and single syringe device is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).,6/6/2019,,,GlaxoSmithKline LLC,Nucala,mepolizumab,GlaxoSmithKline,BLA,125526,,2014-11-04,2015-11-04,2015,,"NUCALA is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Limitations of Use:
- NUCALA is not indicated for treatment of other eosinophilic conditions. 
- NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus. ",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; NUCALA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NUCALA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 89946,2016-29838,https://www.federalregister.gov/documents/2016/12/13/2016-29838/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nucala,https://www.govinfo.gov/content/pkg/FR-2016-12-13/pdf/2016-29838.pdf,12/13/2016, NUCALA,,Jonathan,NUCALA,1,141,Jonathan,5693323,,,,GlaxoSmithKline LLC,6862,6496,366,1997-01-22,1997-01-22,2015-11-04,BLA 125526,5,125526,7/14/2011,Treatment of Churg-Strauss Syndrome,Designated/Approved,,,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA),12/12/2017,12/12/2024,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA),GlaxoSmithKline LLC,Nucala,mepolizumab,GlaxoSmithKline,BLA,125526,,2014-11-04,2015-11-04,2015,,"NUCALA is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Limitations of Use:
- NUCALA is not indicated for treatment of other eosinophilic conditions. 
- NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus. ",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TRULICITY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for TRULICITY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 91938,2016-30399,https://www.federalregister.gov/documents/2016/12/19/2016-30399/determination-of-regulatory-review-period-for-purposes-of-patent-extension-trulicity,https://www.govinfo.gov/content/pkg/FR-2016-12-19/pdf/2016-30399.pdf,12/19/2016, TRULICITY,,Jonathan,TRULICITY,1,142,Jonathan,7452966,,,,Eli Lilly,3303,2937,366,2005-09-04,2005-09-04,2014-09-18,BLA 125469,1249,125469,,,,,,,,,,,Trulicity,dulaglutide,Eli Lilly,BLA,125469,,2013-09-18,2014-09-18,2014,,"TRULICITY is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 
Limitations of Use: 
- TRULICITY is not recommended as a first-line therapy for patients who have inadequate glycemic control on diet and exercise. 
- TRULICITY has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis. 
- TRULICITY should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. TRULICITY is not a substitute for insulin. 
- TRULICITY has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis. The use of TRULICITY is not recommended in patients with pre-existing severe gastrointestinal disease. 
- The concurrent use of TRULICITY and basal insulin has not been studied.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; COSENTYX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for COSENTYX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 92832,2016-30528,https://www.federalregister.gov/documents/2016/12/20/2016-30528/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cosentyx,https://www.govinfo.gov/content/pkg/FR-2016-12-20/pdf/2016-30528.pdf,12/20/2016, COSENTYX,,Jonathan,COSENTYX,1,143,Jonathan,7807155,,,,Novartis AG,3381,2926,455,2005-10-21,2005-10-21,2015-01-21,BLA 125504,629,125504,,,,,,,,,,,Cosentyx,secukinumab,Novartis Pharmaceuticals,BLA,125504,,2013-10-24,2015-01-21,2015,,COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; IMLYGIC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for IMLYGIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",81 FR 95618,2016-31322,https://www.federalregister.gov/documents/2016/12/28/2016-31322/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imlygic,https://www.govinfo.gov/content/pkg/FR-2016-12-28/pdf/2016-31322.pdf,12/28/2016, IMLYGIC,,Jonathan,IMLYGIC,3,146,Jonathan,7063835; 7223593; and 7537924,,,,BioVex Limited,3809,3352,457,2005-05-25,2005-05-25,2015-10-27,BLA 125518,1826,125518,3/14/2011,Treatment of stage IIb-stage IV melanoma,Designated/Approved,,,"Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery",10/27/2015,10/27/2022,"Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery","BioVex, Inc. (subsidiary of Amgen)",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; EMPLICITI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EMPLICITI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",82 FR 2380,2017-00108,https://www.federalregister.gov/documents/2017/01/09/2017-00108/determination-of-regulatory-review-period-for-purposes-of-patent-extension-empliciti,https://www.govinfo.gov/content/pkg/FR-2017-01-09/pdf/2017-00108.pdf,1/9/2017, EMPLICITI,,Jonathan,EMPLICITI,1,147,Jonathan,7709610,,,,"AbbVie Biotherapeutics, Inc.",3400,3245,155,2006-08-11,2006-08-11,2015-11-30,BLA 761035,1095,761035,9/1/2011,Treatment of multiple myeloma,Designated/Approved,,,EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.,11/6/2018,11/6/2025,"Indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, excluding adult patients covered by Emplicitis previously approved indication for multiple myeloma.",Bristol-Myers Squibb Co.,Empliciti,elotuzumab,Bristol-Myers Squibb,BLA,761035,,2015-06-29,2015-11-30,2015,,EMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.,Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; EMPLICITI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for EMPLICITI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",82 FR 2380,2017-00108,https://www.federalregister.gov/documents/2017/01/09/2017-00108/determination-of-regulatory-review-period-for-purposes-of-patent-extension-empliciti,https://www.govinfo.gov/content/pkg/FR-2017-01-09/pdf/2017-00108.pdf,1/9/2017, EMPLICITI,,Jonathan,EMPLICITI,1,148,Jonathan,7709610,,,,"AbbVie Biotherapeutics, Inc.",3400,3245,155,2006-08-11,2006-08-11,2015-11-30,BLA 761035,1095,761035,9/1/2011,Treatment of multiple myeloma,Designated/Approved,,,Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies,11/30/2015,11/30/2022,Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies,Bristol-Myers Squibb Co.,Empliciti,elotuzumab,Bristol-Myers Squibb,BLA,761035,,2015-06-29,2015-11-30,2015,,EMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.,Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ADYNOVATE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for ADYNOVATE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",82 FR 2378,2017-00095,https://www.federalregister.gov/documents/2017/01/09/2017-00095/determination-of-regulatory-review-period-for-purposes-of-patent-extension-adynovate,https://www.govinfo.gov/content/pkg/FR-2017-01-09/pdf/2017-00095.pdf,1/9/2017, ADYNOVATE,,Jonathan,ADYNOVATE,2,150,Jonathan,7199223 and 8247536,,,,Nektar Therapeutics,1061,707,354,2012-12-19,2012-12-19,2015-11-13,BLA 125566,708,125566,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; HETLIOZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HETLIOZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 27261,2017-12323,https://www.federalregister.gov/documents/2017/06/14/2017-12323/determination-of-regulatory-review-period-for-purposes-of-patent-extension-hetlioz,https://www.govinfo.gov/content/pkg/FR-2017-06-14/pdf/2017-12323.pdf,6/14/2017, HETLIOZ,,Jonathan,HETLIOZ,1,151,Jonathan,5856529,,,,"Vanda Pharmaceuticals, Inc.",5802,5556,246,1998-03-16,2013-05-31,2014-01-31,NDA 205677,5,205677,1/19/2010,Non-24-hour sleepwake disorder in blind individuals without light perception,Designated/Approved,,,Treatment of non-24-hour sleep-wake disorder,1/31/2014,1/31/2021,Treatment of non-24-hour sleep-wake disorder,"Vanda Pharmaceuticals, Inc.",Hetlioz,tasimelteon,Vanda Pharmaceuticals,NDA,205677,,2013-05-31,2014-01-31,2014,,HETLIOZ is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).,Priority,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; HETLIOZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HETLIOZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 27261,2017-12323,https://www.federalregister.gov/documents/2017/06/14/2017-12323/determination-of-regulatory-review-period-for-purposes-of-patent-extension-hetlioz,https://www.govinfo.gov/content/pkg/FR-2017-06-14/pdf/2017-12323.pdf,6/14/2017, HETLIOZ,,Jonathan,HETLIOZ,1,152,Jonathan,5856529,,,,"Vanda Pharmaceuticals, Inc.",5802,5556,246,1998-03-16,2013-05-31,2014-01-31,NDA 205677,5,205677,4/30/2010,Treatment of sleep disorder in Smith-Magenis syndrome associated with diurnal melatonin secretion,Designated/Approved,,,Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older,12/1/2020,12/1/2027,Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older.,"Vanda Pharmaceuticals, Inc.",Hetlioz,tasimelteon,Vanda Pharmaceuticals,NDA,205677,,2013-05-31,2014-01-31,2014,,HETLIOZ is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).,Priority,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; NEUROPACE RNS SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NEUROPACE RNS SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",82 FR 27266,2017-12322,https://www.federalregister.gov/documents/2017/06/14/2017-12322/determination-of-regulatory-review-period-for-purposes-of-patent-extension-neuropace-rns-system,https://www.govinfo.gov/content/pkg/FR-2017-06-14/pdf/2017-12322.pdf,6/14/2017, NEUROPACE RNS SYSTEM,,Jonathan,NEUROPACE RNS SYSTEM,3,155,Jonathan,6016449; 6360122; and 6810285,,,,"NeuroPace, Inc.",3796,2694,1102,2003-06-26,2003-06-26,2013-11-14,PMA P100026,5,100026,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NATPARA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for NATPARA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",82 FR 27496,2017-12359,https://www.federalregister.gov/documents/2017/06/15/2017-12359/determination-of-regulatory-review-period-for-purposes-of-patent-extension-natpara,https://www.govinfo.gov/content/pkg/FR-2017-06-15/pdf/2017-12359.pdf,6/15/2017, NATPARA,,Jonathan,NATPARA,1,156,Jonathan,5496801,,,,NPS Pharmaceuticals Inc.,7268,6811,457,1995-03-03,1995-03-03,2015-01-23,BLA 125511,5,125511,8/31/2007,Treatment of hypoparathyroidism,Designated/Approved,,,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism,1/23/2015,1/23/2022,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism,"Takeda Pharmaceuticals U.S.A., Inc.",Natpara,parathyroid hormone,NPS Pharmaceuticals,BLA,125511,,2013-10-24,2015-01-23,2015,,"NATPARA is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.  
Limitations of use: 
- Because of the potential risk of osteosarcoma, NATPARA is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. 
- NATPARA was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations.  
- NATPARA was not studied in patients with acute post-surgical hypoparathyroidism.",Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Intercept Blood System for Plasma,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for INTERCEPT BLOOD SYSTEM FOR PLASMA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",82 FR 31974,2017-14454,https://www.federalregister.gov/documents/2017/07/11/2017-14454/determination-of-regulatory-review-period-for-purposes-of-patent-extension-intercept-blood-system,https://www.govinfo.gov/content/pkg/FR-2017-07-11/pdf/2017-14454.pdf,7/11/2017, Intercept Blood System for Plasma,,Jonathan,INTERCEPT BLOOD SYSTEM FOR PLASMA,2,158,Jonathan,5593823 and 6951713,,,,Cerus Corporation,6497,6114,383,1997-03-05,1997-03-05,2014-12-16,PMA BP130076,1860,130076,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Intercept Blood System for Platelets,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Intercept Blood System for Platelets and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",82 FR 32002,2017-14455,https://www.federalregister.gov/documents/2017/07/11/2017-14455/determination-of-regulatory-review-period-for-purposes-of-patent-extension-intercept-blood-system,https://www.govinfo.gov/content/pkg/FR-2017-07-11/pdf/2017-14455.pdf,7/11/2017, Intercept Blood System for Platelets,,Jonathan,Intercept Blood System for Platelets,2,160,Jonathan,7037642 and 7611831,,,,Cerus Corporation,7080,6909,171,1995-08-02,1995-08-02,2014-12-18,PMA BP140143,999,140143,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CINQAIR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CINQAIR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",82 FR 36790,2017-16516,https://www.federalregister.gov/documents/2017/08/07/2017-16516/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cinqair,https://www.govinfo.gov/content/pkg/FR-2017-08-07/pdf/2017-16516.pdf,8/7/2017, CINQAIR,,Jonathan,CINQAIR,1,161,Jonathan,RE39548,,,,UCB Celltech,5685,5325,360,2000-08-31,2000-08-31,2016-03-23,BLA 761033,1660,761033,,,,,,,,,,,Cinqair,reslizumab,Teva Respiratory,BLA,761033,,2015-03-30,2016-03-23,2016,,"CINQAIR is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype.
Limitation of Use:
- CINQAIR is not indicated for treatment of other eosinophilic conditions.
- CINQAIR is not indicated for the relief of acute bronchospasm or status asthmaticus.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VONVENDI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VONVENDI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",82 FR 36794,2017-16515,https://www.federalregister.gov/documents/2017/08/07/2017-16515/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vonvendi,https://www.govinfo.gov/content/pkg/FR-2017-08-07/pdf/2017-16515.pdf,8/7/2017, VONVENDI,,Jonathan,VONVENDI,3,164,Jonathan,6465624; 6531577; and 6579723,,,,Baxalta GmbH,2690,2335,355,2008-07-29,2008-07-29,2015-12-08,BLA 125577,1521,125577,11/23/2010,Treatment of von Willebrand disease,Designated/Approved,,,For use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 VWD receiving on-demand therapy,1/28/2022,1/28/2029,For use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 VWD receiving on-demand therapy,"Takeda Pharmaceuticals U.S.A., Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; RECUVYRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RECUVYRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that animal drug product.",82 FR 39587,2017-17566,https://www.federalregister.gov/documents/2017/08/21/2017-17566/determination-of-regulatory-review-period-for-purposes-of-patent-extension-recuvyra,https://www.govinfo.gov/content/pkg/FR-2017-08-21/pdf/2017-17566.pdf,8/21/2017, RECUVYRA,,Jonathan,RECUVYRA,3,167,Jonathan,6299900; 6818226; and 6916486,,,,Acrux DDS Pty. Ltd.,2092,2037,55,2006-10-03,2012-06-23,2012-06-23,NADA 141-337,1279,141337,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; RECUVYRA; Affirmation,Notice,Health and Human Services Department; Food and Drug Administration,,82 FR 40008,2017-17961,https://www.federalregister.gov/documents/2017/08/23/2017-17961/determination-of-regulatory-review-period-for-purposes-of-patent-extension-recuvyra-affirmation,https://www.govinfo.gov/content/pkg/FR-2017-08-23/pdf/2017-17961.pdf,8/23/2017, RECUVYRA, Affirmation,Jonathan,,0,167,Jonathan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; XTORO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XTORO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 41271,2017-18379,https://www.federalregister.gov/documents/2017/08/30/2017-18379/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xtoro,https://www.govinfo.gov/content/pkg/FR-2017-08-30/pdf/2017-18379.pdf,8/30/2017, XTORO,,Jonathan,XTORO,1,168,Jonathan,6133260,,,,Alcon Pharmaceutials Ltd. for Bayer Intellectual Property GmbH,1880,1643,237,2009-10-26,2009-10-26,2014-12-17,NDA 206307,1058,206307,,,,,,,,,,,Xtoro,finafloxacin,Alcon Research,NDA,206307,,2014-04-25,2014-12-17,2014,,"XTORO (finafloxacin otic suspension), 0.3% is indicated for the treatment of acute otitis externa (AOE) with or without an otowick, caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus inpatients age 1 year and older.",Priority,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KENGREAL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KENGREAL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 41274,2017-18380,https://www.federalregister.gov/documents/2017/08/30/2017-18380/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kengreal,https://www.govinfo.gov/content/pkg/FR-2017-08-30/pdf/2017-18380.pdf,8/30/2017, KENGREAL,,Jonathan,KENGREAL,2,170,Jonathan,6114313 and 6130208,,,,AstraZeneca UK Limited,6122,5338,784,1998-09-19,1998-09-19,2015-06-22,NDA 204958,5,204958,,,,,,,,,,,Kengreal,cangrelor,The Medicines Company,NDA,204958,,2013-04-30,2015-06-22,2015,,"KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KOVALTRY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KOVALTRY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",82 FR 46496,2017-21421,https://www.federalregister.gov/documents/2017/10/05/2017-21421/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kovaltry,https://www.govinfo.gov/content/pkg/FR-2017-10-05/pdf/2017-21421.pdf,10/5/2017, KOVALTRY,,Jonathan,KOVALTRY,1,171,Jonathan,5804420,,,,Bayer HealthCare LLC,2478,2021,457,2009-06-05,2009-06-05,2016-03-16,BLA 125574,1466,125574,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TECFIDERA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TECFIDERA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 46502,2017-21435,https://www.federalregister.gov/documents/2017/10/05/2017-21435/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tecfidera,https://www.govinfo.gov/content/pkg/FR-2017-10-05/pdf/2017-21435.pdf,10/5/2017, TECFIDERA,,Jonathan,TECFIDERA,4,175,Jonathan,6509376; 7320999; 7619001; and 7803840,,,,Biogen Idec International GmbH,2480,2085,395,2006-06-14,2006-06-14,2013-03-27,NDA 204063,654,204063,,,,,,,,,,,Tecfidera,dimethyl fumarate,Biogen Idec,NDA,204063,,2012-02-27,2013-03-27,2013,,TECFIDERA is indicated for the treatment of patients with relapsing forms of multiple sclerosis.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; IMPELLA 2.5 SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMPELLA 2.5 SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",82 FR 46498,2017-21436,https://www.federalregister.gov/documents/2017/10/05/2017-21436/determination-of-regulatory-review-period-for-purposes-of-patent-extension-impella-25-system,https://www.govinfo.gov/content/pkg/FR-2017-10-05/pdf/2017-21436.pdf,10/5/2017, IMPELLA 2.5 SYSTEM,,Jonathan,,0,175,Jonathan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; OBIZUR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OBIZUR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",82 FR 49031,2017-22898,https://www.federalregister.gov/documents/2017/10/23/2017-22898/determination-of-regulatory-review-period-for-purposes-of-patent-extension-obizur,https://www.govinfo.gov/content/pkg/FR-2017-10-23/pdf/2017-22898.pdf,10/23/2017, OBIZUR,,Jonathan,OBIZUR,3,178,Jonathan,6180371; 6458563; and 7560107,,,,Emory University,4216,3883,333,2003-04-10,2003-04-10,2014-10-23,BLA 125512,5,125512,3/16/2004,Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII,Designated/Approved,,,Treatment of bleeding episodes in adults with acquired hemophilia A.,10/23/2014,10/23/2021,Treatment of bleeding episodes in adults with acquired hemophilia A.,"Takeda Development Center Americas, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MITRACLIP CDS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MITRACLIP CDS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",82 FR 49027,2017-22895,https://www.federalregister.gov/documents/2017/10/23/2017-22895/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mitraclip-cds,https://www.govinfo.gov/content/pkg/FR-2017-10-23/pdf/2017-22895.pdf,10/23/2017, MITRACLIP CDS,,Jonathan,,0,178,Jonathan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Inspire Upper Airway Stimulation System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Inspire Upper Airway Stimulation System (Inspire UAS System) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",82 FR 49029,2017-22897,https://www.federalregister.gov/documents/2017/10/23/2017-22897/determination-of-regulatory-review-period-for-purposes-of-patent-extension-inspire-upper-airway,https://www.govinfo.gov/content/pkg/FR-2017-10-23/pdf/2017-22897.pdf,10/23/2017, Inspire Upper Airway Stimulation System,,Jonathan,INSPIRE UAS SYSTEM,1,179,Jonathan,6021352,,,,"Inspire Medical Systems, Inc.",2002,1653,349,2008-11-07,2008-11-07,2014-04-30,PMA P130008,1184,130008,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; RAPIVAB,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RAPIVAB and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 56244,2017-25676,https://www.federalregister.gov/documents/2017/11/28/2017-25676/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rapivab,https://www.govinfo.gov/content/pkg/FR-2017-11-28/pdf/2017-25676.pdf,11/28/2017, RAPIVAB,,Jonathan,RAPIVAB,2,181,Jonathan,6503745 and 6562861,,,,"BioCryst Pharmaceuticals, Inc.",3287,2925,362,2005-12-21,2013-12-23,2014-12-19,NDA 206426,1824,206426,,,,,,,,,,,Rapivab,peramivir,BioCryst Pharmaceuticals,NDA,206426,,2013-12-23,2014-12-19,2014,,"RAPIVAB is indicated for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than 2 days. 
Limitations of Use: 
- Efficacy of RAPIVAB is based on clinical trials of naturally occurring influenza in which the predominant influenza infections were influenza A virus; a limited number of subjects infected with influenza B virus were enrolled. 
- Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness.  Other factors (for example, change in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patters and treatment effects when deciding whether to use RAPIVAB.  
- The efficacy of RAPIVAB could not be established in patients with serious influenza requiring hospitalization.",Standard,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; YONDELIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for YONDELIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 56246,2017-25683,https://www.federalregister.gov/documents/2017/11/28/2017-25683/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yondelis,https://www.govinfo.gov/content/pkg/FR-2017-11-28/pdf/2017-25683.pdf,11/28/2017, YONDELIS,,Jonathan,YONDELIS,1,182,Jonathan,7420051,,,,"Pharma Mar, S.A.",7107,6773,334,1996-05-10,1996-05-10,2015-10-23,NDA 207953,1471,207953,9/30/2004,Treatment of soft tissue sarcoma,Designated/Approved,,,For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen,10/23/2015,10/23/2022,For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen,"Janssen Research & Development, LLC",Yondelis,trabectedin,Janssen Products,NDA,207953,,2014-11-24,2015-10-23,2015,,YONDELIS is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.,Priority,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SAVAYSA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SAVAYSA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 56252,2017-25703,https://www.federalregister.gov/documents/2017/11/28/2017-25703/determination-of-regulatory-review-period-for-purposes-of-patent-extension-savaysa,https://www.govinfo.gov/content/pkg/FR-2017-11-28/pdf/2017-25703.pdf,11/28/2017, SAVAYSA,,Jonathan,SAVAYSA,1,183,Jonathan,7365205,,,,"Daiichi Sankyo Co., Ltd.",10,3845,3479,2004-07-01,2014-01-08,2015-01-08,NDA 206316,1406,206316,,,,,,,,,,,Savaysa,edoxaban tosylate,Daiichi Sankyo,NDA,206316,,2014-01-08,2015-01-08,2015,,"SAVAYSA is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). 
Limitation of Use for NVAF: 
SAVAYSA should not be used in patients with CrCL > 95 mL/min because of an increased risk of ischemic stroke compared to warfarin. SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ZERBAXA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZERBAXA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 56253,2017-25682,https://www.federalregister.gov/documents/2017/11/28/2017-25682/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zerbaxa,https://www.govinfo.gov/content/pkg/FR-2017-11-28/pdf/2017-25682.pdf,11/28/2017, ZERBAXA,,Jonathan,ZERBAXA,1,184,Jonathan,7129232,,,,"Astellas Pharma, Inc.",2360,2117,243,2008-07-05,2008-07-05,2014-12-19,NDA 206829,1302,206829,,,,,,,,,,,Zerbaxa,"ceftolozane, tazobactam",Cubist Pharmaceuticals,NDA,206829,,2014-04-21,2014-12-19,2014,,"ZERBAXA (ceftolozane/tazobactam) for Injection is indicated for the treatment of patients 18 years or older with the following infections caused by designated susceptible microorganisms. 
ZERBAXA used in combination with metronidazole is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by the following Gram-negative and Gram-positive microorganisms: Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumonia, Proteus mirabilis, Pseudomonas aeruginosa, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, and Streptococcus salivarius. 
ZERBAXA is indicated for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following Gram-negative microorganisms: Escherichia coli, Klebsiella pneumonia, Proteus mirabilis, and Pseudomonas aeruginosa. 
Usage: 
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZERBAXA and other antibacterial drugs, ZERBAXA should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; Senza Spinal Cord Stimulation System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Senza Spinal Cord Stimulation System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",82 FR 56250,2017-25684,https://www.federalregister.gov/documents/2017/11/28/2017-25684/determination-of-regulatory-review-period-for-purposes-of-patent-extension-senza-spinal-cord,https://www.govinfo.gov/content/pkg/FR-2017-11-28/pdf/2017-25684.pdf,11/28/2017, Senza Spinal Cord Stimulation System,,Jonathan,Senza Spinal Cord Stimulation System,2,186,Jonathan,8712533 and 8768472,,,,Nevro Corporation,1136,820,316,2012-03-30,2012-03-30,2015-05-08,PMA P130022,312,130022,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; XURIDEN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XURIDEN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 56605,2017-25770,https://www.federalregister.gov/documents/2017/11/29/2017-25770/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xuriden,https://www.govinfo.gov/content/pkg/FR-2017-11-29/pdf/2017-25770.pdf,11/29/2017, XURIDEN,,Jonathan,XURIDEN,1,187,Jonathan,6258795,,,,Wellstat Therapeutics Corp.,8494,8254,240,1992-06-04,1992-06-04,2015-09-04,NDA 208169,5,208169,,,,,,,,,,,Xuriden,uridine triacetate,Wellstat Therapeutics,NDA,208169,,2015-01-08,2015-09-04,2015,,XURIDEN is indicated for the treatment of hereditary orotic aciduria.,Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VELTASSA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VELTASSA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 56609,2017-25761,https://www.federalregister.gov/documents/2017/11/29/2017-25761/determination-of-regulatory-review-period-for-purposes-of-patent-extension-veltassa,https://www.govinfo.gov/content/pkg/FR-2017-11-29/pdf/2017-25761.pdf,11/29/2017, VELTASSA,,Jonathan,VELTASSA,1,188,Jonathan,8147873,,,,"Relypsa, Inc.",2844,2478,366,2008-01-09,2014-10-21,2015-10-21,NDA 205739,832,205739,,,,,,,,,,,Veltassa,patiromer,Relypsa,NDA,205739,,2014-10-21,2015-10-21,2015,,"Veltassa is indicated for the treatment of hyperkalemia._x000D_
Limitation of Use: Veltassa should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; REXULTI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REXULTI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 56612,2017-25772,https://www.federalregister.gov/documents/2017/11/29/2017-25772/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rexulti,https://www.govinfo.gov/content/pkg/FR-2017-11-29/pdf/2017-25772.pdf,11/29/2017, REXULTI,,Jonathan,REXULTI,1,189,Jonathan,7888362,,,,"Otsuka Pharmaceutical Co., Ltd.",2636,2271,365,2008-04-23,2008-04-23,2015-07-10,NDA 205422,868,205422,,,,,,,,,,,Rexulti,brexpiprazole,Otsuka Pharmaceutical,NDA,205422,,2014-07-11,2015-07-10,2015,,"REXULTI is indicated for:
- Adjunctive treatment of major depressive disorder (MDD).
- Treatment of schizophrenia.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SOLX SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SOLX SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 56613,2017-25773,https://www.federalregister.gov/documents/2017/11/29/2017-25773/determination-of-regulatory-review-period-for-purposes-of-patent-extension-solx-system,https://www.govinfo.gov/content/pkg/FR-2017-11-29/pdf/2017-25773.pdf,11/29/2017, SOLX SYSTEM,,Jonathan,,0,189,Jonathan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ADVANTAME,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ADVANTAME and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that food additive.",82 FR 56828,2017-25780,https://www.federalregister.gov/documents/2017/11/30/2017-25780/determination-of-regulatory-review-period-for-purposes-of-patent-extension-advantame,https://www.govinfo.gov/content/pkg/FR-2017-11-30/pdf/2017-25780.pdf,11/30/2017, ADVANTAME,,Jonathan,,0,189,Jonathan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SIVEXTRO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SIVEXTRO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 61008,2017-27684,https://www.federalregister.gov/documents/2017/12/26/2017-27684/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sivextro,https://www.govinfo.gov/content/pkg/FR-2017-12-26/pdf/2017-27684.pdf,12/26/2017, SIVEXTRO,,Jonathan,SIVEXTRO,1,190,Jonathan,7816379,,,,"Trius Therapeutics, Inc.",2366,2123,243,2007-12-30,2007-12-30,2014-06-20,NDA 205435,118,205435,,,,,,,,,,,Sivextro,tedizolid phosphate,Cubist Pharmaceuticals,NDA,205435,205436,2013-10-21,2014-06-20,2014,,"SIVEXTRO is an oxazolidinone-class antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecalis. 
Usage: 
To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat ABSSSI that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ZYKADIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZYKADIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 61010,2017-27745,https://www.federalregister.gov/documents/2017/12/26/2017-27745/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zykadia,https://www.govinfo.gov/content/pkg/FR-2017-12-26/pdf/2017-27745.pdf,12/26/2017, ZYKADIA,,Jonathan,,0,190,Jonathan,,,,,,,,,,,,,,,9/27/2013,Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive,Designated/Approved,,,ZYKADIA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic nonsmall cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.,4/29/2014,4/29/2021,Treatment of patients with anaplastic lymphoma kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.,Novartis Pharmaceuticals Corp.,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZYKADIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZYKADIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 61010,2017-27745,https://www.federalregister.gov/documents/2017/12/26/2017-27745/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zykadia,https://www.govinfo.gov/content/pkg/FR-2017-12-26/pdf/2017-27745.pdf,12/26/2017, ZYKADIA,,Jonathan,,0,190,Jonathan,,,,,,,,,,,,,,,9/27/2013,Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive,Designated/Approved,,,Treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test,5/26/2017,5/26/2024,Treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test,Novartis Pharmaceuticals Corp.,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; STRIVERDI RESPIMAT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for STRIVERDI RESPIMAT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",82 FR 61006,2017-27710,https://www.federalregister.gov/documents/2017/12/26/2017-27710/determination-of-regulatory-review-period-for-purposes-of-patent-extension-striverdi-respimat,https://www.govinfo.gov/content/pkg/FR-2017-12-26/pdf/2017-27710.pdf,12/26/2017, STRIVERDI RESPIMAT,,Jonathan,STRIVERDI RESPIMAT,1,191,Jonathan,7727984,,,,Boehringer Ingelheim Pharma GmbH & Co. KG,2712,1903,809,2007-02-28,2012-05-14,2014-07-31,NDA 203108,1166,203108,,,,,,,,,,,Striverdi Respimat,olodaterol,Boehringer Ingelheim Pharmaceuticals,NDA,203108,,2012-05-14,2014-07-31,2014,,"STRIVERDI RESPIMAT is a long-acting beta2-agonist indicated for long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. _x000D_
STRIVERDI RESPIMAT is not indicated to treat acute deteriorations of COPD._x000D_
STRIVERDI RESPIMAT is not indicated to treat asthma. The safety and effectiveness of STRIVERDI RESPIMAT in asthma have not been established.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; EPANOVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EPANOVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 1366,2018-00353,https://www.federalregister.gov/documents/2018/01/11/2018-00353/determination-of-regulatory-review-period-for-purposes-of-patent-extension-epanova,https://www.govinfo.gov/content/pkg/FR-2018-01-11/pdf/2018-00353.pdf,1/11/2018, EPANOVA,,Jonathan,EPANOVA,4,195,Jonathan,5948818; 7960370; 7792795; and 8383678,,,,AstraZeneca Pharmaceuticals LP,4269,3964,305,2002-08-29,2002-08-29,2014-05-05,NDA 205060,682,205060,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ENTYCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ENTYCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that animal drug product.",83 FR 1365,2018-00358,https://www.federalregister.gov/documents/2018/01/11/2018-00358/determination-of-regulatory-review-period-for-purposes-of-patent-extension-entyce,https://www.govinfo.gov/content/pkg/FR-2018-01-11/pdf/2018-00358.pdf,1/11/2018, ENTYCE,,Jonathan,ENTYCE,2,197,Jonathan,6107306 and 6673929,,,,RaQualia Pharma Inc.,1645,1589,56,2011-11-16,2016-05-16,2016-05-16,NADA 141-457,1827,141457,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MICRA TRANSCATHETER PACING SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MICRA TRANSCATHETER PACING SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 1370,2018-00355,https://www.federalregister.gov/documents/2018/01/11/2018-00355/determination-of-regulatory-review-period-for-purposes-of-patent-extension-micra-transcatheter,https://www.govinfo.gov/content/pkg/FR-2018-01-11/pdf/2018-00355.pdf,1/11/2018, MICRA TRANSCATHETER PACING SYSTEM,,Jonathan,MICRA TRANSCATHETER PACING SYSTEM,2,199,Jonathan,7824805 and 8129622,,,,"Medtronic, Inc.",788,585,203,2014-02-10,2014-02-10,2016-04-06,PMA P150033,494,150033,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PROACT ADJUSTABLE CONTINENCE THERAPY FOR MEN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PROACT ADJUSTABLE CONTINENCE THERAPY FOR MEN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 1620,2018-00404,https://www.federalregister.gov/documents/2018/01/12/2018-00404/determination-of-regulatory-review-period-for-purposes-of-patent-extension-proact-adjustable,https://www.govinfo.gov/content/pkg/FR-2018-01-12/pdf/2018-00404.pdf,1/12/2018, PROACT ADJUSTABLE CONTINENCE THERAPY FOR MEN,,Jonathan,PROACT ADJUSTABLE CONTINENCE THERAPY FOR MEN,2,201,Jonathan,7014606 and 7828716,,,,"Uromedica, Inc.",3892,3179,713,2005-03-31,2005-03-31,2015-11-24,PMA 130018,1827,130018,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DAKLINZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DAKLINZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 2454,2018-00675,https://www.federalregister.gov/documents/2018/01/17/2018-00675/determination-of-regulatory-review-period-for-purposes-of-patent-extension-daklinza,https://www.govinfo.gov/content/pkg/FR-2018-01-17/pdf/2018-00675.pdf,1/17/2018, DAKLINZA,,Jonathan,DAKLINZA,1,202,Jonathan,8329159,,,,Bristol-Myers Squibb Company,2808,2327,481,2007-11-17,2007-11-17,2015-07-24,NDA 206843,467,206843,,,,,,,,,,,Daklinza,daclatasvir,Bristol-Myers Squibb,NDA,206843,,2014-03-31,2015-07-24,2015,,"DAKLINZA is indicated for use with sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection.
Limitations of Use:
- Sustained virologic response (SVR) rates are reduced in HCV genotype 3-infected patients with cirrhosis receiving DAKLINZA in combination with sofosbuvir for 12 weeks.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AVYCAZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AVYCAZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 2449,2018-00678,https://www.federalregister.gov/documents/2018/01/17/2018-00678/determination-of-regulatory-review-period-for-purposes-of-patent-extension-avycaz,https://www.govinfo.gov/content/pkg/FR-2018-01-17/pdf/2018-00678.pdf,1/17/2018, AVYCAZ,,Jonathan,AVYCAZ,1,203,Jonathan,7112592,,,,Forest Laboratories Holdings Ltd.,2579,2333,246,2008-02-05,2014-06-25,2015-02-25,NDA 206494,1411,206494,,,,,,,,,,,Avycaz,ceftazidime and avibactam,Forest Research Institute,NDA,206494,,2014-06-25,2015-02-25,2015,,"AVYCAZ (ceftazidime-avibactam), in combination with metronidazole, is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Providencia stuartii, Enterobacter cloacae, Klebsiella oxytoca, and Pseudomonas aeruginosa in patients 18 years or older. 
As only limited clinical safety and efficacy data for AVYCAZ are currently available, reserve AVYCAZ for use in patients who have limited or no alternative treatment options. 
AVYCAZ (ceftazidime-avibactam) is indicated for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter koseri, Enterobacter aerogenes, Enterobacter cloacae, Citrobacter freundii, Proteus spp., and Pseudomonas aeruginosa in patients 18 years or older. 
As only limited clinical safety and efficacy data for AVYCAZ are currently available, reserve AVYCAZ for use in patients who have limited or no alternative treatment options. 
Usage: 
To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVYCAZ and other antibacterial drugs, AVYCAZ should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AXUMIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AXUMIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 2459,2018-00684,https://www.federalregister.gov/documents/2018/01/17/2018-00684/determination-of-regulatory-review-period-for-purposes-of-patent-extension-axumin,https://www.govinfo.gov/content/pkg/FR-2018-01-17/pdf/2018-00684.pdf,1/17/2018, AXUMIN,,Jonathan,AXUMIN,1,204,Jonathan,5808146,,,,Emory University,4006,3763,243,2005-06-10,2005-06-10,2016-05-27,NDA 208054,5,208054,,,,,,,,,,,Axumin,fluciclovine F 18,Blue Earth Diagnostics,NDA,208054,,2015-09-28,2016-05-27,2016,,Axumin is indicated for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.,Priority,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SYNERGY EVEROLIMUS-ELUTING PLATINUM CHROMIUM CORONARY STENT SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SYNERGY EVEROLIMUS-ELUTING PLATINUM CHROMIUM CORONARY STENT SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 2452,2018-00679,https://www.federalregister.gov/documents/2018/01/17/2018-00679/determination-of-regulatory-review-period-for-purposes-of-patent-extension-synergy,https://www.govinfo.gov/content/pkg/FR-2018-01-17/pdf/2018-00679.pdf,1/17/2018, SYNERGY EVEROLIMUS-ELUTING PLATINUM CHROMIUM CORONARY STENT SYSTEM,,Jonathan,SYNERGY,1,205,Jonathan,8348992,,,,"Boston Scientific Scimed, Inc.",1206,950,256,2012-06-15,2012-06-15,2015-10-02,PMA P150003,629,150003,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NINLARO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NINLARO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 3000,2018-00994,https://www.federalregister.gov/documents/2018/01/22/2018-00994/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ninlaro,https://www.govinfo.gov/content/pkg/FR-2018-01-22/pdf/2018-00994.pdf,1/22/2018, NINLARO,,Jonathan,NINLARO,4,209,Jonathan,7442830; 7687662; 8003819; and 8859504,,,,"Millennium Pharmaceuticals, Inc.",2538,2404,134,2008-12-10,2008-12-10,2015-11-20,NDA 208462,157,208462,2/18/2011,Treatment of multiple myeloma,Designated/Approved,,,Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy,11/20/2015,11/20/2022,Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy,"Takeda Development Center Americas, Inc.",Ninlaro,ixazomib,Millennium Pharmaceuticals,NDA,208462,,2015-07-10,2015-11-20,2015,,NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.,Priority,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ZURAMPIC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZURAMPIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 2999,2018-00992,https://www.federalregister.gov/documents/2018/01/22/2018-00992/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zurampic,https://www.govinfo.gov/content/pkg/FR-2018-01-22/pdf/2018-00992.pdf,1/22/2018, ZURAMPIC,,Jonathan,ZURAMPIC,5,214,Jonathan,8003681; 8084483; 8283369; 8357713; and 8546437,,,,"Ardea Biosciences, Inc.",2245,1886,359,2009-10-31,2009-10-31,2015-12-22,NDA 207988,237,207988,,,,,,,,,,,Zurampic,lesinurad,Ardea Biosciences,NDA,207988,,2014-12-29,2015-12-22,2015,,"ZURAMPIC is indicated in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone.
Limitations of Use:
ZURAMPIC is not recommended for the treatment of asymptomatic hyperuricemia. 
ZURAMPIC should not be used as monotherapy.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; PERCEVAL SUTURELESS HEART VALVE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PERCEVAL SUTURELESS HEART VALVE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 2997,2018-00995,https://www.federalregister.gov/documents/2018/01/22/2018-00995/determination-of-regulatory-review-period-for-purposes-of-patent-extension-perceval-sutureless-heart,https://www.govinfo.gov/content/pkg/FR-2018-01-22/pdf/2018-00995.pdf,1/22/2018, PERCEVAL SUTURELESS HEART VALVE,,Jonathan,PERCEVAL SUTURELESS HEART VALVE,1,215,Jonathan,8540768,,,,Sorin Group Italia S.r.l.,1003,694,309,2013-04-12,2013-04-12,2016-01-08,PMA P150011,576,150011,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; VARUBI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VARUBI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 3732,2018-01373,https://www.federalregister.gov/documents/2018/01/26/2018-01373/determination-of-regulatory-review-period-for-purposes-of-patent-extension-varubi,https://www.govinfo.gov/content/pkg/FR-2018-01-26/pdf/2018-01373.pdf,1/26/2018, VARUBI,,Jonathan,VARUBI,1,216,Jonathan,7049320,,,,"OPKO Health, Inc.",3070,2708,362,2007-04-08,2007-04-08,2015-09-01,NDA 206500,1716,206500,,,,,,,,,,,Varubi,rolapitant,Tesaro,NDA,206500,,2014-09-05,2015-09-01,2015,,"VARUBI is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VRAYLAR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VRAYLAR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 3737,2018-01368,https://www.federalregister.gov/documents/2018/01/26/2018-01368/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vraylar,https://www.govinfo.gov/content/pkg/FR-2018-01-26/pdf/2018-01368.pdf,1/26/2018, VRAYLAR,,Jonathan,VRAYLAR,2,218,Jonathan,7737142 and 7943621,,,,"Forest Laboratories, LLC",3742,2709,1033,2005-06-21,2005-06-21,2015-09-17,NDA 204370,275,204370,,,,,,,,,,,Vraylar,cariprazine,Forest Laboratories,NDA,204370,,2012-11-19,2015-09-17,2015,,"VRAYLAR is indicated for the: 
- Treatment of schizophrenia.
- Acute treatment of manic or mixed episodes associated with bipolar I disorder.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; UPTRAVI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for UPTRAVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 4219,2018-01637,https://www.federalregister.gov/documents/2018/01/30/2018-01637/determination-of-regulatory-review-period-for-purposes-of-patent-extension-uptravi,https://www.govinfo.gov/content/pkg/FR-2018-01-30/pdf/2018-01637.pdf,1/30/2018, UPTRAVI,,Jonathan,UPTRAVI,1,219,Jonathan,7205302,,,,"Actelion Pharmaceuticals, Ltd.",2246,1881,365,2009-10-29,2009-10-29,2015-12-21,NDA 207947,1305,207947,4/30/2010,Treatment of pulmonary arterial hypertension,Designated/Approved,,,"For treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH",12/21/2015,12/21/2022,"For treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH",Actelion Pharmaceuticals Ltd,Uptravi,selexipag,Actelion Pharmaceuticals,NDA,207947,,2014-12-22,2015-12-21,2015,,"UPTRAVI is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH._x000D_
Effectiveness was established in a long-term study in PAH patients with WHO Functional Class II-III symptoms._x000D_
Patients had idiopathic and heritable PAH (58%), PAH associated with connective tissue disease (29%), PAH associated with congenital heart disease with repaired shunts (10%).",Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; UPTRAVI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for UPTRAVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 4219,2018-01637,https://www.federalregister.gov/documents/2018/01/30/2018-01637/determination-of-regulatory-review-period-for-purposes-of-patent-extension-uptravi,https://www.govinfo.gov/content/pkg/FR-2018-01-30/pdf/2018-01637.pdf,1/30/2018, UPTRAVI,,Jonathan,UPTRAVI,1,220,Jonathan,7205302,,,,"Actelion Pharmaceuticals, Ltd.",2246,1881,365,2009-10-29,2009-10-29,2015-12-21,NDA 207947,1305,207947,4/30/2010,Treatment of pulmonary arterial hypertension,Designated/Approved,,,"Treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH",7/29/2021,,,Actelion Pharmaceuticals Ltd,Uptravi,selexipag,Actelion Pharmaceuticals,NDA,207947,,2014-12-22,2015-12-21,2015,,"UPTRAVI is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH._x000D_
Effectiveness was established in a long-term study in PAH patients with WHO Functional Class II-III symptoms._x000D_
Patients had idiopathic and heritable PAH (58%), PAH associated with connective tissue disease (29%), PAH associated with congenital heart disease with repaired shunts (10%).",Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ZEPATIER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZEPATIER and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 4213,2018-01642,https://www.federalregister.gov/documents/2018/01/30/2018-01642/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zepatier,https://www.govinfo.gov/content/pkg/FR-2018-01-30/pdf/2018-01642.pdf,1/30/2018, ZEPATIER,,Jonathan,ZEPATIER,1,221,Jonathan,7973040,,,,Merck Sharp & Dohme Corp.,1865,1619,246,2010-12-22,2010-12-22,2016-01-28,NDA 208-261,188,208261,,,,,,,,,,,Zepatier,elbasvir and grazoprevir,Merck,NDA,208261,,2015-05-28,2016-01-28,2016,,ZEPATIER is indicated with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 or 4 infection in adults.,Priority,No,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; GALLIPRANT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GALLIPRANT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that animal drug product.",83 FR 4214,2018-01640,https://www.federalregister.gov/documents/2018/01/30/2018-01640/determination-of-regulatory-review-period-for-purposes-of-patent-extension-galliprant,https://www.govinfo.gov/content/pkg/FR-2018-01-30/pdf/2018-01640.pdf,1/30/2018, GALLIPRANT,,Jonathan,,0,221,Jonathan,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LONSURF,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LONSURF and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 4223,2018-01641,https://www.federalregister.gov/documents/2018/01/30/2018-01641/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lonsurf,https://www.govinfo.gov/content/pkg/FR-2018-01-30/pdf/2018-01641.pdf,1/30/2018, LONSURF,,Jonathan,LONSURF,2,223,Jonathan,6479500 and 7799783,,,,"Taiho Pharmaceutical Co., Ltd.",6083,5805,278,1999-01-28,2014-12-19,2015-09-22,NDA 207981,1013,207981,4/17/2017,Treatment of gastric cancer including cancer of the gastroesophageal junction,Designated/Approved,,,"LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.",2/22/2019,2/22/2026,"LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.","Taiho Oncology, Inc.",Lonsurf,trifluridine and tipiracil,Taiho Oncology,NDA,207981,,2014-12-19,2015-09-22,2015,,"LONSURF is indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.",Standard,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; VIEKIRA PAK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VIEKIRA PAK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 4218,2018-01651,https://www.federalregister.gov/documents/2018/01/30/2018-01651/determination-of-regulatory-review-period-for-purposes-of-patent-extension-viekira-pak,https://www.govinfo.gov/content/pkg/FR-2018-01-30/pdf/2018-01651.pdf,1/30/2018, VIEKIRA PAK,,Jonathan,VIEKIRA PAK,1,224,Jonathan,8501238,,,,AbbVie Inc.,2391,2148,243,2008-06-04,2014-04-21,2014-12-19,NDA 206619,93,206619,,,,,,,,,,,Viekira Pak,"ombitasvir, paritaprevir, ritonavir; dasabuvir (co-packaged)",AbbVie,NDA,206619,,2014-04-21,2014-12-19,2014,,"VIEKIRA PAK with or without ribavirin is indicated for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis.  
Limitation of Use:  
VIEKIRA PAK is not recommended for use in patients with decompensated liver disease.",Priority,No,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; Cardiomems HF Monitoring System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CARDIOMEMS HF MONITORING SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 4211,2018-01644,https://www.federalregister.gov/documents/2018/01/30/2018-01644/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cardiomems-hf-monitoring,https://www.govinfo.gov/content/pkg/FR-2018-01-30/pdf/2018-01644.pdf,1/30/2018, Cardiomems HF Monitoring System,,Jonathan,CARDIOMEMS HF MONITORING SYSTEM,1,225,Jonathan,7839153,,,,"CardioMEMS, Inc.",2786,1525,1261,2006-10-13,2006-10-13,2014-05-28,PMA P100045,1026,100045,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SAPIEN 3 TRANSCATHETER HEART VALVE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SAPIEN 3 TRANSCATHETER HEART VALVE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 4224,2018-01655,https://www.federalregister.gov/documents/2018/01/30/2018-01655/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sapien-3-transcatheter,https://www.govinfo.gov/content/pkg/FR-2018-01-30/pdf/2018-01655.pdf,1/30/2018, SAPIEN 3 TRANSCATHETER HEART VALVE,,Jonathan,SAPIEN 3 TRANSCATHETER HEART VALVE,2,227,Jonathan,7585321 and 8591575,,,,"Edwards Lifesciences PVT, Inc.",30,1736,1558,2010-09-17,2010-09-17,2015-06-17,PMA P140031,250,140031,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CRESEMBA-New Drug Aapplication 207500,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CRESEMBA as approved under new drug application (NDA) 207500 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product as approved under NDA 207500.",83 FR 4221,2018-01645,https://www.federalregister.gov/documents/2018/01/30/2018-01645/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cresemba-new-drug,https://www.govinfo.gov/content/pkg/FR-2018-01-30/pdf/2018-01645.pdf,1/30/2018, CRESEMBA-New Drug Aapplication 207500,,Jonathan,CRESEMBA as approved under NDA 207500,2,229,Jonathan,6812238 and 7459561,,,,Basilea Pharmaceutica International Ltd.,3528,3286,242,2005-07-10,2018-04-02,2015-03-06,NDA 207500,1264,207500,,,,,,,,,,,Cresemba,isavuconazonium sulfate,Astellas Pharma,NDA,207500,207501,2014-07-08,2015-03-06,2015,,"CRESEMBA is an azole antifungal indicated for patients 18 years of age and older for the treatment of invasive aspergillosis.
CRESEMBA is an azole antifungal indicated for patients 18 years of age and older for the treatment of invasive mucormycosis.
Usage:
Specimens for fungal culture and other relevant laboratory studies (including histopathology) to isolate and identify causative organism(s) should be obtained prior to initiating antifungal therapy. Therapy may be instituted before the results of the cultures and other laboratory studies are known. However, once these results become available, antifungal therapy should be adjusted accordingly.",Priority,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LENVIMA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LENVIMA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 4489,2018-01920,https://www.federalregister.gov/documents/2018/01/31/2018-01920/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lenvima,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01920.pdf,1/31/2018, LENVIMA,,Jonathan,LENVIMA,1,230,Jonathan,7253286,,,,"EISAI R&D Management Co., Ltd.",3580,3396,184,2005-04-28,2014-08-14,2015-02-13,NDA 206947,1465,206947,3/27/2014,Treatment of hepatocellular carcinoma,Designated/Approved,,,LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC),8/15/2018,8/15/2025,LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC),Eisai Inc.,Lenvima,lenvatinib,Eisai,NDA,206947,,2014-08-14,2015-02-13,2015,,"LENVIMA is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).",Priority,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LENVIMA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LENVIMA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 4489,2018-01920,https://www.federalregister.gov/documents/2018/01/31/2018-01920/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lenvima,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01920.pdf,1/31/2018, LENVIMA,,Jonathan,LENVIMA,1,231,Jonathan,7253286,,,,"EISAI R&D Management Co., Ltd.",3580,3396,184,2005-04-28,2014-08-14,2015-02-13,NDA 206947,1465,206947,12/27/2012,"Treatment of follicullar, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer",Designated/Approved,,,"Treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancer",2/13/2015,2/13/2022,"Treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancer","Eisai, Inc.",Lenvima,lenvatinib,Eisai,NDA,206947,,2014-08-14,2015-02-13,2015,,"LENVIMA is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).",Priority,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; DUAVEE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DUAVEE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 4487,2018-01894,https://www.federalregister.gov/documents/2018/01/31/2018-01894/determination-of-regulatory-review-period-for-purposes-of-patent-extension-duavee,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01894.pdf,1/31/2018, DUAVEE,,Jonathan,DUAVEE,2,233,Jonathan,5998402 and 6479535,,,,Wyeth LLC,5683,5317,366,1998-03-15,2012-10-03,2013-10-03,NDA 022247,5,22247,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; KEYTRUDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEYTRUDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 4492,2018-01890,https://www.federalregister.gov/documents/2018/01/31/2018-01890/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keytruda,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01890.pdf,1/31/2018, KEYTRUDA,,Jonathan,KEYTRUDA,1,234,Jonathan,8354509,,,,Merck Sharp & Dohme B.V.,1338,1148,190,2011-01-07,2011-01-07,2014-09-04,BLA 125514,83,125514,6/16/2015,"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma",Designated/Approved,,,"in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma",11/16/2023,11/16/2030,"for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma, excluding patients covered by Keytruda's previous indications for gastric or GEJ adenocarcinoma",Merck Sharp & Dohme LLC,Keytruda,pembrolizumab,Merck Sharp & Dohme,BLA,125514,,2014-02-27,2014-09-04,2014,,"KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KEYTRUDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEYTRUDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 4492,2018-01890,https://www.federalregister.gov/documents/2018/01/31/2018-01890/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keytruda,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01890.pdf,1/31/2018, KEYTRUDA,,Jonathan,KEYTRUDA,1,235,Jonathan,8354509,,,,Merck Sharp & Dohme B.V.,1338,1148,190,2011-01-07,2011-01-07,2014-09-04,BLA 125514,83,125514,11/19/2012,Treatment of Stage IIB through IV malignant melanoma,Designated/Approved,,,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.,2/15/2019,2/15/2026,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.,Merck Sharp & Dohme LLC,Keytruda,pembrolizumab,Merck Sharp & Dohme,BLA,125514,,2014-02-27,2014-09-04,2014,,"KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KEYTRUDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEYTRUDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 4492,2018-01890,https://www.federalregister.gov/documents/2018/01/31/2018-01890/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keytruda,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01890.pdf,1/31/2018, KEYTRUDA,,Jonathan,KEYTRUDA,1,236,Jonathan,8354509,,,,Merck Sharp & Dohme B.V.,1338,1148,190,2011-01-07,2011-01-07,2014-09-04,BLA 125514,83,125514,11/19/2012,Treatment of Stage IIB through IV malignant melanoma,Designated/Approved,,,Treatment of patients with unresectable or metastatic melanoma.,12/18/2015,12/18/2022,Initial treatment of patients with unresectable or metastatic melanoma,Merck Sharp & Dohme LLC,Keytruda,pembrolizumab,Merck Sharp & Dohme,BLA,125514,,2014-02-27,2014-09-04,2014,,"KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KEYTRUDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEYTRUDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 4492,2018-01890,https://www.federalregister.gov/documents/2018/01/31/2018-01890/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keytruda,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01890.pdf,1/31/2018, KEYTRUDA,,Jonathan,KEYTRUDA,1,237,Jonathan,8354509,,,,Merck Sharp & Dohme B.V.,1338,1148,190,2011-01-07,2011-01-07,2014-09-04,BLA 125514,83,125514,1/14/2016,Treatment of primary mediastinal B cell lymphoma.,Designated/Approved,,,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy",6/13/2018,6/13/2025,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy",Merck Sharp & Dohme LLC,Keytruda,pembrolizumab,Merck Sharp & Dohme,BLA,125514,,2014-02-27,2014-09-04,2014,,"KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KEYTRUDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEYTRUDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 4492,2018-01890,https://www.federalregister.gov/documents/2018/01/31/2018-01890/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keytruda,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01890.pdf,1/31/2018, KEYTRUDA,,Jonathan,KEYTRUDA,1,238,Jonathan,8354509,,,,Merck Sharp & Dohme B.V.,1338,1148,190,2011-01-07,2011-01-07,2014-09-04,BLA 125514,83,125514,12/28/2016,Treatment of Merkel cell carcinoma,Designated/Approved,,,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma,12/19/2018,12/19/2025,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma,Merck Sharp & Dohme LLC,Keytruda,pembrolizumab,Merck Sharp & Dohme,BLA,125514,,2014-02-27,2014-09-04,2014,,"KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KEYTRUDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEYTRUDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 4492,2018-01890,https://www.federalregister.gov/documents/2018/01/31/2018-01890/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keytruda,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01890.pdf,1/31/2018, KEYTRUDA,,Jonathan,KEYTRUDA,1,239,Jonathan,8354509,,,,Merck Sharp & Dohme B.V.,1338,1148,190,2011-01-07,2011-01-07,2014-09-04,BLA 125514,83,125514,10/3/2017,Treatment of Small Cell Lung Cancer,Designated/Approved,,,KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. (Indication withdrawn),6/17/2019,3/30/2021,Indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. (Indication withdrawn),"Merck Sharp & Dohme, LLC",Keytruda,pembrolizumab,Merck Sharp & Dohme,BLA,125514,,2014-02-27,2014-09-04,2014,,"KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KEYTRUDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEYTRUDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 4492,2018-01890,https://www.federalregister.gov/documents/2018/01/31/2018-01890/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keytruda,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01890.pdf,1/31/2018, KEYTRUDA,,Jonathan,KEYTRUDA,1,240,Jonathan,8354509,,,,Merck Sharp & Dohme B.V.,1338,1148,190,2011-01-07,2011-01-07,2014-09-04,BLA 125514,83,125514,6/15/2017,Treatment of esophageal carcinoma,Designated/Approved,,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.",7/30/2019,7/30/2026,"Indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (Combined Positive Score [CPS] =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.","Merck Sharp & Dohme, LLC",Keytruda,pembrolizumab,Merck Sharp & Dohme,BLA,125514,,2014-02-27,2014-09-04,2014,,"KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KEYTRUDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEYTRUDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 4492,2018-01890,https://www.federalregister.gov/documents/2018/01/31/2018-01890/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keytruda,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01890.pdf,1/31/2018, KEYTRUDA,,Jonathan,KEYTRUDA,1,241,Jonathan,8354509,,,,Merck Sharp & Dohme B.V.,1338,1148,190,2011-01-07,2011-01-07,2014-09-04,BLA 125514,83,125514,11/19/2012,Treatment of Stage IIB through IV malignant melanoma,Designated/Approved,,,"adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection",12/3/2021,12/3/2028,"adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC melanoma following complete resection, and adjuvant treatment of pediatric (12 years and older) patients with Stage III melanoma following complete resection",Merck Sharp & Dohme LLC,Keytruda,pembrolizumab,Merck Sharp & Dohme,BLA,125514,,2014-02-27,2014-09-04,2014,,"KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KEYTRUDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEYTRUDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 4492,2018-01890,https://www.federalregister.gov/documents/2018/01/31/2018-01890/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keytruda,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01890.pdf,1/31/2018, KEYTRUDA,,Jonathan,KEYTRUDA,1,242,Jonathan,8354509,,,,Merck Sharp & Dohme B.V.,1338,1148,190,2011-01-07,2011-01-07,2014-09-04,BLA 125514,83,125514,6/16/2015,"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma",Designated/Approved,,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy (Indication withdrawn)",9/22/2017,2/4/2022,"Treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) >or =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu targeted therapy excluding microsatellite instability-high or mismatch repair deficient gastric or gastroesophageal adenocarcinomas that have progressed and have no satisfactory alternative treatment options (Indication withdrawn)",Merck Sharp & Dohme LLC,Keytruda,pembrolizumab,Merck Sharp & Dohme,BLA,125514,,2014-02-27,2014-09-04,2014,,"KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KEYTRUDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEYTRUDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 4492,2018-01890,https://www.federalregister.gov/documents/2018/01/31/2018-01890/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keytruda,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01890.pdf,1/31/2018, KEYTRUDA,,Jonathan,KEYTRUDA,1,243,Jonathan,8354509,,,,Merck Sharp & Dohme B.V.,1338,1148,190,2011-01-07,2011-01-07,2014-09-04,BLA 125514,83,125514,10/9/2019,Treatment of Biliary Tract Carcinoma,Designated/Approved,,,"in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC)",10/31/2023,10/31/2030,treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC),"Merck Sharp & Dohme, LLC",Keytruda,pembrolizumab,Merck Sharp & Dohme,BLA,125514,,2014-02-27,2014-09-04,2014,,"KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KEYTRUDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEYTRUDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 4492,2018-01890,https://www.federalregister.gov/documents/2018/01/31/2018-01890/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keytruda,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01890.pdf,1/31/2018, KEYTRUDA,,Jonathan,KEYTRUDA,1,244,Jonathan,8354509,,,,Merck Sharp & Dohme B.V.,1338,1148,190,2011-01-07,2011-01-07,2014-09-04,BLA 125514,83,125514,6/15/2017,Treatment of esophageal carcinoma,Designated/Approved,,,"treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation, in combination with platinum- and fluoropyrimidine-based chemotherapy",3/22/2021,3/22/2028,"treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation, excluding patients covered by Keytrudas previously approved indication for esophageal cancer","Merck Sharp & Dohme, LLC",Keytruda,pembrolizumab,Merck Sharp & Dohme,BLA,125514,,2014-02-27,2014-09-04,2014,,"KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KEYTRUDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEYTRUDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 4492,2018-01890,https://www.federalregister.gov/documents/2018/01/31/2018-01890/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keytruda,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01890.pdf,1/31/2018, KEYTRUDA,,Jonathan,KEYTRUDA,1,245,Jonathan,8354509,,,,Merck Sharp & Dohme B.V.,1338,1148,190,2011-01-07,2011-01-07,2014-09-04,BLA 125514,83,125514,6/12/2017,Treatment of hepatocellular carcinoma (HCC),Designated/Approved,,,treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen,1/25/2024,1/25/2031,treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen and other than sorafenib,Merck Sharp & Dohme LLC,Keytruda,pembrolizumab,Merck Sharp & Dohme,BLA,125514,,2014-02-27,2014-09-04,2014,,"KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KEYTRUDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEYTRUDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 4492,2018-01890,https://www.federalregister.gov/documents/2018/01/31/2018-01890/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keytruda,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01890.pdf,1/31/2018, KEYTRUDA,,Jonathan,KEYTRUDA,1,246,Jonathan,8354509,,,,Merck Sharp & Dohme B.V.,1338,1148,190,2011-01-07,2011-01-07,2014-09-04,BLA 125514,83,125514,6/12/2017,Treatment of hepatocellular carcinoma (HCC),Designated/Approved,,,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,11/9/2018,11/9/2025,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,Merck Sharp & Dohme LLC,Keytruda,pembrolizumab,Merck Sharp & Dohme,BLA,125514,,2014-02-27,2014-09-04,2014,,"KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KEYTRUDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEYTRUDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 4492,2018-01890,https://www.federalregister.gov/documents/2018/01/31/2018-01890/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keytruda,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01890.pdf,1/31/2018, KEYTRUDA,,Jonathan,KEYTRUDA,1,247,Jonathan,8354509,,,,Merck Sharp & Dohme B.V.,1338,1148,190,2011-01-07,2011-01-07,2014-09-04,BLA 125514,83,125514,12/30/2015,Treatment of Hodgkin lymphoma.,Designated/Approved,,,"Treatment for adult and pediatric patients with refractory classical Hodgkin Lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy.",3/14/2017,3/14/2024,"Treatment of adult and pediatric patients with refractory classical Hodgkin Lymphoma, or who have relapsed after 3 or more prior lines of therapy.",Merck Sharp & Dohme LLC,Keytruda,pembrolizumab,Merck Sharp & Dohme,BLA,125514,,2014-02-27,2014-09-04,2014,,"KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KEYTRUDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEYTRUDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 4492,2018-01890,https://www.federalregister.gov/documents/2018/01/31/2018-01890/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keytruda,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01890.pdf,1/31/2018, KEYTRUDA,,Jonathan,KEYTRUDA,1,248,Jonathan,8354509,,,,Merck Sharp & Dohme B.V.,1338,1148,190,2011-01-07,2011-01-07,2014-09-04,BLA 125514,83,125514,12/30/2015,Treatment of Hodgkin lymphoma.,Designated/Approved,,,"treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL); and treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy",10/14/2020,,,Merck Sharp & Dohme LLC,Keytruda,pembrolizumab,Merck Sharp & Dohme,BLA,125514,,2014-02-27,2014-09-04,2014,,"KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KEYTRUDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEYTRUDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 4492,2018-01890,https://www.federalregister.gov/documents/2018/01/31/2018-01890/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keytruda,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01890.pdf,1/31/2018, KEYTRUDA,,Jonathan,KEYTRUDA,1,249,Jonathan,8354509,,,,Merck Sharp & Dohme B.V.,1338,1148,190,2011-01-07,2011-01-07,2014-09-04,BLA 125514,83,125514,6/16/2015,"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma",Designated/Approved,,,"in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma",5/5/2021,5/5/2028,"for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, excluding patients covered by Keytruda's previous indication for gastric or GEJ adenocarcinoma approved on September 22, 2017",Merck Sharp & Dohme LLC,Keytruda,pembrolizumab,Merck Sharp & Dohme,BLA,125514,,2014-02-27,2014-09-04,2014,,"KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KEYTRUDA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEYTRUDA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 4492,2018-01890,https://www.federalregister.gov/documents/2018/01/31/2018-01890/determination-of-regulatory-review-period-for-purposes-of-patent-extension-keytruda,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01890.pdf,1/31/2018, KEYTRUDA,,Jonathan,KEYTRUDA,1,250,Jonathan,8354509,,,,Merck Sharp & Dohme B.V.,1338,1148,190,2011-01-07,2011-01-07,2014-09-04,BLA 125514,83,125514,11/19/2012,Treatment of Stage IIB through IV malignant melanoma,Designated/Approved,,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.",9/4/2014,9/4/2021,,Merck Sharp & Dohme LLC,Keytruda,pembrolizumab,Merck Sharp & Dohme,BLA,125514,,2014-02-27,2014-09-04,2014,,"KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; MOBI-C CERVICAL DISC PROSTHESIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MOBI-C CERVICAL DISC PROSTHESIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 4490,2018-01889,https://www.federalregister.gov/documents/2018/01/31/2018-01889/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mobi-c-cervical-disc,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01889.pdf,1/31/2018, MOBI-C CERVICAL DISC PROSTHESIS,,Jonathan,MOBI-C CERVICAL DISC PROSTHESIS,1,251,Jonathan,8627999,,,,Beaurain et al.,2758,1821,937,2006-01-20,2006-01-20,2013-08-07,PMA P110002,323,110002,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SAPIEN XT TRANSCATHETER HEART VALVE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SAPIEN XT TRANSCATHETER HEART VALVE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 4486,2018-01891,https://www.federalregister.gov/documents/2018/01/31/2018-01891/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sapien-xt-transcatheter,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01891.pdf,1/31/2018, SAPIEN XT TRANSCATHETER HEART VALVE,,Jonathan,SAPIEN XT TRANSCATHETER HEART VALVE,2,253,Jonathan,7510575 and 7585321,,,,"Edwards Lifesciences PVT, Inc.",30,1370,959,"the 23, 26",2010-09-17,2014-06-16,PMA P130009,889,130009,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CRESEMBA-New Drug Application 207501,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CRESEMBA as approved under new drug application (NDA) 207501 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product as approved under NDA 207501.",83 FR 4494,2018-01892,https://www.federalregister.gov/documents/2018/01/31/2018-01892/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cresemba-new-drug,https://www.govinfo.gov/content/pkg/FR-2018-01-31/pdf/2018-01892.pdf,1/31/2018, CRESEMBA-New Drug Application 207501,,Jonathan,CRESEMBA as approved under NDA 207501,2,255,Jonathan,6812238 and 7459561,,,,Basilea Pharmaceutica International Ltd.,3528,3286,242,2018-04-02,2018-04-02,2015-03-06,NDA 207501,1264,207501,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CORLANOR,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CORLANOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 4661,2018-01979,https://www.federalregister.gov/documents/2018/02/01/2018-01979/determination-of-regulatory-review-period-for-purposes-of-patent-extension-corlanor,https://www.govinfo.gov/content/pkg/FR-2018-02-01/pdf/2018-01979.pdf,2/1/2018, CORLANOR,,Jonathan,CORLANOR,2,257,Jonathan,7879842 and 7867996,,,,Les Laboratoires Servier,293,0,293,2014-06-27,2014-06-27,2015-04-15,NDA 206143,292,206143,3/23/2016,Treatment of pediatric patients (0 through 16 years of age) with dilated cardiomyopathy.,Designated/Approved,,,"Corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.",4/22/2019,4/22/2026,"Corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.","Amgen, Inc.,",Corlanor,ivabradine,Amgen,NDA,206143,,2014-06-27,2015-04-15,2015,,"Corlanor is indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction <= 35%, who are in sinus rhythm with resting heart rate >= 70 beats per minute and either are on maximally tolerated doses of betablockers or have a contraindication to beta-blocker use.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; VIBERZI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VIBERZI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5105,2018-02187,https://www.federalregister.gov/documents/2018/02/05/2018-02187/determination-of-regulatory-review-period-for-purposes-of-patent-extension-viberzi,https://www.govinfo.gov/content/pkg/FR-2018-02-05/pdf/2018-02187.pdf,2/5/2018, VIBERZI,,Nicolas,VIBERZI,3,260,Jonathan,7741356; 8344011; and 8609709,,,,"Janssen Pharmaceutica, N.V.",2716,2381,335,2007-12-21,2014-06-27,2015-05-27,NDA 206940,431,206940,,,,,,,,,,,Viberzi,eluxadoline,Furiex Pharmaceuticals,NDA,206940,,2014-06-27,2015-05-27,2015,,VIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).,Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; FARXIGA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FARXIGA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5436,2018-02418,https://www.federalregister.gov/documents/2018/02/07/2018-02418/determination-of-regulatory-review-period-for-purposes-of-patent-extension-farxiga,https://www.govinfo.gov/content/pkg/FR-2018-02-07/pdf/2018-02418.pdf,2/7/2018, FARXIGA,,Nicolas,FARXIGA,2,262,Jonathan,6414126 and 6515117,,,,AstraZeneca AB,3673,2565,1108,2003-12-21,2003-12-21,2014-01-08,NDA 202293,1825,202293,,,,,,,,,,,Farxiga,dapagliflozin,Bristol-Myers Squibb,NDA,202293,,2010-12-28,2014-01-08,2014,,FARXIGA is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of use: Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BLINCYTO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BLINCYTO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 5440,2018-02419,https://www.federalregister.gov/documents/2018/02/07/2018-02419/determination-of-regulatory-review-period-for-purposes-of-patent-extension-blincyto,https://www.govinfo.gov/content/pkg/FR-2018-02-07/pdf/2018-02419.pdf,2/7/2018, BLINCYTO,,Nicolas,BLINCYTO,2,264,Jonathan,7112324 and 8007796,,,,Amgen Research (Munich) GMBH,2850,2774,76,2007-02-15,2007-02-15,2014-12-03,BLA 125557,432,125557,5/16/2008,Treatment of acute lymphocytic leukemia,Designated/Approved,,,treatment of CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy in adult and pediatric patients one month and older,6/14/2024,6/14/2031,treatment of CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy in adult and pediatric patients one month and older,"Amgen, Inc.",Blincyto,blinatumomab,Amgen,BLA,125557,,2014-09-19,2014-12-03,2014,,"BLINCYTO is indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). _x000D_
This indication is approved under accelerated approval.  Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BLINCYTO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BLINCYTO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 5440,2018-02419,https://www.federalregister.gov/documents/2018/02/07/2018-02419/determination-of-regulatory-review-period-for-purposes-of-patent-extension-blincyto,https://www.govinfo.gov/content/pkg/FR-2018-02-07/pdf/2018-02419.pdf,2/7/2018, BLINCYTO,,Nicolas,BLINCYTO,2,266,Jonathan,7112324 and 8007796,,,,Amgen Research (Munich) GMBH,2850,2774,76,2007-02-15,2007-02-15,2014-12-03,BLA 125557,432,125557,5/16/2008,Treatment of acute lymphocytic leukemia,Designated/Approved,,,treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children,7/11/2017,7/11/2024,treatment of Philadelphia chromosome-positive relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children,"Amgen, Inc.",Blincyto,blinatumomab,Amgen,BLA,125557,,2014-09-19,2014-12-03,2014,,"BLINCYTO is indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). _x000D_
This indication is approved under accelerated approval.  Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BLINCYTO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BLINCYTO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 5440,2018-02419,https://www.federalregister.gov/documents/2018/02/07/2018-02419/determination-of-regulatory-review-period-for-purposes-of-patent-extension-blincyto,https://www.govinfo.gov/content/pkg/FR-2018-02-07/pdf/2018-02419.pdf,2/7/2018, BLINCYTO,,Nicolas,BLINCYTO,2,268,Jonathan,7112324 and 8007796,,,,Amgen Research (Munich) GMBH,2850,2774,76,2007-02-15,2007-02-15,2014-12-03,BLA 125557,432,125557,5/16/2008,Treatment of acute lymphocytic leukemia,Designated/Approved,,,treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL),8/30/2016,8/30/2023,treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in patients weighing less than 45 kg,"Amgen, Inc.",Blincyto,blinatumomab,Amgen,BLA,125557,,2014-09-19,2014-12-03,2014,,"BLINCYTO is indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). _x000D_
This indication is approved under accelerated approval.  Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BLINCYTO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BLINCYTO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 5440,2018-02419,https://www.federalregister.gov/documents/2018/02/07/2018-02419/determination-of-regulatory-review-period-for-purposes-of-patent-extension-blincyto,https://www.govinfo.gov/content/pkg/FR-2018-02-07/pdf/2018-02419.pdf,2/7/2018, BLINCYTO,,Nicolas,BLINCYTO,2,270,Jonathan,7112324 and 8007796,,,,Amgen Research (Munich) GMBH,2850,2774,76,2007-02-15,2007-02-15,2014-12-03,BLA 125557,432,125557,5/16/2008,Treatment of acute lymphocytic leukemia,Designated/Approved,,,BLINCYTO is indicated for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children.,3/29/2018,3/29/2025,For the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children,"Amgen, Inc.",Blincyto,blinatumomab,Amgen,BLA,125557,,2014-09-19,2014-12-03,2014,,"BLINCYTO is indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). _x000D_
This indication is approved under accelerated approval.  Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BLINCYTO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BLINCYTO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 5440,2018-02419,https://www.federalregister.gov/documents/2018/02/07/2018-02419/determination-of-regulatory-review-period-for-purposes-of-patent-extension-blincyto,https://www.govinfo.gov/content/pkg/FR-2018-02-07/pdf/2018-02419.pdf,2/7/2018, BLINCYTO,,Nicolas,BLINCYTO,2,272,Jonathan,7112324 and 8007796,,,,Amgen Research (Munich) GMBH,2850,2774,76,2007-02-15,2007-02-15,2014-12-03,BLA 125557,432,125557,5/16/2008,Treatment of acute lymphocytic leukemia,Designated/Approved,,,Treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).,12/3/2014,12/3/2021,Treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).,"Amgen, Inc.",Blincyto,blinatumomab,Amgen,BLA,125557,,2014-09-19,2014-12-03,2014,,"BLINCYTO is indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). _x000D_
This indication is approved under accelerated approval.  Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; GENVOYA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GENVOYA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5431,2018-02403,https://www.federalregister.gov/documents/2018/02/07/2018-02403/determination-of-regulatory-review-period-for-purposes-of-patent-extension-genvoya,https://www.govinfo.gov/content/pkg/FR-2018-02-07/pdf/2018-02403.pdf,2/7/2018, GENVOYA,,Nicolas,GENVOYA,2,274,Jonathan,7390791 and 7803788,,,,"Gilead Sciences, Inc.",5031,4665,366,2002-01-28,2002-01-28,2015-11-05,NDA 207561,1116,207561,,,,,,,,,,,Genvoya,"elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide",Gilead Sciences,NDA,207561,,2014-11-05,2015-11-05,2015,,GENVOYA is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of GENVOYA.,Standard,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; SEDASYS SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for SEDASYS SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 5429,2018-02432,https://www.federalregister.gov/documents/2018/02/07/2018-02432/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sedasys-system,https://www.govinfo.gov/content/pkg/FR-2018-02-07/pdf/2018-02432.pdf,2/7/2018, SEDASYS SYSTEM,,Nicolas,SEDASYS SYSTEM,1,275,Jonathan,6807965,,,,"Scott Laboratories, Inc.",2816,950,1866,2005-08-19,2005-08-19,2013-05-03,PMA P080009,2283,80009,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; JUBLIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for JUBLIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5633,2018-02522,https://www.federalregister.gov/documents/2018/02/08/2018-02522/determination-of-regulatory-review-period-for-purposes-of-patent-extension-jublia,https://www.govinfo.gov/content/pkg/FR-2018-02-08/pdf/2018-02522.pdf,2/8/2018, JUBLIA,,Nicolas,JUBLIA,1,276,Jonathan,7214506,,,,"Kaken Pharmaceutical Co., Ltd.",2521,1840,681,2007-07-14,2007-07-14,2014-06-06,NDA 203567,1601,203567,,,,,,,,,,,Jublia,efinaconazole,Dow Pharmaceutical Sciences,NDA,203567,,2012-07-26,2014-06-06,2014,,"Jublia (efinaconazole) topical solution, 10% is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; STRENSIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for STRENSIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 5776,2018-02588,https://www.federalregister.gov/documents/2018/02/09/2018-02588/determination-of-regulatory-review-period-for-purposes-of-patent-extension-strensiq,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02588.pdf,2/9/2018, STRENSIQ,,Nicolas,STRENSIQ,1,277,Jonathan,7763712,,,,"Alexion Pharmaceuticals, Inc.",2670,2365,305,2008-07-03,2008-07-03,2015-10-23,BLA 125513,1109,125513,9/12/2008,Treatment of hypophosphatasia,Designated/Approved,,,For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP),10/23/2015,10/23/2022,For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP),"Alexion Pharmaceuticals, Inc.",Strensiq,asfotase alfa,Alexion Pharmaceuticals,BLA,125513,,2014-12-23,2015-10-23,2015,,Strensiq is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).,Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ODOMZO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ODOMZO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5780,2018-02658,https://www.federalregister.gov/documents/2018/02/09/2018-02658/determination-of-regulatory-review-period-for-purposes-of-patent-extension-odomzo,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02658.pdf,2/9/2018, ODOMZO,,Nicolas,ODOMZO,1,278,Jonathan,8178563,,,,Novartis AG,2414,2112,302,2008-12-15,2014-09-26,2015-07-24,NDA 205266,169,205266,,,,,,,,,,,Odomzo,sonidegib,Novartis Pharmaceuticals,NDA,205266,,2014-09-26,2015-07-24,2015,,"ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; IDELVION,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IDELVION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 5787,2018-02666,https://www.federalregister.gov/documents/2018/02/09/2018-02666/determination-of-regulatory-review-period-for-purposes-of-patent-extension-idelvion,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02666.pdf,2/9/2018, IDELVION,,Nicolas,IDELVION,1,279,Jonathan,7939632,,,,CSL Behring GmbH,1479,1023,456,2012-02-17,2012-02-17,2016-03-04,BLA 125582,531,125582,4/27/2012,Treatment of patients with congenital factor IX deficiency (hemophilia B).,Designated/Approved,,,"Indicated in children and adults with hemophilia B (congenital Factor IX deficiency) for the (1) on-demand control and prevention of bleeding episodes, (2) perioperative management of bleeding, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes.",3/4/2016,3/4/2023,"Indicated for the (1) on-demand control and prevention of bleeding episodes, (2) perioperative management of bleeding, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes.","CSL Behring, LLC",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LYNPARZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LYNPARZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5788,2018-02591,https://www.federalregister.gov/documents/2018/02/09/2018-02591/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lynparza,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02591.pdf,2/9/2018, LYNPARZA,,Nicolas,LYNPARZA,1,280,Jonathan,7449464,,,,Kudos Pharmaceuticals Limited,3012,2692,320,2006-09-22,2014-02-03,2014-12-19,NDA 206162,1275,206162,10/16/2013,Treatment of ovarian cancer,Designated/Approved,,,"Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza.",12/19/2018,12/19/2025,Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian cancer who are in complete or partial response to first-line platinum based chemotherapy.,AstraZeneca Pharmaceuticals LP,Lynparza,olaparib,AstraZeneca Pharmaceuticals,NDA,206162,,2014-02-03,2014-12-19,2014,,"Lynparza is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. _x000D_
The indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LYNPARZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LYNPARZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5788,2018-02591,https://www.federalregister.gov/documents/2018/02/09/2018-02591/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lynparza,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02591.pdf,2/9/2018, LYNPARZA,,Nicolas,LYNPARZA,1,281,Jonathan,7449464,,,,Kudos Pharmaceuticals Limited,3012,2692,320,2006-09-22,2014-02-03,2014-12-19,NDA 206162,1275,206162,5/15/2018,Treatment of primary peritoneal cancer,Designated/Approved,,,"Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",5/8/2020,5/8/2027,"LYNPARZA is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by genomic instability.",AstraZeneca Pharmaceuticals LP,Lynparza,olaparib,AstraZeneca Pharmaceuticals,NDA,206162,,2014-02-03,2014-12-19,2014,,"Lynparza is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. _x000D_
The indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LYNPARZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LYNPARZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5788,2018-02591,https://www.federalregister.gov/documents/2018/02/09/2018-02591/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lynparza,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02591.pdf,2/9/2018, LYNPARZA,,Nicolas,LYNPARZA,1,282,Jonathan,7449464,,,,Kudos Pharmaceuticals Limited,3012,2692,320,2006-09-22,2014-02-03,2014-12-19,NDA 206162,1275,206162,5/15/2018,Treatment of primary peritoneal cancer,Designated/Approved,,,"Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza.",12/19/2018,12/19/2025,Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy.,AstraZeneca Pharmaceuticals LP,Lynparza,olaparib,AstraZeneca Pharmaceuticals,NDA,206162,,2014-02-03,2014-12-19,2014,,"Lynparza is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. _x000D_
The indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LYNPARZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LYNPARZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5788,2018-02591,https://www.federalregister.gov/documents/2018/02/09/2018-02591/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lynparza,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02591.pdf,2/9/2018, LYNPARZA,,Nicolas,LYNPARZA,1,283,Jonathan,7449464,,,,Kudos Pharmaceuticals Limited,3012,2692,320,2006-09-22,2014-02-03,2014-12-19,NDA 206162,1275,206162,5/15/2018,Treatment of Fallopian Tube Cancer,Designated/Approved,,,"Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza.",12/19/2018,12/19/2025,Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced fallopian tube cancer who are in complete or partial response to first-line platinum based chemotherapy.,AstraZeneca Pharmaceuticals LP,Lynparza,olaparib,AstraZeneca Pharmaceuticals,NDA,206162,,2014-02-03,2014-12-19,2014,,"Lynparza is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. _x000D_
The indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LYNPARZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LYNPARZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5788,2018-02591,https://www.federalregister.gov/documents/2018/02/09/2018-02591/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lynparza,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02591.pdf,2/9/2018, LYNPARZA,,Nicolas,LYNPARZA,1,284,Jonathan,7449464,,,,Kudos Pharmaceuticals Limited,3012,2692,320,2006-09-22,2014-02-03,2014-12-19,NDA 206162,1275,206162,10/16/2013,Treatment of ovarian cancer,Designated/Approved,,,Indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy,12/19/2014,12/19/2021,Use as monotherapy for patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy,AstraZeneca Pharmaceuticals LP,Lynparza,olaparib,AstraZeneca Pharmaceuticals,NDA,206162,,2014-02-03,2014-12-19,2014,,"Lynparza is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. _x000D_
The indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LYNPARZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LYNPARZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5788,2018-02591,https://www.federalregister.gov/documents/2018/02/09/2018-02591/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lynparza,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02591.pdf,2/9/2018, LYNPARZA,,Nicolas,LYNPARZA,1,285,Jonathan,7449464,,,,Kudos Pharmaceuticals Limited,3012,2692,320,2006-09-22,2014-02-03,2014-12-19,NDA 206162,1275,206162,10/16/2013,Treatment of ovarian cancer,Designated/Approved,,,"Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.",8/17/2017,8/17/2024,"Maintenance treatment of adult patients with recurrent epithelial ovarian cancer, who are in a complete or partial response to platinum-based chemotherapy.",AstraZeneca Pharmaceuticals LP,Lynparza,olaparib,AstraZeneca Pharmaceuticals,NDA,206162,,2014-02-03,2014-12-19,2014,,"Lynparza is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. _x000D_
The indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LYNPARZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LYNPARZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5788,2018-02591,https://www.federalregister.gov/documents/2018/02/09/2018-02591/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lynparza,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02591.pdf,2/9/2018, LYNPARZA,,Nicolas,LYNPARZA,1,286,Jonathan,7449464,,,,Kudos Pharmaceuticals Limited,3012,2692,320,2006-09-22,2014-02-03,2014-12-19,NDA 206162,1275,206162,5/15/2018,Treatment of Fallopian Tube Cancer,Designated/Approved,,,"Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",5/8/2020,5/8/2027,"LYNPARZA is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by genomic instability.",AstraZeneca Pharmaceuticals LP,Lynparza,olaparib,AstraZeneca Pharmaceuticals,NDA,206162,,2014-02-03,2014-12-19,2014,,"Lynparza is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. _x000D_
The indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LYNPARZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LYNPARZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5788,2018-02591,https://www.federalregister.gov/documents/2018/02/09/2018-02591/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lynparza,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02591.pdf,2/9/2018, LYNPARZA,,Nicolas,LYNPARZA,1,287,Jonathan,7449464,,,,Kudos Pharmaceuticals Limited,3012,2692,320,2006-09-22,2014-02-03,2014-12-19,NDA 206162,1275,206162,10/11/2018,Treatment of pancreatic cancer,Designated/Approved,,,Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,12/27/2019,12/27/2026,Indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,AstraZeneca Pharmaceuticals LP,Lynparza,olaparib,AstraZeneca Pharmaceuticals,NDA,206162,,2014-02-03,2014-12-19,2014,,"Lynparza is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. _x000D_
The indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LYNPARZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LYNPARZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5788,2018-02591,https://www.federalregister.gov/documents/2018/02/09/2018-02591/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lynparza,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02591.pdf,2/9/2018, LYNPARZA,,Nicolas,LYNPARZA,1,288,Jonathan,7449464,,,,Kudos Pharmaceuticals Limited,3012,2692,320,2006-09-22,2014-02-03,2014-12-19,NDA 206162,1275,206162,10/16/2013,Treatment of ovarian cancer,Designated/Approved,,,"Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",5/8/2020,5/8/2027,"LYNPARZA is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by genomic instability.",AstraZeneca Pharmaceuticals LP,Lynparza,olaparib,AstraZeneca Pharmaceuticals,NDA,206162,,2014-02-03,2014-12-19,2014,,"Lynparza is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. _x000D_
The indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LYNPARZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LYNPARZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5788,2018-02591,https://www.federalregister.gov/documents/2018/02/09/2018-02591/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lynparza,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02591.pdf,2/9/2018, LYNPARZA,,Nicolas,LYNPARZA,1,289,Jonathan,7449464,,,,Kudos Pharmaceuticals Limited,3012,2692,320,2006-09-22,2014-02-03,2014-12-19,NDA 206162,1275,206162,5/15/2018,Treatment of Fallopian Tube Cancer,Designated/Approved,,,"Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; and treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.",8/17/2017,8/17/2024,Maintenance treatment of adult patients with recurrent fallopian tube cancer who are in a complete or partial response to platinum-based chemotherapy.,AstraZeneca Pharmaceuticals LP,Lynparza,olaparib,AstraZeneca Pharmaceuticals,NDA,206162,,2014-02-03,2014-12-19,2014,,"Lynparza is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. _x000D_
The indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LYNPARZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LYNPARZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5788,2018-02591,https://www.federalregister.gov/documents/2018/02/09/2018-02591/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lynparza,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02591.pdf,2/9/2018, LYNPARZA,,Nicolas,LYNPARZA,1,290,Jonathan,7449464,,,,Kudos Pharmaceuticals Limited,3012,2692,320,2006-09-22,2014-02-03,2014-12-19,NDA 206162,1275,206162,5/15/2018,Treatment of primary peritoneal cancer,Designated/Approved,,,"Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; and treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.",8/17/2017,8/17/2024,Maintenance treatment of adult patients with recurrent primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.,AstraZeneca Pharmaceuticals LP,Lynparza,olaparib,AstraZeneca Pharmaceuticals,NDA,206162,,2014-02-03,2014-12-19,2014,,"Lynparza is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. _x000D_
The indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ONIVYDE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ONIVYDE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5790,2018-02590,https://www.federalregister.gov/documents/2018/02/09/2018-02590/determination-of-regulatory-review-period-for-purposes-of-patent-extension-onivyde,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02590.pdf,2/9/2018, ONIVYDE,,Nicolas,ONIVYDE,2,292,Jonathan,8147867 and 8329213,,,,"Merrimack Pharmaceuticals, Inc.",2536,2354,182,2008-11-13,2015-04-24,2015-10-22,NDA 207793,1215,207793,7/21/2011,Treatment of pancreatic cancer,Designated/Approved,,,"in combination with oxaliplatin, fluorouracil and leucovorin for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma",2/13/2024,2/13/2031,first-line treatment of adult patients with metastatic pancreatic adenocarcinoma,"Ipsen Biopharmaceuticals, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ENTRESTO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ENTRESTO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 5781,2018-02592,https://www.federalregister.gov/documents/2018/02/09/2018-02592/determination-of-regulatory-review-period-for-purposes-of-patent-extension-entresto,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02592.pdf,2/9/2018, ENTRESTO,,Nicolas,ENTRESTO,5,297,Jonathan,7468390; 8101659; 8404744; 8796331; and 8877938,,,,Novartis Pharmaceuticals Corporation,3148,2945,203,2006-11-25,2014-12-17,2015-07-07,NDA 207620,225,207620,,,,,,,,,,,Entresto,"sacubitril, valsartan",Novartis Pharmaceuticals,NDA,207620,,2014-12-17,2015-07-07,2015,,"ENTRESTO is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction._x000D_
ENTRESTO is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; KAMRA INLAY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KAMRA INLAY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 5778,2018-02582,https://www.federalregister.gov/documents/2018/02/09/2018-02582/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kamra-inlay,https://www.govinfo.gov/content/pkg/FR-2018-02-09/pdf/2018-02582.pdf,2/9/2018, KAMRA INLAY,,Nicolas,KAMRA INLAY,1,298,Jonathan,8460374,,,,"AcuFocus, Inc.",2347,1541,806,2016-07-12,2008-11-14,2015-04-17,PMA P120023,676,120023,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; IMBRUVICA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMBRUVICA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6028,2018-02791,https://www.federalregister.gov/documents/2018/02/12/2018-02791/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imbruvica,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02791.pdf,2/12/2018, IMBRUVICA,,Nicolas,IMBRUVICA,1,299,Jonathan,8008309,,,,"Pharmacyclics, Inc.",1865,1726,139,2008-10-07,2008-10-07,2013-11-13,NDA 205552,320,205552,6/23/2016,Treatment of chronic Graft versus Host disease,Designated/Approved,,,Treatment of adult and pediatric patients age 1 year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy,8/24/2022,8/24/2029,Treatment of pediatric patients age 1 year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy,"Pharmacyclics, LLC",Imbruvica,ibrutinib,Pharmacyclics,NDA,205552,,2013-06-28,2013-11-13,2013,,IMBRUVICA is indicated for the treatment of patients with mantel cell lymphoma (MCL) who have received at least one prior therapy.  This indication is based on overall response rate.  An improvement in survival or disease-related symptoms has not been established.,Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; IMBRUVICA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMBRUVICA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6028,2018-02791,https://www.federalregister.gov/documents/2018/02/12/2018-02791/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imbruvica,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02791.pdf,2/12/2018, IMBRUVICA,,Nicolas,IMBRUVICA,1,300,Jonathan,8008309,,,,"Pharmacyclics, Inc.",1865,1726,139,2008-10-07,2008-10-07,2013-11-13,NDA 205552,320,205552,2/2/2016,Treatment of patients with extranodal marginal zone lymphoma (mucosa associated lymphoid tissue [MALT type] lymphoma),Designated/Approved,,,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy (indication withdrawn),1/18/2017,5/18/2023,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy (indication withdrawn),"Pharmacyclics, LLC",Imbruvica,ibrutinib,Pharmacyclics,NDA,205552,,2013-06-28,2013-11-13,2013,,IMBRUVICA is indicated for the treatment of patients with mantel cell lymphoma (MCL) who have received at least one prior therapy.  This indication is based on overall response rate.  An improvement in survival or disease-related symptoms has not been established.,Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; IMBRUVICA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMBRUVICA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6028,2018-02791,https://www.federalregister.gov/documents/2018/02/12/2018-02791/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imbruvica,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02791.pdf,2/12/2018, IMBRUVICA,,Nicolas,IMBRUVICA,1,301,Jonathan,8008309,,,,"Pharmacyclics, Inc.",1865,1726,139,2008-10-07,2008-10-07,2013-11-13,NDA 205552,320,205552,6/23/2016,Treatment of chronic Graft versus Host disease,Designated/Approved,,,Treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.,8/2/2017,8/2/2024,Treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.,"Pharmacyclics, LLC",Imbruvica,ibrutinib,Pharmacyclics,NDA,205552,,2013-06-28,2013-11-13,2013,,IMBRUVICA is indicated for the treatment of patients with mantel cell lymphoma (MCL) who have received at least one prior therapy.  This indication is based on overall response rate.  An improvement in survival or disease-related symptoms has not been established.,Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; IMBRUVICA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMBRUVICA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6028,2018-02791,https://www.federalregister.gov/documents/2018/02/12/2018-02791/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imbruvica,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02791.pdf,2/12/2018, IMBRUVICA,,Nicolas,IMBRUVICA,1,302,Jonathan,8008309,,,,"Pharmacyclics, Inc.",1865,1726,139,2008-10-07,2008-10-07,2013-11-13,NDA 205552,320,205552,4/6/2012,Treatment of chronic lymphocytic leukemia (CLL),Designated/Approved,,,Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy,2/12/2014,2/12/2021,Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy,"Pharmacyclics, LLC",Imbruvica,ibrutinib,Pharmacyclics,NDA,205552,,2013-06-28,2013-11-13,2013,,IMBRUVICA is indicated for the treatment of patients with mantel cell lymphoma (MCL) who have received at least one prior therapy.  This indication is based on overall response rate.  An improvement in survival or disease-related symptoms has not been established.,Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; IMBRUVICA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMBRUVICA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6028,2018-02791,https://www.federalregister.gov/documents/2018/02/12/2018-02791/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imbruvica,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02791.pdf,2/12/2018, IMBRUVICA,,Nicolas,IMBRUVICA,1,303,Jonathan,8008309,,,,"Pharmacyclics, Inc.",1865,1726,139,2008-10-07,2008-10-07,2013-11-13,NDA 205552,320,205552,10/15/2013,Treatment of Waldenstrom's macroglobulinemia,Designated/Approved,,,Treatment of patients with Waldenstrom's macroglobulinemia,1/29/2015,1/29/2022,Treatment of patients with Waldenstrom's macroglobulinemia,"Pharmacyclics, LLC",Imbruvica,ibrutinib,Pharmacyclics,NDA,205552,,2013-06-28,2013-11-13,2013,,IMBRUVICA is indicated for the treatment of patients with mantel cell lymphoma (MCL) who have received at least one prior therapy.  This indication is based on overall response rate.  An improvement in survival or disease-related symptoms has not been established.,Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; IMBRUVICA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMBRUVICA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6028,2018-02791,https://www.federalregister.gov/documents/2018/02/12/2018-02791/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imbruvica,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02791.pdf,2/12/2018, IMBRUVICA,,Nicolas,IMBRUVICA,1,304,Jonathan,8008309,,,,"Pharmacyclics, Inc.",1865,1726,139,2008-10-07,2008-10-07,2013-11-13,NDA 205552,320,205552,12/3/2012,Treatment of mantle cell lymphoma,Designated/Approved,,,Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy,11/13/2013,11/13/2020,Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy,"Pharmacyclics, LLC",Imbruvica,ibrutinib,Pharmacyclics,NDA,205552,,2013-06-28,2013-11-13,2013,,IMBRUVICA is indicated for the treatment of patients with mantel cell lymphoma (MCL) who have received at least one prior therapy.  This indication is based on overall response rate.  An improvement in survival or disease-related symptoms has not been established.,Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; IMBRUVICA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMBRUVICA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6028,2018-02791,https://www.federalregister.gov/documents/2018/02/12/2018-02791/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imbruvica,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02791.pdf,2/12/2018, IMBRUVICA,,Nicolas,IMBRUVICA,1,305,Jonathan,8008309,,,,"Pharmacyclics, Inc.",1865,1726,139,2008-10-07,2008-10-07,2013-11-13,NDA 205552,320,205552,2/5/2015,Treatment of nodal marginal zone lymphoma,Designated/Approved,,,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy (indication withdrawn),1/18/2017,5/18/2023,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy (indication withdrawn),"Pharmacyclics, LLC",Imbruvica,ibrutinib,Pharmacyclics,NDA,205552,,2013-06-28,2013-11-13,2013,,IMBRUVICA is indicated for the treatment of patients with mantel cell lymphoma (MCL) who have received at least one prior therapy.  This indication is based on overall response rate.  An improvement in survival or disease-related symptoms has not been established.,Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; IMBRUVICA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMBRUVICA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6028,2018-02791,https://www.federalregister.gov/documents/2018/02/12/2018-02791/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imbruvica,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02791.pdf,2/12/2018, IMBRUVICA,,Nicolas,IMBRUVICA,1,306,Jonathan,8008309,,,,"Pharmacyclics, Inc.",1865,1726,139,2008-10-07,2008-10-07,2013-11-13,NDA 205552,320,205552,2/5/2015,Treatment of splenic marginal zone lymphoma,Designated/Approved,,,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy (indication withdrawn),1/18/2017,5/18/2023,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy (indication withdrawn),"Pharmacyclics, LLC",Imbruvica,ibrutinib,Pharmacyclics,NDA,205552,,2013-06-28,2013-11-13,2013,,IMBRUVICA is indicated for the treatment of patients with mantel cell lymphoma (MCL) who have received at least one prior therapy.  This indication is based on overall response rate.  An improvement in survival or disease-related symptoms has not been established.,Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; IMBRUVICA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMBRUVICA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6028,2018-02791,https://www.federalregister.gov/documents/2018/02/12/2018-02791/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imbruvica,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02791.pdf,2/12/2018, IMBRUVICA,,Nicolas,IMBRUVICA,1,307,Jonathan,8008309,,,,"Pharmacyclics, Inc.",1865,1726,139,2008-10-07,2008-10-07,2013-11-13,NDA 205552,320,205552,4/6/2012,Treatment of chronic lymphocytic leukemia (CLL),Designated/Approved,,,Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion,7/28/2014,7/28/2021,Treatment of chronic lymphocytic leukemia with 17p deletion who have not received at least one prior therapy,"Pharmacyclics, LLC",Imbruvica,ibrutinib,Pharmacyclics,NDA,205552,,2013-06-28,2013-11-13,2013,,IMBRUVICA is indicated for the treatment of patients with mantel cell lymphoma (MCL) who have received at least one prior therapy.  This indication is based on overall response rate.  An improvement in survival or disease-related symptoms has not been established.,Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; IMBRUVICA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMBRUVICA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6028,2018-02791,https://www.federalregister.gov/documents/2018/02/12/2018-02791/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imbruvica,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02791.pdf,2/12/2018, IMBRUVICA,,Nicolas,IMBRUVICA,1,308,Jonathan,8008309,,,,"Pharmacyclics, Inc.",1865,1726,139,2008-10-07,2008-10-07,2013-11-13,NDA 205552,320,205552,4/6/2012,Treatment of chronic lymphocytic leukemia (CLL),Designated/Approved,,,Indicated for the treatment of patients with chronic lymphocytic leukemia,3/4/2016,3/4/2023,Indicated for the treatment of patients with chronic lymphocytic leukemia without 17p deletion who have not received at least one prior therapy (first line therapy).,"Pharmacyclics, LLC",Imbruvica,ibrutinib,Pharmacyclics,NDA,205552,,2013-06-28,2013-11-13,2013,,IMBRUVICA is indicated for the treatment of patients with mantel cell lymphoma (MCL) who have received at least one prior therapy.  This indication is based on overall response rate.  An improvement in survival or disease-related symptoms has not been established.,Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; IMBRUVICA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMBRUVICA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6028,2018-02791,https://www.federalregister.gov/documents/2018/02/12/2018-02791/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imbruvica,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02791.pdf,2/12/2018, IMBRUVICA,,Nicolas,IMBRUVICA,1,309,Jonathan,8008309,,,,"Pharmacyclics, Inc.",1865,1726,139,2008-10-07,2008-10-07,2013-11-13,NDA 205552,320,205552,5/30/2013,Treatment of small lymphocytic lymphoma,Designated/Approved,,,Indicated for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and indicated for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) with 17p deletion.,5/6/2016,5/6/2023,For treatment of patients with small lymphocytic lymphoma (SLL),"Pharmacyclics, LLC",Imbruvica,ibrutinib,Pharmacyclics,NDA,205552,,2013-06-28,2013-11-13,2013,,IMBRUVICA is indicated for the treatment of patients with mantel cell lymphoma (MCL) who have received at least one prior therapy.  This indication is based on overall response rate.  An improvement in survival or disease-related symptoms has not been established.,Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; DALVANCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DALVANCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6031,2018-02768,https://www.federalregister.gov/documents/2018/02/12/2018-02768/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dalvance,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02768.pdf,2/12/2018, DALVANCE,,Nicolas,DALVANCE,1,310,Jonathan,6900175,,,,"Vicuron Pharmaceuticals, Inc.",5033,1592,3441,2000-08-13,2000-08-13,2014-05-23,NDA 21883,1612,21883,,,,,,,,,,,Dalvance,dalbavancin,Durata Therapeutics International,NDA,21883,,2004-12-21,2014-05-23,2014,,"DALVANCE (dalbavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae and Streptococcus anginosus group (including S. anginosus, S. intermedius, S. constellatus). Usage: To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALVANCE and other antibacterial agents, DALVANCE should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; BELSOMRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BELSOMRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6034,2018-02763,https://www.federalregister.gov/documents/2018/02/12/2018-02763/determination-of-regulatory-review-period-for-purposes-of-patent-extension-belsomra,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02763.pdf,2/12/2018, BELSOMRA,,Nicolas,BELSOMRA,1,311,Jonathan,7951797,,,,Merck Sharp & Dohme Corp.,2291,1577,714,2008-05-07,2008-05-07,2014-08-13,NDA 204569,0,204569,,,,,,,,,,,Belsomra,suvorexant,Merck,NDA,204569,,2012-08-30,2014-08-13,2014,,BELSOMRA (surovexant) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; AKYNZEO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AKYNZEO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6038,2018-02756,https://www.federalregister.gov/documents/2018/02/12/2018-02756/determination-of-regulatory-review-period-for-purposes-of-patent-extension-akynzeo,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02756.pdf,2/12/2018, AKYNZEO,,Nicolas,AKYNZEO,1,312,Jonathan,6297375,,,,Hoffmann-La Roche Inc.,1858,1479,379,2009-09-10,2013-09-27,2014-10-10,NDA 205718,1118,205718,,,,,,,,,,,Akynzeo,"netupitant, palonosetron",Helsinn Healthcare,NDA,205718,,2013-09-27,2014-10-10,2014,,"AKYNZEO is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO is an oral fixed combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; GILOTRIF,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GILOTRIF and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6026,2018-02767,https://www.federalregister.gov/documents/2018/02/12/2018-02767/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gilotrif,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02767.pdf,2/12/2018, GILOTRIF,,Nicolas,GILOTRIF,1,313,Jonathan,RE43431,,,,"Boehringer Ingelheim Pharma Gmbh & Co., KG",3453,3213,240,2004-01-30,2012-11-15,2013-07-12,NDA 201292,1057,201292,12/3/2012,Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).,Designated/Approved,,,First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.,7/12/2013,7/12/2020,First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.,"Boehringer Ingelheim Pharmaceuticals, Inc.",Gilotrif,afatinib,Boehringer Ingelheim Pharmaceuticals,NDA,201292,,2012-11-15,2013-07-12,2013,,"GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.  
Limitation of Use: Safety and efficacy of GILOTRIF have not been established in patients whose tumors have other EGFR mutations.",Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; GILOTRIF,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GILOTRIF and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6026,2018-02767,https://www.federalregister.gov/documents/2018/02/12/2018-02767/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gilotrif,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02767.pdf,2/12/2018, GILOTRIF,,Nicolas,GILOTRIF,1,314,Jonathan,RE43431,,,,"Boehringer Ingelheim Pharma Gmbh & Co., KG",3453,3213,240,2004-01-30,2012-11-15,2013-07-12,NDA 201292,1057,201292,8/3/2015,Treatment of non-small cell lung cancer with squamous histology.,Designated/Approved,,,"Treatment of patients with metastatic, squamous, non-small cell lung cancer progressing after platinum-based chemotherapy",4/15/2016,4/15/2023,"Treatment of patients with metastatic, squamous, non-small cell lung cancer progressing after platinum-based chemotherapy","Boehringer Ingelheim Pharmaceuticals, Inc.",Gilotrif,afatinib,Boehringer Ingelheim Pharmaceuticals,NDA,201292,,2012-11-15,2013-07-12,2013,,"GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.  
Limitation of Use: Safety and efficacy of GILOTRIF have not been established in patients whose tumors have other EGFR mutations.",Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; GILOTRIF,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GILOTRIF and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6026,2018-02767,https://www.federalregister.gov/documents/2018/02/12/2018-02767/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gilotrif,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02767.pdf,2/12/2018, GILOTRIF,,Nicolas,GILOTRIF,1,315,Jonathan,RE43431,,,,"Boehringer Ingelheim Pharma Gmbh & Co., KG",3453,3213,240,2004-01-30,2012-11-15,2013-07-12,NDA 201292,1057,201292,12/3/2012,Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).,Designated/Approved,,,GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.,1/12/2018,1/12/2025,GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations other than exon 19 deletions or exon 21 (L858R) substiution mutationas as detected by an FDA-approved test.,"Boehringer Ingelheim Pharmaceuticals, Inc.",Gilotrif,afatinib,Boehringer Ingelheim Pharmaceuticals,NDA,201292,,2012-11-15,2013-07-12,2013,,"GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.  
Limitation of Use: Safety and efficacy of GILOTRIF have not been established in patients whose tumors have other EGFR mutations.",Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; BRAVECTO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRAVECTO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that animal drug product.",83 FR 6033,2018-02761,https://www.federalregister.gov/documents/2018/02/12/2018-02761/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bravecto,https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02761.pdf,2/12/2018, BRAVECTO,,Nicolas,BRAVECTO,1,316,Jonathan,7662972,,,,"Nissan Chemical Industries, Ltd.",1017,979,38,2011-08-04,2014-04-08,2014-05-15,NADA 141-426,792,141426,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; VASCEPA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VASCEPA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6192,2018-02851,https://www.federalregister.gov/documents/2018/02/13/2018-02851/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vascepa,https://www.govinfo.gov/content/pkg/FR-2018-02-13/pdf/2018-02851.pdf,2/13/2018, VASCEPA,,Nicolas,VASCEPA,1,317,Jonathan,8188146,,,,Amarin Pharmaceuticals Ireland Limited,1133,828,305,2009-06-21,2009-06-21,2012-07-26,NDA 202057,58,202057,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FARYDAK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FARYDAK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6198,2018-02868,https://www.federalregister.gov/documents/2018/02/13/2018-02868/determination-of-regulatory-review-period-for-purposes-of-patent-extension-farydak,https://www.govinfo.gov/content/pkg/FR-2018-02-13/pdf/2018-02868.pdf,2/13/2018, FARYDAK,,Nicolas,FARYDAK,3,320,Jonathan,6552065; 6833384; and 7067551,,,,Novartis AG,4334,3997,337,2003-04-15,2003-04-15,2015-02-23,NDA 205353,1751,205353,8/20/2012,Treatment of multiple myeloma,Designated/Approved,,,"FARYDAK (panobinostat) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent",2/23/2015,2/23/2022,"FARYDAK (panobinostat) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent",zr pharma& GmbH,Farydak,panobinostat,Novartis Pharmaceuticals,NDA,205353,,2014-03-24,2015-02-23,2015,,"FARYDAK, a histone deacetylase inhibitor, in combination with bortezomin and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent.  This indication is approved under accelerated approval based on progression free survival.  Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BELEODAQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for BELEODAQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6576,2018-03041,https://www.federalregister.gov/documents/2018/02/14/2018-03041/determination-of-regulatory-review-period-for-purposes-of-patent-extension-beleodaq,https://www.govinfo.gov/content/pkg/FR-2018-02-14/pdf/2018-03041.pdf,2/14/2018, BELEODAQ,,Nicolas,BELEODAQ,1,321,Jonathan,6888027,,,,"Spectrum Pharmaceuticals, Inc.",3488,3281,207,2004-12-16,2013-12-09,2014-07-03,NDA 206256,1779,206256,9/3/2009,Treatment of peripheral T-cell lymphoma (PTCL).,Designated/Approved,,,Treatment of patients with relapsed or refractory peripheral T-cell lymphoma,7/3/2014,7/3/2021,Treatment of patients with relapsed or refractory peripheral T-cell lymphoma,Acrotech Biopharma LLC,Beleodaq,belinostat,Spectrum Pharmaceuticals,NDA,206256,,2013-12-09,2014-07-03,2014,,"Beleodaq is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). _x000D_
This indication is approved under accelerated approval based on tumor response rate and duration of response.  An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.",Priority,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; IBRANCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IBRANCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6581,2018-03029,https://www.federalregister.gov/documents/2018/02/14/2018-03029/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ibrance,https://www.govinfo.gov/content/pkg/FR-2018-02-14/pdf/2018-03029.pdf,2/14/2018, IBRANCE,,Nicolas,IBRANCE,2,323,Jonathan,6936612 and 7208489,,,,"Warner-Lambert Company, LLC",3954,3779,175,2004-04-09,2014-08-13,2015-02-03,NDA 207103,1509,207103,,,,,,,,,,,Ibrance,palbociclib,Pfizer,NDA,207103,,2014-08-13,2015-02-03,2015,,"IBRANCE is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. 
This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,No,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; JARDIANCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for JARDIANCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6583,2018-02992,https://www.federalregister.gov/documents/2018/02/14/2018-02992/determination-of-regulatory-review-period-for-purposes-of-patent-extension-jardiance,https://www.govinfo.gov/content/pkg/FR-2018-02-14/pdf/2018-02992.pdf,2/14/2018, JARDIANCE,,Nicolas,JARDIANCE,1,324,Jonathan,7579449,,,,Boehringer Ingelheim International GmbH,2275,1760,515,2008-05-11,2008-05-11,2014-08-01,NDA 204629,1001,204629,,,,,,,,,,,Jardiance,empagliflozin,Boehringer Ingelheim Pharmaceuticals,NDA,204629,,2013-03-05,2014-08-01,2014,,Jardiance is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: Jardiance is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KERYDIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KERYDIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6579,2018-02993,https://www.federalregister.gov/documents/2018/02/14/2018-02993/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kerydin,https://www.govinfo.gov/content/pkg/FR-2018-02-14/pdf/2018-02993.pdf,2/14/2018, KERYDIN,,Nicolas,KERYDIN,1,325,Jonathan,7582621,,,,"Anacor Pharmaceuticals, Inc.",3112,2768,344,2005-12-31,2013-07-29,2014-07-07,NDA 204427,408,204427,,,,,,,,,,,Kerydin,tavaborole,Anacor Pharmaceuticals,NDA,204427,,2013-07-29,2014-07-07,2014,,"KERYDIN (tavaborole) topical solution, 5% is an oxaborole antifungal indicated for the treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; OSURNIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OSURNIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that animal drug product.",83 FR 6577,2018-02991,https://www.federalregister.gov/documents/2018/02/14/2018-02991/determination-of-regulatory-review-period-for-purposes-of-patent-extension-osurnia,https://www.govinfo.gov/content/pkg/FR-2018-02-14/pdf/2018-02991.pdf,2/14/2018, OSURNIA,,Nicolas,OSURNIA,1,326,Jonathan,7854943,,,,IDEXX,4034,3980,54,2003-10-21,2014-11-04,2014-11-04,NADA 141-,235,141,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; JUVEDERM VOLUMA XC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for JUVEDERM VOLUMA XC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 6574,2018-03017,https://www.federalregister.gov/documents/2018/02/14/2018-03017/determination-of-regulatory-review-period-for-purposes-of-patent-extension-juvederm-voluma-xc,https://www.govinfo.gov/content/pkg/FR-2018-02-14/pdf/2018-03017.pdf,2/14/2018, JUVEDERM VOLUMA XC,,Nicolas,JUVEDERM VOLUMA XC,1,327,Jonathan,7741476,,,,Pierre Lebreton,1896,1110,786,2015-10-30,2015-10-30,2013-10-22,PMA P110033,567,110033,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SYLVANT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for SYLVANT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 6866,2018-03126,https://www.federalregister.gov/documents/2018/02/15/2018-03126/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sylvant,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03126.pdf,2/15/2018, SYLVANT,,Nicolas,SYLVANT,2,329,Jonathan,7612182 and 7291721,,,,"Janssen Biotech, Inc.",3747,3510,237,2004-01-21,2004-01-21,2014-04-23,BLA 125496,1300,125496,5/26/2006,Treatment of Castleman's disease,Designated/Approved,,,Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.,4/23/2014,4/23/2021,Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.,Recordati Rare Diseases Inc.,Sylvant,siltuximab,Janssen Biotech,BLA,125496,,2013-08-30,2014-04-23,2014,,"SYLVANT is indicated for the treatment of patients with multicentric Castlemans disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. 
Limitation of Use: 
SYLVANT was not studied in patients with MCD who are HIV positive or HHV-8 positive because SYLVANT did not bind to virally produced IL-6 in a nonclinical study.",Priority,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; AVEED,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AVEED and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6858,2018-03136,https://www.federalregister.gov/documents/2018/02/15/2018-03136/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aveed,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03136.pdf,2/15/2018, AVEED,,Nicolas,AVEED,1,330,Jonathan,8338395,,,,Bayer Intellectual Property GmbH,2923,541,2382,2006-03-06,2006-03-06,2014-03-05,NDA 022219,435,22219,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; FETZIMA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FETZIMA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6859,2018-03129,https://www.federalregister.gov/documents/2018/02/15/2018-03129/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fetzima,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03129.pdf,2/15/2018, FETZIMA,,Nicolas,FETZIMA,1,331,Jonathan,RE43879,,,,Pierre Fabre Medicament,1602,1298,304,2009-03-08,2012-09-25,2013-07-25,NDA 204168,954,204168,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZONTIVITY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZONTIVITY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6864,2018-03170,https://www.federalregister.gov/documents/2018/02/15/2018-03170/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zontivity,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03170.pdf,2/15/2018, ZONTIVITY,,Nicolas,ZONTIVITY,1,332,Jonathan,7304078,,,,Merck Sharp & Dohme Corp.,3401,3037,364,2005-01-16,2013-05-10,2014-05-08,NDA 204886,1357,204886,,,,,,,,,,,Zontivity,vorapaxar,Merck Sharp & Dohme,NDA,204886,,2013-05-10,2014-05-08,2014,,"ZONTIVITY is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). ZONTIVITY has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and urgent coronary revascularization (UCR).",Standard,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; BRIDION,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRIDION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6856,2018-03137,https://www.federalregister.gov/documents/2018/02/15/2018-03137/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bridion,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03137.pdf,2/15/2018, BRIDION,,Nicolas,BRIDION,1,333,Jonathan,RE44733,,,,"Merck Sharp & Dohme, B.V.",4265,1297,2968,2004-04-13,2004-04-13,2015-12-15,NDA 022225,1826,22225,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ORKAMBI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ORKAMBI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6868,2018-03127,https://www.federalregister.gov/documents/2018/02/15/2018-03127/determination-of-regulatory-review-period-for-purposes-of-patent-extension-orkambi,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03127.pdf,2/15/2018, ORKAMBI,,Nicolas,ORKAMBI,3,336,Jonathan,8653103; 8741933; and 8846718,,,,Vertex Pharmaceuticals Inc.,2785,2545,240,2007-11-18,2014-11-05,2015-07-02,NDA 206038,317,206038,6/30/2014,Treatment of cystic fibrosis,Designated/Approved,,,Treatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene,9/2/2022,9/2/2029,Treatment of cystic fibrosis (CF) in patients aged 1 year to less than 2 years who are homozygous for the F508del mutation in the CFTR gene,Vertex Pharmaceuticals Inc.,Orkambi,"lumacaftor, ivacaftor",Vertex Pharmaceuticals,NDA,206038,,2014-11-05,2015-07-02,2015,,"ORKAMBI is a combination of lumacaftor and ivacaftor indicated for the treatment of cystic fibrosis (CF) in patients age 12 years and older who are homozygous for the F508del mutation in the CFTR gene. If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene.
Limitations of Use:
The efficacy and safety of ORKAMBI have not been established in patients with CF other than those homozygous for the F508del mutation.",Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ORKAMBI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ORKAMBI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6868,2018-03127,https://www.federalregister.gov/documents/2018/02/15/2018-03127/determination-of-regulatory-review-period-for-purposes-of-patent-extension-orkambi,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03127.pdf,2/15/2018, ORKAMBI,,Nicolas,ORKAMBI,3,339,Jonathan,8653103; 8741933; and 8846718,,,,Vertex Pharmaceuticals Inc.,2785,2545,240,2007-11-18,2014-11-05,2015-07-02,NDA 206038,317,206038,6/30/2014,Treatment of cystic fibrosis,Designated/Approved,,,Treatment of cystic fibrosis in patients age 12 years and older who are homozygous for F508del mutation in the CFTR gene,7/2/2015,7/2/2022,Treatment of cystic fibrosis in patients age 12 years and older who are homozygous for F508del mutation in the CFTR gene,Vertex Pharmaceuticals Inc.,Orkambi,"lumacaftor, ivacaftor",Vertex Pharmaceuticals,NDA,206038,,2014-11-05,2015-07-02,2015,,"ORKAMBI is a combination of lumacaftor and ivacaftor indicated for the treatment of cystic fibrosis (CF) in patients age 12 years and older who are homozygous for the F508del mutation in the CFTR gene. If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene.
Limitations of Use:
The efficacy and safety of ORKAMBI have not been established in patients with CF other than those homozygous for the F508del mutation.",Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ORKAMBI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ORKAMBI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6868,2018-03127,https://www.federalregister.gov/documents/2018/02/15/2018-03127/determination-of-regulatory-review-period-for-purposes-of-patent-extension-orkambi,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03127.pdf,2/15/2018, ORKAMBI,,Nicolas,ORKAMBI,3,342,Jonathan,8653103; 8741933; and 8846718,,,,Vertex Pharmaceuticals Inc.,2785,2545,240,2007-11-18,2014-11-05,2015-07-02,NDA 206038,317,206038,6/30/2014,Treatment of cystic fibrosis,Designated/Approved,,,ORKAMBI is a combination of lumacaftor and ivacaftor indicated for the treatment of cystic fibrosis (CF) in patients age 2 years and older who are homozygous for the F508del mutation in the CFTR gene.,8/7/2018,8/7/2025,ORKAMBI (lumacaftor/ivacaftor) oral granules indicated for the treatment of cystic fibrosis (CF) in patients age 2 through 5 years old who are homozygous for the F508del mutation in the CFTR gene.,Vertex Pharmaceuticals Inc.,Orkambi,"lumacaftor, ivacaftor",Vertex Pharmaceuticals,NDA,206038,,2014-11-05,2015-07-02,2015,,"ORKAMBI is a combination of lumacaftor and ivacaftor indicated for the treatment of cystic fibrosis (CF) in patients age 12 years and older who are homozygous for the F508del mutation in the CFTR gene. If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene.
Limitations of Use:
The efficacy and safety of ORKAMBI have not been established in patients with CF other than those homozygous for the F508del mutation.",Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ORKAMBI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ORKAMBI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6868,2018-03127,https://www.federalregister.gov/documents/2018/02/15/2018-03127/determination-of-regulatory-review-period-for-purposes-of-patent-extension-orkambi,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03127.pdf,2/15/2018, ORKAMBI,,Nicolas,ORKAMBI,3,345,Jonathan,8653103; 8741933; and 8846718,,,,Vertex Pharmaceuticals Inc.,2785,2545,240,2007-11-18,2014-11-05,2015-07-02,NDA 206038,317,206038,6/30/2014,Treatment of cystic fibrosis,Designated/Approved,,,Treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene,9/28/2016,9/28/2023,Treatment of cystic fibrosis (CF) in patients age 6-11 years old who are homozygous for the F508del mutation in the CFTR gene,Vertex Pharmaceuticals Inc.,Orkambi,"lumacaftor, ivacaftor",Vertex Pharmaceuticals,NDA,206038,,2014-11-05,2015-07-02,2015,,"ORKAMBI is a combination of lumacaftor and ivacaftor indicated for the treatment of cystic fibrosis (CF) in patients age 12 years and older who are homozygous for the F508del mutation in the CFTR gene. If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene.
Limitations of Use:
The efficacy and safety of ORKAMBI have not been established in patients with CF other than those homozygous for the F508del mutation.",Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ADDYI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ADDYI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 6855,2018-03130,https://www.federalregister.gov/documents/2018/02/15/2018-03130/determination-of-regulatory-review-period-for-purposes-of-patent-extension-addyi,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03130.pdf,2/15/2018, ADDYI,,Nicolas,ADDYI,2,347,Jonathan,7151103 and 7420057,,,,"Sprout Pharmaceuticals, Inc.",6852,4730,2122,1996-11-15,2009-10-27,2015-08-18,NDA 22-526,5,22526,,,,,,,,,,,Addyi,flibanserin,Sprout Pharmaceuticals,NDA,22526,,2009-10-27,2015-08-18,2015,,"ADDYI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: 
- A co-existing medical or psychiatric condition, 
- Problems within the relationship, or 
- The effects of a medication or other drug substance. 
Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner. 
Limitations of Use:
- ADDYI is not indicated for the treatment of HSDD in postmenopausal women or in men. 
- ADDYI is not indicated to enhance sexual performance.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ZYDELIG-New Drug Application 205858,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZYDELIG based on new drug application (NDA) 205858 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product and that NDA.",83 FR 6861,2018-03134,https://www.federalregister.gov/documents/2018/02/15/2018-03134/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zydelig-new-drug,https://www.govinfo.gov/content/pkg/FR-2018-02-15/pdf/2018-03134.pdf,2/15/2018, ZYDELIG-New Drug Application 205858,,Nicolas,ZYDELIG,2,349,Jonathan,RE44599 and RE44638,,,,ICOS Corporation,2247,1931,316,2008-05-30,2018-04-16,2014-07-23,NDA 205858,751,205858,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; HYMOVIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) has determined the regulatory review period for HYMOVIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 7059,2018-03229,https://www.federalregister.gov/documents/2018/02/16/2018-03229/determination-of-regulatory-review-period-for-purposes-of-patent-extension-hymovis,https://www.govinfo.gov/content/pkg/FR-2018-02-16/pdf/2018-03229.pdf,2/16/2018, HYMOVIS,,Nicolas,HYMOVIS,1,350,Jonathan,7863256,,,,Fidia Farmaceutici S.p.A.,1845,1665,180,2010-08-11,2010-08-11,2015-08-28,PMA P150010,938,150010,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; COTELLIC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for COTELLIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 7054,2018-03218,https://www.federalregister.gov/documents/2018/02/16/2018-03218/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cotellic,https://www.govinfo.gov/content/pkg/FR-2018-02-16/pdf/2018-03218.pdf,2/16/2018, COTELLIC,,Nicolas,COTELLIC,2,352,Jonathan,7803839 and 8362002,,,,"Exelixis, Inc.",3219,2884,335,2007-01-19,2014-12-11,2015-11-10,NDA 206192,676,206192,4/26/2021,Treatment for histiocytic neoplasms,Designated/Approved,,,as a single agent for the treatment of adult patients with histiocytic neoplasms,10/28/2022,10/28/2029,treatment of adult patients with histiocytic neoplasms,"Genentech, Inc.",Cotellic,cobimetinib,Genentech,NDA,206192,,2014-12-11,2015-11-10,2015,,"COTELLIC is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. _x000D_
Limitation of Use: COTELLIC is not indicated for treatment of patients with wild-type BRAF melanoma.",Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; MOVANTIK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MOVANTIK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 7042,2018-03245,https://www.federalregister.gov/documents/2018/02/16/2018-03245/determination-of-regulatory-review-period-for-purposes-of-patent-extension-movantik,https://www.govinfo.gov/content/pkg/FR-2018-02-16/pdf/2018-03245.pdf,2/16/2018, MOVANTIK,,Nicolas,MOVANTIK,2,354,Jonathan,7662365 and 7786133,,,,Nektar Therapeutics,2493,2127,366,2007-11-21,2007-11-21,2014-09-16,NDA 204760,272,204760,,,,,,,,,,,Movantik,naloxegol,AstraZeneca Pharmaceuticals,NDA,204760,,2013-09-16,2014-09-16,2014,,MOVANTIK (naloxegol) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; PORTRAZZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PORTRAZZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 7191,2018-03345,https://www.federalregister.gov/documents/2018/02/20/2018-03345/determination-of-regulatory-review-period-for-purposes-of-patent-extension-portrazza,https://www.govinfo.gov/content/pkg/FR-2018-02-20/pdf/2018-03345.pdf,2/20/2018, PORTRAZZA,,Nicolas,PORTRAZZA,1,355,Jonathan,7598350,,,,Eli Lilly,2533,2175,358,2008-12-19,2008-12-19,2015-11-24,BLA 125547,1321,125547,,,,,,,,,,,Portrazza,necitumumab,Eli Lilly,BLA,125547,,2014-12-02,2015-11-24,2015,,"PORTRAZZA is indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer. 
Limitation of Use:
PORTRAZZA is not indicated for treatment of non-squamous non-small cell lung cancer.",Standard,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; DARZALEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DARZALEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 7192,2018-03342,https://www.federalregister.gov/documents/2018/02/20/2018-03342/determination-of-regulatory-review-period-for-purposes-of-patent-extension-darzalex,https://www.govinfo.gov/content/pkg/FR-2018-02-20/pdf/2018-03342.pdf,2/20/2018, DARZALEX,,Nicolas,DARZALEX,1,1,Nicolas,7829673,,,,Genmab A/S,1939,1808,131,2010-07-28,2010-07-28,2015-11-16,BLA 761,1000,761,5/6/2013,Treatment of multiple myeloma,Designated/Approved,,,Treatment of adult patients with multiple myeloma in combination with carfilzomib and dexamethasone in patients who have received one to three prior lines of therapy,8/20/2020,,,"Janssen Biotech, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DARZALEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DARZALEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 7192,2018-03342,https://www.federalregister.gov/documents/2018/02/20/2018-03342/determination-of-regulatory-review-period-for-purposes-of-patent-extension-darzalex,https://www.govinfo.gov/content/pkg/FR-2018-02-20/pdf/2018-03342.pdf,2/20/2018, DARZALEX,,Nicolas,DARZALEX,1,2,Nicolas,7829673,,,,Genmab A/S,1939,1808,131,2010-07-28,2010-07-28,2015-11-16,BLA 761,1000,761,5/6/2013,Treatment of multiple myeloma,Designated/Approved,,,"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor; and as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.",6/16/2017,6/16/2024,"In combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, not including any overlap with the exclusivity awarded for the 2015 approval for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and immunomodulary agent or are double refractory to a proteasome inhibitor and immunomodulatory agent.","Janssen Biotech, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DARZALEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DARZALEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 7192,2018-03342,https://www.federalregister.gov/documents/2018/02/20/2018-03342/determination-of-regulatory-review-period-for-purposes-of-patent-extension-darzalex,https://www.govinfo.gov/content/pkg/FR-2018-02-20/pdf/2018-03342.pdf,2/20/2018, DARZALEX,,Nicolas,DARZALEX,1,3,Nicolas,7829673,,,,Genmab A/S,1939,1808,131,2010-07-28,2010-07-28,2015-11-16,BLA 761,1000,761,5/6/2013,Treatment of multiple myeloma,Designated/Approved,,,"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.",11/21/2016,11/21/2023,"DARZALEX in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.","Janssen Biotech, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DARZALEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DARZALEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 7192,2018-03342,https://www.federalregister.gov/documents/2018/02/20/2018-03342/determination-of-regulatory-review-period-for-purposes-of-patent-extension-darzalex,https://www.govinfo.gov/content/pkg/FR-2018-02-20/pdf/2018-03342.pdf,2/20/2018, DARZALEX,,Nicolas,DARZALEX,1,4,Nicolas,7829673,,,,Genmab A/S,1939,1808,131,2010-07-28,2010-07-28,2015-11-16,BLA 761,1000,761,5/6/2013,Treatment of multiple myeloma,Designated/Approved,,,"Treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant (ASCT) and in patients with relapsed or refractory multiple myeloma who have received at least 1 prior therapy; in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for ASCT; in combination with bortezomib, thalidomide and dexamethasone in newly diagnosed patients who are eligible for ASCT; in combination with bortezomib and dexamethasone in patients who have received at least 1 prior therapy; in combination with pomalidomide and dexamethasone in patients who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor (PI); and as monotherapy, in patients who have received at least 3 prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immodulatory agent.",9/26/2019,9/26/2026,"Indicated for the treatment of adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant","Janssen Biotech, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DARZALEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DARZALEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 7192,2018-03342,https://www.federalregister.gov/documents/2018/02/20/2018-03342/determination-of-regulatory-review-period-for-purposes-of-patent-extension-darzalex,https://www.govinfo.gov/content/pkg/FR-2018-02-20/pdf/2018-03342.pdf,2/20/2018, DARZALEX,,Nicolas,DARZALEX,1,5,Nicolas,7829673,,,,Genmab A/S,1939,1808,131,2010-07-28,2010-07-28,2015-11-16,BLA 761,1000,761,5/6/2013,Treatment of multiple myeloma,Designated/Approved,,,"DARZALEX is indicated in combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; and in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor; and as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.",5/7/2018,5/7/2025,"In combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant","Janssen Biotech, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DARZALEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DARZALEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 7192,2018-03342,https://www.federalregister.gov/documents/2018/02/20/2018-03342/determination-of-regulatory-review-period-for-purposes-of-patent-extension-darzalex,https://www.govinfo.gov/content/pkg/FR-2018-02-20/pdf/2018-03342.pdf,2/20/2018, DARZALEX,,Nicolas,DARZALEX,1,6,Nicolas,7829673,,,,Genmab A/S,1939,1808,131,2010-07-28,2010-07-28,2015-11-16,BLA 761,1000,761,5/6/2013,Treatment of multiple myeloma,Designated/Approved,,,For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent,11/16/2015,11/16/2022,For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent,"Janssen Biotech, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DARZALEX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DARZALEX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 7192,2018-03342,https://www.federalregister.gov/documents/2018/02/20/2018-03342/determination-of-regulatory-review-period-for-purposes-of-patent-extension-darzalex,https://www.govinfo.gov/content/pkg/FR-2018-02-20/pdf/2018-03342.pdf,2/20/2018, DARZALEX,,Nicolas,DARZALEX,1,7,Nicolas,7829673,,,,Genmab A/S,1939,1808,131,2010-07-28,2010-07-28,2015-11-16,BLA 761,1000,761,5/6/2013,Treatment of multiple myeloma,Designated/Approved,,,DARZALEX is indicated for the treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.,6/27/2019,,,"Janssen Biotech, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MAESTRO RECHARGEABLE SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MAESTRO RECHARGEABLE SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 7196,2018-03343,https://www.federalregister.gov/documents/2018/02/20/2018-03343/determination-of-regulatory-review-period-for-purposes-of-patent-extension-maestro-rechargeable,https://www.govinfo.gov/content/pkg/FR-2018-02-20/pdf/2018-03343.pdf,2/20/2018, MAESTRO RECHARGEABLE SYSTEM,,Nicolas,MAESTRO RECHARGEABLE SYSTEM,1,8,Nicolas,7672727,,,,EnteroMedics Inc.,2866,2296,570,2007-03-13,2007-03-13,2015-01-14,PMA P130019,385,130019,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LYMPHOSEEK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LYMPHOSEEK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 7734,2018-03610,https://www.federalregister.gov/documents/2018/02/22/2018-03610/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lymphoseek,https://www.govinfo.gov/content/pkg/FR-2018-02-22/pdf/2018-03610.pdf,2/22/2018, LYMPHOSEEK,,Nicolas,LYMPHOSEEK,1,9,Nicolas,6409990,,,,"Navidea Biopharmaceuticals, Inc.",4398,3816,582,2001-02-28,2001-02-28,2013-03-13,NDA 202207,1826,202207,9/17/2014,"Use in sentinel lymph node detection (SLN) with a hand-held gamma-counter, with scintigraphic imaging, in patients with cancer of the head and neck",Designated/Approved,,,"Guiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.",6/13/2014,6/13/2021,"Guiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.","Cardinal Health 414, LLC",Lymphoseek,technetium Tc 99m tilmanocept,Navidea Biopharmaceuticals,NDA,202207,,2011-08-10,2013-03-13,2013,,Lymphoseek (technetium Tc 99m tilmanocept) Injection is indicated for lymphatic mapping with a handheld gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; OFEV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OFEV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 7747,2018-03606,https://www.federalregister.gov/documents/2018/02/22/2018-03606/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ofev,https://www.govinfo.gov/content/pkg/FR-2018-02-22/pdf/2018-03606.pdf,2/22/2018, OFEV,,Nicolas,OFEV,1,10,Nicolas,6762180,,,,Boehringer Ingelheim Pharma Gmbh & Co. KG,3480,3313,167,2005-04-07,2005-04-07,2014-10-15,NDA 205832,1822,205832,6/29/2011,Treatment of patients with idiopathic pulmonary fibrosis.,Designated/Approved,,,Treatment of idiopathic pulmonary fibrosis,10/15/2014,10/15/2021,Treatment of idiopathic pulmonary fibrosis,"Boehringer Ingelheim Pharmaceuticals, Inc.",Ofev,nintedanib,Boehringer Ingelheim Pharmaceuticals,NDA,205832,,2014-05-02,2014-10-15,2014,,OFEV is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).,Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OFEV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OFEV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 7747,2018-03606,https://www.federalregister.gov/documents/2018/02/22/2018-03606/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ofev,https://www.govinfo.gov/content/pkg/FR-2018-02-22/pdf/2018-03606.pdf,2/22/2018, OFEV,,Nicolas,OFEV,1,11,Nicolas,6762180,,,,Boehringer Ingelheim Pharma Gmbh & Co. KG,3480,3313,167,2005-04-07,2005-04-07,2014-10-15,NDA 205832,1822,205832,7/6/2016,Treatment of systemic sclerosis (including the associated interstitial lung disease).,Designated/Approved,,,OFEV is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD).,9/6/2019,9/6/2026,Indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).,"Boehringer Ingelheim Pharmaceuticals, Inc.",Ofev,nintedanib,Boehringer Ingelheim Pharmaceuticals,NDA,205832,,2014-05-02,2014-10-15,2014,,OFEV is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).,Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ESBRIET,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ESBRIET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 7732,2018-03612,https://www.federalregister.gov/documents/2018/02/22/2018-03612/determination-of-regulatory-review-period-for-purposes-of-patent-extension-esbriet,https://www.govinfo.gov/content/pkg/FR-2018-02-22/pdf/2018-03612.pdf,2/22/2018, ESBRIET,,Nicolas,ESBRIET,5,16,Nicolas,7767225; 7767700; 7988994; 8383150; and 8420674,,,,InterMune Inc.,14993,13186,1807,1973-09-29,1973-09-29,2014-10-15,NDA 22-535,754,22535,3/5/2004,Treatment of idiopathic pulmonary fibrosis,Designated/Approved,,,Treatment of idiopathic pulmonary fibrosis,10/15/2014,10/15/2021,Treatment of idiopathic pulmonary fibrosis,Genentech,Esbriet,pirfenidone,Intermune,NDA,22535,,2009-11-04,2014-10-15,2014,,ESBRIET is indicated for the treatment of idiopathic pulmonary fibrosis (IPF),Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ZYDELIG-New Drug Application 206545,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZYDELIG based on new drug application (NDA) 206545 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 8088,2018-03701,https://www.federalregister.gov/documents/2018/02/23/2018-03701/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zydelig-new-drug,https://www.govinfo.gov/content/pkg/FR-2018-02-23/pdf/2018-03701.pdf,2/23/2018, ZYDELIG-New Drug Application 206545,,Nicolas,ZYDELIG,2,18,Nicolas,RE44599 and RE44638,,,,ICOS Corporation,2247,2017,230,2008-05-30,2018-04-24,2014-07-23,NDA 206545,708,206545,,,,,,,,,,,Zydelig,idelalisib,Gilead Sciences,NDA,206545,205858,2013-09-11,2014-07-23,2014,,"[A] Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
[B] Zydelig is indicated for the treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least two prior systemic therapies. Accelerated approval was granted for this indication based on Overall Response Rate.  An improvement in patient survival or disease related symptoms has not been established. Continues approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials. 
[C] Zydelig is indicated for the treatment of patients with relapsed small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.  Accelerated approval was granted for this indication based on Overall Response Rate. An improvement in patient survival or disease related symptoms has not been established. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.",Priority (indication [A] only),Yes,Yes (indications [B] and [C] only),Yes (indication [A] only),Yes (indication [A] only)
Determination of Regulatory Review Period for Purposes of Patent Extension; TREMFYA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TREMFYA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 52471,2018-22571,https://www.federalregister.gov/documents/2018/10/17/2018-22571/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tremfya,https://www.govinfo.gov/content/pkg/FR-2018-10-17/pdf/2018-22571.pdf,10/17/2018, TREMFYA,,Nicolas,TREMFYA,2,20,Nicolas,and 7993645,,,,"Janssen Biotech, Inc.",2968,2728,240,2009-05-30,2009-05-30,2017-07-13,BLA 761061,1203,761061,,,,,,,,,,,Tremfya,guselkumab,Janssen Biotech,BLA,761061,,2016-11-16,2017-07-13,2017,,TREMFYA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.,Priority (used priority review voucher),No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; DUPIXENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DUPIXENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 52481,2018-22566,https://www.federalregister.gov/documents/2018/10/17/2018-22566/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dupixent,https://www.govinfo.gov/content/pkg/FR-2018-10-17/pdf/2018-22566.pdf,10/17/2018, DUPIXENT,,Nicolas,DUPIXENT,1,21,Nicolas,7608693,2009-10-27,"Regeneron Pharmaceuticals, Inc.",1273,"Regeneron Pharmaceuticals, Inc.",2728,2485,243,2009-10-10,2009-10-10,2017-03-28,BLA 761055,1273,761055,9/5/2017,Treatment of eosinophilic esophagitis,Designated/Approved,,,"Treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE)",5/20/2022,5/20/2029,"Treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE)","Regeneron Pharmaceuticals, Inc.",Dupixent,dupilumab,Regeneron Pharmaceuticals,BLA,761055,,2016-07-29,2017-03-28,2017,,DUPIXENT is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.,Priority,No,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; DUPIXENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DUPIXENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 52481,2018-22566,https://www.federalregister.gov/documents/2018/10/17/2018-22566/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dupixent,https://www.govinfo.gov/content/pkg/FR-2018-10-17/pdf/2018-22566.pdf,10/17/2018, DUPIXENT,,Nicolas,DUPIXENT,1,22,Nicolas,7608693,,,,"Regeneron Pharmaceuticals, Inc.",2728,2485,243,2009-10-10,2009-10-10,2017-03-28,BLA 761055,1273,761055,9/5/2017,Treatment of eosinophilic esophagitis,Designated/Approved,,,"treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE)",1/25/2024,1/25/2031,treatment of pediatric patients aged 1 year and older weighing at least 15 kg who are less than 12 years of age or less than 40 kg in weight with eosinophilic esophagitis (EoE),"Regeneron Pharmaceuticals, Inc.",Dupixent,dupilumab,Regeneron Pharmaceuticals,BLA,761055,,2016-07-29,2017-03-28,2017,,DUPIXENT is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.,Priority,No,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BRINEURA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRINEURA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 52483,2018-22559,https://www.federalregister.gov/documents/2018/10/17/2018-22559/determination-of-regulatory-review-period-for-purposes-of-patent-extension-brineura,https://www.govinfo.gov/content/pkg/FR-2018-10-17/pdf/2018-22559.pdf,10/17/2018, BRINEURA,,Nicolas,BRINEURA,1,23,Nicolas,8029781,,,,"Rutgers, the State University of New Jersey",995,659,336,2014-08-08,2014-08-08,2017-04-27,BLA 761052,666,761052,4/1/2013,Treatment of neuronal ceroid lipofuscinosis type 2,Designated/Approved,,,"To slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.",4/27/2017,4/27/2024,"To slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.","BioMarin Pharmaceutical, Inc.",Brineura,cerliponase alfa,BioMarin Pharmaceutical,BLA,761052,,2016-05-27,2017-04-27,2017,,"Brineura is indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.",Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BRINEURA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRINEURA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 52483,2018-22559,https://www.federalregister.gov/documents/2018/10/17/2018-22559/determination-of-regulatory-review-period-for-purposes-of-patent-extension-brineura,https://www.govinfo.gov/content/pkg/FR-2018-10-17/pdf/2018-22559.pdf,10/17/2018, BRINEURA,,Nicolas,BRINEURA,1,24,Nicolas,8029781,,,,"Rutgers, the State University of New Jersey",995,659,336,2014-08-08,2014-08-08,2017-04-27,BLA 761052,666,761052,4/1/2013,Treatment of neuronal ceroid lipofuscinosis type 2,Designated/Approved,,,"to slow the loss of ambulation in pediatric patients with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as tripeptidyl peptidase 1 (TPP1) deficiency",7/24/2024,7/24/2031,"to slow the loss of ambulation in pediatric patients less than 3 years of age with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as tripeptidyl peptidase 1 (TPP1) deficiency, and to slow the loss of ambulation in asymptomatic pediatric patients 3 years of age and older with CLN2 disease, also known as TPP1 deficiency","BioMarin Pharmaceutical, Inc.",Brineura,cerliponase alfa,BioMarin Pharmaceutical,BLA,761052,,2016-05-27,2017-04-27,2017,,"Brineura is indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.",Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; OCREVUS,Notice,Health and Human Services Department; Food and Drug Administration,The Food and Drug Administration (FDA or the Agency) has,83 FR 52837,2018-22699,https://www.federalregister.gov/documents/2018/10/18/2018-22699/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ocrevus,https://www.govinfo.gov/content/pkg/FR-2018-10-18/pdf/2018-22699.pdf,10/18/2018, OCREVUS,,Nicolas,OCREVUS,2,26,Nicolas,7799900 and 8562992,,,,"Genentech, Inc.",4844,4509,335,2003-12-25,2003-12-25,2017-03-28,BLA 761053,795,761053,,,,,,,,,,,Ocrevus,ocrelizumab,Genentech,BLA,761053,,2016-04-28,2017-03-28,2017,,OCREVUS is indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis.,Priority,No,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; AFSTYLA,Notice,Health and Human Services Department; Food and Drug Administration,The Food and Drug Administration (FDA or the Agency) has,83 FR 52839,2018-22696,https://www.federalregister.gov/documents/2018/10/18/2018-22696/determination-of-regulatory-review-period-for-purposes-of-patent-extension-afstyla,https://www.govinfo.gov/content/pkg/FR-2018-10-18/pdf/2018-22696.pdf,10/18/2018, AFSTYLA,,Nicolas,AFSTYLA,1,27,Nicolas,7041635,,,,"SK Chemicals Co, LTD.",1734,1371,363,2011-08-28,2011-08-28,2016-05-25,BLA 125591,1047,125591,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; IMFINZI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMFINZI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 53067,2018-22806,https://www.federalregister.gov/documents/2018/10/19/2018-22806/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imfinzi,https://www.govinfo.gov/content/pkg/FR-2018-10-19/pdf/2018-22806.pdf,10/19/2018, IMFINZI,,Nicolas,IMFINZI,2,29,Nicolas,8779108 and 9493565,,,,MedImmune Limited,1755,1554,201,2012-07-13,2012-07-13,2017-05-01,BLA 761069,159,761069,12/10/2020,Treatment of biliary tract cancer,Designated/Approved,,,"In combination with gemcitabine and cisplatin, for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC)",9/2/2022,9/2/2029,treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC),AstraZeneca Pharmaceuticals LP,Imfinzi,durvalumab,AstraZeneca UK Limited,BLA,761069,,2016-10-13,2017-05-01,2017,,"IMFINZI is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
- have disease progression during or following platinum-containing chemotherapy.
- have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,No,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; IMFINZI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMFINZI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 53067,2018-22806,https://www.federalregister.gov/documents/2018/10/19/2018-22806/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imfinzi,https://www.govinfo.gov/content/pkg/FR-2018-10-19/pdf/2018-22806.pdf,10/19/2018, IMFINZI,,Nicolas,IMFINZI,2,31,Nicolas,8779108 and 9493565,,,,MedImmune Limited,1755,1554,201,2012-07-13,2012-07-13,2017-05-01,BLA 761069,159,761069,1/15/2020,Treatment of hepatocellular carcinoma,Designated/Approved,,,In combination with tremelimumab-actl for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC),10/21/2022,10/21/2029,treatment of adult patients with unresectable hepatocellular carcinoma (uHCC),AstraZeneca Pharmaceuticals LP,Imfinzi,durvalumab,AstraZeneca UK Limited,BLA,761069,,2016-10-13,2017-05-01,2017,,"IMFINZI is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
- have disease progression during or following platinum-containing chemotherapy.
- have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,No,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; IMFINZI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMFINZI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 53067,2018-22806,https://www.federalregister.gov/documents/2018/10/19/2018-22806/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imfinzi,https://www.govinfo.gov/content/pkg/FR-2018-10-19/pdf/2018-22806.pdf,10/19/2018, IMFINZI,,Nicolas,IMFINZI,2,33,Nicolas,8779108 and 9493565,,,,MedImmune Limited,1755,1554,201,2012-07-13,2012-07-13,2017-05-01,BLA 761069,159,761069,7/10/2019,Treatment of small cell lung cancer,Designated/Approved,,,"IMFINZI is indicated for use, in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).",3/27/2020,3/27/2027,"Indicated in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).",AstraZeneca Pharmaceuticals LP,Imfinzi,durvalumab,AstraZeneca UK Limited,BLA,761069,,2016-10-13,2017-05-01,2017,,"IMFINZI is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
- have disease progression during or following platinum-containing chemotherapy.
- have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,No,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TYMLOS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TYMLOS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 53260,2018-22956,https://www.federalregister.gov/documents/2018/10/22/2018-22956/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tymlos,https://www.govinfo.gov/content/pkg/FR-2018-10-22/pdf/2018-22956.pdf,10/22/2018, TYMLOS,,Nicolas,TYMLOS,3,36,Nicolas,7803770; 8148333; and 8748382,,,,"Radius Health, Inc.",4130,3735,395,2006-01-08,2006-01-08,2017-04-28,NDA 208743,1128,208743,,,,,,,,,,,Tymlos,abaloparatide,Radius Health,NDA,208743,,2016-03-30,2017-04-28,2017,,"TYMLOS is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, TYMLOS reduces the risk of vertebral fractures and nonvertebral fractures.
Limitations of Use:
Because of the unknown relevance of the rodent osteosarcoma findings to humans, cumulative use of TYMLOS and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patients lifetime is not recommended.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BESPONSA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BESPONSA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 53273,2018-22958,https://www.federalregister.gov/documents/2018/10/22/2018-22958/determination-of-regulatory-review-period-for-purposes-of-patent-extension-besponsa,https://www.govinfo.gov/content/pkg/FR-2018-10-22/pdf/2018-22958.pdf,10/22/2018, BESPONSA,,Nicolas,BESPONSA,3,39,Nicolas,8153768; 8835611; and 8747857,,,,Wyeth Holdings LLC,5298,5057,241,2003-02-16,2003-02-16,2017-08-17,BLA 761040,1099,761040,3/25/2013,Treatment of B-cell acute lymphoblastic leukemia,Designated/Approved,,,treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older,3/6/2024,3/6/2031,treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older,"Wyeth Pharmaceuticals, LLC",Besponsa,inotuzumab ozogamicin,Pfizer,BLA,761040,,2016-12-20,2017-08-17,2017,,BESPONSA is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).,Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TECENTRIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TECENTRIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 53259,2018-22957,https://www.federalregister.gov/documents/2018/10/22/2018-22957/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tecentriq,https://www.govinfo.gov/content/pkg/FR-2018-10-22/pdf/2018-22957.pdf,10/22/2018, TECENTRIQ,,Nicolas,TECENTRIQ,1,40,Nicolas,8217149,,,,"Genentech, Inc.",1836,1708,128,2011-05-11,2011-05-11,2016-05-18,BLA 761034,769,761034,10/13/2016,Treatment of small cell lung cancer (SCLC),Designated/Approved,,,"TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)",3/18/2019,3/18/2026,"TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)","Genentech, Inc.",Tecentriq,atezolizumab,Genentech,BLA,761034,,2016-01-12,2016-05-18,2016,,"TECENTRIQ (atezolizumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
- Have disease progression during or following platinum-containing chemotherapy
- Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,No,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TECENTRIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TECENTRIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 53259,2018-22957,https://www.federalregister.gov/documents/2018/10/22/2018-22957/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tecentriq,https://www.govinfo.gov/content/pkg/FR-2018-10-22/pdf/2018-22957.pdf,10/22/2018, TECENTRIQ,,Nicolas,TECENTRIQ,1,41,Nicolas,8217149,,,,"Genentech, Inc.",1836,1708,128,2011-05-11,2011-05-11,2016-05-18,BLA 761034,769,761034,10/8/2020,treatment of soft tissue sarcoma,Designated/Approved,,,as a single agent for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS),12/9/2022,12/9/2029,treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS),"Genentech, Inc.",Tecentriq,atezolizumab,Genentech,BLA,761034,,2016-01-12,2016-05-18,2016,,"TECENTRIQ (atezolizumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
- Have disease progression during or following platinum-containing chemotherapy
- Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,No,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; NUPLAZID,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NUPLAZID and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 53481,2018-23057,https://www.federalregister.gov/documents/2018/10/23/2018-23057/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nuplazid,https://www.govinfo.gov/content/pkg/FR-2018-10-23/pdf/2018-23057.pdf,10/23/2018, NUPLAZID,,Nicolas,NUPLAZID,3,44,Nicolas,7601740; 7659285; and 7732615,,,,ACADIA Pharmaceuticals Inc.,4557,4315,242,2003-11-09,2003-11-09,2016-04-29,NDA 207-318,1316,207318,,,,,,,,,,,Nuplazid,pimavanserin,Acadia Pharmaceuticals,NDA,207318,,2015-09-01,2016-04-29,2016,,NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinsons disease psychosis.,Priority,No,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SILIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SILIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 53476,2018-23058,https://www.federalregister.gov/documents/2018/10/23/2018-23058/determination-of-regulatory-review-period-for-purposes-of-patent-extension-siliq,https://www.govinfo.gov/content/pkg/FR-2018-10-23/pdf/2018-23058.pdf,10/23/2018, SILIQ,,Nicolas,SILIQ,4,48,Nicolas,7767206; 7939070; 8435518; and 8545842,,,,"Kirin-Amgen, Inc.",3101,2643,458,2008-08-22,2008-08-22,2017-02-15,BLA 761032,847,761032,,,,,,,,,,,Siliq,brodalumab,Valeant Pharmaceuticals,BLA,761032,,2015-11-16,2017-02-15,2017,,SILIQ is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LARTRUVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LARTRUVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 53640,2018-23219,https://www.federalregister.gov/documents/2018/10/24/2018-23219/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lartruvo,https://www.govinfo.gov/content/pkg/FR-2018-10-24/pdf/2018-23219.pdf,10/24/2018, LARTRUVO,,Nicolas,LARTRUVO,1,49,Nicolas,8128929,,,,Imclone LLC,3766,3527,239,2006-06-30,2006-06-30,2016-10-19,BLA 761038,1003,761038,10/9/2014,Treatment of soft tissue sarcoma,Designated/Approved,,,"In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. (Indication withdrawn)",10/19/2016,2/25/2020,"In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. (Indication withdrawn)",Eli Lilly and Company,Lartruvo,olaratumab,Eli Lilly,BLA,761038,,2016-02-24,2016-10-19,2016,,"LARTRUVO is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; TALTZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TALTZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 54108,2018-23438,https://www.federalregister.gov/documents/2018/10/26/2018-23438/determination-of-regulatory-review-period-for-purposes-of-patent-extension-taltz,https://www.govinfo.gov/content/pkg/FR-2018-10-26/pdf/2018-23438.pdf,10/26/2018, TALTZ,,Nicolas,TALTZ,2,51,Nicolas,7838638 and 8110191,,,,Eli Lilly,3036,2670,366,2007-12-01,2007-12-01,2016-03-22,BLA 125521,935,125521,,,,,,,,,,,Taltz,ixekizumab,Eli Lilly,BLA,125521,,2015-03-23,2016-03-22,2016,,TALTZ is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; REBINYN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REBINYN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 54112,2018-23437,https://www.federalregister.gov/documents/2018/10/26/2018-23437/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rebinyn,https://www.govinfo.gov/content/pkg/FR-2018-10-26/pdf/2018-23437.pdf,10/26/2018, REBINYN,,Nicolas,REBINYN,2,53,Nicolas,7138371 and 7179617,,,,Novo Nordisk A/S,2793,2412,381,2009-10-09,2009-10-09,2017-05-31,BLA 125611,1660,125611,3/18/2013,Routine prophylactic administration for prevention of bleeding in patients with hemophilia B (Christmas disease),Designated/Approved,,,Routine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hemophilia B (congenital Factor IX deficiency),7/29/2022,,,"Novo Nordisk, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; RAINDROP NEAR VISION INLAY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RAINDROP NEAR VISION INLAY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 54360,2018-23527,https://www.federalregister.gov/documents/2018/10/29/2018-23527/determination-of-regulatory-review-period-for-purposes-of-patent-extension-raindrop-near-vision,https://www.govinfo.gov/content/pkg/FR-2018-10-29/pdf/2018-23527.pdf,10/29/2018, RAINDROP NEAR VISION INLAY,,Nicolas,RAINDROP NEAR VISION INLAY,1,54,Nicolas,8057541,,,,"ReVision Optics, Inc.",2354,2074,280,2017-09-20,2010-01-20,2016-06-29,PMA P150034,828,150034,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; KEVZARA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KEVZARA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",83 FR 61643,2018-26033,https://www.federalregister.gov/documents/2018/11/30/2018-26033/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kevzara,https://www.govinfo.gov/content/pkg/FR-2018-11-30/pdf/2018-26033.pdf,11/30/2018, KEVZARA,,Nicolas,KEVZARA,2,56,Nicolas,7582298 and 8568721,,,,"Regeneron Pharmaceuticals, Inc.",3478,2907,571,2007-11-15,2007-11-15,2017-05-22,BLA 761037,937,761037,,,,,,,,,,,Kevzara,sarilumab,Sanofi,BLA,761037,,2015-10-30,2017-05-22,2017,,KEVZARA is indicated for treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; PROVAYBLUE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PROVAYBLUE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 61645,2018-26035,https://www.federalregister.gov/documents/2018/11/30/2018-26035/determination-of-regulatory-review-period-for-purposes-of-patent-extension-provayblue,https://www.govinfo.gov/content/pkg/FR-2018-11-30/pdf/2018-26035.pdf,11/30/2018, PROVAYBLUE,,Nicolas,PROVAYBLUE,1,57,Nicolas,8765942,,,,Provepharm S.A.S.,415,232,183,2015-02-20,2015-02-20,2016-04-08,NDA 204630,298,204630,12/18/2012,Treatment of hereditary and acquired methemoglobinemia,Designated/Approved,,,For treatment of pediatric and adult patients with acquired methemoglobinemia.,4/8/2016,4/8/2023,For treatment of pediatric and adult patients with acquired methemoglobinemia.,Provepharm SAS,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TRULANCE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TRULANCE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 62590,2018-26289,https://www.federalregister.gov/documents/2018/12/04/2018-26289/determination-of-regulatory-review-period-for-purposes-of-patent-extension-trulance,https://www.govinfo.gov/content/pkg/FR-2018-12-04/pdf/2018-26289.pdf,12/4/2018, TRULANCE,,Nicolas,TRULANCE,1,58,Nicolas,7041786,,,,"Synergy Pharmaceuticals, Inc.",3186,2829,357,2008-05-02,2008-05-02,2017-01-19,NDA 208745,1771,208745,,,,,,,,,,,Trulance,plecanatide,Synergy Pharmaceuticals,NDA,208745,,2016-01-29,2017-01-19,2017,,TRULANCE is indicated in adults for the treatment of chronic idiopathic constipation (CIC).,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; OCALIVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OCALIVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 62591,2018-26288,https://www.federalregister.gov/documents/2018/12/04/2018-26288/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ocaliva,https://www.govinfo.gov/content/pkg/FR-2018-12-04/pdf/2018-26288.pdf,12/4/2018, OCALIVA,,Nicolas,OCALIVA,1,59,Nicolas,7138390,,,,"Intercept Pharmaceuticals, Inc.",3742,3408,334,2006-03-01,2006-03-01,2016-05-27,NDA 207999,1826,207999,4/9/2008,Treatment of primary biliary cirrhosis,Designated/Approved,,,"Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA",5/27/2016,5/27/2023,"Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA","Intercept Pharmaceuticals, Inc.",Ocaliva,obeticholic acid,Intercept Pharmaceuticals,NDA,207999,,2015-06-29,2016-05-27,2016,,"OCALIVA is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA._x000D_
This indication is approved under accelerated approval based on a reduction in alkaline phosphatase (ALP). An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ASPIRE ASSIST,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ASPIRE ASSIST and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 62580,2018-26290,https://www.federalregister.gov/documents/2018/12/04/2018-26290/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aspire-assist,https://www.govinfo.gov/content/pkg/FR-2018-12-04/pdf/2018-26290.pdf,12/4/2018, ASPIRE ASSIST,,Nicolas,ASPIRE ASSIST,1,60,Nicolas,9039677,,,,"Aspire Bariatrics, Inc.",2785,2444,341,2008-10-31,2008-10-31,2016-06-14,PMA P150024,385,150024,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; EXABLATE NEURO MODEL 4000 TYPE 1.0 SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EXABLATE NEURO MODEL 4000 TYPE 1.0 SYSTEM (EXABLATE) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 62593,2018-26282,https://www.federalregister.gov/documents/2018/12/04/2018-26282/determination-of-regulatory-review-period-for-purposes-of-patent-extension-exablate-neuro-model-4000,https://www.govinfo.gov/content/pkg/FR-2018-12-04/pdf/2018-26282.pdf,12/4/2018, EXABLATE NEURO MODEL 4000 TYPE 1.0 SYSTEM,,Nicolas,EXABLATE,1,61,Nicolas,6612988,,,,Brigham,2050,1785,265,2019-02-04,2010-12-02,2016-07-11,PMA P150038,1158,150038,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ABSORB GT1 BIORESORBABLE SCAFFOLD,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ABSORB GT1 Bioresorbable Scaffold and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",83 FR 65680,2018-27678,https://www.federalregister.gov/documents/2018/12/21/2018-27678/determination-of-regulatory-review-period-for-purposes-of-patent-extension-absorb-gt1-bioresorbable,https://www.govinfo.gov/content/pkg/FR-2018-12-21/pdf/2018-27678.pdf,12/21/2018, ABSORB GT1 BIORESORBABLE SCAFFOLD,,Nicolas,ABSORB GT1 BIORESORBABLE SCAFFOLD,2,63,Nicolas,7971333 and 8323329,,,,Abbott Cardiovascular Systems Inc.,1303,932,371,2012-12-12,2012-12-12,2016-07-05,PMA P150023,841,150023,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ADLYXIN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for ADLYXIN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 66279,2018-27805,https://www.federalregister.gov/documents/2018/12/26/2018-27805/determination-of-regulatory-review-period-for-purposes-of-patent-extension-adlyxin,https://www.govinfo.gov/content/pkg/FR-2018-12-26/pdf/2018-27805.pdf,12/26/2018, ADLYXIN,,Nicolas,ADLYXIN,1,64,Nicolas,RE45313,,,,ZP Holding SPV K/S,5500,5133,367,2001-07-08,2001-07-08,2016-07-27,NDA 208471,1826,208471,,,,,,,,,,,Adlyxin,lixisenatide,Sanofi,BLA,208471,,2015-07-27,2016-07-27,2016,,"ADLYXIN is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use:
- ADLYXIN has not been studied in patients with chronic pancreatitis or a history of unexplained pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
- ADLYXIN is not a substitute for insulin. ADLYXIN is not indicated for use in patients with type 1 diabetes mellitus or for treatment of diabetic ketoacidosis.
- The concurrent use of ADLYXIN with short acting insulin has not been studied and is not recommended.
- ADLYXIN has not been studied in patients with gastroparesis and is not recommended in patients with gastroparesis. ",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; PARSABIV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PARSABIV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 67293,2018-28221,https://www.federalregister.gov/documents/2018/12/28/2018-28221/determination-of-regulatory-review-period-for-purposes-of-patent-extension-parsabiv,https://www.govinfo.gov/content/pkg/FR-2018-12-28/pdf/2018-28221.pdf,12/28/2018, PARSABIV,,Nicolas,PARSABIV,3,67,Nicolas,8377880; 8999932; and 9278995,,,,"KAI Pharmaceuticals, Inc.",2335,1801,534,2010-09-19,2010-09-19,2017-02-07,NDA 208325,193,208325,,,,,,,,,,,Parsabiv,etelcalcetide,Amgen,NDA,208325,,2015-08-24,2017-02-07,2017,,"PARSABIV is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
Limitations of Use:
PARSABIV has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with chronic kidney disease who are not on hemodialysis and is not recommended for use in these populations.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; XERMELO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XERMELO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 67296,2018-28218,https://www.federalregister.gov/documents/2018/12/28/2018-28218/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xermelo,https://www.govinfo.gov/content/pkg/FR-2018-12-28/pdf/2018-28218.pdf,12/28/2018, XERMELO,,Nicolas,XERMELO,1,68,Nicolas,7709493,,,,"Lexicon Pharmaceuticals, Inc.",3329,2993,336,2008-01-20,2008-01-20,2017-02-28,NDA 208794,1175,208794,3/9/2012,Treatment of carcinoid syndrome in patients with neuroendocrine tumors,Designated/Approved,,,Treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.,2/28/2017,2/28/2024,Treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.,"TerSera Therapeutics, LLC",Xermelo,telotristat ethyl,Lexicon Pharmaceuticals,NDA,208794,,2016-03-30,2017-02-28,2017,,Xermelo is indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.,Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; RUBRACA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RUBRACA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 67290,2018-28217,https://www.federalregister.gov/documents/2018/12/28/2018-28217/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rubraca,https://www.govinfo.gov/content/pkg/FR-2018-12-28/pdf/2018-28217.pdf,12/28/2018, RUBRACA,,Nicolas,RUBRACA,1,69,Nicolas,6495541,,,,"Agouron Pharmaceuticals, LLC",2644,2464,180,2009-09-25,2009-09-25,2016-12-19,NDA 209115,1412,209115,7/31/2012,Treatment of ovarian cancer,Designated/Approved,,,"For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.",4/6/2018,4/6/2025,For the maintenance treatment of adult patients with recurrent epithelial ovarian cancer who are in complete or partial response to platinum-based chemotherapy.,"Clovis Oncology, Inc.",Rubraca,rucaparib,Clovis Oncology,NDA,209115,,2016-06-23,2016-12-19,2016,,"Rubraca is indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for Rubraca.
This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; RUBRACA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RUBRACA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 67290,2018-28217,https://www.federalregister.gov/documents/2018/12/28/2018-28217/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rubraca,https://www.govinfo.gov/content/pkg/FR-2018-12-28/pdf/2018-28217.pdf,12/28/2018, RUBRACA,,Nicolas,RUBRACA,1,70,Nicolas,6495541,,,,"Agouron Pharmaceuticals, LLC",2644,2464,180,2009-09-25,2009-09-25,2016-12-19,NDA 209115,1412,209115,7/31/2012,Treatment of ovarian cancer,Designated/Approved,,,As monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies (Indication withdrawn),12/19/2016,6/10/2022,As monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies (Indication withdrawn),"Clovis Oncology, Inc.",Rubraca,rucaparib,Clovis Oncology,NDA,209115,,2016-06-23,2016-12-19,2016,,"Rubraca is indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for Rubraca.
This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; RYDAPT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RYDAPT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 67295,2018-28216,https://www.federalregister.gov/documents/2018/12/28/2018-28216/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rydapt,https://www.govinfo.gov/content/pkg/FR-2018-12-28/pdf/2018-28216.pdf,12/28/2018, RYDAPT,,Nicolas,RYDAPT,3,73,Nicolas,7973031; 8222244; and 8575146,,,,Novartis AG,6737,6494,243,1998-11-19,1998-11-19,2017-04-28,NDA 207997,1183,207997,7/7/2009,Treatment of acute myeloid leukemia,Designated/Approved,,,"Treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.",4/28/2017,4/28/2024,"Treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.",Novartis Pharmaceuticals Corporation,Rydapt,midostaurin,Novartis Pharmaceuticals,NDA,207997,,2016-08-29,2017-04-28,2017,,"[A] RYDAPT is indicated, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive, as detected by a FDA approved test.
Limitations of Use:  RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.
[B] RYDAPT is indicated for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).",Priority,Yes,No,Yes (indication [A] only),Yes (indication [B] only)
Determination of Regulatory Review Period for Purposes of Patent Extension; RYDAPT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RYDAPT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",83 FR 67295,2018-28216,https://www.federalregister.gov/documents/2018/12/28/2018-28216/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rydapt,https://www.govinfo.gov/content/pkg/FR-2018-12-28/pdf/2018-28216.pdf,12/28/2018, RYDAPT,,Nicolas,RYDAPT,3,76,Nicolas,7973031; 8222244; and 8575146,,,,Novartis AG,6737,6494,243,1998-11-19,1998-11-19,2017-04-28,NDA 207997,1183,207997,4/30/2010,Treatment of mastocytosis,Designated/Approved,,,"Treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)",4/28/2017,4/28/2024,"Treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)",Novartis Pharmaceuticals Corporation,Rydapt,midostaurin,Novartis Pharmaceuticals,NDA,207997,,2016-08-29,2017-04-28,2017,,"[A] RYDAPT is indicated, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive, as detected by a FDA approved test.
Limitations of Use:  RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.
[B] RYDAPT is indicated for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).",Priority,Yes,No,Yes (indication [A] only),Yes (indication [B] only)
Determination of Regulatory Review Period for Purposes of Patent Extension; EXONDYS 51,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EXONDYS 51 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 3186,2019-01851,https://www.federalregister.gov/documents/2019/02/11/2019-01851/determination-of-regulatory-review-period-for-purposes-of-patent-extension-exondys-51,https://www.govinfo.gov/content/pkg/FR-2019-02-11/pdf/2019-01851.pdf,2/11/2019, EXONDYS 51,,Nicolas,EXONDYS 51,2,78,Nicolas,7807816 and 9018368,,,,the University of Western Australia,2280,1828,452,2015-09-18,2010-06-25,2016-09-19,NDA 206488,481,206488,10/23/2007,Treatment of Duchenne Muscular Dystrophy.,Designated/Approved,,,Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping,9/19/2016,9/19/2023,Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping,"Sarepta Therapeutics, Inc.",Exondys 51,eteplirsen,Sarepta Therapeutics,NDA,206488,,2015-06-26,2016-09-19,2016,,EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51. A clinical benefit of EXONDYS 51 has not been established. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.,Priority,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; EUCRISA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EUCRISA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",84 FR 3458,2019-01956,https://www.federalregister.gov/documents/2019/02/12/2019-01956/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eucrisa,https://www.govinfo.gov/content/pkg/FR-2019-02-12/pdf/2019-01956.pdf,2/12/2019, EUCRISA,,Nicolas,EUCRISA,2,80,Nicolas,8039451 and 8168614,,,,"Anacor Pharmaceuticals, Inc.",3121,2778,343,2008-05-31,2008-05-31,2016-12-14,NDA 207695,1114,207695,,,,,,,,,,,Eucrisa,crisaborole,Anacor Pharmacueticals,NDA,207695,,2016-01-07,2016-12-14,2016,,EUCRISA is indicated for topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ZEJULA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZEJULA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 3470,2019-02036,https://www.federalregister.gov/documents/2019/02/12/2019-02036/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zejula,https://www.govinfo.gov/content/pkg/FR-2019-02-12/pdf/2019-02036.pdf,2/12/2019, ZEJULA,,Nicolas,ZEJULA,1,81,Nicolas,8071623,,,,MSD Italia S.R.l.,3234,3086,148,2008-05-21,2008-05-21,2017-03-27,NDA 208447,370,208447,4/30/2010,Treatment of ovarian cancer,Designated/Approved,,,"Indicated for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy",3/27/2017,3/27/2024,Indicated for maintenance treatment of adult patients with recurrent epithelial ovarian cancer who are in a complete or partial response to platinum-based chemotherapy,"GlaxoSmithKline, LLC.",Zejula,niraparib,Tesaro,NDA,208447,,2016-10-31,2017-03-27,2017,,"ZEJULA is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ZEJULA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZEJULA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 3470,2019-02036,https://www.federalregister.gov/documents/2019/02/12/2019-02036/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zejula,https://www.govinfo.gov/content/pkg/FR-2019-02-12/pdf/2019-02036.pdf,2/12/2019, ZEJULA,,Nicolas,ZEJULA,1,82,Nicolas,8071623,,,,MSD Italia S.R.l.,3234,3086,148,2008-05-21,2008-05-21,2017-03-27,NDA 208447,370,208447,4/30/2010,Treatment of ovarian cancer,Designated/Approved,,,"ZEJULA? is indicated for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either, (1) a deleterious or suspected deleterious BRCA mutation, or (2) genomic instability and who have progressed more than six months after response to the last platinum-based chemotherapy (Indication withdrawn)",10/23/2019,9/14/2022,"Indicated for the treatment of adult patients with advanced ovarian cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation, or genomic instability and who have progressed more than six months after response to the last platinum-based chemotherapy (Indication withdrawn)","GlaxoSmithKline, LLC.",Zejula,niraparib,Tesaro,NDA,208447,,2016-10-31,2017-03-27,2017,,"ZEJULA is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ZEJULA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZEJULA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 3470,2019-02036,https://www.federalregister.gov/documents/2019/02/12/2019-02036/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zejula,https://www.govinfo.gov/content/pkg/FR-2019-02-12/pdf/2019-02036.pdf,2/12/2019, ZEJULA,,Nicolas,ZEJULA,1,83,Nicolas,8071623,,,,MSD Italia S.R.l.,3234,3086,148,2008-05-21,2008-05-21,2017-03-27,NDA 208447,370,208447,4/30/2010,Treatment of ovarian cancer,Designated/Approved,,,"ZEJULA is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy",4/29/2020,4/29/2027,Indicated for the maintenance treatment of adult patients with advanced epithelial ovarian cancer who are in a complete or partial response to first-line platinum-based chemotherapy.,"GlaxoSmithKline, LLC.",Zejula,niraparib,Tesaro,NDA,208447,,2016-10-31,2017-03-27,2017,,"ZEJULA is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; XADAGO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XADAGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 3456,2019-02044,https://www.federalregister.gov/documents/2019/02/12/2019-02044/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xadago,https://www.govinfo.gov/content/pkg/FR-2019-02-12/pdf/2019-02044.pdf,2/12/2019, XADAGO,,Nicolas,XADAGO,2,85,Nicolas,8076515 and 8283380,,,,Newron Pharmaceuticals S.p.A.,5019,4205,814,2003-06-26,2003-06-26,2017-03-21,NDA 207145,831,207145,,,,,,,,,,,Xadago,safinamide,Newron Pharmaceuticals,NDA,207145,,2014-12-29,2017-03-21,2017,,"XADAGO is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinsons disease (PD) experiencing off episodes._x000D_
Limitations of Use:_x000D_
XADAGO has not been shown to be effective as monotherapy for the treatment of PD.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SYMPROIC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SYMPROIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 15226,2019-07459,https://www.federalregister.gov/documents/2019/04/15/2019-07459/determination-of-regulatory-review-period-for-purposes-of-patent-extension-symproic,https://www.govinfo.gov/content/pkg/FR-2019-04-15/pdf/2019-07459.pdf,4/15/2019, SYMPROIC,,Nicolas,SYMPROIC,1,86,Nicolas,RE46365,,,,"Shionogi & Co., Ltd.",2523,2157,366,2010-04-28,2010-04-28,2017-03-23,NDA 208854,1140,208854,,,,,,,,,,,Symproic,naldemedine,Shionogi,NDA,208854,,2016-03-23,2017-03-23,2017,,Symproic is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; YESCARTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for YESCARTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 18055,2019-08609,https://www.federalregister.gov/documents/2019/04/29/2019-08609/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yescarta,https://www.govinfo.gov/content/pkg/FR-2019-04-29/pdf/2019-08609.pdf,4/29/2019, YESCARTA,,Nicolas,YESCARTA,1,87,Nicolas,7741465,,,,Cabaret Biotech Ltd.,3243,3041,202,2008-12-03,2008-12-03,2017-10-18,BLA 125643,1498,125643,3/27/2014,Treatment of diffuse large B-cell lymphoma,Designated/Approved,,,Treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Limitations of Use: Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.,4/1/2022,4/1/2029,"treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy, treatment of adult patients with DLBCL arising from follicular lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy, and treatment of adult patients with primary mediastinal B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy (not including treatment of patients with primary central nervous system lymphoma and excluding patients covered by the indication that received marketing approval on October 18, 2017 for Yescarta)","Kite Pharma, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; YESCARTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for YESCARTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 18055,2019-08609,https://www.federalregister.gov/documents/2019/04/29/2019-08609/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yescarta,https://www.govinfo.gov/content/pkg/FR-2019-04-29/pdf/2019-08609.pdf,4/29/2019, YESCARTA,,Nicolas,YESCARTA,1,88,Nicolas,7741465,,,,Cabaret Biotech Ltd.,3243,3041,202,2008-12-03,2008-12-03,2017-10-18,BLA 125643,1498,125643,4/25/2016,Treatment of follicular lymphoma.,Designated/Approved,,,Treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy,3/5/2021,3/5/2028,"Treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, excluding patients with diffuse large B-cell lymphoma arising from follicular lymphoma.","Kite Pharma, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; YESCARTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for YESCARTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 18055,2019-08609,https://www.federalregister.gov/documents/2019/04/29/2019-08609/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yescarta,https://www.govinfo.gov/content/pkg/FR-2019-04-29/pdf/2019-08609.pdf,4/29/2019, YESCARTA,,Nicolas,YESCARTA,1,89,Nicolas,7741465,,,,Cabaret Biotech Ltd.,3243,3041,202,2008-12-03,2008-12-03,2017-10-18,BLA 125643,1498,125643,4/25/2016,Treatment of follicular lymphoma.,Designated/Approved,,,Treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Limitations of Use: Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.,4/1/2022,4/1/2029,"treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy, treatment of adult patients with DLBCL arising from follicular lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy, and treatment of adult patients with primary mediastinal B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy (not including treatment of patients with primary central nervous system lymphoma and excluding patients covered by the indication that received marketing approval on October 18, 2017 for Yescarta)","Kite Pharma, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; YESCARTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for YESCARTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 18055,2019-08609,https://www.federalregister.gov/documents/2019/04/29/2019-08609/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yescarta,https://www.govinfo.gov/content/pkg/FR-2019-04-29/pdf/2019-08609.pdf,4/29/2019, YESCARTA,,Nicolas,YESCARTA,1,90,Nicolas,7741465,,,,Cabaret Biotech Ltd.,3243,3041,202,2008-12-03,2008-12-03,2017-10-18,BLA 125643,1498,125643,4/20/2016,Treatment of primary mediastinal B-cell lymphoma.,Designated/Approved,,,Treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Limitations of Use: Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.,4/1/2022,4/1/2029,"treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy, treatment of adult patients with DLBCL arising from follicular lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy, and treatment of adult patients with primary mediastinal B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy (not including treatment of patients with primary central nervous system lymphoma and excluding patients covered by the indication that received marketing approval on October 18, 2017 for Yescarta)","Kite Pharma, inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; YESCARTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for YESCARTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 18055,2019-08609,https://www.federalregister.gov/documents/2019/04/29/2019-08609/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yescarta,https://www.govinfo.gov/content/pkg/FR-2019-04-29/pdf/2019-08609.pdf,4/29/2019, YESCARTA,,Nicolas,YESCARTA,1,91,Nicolas,7741465,,,,Cabaret Biotech Ltd.,3243,3041,202,2008-12-03,2008-12-03,2017-10-18,BLA 125643,1498,125643,4/20/2016,Treatment of primary mediastinal B-cell lymphoma.,Designated/Approved,,,"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma",10/18/2017,10/18/2024,"Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma)","Kite Pharma, inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; YESCARTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for YESCARTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 18055,2019-08609,https://www.federalregister.gov/documents/2019/04/29/2019-08609/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yescarta,https://www.govinfo.gov/content/pkg/FR-2019-04-29/pdf/2019-08609.pdf,4/29/2019, YESCARTA,,Nicolas,YESCARTA,1,92,Nicolas,7741465,,,,Cabaret Biotech Ltd.,3243,3041,202,2008-12-03,2008-12-03,2017-10-18,BLA 125643,1498,125643,3/27/2014,Treatment of diffuse large B-cell lymphoma,Designated/Approved,,,"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma",10/18/2017,10/18/2024,"Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma)","Kite Pharma, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; YESCARTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for YESCARTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 18055,2019-08609,https://www.federalregister.gov/documents/2019/04/29/2019-08609/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yescarta,https://www.govinfo.gov/content/pkg/FR-2019-04-29/pdf/2019-08609.pdf,4/29/2019, YESCARTA,,Nicolas,YESCARTA,1,93,Nicolas,7741465,,,,Cabaret Biotech Ltd.,3243,3041,202,2008-12-03,2008-12-03,2017-10-18,BLA 125643,1498,125643,4/25/2016,Treatment of follicular lymphoma.,Designated/Approved,,,"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma",10/18/2017,10/18/2024,"Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma)","Kite Pharma, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AUSTEDO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AUSTEDO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 20896,2019-09805,https://www.federalregister.gov/documents/2019/05/13/2019-09805/determination-of-regulatory-review-period-for-purposes-of-patent-extension-austedo,https://www.govinfo.gov/content/pkg/FR-2019-05-13/pdf/2019-09805.pdf,5/13/2019, AUSTEDO,,Nicolas,AUSTEDO,1,94,Nicolas,8524733,,,,"Auspex Pharmaceuticals, Inc.",1736,1060,676,2012-07-03,2012-07-03,2017-04-03,NDA 208082,8,208082,11/5/2014,Treatment of Huntington's Disease,Designated/Approved,,,Treatment of chorea associated with Huntingtons disease,4/3/2017,4/3/2024,Treatment of chorea associated with Huntingtons disease,"Teva Branded Pharmaceutical Products R&D, Inc.",Austedo,deutetrabenazine,Teva Pharmaceuticals,NDA,208082,,2015-05-29,2017-04-03,2017,,AUSTEDO is indicated for the treatment of chorea associated with Huntingtons disease.,Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; GORE VIABAHN VBX BALLOON EXPANDABLE ENDOPROSTHESIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for the GORE VIABAHN VBX BALLOON EXPANDABLE ENDOPROSTHESIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",84 FR 20894,2019-09817,https://www.federalregister.gov/documents/2019/05/13/2019-09817/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gore-viabahn-vbx-balloon,https://www.govinfo.gov/content/pkg/FR-2019-05-13/pdf/2019-09817.pdf,5/13/2019, GORE VIABAHN VBX BALLOON EXPANDABLE ENDOPROSTHESIS,,Nicolas,the GORE VIABAHN VBX BALLOON EXPANDABLE ENDOPROSTHESIS,1,95,Nicolas,6461665,,,,"W.L. Gore & Associates, Inc.",1136,931,205,2013-12-20,2013-12-20,2017-01-27,PMA P160021,669,160021,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; EDWARDS INTUITY ELITE AORTIC VALVE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EDWARDS INTUITY ELITE AORTIC VALVE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",84 FR 24158,2019-10889,https://www.federalregister.gov/documents/2019/05/24/2019-10889/determination-of-regulatory-review-period-for-purposes-of-patent-extension-edwards-intuity-elite,https://www.govinfo.gov/content/pkg/FR-2019-05-24/pdf/2019-10889.pdf,5/24/2019, EDWARDS INTUITY ELITE AORTIC VALVE,,Nicolas,EDWARDS INTUITY ELITE AORTIC VALVE,1,96,Nicolas,8911493,,,,Edwards Lifesciences Corp.,1508,1203,305,2012-06-28,2012-06-28,2016-08-12,PMA P150036,605,150036,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ALUNBRIG,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ALUNBRIG and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 27137,2019-12320,https://www.federalregister.gov/documents/2019/06/11/2019-12320/determination-of-regulatory-review-period-for-purposes-of-patent-extension-alunbrig,https://www.govinfo.gov/content/pkg/FR-2019-06-11/pdf/2019-12320.pdf,6/11/2019, ALUNBRIG,,Nicolas,ALUNBRIG,1,97,Nicolas,9012462,,,,"ARIAD Pharmaceutials, Inc.",2105,1862,243,2011-07-26,2011-07-26,2017-04-28,NDA 208772,81,208772,4/28/2016,"Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC).",Designated/Approved,,,Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib,4/28/2017,4/28/2024,Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib,"Takeda Development Center Americas, Inc.",Alunbrig,brigatinib,Ariad Pharmaceuticals,NDA,208772,,2016-08-29,2017-04-28,2017,,"ALUNBRIG is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ALUNBRIG,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ALUNBRIG and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 27137,2019-12320,https://www.federalregister.gov/documents/2019/06/11/2019-12320/determination-of-regulatory-review-period-for-purposes-of-patent-extension-alunbrig,https://www.govinfo.gov/content/pkg/FR-2019-06-11/pdf/2019-12320.pdf,6/11/2019, ALUNBRIG,,Nicolas,ALUNBRIG,1,98,Nicolas,9012462,,,,"ARIAD Pharmaceutials, Inc.",2105,1862,243,2011-07-26,2011-07-26,2017-04-28,NDA 208772,81,208772,4/28/2016,"Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC).",Designated/Approved,,,ALUNBRIG (brigatinib) is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.,5/22/2020,5/22/2027,"For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test, not including patients who have progressed on or are intolerant to crizotinib.","Takeda Development Center Americas, Inc.",Alunbrig,brigatinib,Ariad Pharmaceuticals,NDA,208772,,2016-08-29,2017-04-28,2017,,"ALUNBRIG is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KISQALI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KISQALI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",84 FR 27128,2019-12305,https://www.federalregister.gov/documents/2019/06/11/2019-12305/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kisqali,https://www.govinfo.gov/content/pkg/FR-2019-06-11/pdf/2019-12305.pdf,6/11/2019, KISQALI,,Nicolas,KISQALI,5,103,Nicolas,8324225; 8415355; 8685980; 8962630; and 9416136,,,,Novartis AG,2393,2196,197,2010-08-26,2010-08-26,2017-03-13,NDA 209092,204,209092,,,,,,,,,,,Kisqali,ribociclib,Novartis Pharmaceuticals,NDA,209092,,2016-08-29,2017-03-13,2017,,"KISQALI is indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- negative advanced or metastatic breast cancer.",Priority,No,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BAXDELA TABLETS-NDA 208610,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BAXDELA TABLETS under NDA 208610 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 27133,2019-12299,https://www.federalregister.gov/documents/2019/06/11/2019-12299/determination-of-regulatory-review-period-for-purposes-of-patent-extension-baxdela-tablets-nda,https://www.govinfo.gov/content/pkg/FR-2019-06-11/pdf/2019-12299.pdf,6/11/2019, BAXDELA TABLETS-NDA 208610,,Nicolas,BAXDELA,2,105,Nicolas,7728143 and 8252813,,,,"Melinta Therapeutics, Inc.",5813,5569,244,2001-07-22,2001-07-22,2017-06-19,NDA 208610,1001,208610,,,,,,,,,,,Baxdela,delafloxacin,Melinta Therapeutics,NDA,208610,208611,2016-10-19,2017-06-19,2017,,"BAXDELA is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following:
Gram-positive organisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillinsusceptible [MSSA] isolates), Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), Streptococcus pyogenes, and Enterococcus faecalis.
Gram-negative organisms: Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Usage:
To reduce the development of drug-resistant bacteria and maintain the effectiveness of BAXDELA and other antibacterial drugs, BAXDELA should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; BAXDELA IV INJECTION-NDA 208611,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BAXDELA IV INJECTION under new drug application (NDA) 208611 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 27126,2019-12298,https://www.federalregister.gov/documents/2019/06/11/2019-12298/determination-of-regulatory-review-period-for-purposes-of-patent-extension-baxdela-iv-injection-nda,https://www.govinfo.gov/content/pkg/FR-2019-06-11/pdf/2019-12298.pdf,6/11/2019, BAXDELA IV INJECTION-NDA 208611,,Nicolas,BAXDELA,2,107,Nicolas,7728143 and 8252813,,,,"Melinta Therapeutics, Inc.",5813,5569,244,2001-07-22,2019-08-12,2017-06-19,NDA 208611,1001,208611,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; NERLYNX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NERLYNX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 45769,2019-18816,https://www.federalregister.gov/documents/2019/08/30/2019-18816/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nerlynx,https://www.govinfo.gov/content/pkg/FR-2019-08-30/pdf/2019-18816.pdf,8/30/2019, NERLYNX,,Nicolas,NERLYNX,2,109,Nicolas,7399865 and 9211291,,,,"Puma Biotechnology, Inc.",5102,4738,364,2003-07-31,2003-07-31,2017-07-17,NDA 208051,1826,208051,,,,,,,,,,,Nerlynx,neratinib,Puma Biotechnology,NDA,208051,,2016-07-19,2017-07-17,2017,,"NERLYNX is indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab based therapy.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; MACI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MACI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 45776,2019-18805,https://www.federalregister.gov/documents/2019/08/30/2019-18805/determination-of-regulatory-review-period-for-purposes-of-patent-extension-maci,https://www.govinfo.gov/content/pkg/FR-2019-08-30/pdf/2019-18805.pdf,8/30/2019, MACI,,Nicolas,MACI,1,110,Nicolas,8029992,,,,Vericel Corporation,345,0,345,2016-01-04,2016-01-04,2016-12-13,BLA 125603,345,125603,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; BEVYXXA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BEVYXXA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 45778,2019-18788,https://www.federalregister.gov/documents/2019/08/30/2019-18788/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bevyxxa,https://www.govinfo.gov/content/pkg/FR-2019-08-30/pdf/2019-18788.pdf,8/30/2019, BEVYXXA,,Nicolas,BEVYXXA,4,114,Nicolas,6376515; 6835739; 7598276; and 8518977,,,,"Millennium Pharmaceuticals, Inc.",4244,4001,243,2005-11-11,2005-11-11,2017-06-23,NDA 208383,821,208383,,,,,,,,,,,Bevyxxa,betrixaban,Portola Pharmaceuticals,NDA,208383,,2016-10-24,2017-06-23,2017,,"BEVYXXA is indicated for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.
Limitations of Use:
The safety and effectiveness of BEVYXXA have not been established in patients with prosthetic heart valves because this population has not been studied.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; GIAPREZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GIAPREZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 46740,2019-19110,https://www.federalregister.gov/documents/2019/09/05/2019-19110/determination-of-regulatory-review-period-for-purposes-of-patent-extension-giapreza,https://www.govinfo.gov/content/pkg/FR-2019-09-05/pdf/2019-19110.pdf,9/5/2019, GIAPREZA,,Nicolas,GIAPREZA,1,115,Nicolas,9572856,,,,George Washington University,1639,1463,176,2013-06-28,2013-06-28,2017-12-21,NDA 209360,241,209360,,,,,,,,,,,Giapreza,angiotensin II,La Jolla Pharmaceuticals,NDA,209360,,2017-06-29,2017-12-21,2017,,GIAPREZA increases blood pressure in adults with septic or other distributive shock.,Priority,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SHINGRIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SHINGRIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 46953,2019-19205,https://www.federalregister.gov/documents/2019/09/06/2019-19205/determination-of-regulatory-review-period-for-purposes-of-patent-extension-shingrix,https://www.govinfo.gov/content/pkg/FR-2019-09-06/pdf/2019-19205.pdf,9/6/2019, SHINGRIX,,Nicolas,SHINGRIX,1,116,Nicolas,7939084,,,,GlaxoSmithKline Biologicals SA,3257,2892,365,2008-11-21,2008-11-21,2017-10-20,BLA 125614,1361,125614,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AEGEA VAPOR SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AEGEA VAPOR SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",84 FR 47520,2019-19496,https://www.federalregister.gov/documents/2019/09/10/2019-19496/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aegea-vapor-system,https://www.govinfo.gov/content/pkg/FR-2019-09-10/pdf/2019-19496.pdf,9/10/2019, AEGEA VAPOR SYSTEM,,Nicolas,AEGEA VAPOR SYSTEM,1,117,Nicolas,8574226,,,,"Tsunami MedTech, LLC",1381,1148,233,2013-09-04,2013-09-04,2017-06-14,PMA P160047,931,160047,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Edwards Pericardial Aortic Bioprosthesis,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EDWARDS PERICARDIAL AORTIC BIOPROSTHESIS (Models 11000A and 11500A) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",84 FR 47960,2019-19600,https://www.federalregister.gov/documents/2019/09/11/2019-19600/determination-of-regulatory-review-period-for-purposes-of-patent-extension-edwards-pericardial,https://www.govinfo.gov/content/pkg/FR-2019-09-11/pdf/2019-19600.pdf,9/11/2019, Edwards Pericardial Aortic Bioprosthesis,,Nicolas,EDWARDS PERICARDIAL AORTIC BIOPROSTHESIS MODEL 11000A and MODEL 11500A,4,121,Nicolas,7972376; 8007992; 8357387; and 9029418,,,,Edwards Lifesciences Corporation,1858,1491,367,2012-05-30,2012-05-30,2017-06-29,PMA P150048,1111,150048,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Med-El Electric and Acoustic Stimulation Hybrid Hearing Prosthesis System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MED-EL Electric and Acoustic Stimulation Hybrid Hearing Prosthesis System (MED-EL EAS) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",84 FR 50042,2019-20657,https://www.federalregister.gov/documents/2019/09/24/2019-20657/determination-of-regulatory-review-period-for-purposes-of-patent-extension-med-el-electric-and,https://www.govinfo.gov/content/pkg/FR-2019-09-24/pdf/2019-20657.pdf,9/24/2019, Med-El Electric and Acoustic Stimulation Hybrid Hearing Prosthesis System,,Nicolas,MED-EL EAS,1,122,Nicolas,7917224,,,,Med-El Electromedizinische Gerate GmbH,4537,4269,268,2004-04-16,2004-04-16,2016-09-15,PMA P000025,998,25,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CRYSVITA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CRYSVITA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human biological product.",84 FR 65823,2019-25821,https://www.federalregister.gov/documents/2019/11/29/2019-25821/determination-of-regulatory-review-period-for-purposes-of-patent-extension-crysvita,https://www.govinfo.gov/content/pkg/FR-2019-11-29/pdf/2019-25821.pdf,11/29/2019, CRYSVITA,,Nicolas,CRYSVITA,3,125,Nicolas,7314618; 7883705; and 9290569,,,,Indiana University Research,3485,3241,244,2008-10-03,2008-10-03,2018-04-17,BLA 761068,"5 days, 1,168 days, or 501 days",761068,12/14/2009,Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets),Designated/Approved,,,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older,4/17/2018,4/17/2025,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older,"Kyowa Kirin, Inc.",Crysvita,burosumab-twza,Ultragenyx Pharmaceutical,BLA,761068,,2017-08-17,2018-04-17,2018,,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.,Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; CRYSVITA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CRYSVITA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human biological product.",84 FR 65823,2019-25821,https://www.federalregister.gov/documents/2019/11/29/2019-25821/determination-of-regulatory-review-period-for-purposes-of-patent-extension-crysvita,https://www.govinfo.gov/content/pkg/FR-2019-11-29/pdf/2019-25821.pdf,11/29/2019, CRYSVITA,,Nicolas,CRYSVITA,3,128,Nicolas,7314618; 7883705; and 9290569,,,,Indiana University Research,3485,3241,244,2008-10-03,2008-10-03,2018-04-17,BLA 761068,"5 days, 1,168 days, or 501 days",761068,6/15/2017,Treatment of tumor-induced osteomalacia (TIO) syndrome,Designated/Approved,,,Crysvita (burosumab-twza) is indicated for the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized.,6/18/2020,6/18/2027,For the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older,"Kyowa Kirin, Inc.",Crysvita,burosumab-twza,Ultragenyx Pharmaceutical,BLA,761068,,2017-08-17,2018-04-17,2018,,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.,Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; CRYSVITA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CRYSVITA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human biological product.",84 FR 65823,2019-25821,https://www.federalregister.gov/documents/2019/11/29/2019-25821/determination-of-regulatory-review-period-for-purposes-of-patent-extension-crysvita,https://www.govinfo.gov/content/pkg/FR-2019-11-29/pdf/2019-25821.pdf,11/29/2019, CRYSVITA,,Nicolas,CRYSVITA,3,131,Nicolas,7314618; 7883705; and 9290569,,,,Indiana University Research,3485,3241,244,2008-10-03,2008-10-03,2018-04-17,BLA 761068,"5 days, 1,168 days, or 501 days",761068,12/14/2009,Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets),Designated/Approved,,,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.,9/27/2019,9/27/2026,For the treatment of X-linked hypophosphatemia (XLH) in pediatric patients 6 months of age to less than 1 year of age,"Kyowa Kirin, Inc.",Crysvita,burosumab-twza,Ultragenyx Pharmaceutical,BLA,761068,,2017-08-17,2018-04-17,2018,,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.,Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OZEMPIC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OZEMPIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 65826,2019-25850,https://www.federalregister.gov/documents/2019/11/29/2019-25850/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ozempic,https://www.govinfo.gov/content/pkg/FR-2019-11-29/pdf/2019-25850.pdf,11/29/2019, OZEMPIC,,Nicolas,OZEMPIC,1,132,Nicolas,8129343,,,,Novo Nordisk A/S,3336,2970,366,2008-10-19,2008-10-19,2017-12-05,NDA 209637,1040,209637,,,,,,,,,,,Ozempic,semaglutide,Novo Nordisk,NDA,209637,,2016-12-05,2017-12-05,2017,,"OZEMPIC is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use:
- OZEMPIC is not recommended as a first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of rodent C-cell tumor findings to humans.
- OZEMPIC has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
- OZEMPIC is not a substitute for insulin. OZEMPIC is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; AIMOVIG,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AIMOVIG and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 66201,2019-26081,https://www.federalregister.gov/documents/2019/12/03/2019-26081/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aimovig,https://www.govinfo.gov/content/pkg/FR-2019-12-03/pdf/2019-26081.pdf,12/3/2019, AIMOVIG,,Nicolas,AIMOVIG,1,133,Nicolas,9102731,,,,"Amgen, Inc.",2042,1675,367,2012-10-16,2012-10-16,2018-05-17,BLA 761077,689,761077,,,,,,,,,,,Aimovig,erenumab-aooe,Amgen,BLA,761077,,2017-05-17,2018-05-17,2018,,AIMOVIG is indicated for the preventive treatment of migraine in adults.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LUXTURNA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LUXTURNA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 66682,2019-26252,https://www.federalregister.gov/documents/2019/12/05/2019-26252/determination-of-regulatory-review-period-for-purposes-of-patent-extension-luxturna,https://www.govinfo.gov/content/pkg/FR-2019-12-05/pdf/2019-26252.pdf,12/5/2019, LUXTURNA,,Nicolas,LUXTURNA,1,134,Nicolas,9433688,,,,"Trustees of the University of Pennsylvania, the University of Florida Research Foundation, Inc.",3809,3591,218,2007-07-18,2007-07-18,2017-12-19,BLA 125610,344,125610,3/18/2015,Treatment of inherited retinal dystrophy due to biallelic RPE65 gene mutations,Designated/Approved,,,an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells determined by a treating physician,12/19/2017,12/19/2024,Treatment of patients with confirmed biallelic RPE65 mutation-associated retinal distrophy. Patients must have viable retinal cells determined by a treating physician.,"Spark Therapeutics, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ANDEXXA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ANDEXXA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human biological product.",84 FR 66671,2019-26251,https://www.federalregister.gov/documents/2019/12/05/2019-26251/determination-of-regulatory-review-period-for-purposes-of-patent-extension-andexxa,https://www.govinfo.gov/content/pkg/FR-2019-12-05/pdf/2019-26251.pdf,12/5/2019, ANDEXXA,,Nicolas,ANDEXXA,3,137,Nicolas,8153590; 8889129; and 9388401,,,,"Portola Pharmaceuticals, Inc.",2171,1302,869,2012-05-25,2012-05-25,2018-05-03,BLA 125586,1066,125586,2/23/2015,For reversing the anticoagulant effect of direct or indirect factor Xa inhibitors in patients experiencing a serious uncontrolled bleeding event or who require urgent or emergent surgery,Designated/Approved,,,"Coagulation factor Xa (recombinant), inactivated-zhzo is indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding",5/3/2018,5/3/2025,"Coagulation factor Xa (recombinant), inactivated-zhzo is indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding","Alexion Pharmaceuticals, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PALYNZIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PALYNZIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",84 FR 66916,2019-26327,https://www.federalregister.gov/documents/2019/12/06/2019-26327/determination-of-regulatory-review-period-for-purposes-of-patent-extension-palynziq,https://www.govinfo.gov/content/pkg/FR-2019-12-06/pdf/2019-26327.pdf,12/6/2019, PALYNZIQ,,Nicolas,PALYNZIQ,2,139,Nicolas,7534595 and 7537923,,,,Biomarin Pharmaceutical Inc.,3803,3474,329,2007-12-27,2007-12-27,2018-05-24,BLA B761079,1743,761079,3/8/1995,Treatment of hyperphenylalaninemia,Designated/Approved,,,Palynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management,5/24/2018,5/24/2025,Palynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management,BioMarin Pharmaceutical Inc.,Palynziq,pegvaliase-pqpz,BioMarin Pharmaceutical,BLA,761079,,2017-06-30,2018-05-24,2018,,Palynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management.,Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; VABOMERE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VABOMERE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 67746,2019-26655,https://www.federalregister.gov/documents/2019/12/11/2019-26655/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vabomere,https://www.govinfo.gov/content/pkg/FR-2019-12-11/pdf/2019-26655.pdf,12/11/2019, VABOMERE,,Nicolas,VABOMERE,1,140,Nicolas,8680136,,,,"Rempex Pharmaceuticals, Inc.",1316,1072,244,2014-01-23,2014-01-23,2017-08-29,NDA 209776,12,209776,,,,,,,,,,,Vabomere,meropenem and vaborbactam,The Medicines Company,NDA,209776,,2016-12-29,2017-08-29,2017,,"VABOMERE is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.
Usage:
To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; BRIVIACT INJECTION New Drug Application 205837,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRIVIACT INJECTION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 67945,2019-26812,https://www.federalregister.gov/documents/2019/12/12/2019-26812/determination-of-regulatory-review-period-for-purposes-of-patent-extension-briviact-injection-new,https://www.govinfo.gov/content/pkg/FR-2019-12-12/pdf/2019-26812.pdf,12/12/2019, BRIVIACT INJECTION New Drug Application 205837,,Nicolas,BRIVIACT INJECTION,1,141,Nicolas,6784197,,,,UCB Biopharma SPRL,4293,3753,540,2004-08-12,2017-01-18,2016-02-18,NDA 205837,1547,205837,,,,,,,,,,,,,,,,,,,,,,,,,,
"Determination of Regulatory Review Period for Purposes of Patent Extension; BRIVIACT ORAL TABLETS, New Drug Application 205836",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRIVIACT ORAL TABLETS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 67947,2019-26813,https://www.federalregister.gov/documents/2019/12/12/2019-26813/determination-of-regulatory-review-period-for-purposes-of-patent-extension-briviact-oral-tablets-new,https://www.govinfo.gov/content/pkg/FR-2019-12-12/pdf/2019-26813.pdf,12/12/2019," BRIVIACT ORAL TABLETS, New Drug Application 205836",,Nicolas,BRIVIACT ORAL TABLETS,1,142,Nicolas,6911461,,,,UCB Biopharma SPRL,4293,3753,540,2004-08-12,2017-01-18,2016-02-18,NDA 205836,5,205836,,,,,,,,,,,Briviact,brivaracetam,UCB,NDA,205836,205837,2014-11-24,2016-02-18,2016,,BRIVIACT is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.,Standard,No,No,No,No
"Determination of Regulatory Review Period for Purposes of Patent Extension; BRIVIACT ORAL SOLUTION, New Drug Application 205838",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BRIVIACT ORAL SOLUTION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",84 FR 67942,2019-26814,https://www.federalregister.gov/documents/2019/12/12/2019-26814/determination-of-regulatory-review-period-for-purposes-of-patent-extension-briviact-oral-solution,https://www.govinfo.gov/content/pkg/FR-2019-12-12/pdf/2019-26814.pdf,12/12/2019," BRIVIACT ORAL SOLUTION, New Drug Application 205838",,Nicolas,BRIVIACT ORAL SOLUTION,1,143,Nicolas,8492416,,,,UCB Biopharma SPRL,4293,3753,540,2004-08-12,2017-01-18,2016-02-18,NDA 205836,698,205836,,,,,,,,,,,Briviact,brivaracetam,UCB,NDA,205836,205837,2014-11-24,2016-02-18,2016,,BRIVIACT is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; MAVYRET,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MAVYRET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",85 FR 3694,2020-00936,https://www.federalregister.gov/documents/2020/01/22/2020-00936/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mavyret,https://www.govinfo.gov/content/pkg/FR-2020-01-22/pdf/2020-00936.pdf,1/22/2020, MAVYRET,,Nicolas,MAVYRET,2,145,Nicolas,8937150 and 9586978,,,,"AbbVie, Inc.",1725,1492,233,2012-11-14,2012-11-12,2017-08-03,NDA 209394,150,209394,1/9/2017,Treatment of pediatric patients with chronic hepatitis C virus infection,Designated/Approved,,,"MAVYRET is indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.",4/30/2019,4/30/2026,"For the treatment of pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), and also for the treatment of pediatric patients 12 years and older or weighing at least 45 kg with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.","AbbVie, Inc.",Mavyret,"glecaprevir, pibrentasvir",AbbVie,NDA,209394,,2016-12-14,2017-08-03,2017,,"MAVYRET is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.",Priority,No,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; MAVYRET,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MAVYRET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",85 FR 3694,2020-00936,https://www.federalregister.gov/documents/2020/01/22/2020-00936/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mavyret,https://www.govinfo.gov/content/pkg/FR-2020-01-22/pdf/2020-00936.pdf,1/22/2020, MAVYRET,,Nicolas,MAVYRET,2,147,Nicolas,8937150 and 9586978,,,,"AbbVie, Inc.",1725,1492,233,2012-11-14,2012-11-12,2017-08-03,NDA 209394,150,209394,1/9/2017,Treatment of pediatric patients with chronic hepatitis C virus infection,Designated/Approved,,,"treatment of adult and pediatric patients 3 years and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), and treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both",6/10/2021,6/10/2028,"treatment of pediatric patients 3 years of age to less than 12 years of age weighing less than 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), and treatment of pediatric patients 3 years of age to less than 12 years of age weighing less than 45 kg with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both","AbbVie, Inc.",Mavyret,"glecaprevir, pibrentasvir",AbbVie,NDA,209394,,2016-12-14,2017-08-03,2017,,"MAVYRET is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.",Priority,No,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; INTRAROSA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for INTRAROSA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",85 FR 8879,2020-03115,https://www.federalregister.gov/documents/2020/02/18/2020-03115/determination-of-regulatory-review-period-for-purposes-of-patent-extension-intrarosa,https://www.govinfo.gov/content/pkg/FR-2020-02-18/pdf/2020-03115.pdf,2/18/2020, INTRAROSA,,Nicolas,INTRAROSA,2,149,Nicolas,8629129 and 8957054,,,,"Endorecherche, Inc.",3381,2983,398,2007-08-17,2007-08-17,2016-11-16,NDA 208470,518,208470,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ILUMYA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ILUMYA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",85 FR 12565,2020-04362,https://www.federalregister.gov/documents/2020/03/03/2020-04362/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ilumya,https://www.govinfo.gov/content/pkg/FR-2020-03-03/pdf/2020-04362.pdf,3/3/2020, ILUMYA,,Nicolas,ILUMYA,2,151,Nicolas,8293883 and 8404813,,,,Merck Sharp & Dohme Corp.,3452,3089,363,2008-10-08,2008-10-08,2018-03-20,BLA 761067,1092,761067,,,,,,,,,,,Ilumya,tildrakizumab-asmn,Merck Sharp & Dohme,BLA,761067,,2017-03-23,2018-03-20,2018,,ILUMYA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; FASENRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FASENRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",85 FR 12793,2020-04363,https://www.federalregister.gov/documents/2020/03/04/2020-04363/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fasenra,https://www.govinfo.gov/content/pkg/FR-2020-03-04/pdf/2020-04363.pdf,3/4/2020, FASENRA,,Nicolas,FASENRA,3,154,Nicolas,7179464; 7718175; and 8101185,,,,"Kyowa Hakko Kirin Co., Ltd.",4127,3763,364,2006-07-30,2006-07-30,2017-11-14,BLA 761070,1244,761070,11/21/2018,Treatment of eosinophilic granulomatosis with polyangiitis,Designated/Approved,,,treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA),9/17/2024,,,AstraZeneca Pharmaceuticals LP,Fasenra,benralizumab,AstraZeneca Pharmaceuticals,BLA,761070,,2016-11-16,2017-11-14,2017,,"FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Limitations of use:
- FASENRA is not indicated for treatment of other eosinophilic conditions.
- FASENRA is not indicated for the relief of acute bronchospasm or status asthmaticus.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; INGREZZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for INGREZZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",85 FR 12928,2020-04545,https://www.federalregister.gov/documents/2020/03/05/2020-04545/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ingrezza,https://www.govinfo.gov/content/pkg/FR-2020-03-05/pdf/2020-04545.pdf,3/5/2020, INGREZZA,,Nicolas,INGREZZA,1,155,Nicolas,8039627,,,,"Neurocrine Biosciences, Inc.",2071,1827,244,2011-08-12,2011-08-12,2017-04-11,NDA 209241,552,209241,5/10/2022,Treatment of Huntington disease,Designated/Approved,,,treatment of adults with chorea associated with Huntington's disease,4/30/2024,,,Neurocrine Biosciences Inc.,Ingrezza,valbenazine,Neurocrine Biosciences,NDA,209241,,2016-08-11,2017-04-11,2017,,INGREZZA is indicated for the treatment of adults with tardive dyskinesia.,Priority,No,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; INGREZZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for INGREZZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",85 FR 12928,2020-04545,https://www.federalregister.gov/documents/2020/03/05/2020-04545/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ingrezza,https://www.govinfo.gov/content/pkg/FR-2020-03-05/pdf/2020-04545.pdf,3/5/2020, INGREZZA,,Nicolas,INGREZZA,1,156,Nicolas,8039627,,,,"Neurocrine Biosciences, Inc.",2071,1827,244,2011-08-12,2011-08-12,2017-04-11,NDA 209241,552,209241,5/10/2022,Treatment of Huntington disease,Designated/Approved,,,treatment of adults with chorea associated with Huntington's disease,8/18/2023,8/18/2030,treatment of adults with chorea associated with Huntington's disease,Neurocrine Biosciences Inc.,Ingrezza,valbenazine,Neurocrine Biosciences,NDA,209241,,2016-08-11,2017-04-11,2017,,INGREZZA is indicated for the treatment of adults with tardive dyskinesia.,Priority,No,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; CARTIVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CARTIVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",85 FR 41999,2020-15011,https://www.federalregister.gov/documents/2020/07/13/2020-15011/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cartiva,https://www.govinfo.gov/content/pkg/FR-2020-07-13/pdf/2020-15011.pdf,7/13/2020, CARTIVA,,Nicolas,CARTIVA,1,157,Nicolas,5981826,,,,"Cartiva, Inc.",2407,1979,428,2020-09-11,2016-07-01,2016-07-01,PMA 150017,1429,150017,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; XEPI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XEPI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",85 FR 41996,2020-15013,https://www.federalregister.gov/documents/2020/07/13/2020-15013/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xepi,https://www.govinfo.gov/content/pkg/FR-2020-07-13/pdf/2020-15013.pdf,7/13/2020, XEPI,,Nicolas,XEPI,1,158,Nicolas,6335447,,,,"Toyama Chemical Co., Ltd.",2819,2282,537,2020-09-11,2010-03-26,2017-12-11,NDA 208945,1678,208945,,,,,,,,,,,Xepi,ozenoxacin,Ferrer Internacional S.A.,NDA,208945,,2016-06-23,2017-12-11,2017,,XEPI is indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ISTENT INJECT TRABECULAR MICRO-BYPASS SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ISTENT INJECT TRABECULAR MICRO-BYPASS SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that medical device.",85 FR 42863,2020-15295,https://www.federalregister.gov/documents/2020/07/15/2020-15295/determination-of-regulatory-review-period-for-purposes-of-patent-extension-istent-inject-trabecular,https://www.govinfo.gov/content/pkg/FR-2020-07-15/pdf/2020-15295.pdf,7/15/2020, ISTENT INJECT TRABECULAR MICRO-BYPASS SYSTEM,,Nicolas,ISTENT INJECT TRABECULAR MICRO-BYPASS SYSTEM,3,161,Nicolas,7867186; 9301875; and 9597230,,,,Glaukos Corporation,2508,2330,178,2020-09-14,2011-08-11,2018-06-21,PMA 170043,1783,170043,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; OXERVATE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OXERVATE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",85 FR 51446,2020-18239,https://www.federalregister.gov/documents/2020/08/20/2020-18239/determination-of-regulatory-review-period-for-purposes-of-patent-extension-oxervate,https://www.govinfo.gov/content/pkg/FR-2020-08-20/pdf/2020-18239.pdf,8/20/2020, OXERVATE,,Nicolas,OXERVATE,1,162,Nicolas,8501439,,,,Dompe Farmaceutici S.p.A.,1484,1240,244,2020-10-19,2014-08-01,2018-08-22,BLA 761094,863,761094,6/23/2014,Treatment of neurotrophic keratitis,Designated/Approved,,,Treatment of neurotrophic keratitis,8/22/2018,8/22/2025,Treatment of neurotrophic keratitis,Dompe S.p.A.,Oxervate,cenegermin-bkbj,Domp farmaceutici S.p.A.,BLA,761094,,2017-12-22,2018-08-22,2018,,OXERVATE (cenegermin-bkbj) ophthalmic solution 0.002% is indicated for the treatment of neurotrophic keratitis.,Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; VYLEESI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VYLEESI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",85 FR 51448,2020-18240,https://www.federalregister.gov/documents/2020/08/20/2020-18240/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vyleesi,https://www.govinfo.gov/content/pkg/FR-2020-08-20/pdf/2020-18240.pdf,8/20/2020, VYLEESI,,Nicolas,VYLEESI,2,164,Nicolas,6579968 and 6794489,,,,"Palatin Technologies, Inc.",6721,6265,456,2020-10-19,2001-01-27,2019-06-21,NDA 210557,1826,210557,,,,,,,,,,,Vyleesi,bremelanotide,AMAG Pharmaceuticals,NDA,210557,,2018-03-23,2019-06-21,2019,,"VYLEESI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to:
- A co-existing medical or psychiatric condition,
- Problems with the relationship, or
- The effects of a medication or drug substance.
Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire.
Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner.
Limitations of Use:
- VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men.
- VYLEESI is not indicated to enhance sexual performance.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; POTELIGEO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for POTELIGEO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",85 FR 53823,2020-19036,https://www.federalregister.gov/documents/2020/08/31/2020-19036/determination-of-regulatory-review-period-for-purposes-of-patent-extension-poteligeo,https://www.govinfo.gov/content/pkg/FR-2020-08-31/pdf/2020-19036.pdf,8/31/2020, POTELIGEO,,Nicolas,POTELIGEO,2,166,Nicolas,6989145 and 7504104,,,,Kyowa Hakko Kirin,3536,3227,309,2020-10-30,2008-12-04,2018-08-08,BLA 761051,1826,761051,11/2/2010,Treatment of patients with cutaneous T-cell lymphoma.,Designated/Approved,,,POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Szary syndrome (SS) after at least one prior systemic therapy.,8/8/2018,8/8/2025,POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Szary syndrome (SS) after at least one prior systemic therapy.,Kyowa Kirin Pharmaceutical Development Inc.,Poteligeo,mogamulizumab-kpkc,Kyowa Kirin Pharmaceutical Development,BLA,761051,,2017-10-04,2018-08-08,2018,,POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sezary syndrome (SS) after at least one prior systemic therapy.,Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ELZONRIS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ELZONRIS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",85 FR 53824,2020-19085,https://www.federalregister.gov/documents/2020/08/31/2020-19085/determination-of-regulatory-review-period-for-purposes-of-patent-extension-elzonris,https://www.govinfo.gov/content/pkg/FR-2020-08-31/pdf/2020-19085.pdf,8/31/2020, ELZONRIS,,Nicolas,ELZONRIS,2,168,Nicolas,9181317 and 9631006,,,,Scott & White Memorial Hospital,5541,5357,184,2020-10-30,2003-10-22,2018-12-21,BLA 761116,394,761116,6/6/2013,Treatment of blastic plasmacytoid dendritic cell neoplasm,Designated/Approved,,,ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.,12/21/2018,12/21/2025,ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.,"Stemline Therapeutics, Inc.",Elzonris,tagraxofusp-erzs,Stemline Therapeutics,BLA,761116,,2018-06-21,2018-12-21,2018,,ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.,Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LUMOXITI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LUMOXITI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human biological product.",85 FR 54388,2020-19214,https://www.federalregister.gov/documents/2020/09/01/2020-19214/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lumoxiti,https://www.govinfo.gov/content/pkg/FR-2020-09-01/pdf/2020-19214.pdf,9/1/2020, LUMOXITI,,Nicolas,LUMOXITI,3,171,Nicolas,8809502; 9580461; and 10072083,,,,the U.S. Department of Health,4320,4092,228,2020-11-02,2006-11-17,2018-09-13,BLA 761104,2,761104,11/15/2007,Treatment of hairy cell leukemia,Designated/Approved,,,"LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).",9/13/2018,9/13/2025,"LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).",AstraZeneca Pharmaceuticals LP,Lumoxiti,moxetumomab pasudotox-tdfk,AstraZeneca Pharmaceuticals,BLA,761104,,2018-01-29,2018-09-13,2018,,"LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).
Limitations of Use:
LUMOXITI is not recommended in patients with severe renal impairment (CrCl = 29 mL/min).",Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; EVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM (EVERSENSE CGM SYSTEM) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",85 FR 56229,2020-20040,https://www.federalregister.gov/documents/2020/09/11/2020-20040/determination-of-regulatory-review-period-for-purposes-of-patent-extension-eversense-continuous,https://www.govinfo.gov/content/pkg/FR-2020-09-11/pdf/2020-20040.pdf,9/11/2020, EVERSENSE CONTINUOUS GLUCOSE MONITORING SYSTEM,,Nicolas,EVERSENSE CGM SYSTEM,1,172,Nicolas,6400974,,,,"Senseonics, Inc.",90,3727,3123,2020-11-10,2020-11-10,2018-06-21,PMA P160048,5,160048,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TAKHZYRO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TAKHZYRO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",85 FR 56622,2020-20104,https://www.federalregister.gov/documents/2020/09/14/2020-20104/determination-of-regulatory-review-period-for-purposes-of-patent-extension-takhzyro,https://www.govinfo.gov/content/pkg/FR-2020-09-14/pdf/2020-20104.pdf,9/14/2020, TAKHZYRO,,Nicolas,TAKHZYRO,1,173,Nicolas,8816055,,,,Dyax Corp.,1857,1616,241,2020-11-13,2013-07-25,2018-08-23,BLA 761090,849,761090,11/26/2013,Treatment of angioedema,Designated/Approved,,,Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older,8/23/2018,8/23/2025,Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older,"Takeda Pharmaceuticals U.S.A., Inc.",Takhzyro,lanadelumab-flyo,Dyax Corporation,BLA,761090,,2017-12-26,2018-08-23,2018,,TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older.,Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; TAKHZYRO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TAKHZYRO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",85 FR 56622,2020-20104,https://www.federalregister.gov/documents/2020/09/14/2020-20104/determination-of-regulatory-review-period-for-purposes-of-patent-extension-takhzyro,https://www.govinfo.gov/content/pkg/FR-2020-09-14/pdf/2020-20104.pdf,9/14/2020, TAKHZYRO,,Nicolas,TAKHZYRO,1,174,Nicolas,8816055,,,,Dyax Corp.,1857,1616,241,2020-11-13,2013-07-25,2018-08-23,BLA 761090,849,761090,11/26/2013,Treatment of angioedema,Designated/Approved,,,prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older,2/3/2023,2/3/2030,prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients aged 2 years to less than 12 years,"Takeda Pharmaceuticals U.S.A., Inc.",Takhzyro,lanadelumab-flyo,Dyax Corporation,BLA,761090,,2017-12-26,2018-08-23,2018,,TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older.,Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OCS LUNG SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for OCS LUNG SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 14455,2021-05372,https://www.federalregister.gov/documents/2021/03/16/2021-05372/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ocs-lung-system,https://www.govinfo.gov/content/pkg/FR-2021-03-16/pdf/2021-05372.pdf,3/16/2021, OCS LUNG SYSTEM,,Nicolas,OCS LUNG SYSTEM,1,175,Nicolas,6100082,,,,"TransMedics, Inc.",2341,1672,669,2021-09-13,2021-09-13,2018-03-22,PMA P160013,1687,160013,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; HINTERMANN SERIES H3 TOTAL ANKLE REPLACEMENT SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for HINTERMANN SERIES H3 TOTAL ANKLE REPLACEMENT SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 14445,2021-05371,https://www.federalregister.gov/documents/2021/03/16/2021-05371/determination-of-regulatory-review-period-for-purposes-of-patent-extension-hintermann-series-h3,https://www.govinfo.gov/content/pkg/FR-2021-03-16/pdf/2021-05371.pdf,3/16/2021, HINTERMANN SERIES H3 TOTAL ANKLE REPLACEMENT SYSTEM,,Nicolas,HINTERMANN SERIES H3 TOTAL ANKLE REPLACEMENT SYSTEM,1,176,Nicolas,6409767,,,,European Foot Platform,4676,3661,1015,2021-09-13,2006-08-17,2019-06-04,PMA 160036,1825,160036,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; BAROSTIM NEO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BAROSTIM NEO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 15950,2021-06210,https://www.federalregister.gov/documents/2021/03/25/2021-06210/determination-of-regulatory-review-period-for-purposes-of-patent-extension-barostim-neo,https://www.govinfo.gov/content/pkg/FR-2021-03-25/pdf/2021-06210.pdf,3/25/2021, BAROSTIM NEO,,Nicolas,BAROSTIM NEO,3,179,Nicolas,8606359; 9044609; and 9427583,,,,"CVRx, Inc.",2550,2310,240,2021-09-21,2021-09-21,2019-08-16,PMA 180050,1038,180050,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; IBSRELA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IBSRELA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 17157,2021-06693,https://www.federalregister.gov/documents/2021/04/01/2021-06693/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ibsrela,https://www.govinfo.gov/content/pkg/FR-2021-04-01/pdf/2021-06693.pdf,4/1/2021, IBSRELA,,Nicolas,IBSRELA,1,180,Nicolas,8541448,,,,"Ardelyx, Inc.",3219,2853,366,2021-09-28,2010-11-21,2019-09-12,NDA 211801,1272,211801,,,,,,,,,,,Ibsrela,tenapanor,Ardelyx,NDA,211801,,2018-09-12,2019-09-12,2019,,IBSRELA is indicated for treatment of irritable bowel syndrome with constipation (IBS-C) in adults.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TPOXX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for TPOXX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 17160,2021-06696,https://www.federalregister.gov/documents/2021/04/01/2021-06696/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tpoxx,https://www.govinfo.gov/content/pkg/FR-2021-04-01/pdf/2021-06696.pdf,4/1/2021, TPOXX,,Nicolas,TPOXX,2,182,Nicolas,7737168 and 8124643,,,,"SIGA Technologies, Inc.",4601,4383,218,2021-09-28,2005-12-09,2018-07-13,NDA 208627,1585,208627,12/27/2006,Treatment of smallpox,Designated/Approved,,,Treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 3 kg,5/18/2022,,,"SIGA Technologies, Inc.",Tpoxx,tecovirimat,SIGA Technologies,NDA,208627,,2017-12-08,2018-07-13,2018,,"TPOXX is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg.
Limitations of Use:
The effectiveness of TPOXX for treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible, and inducing smallpox disease in humans to study the drugs efficacy is not ethical.
TPOXX efficacy may be reduced in immunocompromised patients based on studies demonstrating reduced efficacy in immunocompromised animal models.",Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; TPOXX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for TPOXX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 17160,2021-06696,https://www.federalregister.gov/documents/2021/04/01/2021-06696/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tpoxx,https://www.govinfo.gov/content/pkg/FR-2021-04-01/pdf/2021-06696.pdf,4/1/2021, TPOXX,,Nicolas,TPOXX,2,184,Nicolas,7737168 and 8124643,,,,"SIGA Technologies, Inc.",4601,4383,218,2021-09-28,2005-12-09,2018-07-13,NDA 208627,1585,208627,12/27/2006,Treatment of smallpox,Designated/Approved,,,TPOXX is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg.,7/13/2018,7/13/2025,TPOXX is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg.,"SIGA Technologies, Inc.",Tpoxx,tecovirimat,SIGA Technologies,NDA,208627,,2017-12-08,2018-07-13,2018,,"TPOXX is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg.
Limitations of Use:
The effectiveness of TPOXX for treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible, and inducing smallpox disease in humans to study the drugs efficacy is not ethical.
TPOXX efficacy may be reduced in immunocompromised patients based on studies demonstrating reduced efficacy in immunocompromised animal models.",Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; BIOMIMICS 3D VASCULAR STENT SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BIOMIMICS 3D VASCULAR STENT SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 17167,2021-06709,https://www.federalregister.gov/documents/2021/04/01/2021-06709/determination-of-regulatory-review-period-for-purposes-of-patent-extension-biomimics-3d-vascular,https://www.govinfo.gov/content/pkg/FR-2021-04-01/pdf/2021-06709.pdf,4/1/2021, BIOMIMICS 3D VASCULAR STENT SYSTEM,,Nicolas,BIOMIMICS 3D VASCULAR STENT SYSTEM,1,185,Nicolas,9314353,,,,Veryan Medical Limited,1234,973,261,2021-09-28,2021-09-28,2018-10-04,PMA 180003,580,180003,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; OPTIMIZER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OPTIMIZER and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 30957,2021-12192,https://www.federalregister.gov/documents/2021/06/10/2021-12192/determination-of-regulatory-review-period-for-purposes-of-patent-extension-optimizer,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12192.pdf,6/10/2021, OPTIMIZER,,Nicolas,OPTIMIZER,2,187,Nicolas,8260416 and 8311629,,,,Impulse Dynamics N.V.,5434,5236,198,2021-12-07,2004-05-06,2019-03-21,PMA 180036,1293,180036,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; WAKIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for WAKIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 30947,2021-12148,https://www.federalregister.gov/documents/2021/06/10/2021-12148/determination-of-regulatory-review-period-for-purposes-of-patent-extension-wakix,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12148.pdf,6/10/2021, WAKIX,,Nicolas,WAKIX,2,189,Nicolas,8207197 and 8486947,,,,Bioprojet,505,261,244,2021-12-07,2018-03-29,2019-08-14,NDA 211150,389,211150,5/17/2010,Treatment of narcolepsy,Designated/Approved,,,treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy and treatment of EDS in pediatric patients 6 years of age and older with narcolepsy,6/21/2024,6/21/2031,treatment of excessive daytime sleepiness (EDS) in pediatric patients 6 years of age and older with narcolepsy,"Harmony Biosciences, LLC",Wakix,pitolisant,Bioprojet Pharma,NDA,211150,,2018-12-14,2019-08-14,2019,,WAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy.,Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; WAKIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for WAKIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 30947,2021-12148,https://www.federalregister.gov/documents/2021/06/10/2021-12148/determination-of-regulatory-review-period-for-purposes-of-patent-extension-wakix,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12148.pdf,6/10/2021, WAKIX,,Nicolas,WAKIX,2,191,Nicolas,8207197 and 8486947,,,,Bioprojet,505,261,244,2021-12-07,2018-03-29,2019-08-14,NDA 211150,389,211150,5/17/2010,Treatment of narcolepsy,Designated/Approved,,,WAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy,8/14/2019,8/14/2026,For the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy,"Harmony Biosciences, LLC",Wakix,pitolisant,Bioprojet Pharma,NDA,211150,,2018-12-14,2019-08-14,2019,,WAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy.,Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; SARCLISA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SARCLISA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 30950,2021-12189,https://www.federalregister.gov/documents/2021/06/10/2021-12189/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sarclisa,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12189.pdf,6/10/2021, SARCLISA,,Nicolas,SARCLISA,2,193,Nicolas,8153765 and 10342869,,,,SANOFI,3718,3410,308,2021-12-07,2009-12-29,2020-03-02,BLA 761113,1596,761113,5/22/2014,Treatment of multiple myeloma,Designated/Approved,,,"in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT)",9/20/2024,,,Sanofi-Aventis U.S. LLC,Sarclisa,isatuximab-irfc,Sanofi Aventis US LLC,BLA,761113,,2019-04-30,2020-03-02,2020,,"Sarclisa is indicated in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor",Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SARCLISA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SARCLISA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 30950,2021-12189,https://www.federalregister.gov/documents/2021/06/10/2021-12189/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sarclisa,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12189.pdf,6/10/2021, SARCLISA,,Nicolas,SARCLISA,2,195,Nicolas,8153765 and 10342869,,,,SANOFI,3718,3410,308,2021-12-07,2009-12-29,2020-03-02,BLA 761113,1596,761113,5/22/2014,Treatment of multiple myeloma,Designated/Approved,,,"in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy",3/31/2021,3/31/2028,"treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 prior line of therapy, and for treatment of adult patients with relapsed or refractory multiple myeloma who have received 2 to 3 prior therapies excluding patients covered by the indication approved on March 2, 2020",Sanofi-Aventis U.S. LLC,Sarclisa,isatuximab-irfc,Sanofi Aventis US LLC,BLA,761113,,2019-04-30,2020-03-02,2020,,"Sarclisa is indicated in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor",Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SARCLISA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SARCLISA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 30950,2021-12189,https://www.federalregister.gov/documents/2021/06/10/2021-12189/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sarclisa,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12189.pdf,6/10/2021, SARCLISA,,Nicolas,SARCLISA,2,197,Nicolas,8153765 and 10342869,,,,SANOFI,3718,3410,308,2021-12-07,2009-12-29,2020-03-02,BLA 761113,1596,761113,5/22/2014,Treatment of multiple myeloma,Designated/Approved,,,"SARCLISA is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.",3/2/2020,3/2/2027,"Indicated in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.",Sanofi-Aventis U.S. LLC,Sarclisa,isatuximab-irfc,Sanofi Aventis US LLC,BLA,761113,,2019-04-30,2020-03-02,2020,,"Sarclisa is indicated in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor",Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SPRAVATO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SPRAVATO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 30955,2021-12193,https://www.federalregister.gov/documents/2021/06/10/2021-12193/determination-of-regulatory-review-period-for-purposes-of-patent-extension-spravato,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12193.pdf,6/10/2021, SPRAVATO,,Nicolas,SPRAVATO,2,199,Nicolas,8785500 and 9592207,,,,"Icahn School of Medicine at Mt. Sinai, Yale University",2456,2273,183,2021-12-07,2012-06-15,2019-03-05,NDA 211243,596,211243,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; EVENITY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EVENITY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 30942,2021-12199,https://www.federalregister.gov/documents/2021/06/10/2021-12199/determination-of-regulatory-review-period-for-purposes-of-patent-extension-evenity,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12199.pdf,6/10/2021, EVENITY,,Nicolas,EVENITY,3,202,Nicolas,7592429; 8017120; and 8440193,,,,Amgen Inc.,4519,3524,995,2021-12-07,2006-11-26,2019-04-09,BLA 761062,1827,761062,,,,,,,,,,,Evenity,romosozumab-aqqg,Amgen,BLA,761062,,2016-07-19,2019-04-09,2019,,"EVENITY is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
Limitations of Use:
The anabolic effect of EVENITY wanes after 12 monthly doses of therapy. Therefore, the duration of EVENITY use should be limited to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an anti-resorptive agent should be considered.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; XPOVIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XPOVIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 30945,2021-12167,https://www.federalregister.gov/documents/2021/06/10/2021-12167/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xpovio,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12167.pdf,6/10/2021, XPOVIO,,Nicolas,XPOVIO,1,203,Nicolas,8999996,,,,Karyopharm Therapeutics Inc.,2585,2253,332,2021-12-07,2012-06-06,2019-07-03,NDA 212306,291,212306,1/5/2015,Treatment of multiple myeloma,Designated/Approved,,,"XPOVIO is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.",7/3/2019,7/3/2026,"Indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.","Karyopharm Therapeutics, Inc.",Xpovio,selinexor,Karyopharm Therapeutics,NDA,212306,,2018-08-06,2019-07-03,2019,,"XPOVIO is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; XPOVIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XPOVIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 30945,2021-12167,https://www.federalregister.gov/documents/2021/06/10/2021-12167/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xpovio,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12167.pdf,6/10/2021, XPOVIO,,Nicolas,XPOVIO,1,204,Nicolas,8999996,,,,Karyopharm Therapeutics Inc.,2585,2253,332,2021-12-07,2012-06-06,2019-07-03,NDA 212306,291,212306,5/14/2014,Treatment of diffuse large B-cell lymphoma,Designated/Approved,,,"XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.",6/22/2020,6/22/2027,"For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy","Karyopharm Therapeutics, Inc.",Xpovio,selinexor,Karyopharm Therapeutics,NDA,212306,,2018-08-06,2019-07-03,2019,,"XPOVIO is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; XPOVIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XPOVIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 30945,2021-12167,https://www.federalregister.gov/documents/2021/06/10/2021-12167/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xpovio,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12167.pdf,6/10/2021, XPOVIO,,Nicolas,XPOVIO,1,205,Nicolas,8999996,,,,Karyopharm Therapeutics Inc.,2585,2253,332,2021-12-07,2012-06-06,2019-07-03,NDA 212306,291,212306,1/5/2015,Treatment of multiple myeloma,Designated/Approved,,,in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy,12/18/2020,12/18/2027,"for the treatment of adult patients with multiple myeloma who have received at least one prior therapy, excluding adult patients covered by Xpovio's previous indication for multiple myeloma approved on July 3, 2019","Karyopharm Therapeutics, Inc.",Xpovio,selinexor,Karyopharm Therapeutics,NDA,212306,,2018-08-06,2019-07-03,2019,,"XPOVIO is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; MAYZENT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MAYZENT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 30949,2021-12171,https://www.federalregister.gov/documents/2021/06/10/2021-12171/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mayzent,https://www.govinfo.gov/content/pkg/FR-2021-06-10/pdf/2021-12171.pdf,6/10/2021, MAYZENT,,Nicolas,MAYZENT,2,207,Nicolas,7939519 and 8492441,,,,Novartis AG,4544,4299,245,2021-12-07,2006-10-19,2019-03-26,NDA 209884,848,209884,,,,,,,,,,,Mayzent,siponimod,Novartis Pharmaceuticals,NDA,209884,,2018-07-26,2019-03-26,2019,,"MAYZENT is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.",Priority (used priority review voucher),No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BRAVECTO; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) published a notice in the Federal Register of February 12, 2018. After review of a timely request for reconsideration by the applicant of the determination of the regulatory review period of the animal drug, BRAVECTO, in that notice, FDA has determined that a revision of the SUPPLEMENTARY INFORMATION section is warranted. This document presents the revised regulatory review period.",86 FR 31318,2021-12284,https://www.federalregister.gov/documents/2021/06/11/2021-12284/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bravecto-correction,https://www.govinfo.gov/content/pkg/FR-2021-06-11/pdf/2021-12284.pdf,6/11/2021, BRAVECTO, Correction,Nicolas,,0,207,Nicolas,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; GIVLAARI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GIVLAARI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 32936,2021-13176,https://www.federalregister.gov/documents/2021/06/23/2021-13176/determination-of-regulatory-review-period-for-purposes-of-patent-extension-givlaari,https://www.govinfo.gov/content/pkg/FR-2021-06-23/pdf/2021-13176.pdf,6/23/2021, GIVLAARI,,Nicolas,GIVLAARI,1,208,Nicolas,9133461,,,,"Alnylam Pharmaceuticals, Inc.",1533,1363,170,2021-12-20,2015-09-11,2019-11-20,NDA 212194,190,212194,8/29/2016,Treatment of acute hepatic porphyria,Designated/Approved,,,GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP).,11/20/2019,11/20/2026,Indicated for the treatment of adults with acute hepatic porphyria (AHP).,"Alnylam Pharmaceuticals, Inc.",Givlaari,givosiran,Alnylam Pharmaceuticals,NDA,212194,,2019-06-04,2019-11-20,2019,,GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP).,Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TURALIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TURALIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 32950,2021-13186,https://www.federalregister.gov/documents/2021/06/23/2021-13186/determination-of-regulatory-review-period-for-purposes-of-patent-extension-turalio,https://www.govinfo.gov/content/pkg/FR-2021-06-23/pdf/2021-13186.pdf,6/23/2021, TURALIO,,Nicolas,TURALIO,3,211,Nicolas,7893075; 8461169; and 9169250,,,,Plexxikon Inc.,3637,3394,243,2021-12-20,2009-08-19,2019-08-02,NDA 211810,810,211810,2/14/2014,Treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath,Designated/Approved,,,TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.,8/2/2019,8/2/2026,For the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery,"Daiichi Sankyo, Inc.",Turalio,pexidartinib,Daiichi Sankyo,NDA,211810,,2018-12-03,2019-08-02,2019,,TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.,Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ZOLGENSMA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZOLGENSMA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 33307,2021-13411,https://www.federalregister.gov/documents/2021/06/24/2021-13411/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zolgensma,https://www.govinfo.gov/content/pkg/FR-2021-06-24/pdf/2021-13411.pdf,6/24/2021, ZOLGENSMA,,Nicolas,ZOLGENSMA,1,212,Nicolas,7906111,,,,"REGENXBIO, Inc.",2088,1852,236,2021-12-21,2013-09-06,2019-05-24,BLA 125694,1162,125694,9/30/2014,Treatment of spinal muscular atrophy,Designated/Approved,,,Indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.,5/24/2019,5/24/2026,Indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.,"AveXis, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TAZVERIK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TAZVERIK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 34022,2021-13743,https://www.federalregister.gov/documents/2021/06/28/2021-13743/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tazverik,https://www.govinfo.gov/content/pkg/FR-2021-06-28/pdf/2021-13743.pdf,6/28/2021, TAZVERIK,,Nicolas,TAZVERIK,1,213,Nicolas,8410088,,,,"Epizyme, Inc.",1618,1372,246,2021-12-27,2015-08-21,2020-01-23,NDA 211723,650,211723,11/14/2017,Treatment of follicular lymphoma,Designated/Approved,,,TAZVERIK (tazemetostat) is indicated for: the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies; and the treatment of adult patients with R/R FL who have no satisfactory alternative treatment options.,6/18/2020,6/18/2027,"For the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for the treatment of adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options","Epizyme, Inc.",Tazverik,tazemetostat,"Epizyme, Inc.",NDA,211723,,2019-05-23,2020-01-23,2020,,Tazverik is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection,Priority,Yes,Yes,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; GORE CARDIOFORM ASD OCCLUDER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or Agency) has determined the regulatory review period for GORE CARDIOFORM ASD OCCLUDER and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 34023,2021-13687,https://www.federalregister.gov/documents/2021/06/28/2021-13687/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gore-cardioform-asd,https://www.govinfo.gov/content/pkg/FR-2021-06-28/pdf/2021-13687.pdf,6/28/2021, GORE CARDIOFORM ASD OCCLUDER,,Nicolas,GORE CARDIOFORM ASD OCCLUDER,1,214,Nicolas,9474517,,,,"W.L. Gore & Associates, Inc.",931,751,556,2021-12-27,2016-11-10,2019-05-28,PMA 050006,556,50006,,,,,,,,,,,,,,,,,,,,,,,,,,
"Determination of Regulatory Review Period for Purposes of Patent Extension; Smallpox and Monkeypox Vaccine, Live",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Smallpox and Monkeypox Vaccine, Live and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 34018,2021-13686,https://www.federalregister.gov/documents/2021/06/28/2021-13686/determination-of-regulatory-review-period-for-purposes-of-patent-extension-smallpox-and-monkeypox,https://www.govinfo.gov/content/pkg/FR-2021-06-28/pdf/2021-13686.pdf,6/28/2021," Smallpox and Monkeypox Vaccine, Live",,Nicolas,"Smallpox and Monkeypox Vaccine, Live",1,215,Nicolas,7335364,,,,Bavarian Nordic A/S,5650,5315,335,2021-12-27,2004-04-07,2019-09-24,BLA 125678,1825,125678,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; OXBRYTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OXBRYTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 34767,2021-13976,https://www.federalregister.gov/documents/2021/06/30/2021-13976/determination-of-regulatory-review-period-for-purposes-of-patent-extension-oxbryta,https://www.govinfo.gov/content/pkg/FR-2021-06-30/pdf/2021-13976.pdf,6/30/2021, OXBRYTA,,Nicolas,OXBRYTA,3,218,Nicolas,9018210; 10017491; and 10034879,,,,"Global Blood Therapeutics, Inc.",1847,1694,153,2021-12-27,2014-11-06,2019-11-25,NDA 213137,332,213137,12/29/2015,Treatment of sickle cell disease,Designated/Approved,,,OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.,11/25/2019,11/25/2026,Indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.,"Global Blood Therapeutics, Inc.",Oxbryta,voxelotor,Global Blood Therapeutics,NDA,213137,,2019-06-26,2019-11-25,2019,,"OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.
This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OXBRYTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OXBRYTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 34767,2021-13976,https://www.federalregister.gov/documents/2021/06/30/2021-13976/determination-of-regulatory-review-period-for-purposes-of-patent-extension-oxbryta,https://www.govinfo.gov/content/pkg/FR-2021-06-30/pdf/2021-13976.pdf,6/30/2021, OXBRYTA,,Nicolas,OXBRYTA,3,221,Nicolas,9018210; 10017491; and 10034879,,,,"Global Blood Therapeutics, Inc.",1847,1694,153,2021-12-27,2014-11-06,2019-11-25,NDA 213137,332,213137,12/29/2015,Treatment of sickle cell disease,Designated/Approved,,,treatment of sickle cell disease (SCD) in adults and pediatric patients 4 years of age and older,12/17/2021,12/17/2028,treatment of sickle cell disease (SCD) in pediatric patients 4 years of age to less than 12 years of age,"Global Blood Therapeutics, Inc.",Oxbryta,voxelotor,Global Blood Therapeutics,NDA,213137,,2019-06-26,2019-11-25,2019,,"OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.
This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; FETROJA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FETROJA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 34762,2021-13971,https://www.federalregister.gov/documents/2021/06/30/2021-13971/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fetroja,https://www.govinfo.gov/content/pkg/FR-2021-06-30/pdf/2021-13971.pdf,6/30/2021, FETROJA,,Nicolas,FETROJA,1,222,Nicolas,9238657,,,,"Shionogi & Co., Ltd.",2400,2064,336,2021-12-27,2013-04-21,2019-11-14,NDA 209445,726,209445,,,,,,,,,,,Fetroja,cefiderocol,Shionogi,NDA,209445,,2018-12-14,2019-11-14,2019,,"FETROJA is indicated in patients 18 years of age or older who have limited or no alternative treatment options for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.
Approval of this indication is based on limited clinical safety and efficacy data for FETROJA.
Usage:
To reduce the development of drug-resistant bacteria and maintain the effectiveness of FETROJA and other antibacterial drugs, FETROJA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; BALVERSA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BALVERSA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 34764,2021-13973,https://www.federalregister.gov/documents/2021/06/30/2021-13973/determination-of-regulatory-review-period-for-purposes-of-patent-extension-balversa,https://www.govinfo.gov/content/pkg/FR-2021-06-30/pdf/2021-13973.pdf,6/30/2021, BALVERSA,,Nicolas,BALVERSA,1,223,Nicolas,8895601,,,,Astex Therapeutics Ltd.,2179,1972,207,2021-12-27,2013-04-26,2019-04-12,NDA 212018,691,212018,,,,,,,,,,,Balversa,erdafitinib,Janssen Biotech,NDA,212018,,2018-09-18,2019-04-12,2019,,"BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC), that has:
- susceptible FGFR3 or FGFR2 genetic alterations, and
- progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA. 
This indication is approved under accelerated approval based on tumor response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,No,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; POLIVY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for POLIVY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human biological product.",86 FR 34768,2021-13949,https://www.federalregister.gov/documents/2021/06/30/2021-13949/determination-of-regulatory-review-period-for-purposes-of-patent-extension-polivy,https://www.govinfo.gov/content/pkg/FR-2021-06-30/pdf/2021-13949.pdf,6/30/2021, POLIVY,,Nicolas,POLIVY,3,226,Nicolas,8088378; 8545850; and 8691531,,,,"Genentech, Inc.",3050,2876,174,2021-12-27,2011-02-04,2019-06-10,BLA 761121,1445,761121,12/12/2016,Treatment of diffuse large B-cell lymphoma,Designated/Approved,,,"in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater",4/19/2023,4/19/2030,"treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) and who have an International Prognostic Index score of 2 or greater","Genentech, Inc.",Polivy,polatuzumab vedotin-piiq,Genentech,BLA,761121,,2018-12-19,2019-06-10,2019,,"POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies._x000D_
Accelerated approval was granted for this indication based on complete response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; POLIVY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for POLIVY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human biological product.",86 FR 34768,2021-13949,https://www.federalregister.gov/documents/2021/06/30/2021-13949/determination-of-regulatory-review-period-for-purposes-of-patent-extension-polivy,https://www.govinfo.gov/content/pkg/FR-2021-06-30/pdf/2021-13949.pdf,6/30/2021, POLIVY,,Nicolas,POLIVY,3,229,Nicolas,8088378; 8545850; and 8691531,,,,"Genentech, Inc.",3050,2876,174,2021-12-27,2011-02-04,2019-06-10,BLA 761121,1445,761121,12/12/2016,Treatment of diffuse large B-cell lymphoma,Designated/Approved,,,"POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.",6/10/2019,6/10/2026,"In combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.","Genentech, Inc.",Polivy,polatuzumab vedotin-piiq,Genentech,BLA,761121,,2018-12-19,2019-06-10,2019,,"POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies._x000D_
Accelerated approval was granted for this indication based on complete response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; AXONICS SACRAL NEUROMODULATION SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AXONICS SACRAL NEUROMODULATION SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 34757,2021-13972,https://www.federalregister.gov/documents/2021/06/30/2021-13972/determination-of-regulatory-review-period-for-purposes-of-patent-extension-axonics-sacral,https://www.govinfo.gov/content/pkg/FR-2021-06-30/pdf/2021-13972.pdf,6/30/2021, AXONICS SACRAL NEUROMODULATION SYSTEM,,Nicolas,AXONICS SACRAL NEUROMODULATION SYSTEM,1,230,Nicolas,7331499,,,,Alfred E. Mann Foundation for Scientific[[Page 34759]]Research,681,494,187,2021-12-27,2017-10-27,2019-09-06,PMA 190006,434,190006,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; BARHEMSYS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BARHEMSYS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 35803,2021-14461,https://www.federalregister.gov/documents/2021/07/07/2021-14461/determination-of-regulatory-review-period-for-purposes-of-patent-extension-barhemsys,https://www.govinfo.gov/content/pkg/FR-2021-07-07/pdf/2021-14461.pdf,7/7/2021, BARHEMSYS,,Nicolas,BARHEMSYS,1,231,Nicolas,9084765,,,,Acacia Pharma Limited,2960,2085,875,2022-01-03,2012-01-21,2020-02-26,NDA 209510,1085,209510,,,,,,,,,,,Barhemsys,amisulpride,Acacia Pharma Ltd.,NDA,209510,,2017-10-05,2020-02-26,2020,,"Barhemsys is indicated for the treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or who have not received prophylaxis . Is indicated for prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BEOVU,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BEOVU and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 35805,2021-14473,https://www.federalregister.gov/documents/2021/07/07/2021-14473/determination-of-regulatory-review-period-for-purposes-of-patent-extension-beovu,https://www.govinfo.gov/content/pkg/FR-2021-07-07/pdf/2021-14473.pdf,7/7/2021, BEOVU,,Nicolas,BEOVU,2,233,Nicolas,8349322 and 9090684,,,,Novartis AG,3064,2821,243,2022-01-03,2011-05-20,2019-10-07,BLA 761125,1354,761125,,,,,,,,,,,Beovu,brolucizumab-dbll,Novartis Pharmaceuticals,BLA,761125,,2019-02-07,2019-10-07,2019,,BEOVU is indicated for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD).,Priority (used priority review voucher),No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Zephyr Endobronchial Valve Implant,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Zephyr Endobronchial Valve Implant and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",86 FR 35807,2021-14482,https://www.federalregister.gov/documents/2021/07/07/2021-14482/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zephyr-endobronchial,https://www.govinfo.gov/content/pkg/FR-2021-07-07/pdf/2021-14482.pdf,7/7/2021, Zephyr Endobronchial Valve Implant,,Nicolas,ZEPHYR ENDOBRONCHIAL VALVE IMPLANT,2,235,Nicolas,6527761 and 7798147,,,,Pulmonx Corp.,5744,5565,179,2022-01-03,2022-01-03,2018-06-29,PMA 180002,1510,180002,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PIQRAY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PIQRAY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 36142,2021-14490,https://www.federalregister.gov/documents/2021/07/08/2021-14490/determination-of-regulatory-review-period-for-purposes-of-patent-extension-piqray,https://www.govinfo.gov/content/pkg/FR-2021-07-08/pdf/2021-14490.pdf,7/8/2021, PIQRAY,,Nicolas,PIQRAY,2,237,Nicolas,8277462 and 8476268,,,,Novartis AG,3264,3106,158,2022-01-04,2010-06-18,2019-05-24,NDA 212526,1156,212526,,,,,,,,,,,Piqray,alpelisib,Novartis Pharmaceuticals,NDA,212526,,2018-12-18,2019-05-24,2019,,"PIQRAY is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.",Priority,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; AJOVY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AJOVY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 36285,2021-14652,https://www.federalregister.gov/documents/2021/07/09/2021-14652/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ajovy,https://www.govinfo.gov/content/pkg/FR-2021-07-09/pdf/2021-14652.pdf,7/9/2021, AJOVY,,Nicolas,AJOVY,1,238,Nicolas,8007794,,,,Teva Pharmaceuticals International GmbH,3216,2882,334,2022-01-05,2009-11-26,2018-09-14,BLA 761089,1454,761089,,,,,,,,,,,Ajovy,fremanezumab-vfrm,Teva Pharmaceuticals,BLA,761089,,2017-10-16,2018-09-14,2018,,AJOVY is indicated for the preventive treatment of migraine in adults.,Priority (used priority review voucher),No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; NUBEQA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NUBEQA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 58670,2021-23074,https://www.federalregister.gov/documents/2021/10/22/2021-23074/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nubeqa,https://www.govinfo.gov/content/pkg/FR-2021-10-22/pdf/2021-23074.pdf,10/22/2021, NUBEQA,,Nicolas,NUBEQA,1,239,Nicolas,8975254,,,,Orion Corporation,2576,2420,156,2022-04-20,2012-07-13,2019-07-30,NDA 212099,879,212099,,,,,,,,,,,Nubeqa,darolutamide,Bayer HealthCare Pharmaceuticals,NDA,212099,,2019-02-26,2019-07-30,2019,,NUBEQA is indicated for the treatment of patients with non-metastatic castration resistant prostate cancer (nmCRPC).,Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; INREBIC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for INREBIC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 59397,2021-23388,https://www.federalregister.gov/documents/2021/10/27/2021-23388/determination-of-regulatory-review-period-for-purposes-of-patent-extension-inrebic,https://www.govinfo.gov/content/pkg/FR-2021-10-27/pdf/2021-23388.pdf,10/27/2021, INREBIC,,Nicolas,INREBIC,3,242,Nicolas,7528143; 7825246; and 8138199,,,,"Impact Biomedicines, Inc.",4285,4059,226,2022-04-25,2007-11-24,2019-08-16,NDA 212327,1796,212327,5/18/2009,Treatment of secondary and primary myelofibrosis,Designated/Approved,,,INREBIC is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).,8/16/2019,8/16/2026,For the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).,"Impact Biomedicines, Inc. a wholly-owned subsidiary of Celgene Corporation",Inrebic,fedratinib,Celgene,NDA,212327,,2019-01-03,2019-08-16,2019,,INREBIC is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).,Priority,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; XENLETA Tablets New Drug Application 211672,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XENLETA tablets and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 59392,2021-23387,https://www.federalregister.gov/documents/2021/10/27/2021-23387/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xenleta-tablets-new-drug,https://www.govinfo.gov/content/pkg/FR-2021-10-27/pdf/2021-23387.pdf,10/27/2021, XENLETA Tablets New Drug Application 211672,,Nicolas,XENLETA tablets,3,245,Nicolas,8071643; 8153689; and 9120727,,,,Nabriva Therapeutics GMBH,3595,3351,244,2022-04-25,2020-10-13,2019-08-19,NDA 211672,1528,211672,,,,,,,,,,,Xenleta,lefamulin,Nabriva Therapeutics,NDA,211672,211673,2018-12-19,2019-08-19,2019,,"XENLETA is indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.
Usage:
To reduce the development of drug-resistant bacteria and maintain the effectiveness of XENLETA and other antibacterial drugs, XENLETA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; XENLETA Injection New Drug Application 211673,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XENLETA injection new drug application (NDA) 211673 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 59394,2021-23386,https://www.federalregister.gov/documents/2021/10/27/2021-23386/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xenleta-injection-new,https://www.govinfo.gov/content/pkg/FR-2021-10-27/pdf/2021-23386.pdf,10/27/2021, XENLETA Injection New Drug Application 211673,,Nicolas,XENLETA injection,2,247,Nicolas,8071643 and 8153689,,,,Nabriva Therapeutics GMBH,3595,3351,244,2022-04-25,2021-12-27,2019-08-19,NDA 211673,1528,211673,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SPINRAZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SPINRAZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",86 FR 60248,2021-23719,https://www.federalregister.gov/documents/2021/11/01/2021-23719/determination-of-regulatory-review-period-for-purposes-of-patent-extension-spinraza,https://www.govinfo.gov/content/pkg/FR-2021-11-01/pdf/2021-23719.pdf,11/1/2021, SPINRAZA,,Nicolas,SPINRAZA,4,251,Nicolas,"U.S. Patent Nos. 7,838,657; and 8,110,560; from University of Massachusetts, and U.S. Patent Nos. 8,361,977; and 8,980,853 from Biogen MA Inc., and Cold Spring Harbor Laboratory",,,,"University of Massachusetts and Biogen MA Inc., and Cold Spring Harbor Laboratory",1891,1799,92,2011-10-22,2011-10-22,2016-12-23,NDA 209531,992,209531,4/18/2011,Treatment of spinal muscular atrophy,Designated/Approved,,,Treatment of spinal muscular atrophy in pediatric and adult patients,12/23/2016,12/23/2023,Treatment of spinal muscular atrophy in pediatric and adult patients,"Biogen, Inc",Spinraza,nusinersen,Biogen,NDA,209531,,2016-09-23,2016-12-23,2016,,SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.,Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ENHERTU,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ENHERTU and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 60252,2021-23725,https://www.federalregister.gov/documents/2021/11/01/2021-23725/determination-of-regulatory-review-period-for-purposes-of-patent-extension-enhertu,https://www.govinfo.gov/content/pkg/FR-2021-11-01/pdf/2021-23725.pdf,11/1/2021, ENHERTU,,Nicolas,ENHERTU,3,254,Nicolas,9808537; 10155821; and 10195288,,,,"Daiichi Sankyo Company, Limited",1395,186,1209,2016-02-26,2016-02-26,2019-12-20,BLA 761139,71,761139,5/20/2020,"Treatment of gastric cancer, including gastroesophageal junction cancer",Designated/Approved,,,treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen,1/15/2021,1/15/2028,treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen,"Daiichi Sankyo, Inc.",Enhertu,fam-trastuzumab deruxtecan-nxki,Daiichi Sankyo,BLA,761139,,2019-08-29,2019-12-20,2019,,"ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,No,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; VYONDYS 53,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VYONDYS 53 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 60256,2021-23724,https://www.federalregister.gov/documents/2021/11/01/2021-23724/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vyondys-53,https://www.govinfo.gov/content/pkg/FR-2021-11-01/pdf/2021-23724.pdf,11/1/2021, VYONDYS 53,,Nicolas,VYONDYS 53,6,260,Nicolas,9024007; 9994851; 10227590; 10266827; 10421966; and RE47691,,,,The University of Western Australia,1833,1474,359,2014-12-07,2014-12-07,2019-12-12,NDA 211970,888,211970,5/22/2018,Treatment of Duchenne muscular dystrophy (DMD),Designated/Approved,,,VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.,12/12/2019,12/12/2026,Indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping,"Sarepta Therapeutics, Inc.",Vyondys 53,golodirsen,Sarepta Therapeutics,NDA,211970,,2018-12-19,2019-12-12,2019,,VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.,Priority,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ADAKVEO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ADAKVEO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 60829,2021-24070,https://www.federalregister.gov/documents/2021/11/04/2021-24070/determination-of-regulatory-review-period-for-purposes-of-patent-extension-adakveo,https://www.govinfo.gov/content/pkg/FR-2021-11-04/pdf/2021-24070.pdf,11/4/2021, ADAKVEO,,Nicolas,ADAKVEO,2,262,Nicolas,8377440 and 9556266,,,,Novartis AG,3152,2968,184,2011-04-01,2011-04-01,2019-11-15,BLA 761128,601,761128,7/22/2008,Treatment of sickle cell disease,Designated/Approved,,,ADAKVEO is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.,11/15/2019,11/15/2026,Indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.,Novartis Pharmaceuticals Corporation,Adakveo,crizanlizumab-tmca,Novartis Pharmaceuticals,BLA,761128,,2019-05-16,2019-11-15,2019,,ADAKVEO is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.,Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SCENESSE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SCENESSE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 60832,2021-24074,https://www.federalregister.gov/documents/2021/11/04/2021-24074/determination-of-regulatory-review-period-for-purposes-of-patent-extension-scenesse,https://www.govinfo.gov/content/pkg/FR-2021-11-04/pdf/2021-24074.pdf,11/4/2021, SCENESSE,,Nicolas,SCENESSE,1,263,Nicolas,8334265,,,,Clinuvel Pharmaceuticals Limited,3914,3579,335,2009-01-21,2009-01-21,2019-10-08,NDA 210797,1481,210797,,,,,,,,,,,Scenesse,afamelanotide,Clinuvel,NDA,210797,,2018-11-08,2019-10-08,2019,,SCENESSE is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).,Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; SEVENFACT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SEVENFACT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 60827,2021-24065,https://www.federalregister.gov/documents/2021/11/04/2021-24065/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sevenfact,https://www.govinfo.gov/content/pkg/FR-2021-11-04/pdf/2021-24065.pdf,11/4/2021, SEVENFACT,,Nicolas,SEVENFACT,1,264,Nicolas,9029316,,,,Laboratoire Francais du Fractionnement et des Biotechnologies S.A. (LFB S.A.),2785,1518,1267,2012-08-18,2012-08-18,2020-04-01,BLA 125641,482,125641,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; AKLIEF,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AKLIEF and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 60831,2021-24077,https://www.federalregister.gov/documents/2021/11/04/2021-24077/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aklief,https://www.govinfo.gov/content/pkg/FR-2021-11-04/pdf/2021-24077.pdf,11/4/2021, AKLIEF,,Nicolas,AKLIEF,3,267,Nicolas,7807708; 8227507; and 8470871,,,,Galderma Research & Development,3137,2771,366,2011-03-05,2011-03-05,2019-10-04,NDA 211527,1329,211527,,,,,,,,,,,Aklief,trifarotene,Galderma Research and Development,NDA,211527,,2018-10-04,2019-10-04,2019,,AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; DENGVAXIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DENGVAXIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 60835,2021-24067,https://www.federalregister.gov/documents/2021/11/04/2021-24067/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dengvaxia,https://www.govinfo.gov/content/pkg/FR-2021-11-04/pdf/2021-24067.pdf,11/4/2021, DENGVAXIA,,Nicolas,DENGVAXIA,1,268,Nicolas,8142795,,,,Sanofi Pasteur,5710,5466,244,2003-09-14,2003-09-14,2019-05-01,BLA 125682,1248,125682,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; RECARBRIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RECARBRIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 60837,2021-24068,https://www.federalregister.gov/documents/2021/11/04/2021-24068/determination-of-regulatory-review-period-for-purposes-of-patent-extension-recarbrio,https://www.govinfo.gov/content/pkg/FR-2021-11-04/pdf/2021-24068.pdf,11/4/2021, RECARBRIO,,Nicolas,RECARBRIO,1,269,Nicolas,8487093,,,,Merck Sharp & Dohme Corp.,3200,2957,243,2010-10-13,2010-10-13,2019-07-16,NDA 212819,1218,212819,,,,,,,,,,,Recarbrio,"imipenem, cilastatin, and relebactam",Merck Sharp & Dohme,NDA,212819,,2018-11-16,2019-07-16,2019,,"RECARBRIO is indicated in patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis,caused by the following susceptible gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Approval of this indication is based on limited clinical safety and efficacy data for RECARBRIO. 
RECARBRIO is indicated in patients 18 years of age and older who have limited or no alternative treatment options for the treatment of complicated intra-abdominal infections (cIAI) caused by the following susceptible gram-negative microorganisms: Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides stercoris, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Fusobacterium nucleatum, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Parabacteroides distasonis, and Pseudomonas aeruginosa.
Approval of this indication is based on limited clinical safety and efficacy data for RECARBRIO.
Usage:
To reduce the development of drug-resistant bacteria and maintain the effectiveness of RECARBRIO and other antibacterial drugs, RECARBRIO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; DOJOLVI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DOJOLVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.",86 FR 62181,2021-24435,https://www.federalregister.gov/documents/2021/11/09/2021-24435/determination-of-regulatory-review-period-for-purposes-of-patent-extension-dojolvi,https://www.govinfo.gov/content/pkg/FR-2021-11-09/pdf/2021-24435.pdf,11/9/2021, DOJOLVI,,Nicolas,DOJOLVI,2,271,Nicolas,8697748 and 9186344,,,,Ultragenyx Pharmaceutical Inc.,2511,2175,336,2013-08-17,2013-08-17,2020-06-30,NDA 213687,1303,213687,4/15/2015,Treatment of fatty acid oxidation disorders,Designated/Approved,,,DOJOLVI is indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).,6/30/2020,6/30/2027,Indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).,"Ultragenyx Pharmaceutical, Inc.",Dojolvi,triheptanoin,Ultragenyx Pharmaceutical Inc.,NDA,213687,,2019-07-31,2020-06-30,2020,,Dojolvi is indicated for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD),Standard,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; QINLOCK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for QINLOCK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 63402,2021-24978,https://www.federalregister.gov/documents/2021/11/16/2021-24978/determination-of-regulatory-review-period-for-purposes-of-patent-extension-qinlock,https://www.govinfo.gov/content/pkg/FR-2021-11-16/pdf/2021-24978.pdf,11/16/2021, QINLOCK,,Nicolas,QINLOCK,2,273,Nicolas,8188113 and 8461179,,,,Deciphera Pharmaceuticals LLC,1741,1586,155,2015-08-11,2015-08-11,2020-05-15,NDA 213973,947,213973,,,,,,,,,,,Qinlock,ripretinib,"Deciphera Pharmaceuticals, LLC",NDA,213973,,2019-12-13,2020-05-15,2020,,"Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib",Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; SUNOSI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SUNOSI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 64947,2021-25297,https://www.federalregister.gov/documents/2021/11/19/2021-25297/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sunosi,https://www.govinfo.gov/content/pkg/FR-2021-11-19/pdf/2021-25297.pdf,11/19/2021, SUNOSI,,Nicolas,SUNOSI,1,274,Nicolas,8440715,,,,"JAZZ Pharmaceutials, Inc.",8209,7664,545,1996-12-27,1996-12-27,2019-06-17,IND 52082,1386,52082,8/20/2012,Treatment of narcolepsy,Designated/Approved,,,SUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy,6/17/2019,6/17/2026,To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy,"Axsome Malta, Ltd.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TRODELVY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TRODELVY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",86 FR 67065,2021-25612,https://www.federalregister.gov/documents/2021/11/24/2021-25612/determination-of-regulatory-review-period-for-purposes-of-patent-extension-trodelvy,https://www.govinfo.gov/content/pkg/FR-2021-11-24/pdf/2021-25612.pdf,11/24/2021, TRODELVY,,Nicolas,TRODELVY,1,275,Nicolas,7999083,,,,"Immunomedics, Inc.",2856,2150,706,2012-06-29,2012-06-29,2020-04-22,BLA 761115,1780,761115,,,,,,,,,,,Trodelvy,sacituzumab govitecan-hziy,"Immunomedics, Inc",BLA,761115,,2018-05-18,2020-04-22,2020,,Trodelvy is indicated for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease,Priority,No,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ZEPZELCA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZEPZELCA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",86 FR 67960,2021-26009,https://www.federalregister.gov/documents/2021/11/30/2021-26009/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zepzelca,https://www.govinfo.gov/content/pkg/FR-2021-11-30/pdf/2021-26009.pdf,11/30/2021, ZEPZELCA,,Nicolas,ZEPZELCA,1,276,Nicolas,7763615,,,,"Pharma Mar, S.A.",4170,3987,183,2009-01-16,2009-01-16,2020-06-15,NDA 213702,1826,213702,8/1/2018,Treatment of small cell lung cancer (SCLC),Designated/Approved,,,Zepzelca (lurbinectedin) is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after prior platinum-based chemotherapy.,6/15/2020,6/15/2027,For the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.,Jazz Pharmaceuticals Ireland Limited,Zepzelca,lurbinectedin,"Pharma Mar USA, Inc.",NDA,213702,,2019-12-16,2020-06-15,2020,,Zepzelca is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after prior platinum-based chemotherapy,Priority,Yes,Yes,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ENHERTU; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) published a notice in the Federal Register of November 1, 2021, for the determination of a regulatory review period for purposes of patent extension for the human biological product, ENHERTU. This document corrects that notice by adjusting the applicable regulatory review period for the testing phase and approval phase of the product, ENHERTU.",87 FR 1762,2022-00404,https://www.federalregister.gov/documents/2022/01/12/2022-00404/determination-of-regulatory-review-period-for-purposes-of-patent-extension-enhertu-correction,https://www.govinfo.gov/content/pkg/FR-2022-01-12/pdf/2022-00404.pdf,1/12/2022, ENHERTU, Correction,Nicolas,,0,276,Nicolas,,,,,,,,,,,,,,,5/20/2020,"Treatment of gastric cancer, including gastroesophageal junction cancer",Designated/Approved,,,treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen,1/15/2021,1/15/2028,treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen,"Daiichi Sankyo, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DANYELZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DANYELZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 38761,2022-13860,https://www.federalregister.gov/documents/2022/06/29/2022-13860/determination-of-regulatory-review-period-for-purposes-of-patent-extension-danyelza,https://www.govinfo.gov/content/pkg/FR-2022-06-29/pdf/2022-13860.pdf,6/29/2022, DANYELZA,,Nicolas,DANYELZA,1,277,Nicolas,9315585,,,,Memorial Sloan Kettering Cancer Center,3423,3183,240,2011-07-15,2011-07-15,2020-11-25,BLA 761171,3421,761171,,,,,,,,,,,Danyelza,naxitamab-gqgk,"Y-mAbs Therapeutics, Inc.",BLA,761171,,2020-03-31,2020-11-25,2020,,"Danyelza is indicated in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; RUKOBIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RUKOBIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 38763,2022-13856,https://www.federalregister.gov/documents/2022/06/29/2022-13856/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rukobia,https://www.govinfo.gov/content/pkg/FR-2022-06-29/pdf/2022-13856.pdf,6/29/2022, RUKOBIA,,Nicolas,RUKOBIA,1,278,Nicolas,8168615,,,,ViiV Healthcare UK,5322,5110,212,2005-12-08,2005-12-08,2020-07-02,NDA 212950,1597,212950,,,,,,,,,,,Rukobia,fostemsavir,ViiV Healthcare Company,NDA,212950,,2019-12-04,2020-07-02,2020,,"Rukobia is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations",Priority,No,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; TEPEZZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TEPEZZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 39099,2022-13956,https://www.federalregister.gov/documents/2022/06/30/2022-13956/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tepezza,https://www.govinfo.gov/content/pkg/FR-2022-06-30/pdf/2022-13956.pdf,6/30/2022, TEPEZZA,,Nicolas,TEPEZZA,1,279,Nicolas,7572897,,,,Hoffman-La Roche Inc.,2958,2760,198,2011-12-18,2011-12-18,2020-01-21,BLA 761143,1578,761143,,,,,,,,,,,Tepezza,teprotumumab-trbw,Horizon Therapeutics Ireland DAC,BLA,761143,,2019-07-08,2020-01-21,2020,,Tepezza is indicated for the treatment of thyroid eye disease,Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; IMCIVREE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMCIVREE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 39531,2022-14134,https://www.federalregister.gov/documents/2022/07/01/2022-14134/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imcivree,https://www.govinfo.gov/content/pkg/FR-2022-07-01/pdf/2022-14134.pdf,7/1/2022, IMCIVREE,,Nicolas,IMCIVREE,2,281,Nicolas,8039435; 9458195,,,,"RHYTHM PHARMACEUTICALS, INC.",3304,3060,244,2011-11-11,2011-11-11,2020-11-25,NDA 213793,1774,213793,4/4/2016,Treatment of pro-opiomelanocortin (POMC) deficiency due to mutations in the POMC gene,Designated/Approved,,,"chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).",11/25/2020,11/25/2027,"chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).","Rhythm Pharmaceuticals, Inc.",Imcivree,setmelanotide,"Rhythm Pharmaceuticals, Inc.",NDA,213793,,2020-03-27,2020-11-25,2020,,"Imcivree is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC) or proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency confirmed by genetic testing demonstrating variants in POMC or PCSK1 genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). Is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS)",Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; IMCIVREE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMCIVREE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 39531,2022-14134,https://www.federalregister.gov/documents/2022/07/01/2022-14134/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imcivree,https://www.govinfo.gov/content/pkg/FR-2022-07-01/pdf/2022-14134.pdf,7/1/2022, IMCIVREE,,Nicolas,IMCIVREE,2,283,Nicolas,8039435; 9458195,,,,"RHYTHM PHARMACEUTICALS, INC.",3304,3060,244,2011-11-11,2011-11-11,2020-11-25,NDA 213793,1774,213793,11/27/2017,Treatment of leptin receptor deficiency,Designated/Approved,,,"Chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).",11/25/2020,11/25/2027,"Chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).","Rhythm Pharmaceuticals, Inc.",Imcivree,setmelanotide,"Rhythm Pharmaceuticals, Inc.",NDA,213793,,2020-03-27,2020-11-25,2020,,"Imcivree is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC) or proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency confirmed by genetic testing demonstrating variants in POMC or PCSK1 genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). Is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS)",Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; IMCIVREE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMCIVREE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 39531,2022-14134,https://www.federalregister.gov/documents/2022/07/01/2022-14134/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imcivree,https://www.govinfo.gov/content/pkg/FR-2022-07-01/pdf/2022-14134.pdf,7/1/2022, IMCIVREE,,Nicolas,IMCIVREE,2,285,Nicolas,8039435; 9458195,,,,"RHYTHM PHARMACEUTICALS, INC.",3304,3060,244,2011-11-11,2011-11-11,2020-11-25,NDA 213793,1774,213793,9/19/2019,Treatment of Bardet-Biedl syndrome,Designated/Approved,,,For chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to Bardet-Biedl syndrome (BBS),6/16/2022,6/16/2029,For chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to Bardet-Biedl syndrome (BBS),"Rhythm Pharmaceuticals, Inc.",Imcivree,setmelanotide,"Rhythm Pharmaceuticals, Inc.",NDA,213793,,2020-03-27,2020-11-25,2020,,"Imcivree is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC) or proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency confirmed by genetic testing demonstrating variants in POMC or PCSK1 genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). Is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS)",Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VYEPTI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VYEPTI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 40248,2022-14350,https://www.federalregister.gov/documents/2022/07/06/2022-14350/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vyepti,https://www.govinfo.gov/content/pkg/FR-2022-07-06/pdf/2022-14350.pdf,7/6/2022, VYEPTI,,Nicolas,VYEPTI,1,286,Nicolas,9745373,,,,AlderBio Holdings LLC,2599,2233,366,2013-01-11,2013-01-11,2020-02-21,BLA 761119,637,761119,,,,,,,,,,,Vyepti,eptinezumab-jjmr,"Lundbeck Seattle BioPharmaceuticals, Inc.",BLA,761119,,2019-02-21,2020-02-21,2020,,Vyepti is indicated for the preventive treatment of migraine in adults,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; MONJUVI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MONJUVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 40251,2022-14357,https://www.federalregister.gov/documents/2022/07/06/2022-14357/determination-of-regulatory-review-period-for-purposes-of-patent-extension-monjuvi,https://www.govinfo.gov/content/pkg/FR-2022-07-06/pdf/2022-14357.pdf,7/6/2022, MONJUVI,,Nicolas,MONJUVI,2,288,Nicolas,8524867; 9803020,,,,"Xenocor, Inc.",3806,3590,216,2010-03-03,2010-03-03,2020-07-31,BLA 761163,1370,761163,12/1/2014,Treatment of diffuse large B-cell lymphoma,Designated/Approved,,,"MONJUVI is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT)",7/31/2020,7/31/2027,"indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT)",Incyte Corporation,Monjuvi,tafasitamab-cxix,"MorphoSys US, Inc.",BLA,761163,,2019-12-30,2020-07-31,2020,,"Monjuvi is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT)",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; MARGENZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MARGENZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 40256,2022-14360,https://www.federalregister.gov/documents/2022/07/06/2022-14360/determination-of-regulatory-review-period-for-purposes-of-patent-extension-margenza,https://www.govinfo.gov/content/pkg/FR-2022-07-06/pdf/2022-14360.pdf,7/6/2022, MARGENZA,,Nicolas,MARGENZA,1,289,Nicolas,8802093,,,,"MacroGenics, Inc.",3950,3585,365,2010-02-24,2010-02-24,2020-12-16,BLA 761150,1342,761150,,,,,,,,,,,Margenza,margetuximab-cmkb,"MacroGenics, Inc.",BLA,761150,,2019-12-18,2020-12-16,2020,,"Margenza is indicated in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease",Standard,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; XEGLYZE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XEGLYZE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 40534,2022-14430,https://www.federalregister.gov/documents/2022/07/07/2022-14430/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xeglyze,https://www.govinfo.gov/content/pkg/FR-2022-07-07/pdf/2022-14430.pdf,7/7/2022, XEGLYZE,,Nicolas,XEGLYZE,2,291,Nicolas,7812163; 8212038,,,,"Dr. Reddy's Laboratories, S.A.",4573,2797,1776,2008-01-18,2008-01-18,2020-07-24,NDA 206966,1826,206966,,,,,,,,,,,Xeglyze,abametapir,Dr. Reddys Laboratories,NDA,206966,,2015-09-14,2020-07-24,2020,,Xeglyze is indicated for the treatment of head lice infestation in patients 6 months of age and older,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; RINVOQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RINVOQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",87 FR 40536,2022-14431,https://www.federalregister.gov/documents/2022/07/07/2022-14431/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rinvoq,https://www.govinfo.gov/content/pkg/FR-2022-07-07/pdf/2022-14431.pdf,7/7/2022, RINVOQ,,Nicolas,RINVOQ,2,293,Nicolas,8962629; RE47221,,,,AbbVie,2604,2365,239,2012-07-01,2012-07-01,2019-08-16,NDA 211675,989,211675,9/18/2015,Treatment of pediatric (aged 0 through 16 years) juvenile idiopathic arthritis (JIA) ILAR categories excluding systemic JIA,Designated/Approved,,,"treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers, and for the treatment of pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers",4/26/2024,4/26/2031,"treatment of pediatric patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers, and for the treatment of pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers","AbbVie, Inc.",Rinvoq,upadacitinib,Abbvie,NDA,211675,,2018-12-18,2019-08-16,2019,,"RINVOQ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate._x000D_
Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.",Priority (used priority review voucher),No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; UPLIZNA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for UPLIZNA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 40851,2022-14539,https://www.federalregister.gov/documents/2022/07/08/2022-14539/determination-of-regulatory-review-period-for-purposes-of-patent-extension-uplizna,https://www.govinfo.gov/content/pkg/FR-2022-07-08/pdf/2022-14539.pdf,7/8/2022, UPLIZNA,,Nicolas,UPLIZNA,1,294,Nicolas,8323653,,,,"Viela Bio, Inc.",4033,3666,367,2009-05-29,2009-05-29,2020-06-11,BLA 761142,1557,761142,2/10/2016,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders,Designated/Approved,,,Uplizna is indicated for for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.,6/11/2020,6/11/2027,Indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.,Horizon Therapeutics Ireland DAC,Uplizna,inebilizumab-cdon,"Viela Bio, Inc.",BLA,761142,,2019-06-11,2020-06-11,2020,,Uplizna is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,Standard,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; PADCEV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PADCEV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 40847,2022-14548,https://www.federalregister.gov/documents/2022/07/08/2022-14548/determination-of-regulatory-review-period-for-purposes-of-patent-extension-padcev,https://www.govinfo.gov/content/pkg/FR-2022-07-08/pdf/2022-14548.pdf,7/8/2022, PADCEV,,Nicolas,PADCEV,4,298,Nicolas,9078931; 9314538; 9962454; RE48389 (previously U.S. Patent No. 8637642),,,,"AGENSYS, Inc.",2546,2389,157,2012-12-30,2012-12-30,2019-12-18,BLA 761137,811,761137,,,,,,,,,,,Padcev,enfortumab vedotin-ejfv,Astellas Pharma,BLA,761137,,2019-07-15,2019-12-18,2019,,"PADCEV is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.
This indication is approved under accelerated approval based on tumor response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,No,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ROZLYTREK INJECTION,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ROZLYTREK INJECTION and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 40849,2022-14546,https://www.federalregister.gov/documents/2022/07/08/2022-14546/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rozlytrek-injection,https://www.govinfo.gov/content/pkg/FR-2022-07-08/pdf/2022-14546.pdf,7/8/2022, ROZLYTREK INJECTION,,Nicolas,ROZLYTREK INJECTION,4,302,Nicolas,8299057; 8673893; 9029356; and 9085565,,,,"Genentech, Inc.",1968,1727,241,2014-03-28,2014-03-28,2019-08-15,NDA 212726,1104,212726,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; TABRECTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TABRECTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 41133,2022-14674,https://www.federalregister.gov/documents/2022/07/11/2022-14674/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tabrecta,https://www.govinfo.gov/content/pkg/FR-2022-07-11/pdf/2022-14674.pdf,7/11/2022, TABRECTA,,Nicolas,TABRECTA,2,304,Nicolas,7767675; 8420645,,,,Incyte Corp.,4164,4015,149,2008-12-13,2008-12-13,2020-05-06,NDA 213591,5,213591,,,,,,,,,,,Tabrecta,capmatinib,Novartis Pharmaceuticals Corporation,NDA,213591,,2019-12-10,2020-05-06,2020,,Tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test,Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ENSPRYNG,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ENSPRYNG and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human biological product.",87 FR 41724,2022-14930,https://www.federalregister.gov/documents/2022/07/13/2022-14930/determination-of-regulatory-review-period-for-purposes-of-patent-extension-enspryng,https://www.govinfo.gov/content/pkg/FR-2022-07-13/pdf/2022-14930.pdf,7/13/2022, ENSPRYNG,,Nicolas,ENSPRYNG,3,307,Nicolas,8562991; 10022319; 10662245,,,,"Genentech, Inc.",2495,2128,367,2013-10-18,2013-10-18,2020-08-14,BLA 761149,1428,761149,6/30/2014,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder,Designated/Approved,,,treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,8/14/2020,8/14/2027,treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,"Genentech, Inc.",Enspryng,satralizumab-mwge,"Genentech, Inc.",BLA,761149,,2019-08-15,2020-08-14,2020,,Enspryng is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,Standard,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; BLENREP,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BLENREP and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 41727,2022-14916,https://www.federalregister.gov/documents/2022/07/13/2022-14916/determination-of-regulatory-review-period-for-purposes-of-patent-extension-blenrep,https://www.govinfo.gov/content/pkg/FR-2022-07-13/pdf/2022-14916.pdf,7/13/2022, BLENREP,,Nicolas,BLENREP,1,308,Nicolas,9273141,,,,Glaxo Group Ltd,2352,2107,245,2014-02-28,2014-02-28,2020-08-05,BLA 761158,803,761158,6/22/2017,Treatment of multiple myeloma,Designated/Approved,,,"for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent (indication withdrawn)",8/5/2020,2/6/2023,"for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent (indication withdrawn)",GlaxoSmithKline Intellectual Property Development Ltd.,Blenrep,belantamab mafodotin-blmf,GlaxoSmithKline Intellectual Property Development Ltd. England,BLA,761158,,2019-12-05,2020-08-05,2020,,"Blenrep is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TAUVID,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TAUVID and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 43874,2022-15679,https://www.federalregister.gov/documents/2022/07/22/2022-15679/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tauvid,https://www.govinfo.gov/content/pkg/FR-2022-07-22/pdf/2022-15679.pdf,7/22/2022, TAUVID,,Nicolas,TAUVID,1,309,Nicolas,8932557,,,,Eli Lilly,3067,2825,242,2012-01-06,2012-01-06,2020-05-28,NDA 212123,1102,212123,,,,,,,,,,,Tauvid,flortaucipir F 18,"Avid Radiopharmaceuticals, Inc.",NDA,212123,,2019-09-30,2020-05-28,2020,,Tauvid is indicated for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimers disease (AD),Priority,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VUMERITY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VUMERITY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 44126,2022-15823,https://www.federalregister.gov/documents/2022/07/25/2022-15823/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vumerity,https://www.govinfo.gov/content/pkg/FR-2022-07-25/pdf/2022-15823.pdf,7/25/2022, VUMERITY,,Tianlun,VUMERITY (diroximel fumarate),3,312,Nicolas,"8,669,281; 9,090,558; 10,080,733",,,,Alkermes Pharma Ireland Limited,1944,1623,321,2014-07-05,2018-12-13,2019-10-29,NDA 211855,40,211855,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; REBLOZYL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REBLOZYL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 46963,2022-16385,https://www.federalregister.gov/documents/2022/08/01/2022-16385/determination-of-regulatory-review-period-for-purposes-of-patent-extension-reblozyl,https://www.govinfo.gov/content/pkg/FR-2022-08-01/pdf/2022-16385.pdf,8/1/2022, REBLOZYL,,Tianlun,REBLOZYL (luspatercept-aamt),3,315,Nicolas,"8,058,229; 8,343,933; 8,361,957",,,,Acceleron Pharma Inc.,3041,2822,219,2011-07-14,2019-04-04,2019-11-08,BLA 761136,"1,347, 1,361, or 1,548",761136,3/11/2013,Treatment of B-thalassemia,Designated/Approved,,,REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.,11/8/2019,11/8/2026,Indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.,Celgene Corporation,Reblozyl,luspatercept-aamt,Celgene,BLA,761136,,2019-04-04,2019-11-08,2019,,"REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
Limitations of Use:
REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.",Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; REBLOZYL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REBLOZYL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 46963,2022-16385,https://www.federalregister.gov/documents/2022/08/01/2022-16385/determination-of-regulatory-review-period-for-purposes-of-patent-extension-reblozyl,https://www.govinfo.gov/content/pkg/FR-2022-08-01/pdf/2022-16385.pdf,8/1/2022, REBLOZYL,,Tianlun,REBLOZYL (luspatercept-aamt),3,318,Nicolas,"8,058,229; 8,343,933; 8,361,957",,,,Acceleron Pharma Inc.,3041,2822,219,2011-07-14,2019-04-04,2019-11-08,BLA 761136,"1,347, 1,361, or 1,548",761136,3/18/2013,Treatment of myelodysplastic syndrome,Designated/Approved,,,treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naive) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions,8/28/2023,8/28/2030,treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naive) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions,"Celgene Corporation, a Bristol-Myers Squibb Company",Reblozyl,luspatercept-aamt,Celgene,BLA,761136,,2019-04-04,2019-11-08,2019,,"REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
Limitations of Use:
REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.",Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; REBLOZYL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REBLOZYL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",87 FR 46963,2022-16385,https://www.federalregister.gov/documents/2022/08/01/2022-16385/determination-of-regulatory-review-period-for-purposes-of-patent-extension-reblozyl,https://www.govinfo.gov/content/pkg/FR-2022-08-01/pdf/2022-16385.pdf,8/1/2022, REBLOZYL,,Tianlun,REBLOZYL (luspatercept-aamt),3,321,Nicolas,"8,058,229; 8,343,933; 8,361,957",,,,Acceleron Pharma Inc.,3041,2822,219,2011-07-14,2019-04-04,2019-11-08,BLA 761136,"1,347, 1,361, or 1,548",761136,3/18/2013,Treatment of myelodysplastic syndrome,Designated/Approved,,,REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).,4/3/2020,4/3/2027,For the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS),"Celgene Corporation, a Bristol-Myers Squibb Company",Reblozyl,luspatercept-aamt,Celgene,BLA,761136,,2019-04-04,2019-11-08,2019,,"REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
Limitations of Use:
REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.",Priority,Yes,No,No,Yes
"Determination of Regulatory Review Period for Purposes of Patent Extension; ROZLYTREK TABLETS, New Drug Application 212725",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ROZLYTREK TABLETS new drug application (NDA) 212725 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.",87 FR 47217,2022-16504,https://www.federalregister.gov/documents/2022/08/02/2022-16504/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rozlytrek-tablets-new,https://www.govinfo.gov/content/pkg/FR-2022-08-02/pdf/2022-16504.pdf,8/2/2022," ROZLYTREK TABLETS, New Drug Application 212725",,Tianlun,ROZLYTREK TABLETS (entrectinib),4,325,Nicolas,"8,299,057; 8,673,893; 9,029,356; and 9,085,565",,,,"Genentech, Inc.",1968,1727,241,2014-03-28,2018-12-18,2019-08-15,NDA 212725,"864, 899, or 1,104",212725,,,,,,,,,,,Rozlytrek,entrectinib,Genentech,NDA,212725,212726,2018-12-18,2019-08-15,2019,,"[A] ROZLYTREK is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.
[B] ROZLYTREK is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that:
- have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation,
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have either progressed following treatment or have no satisfactory alternative therapy.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes (indication [B] only),Yes (indication [B] only),No
Determination of Regulatory Review Period for Purposes of Patent Extension; UBRELVY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for UBRELVY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 53475,2022-18753,https://www.federalregister.gov/documents/2022/08/31/2022-18753/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ubrelvy,https://www.govinfo.gov/content/pkg/FR-2022-08-31/pdf/2022-18753.pdf,8/31/2022, UBRELVY,,Tianlun,UBRELVY (ubrogepant),2,327,Nicolas,"8,912,210 and 9,833,448",,,,Allergan Sales LLC,2883,2520,363,2012-02-02,2018-12-26,2019-12-23,NDA 211765,555 or 774,211765,,,,,,,,,,,Ubrelvy,ubrogepant,Allergan,NDA,211765,,2018-12-26,2019-12-23,2019,,"UBRELVY is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use:
UBRELVY is not indicated for the preventive treatment of migraine.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; THEROX DOWNSTREAM SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for THEROX DOWNSTREAM SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",87 FR 53474,2022-18754,https://www.federalregister.gov/documents/2022/08/31/2022-18754/determination-of-regulatory-review-period-for-purposes-of-patent-extension-therox-downstream-system,https://www.govinfo.gov/content/pkg/FR-2022-08-31/pdf/2022-18754.pdf,8/31/2022, THEROX DOWNSTREAM SYSTEM,,Tianlun,THEROX DOWNSTREAM SYSTEM,3,330,Nicolas,"6,582,387; 7,820,102; and 8,264,564",,,,TherOx Inc.,7386,6824,562,1999-01-13,2017-09-18,2019-04-02,PMA P170027,"991, 1,591, or 1,826",170027,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ORILISSA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ORILISSA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.",87 FR 55434,2022-19506,https://www.federalregister.gov/documents/2022/09/09/2022-19506/determination-of-regulatory-review-period-for-purposes-of-patent-extension-orilissa,https://www.govinfo.gov/content/pkg/FR-2022-09-09/pdf/2022-19506.pdf,9/9/2022, ORILISSA,,Tianlun,ORILISSA (elagolix sodium),2,332,Nicolas,"7,056,927 and 7,419,983",,,,"Neurocrine Biosciences, Inc.",5452,5117,335,2003-08-21,2017-08-23,2018-07-23,NDA 210450,5 years,210450,,,,,,,,,,,Orilissa,elagolix,AbbVie,NDA,210450,,2017-08-23,2018-07-23,2018,,ORILISSA is indicated for the management of moderate to severe pain associated with endometriosis.,Priority,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; REYVOW,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REYVOW and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 56072,2022-19714,https://www.federalregister.gov/documents/2022/09/13/2022-19714/determination-of-regulatory-review-period-for-purposes-of-patent-extension-reyvow,https://www.govinfo.gov/content/pkg/FR-2022-09-13/pdf/2022-19714.pdf,9/13/2022, REYVOW,,Tianlun,REYVOW (lasmiditan),1,333,Nicolas,7423050,,,,Eli Lilly and Company,3097,2619,478,2011-08-11,2018-10-11,2019-10-11,NDA 211280,1786,211280,,,,,,,,,,,Reyvow,lasmiditan,Eli Lilly,NDA,211280,,2018-10-11,2019-10-11,2019,,"REYVOW is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use:
REYVOW is not indicated for the preventive treatment of migraine.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BULKAMID URETHRAL BULKING SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BULKAMID URETHRAL BULKING SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",87 FR 56062,2022-19723,https://www.federalregister.gov/documents/2022/09/13/2022-19723/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bulkamid-urethral-bulking,https://www.govinfo.gov/content/pkg/FR-2022-09-13/pdf/2022-19723.pdf,9/13/2022, BULKAMID URETHRAL BULKING SYSTEM,,Tianlun,BULKAMID URETHRAL BULKING SYSTEM,3,336,Nicolas,"7,678,146; 7,758,497; and 7,780,958",,,,Contura A/S,4529,3617,912,2007-09-06,2017-07-31,2020-01-28,PMA P170023,5 years,170023,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; CAPLYTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CAPLYTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 56686,2022-19898,https://www.federalregister.gov/documents/2022/09/15/2022-19898/determination-of-regulatory-review-period-for-purposes-of-patent-extension-caplyta,https://www.govinfo.gov/content/pkg/FR-2022-09-15/pdf/2022-19898.pdf,9/15/2022, CAPLYTA,,Tianlun,CAPLYTA (lumateperone tosylate),2,338,Nicolas,"8,598,119 and 8,648,077",,,,"Intra-Cellular Therapies, Inc.",4421,3970,451,2007-11-15,2018-09-27,2019-12-20,NDA 209500,"1,294 or 1,329",209500,,,,,,,,,,,Caplyta,lumateperone,Intra-Cellular Therapies,NDA,209500,,2018-09-27,2019-12-20,2019,,CAPLYTA is indicated for the treatment of schizophrenia in adults.,Standard,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; TAVALISSE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TAVALISSE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 56687,2022-19993,https://www.federalregister.gov/documents/2022/09/15/2022-19993/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tavalisse,https://www.govinfo.gov/content/pkg/FR-2022-09-15/pdf/2022-19993.pdf,9/15/2022, TAVALISSE,,Tianlun,TAVALISSE (fostamatinib disodium hexahydrate),1,339,Nicolas,7449458,,,,"Rigel Pharmaceuticals, Inc.",4564,4198,366,2005-10-20,2017-04-17,2018-04-17,NDA 209299,5 years,209299,,,,,,,,,,,Tavalisse,fostamatinib disodium hexahydrate,Rigel Pharmaceuticals,NDA,209299,,2017-04-17,2018-04-17,2018,,TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.,Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; NURTEC ODT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NURTEC ODT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 58116,2022-20634,https://www.federalregister.gov/documents/2022/09/23/2022-20634/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nurtec-odt,https://www.govinfo.gov/content/pkg/FR-2022-09-23/pdf/2022-20634.pdf,9/23/2022, NURTEC ODT,,Tianlun,NURTEC ODT (rimegepant sulfate),2,341,Nicolas,"8,314,117 and 8,759,372",,,,Biohaven Pharmaceutical Holding Company Ltd.,3390,3144,246,2010-11-18,2019-06-27,2020-02-27,NDA 212728,"368 or 1,102",212728,,,,,,,,,,,Nurtec ODT,rimegepant,Biohaven Pharmaceuticals,NDA,212728,,2019-06-27,2020-02-27,2020,,Nurtec ODT is indicated for the acute treatment of migraine with or without aura in adults,Priority (used priority review voucher),No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; NOURIANZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NOURIANZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 67039,2022-24217,https://www.federalregister.gov/documents/2022/11/07/2022-24217/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nourianz,https://www.govinfo.gov/content/pkg/FR-2022-11-07/pdf/2022-24217.pdf,11/7/2022, NOURIANZ,,Tianlun,NOURIANZ (istradefylline),2,343,Nicolas,"7,727,993 and 7,727,994",,,,"Kyowa Kirin Co., Ltd.",7300,2792,4508,1999-09-03,2007-04-25,2019-08-27,NDA 22075,5 years,22075,,,,,,,,,,,Nourianz,istradefylline,Kyowa Kirin,NDA,22075,,2007-04-25,2019-08-27,2019,,NOURIANZ is indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ANGELMED GUARDIAN SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ANGELMED GUARDIAN SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",87 FR 67042,2022-24216,https://www.federalregister.gov/documents/2022/11/07/2022-24216/determination-of-regulatory-review-period-for-purposes-of-patent-extension-angelmed-guardian-system,https://www.govinfo.gov/content/pkg/FR-2022-11-07/pdf/2022-24216.pdf,11/7/2022, ANGELMED GUARDIAN SYSTEM,,Tianlun,ANGELMED GUARDIAN SYSTEM,1,344,Nicolas,6609023,,,,"Angel Medical Systems, Inc.",4037,2916,1121,2007-03-23,2015-03-16,2018-04-09,PMA P150009,1827,150009,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; XCOPRI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XCOPRI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 67696,2022-24457,https://www.federalregister.gov/documents/2022/11/09/2022-24457/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xcopri,https://www.govinfo.gov/content/pkg/FR-2022-11-09/pdf/2022-24457.pdf,11/9/2022, XCOPRI,,Tianlun,XCOPRI (cenobamate),1,345,Nicolas,7598279,,,,"SK Biopharmaceuticals Co., Ltd.",5326,4850,476,2005-08-12,2018-11-21,2020-03-10,NDA 212839,5 years,212839,,,,,,,,,,,Xcopri,cenobamate,SK Life Science,NDA,212839,,2018-11-21,2019-11-21,2019,,XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TISSUEBLUE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TISSUEBLUE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 67698,2022-24434,https://www.federalregister.gov/documents/2022/11/09/2022-24434/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tissueblue,https://www.govinfo.gov/content/pkg/FR-2022-11-09/pdf/2022-24434.pdf,11/9/2022, TISSUEBLUE,,Tianlun,TISSUEBLUE (Brilliant blue G Ophthalmic Solution),1,346,Nicolas,7731941,,,,"Kyushu University, National University Corporation",4631,4395,236,2007-04-18,2019-04-29,2019-12-20,NDA 209569,1375,209569,,,,,,,,,,,TissueBlue,Brilliant Blue G Ophthalmic Solution,D.O.R.C International b.v,NDA,209569,,2019-04-29,2019-12-20,2019,,TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025% is indicated to selectively stain the internal limiting membrane (ILM).,Priority,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; NEXLETOL,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NEXLETOL and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 67699,2022-24431,https://www.federalregister.gov/documents/2022/11/09/2022-24431/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nexletol,https://www.govinfo.gov/content/pkg/FR-2022-11-09/pdf/2022-24431.pdf,11/9/2022, NEXLETOL,,Tianlun,NEXLETOL (bempedoic acid),1,347,Nicolas,7335799,,,,"Esperion Therapeutics, Inc.",3774,3408,366,2009-10-24,2019-02-21,2020-02-21,NDA 211616,1826,211616,,,,,,,,,,,Nexletol,bempedoic acid,"Esperion Therapeutics, Inc.",NDA,211616,,2019-02-21,2020-02-21,2020,,Nexletol is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C,Standard,No,No,No,No
"Determination of Regulatory Review Period for Purposes of Patent Extension; PREVYMIS, New Drug Application 209939",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA, Agency, or we) has determined the regulatory review period for PREVYMIS, new drug application (NDA) 209939, and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 68177,2022-24718,https://www.federalregister.gov/documents/2022/11/14/2022-24718/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prevymis-new-drug,https://www.govinfo.gov/content/pkg/FR-2022-11-14/pdf/2022-24718.pdf,11/14/2022," PREVYMIS, New Drug Application 209939",,Tianlun,PREVYMIS (letermovir),1,348,Nicolas,RE46791,,,,AiCuris Anti-infective Cures GmbH,3157,2911,246,2009-03-20,2017-03-08,2017-11-08,NDA 209939,1701,209939,,,,,,,,,,,Prevymis,letermovir,Merck,NDA,209939,209940,2017-03-08,2017-11-08,2017,,PREVYMIS is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).,Priority,Yes,No,Yes,Yes
"Determination of Regulatory Review Period for Purposes of Patent Extension; PREVYMIS IV Solution, New Drug Application 209940",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PREVYMIS IV Solution, new drug application (NDA) 209940, and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",87 FR 68174,2022-24719,https://www.federalregister.gov/documents/2022/11/14/2022-24719/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prevymis-iv-solution-new,https://www.govinfo.gov/content/pkg/FR-2022-11-14/pdf/2022-24719.pdf,11/14/2022," PREVYMIS IV Solution, New Drug Application 209940",,Tianlun,PREVYMIS (letermovir),1,349,Nicolas,8513255,,,,AiCuris Anti-infective Cures GmbH,3157,2911,246,2009-03-20,2017-03-08,2017-11-08,NDA 209940,894,209940,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; BYFAVO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BYFAVO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 4185,2023-01220,https://www.federalregister.gov/documents/2023/01/24/2023-01220/determination-of-regulatory-review-period-for-purposes-of-patent-extension-byfavo,https://www.govinfo.gov/content/pkg/FR-2023-01-24/pdf/2023-01220.pdf,1/24/2023, BYFAVO,,Tianlun,BYFAVO (remimazolam),1,350,Nicolas,9827251,,,,Acacia Pharma Limited,4482,3931,551,2008-07-01,2019-04-05,2020-10-06,NDA 212295,796,212295,,,,,,,,,,,Byfavo,remimazolam,"Cosmo Technologies, Ltd.",NDA,212295,,2019-04-05,2020-07-02,2020,,Byfavo is indicated for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; OLUMIANT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OLUMIANT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 7731,2023-02441,https://www.federalregister.gov/documents/2023/02/06/2023-02441/determination-of-regulatory-review-period-for-purposes-of-patent-extension-olumiant,https://www.govinfo.gov/content/pkg/FR-2023-02-06/pdf/2023-02441.pdf,2/6/2023, OLUMIANT,,Tianlun,OLUMIANT (baricitinib),1,351,Nicolas,8158616,,,,Eli Lilly and Co.,3649,2781,868,2008-06-05,2016-01-15,2018-05-31,NDA 207924,723,207924,,,,,,,,,,,Olumiant,baricitinib,Eli Lilly,NDA,207924,,2016-01-15,2018-05-31,2018,,"OLUMIANT (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies._x000D_
Limitation of Use: Use of OLUMIANT in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; XIIDRA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XIIDRA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 7733,2023-02452,https://www.federalregister.gov/documents/2023/02/06/2023-02452/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xiidra,https://www.govinfo.gov/content/pkg/FR-2023-02-06/pdf/2023-02452.pdf,2/6/2023, XIIDRA,,Tianlun,XIIDRA (lifitegrast),5,356,Nicolas,"7,314,938; 7,790,743; 8,084,047; 8,168,655; 8,592,450",,,,SARcode Bioscience Inc.,2883,2380,503,2008-08-21,2015-02-25,2016-07-11,NDA 208073,"1,693, 1,319, 1,081, 1,018 or 731 ",208073,,,,,,,,,,,Xiidra,lifitegrast,Shire Development,NDA,208073,,2015-02-25,2016-07-11,2016,,Xiidra (lifitegrast ophthalmic solution) 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).,Priority,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; DOPTELET,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DOPTELET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 7739,2023-02482,https://www.federalregister.gov/documents/2023/02/06/2023-02482/determination-of-regulatory-review-period-for-purposes-of-patent-extension-doptelet,https://www.govinfo.gov/content/pkg/FR-2023-02-06/pdf/2023-02482.pdf,2/6/2023, DOPTELET,,Tianlun,DOPTELET (avatrombopag maleate),1,1,Helen,7638536,2009-12-29,Astellas Pharma Inc.,1655,Astellas Pharma Inc.,4632,4389,243,2005-09-16,2017-09-21,2018-05-21,NDA 210238,1826,210238,,,,,,,,,,,Doptelet,avatrombopag,Dova Pharmaceuticals,NDA,210238,,2017-09-21,2018-05-21,2018,,DOPTELET (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.,Priority,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; YUPELRI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for YUPELRI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 7979,2023-02498,https://www.federalregister.gov/documents/2023/02/07/2023-02498/determination-of-regulatory-review-period-for-purposes-of-patent-extension-yupelri,https://www.govinfo.gov/content/pkg/FR-2023-02-07/pdf/2023-02498.pdf,2/7/2023, YUPELRI,,Tianlun,YUPELRI (revefenacin),2,3,Helen,"7,288,657 and 7,585,879",2007-10-30,"Theravance Biopharma R&D IP, LLC",1043,"Theravance Biopharma R&D IP, LLC",1724,1362,362,2014-02-21,2017-11-13,2018-11-09,NDA 210598,1042,210598,,,,,,,,,,,Yupelri,revefenacin,Theravance Biopharma,NDA,210598,,2017-11-13,2018-11-09,2018,,YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SKYRIZI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SKYRIZI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",88 FR 8289,2023-02680,https://www.federalregister.gov/documents/2023/02/08/2023-02680/determination-of-regulatory-review-period-for-purposes-of-patent-extension-skyrizi,https://www.govinfo.gov/content/pkg/FR-2023-02-08/pdf/2023-02680.pdf,2/8/2023, SKYRIZI,,Tianlun,SKYRIZI (risankizumab-rzaa),2,5,Helen,"8,778,346 and 10,202,448",2014-07-15,Boehringer Ingelheim International GmbH,538,Boehringer Ingelheim International GmbH,2582,2216,366,2012-03-30,2018-04-23,2019-04-23,BLA 761105,70 or 538,761105,,,,,,,,,,,Skyrizi,risankizumab-rzaa,AbbVie,BLA,761105,,2018-04-23,2019-04-23,2019,,SKYRIZI is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LOKELMA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LOKELMA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 8291,2023-02667,https://www.federalregister.gov/documents/2023/02/08/2023-02667/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lokelma,https://www.govinfo.gov/content/pkg/FR-2023-02-08/pdf/2023-02667.pdf,2/8/2023, LOKELMA,,Tianlun,LOKELMA (sodium zirconium cyclosilicate),2,7,Helen,"8,802,152 and 8,808,750",2014-08-19,"ZS Pharma, Inc.",98,ZS Pharma Inc.,2384,1295,1089,2011-11-09,2015-05-26,2018-05-18,NDA 207078,29 or 98,207078,,,,,,,,,,,Lokelma,sodium zirconium cyclosilicate,AstraZeneca Pharmaceuticals,NDA,207078,,2015-05-26,2018-05-18,2018,,"LOKELMA is indicated for the treatment of hyperkalemia in adults.
Limitation of Use:
LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; REMEDE SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REMEDE SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",88 FR 8287,2023-02669,https://www.federalregister.gov/documents/2023/02/08/2023-02669/determination-of-regulatory-review-period-for-purposes-of-patent-extension-remede-system,https://www.govinfo.gov/content/pkg/FR-2023-02-08/pdf/2023-02669.pdf,2/8/2023, REMEDE SYSTEM,,Tianlun,REMEDE SYSTEM,1,8,Helen,8233987,n/a,,,"Respicardia, Inc.",3685,3289,396,2007-09-06,2016-09-06,2017-10-06,PMA 160039,301,160039,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; XOSPATA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XOSPATA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 8431,2023-02745,https://www.federalregister.gov/documents/2023/02/09/2023-02745/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xospata,https://www.govinfo.gov/content/pkg/FR-2023-02-09/pdf/2023-02745.pdf,2/9/2023, XOSPATA,,Tianlun,XOSPATA (gilteritinib),2,10,Helen,"8,969,336 and 9,487,491",2015-03-03,"Astellas Pharma Inc. and Kotobuki Pharmaceutical Co., Ltd.",671,Astellas Pharma Inc.,2002,1757,245,2013-06-07,2018-03-29,2018-11-28,NDA 211349,671 or 498,211349,7/13/2017,Treatment of acute myeloid leukemia (AML),Designated/Approved,,,XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.,11/28/2018,11/28/2025,XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.,"Astellas Pharma US, Inc.",Xospata,gilteritinib,Astellas Pharma,NDA,211349,,2018-03-29,2018-11-28,2018,,XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.,Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ERLEADA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ERLEADA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 8434,2023-02743,https://www.federalregister.gov/documents/2023/02/09/2023-02743/determination-of-regulatory-review-period-for-purposes-of-patent-extension-erleada,https://www.govinfo.gov/content/pkg/FR-2023-02-09/pdf/2023-02743.pdf,2/9/2023, ERLEADA,,Tianlun,ERLEADA (apalutamide),3,13,Helen,"8,445,507; 8,802,689; 9,388,159",n/a,,,The Regents of the University of California,2795,2667,128,2010-06-23,2017-10-10,2018-02-14,NDA 210951,"518, 706, or 356",210951,,,,,,,,,,,Erleada,apalutamide,Janssen Biotech,NDA,210951,,2017-10-10,2018-02-14,2018,,"ERLEADA is indicated for the treatment of patients with non-metastatic, castration-resistant prostate cancer (NM-CRPC).",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ALIQOPA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ALIQOPA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 9522,2023-03070,https://www.federalregister.gov/documents/2023/02/14/2023-03070/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aliqopa,https://www.govinfo.gov/content/pkg/FR-2023-02-14/pdf/2023-03070.pdf,2/14/2023, ALIQOPA,,Tianlun,ALIQOPA (copanlisib dihydrochloride),2,15,Helen,"7,511,041 and RE46856",n/a,,,ayer Intellectual Property GmbH,3004,2821,183,2009-06-26,2017-03-16,2017-09-14,NDA 209936,"1,594 or 692",209936,2/5/2015,Treatment of follicular lymphoma,Designated/Approved,,,Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies,9/14/2017,9/14/2024,Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies,Bayer US LLC,Aliqopa,copanlisib,Bayer HealthCare Pharmaceuticals,NDA,209936,,2017-03-16,2017-09-14,2017,,"ALIQOPA is indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. _x000D_
Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; VERZENIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VERZENIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 12938,2023-04177,https://www.federalregister.gov/documents/2023/03/01/2023-04177/determination-of-regulatory-review-period-for-purposes-of-patent-extension-verzenio,https://www.govinfo.gov/content/pkg/FR-2023-03-01/pdf/2023-04177.pdf,3/1/2023, VERZENIO,,Tianlun,VERZENIO (abemaciclib),1,16,Helen,7855211,2010-12-21,Eli Lily and Company,652,Eli Lilly and Company,2907,2760,147,2009-10-15,2017-05-05,2017-09-28,NDA 208716,652,208716,,,,,,,,,,,Verzenio,abemaciclib,Eli Lilly,NDA,208716,,2017-05-05,2017-09-28,2017,,"VERZENIO (abemaciclib) is indicated:
- in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
- as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.",Priority,No,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; VYZULTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VYZULTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 12950,2023-04178,https://www.federalregister.gov/documents/2023/03/01/2023-04178/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vyzulta,https://www.govinfo.gov/content/pkg/FR-2023-03-01/pdf/2023-04178.pdf,3/1/2023, VYZULTA,,Tianlun,VYZULTA (latanoprostene bunod),3,19,Helen,"7,273,946; 7,629,345; and 8,058,467",2011-11-15,Nicox S.A.,1508,Nicox S.A.,3879,3043,836,2007-03-23,2015-07-21,2017-11-02,NDA 207795,"1,826 or 1,507",207795,,,,,,,,,,,Vyzulta,latanoprostene bunod,Bausch & Lomb,NDA,207795,,2015-07-21,2017-11-02,2017,,VYZULTA (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; JIVI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for JIVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",88 FR 16639,2023-05570,https://www.federalregister.gov/documents/2023/03/20/2023-05570/determination-of-regulatory-review-period-for-purposes-of-patent-extension-jivi,https://www.govinfo.gov/content/pkg/FR-2023-03-20/pdf/2023-05570.pdf,3/20/2023, JIVI,,Tianlun,"JIVI (antihemophilic factor (recombinant), PEGylated-aucl)",1,20,Helen,7632921,n/a,,,Bayer HealthCare LLC,2991,2626,365,2010-06-23,2017-08-30,2018-08-29,BLA 125661,1677,125661,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; IC-8 APTHERA INTRAOCULAR LENS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IC-8 APTHERA INTRAOCULAR LENS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",88 FR 16642,2023-05641,https://www.federalregister.gov/documents/2023/03/20/2023-05641/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ic-8-apthera-intraocular,https://www.govinfo.gov/content/pkg/FR-2023-03-20/pdf/2023-05641.pdf,3/20/2023, IC-8 APTHERA INTRAOCULAR LENS,,Tianlun,IC-8 APTHERA INTRAOCULAR LENS,1,21,Helen,9005281,n/a,,,"AcuFocus, Inc.",1341,827,514,2018-11-21,2021-02-24,2022-07-22,PMA 210005,928,210005,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ESPEROCT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ESPEROCT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",88 FR 16992,2023-05658,https://www.federalregister.gov/documents/2023/03/21/2023-05658/determination-of-regulatory-review-period-for-purposes-of-patent-extension-esperoct,https://www.govinfo.gov/content/pkg/FR-2023-03-21/pdf/2023-05658.pdf,3/21/2023, ESPEROCT,,Tianlun,"ESPEROCT (antihemophilic factor (recombinant), glycopegylated-exei)",1,22,Helen,8536126,n/a,,,Novo Nordisk A/S,3129,2771,358,2010-07-29,2018-02-27,2019-02-19,BLA 125671,1170,125671,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; MULPLETA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MULPLETA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 17233,2023-05799,https://www.federalregister.gov/documents/2023/03/22/2023-05799/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mulpleta,https://www.govinfo.gov/content/pkg/FR-2023-03-22/pdf/2023-05799.pdf,3/22/2023, MULPLETA,,Tianlun,MULPLETA (lusutrombopag),2,24,Helen,"7,601,746 and 8,889,722",2014-11-18,EDDINGPHARM (HONG KONG) COMPANY LIMITED,785,"Shionogi & Co., Ltd",3464,3246,218,2009-02-06,2017-12-26,2018-07-31,NDA 210923,"784 or 1,715",210923,,,,,,,,,,,Mulpleta,lusutrombopag,Shionogi,NDA,210923,,2017-12-26,2018-07-31,2018,,MULPLETA is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.,Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; GALAFOLD,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GALAFOLD and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 17235,2023-05897,https://www.federalregister.gov/documents/2023/03/22/2023-05897/determination-of-regulatory-review-period-for-purposes-of-patent-extension-galafold,https://www.govinfo.gov/content/pkg/FR-2023-03-22/pdf/2023-05897.pdf,3/22/2023, GALAFOLD,,Tianlun,GALAFOLD (migalastat),2,26,Helen,"8,592,362 and 9,000,011",n/a,,,"Amicus Therapeutics, Inc.",5132,4891,241,2004-07-24,2017-12-13,2018-08-10,NDA 208623,732 or 980,208623,2/25/2004,Treatment of Fabry Disease,Designated/Approved,,,GALAFOLD is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data,8/10/2018,8/10/2025,GALAFOLD is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data,"Amicus Therapeutics, Inc.",Galafold,migalastat,Amicus Therapeutics,NDA,208623,,2017-12-13,2018-08-10,2018,,"GALAFOLD is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data._x000D_
This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; TEGSEDI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TEGSEDI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 17583,2023-05906,https://www.federalregister.gov/documents/2023/03/23/2023-05906/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tegsedi,https://www.govinfo.gov/content/pkg/FR-2023-03-23/pdf/2023-05906.pdf,3/23/2023, TEGSEDI,,Tianlun,TEGSEDI (inotersen sodium),3,29,Helen,"8,101,743; 9,061,044; 9,399,774",n/a,,,"Ionis Pharmaceuticals, Inc. ",2158,1824,334,2012-11-09,2017-11-06,2018-10-05,NDA 211172,"526 or 1,246",211172,,,,,,,,,,,Tegsedi,inotersen,Ionis Pharmaceuticals,NDA,211172,,2017-11-06,2018-10-05,2018,,TEGSEDI is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; CINTEC PLUS CYTOLOGY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CINTEC PLUS CYTOLOGY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",88 FR 17579,2023-05908,https://www.federalregister.gov/documents/2023/03/23/2023-05908/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cintec-plus-cytology,https://www.govinfo.gov/content/pkg/FR-2023-03-23/pdf/2023-05908.pdf,3/23/2023, CINTEC PLUS CYTOLOGY,,Tianlun,CINTEC PLUS CYTOLOGY,1,30,Helen,8367353,n/a,,,"Ventana Medical Systems, Inc.",181,0,181,not applicable,2019-09-12,2020-03-10,PMA P190024,547,190024,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; RECELL AUTOLOGOUS CELL HARVESTING DEVICE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RECELL AUTOLOGOUS CELL HARVESTING DEVICE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological device.",88 FR 17581,2023-05948,https://www.federalregister.gov/documents/2023/03/23/2023-05948/determination-of-regulatory-review-period-for-purposes-of-patent-extension-recell-autologous-cell,https://www.govinfo.gov/content/pkg/FR-2023-03-23/pdf/2023-05948.pdf,3/23/2023, RECELL AUTOLOGOUS CELL HARVESTING DEVICE,,Tianlun,RECELL AUTOLOGOUS CELL HARVESTING DEVICE,1,31,Helen,9029140,2015-05-12,Avita Medical PTY Limited,793,Avita Medical Ltd.,4455,4097,358,2006-07-12,2017-09-28,2018-09-20,BP170122,793,170122,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; M6-C Artificial Cervical Disc,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for M6-C ARTIFICIAL CERVICAL DISC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",88 FR 19155,2023-06580,https://www.federalregister.gov/documents/2023/03/30/2023-06580/determination-of-regulatory-review-period-for-purposes-of-patent-extension-m6-c-artificial-cervical,https://www.govinfo.gov/content/pkg/FR-2023-03-30/pdf/2023-06580.pdf,3/30/2023, M6-C Artificial Cervical Disc,,Tianlun,M6-C ARTIFICIAL CERVICAL DISC,1,32,Helen,8377138,2013-02-19,Spinal Kinetics LLC,1322,"Spinal Kinetics, Inc.",4081,3617,464,2007-12-07,2017-10-31,2019-02-06,PMA 170036,"715 or 1,321",170036,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Detectnet,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Detectnet and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 30133,2023-09891,https://www.federalregister.gov/documents/2023/05/10/2023-09891/determination-of-regulatory-review-period-for-purposes-of-patent-extension-detectnet,https://www.govinfo.gov/content/pkg/FR-2023-05-10/pdf/2023-09891.pdf,5/10/2023, Detectnet,,Tianlun,Detectnet (copper Cu-64 dotatate),1,33,Helen,10383961,n/a,,,Somscan APS,989,744,245,2017-12-21,2020-01-03,2020-09-03,NDA 213227,312,213227,5/18/2016,Diagnostic for the management of neuroendocrine tumors.,Designated/Approved,,,indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients,9/3/2020,9/3/2027,indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients,RadioMedix Inc.,Detectnet,copper Cu 64 dotatate,"RadioMedix, Inc.",NDA,213227,,2020-01-03,2020-09-03,2020,,Detectnet is indicated for positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adults,Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; Zemdri,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Zemdri and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 30982,2023-10316,https://www.federalregister.gov/documents/2023/05/15/2023-10316/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zemdri,https://www.govinfo.gov/content/pkg/FR-2023-05-15/pdf/2023-10316.pdf,5/15/2023, Zemdri,,Tianlun,Zemdri (plazomicin),1,34,Helen,8383596,n/a,,,"Achaogen, Inc. ",3447,3203,244,2009-01-18,2017-10-25,2018-06-25,NDA 210303,389 or 819,210303,,,,,,,,,,,Zemdri,plazomicin,Achaogen,NDA,210303,,2017-10-25,2018-06-25,2018,,"ZEMDRI is indicated in patients 18 years of age or older for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible microorganism(s): Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter cloacae.
As only limited clinical safety and efficacy data for ZEMDRI are currently available, reserve ZEMDRI for use in cUTI patients who have limited or no alternative treatment options.
Usage:
To reduce the development of drug resistant bacteria and maintain the effectiveness of ZEMDRI and other antibacterial drugs, ZEMDRI should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Cablivi,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Cablivi and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",88 FR 30983,2023-10295,https://www.federalregister.gov/documents/2023/05/15/2023-10295/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cablivi,https://www.govinfo.gov/content/pkg/FR-2023-05-15/pdf/2023-10295.pdf,5/15/2023, Cablivi,,Tianlun,Cablivi (caplacizumab-yhdp),2,36,Helen,"7,807,162 and 8,372,398",n/a,,,Ablynx N.V.,2998,2752,246,2010-11-24,2018-06-06,2019-02-06,BLA 761112,"1,216 or 1,621",761112,4/14/2009,Treatment of thrombotic thrombocytopenic purpura,Designated/Approved,,,"CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.",2/6/2019,2/6/2026,"CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.","Ablynx, a wholly owned subsidiary of Sanofi Group",Cablivi,caplacizumab-yhdp,Ablynx NV,BLA,761112,,2018-06-06,2019-02-06,2019,,"CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.",Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; Onpattro,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Onpattro and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 30985,2023-10317,https://www.federalregister.gov/documents/2023/05/15/2023-10317/determination-of-regulatory-review-period-for-purposes-of-patent-extension-onpattro,https://www.govinfo.gov/content/pkg/FR-2023-05-15/pdf/2023-10317.pdf,5/15/2023, Onpattro,,Tianlun,Onpattro (patisiran),3,39,Helen,"8,168,775; 8,741,866; 9,234,196",n/a,,,"Alnylam Pharmaceuticals, Inc.",1901,1658,243,2013-05-29,2017-12-11,2018-08-10,NDA 210922,"593, 887 or 1,025",210922,6/14/2012,Treatment of transthyretin-mediated amyloidosis,Designated/Approved,,,ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,8/10/2018,8/10/2025,ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,"Alnylam Pharmaceuticals, Inc.",Onpattro,patisiran,Alnylam Pharmaceuticals,NDA,210922,,2017-12-11,2018-08-10,2018,,ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; Tack Endovascular System (6F),Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Tack Endovascular System (6F) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that medical device.",88 FR 30987,2023-10297,https://www.federalregister.gov/documents/2023/05/15/2023-10297/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tack-endovascular-system,https://www.govinfo.gov/content/pkg/FR-2023-05-15/pdf/2023-10297.pdf,5/15/2023, Tack Endovascular System (6F),,Tianlun,Tack Endovascular System (6F),2,41,Helen,"9,375,327 and 9,603,730",n/a,,,"INTACT VASCULAR, INC.",1338,1114,224,2015-08-14,2018-08-31,2019-04-11,PMA P180034,485 or 621,180034,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ENSPRYNG; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) is correcting a notice that appeared in the Federal Register of July 13, 2022. The document determined the regulatory review period for ENSPRYNG. After review of a timely request for reconsideration by the applicant of the calculation of the applicable regulatory review period of the biologic product ENSPRYNG in that notice, FDA has determined that a revision of the supplementary information section is warranted. This notice corrects the applicable regulatory review period language.",88 FR 33614,2023-10979,https://www.federalregister.gov/documents/2023/05/24/2023-10979/determination-of-regulatory-review-period-for-purposes-of-patent-extension-enspryng-correction,https://www.govinfo.gov/content/pkg/FR-2023-05-24/pdf/2023-10979.pdf,5/24/2023, ENSPRYNG, Correction,Tianlun,ENSPRYNG (satralizumab-mwge),3,44,Helen,"8,562,991; 10,022,319; 10,662,245",2013-10-22,Chugai Seiyaku Kabushiki Kaisha,1428,"Genentech, Inc.",2494,2128,366,2013-10-18,2019-08-15,2020-08-14,BLA 761149,"81, 563, or 1,428",761149,6/30/2014,Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder,Designated/Approved,,,treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,8/14/2020,8/14/2027,treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,"Genentech, Inc.",Enspryng,satralizumab-mwge,"Genentech, Inc.",BLA,761149,,2019-08-15,2020-08-14,2020,,Enspryng is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,Standard,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; BARRICAID ANULAR CLOSURE DEVICE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BARRICAID ANULAR CLOSURE DEVICE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",88 FR 51839,2023-16614,https://www.federalregister.gov/documents/2023/08/04/2023-16614/determination-of-regulatory-review-period-for-purposes-of-patent-extension-barricaid-anular-closure,https://www.govinfo.gov/content/pkg/FR-2023-08-04/pdf/2023-16614.pdf,8/4/2023, BARRICAID ANULAR CLOSURE DEVICE,,Tianlun,BARRICAID ANULAR CLOSURE DEVICE,3,47,Helen,"6,425,919; 7,524,333; 9,610,106",n/a,,,"Intrinsic Therapeutics, Inc.",2980,2163,817,2010-12-14,2016-11-14,2019-02-08,PMA P160050,676 days or 5 years,160050,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PIFELTRO-New Drug Application 210806,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PIFELTRO, new drug application (NDA) 210806, and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 51837,2023-16607,https://www.federalregister.gov/documents/2023/08/04/2023-16607/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pifeltro-new-drug,https://www.govinfo.gov/content/pkg/FR-2023-08-04/pdf/2023-16607.pdf,8/4/2023, PIFELTRO-New Drug Application 210806,,Tianlun,PIFELTRONDA 210806 (doravirine),1,48,Helen,8486975,2013-07-16,Merck Canada Inc.,328,Merck Canada Inc.,2549,2237,312,2011-09-09,2017-10-23,2018-08-30,NDA 210806,328,210806,,,,,,,,,,,Pifeltro,doravirine,Merck Sharp & Dohme,NDA,210806,,2017-10-23,2018-08-30,2018,,PIFELTRO is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; DELSTRIGO-New Drug Application 210807,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DELSTRIGO, new drug application (NDA) 210807, and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 51836,2023-16606,https://www.federalregister.gov/documents/2023/08/04/2023-16606/determination-of-regulatory-review-period-for-purposes-of-patent-extension-delstrigo-new-drug,https://www.govinfo.gov/content/pkg/FR-2023-08-04/pdf/2023-16606.pdf,8/4/2023, DELSTRIGO-New Drug Application 210807,,Tianlun,"DELSTRIGONDA 210807 (doravirine, lamivudine, and tenofovir disoproxil fumarate)",1,49,Helen,8486975,2013-07-16,Merck Canada Inc.,328,Merck Canada Inc.,2549,2237,312,2011-09-09,2017-10-23,2018-08-30,NDA 210807,328,210807,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; VERCISE DEEP BRAIN STIMULATION SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VERCISE DEEP BRAIN STIMULATION SYSTEM (VERCISE DBS SYSTEM) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",88 FR 51840,2023-16610,https://www.federalregister.gov/documents/2023/08/04/2023-16610/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vercise-deep-brain,https://www.govinfo.gov/content/pkg/FR-2023-08-04/pdf/2023-16610.pdf,8/4/2023, VERCISE DEEP BRAIN STIMULATION SYSTEM,,Tianlun,VERCISE DEEP BRAIN STIMULATION SYSTEM,1,50,Helen,8321025,n/a,,,Boston Scientific Neuromodulation Corp.,393,0,393,Not Applicable,2017-12-22,2019-01-18,PMA P150031 S002,392,150031002,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Vercise Genus Deep Brain Stimulation System,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VERCISE GENUS DEEP BRAIN STIMULATION SYSTEM (VERCISE GENUS DBS SYSTEM) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",88 FR 54615,2023-17259,https://www.federalregister.gov/documents/2023/08/11/2023-17259/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vercise-genus-deep-brain,https://www.govinfo.gov/content/pkg/FR-2023-08-11/pdf/2023-17259.pdf,8/11/2023, Vercise Genus Deep Brain Stimulation System,,Tianlun,VERCISE GENUS DBS SYSTEM,1,51,Helen,8606362,n/a,,,Boston Scientific Neuromodulation Corporation,274,0,274,Not Applicable,2020-04-23,2021-01-21,PMA P150031 S034,273,150031034,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Omegaven,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Omegaven and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 75003,2023-24124,https://www.federalregister.gov/documents/2023/11/01/2023-24124/determination-of-regulatory-review-period-for-purposes-of-patent-extension-omegaven,https://www.govinfo.gov/content/pkg/FR-2023-11-01/pdf/2023-24124.pdf,11/1/2023, Omegaven,,Tianlun,Omegaven (fish oil triglycerides),1,52,Helen,9566260,n/a,,,Children's Medical Center Corporation,4246,4007,239,2006-12-13,2017-12-01,2018-07-27,NDA 210589,383,210589,2/27/2008,Treatment of parenteral nutrition-associated liver disease,Designated/Approved,,,Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC),7/27/2018,7/27/2025,Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC),"Fresenius Kabi USA, LLC",Omegaven,fish oil triglycerides,Fresenius Kabi,NDA,210589,,2017-12-01,2018-07-27,2018,,"Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC).
Limitations of Use:
- Omegaven is not indicated for the prevention of PNAC. It has not been demonstrated that Omegaven prevents PNAC in parenteral nutrition (PN)-dependent patients.
- It has not been demonstrated that the clinical outcomes observed in patients treated with Omegaven are a result of the omega-6:omega-3 fatty acid ratio of the product.",Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ROZLYTREK INJECTION; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of July 8, 2022. The document announced the determination of the regulatory review period for ROZLYTREK INJECTION (entrectinib) for purposes of patent extension. The document was published with an incorrect dosage form. This notice corrects the dosage form of the drug product.",88 FR 80317,2023-25489,https://www.federalregister.gov/documents/2023/11/17/2023-25489/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rozlytrek-injection,https://www.govinfo.gov/content/pkg/FR-2023-11-17/pdf/2023-25489.pdf,11/17/2023, ROZLYTREK INJECTION, Correction,Tianlun,ROZLYTREK CAPSULES (entrectinib),4,56,Helen,"8,299,057; 8,673,893; 9,029,356; and 9,085,565",n/a,,,"Genentech, Inc.",1968,1727,241,2014-03-28,2018-12-18,2018-12-18,NDA 212726,"864, 899, or 1,104 ",212726,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Korsuva,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Korsuva and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83136,2023-26106,https://www.federalregister.gov/documents/2023/11/28/2023-26106/determination-of-regulatory-review-period-for-purposes-of-patent-extension-korsuva,https://www.govinfo.gov/content/pkg/FR-2023-11-28/pdf/2023-26106.pdf,11/28/2023, Korsuva,,Tianlun,Korsuva (difelikefalin acetate),1,57,Helen,7402564,n/a,,,"Cara Therapeutics, Inc.",4625,4381,244,2008-12-26,2020-12-23,2021-08-23,NDA 214916,1827,214916,,,,,,,,,,,Korsuva,difelikefalin,"Cara Therapeutics, Inc.",NDA,214916,,2020-12-23,2021-08-23,2021,,"KORSUVA is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD).
Limitations of Use:
KORSUVA has not been studied in patients on peritoneal dialysis and is not recommended for use in this population.",Priority,No,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Tavneos,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Tavneos and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.",88 FR 83138,2023-26099,https://www.federalregister.gov/documents/2023/11/28/2023-26099/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tavneos,https://www.govinfo.gov/content/pkg/FR-2023-11-28/pdf/2023-26099.pdf,11/28/2023, Tavneos,,Tianlun,Tavneos (avacopan),2,59,Helen,"8,445,515 and 8,906,938",n/a,,,"ChemoCentryx, Inc.",2642,2184,458,2014-07-16,2020-07-07,2021-10-07,NDA 214487,"1,476 or 1,549",214487,6/2/2014,"Treatment of anti-neutrophil cytoplasmic autoantibodies associated vasculitides (granulomatosis with polyangiitis or Wegener's granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome)",Designated/Approved,,,As an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids,10/7/2021,10/7/2028,As an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]),"ChemoCentryx, Inc.",Tavneos,avacopan,"ChemoCentryx, Inc.",NDA,214487,,2020-07-07,2021-10-07,2021,,TAVNEOS is indicated as an adjunctive treatment of adult patients with severe active antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.,Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Cosela,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Cosela and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83140,2023-26098,https://www.federalregister.gov/documents/2023/11/28/2023-26098/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cosela,https://www.govinfo.gov/content/pkg/FR-2023-11-28/pdf/2023-26098.pdf,11/28/2023, Cosela,,Tianlun,Cosela (trilaciclib),2,61,Helen,"8,598,186 and 9,487,530",n/a,,,"GI Therapeutics, Inc.",2081,1838,243,2015-06-05,2020-06-15,2021-02-12,NDA 214200,"335 or 1,162",214200,,,,,,,,,,,Cosela,trilaciclib,"G1 Therapeutics, Inc.",NDA,214200,,2020-06-15,2021-02-12,2021,,COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).,Priority,No,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Zeposia,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Zeposia and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83141,2023-26097,https://www.federalregister.gov/documents/2023/11/28/2023-26097/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zeposia,https://www.govinfo.gov/content/pkg/FR-2023-11-28/pdf/2023-26097.pdf,11/28/2023, Zeposia,,Tianlun,Zeposia (ozanimod hydrochloride),1,62,Helen,8481573,n/a,,,Scripps Research Institute,3383,3016,367,2010-12-22,2019-03-25,2020-03-25,NDA 209899,1410,209899,,,,,,,,,,,Zeposia,ozanimod,Celgene Corporation,NDA,209899,,2019-03-25,2020-03-25,2020,,"Zeposia is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Lupkynis,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Lupkynis and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83411,2023-26247,https://www.federalregister.gov/documents/2023/11/29/2023-26247/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lupkynis,https://www.govinfo.gov/content/pkg/FR-2023-11-29/pdf/2023-26247.pdf,11/29/2023, Lupkynis,,Tianlun,Lupkynis (voclosporin),1,63,Helen,7332472,n/a,,,Aurinia Pharmaceuticals Inc.,7584,7338,246,2000-04-20,2020-05-22,2021-01-22,NDA 213716,5 years,213716,,,,,,,,,,,Lupkynis,voclosporin,"Aurinia Pharmaceuticals, Inc.",NDA,213716,,2020-05-22,2021-01-22,2021,,"LUPKYNIS is indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN).
Limitations of Use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ORGOVYX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Orgovyx and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",88 FR 83412,2023-26258,https://www.federalregister.gov/documents/2023/11/29/2023-26258/determination-of-regulatory-review-period-for-purposes-of-patent-extension-orgovyx,https://www.govinfo.gov/content/pkg/FR-2023-11-29/pdf/2023-26258.pdf,11/29/2023, ORGOVYX,,Tianlun,Orgovyx (relugolix),2,65,Helen,"7,300,935 and 8,058,280",n/a,,,Myovant Sciences on behalf of Takeda Pharmaceutical Company Limited,4875,4632,243,2007-08-16,2020-04-20,2020-12-18,NDA 214621,"1,783 or 1,827",214621,,,,,,,,,,,Orgovyx,relugolix,Myovant Sciences GmbH,NDA,214621,,2020-04-20,2020-12-18,2020,,Orgovyx is indicated for the treatment of adult patients with advanced prostate cancer,Priority,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Kerendia,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Kerendia and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83415,2023-26251,https://www.federalregister.gov/documents/2023/11/29/2023-26251/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kerendia,https://www.govinfo.gov/content/pkg/FR-2023-11-29/pdf/2023-26251.pdf,11/29/2023, Kerendia,,Tianlun,Kerendia (finerenone),1,66,Helen,8436180,n/a,,,Bayer Intellectual Property GmbH,2950,2707,243,2013-06-13,2020-11-09,2021-07-09,NDA 215341,1597,215341,,,,,,,,,,,Kerendia,finerenone,"Bayer HealthCare Pharmaceuticals, Inc.",NDA,215341,,2020-11-09,2021-07-09,2021,,"Kerendia is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; Empaveli,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Empaveli and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83418,2023-26255,https://www.federalregister.gov/documents/2023/11/29/2023-26255/determination-of-regulatory-review-period-for-purposes-of-patent-extension-empaveli,https://www.govinfo.gov/content/pkg/FR-2023-11-29/pdf/2023-26255.pdf,11/29/2023, Empaveli,,Tianlun,Empaveli (pegcetacoplan),3,69,Helen,"10,035,822; 10,125,171; and 10,875,893",n/a,,,"Apellis Pharmaceuticals, Inc.",2501,2258,243,2014-07-11,2020-09-14,2021-05-14,NDA 215014,"137, 545, or 579",215014,4/20/2014,Treatment of paroxysmal nocturnal hemoglobinuria,Designated/Approved,,,Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH),5/14/2021,5/14/2028,Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH),"Apellis Pharmaceuticals, Inc.",Empaveli,pegcetacoplan,"Apellis Pharmaceuticals, Inc.",NDA,215014,,2020-09-14,2021-05-14,2021,,EMPAVELI is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).,Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; Olinvyk,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Olinvyk and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83406,2023-26253,https://www.federalregister.gov/documents/2023/11/29/2023-26253/determination-of-regulatory-review-period-for-purposes-of-patent-extension-olinvyk,https://www.govinfo.gov/content/pkg/FR-2023-11-29/pdf/2023-26253.pdf,11/29/2023, Olinvyk,,Tianlun,Olinvyk (oliceridine fumarate),3,72,Helen,"8,835,488; 9,309,234; 9,642,842",n/a,,,"Trevena, Inc.",3206,2112,1094,2012-01-22,2017-11-02,2020-10-30,NDA 210730,951,210730,,,,,,,,,,,Olinvyk,oliceridine,"Trevena, Inc.",NDA,210730,,2017-11-02,2020-08-07,2020,,Olinvyk is indicated for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate in adults,Standard,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; PYLARIFY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PYLARIFY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.",88 FR 83407,2023-26261,https://www.federalregister.gov/documents/2023/11/29/2023-26261/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pylarify,https://www.govinfo.gov/content/pkg/FR-2023-11-29/pdf/2023-26261.pdf,11/29/2023, PYLARIFY,,Tianlun,PYLARIFY (piflufolastat F18),3,75,Helen,"8,487,129; 8,778,305; and 9,861,713",n/a,,,"Progenics Pharmaceuticals, Inc.",2681,2441,240,2014-01-24,2020-09-29,2021-05-26,NDA 214793,"736, 1,373 or 1,463",214793,,,,,,,,,,,Pylarify,piflufolastat F 18,"Progenics Pharmaceuticals, Inc.",NDA,214793,,2020-09-29,2021-05-26,2021,,"PYLARIFY is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:
- with suspected metastasis who are candidates for initial definitive therapy.
- with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.",Priority,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Azstarys,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Azstarys and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83409,2023-26246,https://www.federalregister.gov/documents/2023/11/29/2023-26246/determination-of-regulatory-review-period-for-purposes-of-patent-extension-azstarys,https://www.govinfo.gov/content/pkg/FR-2023-11-29/pdf/2023-26246.pdf,11/29/2023, Azstarys,,Tianlun,Azstarys (serdexmethylphenidate and dexmethylphenidate),1,76,Helen,9079928,n/a,,,"KemPharm, Inc.",1676,1244,432,2016-10-06,2020-03-02,2021-05-07,NDA 212994,948,212994,,,,,,,,,,,Azstarys,serdexmethylphenidate and dexmethylphenidate,Commave Therapeutics SA,NDA,212994,,2020-03-02,2021-03-02,2021,,Azstarys is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Tukysa,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Tukysa and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83414,2023-26256,https://www.federalregister.gov/documents/2023/11/29/2023-26256/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tukysa,https://www.govinfo.gov/content/pkg/FR-2023-11-29/pdf/2023-26256.pdf,11/29/2023, Tukysa,,Tianlun,Tukysa (tucatinib),4,80,Helen,"7,452,895; 8,648,087; 9,457,093; and 9,693,989",n/a,,,"Array BioPharma Inc. and Seattle Genetics, Inc. (Agent of Array BioPharma Inc.)",4653,4533,120,2007-07-24,2019-12-20,2020-04-17,NDA 213411,"552, 570, 1,101 or 1,826",213411,9/18/2017,Treatment of HER2+ colorectal cancer,Designated/Approved,,,"in combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy",1/19/2023,1/19/2030,"treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy",Seagen Inc.,Tukysa,tucatinib,"Seattle Genetics, Inc.",NDA,213411,,2019-12-20,2020-04-17,2020,,"Tukysa is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting",Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ZEGALOGUE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZEGALOGUE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83547,2023-26260,https://www.federalregister.gov/documents/2023/11/30/2023-26260/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zegalogue,https://www.govinfo.gov/content/pkg/FR-2023-11-30/pdf/2023-26260.pdf,11/30/2023, ZEGALOGUE,,Tianlun,ZEGALOGUE (dasiglucagon),1,81,Helen,10442847,n/a,,,Zealand Pharma A/S,1734,1373,361,2016-06-24,2020-03-27,2021-03-22,NDA 214231,47,214231,,,,,,,,,,,Zegalogue,dasiglucagon,Zealand Pharma A/S,NDA,214231,,2020-03-27,2021-03-22,2021,,ZEGALOGUE is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Qelbree,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Qelbree and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83548,2023-26301,https://www.federalregister.gov/documents/2023/11/30/2023-26301/determination-of-regulatory-review-period-for-purposes-of-patent-extension-qelbree,https://www.govinfo.gov/content/pkg/FR-2023-11-30/pdf/2023-26301.pdf,11/30/2023, Qelbree,,Tianlun,Qelbree (viloxazine),3,84,Helen,"9,358,204; 9,603,853; 9,662,338",n/a,,,"Supernus Pharmaceuticals, Inc. ",4328,3816,512,2009-05-29,2019-11-08,2021-04-02,NDA 211964,785,211964,,,,,,,,,,,Qelbree,viloxazine,"Supernus Pharmaceuticals, Inc.",NDA,211964,,2019-11-08,2021-04-02,2021,,Qelbree is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Koselugo,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Koselugo and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83556,2023-26324,https://www.federalregister.gov/documents/2023/11/30/2023-26324/determination-of-regulatory-review-period-for-purposes-of-patent-extension-koselugo,https://www.govinfo.gov/content/pkg/FR-2023-11-30/pdf/2023-26324.pdf,11/30/2023, Koselugo,,Tianlun,Koselugo (selumetinib),3,87,Helen,"7,425,637; 8,178,693; 9,156,795",n/a,,,AstraZeneca AB and Array BioPharma Inc.,5100,4889,211,2006-04-26,2019-09-13,2020-04-10,NDA 213756,"927 days, 1,550 days, or 5 years",213756,,,,,,,,,,,Koselugo,selumetinib,AstraZeneca Pharmaceuticals LP,NDA,213756,,2019-09-13,2020-04-10,2020,,"Koselugo is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)",Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Rezurock,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Rezurock and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83558,2023-26358,https://www.federalregister.gov/documents/2023/11/30/2023-26358/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rezurock,https://www.govinfo.gov/content/pkg/FR-2023-11-30/pdf/2023-26358.pdf,11/30/2023, Rezurock,,Tianlun,Rezurock (belumosudil mesylate),1,88,Helen,8357693,n/a,,,"Kadmon Pharmaceuticals, LLC (agent for Surface Logix, LLC)",4327,4037,290,2009-09-12,2020-09-30,2021-07-16,NDA 214783,1154,214783,10/5/2017,Treatment of graft versus host disease (GVHD),Designated/Approved,,,Treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy,7/16/2021,7/16/2028,Treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy,"Kadmon Pharmaceuticals, LLC",Rezurock,belumosudil,"Kadmon Pharmaceuticals, LLC",NDA,214783,,2020-09-30,2021-07-16,2021,,REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.,Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Ukoniq,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Ukoniq and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83555,2023-26303,https://www.federalregister.gov/documents/2023/11/30/2023-26303/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ukoniq,https://www.govinfo.gov/content/pkg/FR-2023-11-30/pdf/2023-26303.pdf,11/30/2023, Ukoniq,,Tianlun,Ukoniq (umbralisib tosylate),4,92,Helen,"9,150,579; 9,669,033; 10,072,013; and 10,570,142",n/a,,,Rhizen Pharmaceuticals SA,2963,2727,236,2012-12-28,2020-06-15,2021-02-05,NDA 213176,"291, 577, or 583",213176,4/11/2019,Treatment of extranodal marginal zone lymphoma,Designated/Approved,,,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn),2/5/2021,5/31/2022,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn),"TG Therapeutics, Inc.",Ukoniq,umbralisib,"TG Therapeutics, Inc.",NDA,213176,,2020-06-15,2021-02-05,2021,,"[A] UKONIQ is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
[B] UKONIQ is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority (indication [A] only),Yes,Yes,Yes (indication [A] only),No
Determination of Regulatory Review Period for Purposes of Patent Extension; Ukoniq,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Ukoniq and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83555,2023-26303,https://www.federalregister.gov/documents/2023/11/30/2023-26303/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ukoniq,https://www.govinfo.gov/content/pkg/FR-2023-11-30/pdf/2023-26303.pdf,11/30/2023, Ukoniq,,Tianlun,Ukoniq (umbralisib tosylate),4,96,Helen,"9,150,579; 9,669,033; 10,072,013; and 10,570,142",n/a,,,Rhizen Pharmaceuticals SA,2963,2727,236,2012-12-28,2020-06-15,2021-02-05,NDA 213176,"291, 577, or 583",213176,4/11/2019,Treatment of nodal marginal zone lymphoma,Designated/Approved,,,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn),2/5/2021,5/31/2022,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn),"TG Therapeutics, Inc.",Ukoniq,umbralisib,"TG Therapeutics, Inc.",NDA,213176,,2020-06-15,2021-02-05,2021,,"[A] UKONIQ is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
[B] UKONIQ is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority (indication [A] only),Yes,Yes,Yes (indication [A] only),No
Determination of Regulatory Review Period for Purposes of Patent Extension; Ukoniq,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Ukoniq and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83555,2023-26303,https://www.federalregister.gov/documents/2023/11/30/2023-26303/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ukoniq,https://www.govinfo.gov/content/pkg/FR-2023-11-30/pdf/2023-26303.pdf,11/30/2023, Ukoniq,,Tianlun,Ukoniq (umbralisib tosylate),4,100,Helen,"9,150,579; 9,669,033; 10,072,013; and 10,570,142",n/a,,,Rhizen Pharmaceuticals SA,2963,2727,236,2012-12-28,2020-06-15,2021-02-05,NDA 213176,"291, 577, or 583",213176,3/4/2020,Treatment of Follicular Lymphoma,Designated/Approved,,,Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy (Indication withdrawn),2/5/2021,5/31/2022,Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy (Indication withdrawn),"TG Therapeutics, Inc.",Ukoniq,umbralisib,"TG Therapeutics, Inc.",NDA,213176,,2020-06-15,2021-02-05,2021,,"[A] UKONIQ is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
[B] UKONIQ is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority (indication [A] only),Yes,Yes,Yes (indication [A] only),No
Determination of Regulatory Review Period for Purposes of Patent Extension; Ukoniq,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Ukoniq and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83555,2023-26303,https://www.federalregister.gov/documents/2023/11/30/2023-26303/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ukoniq,https://www.govinfo.gov/content/pkg/FR-2023-11-30/pdf/2023-26303.pdf,11/30/2023, Ukoniq,,Tianlun,Ukoniq (umbralisib tosylate),4,104,Helen,"9,150,579; 9,669,033; 10,072,013; and 10,570,142",n/a,,,Rhizen Pharmaceuticals SA,2963,2727,236,2012-12-28,2020-06-15,2021-02-05,NDA 213176,"291, 577, or 583",213176,4/11/2019,Treatment of splenic marginal zone lymphoma,Designated/Approved,,,treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn),2/5/2021,5/31/2022,treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn),"TG Therapeutics, Inc.",Ukoniq,umbralisib,"TG Therapeutics, Inc.",NDA,213176,,2020-06-15,2021-02-05,2021,,"[A] UKONIQ is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
[B] UKONIQ is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority (indication [A] only),Yes,Yes,Yes (indication [A] only),No
Determination of Regulatory Review Period for Purposes of Patent Extension; Amondys 45,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Amondys 45 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83545,2023-26299,https://www.federalregister.gov/documents/2023/11/30/2023-26299/determination-of-regulatory-review-period-for-purposes-of-patent-extension-amondys-45,https://www.govinfo.gov/content/pkg/FR-2023-11-30/pdf/2023-26299.pdf,11/30/2023, Amondys 45,,Tianlun,Amondys 45 (casimersen),6,110,Helen,"8,524,880; 9,228,187; 9,447,415; 9,758,783; 10,287,586; and 10,781,450",n/a,,,The University of Western Australia,2412,2166,246,2014-07-22,2020-06-25,2021-02-25,NDA 213026,"157, 450, 755, 933, 1,063, or 1,329",213026,6/4/2019,Treatment of Duchenne muscular dystrophy,Designated/Approved,,,treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping,2/25/2021,2/25/2028,treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping,"Sarepta Therapeutics, Inc.",Amondys 45,casimersen,"Sarepta Therapeutics, Inc.",NDA,213026,,2020-06-25,2021-02-25,2021,,AMONDYS 45 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.,Priority,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; Nuzyra Injection (New Drug Application 209817),Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA, the Agency, or we) has determined the regulatory review period for Nuzyra Injection (new drug application (NDA) 209817) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 83550,2023-26363,https://www.federalregister.gov/documents/2023/11/30/2023-26363/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nuzyra-injection-new-drug,https://www.govinfo.gov/content/pkg/FR-2023-11-30/pdf/2023-26363.pdf,11/30/2023, Nuzyra Injection (New Drug Application 209817),,Tianlun,Nuzyra Injection (NDA 209817) (omadacycline),1,111,Helen,7553828,n/a,,,"Paratek Pharmaceuticals, Inc.",4361,4118,243,2006-10-26,2018-02-02,2018-10-02,NDA 209817,1812,209817,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Truseltiq,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Truseltiq and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 85291,2023-26885,https://www.federalregister.gov/documents/2023/12/07/2023-26885/determination-of-regulatory-review-period-for-purposes-of-patent-extension-truseltiq,https://www.govinfo.gov/content/pkg/FR-2023-12-07/pdf/2023-26885.pdf,12/7/2023, Truseltiq,,Tianlun,Truseltiq (infigratinib),1,112,Helen,8552002,n/a,,,"QED Therapeutics, Inc. (agent of Novartis AG)",4258,4016,242,2009-10-02,2020-09-29,2021-05-28,NDA 214622,1516,214622,9/11/2019,Treatment of cholangiocarcinoma,Designated/Approved/Designation Withdrawn or Revoked,8/4/2023,,"Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. (Indication withdrawn 5/16/2024)",5/28/2021,8/4/2023,,"QED Therapeutics, Inc.",Truseltiq,infigratinib,"QED Therapeutics, Inc.",NDA,214622,,2020-09-29,2021-05-28,2021,,"TRUSELTIQ is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; Tivdak,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Tivdak and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human biological product.",88 FR 85625,2023-26992,https://www.federalregister.gov/documents/2023/12/08/2023-26992/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tivdak,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-26992.pdf,12/8/2023, Tivdak,,Tianlun,Tivdak (tisotumab vedotin),3,115,Helen,"9,150,658; 9,168,314; and 9,492,565",n/a,,,Genmab A/S,2959,2736,223,2013-08-16,2021-02-10,2021-09-20,BLA B761208,"997, 1,077, or 1,190",761208,,,,,,,,,,,Tivdak,tisotumab vedotin-tftv,"Seagen, Inc.",BLA,761208,,2021-02-10,2021-09-20,2021,,"TIVDAK is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,No,Yes,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Pemazyre,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Pemazyre and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 85627,2023-26996,https://www.federalregister.gov/documents/2023/12/08/2023-26996/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pemazyre,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-26996.pdf,12/8/2023, Pemazyre,,Tianlun,Pemazyre (pemigatinib),2,117,Helen,"9,611,267; 10,131,667",n/a,,,Incyte Corp. and Incyte Holdings Corp.,1971,1770,201,2014-11-26,2019-09-30,2020-04-17,NDA 213736,309,213736,3/12/2018,Treatment of cholangiocarcinoma,Designated/Approved,,,"PEMAZYRE is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test",4/17/2020,4/17/2027,"For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.",Incyte Corporation,Pemazyre,pemigatinib,Incyte Corporation,NDA,213736,,2019-09-30,2020-04-17,2020,,"Pemazyre is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Pemazyre,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Pemazyre and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 85627,2023-26996,https://www.federalregister.gov/documents/2023/12/08/2023-26996/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pemazyre,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-26996.pdf,12/8/2023, Pemazyre,,Tianlun,Pemazyre (pemigatinib),2,119,Helen,"9,611,267; 10,131,667",n/a,,,Incyte Corp. and Incyte Holdings Corp.,1971,1770,201,2014-11-26,2019-09-30,2020-04-17,NDA 213736,309,213736,8/21/2019,"Treatment of myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2",Designated/Approved,,,Treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement,8/26/2022,8/26/2029,Treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement,Incyte Corporation,Pemazyre,pemigatinib,Incyte Corporation,NDA,213736,,2019-09-30,2020-04-17,2020,,"Pemazyre is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; EXKIVITY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EXKIVITY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",88 FR 85629,2023-27004,https://www.federalregister.gov/documents/2023/12/08/2023-27004/determination-of-regulatory-review-period-for-purposes-of-patent-extension-exkivity,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-27004.pdf,12/8/2023, EXKIVITY,,Tianlun,EXKIVITY (mobocertinib),2,121,Helen,"9,796,712; 10,227,342",n/a,,,Takeda Pharmaceutical Company Limited,2059,1857,202,2016-01-28,2021-02-26,2021-09-15,NDA 215310,126,215310,12/17/2019,"Treatment of non-small cell lung cancer with genetic alterations in EGFR including EGFR mutations and/or EGFR gene amplifications, HER2 mutations, or BRAF G466V mutations",Designated/Approved,,,"Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy",9/15/2021,9/15/2028,"Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy","Takeda Development Center Americas, Inc.",Exkivity,mobocertinib,"Takeda Pharmaceuticals U.S.A., Inc.",NDA,215310,,2021-02-26,2021-09-15,2021,,"EXKIVITY is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",Priority,Yes,Yes,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; Fotivda,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Fotivda and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 85630,2023-26997,https://www.federalregister.gov/documents/2023/12/08/2023-26997/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fotivda,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-26997.pdf,12/8/2023, Fotivda,,Tianlun,Fotivda (tivozanib hydrochloride),2,123,Helen,"6,821,987; 7,166,722",n/a,,,"AVEO Pharmaceuticals, Inc. (agent of Kyowa Kirin Co., Ltd.)",5035,4690,345,2007-05-30,2020-03-31,2021-03-10,NDA 212904 ,1826,212904,,,,,,,,,,,Fotivda,tivozanib,"Aveo Pharmaceuticals, Inc.",NDA,212904,,2020-03-31,2021-03-10,2021,,FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Nextstellis,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Nextstellis and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 85632,2023-26988,https://www.federalregister.gov/documents/2023/12/08/2023-26988/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nextstellis,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-26988.pdf,12/8/2023, Nextstellis,,Tianlun,Nextstellis (drospirenone and estetrol),1,124,Helen,7732430,n/a,,,Mayne Pharma LLC,1732,1366,366,2016-07-20,2020-04-15,2021-04-15,NDA 214154,1048,214154,,,,,,,,,,,Nextstellis,drospirenone and estetrol,"Mayne Pharma, LLC",NDA,214154,,2020-04-15,2021-04-15,2021,,"NEXTSTELLIS is indicated for use by females of reproductive potential to prevent pregnancy.
Limitations of Use:
NEXTSTELLIS may be less effective in females with a BMI >= 30 kg/m2. In females with BMI >= 30 kg/m2, decreasing effectiveness may be associated with increasing BMI.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ZYNLONTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZYNLONTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",88 FR 85633,2023-26982,https://www.federalregister.gov/documents/2023/12/08/2023-26982/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zynlonta,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-26982.pdf,12/8/2023, ZYNLONTA,,Tianlun,ZYNLONTA (loncastuximab tesirine-lpyl),1,125,Helen,9931414,n/a,,,ADC Therapeutics S.A.,1969,1754,215,2015-12-04,2020-09-21,2021-04-23,BLA 761196,559,761196,6/8/2017,Treatment of diffuse large B-cell lymphoma,Designated/Approved,,,"treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma",4/23/2021,4/23/2028,treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy,ADC Therapeutics SA,Zynlonta,loncastuximab tesirine-lpyl,ADC Therapeutics S.A.,BLA,761196,,2020-09-21,2021-04-23,2021,,"ZYNLONTA is indicated for the treatment of adult patients with relapsed or refractory large B cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SEYSARA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SEYSARA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 85635,2023-27003,https://www.federalregister.gov/documents/2023/12/08/2023-27003/determination-of-regulatory-review-period-for-purposes-of-patent-extension-seysara,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-27003.pdf,12/8/2023, SEYSARA,,Tianlun,SEYSARA (sarecycline hydrochloride),1,126,Helen,8318706,n/a,,,"Paratek Pharmaceuticals, Inc.",2946,2599,347,2010-09-09,2017-10-20,2018-10-01,NDA 209521,1227,209521,,,,,,,,,,,Seysara,sarecycline,Allergan,NDA,209521,,2017-10-20,2018-10-01,2018,,"SEYSARA (sarecycline) tablet, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older.
Limitations of Use:
Efficacy of SEYSARA beyond 12 weeks and safety beyond 12 months have not been established. SEYSARA has not been evaluated in the treatment of infections.
To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, SEYSARA should be used only as indicated.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VIZIMPRO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VIZIMPRO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 85645,2023-27012,https://www.federalregister.gov/documents/2023/12/08/2023-27012/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vizimpro,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-27012.pdf,12/8/2023, VIZIMPRO,,Tianlun,VIZIMPRO (dacomitinib),1,127,Helen,7772243,n/a,,,Warner-Lambert Co. LLC ,4794,4554,240,2005-08-14,2018-01-31,2018-09-27,NDA 211288,1493,211288,3/3/2015,"Treatment of non-small cell lung cancer with EGFR, HER2, HER4, or DDR2 mutations.",Designated/Approved,,,For the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R,9/27/2018,9/27/2025,For the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R,"Pfizer, Inc.",Vizimpro,dacomitinib,Pfizer,NDA,211288,,2018-01-31,2018-09-27,2018,,VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.,Priority,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VILTEPSO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VILTEPSO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 85638,2023-27013,https://www.federalregister.gov/documents/2023/12/08/2023-27013/determination-of-regulatory-review-period-for-purposes-of-patent-extension-viltepso,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-27013.pdf,12/8/2023, VILTEPSO,,Tianlun,VILTEPSO (viltolarsen),1,128,Helen,9079934,n/a,,,"Nippon Shinyaku Co., LTD.",1573,1255,318,2016-04-24,2019-09-30,2020-08-12,NDA 212154,1077,212154,1/12/2017,Treatment of Duchenne Muscular Dystrophy,Designated/Approved,,,VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping,8/12/2020,8/12/2027,VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping,"NS Pharma, Inc.",Viltepso,viltolarsen,"Nippon Shinyaku Co., Ltd.",NDA,212154,,2019-12-12,2020-08-12,2020,,Viltepso is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping,Priority,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; Nuzyra Tablets (New Drug Application 209816),Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA, the Agency, or we) has determined the regulatory review period for Nuzyra Tablets (new drug application (NDA) 209816) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 85643,2023-26989,https://www.federalregister.gov/documents/2023/12/08/2023-26989/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nuzyra-tablets-new-drug,https://www.govinfo.gov/content/pkg/FR-2023-12-08/pdf/2023-26989.pdf,12/8/2023, Nuzyra Tablets (New Drug Application 209816),,Tianlun,Nuzyra Tablets (NDA 209816) (omadacycline),1,129,Helen,9265740,n/a,,,"Paratek Pharmaceuticals, Inc.",4361,4118,243,2006-10-26,2018-02-02,2018-10-02,NDA 209816,597,209816,,,,,,,,,,,Nuzyra,omadacycline,Paratek Pharmacueticals,NDA,209816,209817,2018-02-02,2018-10-02,2018,,"NUZYRA is indicated for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.
NUZYRA is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by the following susceptible microorganisms: Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Staphylococcus lugdunensis, Streptococcus pyogenes, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Enterococcus faecalis, Enterobacter cloacae, and Klebsiella pneumoniae.
Usage:
To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; WELIREG,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for WELIREG and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",88 FR 85892,2023-27044,https://www.federalregister.gov/documents/2023/12/11/2023-27044/determination-of-regulatory-review-period-for-purposes-of-patent-extension-welireg,https://www.govinfo.gov/content/pkg/FR-2023-12-11/pdf/2023-27044.pdf,12/11/2023, WELIREG,,Tianlun,WELIREG (belzutifan),2,131,Helen,"9,908,845; 9,969,689",n/a,,,"Peloton Therapeutics, Inc",1752,1541,211,2016-10-28,2021-01-15,2021-08-13,NDA 215383,342,215383,6/24/2020,Treatment of von Hippel-Lindau disease,Designated/Approved,,,"Treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery",8/13/2021,8/13/2028,"Treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery","Merck Sharp & Dohme, LLC",Welireg,belzutifan,Merck Sharp and Dohme Corp.,NDA,215383,,2021-01-15,2021-08-13,2021,,"WELIREG is indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.",Priority,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LYBALVI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LYBALVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 88397,2023-28094,https://www.federalregister.gov/documents/2023/12/21/2023-28094/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lybalvi,https://www.govinfo.gov/content/pkg/FR-2023-12-21/pdf/2023-28094.pdf,12/21/2023, LYBALVI,,Tianlun,LYBALVI (olanzapine and samidorphan),5,136,Helen,"7,262,298; 9,119,848; 9,126,977; 10,300,054; and 10,716,785",n/a,,,Alkermes Inc. ,4564,4003,561,2008-11-30,2019-11-15,2021-05-28,NDA 213378,"311 days, 646 days, 1,325 days, 1,328 days, or 5 years",213378,,,,,,,,,,,Lybalvi,olanzapine and samidorphan,"Alkermes, Inc.",NDA,213378,,2019-11-15,2021-05-28,2021,,"LYBALVI is indicated for treatment of:
- schizophrenia in adults
- bipolar I disorder in adults
-- Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate
-- Maintenance monotherapy treatment",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Emgality,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Emgality and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",88 FR 88625,2023-28233,https://www.federalregister.gov/documents/2023/12/22/2023-28233/determination-of-regulatory-review-period-for-purposes-of-patent-extension-emgality,https://www.govinfo.gov/content/pkg/FR-2023-12-22/pdf/2023-28233.pdf,12/22/2023, Emgality,,Tianlun,Emgality (galcanezumab-gnlm),1,137,Helen,9505838,n/a,,,Eli Lilly and Company,2738,2372,366,2011-04-01,2017-09-27,2018-09-27,BLA B761063,403,761063,,,,,,,,,,,Emgality,galcanezumab-gnlm,Eli Lilly,BLA,761063,,2017-09-27,2018-09-27,2018,,EMGALITY is indicated for the preventive treatment of migraine in adults.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Copiktra,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Copiktra and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 88627,2023-28244,https://www.federalregister.gov/documents/2023/12/22/2023-28244/determination-of-regulatory-review-period-for-purposes-of-patent-extension-copiktra,https://www.govinfo.gov/content/pkg/FR-2023-12-22/pdf/2023-28244.pdf,12/22/2023, Copiktra,,Tianlun,Copiktra (duvelisib),1,138,Helen,8193182,n/a,,,"Verastem, Inc.",2596,2364,232,2011-08-18,2018-02-05,2018-09-24,NDA 211155,954,211155,8/1/2013,Treatment of follicular lymphoma,Designated/Approved,,,Treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior therapies (Indication withdrawn),9/24/2018,12/17/2021,Treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior therapies (Indication withdrawn),"Secura Bio, Inc.",Copiktra,duvelisib,Verastem,NDA,211155,,2018-02-05,2018-09-24,2018,,"[A] COPIKTRA is indicated for the treatment of adult patients with relapsed or refractory CLL or SLL after at least two prior therapies.
[B] COPIKTRA is indicated for the treatment of adult patients with relapsed or refractory FL after at least two prior systemic therapies.
This indication is approved under accelerated approval based on overall response rate (ORR); continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes (indication [B] only),No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; Copiktra,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Copiktra and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 88627,2023-28244,https://www.federalregister.gov/documents/2023/12/22/2023-28244/determination-of-regulatory-review-period-for-purposes-of-patent-extension-copiktra,https://www.govinfo.gov/content/pkg/FR-2023-12-22/pdf/2023-28244.pdf,12/22/2023, Copiktra,,Tianlun,Copiktra (duvelisib),1,139,Helen,8193182,n/a,,,"Verastem, Inc.",2596,2364,232,2011-08-18,2018-02-05,2018-09-24,NDA 211155,954,211155,4/15/2013,Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma,Designated/Approved,,,Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies,9/24/2018,9/24/2025,Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies,"Secura Bio, Inc.",Copiktra,duvelisib,Verastem,NDA,211155,,2018-02-05,2018-09-24,2018,,"[A] COPIKTRA is indicated for the treatment of adult patients with relapsed or refractory CLL or SLL after at least two prior therapies.
[B] COPIKTRA is indicated for the treatment of adult patients with relapsed or refractory FL after at least two prior systemic therapies.
This indication is approved under accelerated approval based on overall response rate (ORR); continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes (indication [B] only),No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; PONVORY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PONVORY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 89455,2023-28509,https://www.federalregister.gov/documents/2023/12/27/2023-28509/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ponvory,https://www.govinfo.gov/content/pkg/FR-2023-12-27/pdf/2023-28509.pdf,12/27/2023, PONVORY,,Tianlun,PONVORY (ponesimod),1,140,Helen,RE43728,n/a,,,Actelion Pharmaceuticals Ltd. ,4459,4092,367,2009-01-04,2020-03-18,2021-03-18,NDA 213498,5 years,213498,,,,,,,,,,,Ponvory,ponesimod,"Janssen Pharmaceuticals, Inc.",NDA,213498,,2020-03-18,2021-03-18,2021,,"PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; CYTALUX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CYTALUX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 89458,2023-28507,https://www.federalregister.gov/documents/2023/12/27/2023-28507/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cytalux,https://www.govinfo.gov/content/pkg/FR-2023-12-27/pdf/2023-28507.pdf,12/27/2023, CYTALUX,,Tianlun,CYTALUX (pafolacianine),1,141,Helen,9061057,n/a,,,Purdue Research Foundation,2610,2274,336,2014-10-09,2020-12-29,2021-11-29,NDA 214907,825,214907,12/23/2014,Detecting folic receptor alpha positive lesions in ovarian cancer patients (diagnostic for the management of ovarian cancer),Designated/Approved,,,As an adjunct for intraoperative identification of malignant lesions in adult patients with ovarian cancer,11/29/2021,11/29/2028,As an adjunct for intraoperative identification of malignant lesions in adult patients with ovarian cancer,"On Target Laboratories, LLC",Cytalux,pafolacianine,"On Target Laboratories, Inc.",NDA,214907,,2020-12-29,2021-11-29,2021,,CYTALUX is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.,Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ZOKINVY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZOKINVY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",88 FR 89453,2023-28511,https://www.federalregister.gov/documents/2023/12/27/2023-28511/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zokinvy,https://www.govinfo.gov/content/pkg/FR-2023-12-27/pdf/2023-28511.pdf,12/27/2023, ZOKINVY,,Tianlun,ZOKINVY (lonafarnib),2,143,Helen,"7,838,531 and 8,828,356",n/a,,,"the Government of the United States of America as represented by the Department of Health and Human Services; the Regents of the University of Michigan; Progeria Research Foundation, Inc.; and the University of North Carolina at Chapel Hill",5023,4777,246,2007-02-21,2020-03-20,2020-11-20,NDA 213969,"1,255 or 1,948",213969,4/18/2011,Treatment of Hutchinson-Gilford progeria syndrome and progeroid laminopathies,Designated/Approved,,,in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above (1) to reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS); and (2) for the treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations,11/20/2020,11/20/2027,in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above: (1) to reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS); and (2) for the treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations,"Sentynl Therapeutics, Inc.",Zokinvy,lonafarnib,"Eiger BioPharmaceuticals, Inc.",NDA,213969,,2020-03-20,2020-11-20,2020,,Zokinvy is indicated for the treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations in patients 12 months of age and older. Is indicated to reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS),Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SCEMBLIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SCEMBLIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 89456,2023-28519,https://www.federalregister.gov/documents/2023/12/27/2023-28519/determination-of-regulatory-review-period-for-purposes-of-patent-extension-scemblix,https://www.govinfo.gov/content/pkg/FR-2023-12-27/pdf/2023-28519.pdf,12/27/2023, SCEMBLIX,,Tianlun,SCEMBLIX (asciminib hydrochloride),1,144,Helen,8829195,n/a,,,Novartis AG,2845,2717,128,2014-01-16,2021-06-24,2021-10-29,NDA 215358,899,215358,2/27/2017,Treatment of chronic myelogenous leukemia,Designated/Approved,,,Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation,10/29/2021,10/29/2028,Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation,Novartis Pharmaceutical Corporation,Scemblix,asciminib,Novartis Pharmaceuticals Corporation,NDA,215358,,2021-06-24,2021-10-29,2021,,"SCEMBLIX is indicated for the treatment of adult patients with:
[A]Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs)
[B] Treatment of adult patients with Ph+ CML in CP with the T315I mutation.  ",Priority,Yes,Yes (indication [A] only),Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; SCEMBLIX,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SCEMBLIX and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",88 FR 89456,2023-28519,https://www.federalregister.gov/documents/2023/12/27/2023-28519/determination-of-regulatory-review-period-for-purposes-of-patent-extension-scemblix,https://www.govinfo.gov/content/pkg/FR-2023-12-27/pdf/2023-28519.pdf,12/27/2023, SCEMBLIX,,Tianlun,SCEMBLIX (asciminib hydrochloride),1,145,Helen,8829195,n/a,,,Novartis AG,2845,2717,128,2014-01-16,2021-06-24,2021-10-29,NDA 215358,899,215358,2/27/2017,Treatment of chronic myelogenous leukemia,Designated/Approved,,,"Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs)",10/29/2021,10/29/2028,"Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs)",Novartis Pharmaceutical Corporation,Scemblix,asciminib,Novartis Pharmaceuticals Corporation,NDA,215358,,2021-06-24,2021-10-29,2021,,"SCEMBLIX is indicated for the treatment of adult patients with:
[A]Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs)
[B] Treatment of adult patients with Ph+ CML in CP with the T315I mutation.  ",Priority,Yes,Yes (indication [A] only),Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; CABENUVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CABENUVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 4954,2024-01439,https://www.federalregister.gov/documents/2024/01/25/2024-01439/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cabenuva,https://www.govinfo.gov/content/pkg/FR-2024-01-25/pdf/2024-01439.pdf,1/25/2024, CABENUVA,,Tianlun,CABENUVA (cabotegravir and rilpivirine),1,146,Helen,8410103,n/a,,,"ViiV Healthcare Company and Shionogi & Co., Ltd.",4719,4085,634,2008-02-22,2019-04-29,2021-01-21,NDA 212888,1742,212888,,,,,,,,,,,Cabenuva,cabotegravir; rilpivirine (co-packaged),ViiV Healthcare Company,NDA,212888,,2019-04-29,2021-01-21,2021,,CABENUVA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.,Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; VOCABRIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VOCABRIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 4959,2024-01438,https://www.federalregister.gov/documents/2024/01/25/2024-01438/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vocabria,https://www.govinfo.gov/content/pkg/FR-2024-01-25/pdf/2024-01438.pdf,1/25/2024, VOCABRIA,,Tianlun,VOCABRIA (cabotegravir sodium),1,147,Helen,8410103,n/a,,,ViiV Healthcare Company,4719,4085,634,2008-02-22,2019-04-29,2021-01-21,NDA 212887 ,1742,212887,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SKYTROFA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SKYTROFA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 11304,2024-03031,https://www.federalregister.gov/documents/2024/02/14/2024-03031/determination-of-regulatory-review-period-for-purposes-of-patent-extension-skytrofa,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03031.pdf,2/14/2024, SKYTROFA,,Tianlun,SKYTROFA (lonapegsomatropin-tcgd),3,150,Helen,"9,272,048; 9,511,122; and 10,682,395",n/a,,,Ascendis Pharma Endocrinology Division A/S,2133,1706,427,2015-10-25,2020-06-25,2021-08-25,BLA 761177,"431, 1,075 or 1,215",761177,4/13/2020,Treatment of growth hormone deficiency,Designated/Approved,,,Treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH),8/25/2021,,,Ascendis Pharma Endocrinology Division A/S,Skytrofa,lonapegsomatropin-tcgd,Ascendis Pharma Endocrinology Division A/S,BLA,761177,,2020-06-25,2021-08-25,2021,,SKYTROFA (lonapegsomatropin-tcgd) is a human growth hormone indicated for the treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH).,Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; QULIPTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for QULIPTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 11306,2024-03019,https://www.federalregister.gov/documents/2024/02/14/2024-03019/determination-of-regulatory-review-period-for-purposes-of-patent-extension-qulipta,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03019.pdf,2/14/2024, QULIPTA,,Tianlun,QULIPTA (atogepant),2,152,Helen,"8,754,096 and 9,499,545",n/a,,,Merck Sharp & Dohme Corp.,3374,3130,244,2012-07-05,2021-01-28,2021-09-28,NDA 215206,"1,008 or 1,166",215206,,,,,,,,,,,Qulipta,atogepant,"AbbVie, Inc.",NDA,215206,,2021-01-28,2021-09-28,2021,,QULIPTA is indicated for the preventive treatment of episodic migraine in adults.,Priority (used priority review voucher),No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ERVEBO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ERVEBO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 11288,2024-03030,https://www.federalregister.gov/documents/2024/02/14/2024-03030/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ervebo,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03030.pdf,2/14/2024, ERVEBO,,Tianlun,"ERVEBO (Ebola Zaire Vaccine, Live)",1,153,Helen,8012489,n/a,,,Merck Sharp & Dohme Corp.,1941,1783,158,2014-08-28,2019-07-15,2019-12-19,BLA 125690/0,1038,1256900,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; WINLEVI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for WINLEVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.",89 FR 11299,2024-03022,https://www.federalregister.gov/documents/2024/02/14/2024-03022/determination-of-regulatory-review-period-for-purposes-of-patent-extension-winlevi,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03022.pdf,2/14/2024, WINLEVI,,Tianlun,WINLEVI (clascoterone),7,160,Helen,"8,143,240; 8,785,427; 8,865,690; 9,211,295; 9,433,628; 9,486,458; and 10,159,682",n/a,,,Cassiopea S.p.A.,3102,2736,366,2012-03-01,2019-08-27,2020-08-26,NDA 213433,"489, 877, 909, 1,042, 1,252, 1,297, or 1,721",213433,,,,,,,,,,,Winlevi,clascoterone,Cassiopea SpA,NDA,213433,,2019-08-27,2020-08-26,2020,,Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VIVISTIM SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VIVISTIM SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",89 FR 11294,2024-03025,https://www.federalregister.gov/documents/2024/02/14/2024-03025/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vivistim-system,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03025.pdf,2/14/2024, VIVISTIM SYSTEM,,Tianlun,VIVISTIM SYSTEM,1,161,Helen,9522274,n/a,,,"MicroTransponder, Inc. (Agent of Board of Regents, The University of Texas System)",2719,2540,179,2014-03-20,2021-03-02,2021-08-27,PMA P210007,1359,210007,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; REACTIV8 SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REACTIV8 SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",89 FR 11289,2024-03026,https://www.federalregister.gov/documents/2024/02/14/2024-03026/determination-of-regulatory-review-period-for-purposes-of-patent-extension-reactiv8-system,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03026.pdf,2/14/2024, REACTIV8 SYSTEM,,Tianlun,REACTIV8 SYSTEM,3,164,Helen,"8,606,358; 9,474,906; and 9,861,811",n/a,,,Mainstay Medical Limited,1729,1436,293,2015-09-24,2019-08-29,2020-06-16,PMA P190021,"591, 812, or 1,011",190021,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SIMPLIFY CERVICAL ARTIFICIAL DISC,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SIMPLIFY CERVICAL ARTIFICIAL DISC and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that medical device.",89 FR 11286,2024-03024,https://www.federalregister.gov/documents/2024/02/14/2024-03024/determination-of-regulatory-review-period-for-purposes-of-patent-extension-simplify-cervical,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03024.pdf,2/14/2024, SIMPLIFY CERVICAL ARTIFICIAL DISC,,Tianlun,SIMPLIFY CERVICAL ARTIFICIAL DISC,2,166,Helen,"7,753,956 and 9,107,762",n/a,,,Simplify Medical Pty Ltd.,2020,1842,178,2015-03-11,2020-03-25,2020-09-18,PMA P200022,1098,200022,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ORGAN CARE SYSTEM HEART,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ORGAN CARE SYSTEM HEART (OCS HEART SYSTEM) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",89 FR 11301,2024-03028,https://www.federalregister.gov/documents/2024/02/14/2024-03028/determination-of-regulatory-review-period-for-purposes-of-patent-extension-organ-care-system-heart,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03028.pdf,2/14/2024, ORGAN CARE SYSTEM HEART,,Tianlun,OCS HEART SYSTEM,1,167,Helen,7651835,n/a,,,"TransMedics, Inc.",5518,4535,983,2006-07-28,2018-12-26,2021-09-03,PMA P180051,1826,180051,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ORGAN CARE SYSTEM LIVER,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ORGAN CARE SYSTEM LIVER (OCS LIVER) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",89 FR 11303,2024-03034,https://www.federalregister.gov/documents/2024/02/14/2024-03034/determination-of-regulatory-review-period-for-purposes-of-patent-extension-organ-care-system-liver,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03034.pdf,2/14/2024, ORGAN CARE SYSTEM LIVER,,Tianlun,OCS LIVER,1,168,Helen,10076112,n/a,,,"TransMedics, Inc.",2275,1819,456,2015-07-09,2020-06-30,2021-09-28,PMA P20031,72,20031,,,,,,,,,,,Paxil,paroxetine hydrochloride,SmithKline Beecham,NDA,20031,,1989-11-21,1992-12-29,1992,treatment of depression,,Standard,No,No,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PORTICO TRANSCATHETER AORTIC VALVE IMPLANT,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for the PORTICO TRANSCATHETER AORTIC VALVE IMPLANT and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",89 FR 11293,2024-03029,https://www.federalregister.gov/documents/2024/02/14/2024-03029/determination-of-regulatory-review-period-for-purposes-of-patent-extension-portico-transcatheter,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03029.pdf,2/14/2024, PORTICO TRANSCATHETER AORTIC VALVE IMPLANT,,Tianlun,PORTICO TRANSCATHETER AORTIC VALVE IMPLANT,5,173,Helen,"9,011,527; 9,039,759; 9,241,791; 9,289,292; and 9,775,707",n/a,,,"St. Jude Medical, Cardiology Division, Inc.",3028,2288,740,2013-06-05,2019-09-09,2021-09-17,PMA P190023,"660; 932; 1,093; 1,459; and 1,486",190023,,,,,,,,,,,,,,,,,,,,,,,,,,
"Determination of Regulatory Review Period for Purposes of Patent Extension; TACK ENDOVASCULAR SYSTEM (4F, 1.5-4.5 MILLIMETERS)",Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TACK ENDOVASCULAR SYSTEM (4F, 1.5-4.5 MILLIMETERS (MM)) and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",89 FR 11291,2024-03032,https://www.federalregister.gov/documents/2024/02/14/2024-03032/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tack-endovascular-system,https://www.govinfo.gov/content/pkg/FR-2024-02-14/pdf/2024-03032.pdf,2/14/2024," TACK ENDOVASCULAR SYSTEM (4F, 1.5-4.5 MILLIMETERS)",,Tianlun,"TACK ENDOVASCULAR SYSTEM (4F, 1.5-4.5 MM)",3,176,Helen,"9,974,670; 10,137,013; and 10,271,973",n/a,,,"Intact Vascular, Inc.",1203,1010,193,2016-12-26,2019-10-01,2020-04-10,PMA P190027,"271, 348, or 442",190027,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Rybrevant,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for Rybrevant and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 14505,2024-03961,https://www.federalregister.gov/documents/2024/02/27/2024-03961/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rybrevant,https://www.govinfo.gov/content/pkg/FR-2024-02-27/pdf/2024-03961.pdf,2/27/2024, Rybrevant,,Tianlun,Rybrevant (amivantamab-vmjw),1,177,Helen,9593164,n/a,,,"Janssen Biotech, Inc.",1284,1105,179,2017-11-16,2020-11-24,2021-05-21,BLA B761210,546,761210,,,,,,,,,,,Rybrevant,amivantamab-vmjw,"Janssen Biotech, Inc.",BLA,761210,,2020-11-24,2021-05-21,2021,,"RYBREVANT is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,No,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; NULIBRY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for NULIBRY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14851,2024-04226,https://www.federalregister.gov/documents/2024/02/29/2024-04226/determination-of-regulatory-review-period-for-purposes-of-patent-extension-nulibry,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04226.pdf,2/29/2024, NULIBRY,,Tianlun,NULIBRY (fosdenopterin),1,178,Helen,7504095,n/a,,,"Origin Biosciences, Inc.",2815,2572,243,2013-06-15,2020-06-29,2021-02-26,NDA 214018,1529,214018,11/5/2009,Treatment of molybdenum cofactor deficiency type A (MoCD),Designated/Approved,,,to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A,2/26/2021,2/26/2028,to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A,"Origin Biosciences, Inc.",Nulibry,fosdenopterin,"Origin Biosciences, Inc.",NDA,214018,,2020-06-29,2021-02-26,2021,,NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.,Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ISTURISA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ISTURISA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",89 FR 14853,2024-04231,https://www.federalregister.gov/documents/2024/02/29/2024-04231/determination-of-regulatory-review-period-for-purposes-of-patent-extension-isturisa,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04231.pdf,2/29/2024, ISTURISA,,Tianlun,ISTURISA (osilodrostat phosphate),2,180,Helen,"8,314,097; 8,609,862",n/a,,,Recordati AG,4393,4026,367,2008-02-28,2019-03-07,2020-03-06,NDA 212801,1148,212801,9/13/2013,Treatment of Cushing's disease,Designated/Approved,,,ISTURISA is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushings disease for whom pituitary surgery is not an option or has not been curative.,3/6/2020,3/6/2027,For the treatment of adult patients with Cushings disease for whom pituitary surgery is not an option or has not been curative.,"Recordati Rare Diseases, Inc",Isturisa,osilodrostat,Novartis Pharmaceuticals Corporation,NDA,212801,,2019-03-07,2020-03-06,2020,,Isturisa is indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative,Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; OPDUALAG,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OPDUALAG and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 14854,2024-04219,https://www.federalregister.gov/documents/2024/02/29/2024-04219/determination-of-regulatory-review-period-for-purposes-of-patent-extension-opdualag,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04219.pdf,2/29/2024, OPDUALAG,,Tianlun,OPDUALAG (nivolumab and relatlimab-rmbw),2,182,Helen,"9,505,839 and 10,377,824",n/a,,,Bristol-Myers Squibb Company,3110,2867,243,2013-09-13,2021-07-19,2022-03-18,BLA 761234,552 or 596,761234,8/18/2017,Treatment of stage IIb to IV melanoma,Designated/Approved,,,Treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma,3/18/2022,3/18/2029,Treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma,Bristol-Myers Squibb Company,Opdualag,nivolumab and relatlimab-rmbw,Bristol-Myers Squibb Company,BLA,761234,,2021-07-19,2022-03-18,2022,,OPDUALAG is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.,Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; MOUNJARO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MOUNJARO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14856,2024-04157,https://www.federalregister.gov/documents/2024/02/29/2024-04157/determination-of-regulatory-review-period-for-purposes-of-patent-extension-mounjaro,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04157.pdf,2/29/2024, MOUNJARO,,Tianlun,MOUNJARO (tirzepatide),1,183,Helen,9474780,n/a,,,Eli Lilly and Company,2208,1967,241,2016-04-28,2021-09-15,2022-05-13,NDA 215866,129,215866,,,,,,,,,,,Mounjaro,tirzepatide,Eli Lilly and Company,NDA,215866,,2021-09-15,2022-05-13,2022,,"MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
mellitus.
Limitations of Use:
MOUNJARO has not been studied in patients with a history of pancreatitis.
MOUNJARO is not indicated for use in patients with type 1 diabetes mellitus.",Priority (used priority review voucher),No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SOGROYA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SOGROYA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 14857,2024-04208,https://www.federalregister.gov/documents/2024/02/29/2024-04208/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sogroya,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04208.pdf,2/29/2024, SOGROYA,,Tianlun,SOGROYA (somapacitan-beco),1,184,Helen,8779109,n/a,,,Novo Nordisk Health Care AG,2200,1833,367,2014-08-22,2019-08-28,2020-08-28,BLA 761156,1284,761156,7/10/1987,1. Treatment of growth failure in children due to inadequate growth hormone secretion 2. Treatment of short stature associated with Turner's syndrome,Designated/Approved,,,Treatment of pediatric patients aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH),4/28/2023,,,Novo Nordisk Pharmaceuticals,Sogroya,somapacitan-beco,"Novo Nordisk, Inc.",BLA,761156,,2019-08-28,2020-08-28,2020,,Sogroya is indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; KLISYRI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KLISYRI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14859,2024-04232,https://www.federalregister.gov/documents/2024/02/29/2024-04232/determination-of-regulatory-review-period-for-purposes-of-patent-extension-klisyri,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04232.pdf,2/29/2024, KLISYRI,,Tianlun,KLISYRI (tirbanibulin),2,186,Helen,"7,300,931; 7,851,470",n/a,,,Athenex Inc.,4899,4548,351,2007-07-19,2019-12-30,2020-12-14,NDA 213189,1827,213189,,,,,,,,,,,Klisyri,tirbanibulin,"Athenex, Inc.",NDA,213189,,2019-12-30,2020-12-14,2020,,Klisyri is indicated for the topical treatment of actinic keratosis of the face or scalp,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TEMBEXA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TEMBEXA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14861,2024-04205,https://www.federalregister.gov/documents/2024/02/29/2024-04205/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tembexa,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04205.pdf,2/29/2024, TEMBEXA,,Tianlun,TEMBEXA (brincidofovir),1,187,Helen,9303051,n/a,,,"Chimerix, Inc.",5463,5222,241,2006-06-22,2020-10-07,2021-06-04,NDA 214460,1064,214460,6/5/2018,Treatment of smallpox,Designated/Approved,,,"Treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates",6/4/2021,6/4/2028,"Treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates",Emergent BioDefense Operations Lansing LLC,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SAPHNELO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SAPHNELO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 14862,2024-04203,https://www.federalregister.gov/documents/2024/02/29/2024-04203/determination-of-regulatory-review-period-for-purposes-of-patent-extension-saphnelo,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04203.pdf,2/29/2024, SAPHNELO,,Tianlun,SAPHNELO (anifrolumab-fnia),4,191,Helen,"7,662,381; 8,460,668; 9,493,570; and 9,988,459",n/a,,,"AstraZeneca AB (agent of E.R. Squibb & Sons, L.L.C.)",4578,4213,365,2009-01-18,2020-07-31,2021-07-30,BLA B761123,"5, 763, 778, and 1,673",761123,,,,,,,,,,,Saphnelo,anifrolumab-fnia,AstraZeneca AB,BLA,761123,,2020-07-31,2021-07-30,2021,,"SAPHNELO (anifrolumab-fnia) is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy.
Limitations of Use: The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations.",Standard,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; EVKEEZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EVKEEZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 14864,2024-04207,https://www.federalregister.gov/documents/2024/02/29/2024-04207/determination-of-regulatory-review-period-for-purposes-of-patent-extension-evkeeza,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04207.pdf,2/29/2024, EVKEEZA,,Tianlun,EVKEEZA (evinacumab-dgnb),1,192,Helen,9018356,n/a,,,Regeneron,3002,2756,246,2012-11-25,2020-06-11,2021-02-11,BLA 761181,972,761181,2/8/2016,Treatment of homozygous familial hypercholesterolemia,Designated/Approved,,,"as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholesterolemia (HoFH)",3/21/2023,3/21/2030,"as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of pediatric patients, aged 5 years to less than 12 years, with homozygous familial hypercholesterolemia (HoFH)","Regeneron Pharmaceuticals, Inc.",Evkeeza,evinacumab-dgnb,"Regeneron Pharmaceuticals, Inc.",BLA,761181,,2020-06-11,2021-02-11,2021,,"EVKEEZA is indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH).
Limitations of Use:
- The safety and effectiveness of EVKEEZA have not been established in patients with other causes of hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH).
- The effects of EVKEEZA on cardiovascular morbidity and mortality have not been determined.",Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; EVKEEZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EVKEEZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 14864,2024-04207,https://www.federalregister.gov/documents/2024/02/29/2024-04207/determination-of-regulatory-review-period-for-purposes-of-patent-extension-evkeeza,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04207.pdf,2/29/2024, EVKEEZA,,Tianlun,EVKEEZA (evinacumab-dgnb),1,193,Helen,9018356,n/a,,,Regeneron,3002,2756,246,2012-11-25,2020-06-11,2021-02-11,BLA 761181,972,761181,2/8/2016,Treatment of homozygous familial hypercholesterolemia,Designated/Approved,,,"adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH)",2/11/2021,2/11/2028,"adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH)","Regeneron Pharmaceuticals, Inc.",Evkeeza,evinacumab-dgnb,"Regeneron Pharmaceuticals, Inc.",BLA,761181,,2020-06-11,2021-02-11,2021,,"EVKEEZA is indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH).
Limitations of Use:
- The safety and effectiveness of EVKEEZA have not been established in patients with other causes of hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH).
- The effects of EVKEEZA on cardiovascular morbidity and mortality have not been determined.",Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VONJO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VONJO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14866,2024-04162,https://www.federalregister.gov/documents/2024/02/29/2024-04162/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vonjo,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04162.pdf,2/29/2024, VONJO,,Tianlun,VONJO (pacritinib citrate),2,195,Helen,"8,153,632 and 9,573,964",n/a,,,CTI BioPharma Corp.,5138,4802,336,2008-02-06,2021-03-30,2022-02-28,NDA 208712,"1,085 days or 5 years",208712,3/13/2008,"Treatment of primary myelofibrosis (MF), post-polycythemia vera MF, and post-essential thrombocythemia MF",Designated/Approved,,,Treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 x 109/L,2/28/2022,2/28/2029,Treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 x 109/L,"Sobi, Inc.",Vonjo,pacritinib,CTI BioPharma Corporation,NDA,208712,,2021-03-30,2022-02-28,2022,,VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50  10^9/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).,Priority,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ADUHELM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ADUHELM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 14869,2024-04214,https://www.federalregister.gov/documents/2024/02/29/2024-04214/determination-of-regulatory-review-period-for-purposes-of-patent-extension-aduhelm,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04214.pdf,2/29/2024, ADUHELM,,Tianlun,ADUHELM (aducanumab-avwa),2,197,Helen,"8,906,367 and 10,131,708",n/a,,,University of Zurich,3689,3353,336,2011-05-04,2020-07-07,2021-06-07,BLA 761178,"634 and 1,197",761178,,,,,,,,,,,Aduhelm,aducanumab-avwa,"Biogen, Inc.",BLA,761178,,2020-07-07,2021-06-07,2021,,ADUHELM is indicated for the treatment of Alzheimers disease. This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).,Priority,No,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; RECORLEV,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RECORLEV and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14870,2024-04156,https://www.federalregister.gov/documents/2024/02/29/2024-04156/determination-of-regulatory-review-period-for-purposes-of-patent-extension-recorlev,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04156.pdf,2/29/2024, RECORLEV,,Tianlun,RECORLEV (levoketoconazole),1,198,Helen,9918984,n/a,,,"Xeris Pharmaceuticals, Inc.",5812,5507,305,2006-02-02,2021-03-01,2021-12-30,NDA 214133,844,214133,3/9/2012,Treatment of endogenous Cushing's syndrome,Designated/Approved,,,Treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome for whom surgery is not an option or has not been curative,12/30/2021,12/30/2028,Treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome for whom surgery is not an option or has not been curative,Strongbridge Dublin Limited,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; VEKLURY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VEKLURY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14874,2024-04224,https://www.federalregister.gov/documents/2024/02/29/2024-04224/determination-of-regulatory-review-period-for-purposes-of-patent-extension-veklury,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04224.pdf,2/29/2024, VEKLURY,,Tianlun,VEKLURY (remdesivir),6,204,Helen,"8,008,264; 8,318,682; 9,724,360; 9,949,994; 10,065,958; and RE46762",n/a,,,"Gilead Sciences, Inc.",1904,1827,77,2015-08-08,2020-08-07,2020-10-22,NDA 214787,"429, 625, or 991",214787,,,,,,,,,,,Veklury,remdesivir,"Gilead Sciences, Inc.",NDA,214787,,2020-08-07,2020-10-22,2020,,Veklury is indicated for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization in adults and pediatric patients (12 years of age and older and weighing at least 40 kg),Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; EVRYSDI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EVRYSDI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14875,2024-04217,https://www.federalregister.gov/documents/2024/02/29/2024-04217/determination-of-regulatory-review-period-for-purposes-of-patent-extension-evrysdi,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04217.pdf,2/29/2024, EVRYSDI,,Tianlun,EVRYSDI (risdiplam),1,205,Helen,9586955,n/a,,,"Genentech, Inc. (agent for PtC Therapeutics Inc. and Hoffmann-La Roche Inc.)",1368,1049,319,2016-11-10,2019-09-24,2020-08-07,NDA 213535,545,213535,1/4/2017,Treatment of spinal muscular atrophy,Designated/Approved,,,Treatment of spinal muscular atrophy (SMA) in pediatric and adult patients,5/27/2022,5/27/2029,Treatment of spinal muscular atrophy (SMA) in pediatric patients between birth and 2 months of age,"Genentech, Inc., a Member of the Roche Group",Evrysdi,risdiplam,"Genentech, Inc.",NDA,213535,,2019-09-24,2020-08-07,2020,,Evrysdi is indicated for the treatment of later-onset spinal muscular atrophy (SMA) in patients 2 months of age and older. Is indicated for the treatment of infantile-onset spinal muscular atrophy (SMA) in patients 2 months of age and older,Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; EVRYSDI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EVRYSDI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14875,2024-04217,https://www.federalregister.gov/documents/2024/02/29/2024-04217/determination-of-regulatory-review-period-for-purposes-of-patent-extension-evrysdi,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04217.pdf,2/29/2024, EVRYSDI,,Tianlun,EVRYSDI (risdiplam),1,206,Helen,9586955,n/a,,,"Genentech, Inc. (agent for PtC Therapeutics Inc. and Hoffmann-La Roche Inc.)",1368,1049,319,2016-11-10,2019-09-24,2020-08-07,NDA 213535,545,213535,1/4/2017,Treatment of spinal muscular atrophy,Designated/Approved,,,treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older,8/7/2020,8/7/2027,treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.,"Genentech, Inc., a Member of the Roche Group",Evrysdi,risdiplam,"Genentech, Inc.",NDA,213535,,2019-09-24,2020-08-07,2020,,Evrysdi is indicated for the treatment of later-onset spinal muscular atrophy (SMA) in patients 2 months of age and older. Is indicated for the treatment of infantile-onset spinal muscular atrophy (SMA) in patients 2 months of age and older,Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; BREXAFEMME,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BREXAFEMME and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14877,2024-04150,https://www.federalregister.gov/documents/2024/02/29/2024-04150/determination-of-regulatory-review-period-for-purposes-of-patent-extension-brexafemme,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04150.pdf,2/29/2024, BREXAFEMME,,Tianlun,BREXAFEMME (ibrexafungerp tablets),1,207,Helen,8188085,n/a,,,"Scynexis, Inc.",4130,3886,244,2010-02-11,2020-10-01,2021-06-01,NDA 214900,1768,214900,,,,,,,,,,,Brexafemme,ibrexafungerp,"Scynexis, Inc.",NDA,214900,,2020-10-01,2021-06-01,2021,,BREXAFEMME is indicated for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC).,Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; CAMZYOS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CAMZYOS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14880,2024-04165,https://www.federalregister.gov/documents/2024/02/29/2024-04165/determination-of-regulatory-review-period-for-purposes-of-patent-extension-camzyos,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04165.pdf,2/29/2024, CAMZYOS,,Tianlun,CAMZYOS (mavacamten),2,209,Helen,"9,181,200; 9,585,883",n/a,,,"Myokardia, Inc. ",2723,2266,457,2014-11-16,2021-01-28,2022-04-28,NDA 214998,679,214998,4/27/2016,Treatment of symptomatic hypertrophic cardiomyopathy,Designated/Approved,,,Treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms,4/28/2022,4/28/2029,Treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms,"MyoKardia, Inc. (A Wholly-Owned Subsidiary of Bristol Myers Squibb)",Camzyos,mavacamten,"MyoKardia, Inc.",NDA,214998,,2021-01-28,2022-04-28,2022,,CAMZYOS is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.,Standard,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; GEMTESA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for GEMTESA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14883,2024-04221,https://www.federalregister.gov/documents/2024/02/29/2024-04221/determination-of-regulatory-review-period-for-purposes-of-patent-extension-gemtesa,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04221.pdf,2/29/2024, GEMTESA,,Tianlun,GEMTESA (vibegron),2,211,Helen,"8,247,415 and 8,653,260",n/a,,,Urovant Sciences GmbH,3953,3589,364,2010-02-28,2019-12-26,2020-12-23,NDA 213006,"1,483 and 1,433",213006,,,,,,,,,,,Gemtesa,vibegron,Urovant Sciences GmbH,NDA,213006,,2019-12-26,2020-12-23,2020,,"Gemtesa is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; XERAVA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XERAVA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14886,2024-04227,https://www.federalregister.gov/documents/2024/02/29/2024-04227/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xerava,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04227.pdf,2/29/2024, XERAVA,,Tianlun,XERAVA (eravacycline dihydrochloride),1,212,Helen,8906887,n/a,,,"Tetraphase Pharmaceutical, Inc.",3265,3022,243,2009-09-20,2017-09-28,2018-08-27,NDA 211109,608,211109,,,,,,,,,,,Xerava,eravacycline,Tetraphase Pharmaceuticals,NDA,211109,,2017-12-28,2018-08-27,2018,,"XERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosus group, Clostridium perfringens, Bacteroides species, and Parabacteroides distasonis in patients 18 years or older.
Limitations of Use:
XERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI).
Usage:
To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; CAMCEVI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CAMCEVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14892,2024-04218,https://www.federalregister.gov/documents/2024/02/29/2024-04218/determination-of-regulatory-review-period-for-purposes-of-patent-extension-camcevi,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04218.pdf,2/29/2024, CAMCEVI,,Tianlun,CAMCEVI (leuprolide mesylate),3,215,Helen,"9,572,857; 9,744,207; 10,646,572",n/a,,,"Foresee Pharmaceutials Co., Ltd.",2569,2266,303,2014-05-15,2020-07-27,2021-05-25,NDA 211488,"340, 834, or 928",211488,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; LEQVIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LEQVIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14867,2024-04230,https://www.federalregister.gov/documents/2024/02/29/2024-04230/determination-of-regulatory-review-period-for-purposes-of-patent-extension-leqvio,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04230.pdf,2/29/2024, LEQVIO,,Tianlun,LEQVIO (inclisiran sodium),5,220,Helen,"8,222,222; 8,809,292; 8,828,956; 9,370,582; 10,125,369",n/a,,,Novartis Pharmaceuticals Corporation,2134,1403,731,2016-02-20,2019-12-23,2021-12-22,NDA 214012,"492, 1,371, or 1,432",214012,,,,,,,,,,,Leqvio,inclisiran,Novartis Pharmaceuticals Corporation,NDA,214012,,2019-12-23,2021-12-22,2021,,"LEQVIO is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C).
Limitations of Use:
The effect of LEQVIO on cardiovascular morbidity and mortality has not been determined.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ONGENTYS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ONGENTYS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14872,2024-04233,https://www.federalregister.gov/documents/2024/02/29/2024-04233/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ongentys,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04233.pdf,2/29/2024, ONGENTYS,,Tianlun,ONGENTYS (opicapone),5,225,Helen,"8,168,793; 8,524,746; 9,550,759; 9,630,955; and 10,071,085",n/a,,,"Bial-Portela & CA., S.A.",3306,2940,366,2011-04-09,2019-04-26,2020-04-24,NDA 212489,"478, 498, 1,323, 1,395, or 1,640",212489,,,,,,,,,,,Ongentys,opicapone,"Neurocrine Biosciences, Inc.",NDA,212489,,2019-04-26,2020-04-24,2020,,"Ongentys is indicated for the adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing ""off"" episodes",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; INQOVI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for INQOVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 14888,2024-04234,https://www.federalregister.gov/documents/2024/02/29/2024-04234/determination-of-regulatory-review-period-for-purposes-of-patent-extension-inqovi,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04234.pdf,2/29/2024, INQOVI,,Tianlun,INQOVI (decitabine and cedazuridine),3,228,Helen,"8,268,800; 8,618,075; and 9,567,363",n/a,,,"Otsuka Pharmaceutical Co., Ltd.",2330,2120,210,2014-02-21,2019-12-11,2020-07-07,NDA 212576,"726, 1,270, or 2,330",212576,8/21/2019,Treatment of myelodysplastic syndromes (including chronic myelomonocytic leukemia),Designated/Approved,,,"Indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.",7/7/2020,7/7/2027,"Indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.","Astex Pharmaceuticals, Inc.",Inqovi,decitabine and cedazuridine,"Astex Pharmaceuticals, Inc.",NDA,212576,,2019-12-11,2020-07-07,2020,,"Inqovi is indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups",Priority,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; AMPLATZER AMULET,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AMPLATZER AMULET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that medical device.",89 FR 14885,2024-04206,https://www.federalregister.gov/documents/2024/02/29/2024-04206/determination-of-regulatory-review-period-for-purposes-of-patent-extension-amplatzer-amulet,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04206.pdf,2/29/2024, AMPLATZER AMULET,,Tianlun,AMPLATZER AMULET,4,232,Helen,"8,034,061; 8,758,389; 8,961,556; and 10,201,337",n/a,,,"St. Jude Medical, Cardiology Division, Inc.",1846,1619,227,2016-07-27,2020-12-31,2021-08-14,PMA P200049,"571, 1,085, 1,296, and 1,616",200049,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PREVNAR-20,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PREVNAR-20 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 14849,2024-04229,https://www.federalregister.gov/documents/2024/02/29/2024-04229/determination-of-regulatory-review-period-for-purposes-of-patent-extension-prevnar-20,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04229.pdf,2/29/2024, PREVNAR-20,,Tianlun,PREVNAR-20,1,233,Helen,7935787,n/a,,,Wyeth LLC,1678,1434,244,2016-11-05,2020-10-08,2021-06-08,BLA 125731,665 or 961,125731,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; EPI-SENSE GUIDED COAGULATION SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for EPI-SENSE GUIDED COAGULATION SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that medical device.",89 FR 14878,2024-04204,https://www.federalregister.gov/documents/2024/02/29/2024-04204/determination-of-regulatory-review-period-for-purposes-of-patent-extension-epi-sense-guided,https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04204.pdf,2/29/2024, EPI-SENSE GUIDED COAGULATION SYSTEM,,Tianlun,EPI-SENSE GUIDED COAGULATION SYSTEM,2,235,Helen,"7,399,300 and 7,572,257",n/a,,,"AtriCure, Inc.",2919,2436,483,2013-05-03,2020-01-02,2021-04-28,PMA P200002,"1,826 or 1,827",200002,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; RELYVRIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RELYVRIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 15588,2024-04480,https://www.federalregister.gov/documents/2024/03/04/2024-04480/determination-of-regulatory-review-period-for-purposes-of-patent-extension-relyvrio,https://www.govinfo.gov/content/pkg/FR-2024-03-04/pdf/2024-04480.pdf,3/4/2024, RELYVRIO,,Tianlun,RELYVRIO (sodium phenylbutyrate and taurursodiol),6,241,Helen,"9,872,865; 10,251,896; 10,857,162; 11,071,742; 10,857,162; and 11,071,742",n/a,,,Amylyx Pharmaceuticals Inc.,3359,3023,336,2013-07-21,2021-10-29,2022-09-29,NDA 216660,"383, 499, 803, or 1,010",216660,7/27/2017,Treatment of amyotrophic lateral sclerosis (ALS),Designated/Approved,,,Treatment of amyotrophic lateral sclerosis (ALS) in adults,9/29/2022,9/29/2029,Treatment of amyotrophic lateral sclerosis (ALS) in adults,"Amylyx Pharmaceuticals, Inc.",Relyvrio,sodium phenylbutyrate and taurursodiol,"Amylyx Pharmaceuticals, Inc.",NDA,216660,,2021-10-29,2022-09-29,2022,,RELYVRIO is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults.,Priority,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; FYARRO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FYARRO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 15591,2024-04481,https://www.federalregister.gov/documents/2024/03/04/2024-04481/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fyarro,https://www.govinfo.gov/content/pkg/FR-2024-03-04/pdf/2024-04481.pdf,3/4/2024, FYARRO,,Tianlun,FYARRO (sirolimus protein-bound injectable suspension/albumin-bound),1,242,Helen,8911786,n/a,,,"Aadi Bioscience, Inc.",5416,5237,179,2007-01-26,2021-05-28,2021-11-22,NDA 213312 ,1357,213312,12/21/2017,Treatment of perivascular epithelioid cell tumors (PEComa),Designated/Approved,,,treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa),11/22/2021,11/22/2028,treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa),"Aadi Bioscience, Inc.",,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SOTYKTU,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SOTYKTU and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 15585,2024-04483,https://www.federalregister.gov/documents/2024/03/04/2024-04483/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sotyktu,https://www.govinfo.gov/content/pkg/FR-2024-03-04/pdf/2024-04483.pdf,3/4/2024, SOTYKTU,,Tianlun,SOTYKTU (deucravacitinib),1,243,Helen,"RE47,929",n/a,,,Bristol-Myers Squibb Company,2136,1770,366,2016-11-06,2021-09-10,2022-09-09,NDA 214958,1037,214958,,,,,,,,,,,Sotyktu,deucravacitinib,Bristol-Myers Squibb Company,NDA,214958,,2021-09-10,2022-09-09,2022,,"SOTYKTU is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Limitations of Use:
SOTYKTU is not recommended for use in combination with other potent immunosuppressants.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VOXZOGO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VOXZOGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 15593,2024-04479,https://www.federalregister.gov/documents/2024/03/04/2024-04479/determination-of-regulatory-review-period-for-purposes-of-patent-extension-voxzogo,https://www.govinfo.gov/content/pkg/FR-2024-03-04/pdf/2024-04479.pdf,3/4/2024, VOXZOGO,,Tianlun,VOXZOGO (vosoritide),1,244,Helen,8198242,n/a,,,BioMarin Pharmaceutical Inc.,3614,3157,457,2011-12-30,2020-08-20,2021-11-19,NDA 214938,1826,214938,1/17/2013,Treatment of achondroplasia,Designated/Approved,,,To increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses,11/19/2021,11/19/2028,To increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses,"BioMarin Pharmaceutical, Inc.",Voxzogo,vosoritide,"BioMarin Pharmaceutical, Inc.",NDA,214938,,2020-08-20,2021-11-19,2021,,VOXZOGO is indicated to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).,Priority,Yes,Yes,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VOXZOGO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VOXZOGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 15593,2024-04479,https://www.federalregister.gov/documents/2024/03/04/2024-04479/determination-of-regulatory-review-period-for-purposes-of-patent-extension-voxzogo,https://www.govinfo.gov/content/pkg/FR-2024-03-04/pdf/2024-04479.pdf,3/4/2024, VOXZOGO,,Tianlun,VOXZOGO (vosoritide),1,245,Helen,8198242,n/a,,,BioMarin Pharmaceutical Inc.,3614,3157,457,2011-12-30,2020-08-20,2021-11-19,NDA 214938,1826,214938,1/17/2013,Treatment of achondroplasia,Designated/Approved,,,to increase linear growth in pediatric patients with achondroplasia with open epiphyses,10/20/2023,10/20/2030,to increase linear growth in pediatric patients less than 5 years of age with achondroplasia with open epiphyses,"BioMarin Pharmaceutical, Inc.",Voxzogo,vosoritide,"BioMarin Pharmaceutical, Inc.",NDA,214938,,2020-08-20,2021-11-19,2021,,VOXZOGO is indicated to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).,Priority,Yes,Yes,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SAPIEN 3 ULTRA TRANSCATHETER HEART VALVE SYSTEM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for the SAPIEN 3 ULTRA TRANSCATHETER HEART VALVE SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",89 FR 15586,2024-04478,https://www.federalregister.gov/documents/2024/03/04/2024-04478/determination-of-regulatory-review-period-for-purposes-of-patent-extension-sapien-3-ultra,https://www.govinfo.gov/content/pkg/FR-2024-03-04/pdf/2024-04478.pdf,3/4/2024, SAPIEN 3 ULTRA TRANSCATHETER HEART VALVE SYSTEM,,Tianlun,SAPIEN 3 ULTRA TRANSCATHETER HEART VALVE SYSTEM,1,246,Helen,7780723,n/a,,,Edwards Lifesciences Corporation,101,0,101,not available,2018-09-18,2018-12-27,PMA P140031S074,184,140031074,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; Light Adjustable Lens,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LIGHT ADJUSTABLE LENS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.",89 FR 17852,2024-05213,https://www.federalregister.gov/documents/2024/03/12/2024-05213/determination-of-regulatory-review-period-for-purposes-of-patent-extension-light-adjustable-lens,https://www.govinfo.gov/content/pkg/FR-2024-03-12/pdf/2024-05213.pdf,3/12/2024, Light Adjustable Lens,,Tianlun,LIGHT ADJUSTABLE LENS,2,248,Helen,"6,851,804 and 6,905,641",n/a,,,"RxSight, Inc.",3346,3031,315,2008-09-26,2017-01-12,2017-11-22,PMA P160055,1825,160055,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; DAURISMO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DAURISMO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claims that human drug product.",89 FR 18423,2024-05305,https://www.federalregister.gov/documents/2024/03/13/2024-05305/determination-of-regulatory-review-period-for-purposes-of-patent-extension-daurismo,https://www.govinfo.gov/content/pkg/FR-2024-03-13/pdf/2024-05305.pdf,3/13/2024, DAURISMO,,Tianlun,DAURISMO (glasdegib),2,250,Helen,"8,148,401; 8,431,597",n/a,,,"Pfizer, Inc. ",3388,3179,209,2009-08-14,2018-04-27,2018-11-21,NDA 210656,"661 or 1,121",210656,6/28/2017,Treatment of acute myeloid leukemia (AML),Designated/Approved,,,"DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are >75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.",11/21/2018,11/21/2025,"DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are >75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.","Pfizer, Inc.",Daurismo,glasdegib,Pfizer,NDA,210656,,2018-04-27,2018-11-21,2018,,"DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are >75 years old or who have comorbidities that preclude use of intensive induction chemotherapy._x000D_
Limitation of Use: DAURISMO has not been studied in patients with the comorbidities of severe renal impairment or moderate-to-severe hepatic impairment.",Priority,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; PYRUKYND,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PYRUKYND and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.",89 FR 18641,2024-05407,https://www.federalregister.gov/documents/2024/03/14/2024-05407/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pyrukynd,https://www.govinfo.gov/content/pkg/FR-2024-03-14/pdf/2024-05407.pdf,3/14/2024, PYRUKYND,,Tianlun,PYRUKYND (mitapivat hemisulfate sesquihydrate),2,252,Helen,"9,193,701 and RE49,582",n/a,,,"Agios Pharmaceuticals, Inc.",2885,2639,246,2014-03-28,2021-06-17,2022-02-17,NDA 216196,"1,209 or 1,507",216196,3/24/2015,Treatment of pyruvate kinase deficiency,Designated/Approved,,,Treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency,2/17/2022,2/17/2029,Treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency,"Agios Pharmaceuticals, Inc.",Pyrukynd,mitapivat,"Agios Pharmaceuticals, Inc.",NDA,216196,,2021-06-17,2022-02-17,2022,,PYRUKYND is indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.,Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; VTAMA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VTAMA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 18646,2024-05408,https://www.federalregister.gov/documents/2024/03/14/2024-05408/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vtama,https://www.govinfo.gov/content/pkg/FR-2024-03-14/pdf/2024-05408.pdf,3/14/2024, VTAMA,,Tianlun,VTAMA (tapinarof),1,253,Helen,10195160,n/a,,,"Dermavant Sciences, GmbH",3134,2771,363,2013-10-25,2021-05-26,2022-05-23,NDA 215272,4 days,215272,,,,,,,,,,,Vtama,tapinarof,"Dermavant Sciences, Inc.",NDA,215272,,2021-05-26,2022-05-23,2022,,"VTAMA (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; CIBINQO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for CIBINQO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 18643,2024-05421,https://www.federalregister.gov/documents/2024/03/14/2024-05421/determination-of-regulatory-review-period-for-purposes-of-patent-extension-cibinqo,https://www.govinfo.gov/content/pkg/FR-2024-03-14/pdf/2024-05421.pdf,3/14/2024, CIBINQO,,Tianlun,CIBINQO (abrocitinib),2,255,Helen,"9,035,074; 9,545,405",n/a,,,PFIZER Inc.,3173,2665,508,2013-05-10,2020-08-25,2022-01-14,NDA 213871,695,213871,,,,,,,,,,,Cibinqo,abrocitinib,"Pfizer, Inc.",NDA,213871,,2020-08-25,2022-01-14,2022,,"CIBINQO is indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
Limitations of Use:
CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.",Priority,No,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; JEMPERLI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for JEMPERLI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 41443,2024-10361,https://www.federalregister.gov/documents/2024/05/13/2024-10361/determination-of-regulatory-review-period-for-purposes-of-patent-extension-jemperli,https://www.govinfo.gov/content/pkg/FR-2024-05-13/pdf/2024-10361.pdf,5/13/2024, JEMPERLI,,Tianlun,JEMPERLI (dostarlimab-gxly),2,257,Helen,"9,815,897 and 10,738,117",n/a,,,"GlaxoSmithKline (agent for AnaptysBio, Inc.)",1919,1428,491,2016-01-22,2019-12-19,2021-04-22,BLA 761174,355,761174,,,,,,,,,,,Jemperli,dostarlimab-gxly,"GlaxoSmithKline, LLC",BLA,761174,,2019-12-19,2021-04-22,2021,,"JEMPERLI is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,No,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ELFABRIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ELFABRIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 54839,2024-14536,https://www.federalregister.gov/documents/2024/07/02/2024-14536/determination-of-regulatory-review-period-for-purposes-of-patent-extension-elfabrio,https://www.govinfo.gov/content/pkg/FR-2024-07-02/pdf/2024-14536.pdf,7/2/2024, ELFABRIO,,Tianlun,ELFABRIO (pegunigalsidase alfa-iwxj),2,259,Helen,"9,194,011 and 10,280,414",n/a,,,Protalix Ltd.,3927,2849,1078,2012-08-09,2020-05-27,2023-05-09,BLA 761161,"1,271 or 1,826",761161,,,,,,,,,,,Elfabrio,pegunigalsidase alfa-iwxj,Chiesi Farmaceutici SpA,BLA,761161,,2020-05-27,2023-05-09,2023,,ELFABRIO is indicated for the treatment of adults with confirmed Fabry disease.,Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; XENPOZYME,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XENPOZYME and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 54829,2024-14538,https://www.federalregister.gov/documents/2024/07/02/2024-14538/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xenpozyme,https://www.govinfo.gov/content/pkg/FR-2024-07-02/pdf/2024-14538.pdf,7/2/2024, XENPOZYME,,Tianlun,XENPOZYME (olipudase alfa-rcpc),2,261,Helen,"8,314,319 and 8,658,162",n/a,,,Genzyme Corporation and Icahn School of Medicine at Mount Sinai,5971,5669,302,2006-04-28,2021-11-03,2022-08-31,BLA 761261,1827,761261,8/3/2000,Treatment of acid sphingomyelinase deficiency (Niemann-Pick disease),Designated/Approved,,,Treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients,8/31/2022,8/31/2029,Treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients,Genzyme Corporation,Xenpozyme,olipudase alfa-rpcp,Genzyme Corporation,BLA,761261,,2021-11-03,2022-08-31,2022,,XENPOZYME is indicated for treatment of noncentral nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.,Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; TEZSPIRE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TEZSPIRE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 54831,2024-14577,https://www.federalregister.gov/documents/2024/07/02/2024-14577/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tezspire,https://www.govinfo.gov/content/pkg/FR-2024-07-02/pdf/2024-14577.pdf,7/2/2024, TEZSPIRE,,Tianlun,TEZSPIRE (tezepelumab-ekko),2,263,Helen,"7,982,016 and 8,163,284",n/a,,,Amgen Inc.,4848,4623,225,2008-09-10,2021-05-07,2021-12-17,BLA 761224,5 years,761224,,,,,,,,,,,Tezspire,tezepelumab-ekko,AstraZeneca AB,BLA,761224,,2021-05-07,2021-12-17,2021,,"TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
Limitations of Use:
TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus.",Priority,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VYVGART,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VYVGART and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 54832,2024-14532,https://www.federalregister.gov/documents/2024/07/02/2024-14532/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vyvgart,https://www.govinfo.gov/content/pkg/FR-2024-07-02/pdf/2024-14532.pdf,7/2/2024, VYVGART,,Tianlun,VYVGART (efgartigimod),2,265,Helen,"8,163,881 and 8,834,871",n/a,,,The Board of Regents of the University of Texas System,1710,1344,366,2017-04-14,2020-12-17,2021-12-17,BLA 761195,1038,761195,9/20/2017,Treatment of myasthenia gravis,Designated/Approved,,,treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive,12/17/2021,12/17/2028,treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive,argenx BV,Vyvgart,efgartigimod alfa-fcab,argenx BV,BLA,761195,,2020-12-17,2021-12-17,2021,,VYVGART is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.,Standard,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; KIMMTRAK,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for KIMMTRAK and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 54834,2024-14540,https://www.federalregister.gov/documents/2024/07/02/2024-14540/determination-of-regulatory-review-period-for-purposes-of-patent-extension-kimmtrak,https://www.govinfo.gov/content/pkg/FR-2024-07-02/pdf/2024-14540.pdf,7/2/2024, KIMMTRAK,,Tianlun,KIMMTRAK (tebentafusp-tebn),1,266,Helen,8519100,n/a,,,Immunocore Ltd.,3641,3424,217,2012-02-08,2021-06-23,2022-01-25,BLA 761228,1739,761228,1/21/2016,Treatment of uveal melanoma,Designated/Approved,,,treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma,1/25/2022,1/25/2029,treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma,Immunocore Ltd,Kimmtrak,tebentafusp-tebn,Immunocore Limited,BLA,761228,,2021-06-23,2022-01-25,2022,,KIMMTRAK is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.,Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ZYNYZ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZYNYZ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 54836,2024-14541,https://www.federalregister.gov/documents/2024/07/02/2024-14541/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zynyz,https://www.govinfo.gov/content/pkg/FR-2024-07-02/pdf/2024-14541.pdf,7/2/2024, ZYNYZ,,Tianlun,ZYNYZ (retifanlimab-dlwr),1,267,Helen,10577422,n/a,,,"Incyte Corporation (Agent of MacroGenics, Inc.)",2372,2145,227,2016-09-24,2022-08-08,2023-03-22,BLA 761334,138,761334,10/26/2020,Treatment of Merkel cell carcinoma,Designated/Approved,,,treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC),3/22/2023,3/22/2030,treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC),Incyte Corporation,Zynyz,retifanlimab-dlwr,Incyte Corporation,BLA,761334,,2022-08-08,2023-03-22,2023,,"ZYNYZ is indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; TECVAYLI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TECVAYLI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 54837,2024-14535,https://www.federalregister.gov/documents/2024/07/02/2024-14535/determination-of-regulatory-review-period-for-purposes-of-patent-extension-tecvayli,https://www.govinfo.gov/content/pkg/FR-2024-07-02/pdf/2024-14535.pdf,7/2/2024, TECVAYLI,,Tianlun,TECVAYLI (teclistamab-cqyv),1,268,Helen,10072088,n/a,,,"Janssen Biotech, Inc.",2050,1748,302,2017-03-17,2021-12-28,2022-10-25,BLA 761291,70,761291,11/24/2020,Treatment of multiple myeloma,Designated/Approved,,,"Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody",10/25/2022,10/25/2029,"Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody","Janssen Biotech, Inc.",Tecvayli,teclistamab-cqyv,"Janssen Biotech, Inc.",BLA,761291,,2021-12-28,2022-10-25,2022,,"TECVAYLI is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; RYSTIGGO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for RYSTIGGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 55598,2024-14723,https://www.federalregister.gov/documents/2024/07/05/2024-14723/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rystiggo,https://www.govinfo.gov/content/pkg/FR-2024-07-05/pdf/2024-14723.pdf,7/5/2024, RYSTIGGO,,Tianlun,RYSTIGGO (rozanolixizumab-noli),1,269,Helen,10233243,n/a,,,UCB Biopharma SRL,2283,2036,247,2017-03-29,2022-10-24,2023-06-26,BLA 761286,902,761286,2/1/2019,Treatment of myasthenia gravis,Designated/Approved,,,treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive,6/26/2023,6/26/2030,treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive,"UCB, Inc.",Rystiggo,rozanolixizumab-noli,"UCB, Inc.",BLA,761286,,2022-10-24,2023-06-26,2023,,RYSTIGGO is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.,Priority,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VABYSMO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VABYSMO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 55600,2024-14720,https://www.federalregister.gov/documents/2024/07/05/2024-14720/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vabysmo,https://www.govinfo.gov/content/pkg/FR-2024-07-05/pdf/2024-14720.pdf,7/5/2024, VABYSMO,,Tianlun,VABYSMO (faricimab-svoa),2,271,Helen,"8,268,314 and 9,695,233",n/a,,,"Genentech, Inc.(Agent of Hoffmann-La Roche Inc.)",3046,2800,246,2013-09-28,2021-05-28,2022-01-28,BLA 761235,"931 and 1,646",761235,,,,,,,,,,,Vabysmo,faricimab-svoa,"Genentech, Inc.",BLA,761235,,2021-05-28,2022-01-28,2022,,"VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor indicated for the treatment of patients with:
- Neovascular (wet) Age-Related Macular Degeneration (nAMD)
- Diabetic Macular Edema (DME)",Priority (used priority review voucher),No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ENJAYMO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ENJAYMO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 55611,2024-14729,https://www.federalregister.gov/documents/2024/07/05/2024-14729/determination-of-regulatory-review-period-for-purposes-of-patent-extension-enjaymo,https://www.govinfo.gov/content/pkg/FR-2024-07-05/pdf/2024-14729.pdf,7/5/2024, ENJAYMO,,Tianlun,ENJAYMO (sutimlimab-jome),2,273,Helen,"8,877,197 and 10,450,382",n/a,,,Bioverativ USA Inc.,1845,1151,694,2017-01-18,2020-03-13,2022-02-04,BLA 761164,766 or 825,761164,7/27/2016,Treatment of autoimmune hemolytic anemia,Designated/Approved,,,To decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD),2/4/2022,2/4/2029,To decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD),Bioverativ USA Inc. (a fully owned subsidiary of Sanofi),Enjaymo,sutimlimab-jome,"Bioverativ USA, Inc.",BLA,761164,,2020-03-13,2022-02-04,2022,,ENJAYMO (sutimlimab-jome) is indicated to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD),Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ENJAYMO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ENJAYMO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 55611,2024-14729,https://www.federalregister.gov/documents/2024/07/05/2024-14729/determination-of-regulatory-review-period-for-purposes-of-patent-extension-enjaymo,https://www.govinfo.gov/content/pkg/FR-2024-07-05/pdf/2024-14729.pdf,7/5/2024, ENJAYMO,,Tianlun,ENJAYMO (sutimlimab-jome),2,275,Helen,"8,877,197 and 10,450,382",n/a,,,Bioverativ USA Inc.,1845,1151,694,2017-01-18,2020-03-13,2022-02-04,BLA 761164,766 or 825,761164,7/27/2016,Treatment of autoimmune hemolytic anemia,Designated/Approved,,,treatment of hemolysis in adults with cold agglutinin disease (CAD),1/25/2023,,,Bioverativ USA Inc. (a fully owned subsidiary of Sanofi),Enjaymo,sutimlimab-jome,"Bioverativ USA, Inc.",BLA,761164,,2020-03-13,2022-02-04,2022,,ENJAYMO (sutimlimab-jome) is indicated to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD),Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; LUNSUMIO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for LUNSUMIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 55628,2024-14728,https://www.federalregister.gov/documents/2024/07/05/2024-14728/determination-of-regulatory-review-period-for-purposes-of-patent-extension-lunsumio,https://www.govinfo.gov/content/pkg/FR-2024-07-05/pdf/2024-14728.pdf,7/5/2024, LUNSUMIO,,Tianlun,LUNSUMIO (mosunetuzumab-axgb),2,277,Helen,"10,174,124 and 11,186,650",n/a,,,"Genentech, Inc.",2809,2571,238,2015-04-16,2022-04-29,2022-12-22,BLA 761263,313 or 842,761263,12/17/2018,Treatment of follicular lymphoma,Designated/Approved,,,treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy,12/22/2022,12/22/2029,treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy,"Genentech, Inc.",Lunsumio,mosunetuzumab-axgb,"Genentech, Inc.",BLA,761263,,2022-04-29,2022-12-22,2022,,"LUNSUMIO is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; DAXXIFY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DAXXIFY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 55597,2024-14732,https://www.federalregister.gov/documents/2024/07/05/2024-14732/determination-of-regulatory-review-period-for-purposes-of-patent-extension-daxxify,https://www.govinfo.gov/content/pkg/FR-2024-07-05/pdf/2024-14732.pdf,7/5/2024, DAXXIFY,,Tianlun,DAXXIFY (daxibotulinumtoxinA-lanm),3,280,Helen,"9,340,587; 9,956,435; and 10,111,939",n/a,,,"Revance Therapeutics, Inc.",2339,1321,1018,2016-04-14,2019-11-25,2022-09-07,BLA 761127,"1,214, 1,305, or 1,587",761127,11/16/2017,Treatment of cervical dystonia,Designated/Approved,,,treatment of cervical dystonia in adult patients,8/11/2023,,,"Revance Therapeutics, Inc.",Daxxify,daxibotulinumtoxinA-lanm,"Revance Therapeutics, Inc.",BLA,761127,,2019-11-25,2022-09-07,2022,,DAXXIFY (daxibotulinumtoxinA-lanm) is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; Imjudo,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for IMJUDO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 55626,2024-14716,https://www.federalregister.gov/documents/2024/07/05/2024-14716/determination-of-regulatory-review-period-for-purposes-of-patent-extension-imjudo,https://www.govinfo.gov/content/pkg/FR-2024-07-05/pdf/2024-14716.pdf,7/5/2024, Imjudo,,Tianlun,IMJUDO (tremelimumab-actl),3,283,Helen,"9,487,581; 10,232,040; and 11,446,377",n/a,,,AstraZeneca AB,7634,7393,241,2001-11-28,2022-02-23,2022-10-21,BLA 761289,"32, 529, or 1,208",761289,1/15/2020,Treatment of hepatocellular carcinoma,Designated/Approved,,,In combination with durvalumab for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC),10/21/2022,10/21/2029,treatment of adult patients with unresectable hepatocellular carcinoma (uHCC),AstraZeneca Pharmaceuticals LP,Imjudo,tremelimumab-actl,AstraZeneca AB,BLA,761289,,2022-02-23,2022-10-21,2022,,IMJUDO in combination with durvalumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).,Priority (used priority review voucher),Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SPEVIGO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SPEVIGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 56883,2024-15239,https://www.federalregister.gov/documents/2024/07/11/2024-15239/determination-of-regulatory-review-period-for-purposes-of-patent-extension-spevigo,https://www.govinfo.gov/content/pkg/FR-2024-07-11/pdf/2024-15239.pdf,7/11/2024, SPEVIGO,,Tianlun,SPEVIGO (spesolimab-sbzo),1,284,Helen,9023995,n/a,,,Boehringer Ingelheim International GmbH,1729,1393,336,2017-12-09,2021-10-01,2022-09-01,BLA 761244,1033,761244,10/3/2018,Treatment of generalized pustular psoriasis,Designated/Approved,,,Treatment of generalized pustular psoriasis (GPP) flares in adults,9/1/2022,9/1/2029,Treatment of generalized pustular psoriasis (GPP) flares in adults,"Boehringer Ingelheim Pharmaceuticals, Inc. (BI)",Spevigo,spesolimab-sbzo,"Boehringer Ingelheim Pharmaceuticals, Inc.",BLA,761244,,2021-10-01,2022-09-01,2022,,SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults.,Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; SPEVIGO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SPEVIGO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.",89 FR 56883,2024-15239,https://www.federalregister.gov/documents/2024/07/11/2024-15239/determination-of-regulatory-review-period-for-purposes-of-patent-extension-spevigo,https://www.govinfo.gov/content/pkg/FR-2024-07-11/pdf/2024-15239.pdf,7/11/2024, SPEVIGO,,Tianlun,SPEVIGO (spesolimab-sbzo),1,285,Helen,9023995,n/a,,,Boehringer Ingelheim International GmbH,1729,1393,336,2017-12-09,2021-10-01,2022-09-01,BLA 761244,1033,761244,10/3/2018,Treatment of generalized pustular psoriasis,Designated/Approved,,,treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg,3/18/2024,3/18/2031,"treatment of generalized pustular psoriasis (GPP) flares in pediatric patients 12 years of age and older and weighing at least 40 kg, and treatment of GPP in adults and pediatric patients 12 years of age and older and weighing at least 40 kg who are not experiencing a flare","Boehringer Ingelheim Pharmaceuticals, Inc. (BI)",Spevigo,spesolimab-sbzo,"Boehringer Ingelheim Pharmaceuticals, Inc.",BLA,761244,,2021-10-01,2022-09-01,2022,,SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults.,Priority,Yes,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; XENPOZYME; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) is correcting a notice that appeared in the Federal Register of July 2, 2024. The document announced the determination of the regulatory review period for XENPOZYME (olipudase alfa-rpcp) for purposes of patent extension. The document was published with an incorrect patent number. This notice corrects the patent number.",89 FR 59121,2024-15998,https://www.federalregister.gov/documents/2024/07/22/2024-15998/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xenpozyme-correction,https://www.govinfo.gov/content/pkg/FR-2024-07-22/pdf/2024-15998.pdf,7/22/2024, XENPOZYME, Correction,Tianlun,XENPOZYME (olipudase alfa-rcpc),2,287,Helen,"8,349,319 and 8,658,162",n/a,,,Genzyme Corporation and Icahn School of Medicine at Mount Sinai,5971,5669,302,2006-04-28,2021-11-03,2022-08-31,BLA 761261,1827,761261,8/3/2000,Treatment of acid sphingomyelinase deficiency (Niemann-Pick disease),Designated/Approved,,,Treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients,8/31/2022,8/31/2029,Treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients,Genzyme Corporation,Xenpozyme,olipudase alfa-rpcp,Genzyme Corporation,BLA,761261,,2021-11-03,2022-08-31,2022,,XENPOZYME is indicated for treatment of noncentral nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.,Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; REZLIDHIA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REZLIDHIA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 64918,2024-17511,https://www.federalregister.gov/documents/2024/08/08/2024-17511/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rezlidhia,https://www.govinfo.gov/content/pkg/FR-2024-08-08/pdf/2024-17511.pdf,8/8/2024, REZLIDHIA,,Tianlun,REZLIDHIA (olutasidenib),1,288,Helen,9834539,n/a,,,"Forma Therapeutics, Inc.",2563,2273,290,2015-11-27,2022-02-15,2022-12-01,NDA 215814,440,215814,4/27/2017,Treatment of acute myeloid leukemia,Designated/Approved,,,treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test,12/1/2022,12/1/2029,treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test,"Rigel Pharmaceuticals, Inc.",Rezlidhia,olutasidenib,"Forma Therapeutics, Inc.",NDA,215814,,2022-02-15,2022-12-01,2022,,REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.,Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; XOFLUZA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for XOFLUZA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 64920,2024-17648,https://www.federalregister.gov/documents/2024/08/08/2024-17648/determination-of-regulatory-review-period-for-purposes-of-patent-extension-xofluza,https://www.govinfo.gov/content/pkg/FR-2024-08-08/pdf/2024-17648.pdf,8/8/2024, XOFLUZA,,Tianlun,XOFLUZA (baloxavir marboxil),1,289,Helen,8987441,n/a,,,"Shionogi & Co., Ltd.",985,801,184,2016-02-14,2018-04-24,2018-10-24,NDA 210854 ,399,210854,,,,,,,,,,,Xofluza,baloxavir marboxil,Shionogi,NDA,210854,,2018-04-24,2018-10-24,2018,,"XOFLUZA is indicated for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
Limitations of Use:
Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA.",Priority,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TALZENNA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TALZENNA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 64933,2024-17643,https://www.federalregister.gov/documents/2024/08/08/2024-17643/determination-of-regulatory-review-period-for-purposes-of-patent-extension-talzenna,https://www.govinfo.gov/content/pkg/FR-2024-08-08/pdf/2024-17643.pdf,8/8/2024, TALZENNA,,Tianlun,TALZENNA (talazoparib tosylate),1,290,Helen,8012976,n/a,,,Medivation Technologies LLC,2869,2675,194,2010-12-10,2018-04-06,2018-10-16,NDA 211651,1093,211651,,,,,,,,,,,Talzenna,talazoparib,Pfizer,NDA,211651,,2018-04-06,2018-10-16,2018,,TALZENNA is indicated for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA.,Priority,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; INPEFA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for INPEFA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 64934,2024-17639,https://www.federalregister.gov/documents/2024/08/08/2024-17639/determination-of-regulatory-review-period-for-purposes-of-patent-extension-inpefa,https://www.govinfo.gov/content/pkg/FR-2024-08-08/pdf/2024-17639.pdf,8/8/2024, INPEFA,,Tianlun,INPEFA (sotagliflozin),2,292,Helen,"7,781,577 and 8,217,156",n/a,,,"Lexicon Pharmaceuticals, Inc.",5268,4903,365,2008-12-24,2022-05-27,2023-05-26,NDA 216203,5 years,216203,,,,,,,,,,,Inpefa,sotagliflozin,"Lexicon Pharmaceuticals, Inc.",NDA,216203,,2022-05-27,2023-05-26,2023,,"INPEFA is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with:
- heart failure or
- type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VANFLYTA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VANFLYTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 64931,2024-17510,https://www.federalregister.gov/documents/2024/08/08/2024-17510/determination-of-regulatory-review-period-for-purposes-of-patent-extension-vanflyta,https://www.govinfo.gov/content/pkg/FR-2024-08-08/pdf/2024-17510.pdf,8/8/2024, VANFLYTA,,Tianlun,VANFLYTA (quizartinib),5,297,Helen,"7,820,657; 8,129,374; 8,357,690; 8,557,810; and 8,836,218",n/a,,,Ambit Biosciences Corporation,6110,5779,331,2006-10-29,2022-08-24,2023-07-20,NDA 216993,"1,781 or 1,826",216993,3/18/2009,Treatment of acute myeloid leukemia,Designated/Approved,,,"in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test",7/20/2023,7/20/2030,"in combination with standard induction and consolidation, and as maintenance therapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test","Daiichi Sankyo, Inc.",Vanflyta,quizartinib,"Daiichi Sankyo, Inc.",NDA,216993,,2022-08-24,2023-07-20,2023,,"VANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test.
Limitations of Use:
VANFLYTA is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation (HSCT); improvement in overall survival with VANFLYTA in this setting has not been demonstrated.",Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; MIEBO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for MIEBO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 66415,2024-18265,https://www.federalregister.gov/documents/2024/08/15/2024-18265/determination-of-regulatory-review-period-for-purposes-of-patent-extension-miebo,https://www.govinfo.gov/content/pkg/FR-2024-08-15/pdf/2024-18265.pdf,8/15/2024, MIEBO,,Tianlun,MIEBO (perfluorohexyloctane),5,302,Helen,"10,058,615; 10,369,117; 10,449,164; 10,576,154; 11,357,738",n/a,,,Novaliq GmbH,2018,1693,325,2017-11-09,2022-06-28,2023-05-18,NDA 216675,"231, 748, 814, 853, or 1,024",216675,,,,,,,,,,,Miebo,perfluorohexyloctane,"Bausch and Lomb, Inc.",NDA,216675,,2022-06-28,2023-05-18,2023,,MIEBO (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED).,Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; STEGLATRO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for STEGLATRO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 72851,2024-20149,https://www.federalregister.gov/documents/2024/09/06/2024-20149/determination-of-regulatory-review-period-for-purposes-of-patent-extension-steglatro,https://www.govinfo.gov/content/pkg/FR-2024-09-06/pdf/2024-20149.pdf,9/6/2024, STEGLATRO,,Tianlun,STEGLATRO (ertugliflozin),1,303,Helen,8080580,n/a,,,Pfizer Inc.,2976,2610,366,2009-10-28,2016-12-19,2017-12-19,NDA 209803,524,209803,,,,,,,,,,,Steglatro,ertugliflozin,Merck Sharp & Dohme,NDA,209803,,2016-12-19,2017-12-19,2017,,"STEGLATRO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use:
- STEGLATRO is not recommended in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; STEGLUJAN,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for STEGLUJAN and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 72844,2024-20150,https://www.federalregister.gov/documents/2024/09/06/2024-20150/determination-of-regulatory-review-period-for-purposes-of-patent-extension-steglujan,https://www.govinfo.gov/content/pkg/FR-2024-09-06/pdf/2024-20150.pdf,9/6/2024, STEGLUJAN,,Tianlun,STEGLUJAN (ertugliflozin and sitagliptin),2,305,Helen,"9,308,204 and 9,439,901",n/a,,,Pfizer Inc.,2976,2610,366,2009-10-28,2016-12-19,2017-12-19,NDA 209805,415 or 424,209805,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; YCANTH,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for YCANTH and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 72853,2024-20115,https://www.federalregister.gov/documents/2024/09/06/2024-20115/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ycanth,https://www.govinfo.gov/content/pkg/FR-2024-09-06/pdf/2024-20115.pdf,9/6/2024, YCANTH,,Tianlun,YCANTH (cantharidin),1,306,Helen,11052064,n/a,,,Verrica Pharmaceuticals,2285,877,1408,2017-04-20,2019-09-13,2023-07-21,NDA 212905,745,212905,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; SEGLUROMET,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SEGLUROMET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 72855,2024-20148,https://www.federalregister.gov/documents/2024/09/06/2024-20148/determination-of-regulatory-review-period-for-purposes-of-patent-extension-segluromet,https://www.govinfo.gov/content/pkg/FR-2024-09-06/pdf/2024-20148.pdf,9/6/2024, SEGLUROMET,,Tianlun,SEGLUROMET (ertugliflozin and metformin hydrochloride),2,308,Helen,"9,308,204 and 9,439,902",n/a,,,Pfizer Inc.,2976,2610,366,2009-10-28,2016-12-19,2017-12-19,NDA 209806,415 or 424,209806,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; PLUVICTO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for PLUVICTO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 73098,2024-20246,https://www.federalregister.gov/documents/2024/09/09/2024-20246/determination-of-regulatory-review-period-for-purposes-of-patent-extension-pluvicto,https://www.govinfo.gov/content/pkg/FR-2024-09-09/pdf/2024-20246.pdf,9/9/2024, PLUVICTO,,Tianlun,PLUVICTO (lutetium Lu 177 vipivotide tetraxetan),1,309,Helen,10398791,n/a,,,"Advanced Accelerator Applications USA, Inc. (Agent of Deutsches Krebsforschungszentrum & Ruprecht-Karls-Universitat Heidelberg)",1881,1643,238,2017-01-29,2021-07-29,2022-03-23,NDA 215833,523,215833,,,,,,,,,,,Pluvicto,lutetium Lu 177 vipivotide tetraxetan,"Advanced Accelerator Applications USA, Inc.",NDA,215833,,2021-07-29,2022-03-23,2022,,PLUVICTO is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.,Priority,No,No,Yes,No
Determination of Regulatory Review Period for Purposes of Patent Extension; TECHNEGAS,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for TECHNEGAS and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 73660,2024-20555,https://www.federalregister.gov/documents/2024/09/11/2024-20555/determination-of-regulatory-review-period-for-purposes-of-patent-extension-technegas,https://www.govinfo.gov/content/pkg/FR-2024-09-11/pdf/2024-20555.pdf,9/11/2024, TECHNEGAS,,Tianlun,TECHNEGAS (technetium Tc 99m-labeled carbon),1,310,Helen,7722856,n/a,,,Cyclomedica Australia Pty Limited,4322,3039,1283,2011-12-01,2020-03-26,2023-09-29,NDA 22335,1826,22335,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; ZTALMY,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZTALMY and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 73662,2024-20549,https://www.federalregister.gov/documents/2024/09/11/2024-20549/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ztalmy,https://www.govinfo.gov/content/pkg/FR-2024-09-11/pdf/2024-20549.pdf,9/11/2024, ZTALMY,,Tianlun,ZTALMY (ganaxolone),1,311,Helen,8318714,n/a,,,"Marinus Pharmaceuticals, Inc.",10382,10065,317,1993-12-30,2021-07-20,2022-06-01,NDA 215904,5 years,215904,6/28/2017,Treatment of cyclin-dependent kinase-like 5 (CDKL5) gene-related early-onset infantile epileptic encephalopathy,Designated/Approved,,,Treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older,6/1/2022,6/1/2029,Treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older,Marinus Pharmaceuticals,Ztalmy,ganaxolone,"Marinus Pharmaceuticals, Inc.",NDA,215904,,2021-07-20,2022-03-18,2022,,ZTALMY is indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older.,Priority,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; VOQUEZNA TRIPLE PAK-New Drug Application 215152,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VOQUEZNA TRIPLE PAK--new drug application (NDA) 215152 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 73656,2024-20552,https://www.federalregister.gov/documents/2024/09/11/2024-20552/determination-of-regulatory-review-period-for-purposes-of-patent-extension-voquezna-triple-pak-new,https://www.govinfo.gov/content/pkg/FR-2024-09-11/pdf/2024-20552.pdf,9/11/2024, VOQUEZNA TRIPLE PAK-New Drug Application 215152,,Tianlun,VOQUEZNA TRIPLE PAKNDA 215152 (vonoprazan tablets/amoxicillin capsules/clarithromycin tablets),1,312,Helen,7977488,n/a,,,"Phathom Pharmaceuticals, Inc. ",971,727,244,2019-09-08,2021-09-03,2022-05-03,NDA 215152,599,215152,,,,,,,,,,,Voquezna Triple Pak,vonoprazan; amoxicillin; clarithromycin (co-packaged),"Phathom Pharmaceuticals, Inc.",NDA,215152,,2021-09-03,2022-05-03,2022,,"VOQUEZNA TRIPLE PAK or VOQUEZNA DUAL PAK are indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults. 
To reduce the development of drug-resistant bacteria and maintain the effectiveness of VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK and other antibacterial drugs, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; VOQUEZNA DUAL PAK-New Drug Application 215153,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for VOQUEZNA DUAL PAK--new drug application (NDA) 215153 and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 73658,2024-20551,https://www.federalregister.gov/documents/2024/09/11/2024-20551/determination-of-regulatory-review-period-for-purposes-of-patent-extension-voquezna-dual-pak-new,https://www.govinfo.gov/content/pkg/FR-2024-09-11/pdf/2024-20551.pdf,9/11/2024, VOQUEZNA DUAL PAK-New Drug Application 215153,,Tianlun,VOQUEZNA DUAL PAK (vonoprazan fumarate tablets/amoxicillin capsules),1,313,Helen,7977488,n/a,,,"Phathom Pharmaceuticals, Inc.",971,727,244,2019-09-08,2021-09-03,2022-05-03,NDA 215153,599,215153,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; REZZAYO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for REZZAYO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 75546,2024-20894,https://www.federalregister.gov/documents/2024/09/16/2024-20894/determination-of-regulatory-review-period-for-purposes-of-patent-extension-rezzayo,https://www.govinfo.gov/content/pkg/FR-2024-09-16/pdf/2024-20894.pdf,9/16/2024, REZZAYO,,Tianlun,REZZAYO (rezafungin acetate),3,316,Helen,"8,722,619; 9,526,835; and 10,702,573",n/a,,,"Cidara Therapeutics, Inc.",2814,2570,244,2015-07-10,2022-07-22,2023-03-22,NDA 217417,"607, 1,261, or 1,529",217417,2/8/2016,Treatment of candidemia and invasive candidiasis infections caused by susceptible Candida spp.,Designated/Approved,,,in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis,3/22/2023,3/22/2030,in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis,Mundipharma GmbH,Rezzayo,rezafungin,"Cidara Therapeutics, Inc.",NDA,217417,,2022-07-22,2023-03-22,2023,,"REZZAYO is indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data for REZZAYO.
Limitations of Use:
REZZAYO has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida.",Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ORSERDU,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ORSERDU and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 75543,2024-20893,https://www.federalregister.gov/documents/2024/09/16/2024-20893/determination-of-regulatory-review-period-for-purposes-of-patent-extension-orserdu,https://www.govinfo.gov/content/pkg/FR-2024-09-16/pdf/2024-20893.pdf,9/16/2024, ORSERDU,,Tianlun,ORSERDU (elacestrant dihydrochloride),2,318,Helen,"7,612,114 and 8,399,520",n/a,,,"Eisai R&D Management Co., Ltd.",2965,2740,225,2014-12-17,2022-06-17,2023-01-27,NDA 217639,"724, 841, or 1,595",217639,,,,,,,,,,,Orserdu,elacestrant,"Stemline Therapeutics, Inc.",NDA,217639,,2022-06-17,2023-01-27,2023,,"ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; SYMDEKO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SYMDEKO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 77520,2024-21677,https://www.federalregister.gov/documents/2024/09/23/2024-21677/determination-of-regulatory-review-period-for-purposes-of-patent-extension-symdeko,https://www.govinfo.gov/content/pkg/FR-2024-09-23/pdf/2024-21677.pdf,9/23/2024, SYMDEKO,,Tianlun,SYMDEKO (tezacaftor/co-packaged with ivacaftor),6,324,Helen,"7,645,789; 7,776,905; 8,415,387; 8,598,181; 8,623,905; and 9,035,072",n/a,,,Vertex Pharmaceuticals Inc.,2832,2602,230,2010-05-15,2017-06-28,2018-02-12,NDA 210491,"616, 864, 882, 1,001, 1,484, or 1,532",210491,6/15/2017,Treatment of cystic fibrosis (CF),Designated/Approved,,,treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence,12/21/2020,12/21/2027,"treatment of cystic fibrosis (CF) in patients age 6 years and older who have at least one of the additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that have been identified as responsive to tezacaftor/ivacaftor based on in vitro data and identified in the approval on December 21, 2020",Vertex Pharmaceuticals Inc.,Symdeko,"tezacaftor, ivacaftor; ivacaftor (co-packaged)",Vertex Pharmaceuticals,NDA,210491,,2017-06-28,2018-02-12,2018,,"SYMDEKO is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence._x000D_
If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.",Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; SYMDEKO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SYMDEKO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 77520,2024-21677,https://www.federalregister.gov/documents/2024/09/23/2024-21677/determination-of-regulatory-review-period-for-purposes-of-patent-extension-symdeko,https://www.govinfo.gov/content/pkg/FR-2024-09-23/pdf/2024-21677.pdf,9/23/2024, SYMDEKO,,Tianlun,SYMDEKO (tezacaftor/co-packaged with ivacaftor),6,330,Helen,"7,645,789; 7,776,905; 8,415,387; 8,598,181; 8,623,905; and 9,035,072",n/a,,,Vertex Pharmaceuticals Inc.,2832,2602,230,2010-05-15,2017-06-28,2018-02-12,NDA 210491,"616, 864, 882, 1,001, 1,484, or 1,532",210491,6/15/2017,Treatment of cystic fibrosis (CF),Designated/Approved,,,"SYMDEKO a combination of tezacaftor and ivacaftor, is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence",2/12/2018,2/12/2025,"SYMDEKO a combination of tezacaftor and ivacaftor, is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence",Vertex Pharmaceuticals Inc.,Symdeko,"tezacaftor, ivacaftor; ivacaftor (co-packaged)",Vertex Pharmaceuticals,NDA,210491,,2017-06-28,2018-02-12,2018,,"SYMDEKO is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence._x000D_
If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.",Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; SYMDEKO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SYMDEKO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 77520,2024-21677,https://www.federalregister.gov/documents/2024/09/23/2024-21677/determination-of-regulatory-review-period-for-purposes-of-patent-extension-symdeko,https://www.govinfo.gov/content/pkg/FR-2024-09-23/pdf/2024-21677.pdf,9/23/2024, SYMDEKO,,Tianlun,SYMDEKO (tezacaftor/co-packaged with ivacaftor),6,336,Helen,"7,645,789; 7,776,905; 8,415,387; 8,598,181; 8,623,905; and 9,035,072",n/a,,,Vertex Pharmaceuticals Inc.,2832,2602,230,2010-05-15,2017-06-28,2018-02-12,NDA 210491,"616, 864, 882, 1,001, 1,484, or 1,532",210491,6/15/2017,Treatment of cystic fibrosis (CF),Designated/Approved,,,SYMDEKO? is indicated for the treatment of patients with cystic fibrosis (CF) age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.,6/21/2019,6/21/2026,For the treatment of patients with cystic fibrosis (CF) age 6 years to less than 12 years who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence,Vertex Pharmaceuticals Inc.,Symdeko,"tezacaftor, ivacaftor; ivacaftor (co-packaged)",Vertex Pharmaceuticals,NDA,210491,,2017-06-28,2018-02-12,2018,,"SYMDEKO is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence._x000D_
If the patients genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.",Priority,Yes,No,Yes,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; QUVIVIQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for QUVIVIQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 77868,2024-21836,https://www.federalregister.gov/documents/2024/09/24/2024-21836/determination-of-regulatory-review-period-for-purposes-of-patent-extension-quviviq,https://www.govinfo.gov/content/pkg/FR-2024-09-24/pdf/2024-21836.pdf,9/24/2024, QUVIVIQ,,Tianlun,QUVIVIQ (daridorexant hydrochloride),1,337,Helen,9732075,n/a,,,Idorsia Pharmaceuticals Ltd. ,2115,1660,455,2016-06-24,2021-01-08,2022-04-07,NDA 214985,1030,214985,,,,,,,,,,,Quviviq,daridorexant,Idorsia Pharmaceuticals Ltd.,NDA,214985,,2021-01-08,2022-01-07,2022,,"QUVIVIQ is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; OJJAARA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OJJAARA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 77867,2024-21844,https://www.federalregister.gov/documents/2024/09/24/2024-21844/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ojjaara,https://www.govinfo.gov/content/pkg/FR-2024-09-24/pdf/2024-21844.pdf,9/24/2024, OJJAARA,,Tianlun,OJJAARA (momelotinib),2,339,Helen,"8,486,941 and RE48,285",n/a,,,GlaxoSmithKline LLC,5127,4670,457,2009-09-03,2022-06-16,2023-09-15,NDA 216873,828 days or 5 years,216873,8/5/2010,Treatment of myelofibrosis,Designated/Approved,,,"treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia",9/15/2023,9/15/2030,"treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia",GlaxoSmithKline,Ojjaara,momelotinib,"GlaxoSmithKline, LLC",NDA,216873,,2022-06-16,2023-09-15,2023,,"OJJAARA is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.",Standard,Yes,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; BRAVECTO; Correction,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) published a notice in the Federal Register of February 12, 2018, for the determination of the regulatory review period for the animal drug BRAVECTO. In accordance with the Court's order in Nissan Chemical Corp., et al. v. FDA, et al., No. 22-01598 (D.D.C), this document revises the SUPPLEMENTARY INFORMATION section of that notice by adjusting the start date of the testing phase for BRAVECTO. This notice supersedes the June 11, 2021, Federal Register document revising the February 12, 2018, notice.",89 FR 77866,2024-21841,https://www.federalregister.gov/documents/2024/09/24/2024-21841/determination-of-regulatory-review-period-for-purposes-of-patent-extension-bravecto-correction,https://www.govinfo.gov/content/pkg/FR-2024-09-24/pdf/2024-21841.pdf,9/24/2024, BRAVECTO, Correction,Tianlun,BRAVECTO (fluralaner),1,340,Helen,7662972,n/a,,,"Nissan Chemical Industries, Ltd.",1548,1510,38,2011-08-04,2014-04-08,2014-05-15,NADA 141-426,792,141426,,,,,,,,,,,,,,,,,,,,,,,,,,
Determination of Regulatory Review Period for Purposes of Patent Extension; OMLONTI,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OMLONTI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 78306,2024-21847,https://www.federalregister.gov/documents/2024/09/25/2024-21847/determination-of-regulatory-review-period-for-purposes-of-patent-extension-omlonti,https://www.govinfo.gov/content/pkg/FR-2024-09-25/pdf/2024-21847.pdf,9/25/2024, OMLONTI,,Tianlun,OMLONTI (omidenepag isopropyl ophthalmic solution),3,343,Helen,"8,648,097; 8,685,986; 10,702,511",n/a,,,"Santen Pharmaceutical Co., Ltd.",3723,3050,673,2012-07-15,2020-11-19,2022-09-22,NDA 215092,"623 or 1,826",215092,,,,,,,,,,,Omlonti,omidenepag isopropyl,"Santen, Inc.",NDA,215092,,2020-11-19,2022-09-22,2022,,"OMLONTI (omidenepag isopropyl ophthalmic solution) 0.002%, is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; ZAVZPRET,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZAVZPRET and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 78309,2024-21963,https://www.federalregister.gov/documents/2024/09/25/2024-21963/determination-of-regulatory-review-period-for-purposes-of-patent-extension-zavzpret,https://www.govinfo.gov/content/pkg/FR-2024-09-25/pdf/2024-21963.pdf,9/25/2024, ZAVZPRET,,Tianlun,ZAVZPRET (zavegepant hydrochloride),1,344,Helen,8481546,n/a,,,Pfizer Inc. ,1619,1253,366,2018-10-04,2022-03-09,2023-03-09,NDA 216386,993,216386,,,,,,,,,,,Zavzpret,zavegepant,"Pfizer, Inc.",NDA,216386,,2022-03-09,2023-03-09,2023,,"ZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use:
ZAVZPRET is not indicated for the preventive treatment of migraine.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; JESDUVROQ,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for JESDUVROQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 78310,2024-21848,https://www.federalregister.gov/documents/2024/09/25/2024-21848/determination-of-regulatory-review-period-for-purposes-of-patent-extension-jesduvroq,https://www.govinfo.gov/content/pkg/FR-2024-09-25/pdf/2024-21848.pdf,9/25/2024, JESDUVROQ,,Tianlun,JESDUVROQ (daprodustat),1,345,Helen,8324208,n/a,,,GlaxoSmithKline LLC,5328,4962,366,2008-07-03,2022-02-01,2023-02-01,NDA 216951,2038,216951,,,,,,,,,,,Jesduvroq,daprodustat,GlaxoSmithKline Intellectual Property (No. 2) Limited England,NDA,216951,,2022-02-01,2023-02-01,2023,,"JESDUVROQ is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months.
Limitations of Use:
JESDUVROQ has not been shown to improve quality of life, fatigue, or patient well-being.
JESDUVROQ is not indicated for use:
-As a substitute for red blood cell transfusions in patients who require immediate
correction of anemia.
-For treatment of anemia of chronic kidney disease in patients who are not on dialysis.",Standard,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; DAYBUE,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for DAYBUE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 78312,2024-21941,https://www.federalregister.gov/documents/2024/09/25/2024-21941/determination-of-regulatory-review-period-for-purposes-of-patent-extension-daybue,https://www.govinfo.gov/content/pkg/FR-2024-09-25/pdf/2024-21941.pdf,9/25/2024, DAYBUE,,Tianlun,DAYBUE (trofinetide),1,346,Helen,9212204,n/a,,,Acadia Pharmaceuticals Inc.,5106,4864,242,2009-03-19,2022-07-12,2023-03-10,NDA 217026,1443,217026,2/11/2015,Treatment of Rett syndrome,Designated/Approved,,,treatment of Rett syndrome in adults and pediatric patients 2 years of age and older,3/10/2023,3/10/2030,treatment of Rett syndrome in adults and pediatric patients 2 years of age and older,Acadia Pharmaceuticals Inc.,Daybue,trofinetide,"Acadia Pharmaceuticals, Inc.",NDA,217026,,2022-07-12,2023-03-10,2023,,DAYBUE is indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.,Priority,Yes,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; ELUCIREM,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ELUCIREM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 78315,2024-21929,https://www.federalregister.gov/documents/2024/09/25/2024-21929/determination-of-regulatory-review-period-for-purposes-of-patent-extension-elucirem,https://www.govinfo.gov/content/pkg/FR-2024-09-25/pdf/2024-21929.pdf,9/25/2024, ELUCIREM,,Tianlun,ELUCIREM (gadopiclenol),1,347,Helen,8114863,n/a,,,Guerbet LLC,2443,2199,244,2016-01-15,2022-01-21,2022-09-21,NDA 216986,1344,216986,,,,,,,,,,,Elucirem,gadopiclenol,"Guerbet, LLC",NDA,216986,,2022-01-21,2022-09-21,2022,,"ELUCIREM is indicated in adult and pediatric patients aged 2 years and older for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in:
- the central nervous system (brain, spine, and associated tissues),
- the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).",Priority,No,No,No,No
Determination of Regulatory Review Period for Purposes of Patent Extension; FRUZAQLA,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for FRUZAQLA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of patents which claim that human drug product.",89 FR 78307,2024-21930,https://www.federalregister.gov/documents/2024/09/25/2024-21930/determination-of-regulatory-review-period-for-purposes-of-patent-extension-fruzaqla,https://www.govinfo.gov/content/pkg/FR-2024-09-25/pdf/2024-21930.pdf,9/25/2024, FRUZAQLA,,Tianlun,FRUZAQLA (fruquintinib),4,351,Helen,"7,829,574; 8,212,033; 10,519,142; and 11,046,674",n/a,,,HUTCHMED LTD.,2604,2380,224,2016-09-23,2023-03-30,2023-11-08,NDA 217564,"544, 793, or 1,414",217564,,,,,,,,,,,Fruzaqla,fruquintinib,"Takeda Pharmaceuticals USA, Inc.",NDA,217564,,2023-03-30,2023-11-08,2023,,"FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.",Priority,No,No,No,Yes
Determination of Regulatory Review Period for Purposes of Patent Extension; OGSIVEO,Notice,Health and Human Services Department; Food and Drug Administration,"The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OGSIVEO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.",89 FR 78880,2024-22105,https://www.federalregister.gov/documents/2024/09/26/2024-22105/determination-of-regulatory-review-period-for-purposes-of-patent-extension-ogsiveo,https://www.govinfo.gov/content/pkg/FR-2024-09-26/pdf/2024-22105.pdf,9/26/2024, OGSIVEO,,Tianlun,OGSIVEO (nirogacestat hydrobromide),3,354,Helen,"7,342,118; 7,795,447; and 7,951,958",n/a,,,SpringWorks Therapeutics Inc.,5425,5089,336,2009-01-21,2022-12-27,2023-11-27,NDA 217677,1826,217677,6/7/2018,Treatment of desmoid tumor (aggressive fibromatosis),Designated/Approved,,,for adult patients with progressing desmoid tumors who require systemic treatment,11/27/2023,11/27/2030,for adult patients with progressing desmoid tumors who require systemic treatment,"SpringWorks Therapeutics, Inc.",Ogsiveo,nirogacestat,"SpringWorks Therapeutics, Inc.",NDA,217677,,2022-12-27,2023-11-27,2023,,OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.,Priority,Yes,No,Yes,Yes
,,,,,,,,,,,,,1775,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,355,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
